[
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "carfilzomib",
    "date_of_designation_or_refusal": "03/06/2008",
    "intended_use": "Treatment of multiple myeloma",
    "eu_designation_number": "EU/3/08/548",
    "status": "Expired",
    "first_published_date": "17/09/2009",
    "last_updated_date": "28/11/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-548"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "obinutuzumab",
    "date_of_designation_or_refusal": "19/06/2015",
    "intended_use": "Treatment of follicular lymphoma",
    "eu_designation_number": "EU/3/15/1504",
    "status": "Withdrawn",
    "first_published_date": "27/07/2015",
    "last_updated_date": "07/11/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1504"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human N-acetylgalactosamine-6-sulfatase (elosulfase alfa)",
    "date_of_designation_or_refusal": "24/07/2009",
    "intended_use": "Treatment of mucopolysaccharidosis, type IVA (Morquio A syndrome)",
    "eu_designation_number": "EU/3/09/657",
    "status": "Withdrawn",
    "first_published_date": "11/09/2009",
    "last_updated_date": "23/10/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-657"
  },
  {
    "medicine_name": "Rezurock",
    "related_ema_product_number": "EMEA/H/C/006421",
    "active_substance": "2-(3-(4-(1H-Indazol-5-ylamino)quinazolin-2-yl)phenoxy)-N-isopropylacetamide-methane sulfonic acid salt",
    "date_of_designation_or_refusal": "17/10/2019",
    "intended_use": "Treatment of graft-versus-host disease",
    "eu_designation_number": "EU/3/19/2205",
    "status": "Positive",
    "first_published_date": "21/01/2020",
    "last_updated_date": "17/10/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2205"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "idebenone",
    "date_of_designation_or_refusal": "16/02/2007",
    "intended_use": "Treatment of Leber's hereditary optic neuropathy",
    "eu_designation_number": "EU/3/07/434",
    "status": "Expired",
    "first_published_date": "10/07/2008",
    "last_updated_date": "16/09/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-434"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "panobinostat",
    "date_of_designation_or_refusal": "08/11/2012",
    "intended_use": "Treatment of multiple myeloma",
    "eu_designation_number": "EU/3/12/1063",
    "status": "Expired",
    "first_published_date": "13/12/2012",
    "last_updated_date": "16/09/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1063"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "botaretigene sparoparvovec",
    "date_of_designation_or_refusal": "23/07/2025",
    "intended_use": "Treatment of inherited retinal dystrophies due to defects in the RPGR gene",
    "eu_designation_number": "EU/3/16/1715",
    "status": "Positive",
    "first_published_date": "03/10/2016",
    "last_updated_date": "09/09/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1715"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "relacorilant",
    "date_of_designation_or_refusal": "25/07/2023",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/23/2811",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "04/09/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2811"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human IgG1 (296-cysteine,301-glycine,306-cysteine) monoclonal antibody against TREM2",
    "date_of_designation_or_refusal": "13/10/2023",
    "intended_use": "Treatment of CSF1R-related leukoencephalopathy",
    "eu_designation_number": "EU/3/23/2847",
    "status": "Withdrawn",
    "first_published_date": "01/02/2024",
    "last_updated_date": "04/09/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2847"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector containing a modified U7 snRNA gene",
    "date_of_designation_or_refusal": "27/07/2005",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/05/297",
    "status": "Withdrawn",
    "first_published_date": "11/10/2005",
    "last_updated_date": "04/09/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-297"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus vector serotype 9 encoding human gigaxonin gene",
    "date_of_designation_or_refusal": "13/04/2022",
    "intended_use": "Treatment of giant axonal neuropathy",
    "eu_designation_number": "EU/3/22/2598",
    "status": "Withdrawn",
    "first_published_date": "19/07/2022",
    "last_updated_date": "04/09/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2598"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "hydrocortisone",
    "date_of_designation_or_refusal": "20/03/2007",
    "intended_use": "Treatment of adrenal insufficiency",
    "eu_designation_number": "EU/3/07/441",
    "status": "Withdrawn",
    "first_published_date": "21/09/2009",
    "last_updated_date": "04/09/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-441"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "nanatinostat;valganciclovir",
    "date_of_designation_or_refusal": "10/08/2022",
    "intended_use": "Treatment of peripheral T-cell lymphoma",
    "eu_designation_number": "EU/3/22/2673",
    "status": "Withdrawn",
    "first_published_date": "15/12/2022",
    "last_updated_date": "04/09/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2673"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "valganciclovir;nanatinostat",
    "date_of_designation_or_refusal": "13/01/2023",
    "intended_use": "Treatment of diffuse large B-cell lymphoma",
    "eu_designation_number": "EU/3/22/2742",
    "status": "Withdrawn",
    "first_published_date": "23/03/2023",
    "last_updated_date": "04/09/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2742"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-[6-(6,7-Dimethoxyquinolin-3-yl)pyridin-3-yl]-N-[3-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-5-yl]acetamide (zeteletinib)",
    "date_of_designation_or_refusal": "19/02/2021",
    "intended_use": "Treatment of medullary thyroid carcinoma",
    "eu_designation_number": "EU/3/21/2410",
    "status": "Withdrawn",
    "first_published_date": "23/02/2022",
    "last_updated_date": "04/09/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2410"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Interferon gamma",
    "date_of_designation_or_refusal": "09/12/2011",
    "intended_use": "Treatment of Friedreich's ataxia",
    "eu_designation_number": "EU/3/11/935",
    "status": "Withdrawn",
    "first_published_date": "20/12/2011",
    "last_updated_date": "04/09/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-935"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "humanised IgG1 kappa monoclonal antibody against tyrosine-protein phosphatase non-receptor type substrate 1, signal-regulatory protein beta-1 and signal-regulatory protein gamma",
    "date_of_designation_or_refusal": "18/07/2025",
    "intended_use": "Treatment of haemophagocytic lymphohistiocytosis",
    "eu_designation_number": "EU/3/25/3097",
    "status": "Positive",
    "first_published_date": "04/09/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3097"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic peripheral blood-derived T-cells, fratricide-resistant, transduced with a lentivirus vector expressing a chimeric antigen receptor against CD7",
    "date_of_designation_or_refusal": "18/07/2025",
    "intended_use": "Treatment of acute lymphoblastic leukaemia",
    "eu_designation_number": "EU/3/25/3091",
    "status": "Positive",
    "first_published_date": "04/09/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3091"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "aglatimagene besadenovec",
    "date_of_designation_or_refusal": "18/07/2025",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/25/3096",
    "status": "Positive",
    "first_published_date": "04/09/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3096"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "methotrexate",
    "date_of_designation_or_refusal": "18/07/2025",
    "intended_use": "Treatment of non-syndromic inherited retinal dystrophies of the rod-dominant phenotype",
    "eu_designation_number": "EU/3/25/3089",
    "status": "Positive",
    "first_published_date": "04/09/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3089"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sonlicromanol hydrochloride",
    "date_of_designation_or_refusal": "18/07/2025",
    "intended_use": "Treatment of inherited mitochondrial oxidative phosphorylation defects",
    "eu_designation_number": "EU/3/25/3083",
    "status": "Positive",
    "first_published_date": "04/09/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3083"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Ivosidenib",
    "date_of_designation_or_refusal": "18/07/2025",
    "intended_use": "Treatment of myelodysplastic syndromes",
    "eu_designation_number": "EU/3/25/3085",
    "status": "Positive",
    "first_published_date": "04/09/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3085"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "telitacicept",
    "date_of_designation_or_refusal": "18/07/2025",
    "intended_use": "Treatment of myasthenia gravis",
    "eu_designation_number": "EU/3/25/3099",
    "status": "Positive",
    "first_published_date": "04/09/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3099"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "curcumin",
    "date_of_designation_or_refusal": "18/07/2025",
    "intended_use": "Treatment of Charcot-Marie-Tooth disease",
    "eu_designation_number": "EU/3/25/3092",
    "status": "Positive",
    "first_published_date": "04/09/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3092"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ribavirin",
    "date_of_designation_or_refusal": "18/07/2025",
    "intended_use": "Treatment of hepatitis E",
    "eu_designation_number": "EU/3/25/3086",
    "status": "Positive",
    "first_published_date": "04/09/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3086"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "avutometinib;defactinib",
    "date_of_designation_or_refusal": "18/07/2025",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/25/3090",
    "status": "Positive",
    "first_published_date": "04/09/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3090"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "palmitoyl-conjugated tricyclo-DNA antisense oligonucleotide 5'-Palm-C6-*GGA GAT GgC AGT TTC-3",
    "date_of_designation_or_refusal": "18/07/2025",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/25/3084",
    "status": "Positive",
    "first_published_date": "04/09/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3084"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "luminol monosodium",
    "date_of_designation_or_refusal": "18/07/2025",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/25/3095",
    "status": "Positive",
    "first_published_date": "04/09/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3095"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human bispecific monoclonal antibody targeting ALK1 and BMPRII",
    "date_of_designation_or_refusal": "18/07/2025",
    "intended_use": "Treatment of hereditary haemorrhagic telangiectasia",
    "eu_designation_number": "EU/3/25/3098",
    "status": "Positive",
    "first_published_date": "04/09/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3098"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 9 containing the human CTNNB1 gene",
    "date_of_designation_or_refusal": "18/07/2025",
    "intended_use": "Treatment of autosomal dominant polycystic kidney disease",
    "eu_designation_number": "EU/3/25/3101",
    "status": "Positive",
    "first_published_date": "04/09/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3101"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "octreotide hydrochloride",
    "date_of_designation_or_refusal": "18/07/2025",
    "intended_use": "Treatment of autosomal dominant polycystic kidney disease",
    "eu_designation_number": "EU/3/25/3093",
    "status": "Positive",
    "first_published_date": "04/09/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3093"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "phosphorodiamidate morpholino oligonucleotide against the CUG repeat expansion of the DMPK gene mRNA transcript, conjugated to a cell penetrating peptide",
    "date_of_designation_or_refusal": "18/07/2025",
    "intended_use": "Treatment of dystrophic myotonia",
    "eu_designation_number": "EU/3/25/3087",
    "status": "Positive",
    "first_published_date": "04/09/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3087"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "resecabtagene autoleucel",
    "date_of_designation_or_refusal": "18/07/2025",
    "intended_use": "Treatment of idiopathic inflammatory myopathy",
    "eu_designation_number": "EU/3/25/3094",
    "status": "Positive",
    "first_published_date": "04/09/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3094"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Elafibranor",
    "date_of_designation_or_refusal": "18/07/2025",
    "intended_use": "Treatment of primary sclerosing cholangitis",
    "eu_designation_number": "EU/3/25/3100",
    "status": "Positive",
    "first_published_date": "04/09/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3100"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "nuvisertib",
    "date_of_designation_or_refusal": "18/07/2025",
    "intended_use": "Treatment of myelofibrosis",
    "eu_designation_number": "EU/3/25/3088",
    "status": "Positive",
    "first_published_date": "04/09/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3088"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised IgG1 monoclonal antibody against adrenocorticotropic hormone",
    "date_of_designation_or_refusal": "20/06/2025",
    "intended_use": "Treatment of congenital adrenal hyperplasia",
    "eu_designation_number": "EU/3/25/3077",
    "status": "Positive",
    "first_published_date": "25/07/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3077"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "4-Amino-1-[(2R,4S,5S)-5-(1,2-dihydroxyethyl)-4-hydroxyoxolan-2-yl]pyrimidin-2-one",
    "date_of_designation_or_refusal": "20/06/2025",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/25/3076",
    "status": "Positive",
    "first_published_date": "25/07/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3076"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "empasiprubart",
    "date_of_designation_or_refusal": "20/06/2025",
    "intended_use": "Treatment of multifocal motor neuropathy",
    "eu_designation_number": "EU/3/25/3070",
    "status": "Positive",
    "first_published_date": "25/07/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3070"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Exidavnemab",
    "date_of_designation_or_refusal": "20/06/2025",
    "intended_use": "Treatment of multiple system atrophy",
    "eu_designation_number": "EU/3/25/3075",
    "status": "Positive",
    "first_published_date": "25/07/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3075"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Alpha-N-acetyl glucosaminidase fused to a humanised monoclonal antibody against transferrin receptor",
    "date_of_designation_or_refusal": "20/06/2025",
    "intended_use": "Treatment of mucopolysaccharidosis type IIIB (Sanfilippo B syndrome)",
    "eu_designation_number": "EU/3/25/3073",
    "status": "Positive",
    "first_published_date": "25/07/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3073"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-[[Hydroxy[(R)-2-[((5Z,8Z,11Z,14Z)-eicosa-5,8,11,14-tetraenoyl)oxy]-3-(octadecyloxy)propoxy]phosphoryl]oxy]ethan-1-amine",
    "date_of_designation_or_refusal": "20/06/2025",
    "intended_use": "Treatment of Rett syndrome",
    "eu_designation_number": "EU/3/25/3081",
    "status": "Positive",
    "first_published_date": "25/07/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3081"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Dipalmitoyl hydroxyproline",
    "date_of_designation_or_refusal": "20/06/2025",
    "intended_use": "Treatment of Netherton syndrome",
    "eu_designation_number": "EU/3/25/3072",
    "status": "Positive",
    "first_published_date": "25/07/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3072"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised IgG4 bispecific monoclonal antibody against sclerostin and dickkopf-related protein 1",
    "date_of_designation_or_refusal": "20/06/2025",
    "intended_use": "Treatment of osteogenesis imperfecta",
    "eu_designation_number": "EU/3/25/3069",
    "status": "Positive",
    "first_published_date": "25/07/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3069"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "bezuclastinib",
    "date_of_designation_or_refusal": "20/06/2025",
    "intended_use": "Treatment of mastocytosis",
    "eu_designation_number": "EU/3/25/3065",
    "status": "Positive",
    "first_published_date": "25/07/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3065"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Beta-lapachone",
    "date_of_designation_or_refusal": "20/06/2025",
    "intended_use": "Treatment of primary sclerosing cholangitis",
    "eu_designation_number": "EU/3/25/3071",
    "status": "Positive",
    "first_published_date": "25/07/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3071"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "1-(3-Bromobenzyl)-N3-(3,4-dichlorophenyl)-1H-1,2,4-triazole-3,5-diamine",
    "date_of_designation_or_refusal": "20/06/2025",
    "intended_use": "Treatment of radiation induced maculopathy",
    "eu_designation_number": "EU/3/25/3068",
    "status": "Positive",
    "first_published_date": "25/07/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3068"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "3-(Carbamoylamino)-5-[2-(3-fluorophenyl)ethynyl]-N-[(3S)-piperidin-3-yl]thiophene-2-carboxamide hydrochloric acid",
    "date_of_designation_or_refusal": "20/06/2025",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/25/3079",
    "status": "Positive",
    "first_published_date": "25/07/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3079"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "3-((4-(1-((1-(6-(((S)-2,6-Dioxopiperidin-3-yl)carbamoyl)pyridin-3-yl)piperidin-4-yl)methyl)piperidin-4-yl)phenyl)amino)-5-((R)-3-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl)pyrazine-2-carboxamide",
    "date_of_designation_or_refusal": "20/06/2025",
    "intended_use": "Treatment of lymphoplasmacytic lymphoma",
    "eu_designation_number": "EU/3/25/3078",
    "status": "Positive",
    "first_published_date": "25/07/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3078"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Elesclomol-copper",
    "date_of_designation_or_refusal": "22/06/2025",
    "intended_use": "Treatment of Menkes disease",
    "eu_designation_number": "EU/3/23/2858",
    "status": "Positive",
    "first_published_date": "25/07/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2858-0"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "zanidatamab",
    "date_of_designation_or_refusal": "27/06/2025",
    "intended_use": "Treatment of biliary tract cancer",
    "eu_designation_number": "EU/3/21/2458",
    "status": "Positive",
    "first_published_date": "25/07/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2458-0"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised IgG1 monoclonal antibody against human eotaxin-2;nebokitug",
    "date_of_designation_or_refusal": "21/08/2020",
    "intended_use": "Treatment of primary sclerosing cholangitis",
    "eu_designation_number": "EU/3/20/2314",
    "status": "Positive",
    "first_published_date": "25/11/2020",
    "last_updated_date": "17/07/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2314"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Felzartamab",
    "date_of_designation_or_refusal": "11/11/2024",
    "intended_use": "Treatment of primary IgA nephropathy",
    "eu_designation_number": "EU/3/24/2994",
    "status": "Positive",
    "first_published_date": "21/11/2024",
    "last_updated_date": "17/07/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2994"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "68Ga-2,2'-(7-(4-((S)-1-((4S,7S,10S,13R,16S,19R)-4-((R)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-ylcarbamoyl)-10-(4-aminobutyl)-16-(4-((S)-2,6-dioxohexahydropyrimidine-4-carboxamido)benzyl)-7-((R)-1-hydroxyethyl)-6,9,12,15,18-pentaoxo-13-(4-ureidobenzyl)-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-19-ylamino)-3-(4-chlorophenyl)-1-oxopropan-2-ylamino)-1-carboxy-4-oxobutyl)-1,4,7-triazonane-1,4-diyl)diacetic acid (satoreotide trixozetan) ;satoreotide trizoxetan gallium (Ga68)",
    "date_of_designation_or_refusal": "19/02/2014",
    "intended_use": "Diagnosis of gastro-entero-pancreatic neuroendocrine tumours",
    "eu_designation_number": "EU/3/14/1246",
    "status": "Positive",
    "first_published_date": "02/04/2014",
    "last_updated_date": "17/07/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1246"
  },
  {
    "medicine_name": "Amvuttra",
    "related_ema_product_number": "EMEA/H/C/005852",
    "active_substance": "synthetic double-stranded siRNA oligonucleotide targeted against transthyretin mRNA, with six phosphorothioate linkages in the backbone, and nine 2'-fluoro and thirty-five 2'-O-methyl nucleoside residues in the sequence, which is covalently linked via a phosphodiester group to a ligand containing three N-acetylgalactosamine residues (Vutrisiran)",
    "date_of_designation_or_refusal": "25/05/2018",
    "intended_use": "Treatment of transthyretin-mediated amyloidosis (ATTR amyloidosis)",
    "eu_designation_number": "EU/3/18/2026",
    "status": "Positive",
    "first_published_date": "23/07/2018",
    "last_updated_date": "17/07/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2026"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "lepunafusp alfa",
    "date_of_designation_or_refusal": "26/03/2021",
    "intended_use": "Treatment of mucopolysaccharidosis type I",
    "eu_designation_number": "EU/3/21/2414",
    "status": "Positive",
    "first_published_date": "19/01/2022",
    "last_updated_date": "17/07/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2414"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidine-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridine-2-yl)-4-fluoropyrrolidine-2-carboxamide",
    "date_of_designation_or_refusal": "21/03/2018",
    "intended_use": "Treatment of C3 glomerulopathy",
    "eu_designation_number": "EU/3/18/1989",
    "status": "Withdrawn",
    "first_published_date": "08/05/2018",
    "last_updated_date": "17/07/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1989"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "utreloxastat",
    "date_of_designation_or_refusal": "09/12/2022",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/22/2728",
    "status": "Withdrawn",
    "first_published_date": "13/03/2023",
    "last_updated_date": "17/07/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2728"
  },
  {
    "medicine_name": "Aucatzyl",
    "related_ema_product_number": "EMEA/H/C/005907",
    "active_substance": "obecabtagene autoleucel",
    "date_of_designation_or_refusal": "13/04/2022",
    "intended_use": "Treatment of acute lymphoblastic leukaemia",
    "eu_designation_number": "EU/3/22/2605",
    "status": "Withdrawn",
    "first_published_date": "19/07/2022",
    "last_updated_date": "17/07/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2605"
  },
  {
    "medicine_name": "Attrogy",
    "related_ema_product_number": "EMEA/H/C/006248",
    "active_substance": "diflunisal",
    "date_of_designation_or_refusal": "21/06/2022",
    "intended_use": "Treatment of ATTR amyloidosis",
    "eu_designation_number": "EU/3/22/2640",
    "status": "Withdrawn",
    "first_published_date": "22/09/2022",
    "last_updated_date": "17/07/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2640"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised monoclonal antibody targeting B-cell maturation antigen conjugated with maleimidocaproyl monomethyl auristatin F",
    "date_of_designation_or_refusal": "16/10/2017",
    "intended_use": "Treatment of multiple myeloma",
    "eu_designation_number": "EU/3/17/1925",
    "status": "Withdrawn",
    "first_published_date": "08/01/2018",
    "last_updated_date": "17/07/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1925"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "iloprost",
    "date_of_designation_or_refusal": "20/06/2025",
    "intended_use": "Treatment of systemic sclerosis",
    "eu_designation_number": "EU/3/25/3066",
    "status": "Positive",
    "first_published_date": "17/07/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3066"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(R)-3-(5-dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1methylethyl)benzamide",
    "date_of_designation_or_refusal": "",
    "intended_use": "Treatment of fragile X syndrome",
    "eu_designation_number": "EU/3/25/3074",
    "status": "Positive",
    "first_published_date": "17/07/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3074"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-(2-(2-[2-(4-Benzothiazol-2-yl-phenoxy)-ethoxy]-ethoxy)-ethoxy)-ethanol",
    "date_of_designation_or_refusal": "20/06/2025",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/25/3080",
    "status": "Positive",
    "first_published_date": "17/07/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3080"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium 2-(3'(-3-(1-(4-(tert-butyl)benzyl)-4-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)propyl)-4-ethoxy-[1,1'-biphenyl]-3-yl)acetate",
    "date_of_designation_or_refusal": "20/06/2025",
    "intended_use": "Treatment of hepatocellular carcinoma",
    "eu_designation_number": "EU/3/25/3067",
    "status": "Positive",
    "first_published_date": "17/07/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3067"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tasimelteon",
    "date_of_designation_or_refusal": "23/02/2011",
    "intended_use": "Treatment of non-24-hour sleep-wake disorders in blind people with no light perception",
    "eu_designation_number": "EU/3/10/841",
    "status": "Expired",
    "first_published_date": "07/03/2011",
    "last_updated_date": "09/07/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-841"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised IgG1 monoclonal antibody against human epidermal growth factor receptor 2",
    "date_of_designation_or_refusal": "22/05/2025",
    "intended_use": "Treatment of gastric cancer",
    "eu_designation_number": "EU/3/25/3060",
    "status": "Positive",
    "first_published_date": "30/06/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3060"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "taladegib",
    "date_of_designation_or_refusal": "22/05/2025",
    "intended_use": "Treatment of idiopathic pulmonary fibrosis",
    "eu_designation_number": "EU/3/25/3054",
    "status": "Positive",
    "first_published_date": "30/06/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3054"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "1-{4-[2-(5-ethoxymethyl-2-methyl-phenylamino)-oxazol-5-yl]-phenyl}-imidazolidin-2-one",
    "date_of_designation_or_refusal": "22/05/2025",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/25/3059",
    "status": "Positive",
    "first_published_date": "30/06/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3059"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Induced pluripotent stem cells-derived myogenic progenitor cells",
    "date_of_designation_or_refusal": "22/05/2025",
    "intended_use": "Treatment of Becker muscular dystrophy",
    "eu_designation_number": "EU/3/25/3063",
    "status": "Positive",
    "first_published_date": "30/06/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3063"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ramiprilat",
    "date_of_designation_or_refusal": "12/03/2013",
    "intended_use": "Treatment of Stargardt's disease",
    "eu_designation_number": "EU/3/13/1117",
    "status": "Withdrawn",
    "first_published_date": "05/04/2013",
    "last_updated_date": "30/06/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1117"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "octreotide hydrochloride",
    "date_of_designation_or_refusal": "12/06/2009",
    "intended_use": "Treatment of acromegaly",
    "eu_designation_number": "EU/3/09/645",
    "status": "Withdrawn",
    "first_published_date": "17/09/2009",
    "last_updated_date": "30/06/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-645"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(S)-2-isobutyrylamino-pentanedioic acid 5-amide 1-{[(2S,5S,8S,11R,12S,15S,18S,21R)-2,8-bis-((S)-sec-butyl)-21-hydroxy-5-(4-hydroxy-benzyl)-15-isobutyl-4,11-dimethyl-3,6,9,13,16,22-hexaoxo-10-oxa-1,4,7,14,17-pentaaza-bicyclo[16.3.1]docos-12-yl]-amide}",
    "date_of_designation_or_refusal": "17/10/2019",
    "intended_use": "Treatment of Netherton syndrome",
    "eu_designation_number": "EU/3/19/2203",
    "status": "Withdrawn",
    "first_published_date": "21/01/2020",
    "last_updated_date": "30/06/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2203"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus serotype C102 containing the human GLA gene",
    "date_of_designation_or_refusal": "13/04/2022",
    "intended_use": "Treatment of Fabry disease",
    "eu_designation_number": "EU/3/22/2607",
    "status": "Withdrawn",
    "first_published_date": "19/07/2022",
    "last_updated_date": "30/06/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2607"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "radiprodil",
    "date_of_designation_or_refusal": "22/05/2025",
    "intended_use": "Treatment of GRIN-related neurodevelopmental disorder",
    "eu_designation_number": "EU/3/25/3061",
    "status": "Positive",
    "first_published_date": "25/06/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3061"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Doxorubicin, liposomal, pegylated",
    "date_of_designation_or_refusal": "22/05/2025",
    "intended_use": "Treatment of soft-tissue sarcoma",
    "eu_designation_number": "EU/3/25/3056",
    "status": "Positive",
    "first_published_date": "25/06/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3056"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tranilast",
    "date_of_designation_or_refusal": "22/05/2025",
    "intended_use": "Treatment of idiopathic pulmonary fibrosis",
    "eu_designation_number": "EU/3/25/3058",
    "status": "Positive",
    "first_published_date": "25/06/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3058"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "florbetaben (18F)",
    "date_of_designation_or_refusal": "22/05/2025",
    "intended_use": "Diagnosis of ATTR amyloidosis",
    "eu_designation_number": "EU/3/25/3055",
    "status": "Positive",
    "first_published_date": "25/06/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3055"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 2i8 containing the human LAMP2 isoform B transgene",
    "date_of_designation_or_refusal": "22/05/2025",
    "intended_use": "Treatment of Danon disease",
    "eu_designation_number": "EU/3/25/3062",
    "status": "Positive",
    "first_published_date": "24/06/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3062"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Equine polyclonal immunoglobulin F(ab')2 fragments against ricin",
    "date_of_designation_or_refusal": "22/05/2025",
    "intended_use": "Treatment of ricin poisoning",
    "eu_designation_number": "EU/3/25/3057",
    "status": "Positive",
    "first_published_date": "24/06/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3057"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tertomotide",
    "date_of_designation_or_refusal": "22/05/2025",
    "intended_use": "Treatment of progressive supranuclear palsy",
    "eu_designation_number": "EU/3/25/3053",
    "status": "Positive",
    "first_published_date": "24/06/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3053"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human ectonucleotide pyrophosphatase/phosphodiesterase 1 fused to the Fc fragment of IgG1",
    "date_of_designation_or_refusal": "22/05/2025",
    "intended_use": "Treatment of calciphylaxis",
    "eu_designation_number": "EU/3/25/3064",
    "status": "Positive",
    "first_published_date": "24/06/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3064"
  },
  {
    "medicine_name": "Zemcelpro",
    "related_ema_product_number": "EMEA/H/C/005772",
    "active_substance": "haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate",
    "date_of_designation_or_refusal": "20/04/2020",
    "intended_use": "Treatment in haematopoietic stem cell transplantation",
    "eu_designation_number": "EU/3/20/2271",
    "status": "Positive",
    "first_published_date": "12/08/2020",
    "last_updated_date": "20/06/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2271"
  },
  {
    "medicine_name": "Vyjuvek",
    "related_ema_product_number": "EMEA/H/C/006330",
    "active_substance": "genetically modified replication-incompetent herpes simplex virus-1 expressing collagen VII (beremagene geperpavec)",
    "date_of_designation_or_refusal": "16/04/2018",
    "intended_use": "Treatment of epidermolysis bullosa",
    "eu_designation_number": "EU/3/18/2012",
    "status": "Positive",
    "first_published_date": "17/05/2018",
    "last_updated_date": "10/06/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2012"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus serotype rh79 containing the human OTC gene, adeno-associated virus serotype rh79 encoding a meganuclease for targeted editing of the human PCSK9 gene",
    "date_of_designation_or_refusal": "09/12/2022",
    "intended_use": "Treatment of ornithine transcarbamylase deficiency",
    "eu_designation_number": "EU/3/22/2736",
    "status": "Positive",
    "first_published_date": "13/03/2023",
    "last_updated_date": "10/06/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2736"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised IGg1 monoclonal antibody targeting human transferrin receptor conjugated to human iduronate-2-sulfatase",
    "date_of_designation_or_refusal": "26/02/2019",
    "intended_use": "Treatment of mucopolysaccharidosis type II (Hunter's syndrome)",
    "eu_designation_number": "EU/3/19/2140",
    "status": "Positive",
    "first_published_date": "09/04/2019",
    "last_updated_date": "10/06/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2140"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "synthetic oligonucleotide selectively targeting UBE3A antisense RNA transcripts",
    "date_of_designation_or_refusal": "09/12/2020",
    "intended_use": "Treatment of Angelman syndrome",
    "eu_designation_number": "EU/3/20/2379",
    "status": "Positive",
    "first_published_date": "27/05/2021",
    "last_updated_date": "10/06/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2379"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human IgG1 monoclonal antibody against sortilin",
    "date_of_designation_or_refusal": "15/10/2021",
    "intended_use": "Treatment of frontotemporal dementia",
    "eu_designation_number": "EU/3/21/2498",
    "status": "Positive",
    "first_published_date": "20/01/2022",
    "last_updated_date": "10/06/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2498"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Entospletinib",
    "date_of_designation_or_refusal": "16/10/2017",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/17/1922",
    "status": "Withdrawn",
    "first_published_date": "08/01/2018",
    "last_updated_date": "10/06/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1922"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "1-(4-(6-chloropyridazin-3-yl)piperazin-1-yl)-2-(4-cyclopropyl-3-fluorophenyl)ethan-1-one",
    "date_of_designation_or_refusal": "19/07/2021",
    "intended_use": "Treatment of propionic acidaemia",
    "eu_designation_number": "EU/3/21/2462",
    "status": "Withdrawn",
    "first_published_date": "12/11/2021",
    "last_updated_date": "10/06/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2462"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "1-(4-(6-chloropyridazin-3-yl)piperazin-1-yl)-2-(4-cyclopropyl-3-fluorophenyl)ethan-1-one",
    "date_of_designation_or_refusal": "19/07/2021",
    "intended_use": "Treatment of pantothenate kinase-associated neurodegeneration",
    "eu_designation_number": "EU/3/21/2461",
    "status": "Withdrawn",
    "first_published_date": "12/11/2021",
    "last_updated_date": "10/06/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2461"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "nerandomilast",
    "date_of_designation_or_refusal": "28/06/2024",
    "intended_use": "Treatment of idiopathic pulmonary fibrosis",
    "eu_designation_number": "EU/3/24/2931",
    "status": "Withdrawn",
    "first_published_date": "22/08/2024",
    "last_updated_date": "10/06/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2931"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "S-[5-(omega-methoxypoly(oxyethylene)-2-oxopentyl)]-L-cysteinylglycyl-L-serinylglycylgylcyl-L-isoleucyl-L-lysyl-L-glutamyl-L-phenylalanyl-L-leucyl-L-glutaminyl-L-arginyl-L-phenylalanyl-L-isoleucyl-L-histyl-L-isoleucyl-L-valyl-L-glutaminyl-L-serinyl-L-isoleucyl-L-isoleucyl-L-asparaginyl-L-threonyl-L-serinamide, acetate salt",
    "date_of_designation_or_refusal": "13/04/2021",
    "intended_use": "Treatment of cutaneous T-cell lymphoma",
    "eu_designation_number": "EU/3/21/2425",
    "status": "Withdrawn",
    "first_published_date": "21/01/2022",
    "last_updated_date": "10/06/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2425"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 3B encoding human multidrug resistance protein 3A",
    "date_of_designation_or_refusal": "22/04/2020",
    "intended_use": "Treatment of progressive familial intrahepatic cholestasis",
    "eu_designation_number": "EU/3/20/2267",
    "status": "Withdrawn",
    "first_published_date": "11/08/2020",
    "last_updated_date": "10/06/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2267"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "nipocalimab",
    "date_of_designation_or_refusal": "",
    "intended_use": "Prevention of fetal and neonatal alloimmune thrombocytopenia",
    "eu_designation_number": "EU/3/25/3045",
    "status": "Positive",
    "first_published_date": "10/06/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3045"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sirolimus",
    "date_of_designation_or_refusal": "16/04/2025",
    "intended_use": "Treatment of familial adenomatous polyposis (FAP)",
    "eu_designation_number": "EU/3/25/3051",
    "status": "Positive",
    "first_published_date": "10/06/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3051"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Parahydroxybenzoic acid",
    "date_of_designation_or_refusal": "16/04/2025",
    "intended_use": "Treatment of primary ubiquinone deficiency",
    "eu_designation_number": "EU/3/25/3052",
    "status": "Positive",
    "first_published_date": "10/06/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3052"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Adeno-associated viral vector serotype LK03 containing the human CFI gene",
    "date_of_designation_or_refusal": "16/04/2025",
    "intended_use": "Treatment of primary IgA nephropathy",
    "eu_designation_number": "EU/3/25/3048",
    "status": "Positive",
    "first_published_date": "10/06/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3048"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Fragment antibody targeting human TfR1 conjugated to phosphorodiamidate morpholino oligomer",
    "date_of_designation_or_refusal": "16/04/2025",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/25/3047",
    "status": "Positive",
    "first_published_date": "10/06/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3047"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "defibrotide",
    "date_of_designation_or_refusal": "29/07/2004",
    "intended_use": "Prevention of hepatic veno-occlusive disease",
    "eu_designation_number": "EU/3/04/211",
    "status": "Withdrawn",
    "first_published_date": "12/12/2005",
    "last_updated_date": "05/06/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-211"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "defibrotide",
    "date_of_designation_or_refusal": "13/11/2013",
    "intended_use": "Prevention of graft-versus-host disease",
    "eu_designation_number": "EU/3/13/1201",
    "status": "Withdrawn",
    "first_published_date": "02/12/2013",
    "last_updated_date": "05/06/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1201"
  },
  {
    "medicine_name": "Ztalmy",
    "related_ema_product_number": "EMEA/H/C/005825",
    "active_substance": "ganaxolone",
    "date_of_designation_or_refusal": "13/11/2019",
    "intended_use": "Treatment of CDKL5 deficiency disorder",
    "eu_designation_number": "EU/3/19/2224",
    "status": "Positive",
    "first_published_date": "13/02/2020",
    "last_updated_date": "05/06/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2224"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "single guide RNA targeting the human TTR gene, Ziclumeran",
    "date_of_designation_or_refusal": "26/03/2021",
    "intended_use": "Treatment of ATTR amyloidosis",
    "eu_designation_number": "EU/3/21/2419",
    "status": "Positive",
    "first_published_date": "19/01/2022",
    "last_updated_date": "05/06/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2419"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Copper (64Cu) oxodotreotide",
    "date_of_designation_or_refusal": "09/12/2022",
    "intended_use": "Diagnosis of neuroendocrine neoplasms",
    "eu_designation_number": "EU/3/22/2727",
    "status": "Positive",
    "first_published_date": "13/03/2023",
    "last_updated_date": "05/06/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2727"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ganaxolone",
    "date_of_designation_or_refusal": "15/10/2021",
    "intended_use": "Treatment of tuberous sclerosis",
    "eu_designation_number": "EU/3/21/2503",
    "status": "Positive",
    "first_published_date": "20/01/2022",
    "last_updated_date": "05/06/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2503"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "resminostat",
    "date_of_designation_or_refusal": "09/12/2011",
    "intended_use": "Treatment of Hodgkin's lymphoma",
    "eu_designation_number": "EU/3/11/930",
    "status": "Withdrawn",
    "first_published_date": "20/12/2011",
    "last_updated_date": "05/06/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-930"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant adeno-associated viral vector serotype 5 encoding Staphylococcus aureus Cas9 endonuclease and two guide RNAs complementary to two regions of intron 26 of the CEP290 gene",
    "date_of_designation_or_refusal": "16/10/2017",
    "intended_use": "Treatment of Leber's congenital amaurosis",
    "eu_designation_number": "EU/3/17/1928",
    "status": "Withdrawn",
    "first_published_date": "08/01/2018",
    "last_updated_date": "05/06/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1928"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "resminostat",
    "date_of_designation_or_refusal": "27/09/2011",
    "intended_use": "Treatment of hepatocellular carcinoma",
    "eu_designation_number": "EU/3/11/913",
    "status": "Withdrawn",
    "first_published_date": "17/10/2011",
    "last_updated_date": "05/06/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-913"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human decorin fused to the truncated homing peptide CRK",
    "date_of_designation_or_refusal": "18/07/2022",
    "intended_use": "Treatment of epidermolysis bullosa",
    "eu_designation_number": "EU/3/22/2664",
    "status": "Positive",
    "first_published_date": "23/01/2023",
    "last_updated_date": "05/06/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2664"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "posnafusp alfa",
    "date_of_designation_or_refusal": "14/01/2022",
    "intended_use": "Treatment of mucopolysaccharidosis type IIIA (Sanfilippo A syndrome)",
    "eu_designation_number": "EU/3/21/2560",
    "status": "Positive",
    "first_published_date": "09/06/2022",
    "last_updated_date": "05/06/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2560"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous T lymphocyte-enriched population of cells transduced with a lentiviral vector encoding a chimeric antigen receptor targeting human claudin 18.2 antigen with CD28 and CD3-zeta intracellular signalling domains",
    "date_of_designation_or_refusal": "19/02/2021",
    "intended_use": "Treatment of gastric cancer",
    "eu_designation_number": "EU/3/21/2405",
    "status": "Positive",
    "first_published_date": "23/02/2022",
    "last_updated_date": "05/06/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2405"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "small-interfering RNA against soluble fms-like tyrosine kinase-1 e15a mRNA, small-interfering RNA against soluble fms-like tyrosine kinase-1 i13 mRNA",
    "date_of_designation_or_refusal": "16/04/2025",
    "intended_use": "Treatment of pre-eclampsia",
    "eu_designation_number": "EU/3/25/3050",
    "status": "Positive",
    "first_published_date": "05/06/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3050"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "humanised IgG1 monoclonal antibody against muscle specific kinase",
    "date_of_designation_or_refusal": "16/04/2025",
    "intended_use": "Treatment of spinal muscular atrophy",
    "eu_designation_number": "EU/3/25/3049",
    "status": "Positive",
    "first_published_date": "05/06/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3049"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "vamikibart",
    "date_of_designation_or_refusal": "16/04/2025",
    "intended_use": "Treatment of non-infectious uveitis",
    "eu_designation_number": "EU/3/25/3046",
    "status": "Positive",
    "first_published_date": "05/06/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3046"
  },
  {
    "medicine_name": "Ziihera",
    "related_ema_product_number": "EMEA/H/C/006380",
    "active_substance": "zanidatamab",
    "date_of_designation_or_refusal": "19/07/2021",
    "intended_use": "Treatment of biliary tract cancer",
    "eu_designation_number": "EU/3/21/2458",
    "status": "Positive",
    "first_published_date": "12/11/2021",
    "last_updated_date": "25/04/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2458"
  },
  {
    "medicine_name": "Sephience",
    "related_ema_product_number": "EMEA/H/C/006331",
    "active_substance": "(S)-2-amino-6-(2-hydroxypropanoyl)-7,8-dihydropteridin-4(3H)-one",
    "date_of_designation_or_refusal": "20/05/2021",
    "intended_use": "Treatment of hyperphenylalaninemia",
    "eu_designation_number": "EU/3/21/2435",
    "status": "Positive",
    "first_published_date": "18/03/2022",
    "last_updated_date": "25/04/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2435"
  },
  {
    "medicine_name": "Alyftrek",
    "related_ema_product_number": "EMEA/H/C/006382",
    "active_substance": "(14S)-8-[3-(2-{dispiro[2.0.24.13]heptan-7-yl}ethoxy)-1H-pyrazol-1-yl]-12,12-dimethyl-2lamba6-thia-3,9,11,18,23-penta-azatetracyclo[17.3.1.111,14.05,10]tetracosa-1(22),5,7,9,19(23),20-hexaene-2,2,4-trione calcium salt hydrate, deutivacaftor, tezacaftor",
    "date_of_designation_or_refusal": "12/11/2021",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/21/2527",
    "status": "Positive",
    "first_published_date": "07/06/2022",
    "last_updated_date": "25/04/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2527"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "expanded human allogeneic mesenchymal adult stem cells extracted from adipose tissue (darvadstrocel)",
    "date_of_designation_or_refusal": "08/10/2009",
    "intended_use": "Treatment of anal fistula",
    "eu_designation_number": "EU/3/09/667",
    "status": "Withdrawn",
    "first_published_date": "20/10/2009",
    "last_updated_date": "24/04/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-667"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "aglatimagene besadenovec",
    "date_of_designation_or_refusal": "11/10/2022",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/22/2699",
    "status": "Positive",
    "first_published_date": "24/01/2023",
    "last_updated_date": "09/04/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2699"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "imetelstat sodium",
    "date_of_designation_or_refusal": "27/07/2020",
    "intended_use": "Treatment of myelodysplastic syndromes",
    "eu_designation_number": "EU/3/20/2305",
    "status": "Positive",
    "first_published_date": "19/11/2020",
    "last_updated_date": "09/04/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2305"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "unesbulin",
    "date_of_designation_or_refusal": "10/12/2021",
    "intended_use": "Treatment of soft tissue sarcoma",
    "eu_designation_number": "EU/3/21/2550",
    "status": "Withdrawn",
    "first_published_date": "03/05/2022",
    "last_updated_date": "09/04/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2550"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Lactobacillus plantarum",
    "date_of_designation_or_refusal": "16/12/2019",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/19/2232",
    "status": "Withdrawn",
    "first_published_date": "25/02/2020",
    "last_updated_date": "09/04/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2232"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "alrefimotide acetate;riletamotide acetate;tapderimotide acetate",
    "date_of_designation_or_refusal": "21/03/2024",
    "intended_use": "Treatment of mesothelioma",
    "eu_designation_number": "EU/3/24/2902",
    "status": "Withdrawn",
    "first_published_date": "23/07/2024",
    "last_updated_date": "09/04/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2902"
  },
  {
    "medicine_name": "Columvi",
    "related_ema_product_number": "EMEA/H/C/005751",
    "active_substance": "Glofitamab",
    "date_of_designation_or_refusal": "15/10/2021",
    "intended_use": "Treatment of diffuse large B-cell lymphoma",
    "eu_designation_number": "EU/3/21/2497",
    "status": "Withdrawn",
    "first_published_date": "20/01/2022",
    "last_updated_date": "09/04/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2497"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "single guide RNA containing a sequence complementary to human ALB locus gene, intron 1, target region, Ziclumeran",
    "date_of_designation_or_refusal": "25/03/2025",
    "intended_use": "Treatment of haemophilia B",
    "eu_designation_number": "EU/3/25/3039",
    "status": "Positive",
    "first_published_date": "07/04/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3039"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "povetacicept",
    "date_of_designation_or_refusal": "25/03/2025",
    "intended_use": "Treatment of primary IgA nephropathy",
    "eu_designation_number": "EU/3/25/3043",
    "status": "Positive",
    "first_published_date": "07/04/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3043"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "extract from Cannabis flower, containing high levels of cannabidiolic acid and",
    "date_of_designation_or_refusal": "25/03/2025",
    "intended_use": "Treatment of Rett syndrome",
    "eu_designation_number": "EU/3/25/3042",
    "status": "Positive",
    "first_published_date": "07/04/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3042"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allopurinol",
    "date_of_designation_or_refusal": "25/03/2025",
    "intended_use": "Treatment of Marfan syndrome",
    "eu_designation_number": "EU/3/25/3041",
    "status": "Positive",
    "first_published_date": "07/04/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3041"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus vector serotype 8 containing the human F9 gene",
    "date_of_designation_or_refusal": "25/03/2025",
    "intended_use": "Treatment of haemophilia B",
    "eu_designation_number": "EU/3/25/3038",
    "status": "Positive",
    "first_published_date": "07/04/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3038"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "bexmarilimab",
    "date_of_designation_or_refusal": "25/03/2025",
    "intended_use": "Treatment of myelodysplastic syndromes",
    "eu_designation_number": "EU/3/25/3044",
    "status": "Positive",
    "first_published_date": "04/04/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3044"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ixodes ricinus contact phase inhibitor",
    "date_of_designation_or_refusal": "25/03/2025",
    "intended_use": "Treatment of non-traumatic spontaneous intracerebral haemorrhage",
    "eu_designation_number": "EU/3/25/3037",
    "status": "Positive",
    "first_published_date": "04/04/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3037"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous T lymphocyte-enriched population of cells transduced with a lentiviral vector encoding a chimeric antigen receptor targeting human B cell maturation antigen with 4-1BB and CD3-zeta intracellular signalling domains",
    "date_of_designation_or_refusal": "04/06/2020",
    "intended_use": "Treatment of multiple myeloma",
    "eu_designation_number": "EU/3/20/2277",
    "status": "Withdrawn",
    "first_published_date": "19/08/2020",
    "last_updated_date": "04/04/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2277"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Felzartamab",
    "date_of_designation_or_refusal": "13/12/2024",
    "intended_use": "Treatment of in solid organ transplantation",
    "eu_designation_number": "EU/3/24/3002",
    "status": "Positive",
    "first_published_date": "13/01/2025",
    "last_updated_date": "04/04/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3002"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "deucrictibant monohydrate",
    "date_of_designation_or_refusal": "25/03/2025",
    "intended_use": "Treatment of bradykinin-mediated angioedema",
    "eu_designation_number": "EU/3/25/3040",
    "status": "Positive",
    "first_published_date": "04/04/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3040"
  },
  {
    "medicine_name": "Duvyzat",
    "related_ema_product_number": "EMEA/H/C/006079",
    "active_substance": "Givinostat",
    "date_of_designation_or_refusal": "04/07/2012",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/12/1009",
    "status": "Positive",
    "first_published_date": "24/07/2012",
    "last_updated_date": "28/03/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1009"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "octreotide acetate",
    "date_of_designation_or_refusal": "05/08/2013",
    "intended_use": "Treatment of acromegaly",
    "eu_designation_number": "EU/3/13/1170",
    "status": "Withdrawn",
    "first_published_date": "12/09/2013",
    "last_updated_date": "21/03/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1170"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "trehalose",
    "date_of_designation_or_refusal": "19/10/2020",
    "intended_use": "Treatment of neuronal ceroid lipofuscinosis",
    "eu_designation_number": "EU/3/20/2347",
    "status": "Withdrawn",
    "first_published_date": "16/02/2021",
    "last_updated_date": "12/03/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2347"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised IgG4 monoclonal antibody against C1q",
    "date_of_designation_or_refusal": "10/02/2025",
    "intended_use": "Treatment of Guillain-Barré syndrome",
    "eu_designation_number": "EU/3/23/2836",
    "status": "Positive",
    "first_published_date": "24/01/2024",
    "last_updated_date": "12/03/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2836"
  },
  {
    "medicine_name": "Enjaymo",
    "related_ema_product_number": "EMEA/H/C/005776",
    "active_substance": "sutimlimab",
    "date_of_designation_or_refusal": "11/02/2025",
    "intended_use": "Treatment of autoimmune haemolytic anaemia",
    "eu_designation_number": "EU/3/16/1609",
    "status": "Positive",
    "first_published_date": "06/04/2016",
    "last_updated_date": "12/03/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1609"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "upifitamab rilsodotin",
    "date_of_designation_or_refusal": "09/12/2022",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/22/2723",
    "status": "Withdrawn",
    "first_published_date": "13/03/2023",
    "last_updated_date": "12/03/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2723"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pelabresib monohydrate",
    "date_of_designation_or_refusal": "17/02/2025",
    "intended_use": "Treatment of myelofibrosis",
    "eu_designation_number": "EU/3/20/2247",
    "status": "Positive",
    "first_published_date": "05/05/2020",
    "last_updated_date": "12/03/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2247"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Adeno-associated viral vector serotype rh10 containing the human cholesterol 24-hydroxylase gene",
    "date_of_designation_or_refusal": "01/04/2019",
    "intended_use": "Treatment of Huntington’s disease",
    "eu_designation_number": "EU/3/19/2149",
    "status": "Withdrawn",
    "first_published_date": "07/05/2019",
    "last_updated_date": "12/03/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2149"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ornithine phenylacetate",
    "date_of_designation_or_refusal": "20/02/2025",
    "intended_use": "Treatment of acute liver failure",
    "eu_designation_number": "EU/3/11/945",
    "status": "Positive",
    "first_published_date": "01/02/2012",
    "last_updated_date": "12/03/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-945"
  },
  {
    "medicine_name": "Hetronifly",
    "related_ema_product_number": "EMEA/H/C/006170",
    "active_substance": "serplulimab",
    "date_of_designation_or_refusal": "20/02/2025",
    "intended_use": "Treatment of small cell lung cancer",
    "eu_designation_number": "EU/3/22/2731",
    "status": "Positive",
    "first_published_date": "13/03/2023",
    "last_updated_date": "12/03/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2731"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19",
    "date_of_designation_or_refusal": "20/02/2025",
    "intended_use": "Treatment of myasthenia gravis",
    "eu_designation_number": "EU/3/24/3011",
    "status": "Positive",
    "first_published_date": "13/01/2025",
    "last_updated_date": "12/03/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3011"
  },
  {
    "medicine_name": "Lyvdelzi (previously Seladelpar Gilead)",
    "related_ema_product_number": "EMEA/H/C/004692",
    "active_substance": "seladelpar",
    "date_of_designation_or_refusal": "20/02/2025",
    "intended_use": "Treatment of primary biliary cholangitis",
    "eu_designation_number": "EU/3/17/1930",
    "status": "Positive",
    "first_published_date": "10/01/2018",
    "last_updated_date": "12/03/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1930"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Magrolimab",
    "date_of_designation_or_refusal": "26/06/2020",
    "intended_use": "Treatment of myelodysplastic syndromes",
    "eu_designation_number": "EU/3/20/2288",
    "status": "Withdrawn",
    "first_published_date": "22/09/2020",
    "last_updated_date": "12/03/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2288"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Magrolimab",
    "date_of_designation_or_refusal": "11/11/2015",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/15/1582",
    "status": "Withdrawn",
    "first_published_date": "06/01/2016",
    "last_updated_date": "12/03/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1582"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tafasitamab",
    "date_of_designation_or_refusal": "26/02/2025",
    "intended_use": "Treatment of follicular lymphoma",
    "eu_designation_number": "EU/3/25/3027",
    "status": "Positive",
    "first_published_date": "11/03/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3027"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "rimeporide",
    "date_of_designation_or_refusal": "26/02/2025",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/15/1478",
    "status": "Positive",
    "first_published_date": "21/05/2015",
    "last_updated_date": "11/03/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1478"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "hydroxocobalamin acetate",
    "date_of_designation_or_refusal": "26/02/2025",
    "intended_use": "Treatment of homocystinuria and/or methylmalonic acidaemia due to genetic defects of intracellular cobalamin processing",
    "eu_designation_number": "EU/3/25/3030",
    "status": "Positive",
    "first_published_date": "11/03/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3030"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "venetoclax",
    "date_of_designation_or_refusal": "12/12/2017",
    "intended_use": "Treatment of mantle cell lymphoma",
    "eu_designation_number": "EU/3/17/1954",
    "status": "Withdrawn",
    "first_published_date": "23/01/2018",
    "last_updated_date": "11/03/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1954"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus serotype rh.10 containing the human PKP2 gene",
    "date_of_designation_or_refusal": "26/02/2025",
    "intended_use": "Treatment of arrhythmogenic cardiomyopathy caused by pathogenic mutations in the PKP2 gene",
    "eu_designation_number": "EU/3/25/3033",
    "status": "Positive",
    "first_published_date": "11/03/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3033"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(R)-(3-(2'-cyclopropyl-3-(hydroxymethyl)-[1,1'-biphenyl]-4-yl)pyrrolidin-1-yl)(5-hydroxy-6-methylpyridin-2-yl)methanone",
    "date_of_designation_or_refusal": "26/02/2025",
    "intended_use": "Treatment of Olmsted syndrome",
    "eu_designation_number": "EU/3/25/3032",
    "status": "Positive",
    "first_published_date": "11/03/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3032"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "venetoclax",
    "date_of_designation_or_refusal": "14/10/2016",
    "intended_use": "Treatment of diffuse large B-cell lymphoma",
    "eu_designation_number": "EU/3/16/1766",
    "status": "Withdrawn",
    "first_published_date": "15/11/2016",
    "last_updated_date": "11/03/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1766"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "",
    "date_of_designation_or_refusal": "26/02/2025",
    "intended_use": "Treatment of  X-linked hypohidrotic ectodermal dysplasia (Christ-Siemens-Touraine Syndrome)",
    "eu_designation_number": "EU/3/05/334",
    "status": "Positive",
    "first_published_date": "04/12/2007",
    "last_updated_date": "11/03/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-334"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "paltusotine",
    "date_of_designation_or_refusal": "26/02/2025",
    "intended_use": "Treatment of acromegaly",
    "eu_designation_number": "EU/3/25/3035",
    "status": "Positive",
    "first_published_date": "11/03/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3035"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus vector serotype SNY001 containing the human PAH gene",
    "date_of_designation_or_refusal": "26/02/2025",
    "intended_use": "Treatment of hyperphenylalaninaemia",
    "eu_designation_number": "EU/3/25/3026",
    "status": "Positive",
    "first_published_date": "11/03/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3026"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "volixibat potassium",
    "date_of_designation_or_refusal": "26/02/2025",
    "intended_use": "Treatment of primary sclerosing cholangitis",
    "eu_designation_number": "EU/3/25/3029",
    "status": "Positive",
    "first_published_date": "11/03/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3029"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "epertinib",
    "date_of_designation_or_refusal": "26/02/2025",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/25/3028",
    "status": "Positive",
    "first_published_date": "11/03/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3028"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous CD34+ cell enriched population containing haematopoietic stem and progenitor cells transduced ex vivo with a lentiviral vector encoding the human ADA2 gene",
    "date_of_designation_or_refusal": "27/02/2025",
    "intended_use": "Treatment of adenosine deaminase 2 deficiency (DADA2)",
    "eu_designation_number": "EU/3/25/3034",
    "status": "Positive",
    "first_published_date": "11/03/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3034"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus sector serotype rh74 containing the human SGCG gene",
    "date_of_designation_or_refusal": "27/02/2025",
    "intended_use": "Treatment of limb-girdle muscular dystrophy",
    "eu_designation_number": "EU/3/25/3031",
    "status": "Positive",
    "first_published_date": "11/03/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3031"
  },
  {
    "medicine_name": "Holoclar",
    "related_ema_product_number": "EMEA/H/C/002450",
    "active_substance": "ex-vivo-expanded autologous human corneal epithelium-containing stem cells",
    "date_of_designation_or_refusal": "07/11/2008",
    "intended_use": "Corneal lesions, with associated corneal (limbal) stem cell deficiency, due to ocular burns",
    "eu_designation_number": "EU/3/08/579",
    "status": "Positive",
    "first_published_date": "24/04/2009",
    "last_updated_date": "07/03/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-579"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus serotype 9 containing the human RPE65 gene",
    "date_of_designation_or_refusal": "16/01/2025",
    "intended_use": "inherited retinal dystrophy due to defects in the RPE65 gene",
    "eu_designation_number": "EU/3/24/3020",
    "status": "Positive",
    "first_published_date": "24/02/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3020"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-(4-(4-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-7-methyl-7H-pyrrolo[2,3-d] pyrimidin-6-yl)phenyl)methacrylamide hydrochloride",
    "date_of_designation_or_refusal": "10/11/2022",
    "intended_use": "Treatment of biliary tract cancer",
    "eu_designation_number": "EU/3/22/2721",
    "status": "Positive",
    "first_published_date": "23/01/2023",
    "last_updated_date": "24/02/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2721"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "arsenic trioxide",
    "date_of_designation_or_refusal": "13/12/2024",
    "intended_use": "Treatment of acute promyelocytic leukaemia",
    "eu_designation_number": "EU/3/24/3014",
    "status": "Positive",
    "first_published_date": "14/01/2025",
    "last_updated_date": "24/02/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3014"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human anti-promyostatin monoclonal antibody (apitegromab)",
    "date_of_designation_or_refusal": "14/12/2018",
    "intended_use": "Treatment of spinal muscular atrophy",
    "eu_designation_number": "EU/3/18/2115",
    "status": "Positive",
    "first_published_date": "07/03/2019",
    "last_updated_date": "24/02/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2115"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Lomitapide",
    "date_of_designation_or_refusal": "17/12/2010",
    "intended_use": "Treatment of familial chylomicronaemia",
    "eu_designation_number": "EU/3/10/823",
    "status": "Positive",
    "first_published_date": "20/01/2011",
    "last_updated_date": "24/02/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-823"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "synthetic double-stranded siRNA oligonucleotide directed against apolipoprotein C-III mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues",
    "date_of_designation_or_refusal": "19/07/2021",
    "intended_use": "Treatment of familial chylomicronaemia syndrome",
    "eu_designation_number": "EU/3/21/2459",
    "status": "Positive",
    "first_published_date": "12/11/2021",
    "last_updated_date": "24/02/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2459"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "rilzabrutinib",
    "date_of_designation_or_refusal": "16/01/2025",
    "intended_use": "Treatment of autoimmune haemolytic anaemia",
    "eu_designation_number": "EU/3/24/3019",
    "status": "Positive",
    "first_published_date": "20/02/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3019"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "clofutriben",
    "date_of_designation_or_refusal": "16/01/2025",
    "intended_use": "Treatment of Cushing's syndrome of endogenous origin",
    "eu_designation_number": "EU/3/24/3024",
    "status": "Positive",
    "first_published_date": "20/02/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3024"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "xevinapant",
    "date_of_designation_or_refusal": "11/11/2015",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/15/1576",
    "status": "Withdrawn",
    "first_published_date": "06/01/2016",
    "last_updated_date": "20/02/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1576"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus serotype 5 vector encoding C1-esterase inhibitor",
    "date_of_designation_or_refusal": "10/11/2022",
    "intended_use": "Treatment of hereditary angioedema",
    "eu_designation_number": "EU/3/22/2722",
    "status": "Withdrawn",
    "first_published_date": "23/01/2023",
    "last_updated_date": "20/02/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2722"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous CD34+ cells transfected with lentiviral vector containing the Wiskott-Aldrich syndrome protein gene (etuvetidigene autotemcel)",
    "date_of_designation_or_refusal": "07/10/2013",
    "intended_use": "Treatment of Wiskott-Aldrich syndrome",
    "eu_designation_number": "EU/3/13/1196",
    "status": "Withdrawn",
    "first_published_date": "31/10/2013",
    "last_updated_date": "20/02/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1196"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "amitriptyline",
    "date_of_designation_or_refusal": "21/06/2022",
    "intended_use": "Treatment of erythromelalgia",
    "eu_designation_number": "EU/3/22/2626",
    "status": "Withdrawn",
    "first_published_date": "15/09/2022",
    "last_updated_date": "20/02/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2626"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 9 containing the human iduronate-2-sulfatase gene",
    "date_of_designation_or_refusal": "10/08/2015",
    "intended_use": "Treatment of mucopolysaccharidosis type II (Hunter's syndrome)",
    "eu_designation_number": "EU/3/15/1540",
    "status": "Withdrawn",
    "first_published_date": "10/08/2015",
    "last_updated_date": "20/02/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1540"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 9 containing the human N-acetylglucosaminidase-alpha gene",
    "date_of_designation_or_refusal": "24/01/2013",
    "intended_use": "Treatment of mucopolysaccharidosis type IIIB (Sanfilippo B syndrome)",
    "eu_designation_number": "EU/3/12/1095",
    "status": "Withdrawn",
    "first_published_date": "01/03/2013",
    "last_updated_date": "20/02/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1095"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous CD34+ cells transduced with a lentiviral vector containing the human RAG1 gene",
    "date_of_designation_or_refusal": "26/03/2014",
    "intended_use": "Treatment of recombination-activating gene 1 deficient severe combined immunodeficiency",
    "eu_designation_number": "EU/3/14/1257",
    "status": "Positive",
    "first_published_date": "07/05/2014",
    "last_updated_date": "20/02/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1257"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "zopapogene imadenovec",
    "date_of_designation_or_refusal": "12/01/2024",
    "intended_use": "Treatment of recurrent respiratory papillomatosis",
    "eu_designation_number": "EU/3/23/2887",
    "status": "Positive",
    "first_published_date": "11/04/2024",
    "last_updated_date": "20/02/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2887"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-(2-Methoxyethyl)-6-methyl-N-[(3-methyl-2-thienyl)methyl]-2-oxo-1,2-dihydropyridine-4-carboxamide",
    "date_of_designation_or_refusal": "16/01/2025",
    "intended_use": "Treatment of glycogen storage disease type IV",
    "eu_designation_number": "EU/3/24/3023",
    "status": "Positive",
    "first_published_date": "20/02/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3023"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "volixibat potassium",
    "date_of_designation_or_refusal": "16/01/2025",
    "intended_use": "Treatment of primary biliary cholangitis",
    "eu_designation_number": "EU/3/24/3017",
    "status": "Positive",
    "first_published_date": "20/02/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3017"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogenic umbilical cord-derived osteoblast cells",
    "date_of_designation_or_refusal": "16/01/2025",
    "intended_use": "Treatment of non-traumatic osteonecrosis",
    "eu_designation_number": "EU/3/24/3022",
    "status": "Positive",
    "first_published_date": "20/02/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3022"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Elraglusib",
    "date_of_designation_or_refusal": "16/01/2025",
    "intended_use": "Treatment of soft tissue sarcoma",
    "eu_designation_number": "EU/3/24/3016",
    "status": "Positive",
    "first_published_date": "20/02/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3016"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "[4-(Methyl-1H-pyrazol-4-yl)-benzyl]-(6[7-(3-pyrrolidin-1-yl-propoxy)-imidazo[1,2-a]pyridin-3-yl]-pyrimidin-4-yl]-amine",
    "date_of_designation_or_refusal": "16/01/2025",
    "intended_use": "Treatment of gastrointestinal stromal tumours",
    "eu_designation_number": "EU/3/24/3025",
    "status": "Positive",
    "first_published_date": "20/02/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3025"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Elraglusib",
    "date_of_designation_or_refusal": "16/01/2025",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/24/3015",
    "status": "Positive",
    "first_published_date": "20/02/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3015"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "alvelestat",
    "date_of_designation_or_refusal": "16/01/2025",
    "intended_use": "Treatment of congenital alpha-1 antitrypsin deficiency",
    "eu_designation_number": "EU/3/24/3018",
    "status": "Positive",
    "first_published_date": "20/02/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3018"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "camostat mesilate",
    "date_of_designation_or_refusal": "16/01/2025",
    "intended_use": "Treatment of chronic pancreatitis",
    "eu_designation_number": "EU/3/24/3021",
    "status": "Positive",
    "first_published_date": "20/02/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3021"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Colistimethate sodium",
    "date_of_designation_or_refusal": "13/12/2024",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/24/2997",
    "status": "Positive",
    "first_published_date": "15/01/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2997"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tobevibart",
    "date_of_designation_or_refusal": "13/12/2024",
    "intended_use": "Treatment of hepatitis delta virus infection",
    "eu_designation_number": "EU/3/24/3012",
    "status": "Positive",
    "first_published_date": "15/01/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3012"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "mitapivat sulfate",
    "date_of_designation_or_refusal": "13/12/2024",
    "intended_use": "Treatment of sickle cell disease",
    "eu_designation_number": "EU/3/24/2999",
    "status": "Positive",
    "first_published_date": "15/01/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2999"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "4-{[(2R,3S,4R,5S)-4-(4-chloro-2-fluoro-phenyl)-3-(3-chloro-2-fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)-pyrrolidine-2-carbonyl]-amino}-3-methoxy-benzoic acid ",
    "date_of_designation_or_refusal": "22/08/2014",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/14/1328",
    "status": "Withdrawn",
    "first_published_date": "02/10/2014",
    "last_updated_date": "15/01/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1328"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Losmapimod",
    "date_of_designation_or_refusal": "24/03/2020",
    "intended_use": "treatment of facioscapulohumeral muscular dystrophy",
    "eu_designation_number": "EU/3/20/2263",
    "status": "Withdrawn",
    "first_published_date": "12/08/2020",
    "last_updated_date": "15/01/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2263"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "3-(3-(3,5-Dimethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid",
    "date_of_designation_or_refusal": "19/11/2018",
    "intended_use": "Treatment of ATTR amyloidosis",
    "eu_designation_number": "EU/3/18/2081",
    "status": "Withdrawn",
    "first_published_date": "19/02/2019",
    "last_updated_date": "15/01/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2081"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "",
    "date_of_designation_or_refusal": "15/02/2023",
    "intended_use": "Treatment of Huntington's disease",
    "eu_designation_number": "EU/3/23/2754",
    "status": "Withdrawn",
    "first_published_date": "24/01/2024",
    "last_updated_date": "15/01/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2754"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "isotretinoin",
    "date_of_designation_or_refusal": "11/10/2022",
    "intended_use": "Treatment of autosomal recessive congenital ichthyosis",
    "eu_designation_number": "EU/3/22/2701",
    "status": "Withdrawn",
    "first_published_date": "24/01/2023",
    "last_updated_date": "15/01/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2701"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "isotretinoin",
    "date_of_designation_or_refusal": "15/02/2023",
    "intended_use": "Treatment of recessive X-linked ichthyosis",
    "eu_designation_number": "EU/3/23/2760",
    "status": "Withdrawn",
    "first_published_date": "24/01/2024",
    "last_updated_date": "15/01/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2760"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "omigapil maleate",
    "date_of_designation_or_refusal": "08/05/2008",
    "intended_use": "Treatment of congenital muscular dystrophy with merosin (laminin alpha 2) deficiency",
    "eu_designation_number": "EU/3/08/544",
    "status": "Withdrawn",
    "first_published_date": "29/07/2008",
    "last_updated_date": "15/01/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-544"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "omigapil maleate",
    "date_of_designation_or_refusal": "08/05/2008",
    "intended_use": "Treatment of congenital muscular dystrophy with collagen VI deficiency",
    "eu_designation_number": "EU/3/08/540",
    "status": "Withdrawn",
    "first_published_date": "29/07/2008",
    "last_updated_date": "15/01/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-540"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "propagermanium",
    "date_of_designation_or_refusal": "19/11/2018",
    "intended_use": "Treatment of focal segmental glomerulosclerosis",
    "eu_designation_number": "EU/3/18/2100",
    "status": "Withdrawn",
    "first_published_date": "19/02/2019",
    "last_updated_date": "15/01/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2100"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2'-O-4'-C-(S)-ethyl-P-thioadenylyl-(3'-O->5'-O)-2'-O-4'-C-(S)-ethyl-P-thioguanylyl-(3'-O->5'-O)-2'-O-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-fluoro-P-thioadenylyl-(3'-O->5'-O)-2'-fluoro-P-thiocytidylyl-(3'-O->5'-O)-2'-fluoro-P-thiouridylyl-(3'-O->5'-O)-2'-O-methyl-P-thiouridylyl-(3'-O->5'-O)-2'-O-4'-C-(S)-ethyl-P-thiouridylyl-(3'-O->5'-O)-2'-O-4'-C-(S)-ethyl-adenosine",
    "date_of_designation_or_refusal": "13/12/2024",
    "intended_use": "Treatment of autosomal dominant polycystic kidney disease",
    "eu_designation_number": "EU/3/24/3009",
    "status": "Positive",
    "first_published_date": "15/01/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3009"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "monepantel",
    "date_of_designation_or_refusal": "13/12/2024",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/24/3004",
    "status": "Positive",
    "first_published_date": "15/01/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3004"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic cardiosphere-derived cells",
    "date_of_designation_or_refusal": "13/12/2024",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/24/3003",
    "status": "Positive",
    "first_published_date": "15/01/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3003"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "diazoxide choline",
    "date_of_designation_or_refusal": "13/12/2024",
    "intended_use": "Treatment of glycogen storage disease type I",
    "eu_designation_number": "EU/3/24/3008",
    "status": "Positive",
    "first_published_date": "15/01/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3008-0"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "4-(4-(2-(Diethylamino)ethoxy)phenyl)-1-(4-methoxybenzyl)-1H-1,2,3-triazol-5-amine",
    "date_of_designation_or_refusal": "13/12/2024",
    "intended_use": "Treatment of neurofibromatosis type 2",
    "eu_designation_number": "EU/3/24/3005",
    "status": "Positive",
    "first_published_date": "15/01/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3005"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "divesiran",
    "date_of_designation_or_refusal": "13/12/2024",
    "intended_use": "Treatment of polycythaemia vera",
    "eu_designation_number": "EU/3/24/2996",
    "status": "Positive",
    "first_published_date": "15/01/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2996"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Davunetide",
    "date_of_designation_or_refusal": "13/12/2024",
    "intended_use": "Treatment of activity-dependent neuroprotective protein (ADNP) syndrome",
    "eu_designation_number": "EU/3/24/3007",
    "status": "Positive",
    "first_published_date": "13/01/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3007"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "roginolisib",
    "date_of_designation_or_refusal": "13/12/2024",
    "intended_use": "Treatment of uveal melanoma",
    "eu_designation_number": "EU/3/24/3000",
    "status": "Positive",
    "first_published_date": "13/01/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3000"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "vosoritide",
    "date_of_designation_or_refusal": "13/12/2024",
    "intended_use": "Treatment of hypochondroplasia",
    "eu_designation_number": "EU/3/24/2998",
    "status": "Positive",
    "first_published_date": "13/01/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2998"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "votoplam",
    "date_of_designation_or_refusal": "13/12/2024",
    "intended_use": "Treatment of Huntington's disease",
    "eu_designation_number": "EU/3/24/3001",
    "status": "Positive",
    "first_published_date": "13/01/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3001"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "mRNA encoding Cas9-deaminase, single guide RNA against the human TGM1 gene",
    "date_of_designation_or_refusal": "13/12/2024",
    "intended_use": "Treatment of autosomal recessive congenital ichthyosis",
    "eu_designation_number": "EU/3/24/3013",
    "status": "Positive",
    "first_published_date": "13/01/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3013"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "elebsiran",
    "date_of_designation_or_refusal": "13/12/2024",
    "intended_use": "Treatment of hepatitis delta virus infection",
    "eu_designation_number": "EU/3/24/3010",
    "status": "Positive",
    "first_published_date": "13/01/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3010"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus serotype 5 containing the human RORA gene",
    "date_of_designation_or_refusal": "13/12/2024",
    "intended_use": "Treatment of inherited retinal dystrophies due to dysfunction in the ABCA4 gene",
    "eu_designation_number": "EU/3/24/3006",
    "status": "Positive",
    "first_published_date": "13/01/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3006"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "diazoxide choline",
    "date_of_designation_or_refusal": "13/12/2024",
    "intended_use": "Treatment of glycogen storage disease type I",
    "eu_designation_number": "EU/3/24/3008",
    "status": "Positive",
    "first_published_date": "13/01/2025",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-3008"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "[Nle4, D-Phe7]-alfa-melanocyte stimulating hormone (afamelanotide)",
    "date_of_designation_or_refusal": "08/05/2008",
    "intended_use": "Treatment of erythropoietic protoporphyria",
    "eu_designation_number": "EU/3/08/541",
    "status": "Expired",
    "first_published_date": "17/09/2009",
    "last_updated_date": "09/01/2025",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-541"
  },
  {
    "medicine_name": "Emcitate",
    "related_ema_product_number": "EMEA/H/C/005220",
    "active_substance": "tiratricol",
    "date_of_designation_or_refusal": "12/10/2017",
    "intended_use": "Treatment of Allan-Herndon-Dudley syndrome",
    "eu_designation_number": "EU/3/17/1945",
    "status": "Positive",
    "first_published_date": "15/01/2018",
    "last_updated_date": "13/12/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1945"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "garadacimab",
    "date_of_designation_or_refusal": "10/12/2021",
    "intended_use": "Treatment of hereditary angioedema",
    "eu_designation_number": "EU/3/21/2532",
    "status": "Positive",
    "first_published_date": "13/04/2022",
    "last_updated_date": "13/12/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2532"
  },
  {
    "medicine_name": "Wainzua",
    "related_ema_product_number": "EMEA/H/C/006295",
    "active_substance": "eplontersen",
    "date_of_designation_or_refusal": "13/10/2023",
    "intended_use": "Treatment of transthyretin-mediated amyloidosis",
    "eu_designation_number": "EU/3/23/2828",
    "status": "Withdrawn",
    "first_published_date": "24/01/2024",
    "last_updated_date": "03/12/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2828"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human monoclonal IgG1 antibody against tissue factor pathway inhibitor",
    "date_of_designation_or_refusal": "14/10/2016",
    "intended_use": "Treatment of haemophilia A",
    "eu_designation_number": "EU/3/16/1752",
    "status": "Withdrawn",
    "first_published_date": "14/11/2016",
    "last_updated_date": "03/12/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1752"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pasireotide",
    "date_of_designation_or_refusal": "08/10/2009",
    "intended_use": "Treatment of acromegaly",
    "eu_designation_number": "EU/3/09/670",
    "status": "Expired",
    "first_published_date": "20/10/2009",
    "last_updated_date": "28/11/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-670"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Ketoconazole",
    "date_of_designation_or_refusal": "23/04/2012",
    "intended_use": "Treatment of Cushing's syndrome",
    "eu_designation_number": "EU/3/12/965",
    "status": "Expired",
    "first_published_date": "03/05/2012",
    "last_updated_date": "28/11/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-965"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "avenciguat",
    "date_of_designation_or_refusal": "11/11/2024",
    "intended_use": "Treatment of systemic sclerosis",
    "eu_designation_number": "EU/3/24/2989",
    "status": "Positive",
    "first_published_date": "21/11/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2989"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Curcumin E100, Resveratrol",
    "date_of_designation_or_refusal": "11/11/2024",
    "intended_use": "Treatment of Dercum disease",
    "eu_designation_number": "EU/3/24/2995",
    "status": "Positive",
    "first_published_date": "21/11/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2995"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "4-[[(4-Methoxyphenyl)thio]methyl]-N,N-dimethyl-1H-1,2,3-triazole-1-ethanamine",
    "date_of_designation_or_refusal": "11/11/2024",
    "intended_use": "Treatment of non-syndromic inherited retinal dystrophies with a rod-dominant phenotype",
    "eu_designation_number": "EU/3/24/2993",
    "status": "Positive",
    "first_published_date": "21/11/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2993"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "3-chloro-4-fluorophenyl-(4-fluoro-4-(((5-methylpyrimidin-2-ylmethyl)amino)methyl)piperidin-1yl)methanone",
    "date_of_designation_or_refusal": "11/11/2024",
    "intended_use": "Treatment of fragile X syndrome",
    "eu_designation_number": "EU/3/24/2992",
    "status": "Positive",
    "first_published_date": "21/11/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2992"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "H-L-Tryptophanyl-L-seryl-glycyl-L-tryptophanyl-L-seryl-L-seryl-L-cysteinyl-L-seryl-L-arginyl-L-seryl-L-cysteinyl-glycyl-OH (disulfide bond), acetate salt",
    "date_of_designation_or_refusal": "10/11/2024",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/24/2986",
    "status": "Positive",
    "first_published_date": "20/11/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2986"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "navenibart",
    "date_of_designation_or_refusal": "10/11/2024",
    "intended_use": "Treatment of hereditary angioedema",
    "eu_designation_number": "EU/3/24/2979",
    "status": "Positive",
    "first_published_date": "20/11/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2979"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "genetically modified human adenovirus encoding human PH20 hyaluronidase",
    "date_of_designation_or_refusal": "10/11/2024",
    "intended_use": "Treatment of retinoblastoma",
    "eu_designation_number": "EU/3/24/2982",
    "status": "Positive",
    "first_published_date": "20/11/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2982"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium selenate",
    "date_of_designation_or_refusal": "10/11/2024",
    "intended_use": "Treatment of frontotemporal dementia",
    "eu_designation_number": "EU/3/24/2981",
    "status": "Positive",
    "first_published_date": "20/11/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2981"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Ivosidenib",
    "date_of_designation_or_refusal": "10/11/2024",
    "intended_use": "Treatment of chondrosarcoma",
    "eu_designation_number": "EU/3/24/2978",
    "status": "Positive",
    "first_published_date": "20/11/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2978"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "atacicept",
    "date_of_designation_or_refusal": "10/11/2024",
    "intended_use": "Treatment of primary IgA nephropathy",
    "eu_designation_number": "EU/3/24/2985",
    "status": "Positive",
    "first_published_date": "20/11/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2985"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "3-(5-(2-Hydroxy-2-methylpropoxy)-6-methylpyrazin-2-yl)-1H-indole-7-carbonitrile",
    "date_of_designation_or_refusal": "10/11/2024",
    "intended_use": "Treatment of X-linked spinal and bulbar muscular atrophy (Kennedy's disease)",
    "eu_designation_number": "EU/3/24/2987",
    "status": "Positive",
    "first_published_date": "20/11/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2987"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "4,9-Dimethyl-6-(4'-aminophenyl)-2H-furo[2,3-h]-1-benzopyran-2-one",
    "date_of_designation_or_refusal": "10/11/2024",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/24/2976",
    "status": "Positive",
    "first_published_date": "20/11/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2976"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Interleukin-12, human, recombinant",
    "date_of_designation_or_refusal": "10/11/2024",
    "intended_use": "Treatment of cutaneous T-cell lymphoma",
    "eu_designation_number": "EU/3/24/2983",
    "status": "Positive",
    "first_published_date": "20/11/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2983"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "A combination of H-Lys-Lys-Gly-Pro-Arg-Cys(SH)-Leu-Thr-Arg-Tyr-Tyr-Ser-Ser-Phe-Val-Asn-Met-Glu-Gly-Lys-Lys-OH and H-Lys-Lys-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Lys-Lys-OH",
    "date_of_designation_or_refusal": "19/11/2014",
    "intended_use": "Treatment of haemophilia A",
    "eu_designation_number": "EU/3/14/1360",
    "status": "Withdrawn",
    "first_published_date": "15/01/2015",
    "last_updated_date": "19/11/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1360"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "7-ethyl-10-hydroxy-camptothecin",
    "date_of_designation_or_refusal": "11/11/2024",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/24/2988",
    "status": "Positive",
    "first_published_date": "19/11/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2988"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "coramitug",
    "date_of_designation_or_refusal": "11/11/2024",
    "intended_use": "Treatment of ATTR amyloidosis",
    "eu_designation_number": "EU/3/24/2991",
    "status": "Positive",
    "first_published_date": "19/11/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2991"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Mesenchymal stem cells-derived small extracellular vesicles loaded with siRNA against phosphatase and tensin homolog",
    "date_of_designation_or_refusal": "11/11/2024",
    "intended_use": "Treatment of spinal cord injury",
    "eu_designation_number": "EU/3/24/2990",
    "status": "Positive",
    "first_published_date": "19/11/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2990"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "",
    "date_of_designation_or_refusal": "26/06/2020",
    "intended_use": "Treatment of Becker muscular dystrophy",
    "eu_designation_number": "EU/3/20/2293",
    "status": "Withdrawn",
    "first_published_date": "23/09/2020",
    "last_updated_date": "19/11/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2293"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous bone marrow derived CD34+ cells transduced ex vivo with a self-inactivating lentiviral vector containing a normal version of the coding region of the IL2RG gene",
    "date_of_designation_or_refusal": "13/11/2020",
    "intended_use": "Treatment of X-linked severe combined immunodeficiency",
    "eu_designation_number": "EU/3/20/2362",
    "status": "Withdrawn",
    "first_published_date": "15/02/2021",
    "last_updated_date": "19/11/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2362"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous mobilised peripheral blood-derived CD34+ cells transduced ex vivo with a self-inactivating lentiviral vector containing a normal version of the coding region of the IL2RG gene",
    "date_of_designation_or_refusal": "20/05/2021",
    "intended_use": "Treatment of X-linked severe combined immunodeficiency",
    "eu_designation_number": "EU/3/21/2440",
    "status": "Withdrawn",
    "first_published_date": "18/03/2022",
    "last_updated_date": "19/11/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2440"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "6-(4-(tert-butyl)phenoxy)pyridin-3-amine",
    "date_of_designation_or_refusal": "10/12/2021",
    "intended_use": "Treatment of acute lymphoblastic leukaemia",
    "eu_designation_number": "EU/3/21/2546",
    "status": "Withdrawn",
    "first_published_date": "28/04/2022",
    "last_updated_date": "19/11/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2546"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "marstacimab",
    "date_of_designation_or_refusal": "13/12/2023",
    "intended_use": "Treatment of haemophilia B",
    "eu_designation_number": "EU/3/23/2866",
    "status": "Withdrawn",
    "first_published_date": "01/02/2024",
    "last_updated_date": "19/11/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2866"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "H-Lys-Lys-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Lys-Lys-OH",
    "date_of_designation_or_refusal": "10/08/2022",
    "intended_use": "Treatment of  haemophilia A",
    "eu_designation_number": "EU/3/22/2677",
    "status": "Withdrawn",
    "first_published_date": "15/12/2022",
    "last_updated_date": "19/11/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2677"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "glecirasib",
    "date_of_designation_or_refusal": "10/11/2024",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/24/2977",
    "status": "Positive",
    "first_published_date": "19/11/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2977"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "octreotide hydrochloride",
    "date_of_designation_or_refusal": "10/11/2024",
    "intended_use": "Treatment of autosomal dominant polycystic liver disease",
    "eu_designation_number": "EU/3/24/2984",
    "status": "Positive",
    "first_published_date": "19/11/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2984"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-[(1R)-1-phenylethyl]-6-{1H-pyrazolo[3,4-d]pyrimidin-4-yl}quinazolin-2-amine",
    "date_of_designation_or_refusal": "20/04/2017",
    "intended_use": "Treatment of fragile X syndrome",
    "eu_designation_number": "EU/3/17/1868",
    "status": "Withdrawn",
    "first_published_date": "15/05/2017",
    "last_updated_date": "19/11/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1868"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Live attenuated Listeria monocytogenes transfected with plasmids encoding the HPV-16E7 protein fused to a truncated fragment of the Lm protein listeriolysin O",
    "date_of_designation_or_refusal": "11/01/2016",
    "intended_use": "Treatment of anal cancer",
    "eu_designation_number": "EU/3/15/1602",
    "status": "Withdrawn",
    "first_published_date": "05/02/2016",
    "last_updated_date": "19/11/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1602"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pamrevlumab",
    "date_of_designation_or_refusal": "16/12/2019",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/19/2234",
    "status": "Withdrawn",
    "first_published_date": "25/02/2020",
    "last_updated_date": "19/11/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2234"
  },
  {
    "medicine_name": "Kizfizo",
    "related_ema_product_number": "EMEA/H/C/006169",
    "active_substance": "temozolomide",
    "date_of_designation_or_refusal": "21/08/2019",
    "intended_use": "Treatment of neuroblastoma",
    "eu_designation_number": "EU/3/19/2188",
    "status": "Positive",
    "first_published_date": "14/01/2020",
    "last_updated_date": "15/11/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2188"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus vector serotype SAN011 encoding a microRNA against DMPK mRNA",
    "date_of_designation_or_refusal": "11/10/2024",
    "intended_use": "Treatment of dystrophic myotonia type 1",
    "eu_designation_number": "EU/3/24/2980",
    "status": "Positive",
    "first_published_date": "14/11/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2980"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 1 containing the 3' portion of human OTOF gene, Adeno-associated viral vector serotype 1 containing the 5' portion of human OTOF gene",
    "date_of_designation_or_refusal": "20/03/2023",
    "intended_use": "Treatment of otoferlin gene-mediated hearing loss",
    "eu_designation_number": "EU/3/23/2771",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "31/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2771"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "cemdisiran",
    "date_of_designation_or_refusal": "20/08/2021",
    "intended_use": "Treatment of primary IgA nephropathy",
    "eu_designation_number": "EU/3/21/2489",
    "status": "Positive",
    "first_published_date": "01/03/2022",
    "last_updated_date": "31/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2489"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "edaravone",
    "date_of_designation_or_refusal": "16/12/2014",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/14/1399",
    "status": "Positive",
    "first_published_date": "26/02/2015",
    "last_updated_date": "31/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1399"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "6-amino-5-chloro-N-((1R)-1-(5-(((5-chloro-4-(trifluoromethyl)-2-pyridinyl)amino)carbonyl)-2-thiazolyl)ethyl)-4-pyrimidinecarboxamide",
    "date_of_designation_or_refusal": "20/05/2021",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/21/2434",
    "status": "Positive",
    "first_published_date": "18/03/2022",
    "last_updated_date": "31/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2434"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "efineptakin alfa",
    "date_of_designation_or_refusal": "24/05/2024",
    "intended_use": "Treatment of acute radiation syndrome",
    "eu_designation_number": "EU/3/24/2925",
    "status": "Positive",
    "first_published_date": "22/08/2024",
    "last_updated_date": "31/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2925"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "rivoceranib (mesilate)",
    "date_of_designation_or_refusal": "25/07/2024",
    "intended_use": "Treatment of hepatocellular carcinoma",
    "eu_designation_number": "EU/3/24/2950",
    "status": "Positive",
    "first_published_date": "13/09/2024",
    "last_updated_date": "31/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2950"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "heterologous human adult liver-derived progenitor cells",
    "date_of_designation_or_refusal": "17/07/2013",
    "intended_use": "Treatment of argininosuccinic aciduria",
    "eu_designation_number": "EU/3/13/1163",
    "status": "Positive",
    "first_published_date": "21/08/2013",
    "last_updated_date": "28/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1163"
  },
  {
    "medicine_name": "Elahere",
    "related_ema_product_number": "EMEA/H/C/005036",
    "active_substance": "Humanised anti-folate receptor 1 monoclonal antibody conjugated to maytansinoid DM4",
    "date_of_designation_or_refusal": "19/03/2015",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/15/1458",
    "status": "Positive",
    "first_published_date": "11/05/2015",
    "last_updated_date": "28/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1458"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "heterologous human adult liver-derived progenitor cells",
    "date_of_designation_or_refusal": "17/07/2013",
    "intended_use": "Treatment of ornithine-translocase deficiency",
    "eu_designation_number": "EU/3/13/1167",
    "status": "Positive",
    "first_published_date": "22/08/2013",
    "last_updated_date": "28/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1167"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "milademetan tosilate monohydrate",
    "date_of_designation_or_refusal": "20/03/2017",
    "intended_use": "Treatment of soft tissue sarcoma",
    "eu_designation_number": "EU/3/17/1847",
    "status": "Positive",
    "first_published_date": "05/05/2017",
    "last_updated_date": "23/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1847"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant adeno-associated viral vector serotype 9 containing the human N-alpha-acetylglucosaminidase gene",
    "date_of_designation_or_refusal": "12/01/2017",
    "intended_use": "Treatment of mucopolysaccharidosis type IIIB (Sanfilippo B syndrome)",
    "eu_designation_number": "EU/3/16/1825",
    "status": "Positive",
    "first_published_date": "14/07/2017",
    "last_updated_date": "23/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1825"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ganglioside GM1",
    "date_of_designation_or_refusal": "13/04/2021",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/21/2426",
    "status": "Positive",
    "first_published_date": "24/01/2022",
    "last_updated_date": "23/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2426"
  },
  {
    "medicine_name": "Rilonacept FGK Representative Service GmbH",
    "related_ema_product_number": "EMEA/H/C/006537",
    "active_substance": "rilonacept",
    "date_of_designation_or_refusal": "06/01/2021",
    "intended_use": "Treatment of idiopathic pericarditis",
    "eu_designation_number": "EU/3/20/2390",
    "status": "Positive",
    "first_published_date": "18/05/2021",
    "last_updated_date": "23/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2390"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "soticlestat",
    "date_of_designation_or_refusal": "12/11/2021",
    "intended_use": "Treatment of Lennox-Gastaut syndrome",
    "eu_designation_number": "EU/3/21/2529",
    "status": "Positive",
    "first_published_date": "09/06/2022",
    "last_updated_date": "23/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2529"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(S)-N-(1-(3-Fluoro-2'-methoxy-[1,1'-biphenyl]-4-yl)-2-oxopiperidin-3-yl)-5-(pyridin-2-yl)thiophene-2-sulfonamide",
    "date_of_designation_or_refusal": "13/12/2023",
    "intended_use": "Treatment of soft-tissue sarcoma",
    "eu_designation_number": "EU/3/23/2861",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "23/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2861"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant self-complementary adeno-associated viral vector serotype 9 containing the human CLN3 gene",
    "date_of_designation_or_refusal": "21/08/2019",
    "intended_use": "Treatment of neuronal ceroid lipofuscinosis",
    "eu_designation_number": "EU/3/19/2196",
    "status": "Positive",
    "first_published_date": "16/01/2020",
    "last_updated_date": "22/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2196"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant self-complementary adeno-associated viral vector serotype 9 containing the human CLN6 gene",
    "date_of_designation_or_refusal": "21/08/2019",
    "intended_use": "Treatment of neuronal ceroid lipofuscinosis",
    "eu_designation_number": "EU/3/19/2197",
    "status": "Positive",
    "first_published_date": "16/01/2020",
    "last_updated_date": "22/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2197"
  },
  {
    "medicine_name": "Enpaxiq; Epjevy",
    "related_ema_product_number": "EMEA/H/C/004193; EMEA/H/C/004793",
    "active_substance": "11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene",
    "date_of_designation_or_refusal": "25/08/2010",
    "intended_use": "Treatment of primary myelofibrosis",
    "eu_designation_number": "EU/3/10/768",
    "status": "Positive",
    "first_published_date": "18/10/2010",
    "last_updated_date": "22/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-768"
  },
  {
    "medicine_name": "Enpaxiq; Epjevy",
    "related_ema_product_number": "EMEA/H/C/004193; EMEA/H/C/004793",
    "active_substance": "11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene",
    "date_of_designation_or_refusal": "25/08/2010",
    "intended_use": "Treatment of post-polycythaemia vera myelofibrosis",
    "eu_designation_number": "EU/3/10/769",
    "status": "Positive",
    "first_published_date": "18/10/2010",
    "last_updated_date": "22/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-769"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "treprostinil sodium",
    "date_of_designation_or_refusal": "16/03/2022",
    "intended_use": "Treatment of idiopathic pulmonary fibrosis",
    "eu_designation_number": "EU/3/22/2588",
    "status": "Positive",
    "first_published_date": "16/06/2022",
    "last_updated_date": "22/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2588"
  },
  {
    "medicine_name": "Enpaxiq; Epjevy",
    "related_ema_product_number": "EMEA/H/C/004193; EMEA/H/C/004793",
    "active_substance": "11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene",
    "date_of_designation_or_refusal": "25/08/2010",
    "intended_use": "Treatment of post-essential thrombocythaemia myelofibrosis",
    "eu_designation_number": "EU/3/10/767",
    "status": "Positive",
    "first_published_date": "18/10/2010",
    "last_updated_date": "22/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-767"
  },
  {
    "medicine_name": "Skyclarys",
    "related_ema_product_number": "EMEA/H/C/006084",
    "active_substance": "omaveloxolone",
    "date_of_designation_or_refusal": "27/06/2018",
    "intended_use": "Treatment of Friedreich’s ataxia",
    "eu_designation_number": "EU/3/18/2037",
    "status": "Positive",
    "first_published_date": "22/08/2018",
    "last_updated_date": "22/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2037"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "atrasentan",
    "date_of_designation_or_refusal": "10/12/2021",
    "intended_use": "Treatment of primary IgA nephropathy",
    "eu_designation_number": "EU/3/21/2542",
    "status": "Positive",
    "first_published_date": "19/04/2022",
    "last_updated_date": "22/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2542"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "humanised IgG1 monoclonal antibody against annexin-A1",
    "date_of_designation_or_refusal": "15/02/2023",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/23/2752",
    "status": "Positive",
    "first_published_date": "24/01/2024",
    "last_updated_date": "22/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2752"
  },
  {
    "medicine_name": "Filsuvez",
    "related_ema_product_number": "EMEA/H/C/005035",
    "active_substance": "dry extract from birch bark (DER 5-10 : 1), extraction solvent n-heptane 95% (w/w) (birch bark extract)",
    "date_of_designation_or_refusal": "23/02/2011",
    "intended_use": "Treatment of epidermolysis bullosa",
    "eu_designation_number": "EU/3/10/845",
    "status": "Positive",
    "first_published_date": "04/03/2011",
    "last_updated_date": "22/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-845"
  },
  {
    "medicine_name": "Sovrima",
    "related_ema_product_number": "EMEA/H/C/000908",
    "active_substance": "idebenone",
    "date_of_designation_or_refusal": "08/03/2004",
    "intended_use": "Treatment of Friedreich's ataxia",
    "eu_designation_number": "EU/3/04/189",
    "status": "Positive",
    "first_published_date": "10/02/2009",
    "last_updated_date": "22/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-189"
  },
  {
    "medicine_name": "Puldysa",
    "related_ema_product_number": "EMEA/H/C/005123",
    "active_substance": "idebenone",
    "date_of_designation_or_refusal": "20/03/2007",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/07/437",
    "status": "Positive",
    "first_published_date": "19/07/2007",
    "last_updated_date": "22/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-437"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Cyclo-L-glycyl-L-2-allylproline",
    "date_of_designation_or_refusal": "06/01/2021",
    "intended_use": "Treatment of Angelman syndrome",
    "eu_designation_number": "EU/3/20/2389",
    "status": "Positive",
    "first_published_date": "18/05/2021",
    "last_updated_date": "22/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2389"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Cyclo-L-glycyl-L-2-allylproline",
    "date_of_designation_or_refusal": "06/01/2021",
    "intended_use": "Treatment of Phelan-McDermid syndrome",
    "eu_designation_number": "EU/3/20/2394",
    "status": "Positive",
    "first_published_date": "18/05/2021",
    "last_updated_date": "22/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2394"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Cyclo-L-glycyl-L-2-allylproline",
    "date_of_designation_or_refusal": "06/01/2021",
    "intended_use": "Treatment of Pitt-Hopkins syndrome",
    "eu_designation_number": "EU/3/20/2393",
    "status": "Positive",
    "first_published_date": "18/05/2021",
    "last_updated_date": "22/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2393"
  },
  {
    "medicine_name": "Myalepta",
    "related_ema_product_number": "EMEA/H/C/004218",
    "active_substance": "Metreleptin",
    "date_of_designation_or_refusal": "17/07/2012",
    "intended_use": "Treatment of Lawrence syndrome",
    "eu_designation_number": "EU/3/12/1024",
    "status": "Positive",
    "first_published_date": "31/08/2012",
    "last_updated_date": "22/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1024"
  },
  {
    "medicine_name": "Myalepta",
    "related_ema_product_number": "EMEA/H/C/004218",
    "active_substance": "Metreleptin",
    "date_of_designation_or_refusal": "17/07/2012",
    "intended_use": "Treatment of Berardinelli-Seip syndrome",
    "eu_designation_number": "EU/3/12/1025",
    "status": "Positive",
    "first_published_date": "31/08/2012",
    "last_updated_date": "22/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1025"
  },
  {
    "medicine_name": "Myalepta",
    "related_ema_product_number": "EMEA/H/C/004218",
    "active_substance": "Metreleptin",
    "date_of_designation_or_refusal": "17/07/2012",
    "intended_use": "Treatment of Barraquer-Simons syndrome",
    "eu_designation_number": "EU/3/12/1023",
    "status": "Positive",
    "first_published_date": "31/08/2012",
    "last_updated_date": "22/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1023"
  },
  {
    "medicine_name": "Myalepta",
    "related_ema_product_number": "EMEA/H/C/004218",
    "active_substance": "Metreleptin",
    "date_of_designation_or_refusal": "17/07/2012",
    "intended_use": "Treatment of familial partial lipodystrophy",
    "eu_designation_number": "EU/3/12/1022",
    "status": "Positive",
    "first_published_date": "31/08/2012",
    "last_updated_date": "22/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1022"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised IgG4 monoclonal antibody against A proliferation-inducing ligand",
    "date_of_designation_or_refusal": "21/06/2022",
    "intended_use": "Treatment of primary IgA nephropathy",
    "eu_designation_number": "EU/3/22/2623",
    "status": "Positive",
    "first_published_date": "22/09/2022",
    "last_updated_date": "22/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2623"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus serotype 5 containing the human RDH12 gene",
    "date_of_designation_or_refusal": "19/10/2020",
    "intended_use": "Treatment of RDH12 mutation associated retinal dystrophy",
    "eu_designation_number": "EU/3/20/2351",
    "status": "Positive",
    "first_published_date": "18/02/2021",
    "last_updated_date": "22/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2351"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adenovirus associated viral vector serotype 2/8 containing the human CNGA3 gene (entacingene turiparvovec)",
    "date_of_designation_or_refusal": "31/07/2018",
    "intended_use": "Treatment of achromatopsia",
    "eu_designation_number": "EU/3/18/2042",
    "status": "Positive",
    "first_published_date": "11/10/2018",
    "last_updated_date": "22/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2042"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adenovirus associated viral vector serotype 5 containing the human RPE65 gene",
    "date_of_designation_or_refusal": "11/11/2015",
    "intended_use": "Treatment of Leber's congenital amaurosis",
    "eu_designation_number": "EU/3/15/1577",
    "status": "Positive",
    "first_published_date": "22/01/2016",
    "last_updated_date": "22/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1577"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adenovirus associated viral vector serotype 8 containing the human AIPL1 gene",
    "date_of_designation_or_refusal": "12/12/2017",
    "intended_use": "Treatment of Leber's congenital amaurosis",
    "eu_designation_number": "EU/3/17/1950",
    "status": "Positive",
    "first_published_date": "24/01/2018",
    "last_updated_date": "22/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1950"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "relacorilant",
    "date_of_designation_or_refusal": "29/05/2019",
    "intended_use": "Treatment of Cushing's syndrome",
    "eu_designation_number": "EU/3/19/2164",
    "status": "Positive",
    "first_published_date": "09/08/2019",
    "last_updated_date": "22/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2164"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "relacorilant",
    "date_of_designation_or_refusal": "21/08/2019",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/19/2191",
    "status": "Positive",
    "first_published_date": "14/01/2020",
    "last_updated_date": "22/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2191"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adenovirus associated viral vector serotype 8 containing the human CNGB3 gene",
    "date_of_designation_or_refusal": "11/11/2015",
    "intended_use": "Treatment of achromatopsia caused by mutations in the CNGB3 gene",
    "eu_designation_number": "EU/3/15/1578",
    "status": "Positive",
    "first_published_date": "22/01/2016",
    "last_updated_date": "22/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1578"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Asp-Arg-Val-Tyr-Ile-His-Pro (Angiotensin 1-7);talfirastide",
    "date_of_designation_or_refusal": "19/02/2014",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/14/1241",
    "status": "Positive",
    "first_published_date": "01/04/2014",
    "last_updated_date": "22/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1241"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-Hydroxypropyl-β-cyclodextrin",
    "date_of_designation_or_refusal": "26/04/2013",
    "intended_use": "Treatment of Niemann-Pick's disease, type C",
    "eu_designation_number": "EU/3/13/1124",
    "status": "Positive",
    "first_published_date": "14/05/2013",
    "last_updated_date": "22/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1124"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "donidalorsen",
    "date_of_designation_or_refusal": "19/02/2024",
    "intended_use": "Treatment of hereditary angioedema",
    "eu_designation_number": "EU/3/24/2898",
    "status": "Positive",
    "first_published_date": "11/04/2024",
    "last_updated_date": "22/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2898"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "5-fluoro-4-(7'-fluoro-2'-methylspiro[cyclopentane-1,3'-indol]-5'-yl)-N-(5-(1-methylpiperidin-4-yl)pyridin-2-yl)pyrimidin-2-amine;crozbaciclib",
    "date_of_designation_or_refusal": "26/03/2021",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/21/2416",
    "status": "Positive",
    "first_published_date": "19/01/2022",
    "last_updated_date": "22/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2416"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Asp-Arg-Val-Tyr-Ile-His-Pro (Angiotensin 1-7);talfirastide",
    "date_of_designation_or_refusal": "20/06/2017",
    "intended_use": "Treatment of epidermolysis bullosa",
    "eu_designation_number": "EU/3/17/1879",
    "status": "Positive",
    "first_published_date": "17/07/2017",
    "last_updated_date": "22/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1879"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised monoclonal antibody targeting interleukin-15",
    "date_of_designation_or_refusal": "27/06/2016",
    "intended_use": "Treatment of eosinophilic oesophagitis",
    "eu_designation_number": "EU/3/16/1681",
    "status": "Positive",
    "first_published_date": "26/07/2016",
    "last_updated_date": "22/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1681"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "anti-CD123 IgG1 humanised monoclonal antibody conjugated to N1-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)-N6-((S)-1-(((S)-1-((3-((((S)-8-methoxy-6-oxo-11,12,12a,13-tetrahydro-6H-benzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oxy)methyl)-5-((((S)-8-methoxy-6-oxo-12a,13-dihydro-6Hbenzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oxy)methyl)phenyl)amino)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)adipamide;pivekimab sunirine",
    "date_of_designation_or_refusal": "26/06/2020",
    "intended_use": "Treatment of blastic plasmacytoid dendritic cell neoplasm",
    "eu_designation_number": "EU/3/20/2292",
    "status": "Positive",
    "first_published_date": "23/09/2020",
    "last_updated_date": "22/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2292"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "[(2S,3S,4E,6S,7R,10R)-7,10-dihydroxy-3,7-dimethyl-12-oxo-2-[(2E,4E,6R)-6-pyridin-2-ylhepta-2,4-dien-2-yl]-1-oxacyclododec-4-en-6-yl]4-methylpiperazine-1-carboxylate",
    "date_of_designation_or_refusal": "20/06/2023",
    "intended_use": "Treatment of myelodysplastic syndromes",
    "eu_designation_number": "EU/3/23/2796",
    "status": "Positive",
    "first_published_date": "02/02/2024",
    "last_updated_date": "22/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2796"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "camrelizumab",
    "date_of_designation_or_refusal": "25/07/2024",
    "intended_use": "Treatment of hepatocellular carcinoma",
    "eu_designation_number": "EU/3/24/2943",
    "status": "Positive",
    "first_published_date": "13/09/2024",
    "last_updated_date": "22/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2943"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Glycyl-L-2-methylprolyl-L-glutamic acid;trofinetide",
    "date_of_designation_or_refusal": "10/08/2015",
    "intended_use": "Treatment of Rett syndrome",
    "eu_designation_number": "EU/3/15/1534",
    "status": "Positive",
    "first_published_date": "02/10/2015",
    "last_updated_date": "22/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1534"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "enzastaurin hydrochloride",
    "date_of_designation_or_refusal": "27/05/2024",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/05/343",
    "status": "Withdrawn",
    "first_published_date": "08/08/2006",
    "last_updated_date": "16/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-343"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Fosmanogepix",
    "date_of_designation_or_refusal": "15/02/2023",
    "intended_use": "Treatment of fusariosis",
    "eu_designation_number": "EU/3/23/2748",
    "status": "Positive",
    "first_published_date": "25/01/2024",
    "last_updated_date": "15/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2748"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "heterologous human adult liver derived stem cells",
    "date_of_designation_or_refusal": "04/02/2008",
    "intended_use": "Treatment of ornithinine transcarbamylase deficiency",
    "eu_designation_number": "EU/3/08/530",
    "status": "Positive",
    "first_published_date": "10/07/2008",
    "last_updated_date": "15/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-530"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "heterologous human adult liver-derived progenitor cells",
    "date_of_designation_or_refusal": "17/07/2013",
    "intended_use": "Treatment of citrullinaemia type 1",
    "eu_designation_number": "EU/3/13/1162",
    "status": "Positive",
    "first_published_date": "21/08/2013",
    "last_updated_date": "15/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1162"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Mecasermin rinfabate",
    "date_of_designation_or_refusal": "28/08/2006",
    "intended_use": "Prevention of retinopathy of prematurity in neonates of less than 32 weeks of gestational age",
    "eu_designation_number": "EU/3/06/399",
    "status": "Positive",
    "first_published_date": "24/04/2009",
    "last_updated_date": "15/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-399"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "heterologous human adult liver-derived stem cells",
    "date_of_designation_or_refusal": "29/11/2007",
    "intended_use": "Treatment of Crigler-Najjar syndrome",
    "eu_designation_number": "EU/3/07/506",
    "status": "Positive",
    "first_published_date": "02/07/2008",
    "last_updated_date": "15/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-506"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "heterologous human adult liver-derived progenitor cells",
    "date_of_designation_or_refusal": "17/07/2013",
    "intended_use": "Treatment of hyperargininaemia",
    "eu_designation_number": "EU/3/13/1164",
    "status": "Positive",
    "first_published_date": "21/08/2013",
    "last_updated_date": "15/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1164"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "heterologous human adult liver-derived progenitor cells",
    "date_of_designation_or_refusal": "17/07/2013",
    "intended_use": "Treatment of carbamoyl-phosphate synthase-1 deficiency",
    "eu_designation_number": "EU/3/13/1161",
    "status": "Positive",
    "first_published_date": "21/08/2013",
    "last_updated_date": "15/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1161"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Adeno-associated viral vector serotype rh.10 encoding the CLN2 gene",
    "date_of_designation_or_refusal": "11/10/2022",
    "intended_use": "Treatment of neuronal ceroid lipofuscinosis",
    "eu_designation_number": "EU/3/22/2700",
    "status": "Positive",
    "first_published_date": "24/01/2023",
    "last_updated_date": "15/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2700"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "heterologous human adult liver-derived progenitor cells",
    "date_of_designation_or_refusal": "17/08/2013",
    "intended_use": "Treatment of citrullinaemia type 2",
    "eu_designation_number": "EU/3/13/1166",
    "status": "Positive",
    "first_published_date": "22/08/2013",
    "last_updated_date": "15/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1166"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "heterologous human adult liver-derived progenitor cells",
    "date_of_designation_or_refusal": "17/07/2013",
    "intended_use": "Treatment of N-acetylglutamate synthetase (NAGS) deficiency",
    "eu_designation_number": "EU/3/13/1165",
    "status": "Positive",
    "first_published_date": "22/08/2013",
    "last_updated_date": "15/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1165"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adenovirus associated viral vector serotype 5 containing the human pde6β gene",
    "date_of_designation_or_refusal": "19/06/2013",
    "intended_use": "Treatment of retinitis pigmentosa",
    "eu_designation_number": "EU/3/13/1142",
    "status": "Positive",
    "first_published_date": "11/07/2013",
    "last_updated_date": "11/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1142"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic umbilical cord-derived mesenchymal stromal cells, pooled",
    "date_of_designation_or_refusal": "13/12/2023",
    "intended_use": "Treatment of perinatal asphyxia",
    "eu_designation_number": "EU/3/23/2862",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "11/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2862"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised IgG1 kappa antibody against serum amyloid A and AL amyloid",
    "date_of_designation_or_refusal": "08/02/2013",
    "intended_use": "Treatment of amyloid light-chain amyloidosis",
    "eu_designation_number": "EU/3/13/1100",
    "status": "Positive",
    "first_published_date": "04/03/2013",
    "last_updated_date": "11/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1100"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one (tirasemtiv)",
    "date_of_designation_or_refusal": "05/03/2012",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/12/970",
    "status": "Positive",
    "first_published_date": "19/04/2012",
    "last_updated_date": "11/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-970"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous haematopoietic cells genetically modified with a lentiviral vector containing the human gp91(phox) gene",
    "date_of_designation_or_refusal": "09/02/2012",
    "intended_use": "Treatment of X-linked chronic granulomatous disease",
    "eu_designation_number": "EU/3/12/957",
    "status": "Positive",
    "first_published_date": "01/03/2012",
    "last_updated_date": "11/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-957"
  },
  {
    "medicine_name": "Bylvay",
    "related_ema_product_number": "EMEA/H/C/004691",
    "active_substance": "",
    "date_of_designation_or_refusal": "17/07/2012",
    "intended_use": "Treatment of progressive familial intrahepatic cholestasis",
    "eu_designation_number": "EU/3/12/1028",
    "status": "Positive",
    "first_published_date": "30/08/2012",
    "last_updated_date": "11/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1028"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2S, 4R ketoconazole",
    "date_of_designation_or_refusal": "04/07/2012",
    "intended_use": "Treatment of Cushing's syndrome",
    "eu_designation_number": "EU/3/12/1012",
    "status": "Positive",
    "first_published_date": "24/07/2012",
    "last_updated_date": "11/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1012"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "flucytosine",
    "date_of_designation_or_refusal": "22/02/2018",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/18/1978",
    "status": "Positive",
    "first_published_date": "10/04/2018",
    "last_updated_date": "11/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1978"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "vocimagene amiretrorepvec",
    "date_of_designation_or_refusal": "22/02/2018",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/18/1987",
    "status": "Positive",
    "first_published_date": "11/04/2018",
    "last_updated_date": "11/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1987"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "reldesemtiv",
    "date_of_designation_or_refusal": "28/06/2019",
    "intended_use": "Treatment of spinal muscular atrophy",
    "eu_designation_number": "EU/3/19/2169",
    "status": "Positive",
    "first_published_date": "02/10/2019",
    "last_updated_date": "11/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2169"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "reldesemtiv",
    "date_of_designation_or_refusal": "28/02/2020",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/20/2256",
    "status": "Positive",
    "first_published_date": "06/05/2020",
    "last_updated_date": "11/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2256"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "enzastaurin hydrochloride",
    "date_of_designation_or_refusal": "24/02/2022",
    "intended_use": "Treatment of Ehlers-Danlos syndrome",
    "eu_designation_number": "EU/3/22/2582",
    "status": "Positive",
    "first_published_date": "13/05/2022",
    "last_updated_date": "11/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2582"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Cyclo(-gamma-aminobutyryl-L-phenylalanyl-L-tryptophanyl-D-tryptophanyl-L-lysyl-L-threonyl-L phenylalanyl-N-3-carboxypropyl)-glycine amide, acetate salt",
    "date_of_designation_or_refusal": "06/12/2012",
    "intended_use": "Treatment of acromegaly",
    "eu_designation_number": "EU/3/12/1075",
    "status": "Positive",
    "first_published_date": "24/01/2013",
    "last_updated_date": "11/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1075"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "brincidofovir",
    "date_of_designation_or_refusal": "28/04/2016",
    "intended_use": "Prevention of cytomegalovirus disease",
    "eu_designation_number": "EU/3/16/1644",
    "status": "Positive",
    "first_published_date": "30/05/2016",
    "last_updated_date": "11/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1644"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "brincidofovir",
    "date_of_designation_or_refusal": "14/07/2016",
    "intended_use": "Treatment of adenovirus infection in immunocompromised patients",
    "eu_designation_number": "EU/3/16/1697",
    "status": "Positive",
    "first_published_date": "06/09/2016",
    "last_updated_date": "11/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1697"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous CD4+ and CD8+ T cells transduced with lentiviral vector containing an affinity-enhanced T-cell receptor targeting the New York esophageal antigen-1",
    "date_of_designation_or_refusal": "14/07/2016",
    "intended_use": "Treatment of soft tissue sarcoma",
    "eu_designation_number": "EU/3/16/1694",
    "status": "Positive",
    "first_published_date": "06/09/2016",
    "last_updated_date": "11/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1694"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "antisense oligonucleotide complementary to the exonic splicer enhancer sequence at intron 26 of the centrosomal protein 290 pre-mRNA",
    "date_of_designation_or_refusal": "28/04/2016",
    "intended_use": "Treatment of Leber's congenital amaurosis",
    "eu_designation_number": "EU/3/16/1641",
    "status": "Positive",
    "first_published_date": "31/05/2016",
    "last_updated_date": "02/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1641"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ultevursen",
    "date_of_designation_or_refusal": "22/02/2018",
    "intended_use": "Treatment of retinitis pigmentosa",
    "eu_designation_number": "EU/3/18/1973",
    "status": "Positive",
    "first_published_date": "10/04/2018",
    "last_updated_date": "02/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1973"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "erlotinib",
    "date_of_designation_or_refusal": "09/12/2020",
    "intended_use": "Treatment of patients with Olmsted syndrome",
    "eu_designation_number": "EU/3/20/2382",
    "status": "Positive",
    "first_published_date": "27/05/2021",
    "last_updated_date": "02/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2382"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "elamipretide",
    "date_of_designation_or_refusal": "20/05/2021",
    "intended_use": "Treatment of Barth syndrome",
    "eu_designation_number": "EU/3/21/2430",
    "status": "Positive",
    "first_published_date": "17/03/2022",
    "last_updated_date": "02/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2430"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Ibrexafungerp",
    "date_of_designation_or_refusal": "12/11/2021",
    "intended_use": "Treatment of invasive candidiasis",
    "eu_designation_number": "EU/3/21/2525",
    "status": "Positive",
    "first_published_date": "09/06/2022",
    "last_updated_date": "02/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2525"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Epetraborole",
    "date_of_designation_or_refusal": "10/08/2022",
    "intended_use": "Treatment of nontuberculous mycobacterial lung disease",
    "eu_designation_number": "EU/3/22/2680",
    "status": "Positive",
    "first_published_date": "15/12/2022",
    "last_updated_date": "02/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2680"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Fosmanogepix",
    "date_of_designation_or_refusal": "18/07/2022",
    "intended_use": "Treatment of invasive aspergillosis",
    "eu_designation_number": "EU/3/22/2645",
    "status": "Positive",
    "first_published_date": "23/01/2023",
    "last_updated_date": "02/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2645"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Fosmanogepix",
    "date_of_designation_or_refusal": "18/07/2022",
    "intended_use": "Treatment of invasive candidiasis",
    "eu_designation_number": "EU/3/22/2644",
    "status": "Positive",
    "first_published_date": "23/01/2023",
    "last_updated_date": "02/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2644"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "erlotinib",
    "date_of_designation_or_refusal": "18/07/2022",
    "intended_use": "Treatment of pachyonychia congenita",
    "eu_designation_number": "EU/3/22/2668",
    "status": "Positive",
    "first_published_date": "23/01/2023",
    "last_updated_date": "02/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2668"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Fosmanogepix",
    "date_of_designation_or_refusal": "15/02/2023",
    "intended_use": "Treatment of mucormycosis",
    "eu_designation_number": "EU/3/23/2749",
    "status": "Positive",
    "first_published_date": "19/01/2024",
    "last_updated_date": "02/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2749"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Fosmanogepix",
    "date_of_designation_or_refusal": "15/02/2023",
    "intended_use": "Treatment of lomentosporiosis",
    "eu_designation_number": "EU/3/23/2750",
    "status": "Positive",
    "first_published_date": "25/01/2024",
    "last_updated_date": "02/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2750"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Fosmanogepix",
    "date_of_designation_or_refusal": "20/03/2023",
    "intended_use": "Treatment of scedosporiosis",
    "eu_designation_number": "EU/3/23/2763",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "02/10/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2763"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus vector serotype 9 containing the human GCDH gene",
    "date_of_designation_or_refusal": "21/08/2024",
    "intended_use": "Treatment of glutaric aciduria",
    "eu_designation_number": "EU/3/24/2967",
    "status": "Positive",
    "first_published_date": "19/09/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2967"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "gallium (68Ga) boclatixafortide",
    "date_of_designation_or_refusal": "21/08/2024",
    "intended_use": "Diagnosis of marginal zone lymphoma",
    "eu_designation_number": "EU/3/24/2959",
    "status": "Positive",
    "first_published_date": "19/09/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2959"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium valproate",
    "date_of_designation_or_refusal": "21/08/2024",
    "intended_use": "Treatment of pulmonary arterial hypertension",
    "eu_designation_number": "EU/3/24/2972",
    "status": "Positive",
    "first_published_date": "19/09/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2972"
  },
  {
    "medicine_name": "Tryngolza",
    "related_ema_product_number": "EMEA/H/C/006477",
    "active_substance": "olezarsen sodium",
    "date_of_designation_or_refusal": "21/08/2024",
    "intended_use": "Treatment of familial chylomicronaemia syndrome",
    "eu_designation_number": "EU/3/24/2973",
    "status": "Positive",
    "first_published_date": "19/09/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2973"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 3B encoding human CYP27A1",
    "date_of_designation_or_refusal": "",
    "intended_use": "Treatment of inborn errors in primary bile acid synthesis",
    "eu_designation_number": "EU/3/24/2971",
    "status": "Positive",
    "first_published_date": "19/09/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2971"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(E)-2-((4-((4-Benzyl(ethyl)amino)phenyl)diazinyl)phenyl)amino-N,N,N-triethyl-2-oxoethan-1-aminium chloride",
    "date_of_designation_or_refusal": "21/08/2024",
    "intended_use": "Treatment of syndromic inherited retinal dystrophies of the rod-dominant phenotype",
    "eu_designation_number": "EU/3/24/2975",
    "status": "Positive",
    "first_published_date": "19/09/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2975"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "4-(1H-Pyrrolo[2,3-b]pyridin-2-yl)phenol hydrochloride",
    "date_of_designation_or_refusal": "21/08/2024",
    "intended_use": "Prevention of acute liver failure",
    "eu_designation_number": "EU/3/24/2965",
    "status": "Positive",
    "first_published_date": "19/09/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2965"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "4-Benzoyl-D-phenylalanyl-D-seryl-D-tryptophyl-D-seryl-2,3,4,5,6-pentafluoro-D-phenylalanyl-3-cyclohexyl-D-alanyl-D-arginyl-D-arginyl-D-arginyl-D-glutaminyl-D-arginyl-D-arginine acetate",
    "date_of_designation_or_refusal": "21/08/2024",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/24/2974",
    "status": "Positive",
    "first_published_date": "19/09/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2974"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Interleukin 4 - interleukin 10 fusion protein",
    "date_of_designation_or_refusal": "",
    "intended_use": "Treatment of complex regional pain syndrome",
    "eu_designation_number": "EU/3/24/2960",
    "status": "Positive",
    "first_published_date": "19/09/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2960"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised IgG1 monoclonal antibody against misfolded immunoglobulin G, fused with pan-amyloid-reactive peptide p5R",
    "date_of_designation_or_refusal": "",
    "intended_use": "Treatment of AL amyloidosis",
    "eu_designation_number": "EU/3/24/2969",
    "status": "Positive",
    "first_published_date": "19/09/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2969"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "obrixtamig",
    "date_of_designation_or_refusal": "21/08/2024",
    "intended_use": "Treatment of pulmonary neuroendocrine carcinoma",
    "eu_designation_number": "EU/3/24/2961",
    "status": "Positive",
    "first_published_date": "19/09/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2961"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "bemarituzumab",
    "date_of_designation_or_refusal": "21/08/2024",
    "intended_use": "Treatment of gastric cancer",
    "eu_designation_number": "EU/3/24/2966",
    "status": "Positive",
    "first_published_date": "19/09/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2966"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised IgG1 monoclonal antibody against misfolded immunoglobulin G, fused with pan-amyloid-reactive peptide p5R",
    "date_of_designation_or_refusal": "21/08/2024",
    "intended_use": "Treatment of ATTR amyloidosis",
    "eu_designation_number": "EU/3/24/2970",
    "status": "Positive",
    "first_published_date": "19/09/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2970"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(R)-(3-(2'-cyclopropyl-3-(hydroxymethyl)-[1,1'-biphenyl]-4-yl) pyrrolidin-1-yl)(5-fluoropyridin-2-yl)methanone",
    "date_of_designation_or_refusal": "21/08/2024",
    "intended_use": "Treatment of punctate palmoplantar keratoderma",
    "eu_designation_number": "EU/3/24/2968",
    "status": "Positive",
    "first_published_date": "19/09/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2968"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous CD34+ cells edited with a CRISPR/Cas9 system and transduced with an adeno-associated vector containing a codon-optimized version of WAS gene",
    "date_of_designation_or_refusal": "21/08/2024",
    "intended_use": "Treatment of Wiskott-Aldrich syndrome",
    "eu_designation_number": "EU/3/24/2964",
    "status": "Positive",
    "first_published_date": "19/09/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2964"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "obrixtamig",
    "date_of_designation_or_refusal": "21/08/2024",
    "intended_use": "Treatment of extrapulmonary neuroendocrine carcinoma",
    "eu_designation_number": "EU/3/24/2962",
    "status": "Positive",
    "first_published_date": "18/09/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2962"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Polihexanide",
    "date_of_designation_or_refusal": "21/08/2024",
    "intended_use": "Treatment of fungal keratitis",
    "eu_designation_number": "EU/3/24/2963",
    "status": "Positive",
    "first_published_date": "18/09/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2963"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-[(1R)-1-[(S)-(2-Chloro-3-fluorophenyl)hydroxymethyl]butyl]-7-fluoro-2,3-dihydro-2-oxo-1H-indole-4-carboxamide",
    "date_of_designation_or_refusal": "25/07/2024",
    "intended_use": "Treatment of congenital alpha-1 antitrypsin deficiency",
    "eu_designation_number": "EU/3/24/2952",
    "status": "Positive",
    "first_published_date": "13/09/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2952"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N,N'-([Cyclohexylmethylene]di-4,1-phenylene)bis(2-[1-pyrrolidinyl]acetamide)",
    "date_of_designation_or_refusal": "25/07/2024",
    "intended_use": "Treatment of Creutzfeldt-Jakob disease",
    "eu_designation_number": "EU/3/24/2958",
    "status": "Positive",
    "first_published_date": "13/09/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2958"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "emavusertib",
    "date_of_designation_or_refusal": "25/07/2024",
    "intended_use": "Treatment of primary large B-cell lymphoma of immune-privileged sites",
    "eu_designation_number": "EU/3/24/2945",
    "status": "Positive",
    "first_published_date": "13/09/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2945"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium phenylacetate;ursodoxicoltaurine",
    "date_of_designation_or_refusal": "25/07/2024",
    "intended_use": "Treatment of Wolfram syndrome",
    "eu_designation_number": "EU/3/24/2954",
    "status": "Positive",
    "first_published_date": "13/09/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2954"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus vector serotype rh.10 containing the human FXN gene",
    "date_of_designation_or_refusal": "25/07/2024",
    "intended_use": "Treatment of Friedreich's ataxia",
    "eu_designation_number": "EU/3/24/2957",
    "status": "Positive",
    "first_published_date": "13/09/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2957"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "4-[[[4-[5-Chloro-2-[[trans-4-[[(1R)-2-methoxy-1-methyl-ethyl]amino]cyclohexyl]amino]-4-pyridinyl]-2-thiazolyl]amino]methyl]tetrahydro-2H-pyran-4-carbonitrile",
    "date_of_designation_or_refusal": "25/07/2024",
    "intended_use": "Treatment of peripheral T-cell lymphoma",
    "eu_designation_number": "EU/3/24/2949",
    "status": "Positive",
    "first_published_date": "13/09/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2949"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "befiradol fumarate",
    "date_of_designation_or_refusal": "25/07/2024",
    "intended_use": "Treatment of spinocerebellar ataxia",
    "eu_designation_number": "EU/3/24/2951",
    "status": "Positive",
    "first_published_date": "13/09/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2951"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus serotype A101 containing the codon-optimized human CFTRdeltaR",
    "date_of_designation_or_refusal": "25/07/2024",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/24/2956",
    "status": "Positive",
    "first_published_date": "13/09/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2956"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "afamelanotide",
    "date_of_designation_or_refusal": "25/07/2024",
    "intended_use": "Treatment of variegate porphyria",
    "eu_designation_number": "EU/3/24/2947",
    "status": "Positive",
    "first_published_date": "13/09/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2947"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "urokinase, catalytic domain, fused with a single-chain antibody against von Willebrand factor",
    "date_of_designation_or_refusal": "25/07/2024",
    "intended_use": "Treatment of thrombotic thrombocytopenic purpura",
    "eu_designation_number": "EU/3/24/2946",
    "status": "Positive",
    "first_published_date": "13/09/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2946"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus vector serotype 8 containing the human TYMP gene (CpG-depleted)",
    "date_of_designation_or_refusal": "25/07/2024",
    "intended_use": "Treatment of mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)",
    "eu_designation_number": "EU/3/24/2948",
    "status": "Positive",
    "first_published_date": "13/09/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2948"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(E)-2-((4-((4-Benzyl(ethyl)amino)phenyl)diazinyl)phenyl)amino-N,N,N-triethyl-2-oxoethan-1-aminium chloride",
    "date_of_designation_or_refusal": "25/07/2024",
    "intended_use": "Treatment of non-syndromic inherited retinal dystrophies of the rod-dominant phenotype",
    "eu_designation_number": "EU/3/24/2944",
    "status": "Positive",
    "first_published_date": "13/09/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2944"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "heterologous swine glyco-humanised polyclonal antibody against T lymphocytes",
    "date_of_designation_or_refusal": "25/07/2024",
    "intended_use": "Treatment of peripheral T-cell lymphoma",
    "eu_designation_number": "EU/3/24/2955",
    "status": "Positive",
    "first_published_date": "13/09/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2955"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "cannabidiol acid methyl ester",
    "date_of_designation_or_refusal": "25/07/2024",
    "intended_use": "Treatment of Prader-Willi syndrome",
    "eu_designation_number": "EU/3/24/2953",
    "status": "Positive",
    "first_published_date": "13/09/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2953"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "uridine triacetate",
    "date_of_designation_or_refusal": "28/06/2024",
    "intended_use": "Treatment of hereditary orotic aciduria",
    "eu_designation_number": "EU/3/24/2938",
    "status": "Positive",
    "first_published_date": "22/08/2024",
    "last_updated_date": "23/08/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2938"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "nizubaglustat",
    "date_of_designation_or_refusal": "28/06/2024",
    "intended_use": "Treatment of GM1 gangliosidosis",
    "eu_designation_number": "EU/3/24/2940",
    "status": "Positive",
    "first_published_date": "22/08/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2940"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "afatinib",
    "date_of_designation_or_refusal": "28/06/2024",
    "intended_use": "Treatment of complex regional pain syndrome",
    "eu_designation_number": "EU/3/24/2929",
    "status": "Positive",
    "first_published_date": "22/08/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2929"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "topiramate",
    "date_of_designation_or_refusal": "28/06/2024",
    "intended_use": "Treatment of neonatal encephalopathy",
    "eu_designation_number": "EU/3/24/2932",
    "status": "Positive",
    "first_published_date": "22/08/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2932"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Complement factor H",
    "date_of_designation_or_refusal": "28/06/2024",
    "intended_use": "Treatment of C3 glomerulopathy",
    "eu_designation_number": "EU/3/24/2936",
    "status": "Positive",
    "first_published_date": "22/08/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2936"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "L-methionine",
    "date_of_designation_or_refusal": "28/06/2024",
    "intended_use": "Treatment of pulmonary alveolar proteinosis",
    "eu_designation_number": "EU/3/24/2934",
    "status": "Positive",
    "first_published_date": "22/08/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2934"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sargramostim",
    "date_of_designation_or_refusal": "28/06/2024",
    "intended_use": "Treatment of pulmonary alveolar proteinosis",
    "eu_designation_number": "EU/3/24/2928",
    "status": "Positive",
    "first_published_date": "22/08/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2928"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(R)-3-(1-Cyclopropyl-3-(2-fluoro-4-(trifluoromethoxy)benzyl)ureido)piperidine-1-carboxamide",
    "date_of_designation_or_refusal": "28/06/2024",
    "intended_use": "Treatment of hyperphenylalaninaemia",
    "eu_designation_number": "EU/3/24/2930",
    "status": "Positive",
    "first_published_date": "22/08/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2930"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "apilimod",
    "date_of_designation_or_refusal": "28/06/2024",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/24/2942",
    "status": "Positive",
    "first_published_date": "22/08/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2942"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Ethyl(2E,4S)-4-({(2S)-2-[3-{[(5-methyl-1,2-oxazol-3-yl)carbonyl]amino}-2-oxopyridin-1(2H)-yl]pent-4-ynoyl}amino)-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate, Pocapavir",
    "date_of_designation_or_refusal": "28/06/2024",
    "intended_use": "Treatment of poliovirus infection",
    "eu_designation_number": "EU/3/24/2941",
    "status": "Positive",
    "first_published_date": "22/08/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2941"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(R)-(3-(2'-cyclopropyl-3-(hydroxymethyl)-[1,1'-biphenyl]-4-yl) pyrrolidin-1-yl)(5-fluoropyridin-2-yl)methanone",
    "date_of_designation_or_refusal": "28/06/2024",
    "intended_use": "Treatment of pachyonychia congenita",
    "eu_designation_number": "EU/3/24/2935",
    "status": "Positive",
    "first_published_date": "22/08/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2935"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous induced pluripotent stem cells-derived thymic epithelial cells transduced with a lentiviral vector encoding forkhead box protein N1",
    "date_of_designation_or_refusal": "24/05/2024",
    "intended_use": "Treatment of DiGeorge syndrome",
    "eu_designation_number": "EU/3/24/2924",
    "status": "Positive",
    "first_published_date": "22/08/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2924"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous CD34+ cells transduced with a lentiviral vector containing the human RAG1 gene",
    "date_of_designation_or_refusal": "24/05/2024",
    "intended_use": "Treatment of recombination-activating gene 1 (RAG1) deficiency",
    "eu_designation_number": "EU/3/24/2918",
    "status": "Positive",
    "first_published_date": "22/08/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2918"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-(1,3-Benzothiazol-2-yl)-4-[(2-hydroxy-3-methoxyphenyl)methylamino]benzenesulfonamide",
    "date_of_designation_or_refusal": "24/05/2024",
    "intended_use": "Treatment of Platelet-activating anti-Platelet factor 4 (PF4) disorders",
    "eu_designation_number": "EU/3/24/2917",
    "status": "Positive",
    "first_published_date": "22/08/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2917"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "7-ethyl-10-hydroxy-camptothecin;irinotecan hydrochloride trihydrate",
    "date_of_designation_or_refusal": "24/05/2024",
    "intended_use": "Treatment of small cell lung cancer",
    "eu_designation_number": "EU/3/24/2923",
    "status": "Positive",
    "first_published_date": "22/08/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2923"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic non-alloreactive T cells edited with mRNA to disrupt TRAC and CD52 genes and transduced with lentiviral vector expressing a chimeric antigen receptor against CD22 and RQR8 depletion mechanism",
    "date_of_designation_or_refusal": "24/05/2024",
    "intended_use": "Treatment of acute lymphoblastic leukaemia",
    "eu_designation_number": "EU/3/24/2920",
    "status": "Positive",
    "first_published_date": "22/08/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2920"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "quabodepistat",
    "date_of_designation_or_refusal": "24/05/2024",
    "intended_use": "Treatment of tuberculosis",
    "eu_designation_number": "EU/3/24/2916",
    "status": "Positive",
    "first_published_date": "22/08/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2916"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus serotype rh.74 vector containing the human PKP2 gene isoform",
    "date_of_designation_or_refusal": "24/05/2024",
    "intended_use": "Treatment of arrhythmogenic cardiomyopathy caused by pathogenic mutations in the PKP2 gene",
    "eu_designation_number": "EU/3/24/2927",
    "status": "Positive",
    "first_published_date": "22/08/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2927"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "afamelanotide",
    "date_of_designation_or_refusal": "24/05/2024",
    "intended_use": "Treatment of xeroderma pigmentosum",
    "eu_designation_number": "EU/3/24/2926",
    "status": "Positive",
    "first_published_date": "22/08/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2926"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2,4-Diamino-5-[[5-(1H-pyrazol-5-yl)-2-thienyl]methyl]-1H-pyrimidin-6-one",
    "date_of_designation_or_refusal": "24/05/2024",
    "intended_use": "Treatment of hyperphenylalaninaemia",
    "eu_designation_number": "EU/3/24/2921",
    "status": "Positive",
    "first_published_date": "22/08/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2921"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "DNA plasmid containing the COL7A1 gene",
    "date_of_designation_or_refusal": "24/05/2024",
    "intended_use": "Treatment of epidermolysis bullosa",
    "eu_designation_number": "EU/3/24/2919",
    "status": "Positive",
    "first_published_date": "22/08/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2919"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "serdexmethylphenidate",
    "date_of_designation_or_refusal": "24/05/2024",
    "intended_use": "Treatment of idiopathic hypersomnia",
    "eu_designation_number": "EU/3/24/2915",
    "status": "Positive",
    "first_published_date": "22/08/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2915"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus serotype 9 containing CRISPR/Cas13Y and guide RNA against the human MECP2 gene",
    "date_of_designation_or_refusal": "24/05/2024",
    "intended_use": "Treatment of MECP2 duplication syndrome",
    "eu_designation_number": "EU/3/24/2922",
    "status": "Positive",
    "first_published_date": "22/08/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2922"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-(((2E)-3-(3-methoxy-4-(2-propyn-1-yloxy)phenyl)-1-oxo-2-propen-1-yl)amino)benzoic acid",
    "date_of_designation_or_refusal": "28/06/2024",
    "intended_use": "Treatment of systemic sclerosis",
    "eu_designation_number": "EU/3/24/2939",
    "status": "Positive",
    "first_published_date": "05/08/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2939"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "4-[[[4-[5-Chloro-2-[[trans-4-[[(1R)-2-methoxy-1-methyl-ethyl]amino]cyclohexyl]amino]-4-pyridinyl]-2-thiazolyl]amino]methyl]tetrahydro-2H-pyran-4-carbonitrile",
    "date_of_designation_or_refusal": "28/06/2024",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/24/2937",
    "status": "Positive",
    "first_published_date": "05/08/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2937"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human IgG1 monoclonal antibody against hepatitis B virus, surface antigen",
    "date_of_designation_or_refusal": "28/06/2024",
    "intended_use": "Treatment of hepatitis D virus infection",
    "eu_designation_number": "EU/3/24/2933",
    "status": "Positive",
    "first_published_date": "05/08/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2933"
  },
  {
    "medicine_name": "Adzynma",
    "related_ema_product_number": "EMEA/H/C/006198",
    "active_substance": "recombinant human ADAMTS-13",
    "date_of_designation_or_refusal": "03/12/2008",
    "intended_use": "Treatment of thrombotic thrombocytopenic purpura",
    "eu_designation_number": "EU/3/08/588",
    "status": "Positive",
    "first_published_date": "29/06/2009",
    "last_updated_date": "01/08/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-588"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "acetylleucine",
    "date_of_designation_or_refusal": "16/04/2024",
    "intended_use": "Treatment of ataxia-oculomotor apraxia",
    "eu_designation_number": "EU/3/24/2913",
    "status": "Positive",
    "first_published_date": "26/07/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2913"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "annamycin",
    "date_of_designation_or_refusal": "16/04/2024",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/24/2910",
    "status": "Positive",
    "first_published_date": "26/07/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2910"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised IgG1 (K322A) monoclonal antibody against disialoganglioside GD2",
    "date_of_designation_or_refusal": "16/04/2024",
    "intended_use": "Treatment of neuroblastoma",
    "eu_designation_number": "EU/3/24/2914",
    "status": "Positive",
    "first_published_date": "26/07/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2914"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous adipose-derived mesenchymal stem cells embedded in an extracellular matrix with hydroxyapatite/beta-tricalcium phosphate particles",
    "date_of_designation_or_refusal": "16/04/2024",
    "intended_use": "Treatment of congenital pseudarthrosis of long bones",
    "eu_designation_number": "EU/3/24/2912",
    "status": "Positive",
    "first_published_date": "26/07/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2912"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous adipose-derived stem cells",
    "date_of_designation_or_refusal": "16/04/2024",
    "intended_use": "Treatment of spinal cord injury",
    "eu_designation_number": "EU/3/24/2909",
    "status": "Positive",
    "first_published_date": "26/07/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2909"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sevasemten",
    "date_of_designation_or_refusal": "16/04/2024",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/24/2911",
    "status": "Positive",
    "first_published_date": "26/07/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2911"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "4-(4-Methyl-piperazin-1-yl)-N-{6-[2-(4-trifluoromethyl-benzyloxy)-ethoxy]-1H-indazol-3-yl}-benzamide hemioxalate",
    "date_of_designation_or_refusal": "21/03/2024",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/24/2908",
    "status": "Positive",
    "first_published_date": "23/07/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2908"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Mibavademab",
    "date_of_designation_or_refusal": "21/03/2024",
    "intended_use": "Treatment of Lawrence syndrome",
    "eu_designation_number": "EU/3/24/2904",
    "status": "Positive",
    "first_published_date": "23/07/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2904"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sevasemten",
    "date_of_designation_or_refusal": "21/03/2024",
    "intended_use": "Treatment of Becker muscular dystrophy",
    "eu_designation_number": "EU/3/24/2907",
    "status": "Positive",
    "first_published_date": "23/07/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2907"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "zatolmilast",
    "date_of_designation_or_refusal": "21/03/2024",
    "intended_use": "Treatment of fragile X syndrome",
    "eu_designation_number": "EU/3/24/2906",
    "status": "Positive",
    "first_published_date": "23/07/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2906"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Mibavademab",
    "date_of_designation_or_refusal": "21/03/2024",
    "intended_use": "Treatment of Berardinelli-Seip syndrome (congenital generalised lipodystrophy)",
    "eu_designation_number": "EU/3/24/2903",
    "status": "Positive",
    "first_published_date": "23/07/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2903"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous CD3-positive T-cells expressing a chimeric antigen receptor against B cell maturation agent",
    "date_of_designation_or_refusal": "21/03/2024",
    "intended_use": "Treatment of multiple myeloma",
    "eu_designation_number": "EU/3/24/2905",
    "status": "Positive",
    "first_published_date": "23/07/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2905"
  },
  {
    "medicine_name": "Alsitek; Masitinib AB Science",
    "related_ema_product_number": "EMEA/H/C/004398; EMEA/H/C/005897",
    "active_substance": "Masitinib mesilate",
    "date_of_designation_or_refusal": "29/08/2016",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/16/1722",
    "status": "Positive",
    "first_published_date": "03/10/2016",
    "last_updated_date": "28/06/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1722"
  },
  {
    "medicine_name": "Winrevair",
    "related_ema_product_number": "EMEA/H/C/005647",
    "active_substance": "sotatercept",
    "date_of_designation_or_refusal": "09/12/2020",
    "intended_use": "Treatment of  pulmonary arterial hypertension",
    "eu_designation_number": "EU/3/20/2369",
    "status": "Positive",
    "first_published_date": "21/05/2021",
    "last_updated_date": "28/06/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2369"
  },
  {
    "medicine_name": "Ordspono",
    "related_ema_product_number": "EMEA/H/C/006215",
    "active_substance": "odronextamab",
    "date_of_designation_or_refusal": "18/07/2022",
    "intended_use": "Treatment of diffuse large B-cell lymphoma",
    "eu_designation_number": "EU/3/22/2656",
    "status": "Positive",
    "first_published_date": "25/01/2023",
    "last_updated_date": "28/06/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2656"
  },
  {
    "medicine_name": "Ordspono",
    "related_ema_product_number": "EMEA/H/C/006215",
    "active_substance": "odronextamab",
    "date_of_designation_or_refusal": "18/07/2022",
    "intended_use": "Treatment of follicular lymphoma",
    "eu_designation_number": "EU/3/22/2649",
    "status": "Positive",
    "first_published_date": "25/01/2023",
    "last_updated_date": "28/06/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2649"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Brentuximab vedotin",
    "date_of_designation_or_refusal": "11/01/2012",
    "intended_use": "Treatment of cutaneous T-cell lymphoma",
    "eu_designation_number": "EU/3/11/939",
    "status": "Withdrawn",
    "first_published_date": "01/02/2012",
    "last_updated_date": "26/06/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-939"
  },
  {
    "medicine_name": "Adcetris",
    "related_ema_product_number": "EMEA/H/C/002455",
    "active_substance": "monoclonal antibody against human CD30 covalently linked to the cytotoxin monomethylauristatin E (brentuximab vedotin)",
    "date_of_designation_or_refusal": "15/01/2009",
    "intended_use": "Treatment of Hodgkin's lymphoma",
    "eu_designation_number": "EU/3/08/596",
    "status": "Withdrawn",
    "first_published_date": "15/05/2009",
    "last_updated_date": "26/06/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-596"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "monoclonal antibody against human CD30 covalently linked to the cytotoxin monomethylauristatin E",
    "date_of_designation_or_refusal": "21/08/2019",
    "intended_use": "Treatment of peripheral T-cell lymphoma",
    "eu_designation_number": "EU/3/08/595",
    "status": "Withdrawn",
    "first_published_date": "15/05/2009",
    "last_updated_date": "26/06/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-595"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sorafenib tosilate",
    "date_of_designation_or_refusal": "13/11/2013",
    "intended_use": "Treatment of papillary thyroid cancer",
    "eu_designation_number": "EU/3/13/1200",
    "status": "Expired",
    "first_published_date": "02/12/2013",
    "last_updated_date": "07/06/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1200"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sorafenib tosilate",
    "date_of_designation_or_refusal": "13/11/2013",
    "intended_use": "Treatment of follicular thyroid cancer",
    "eu_designation_number": "EU/3/13/1199",
    "status": "Expired",
    "first_published_date": "02/12/2013",
    "last_updated_date": "07/06/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1199"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "chimeric anti-interleukin-6 monoclonal antibody (siltuximab)",
    "date_of_designation_or_refusal": "30/11/2007",
    "intended_use": "Treatment of Castleman's disease",
    "eu_designation_number": "EU/3/07/508",
    "status": "Expired",
    "first_published_date": "29/07/2008",
    "last_updated_date": "07/06/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-508"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "6'-(R)-methyl-5-O-(5-amino-5,6-dideoxy-α-L-talofuranosyl)-paromamine sulfate",
    "date_of_designation_or_refusal": "22/09/2016",
    "intended_use": "Treatment of mucopolysaccharidosis type I",
    "eu_designation_number": "EU/3/16/1714",
    "status": "Positive",
    "first_published_date": "11/10/2016",
    "last_updated_date": "11/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1714"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Diacerein",
    "date_of_designation_or_refusal": "20/02/2014",
    "intended_use": "Treatment of epidermolysis bullosa",
    "eu_designation_number": "EU/3/14/1236",
    "status": "Positive",
    "first_published_date": "31/03/2014",
    "last_updated_date": "11/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1236"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "3,3-Dimethyl-N-(6-methyl-5-{[2-(1-methyl-1H-pyrazol-4-yl)pyridine-4-yl]oxy}pyridine-2-yl)-2-oxopyrrolidine-1-carboxamide hydrochloride hydrate",
    "date_of_designation_or_refusal": "13/12/2023",
    "intended_use": "Treatment of tenosynovial giant cell tumour, localised and diffuse type",
    "eu_designation_number": "EU/3/23/2873",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "11/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2873"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "batoclimab",
    "date_of_designation_or_refusal": "10/08/2022",
    "intended_use": "Treatment of myasthenia gravis",
    "eu_designation_number": "EU/3/22/2684",
    "status": "Positive",
    "first_published_date": "15/12/2022",
    "last_updated_date": "11/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2684"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(S)-8-{2-amino-6-[1-(5-chloro-biphenyl-2-yl)-(R)-2,2,2-trifluoro-ethoxy]-pyrimidin-4-yl}-2,8-diaza-spiro[4.5]decane-3-carboxylic acid ethyl ester",
    "date_of_designation_or_refusal": "20/04/2017",
    "intended_use": "Treatment of pulmonary arterial hypertension",
    "eu_designation_number": "EU/3/17/1861",
    "status": "Positive",
    "first_published_date": "15/05/2017",
    "last_updated_date": "11/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1861"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "cusatuzumab",
    "date_of_designation_or_refusal": "22/04/2020",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/20/2265",
    "status": "Positive",
    "first_published_date": "11/08/2020",
    "last_updated_date": "11/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2265"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "synthetic hypericin",
    "date_of_designation_or_refusal": "28/07/2015",
    "intended_use": "Treatment of cutaneous T-cell lymphoma",
    "eu_designation_number": "EU/3/15/1515",
    "status": "Positive",
    "first_published_date": "18/08/2015",
    "last_updated_date": "11/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1515"
  },
  {
    "medicine_name": "Ezmekly",
    "related_ema_product_number": "EMEA/H/C/006460",
    "active_substance": "N-((R)-2,3-dihydroxypropoxyl)-3,4-difluro-2-(2-fluoro-4-iodo-phenylamino)-benzamide",
    "date_of_designation_or_refusal": "25/07/2019",
    "intended_use": "Treatment of neurofibromatosis type 1",
    "eu_designation_number": "EU/3/19/2184",
    "status": "Positive",
    "first_published_date": "24/09/2019",
    "last_updated_date": "11/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2184"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "anti-CD3 mAb (SPV-T3a)-ricin A chain fusion protein;anti-CD7 mAb (WT1)-ricin A chain fusion protein",
    "date_of_designation_or_refusal": "26/08/2005",
    "intended_use": "Treatment of graft-versus-host disease",
    "eu_designation_number": "EU/3/05/317",
    "status": "Positive",
    "first_published_date": "27/10/2005",
    "last_updated_date": "11/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-317"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tranilast",
    "date_of_designation_or_refusal": "27/07/2010",
    "intended_use": "Prevention of scarring post glaucoma filtration surgery",
    "eu_designation_number": "EU/3/10/756",
    "status": "Positive",
    "first_published_date": "06/08/2010",
    "last_updated_date": "11/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-756"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium (4-{(E)-3-(4-fluorophenyl)-3-[4-(3-morpholin-4-yl-prop1ynyl)phenyl]allyloxy}-2-methylphenoxy)acetate",
    "date_of_designation_or_refusal": "21/08/2020",
    "intended_use": "Treatment of mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes",
    "eu_designation_number": "EU/3/20/2311",
    "status": "Withdrawn",
    "first_published_date": "25/11/2020",
    "last_updated_date": "11/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2311"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium (4-{(E)-3-(4-fluorophenyl)-3-[4-(3-morpholin-4-yl-prop1ynyl)phenyl]allyloxy}-2-methylphenoxy)acetate",
    "date_of_designation_or_refusal": "21/08/2020",
    "intended_use": "Treatment of long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency",
    "eu_designation_number": "EU/3/20/2319",
    "status": "Withdrawn",
    "first_published_date": "25/11/2020",
    "last_updated_date": "11/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2319"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Interferon beta",
    "date_of_designation_or_refusal": "29/11/2007",
    "intended_use": "Treatment of acute respiratory distress syndrome (ARDS)",
    "eu_designation_number": "EU/3/07/505",
    "status": "Withdrawn",
    "first_published_date": "02/07/2008",
    "last_updated_date": "11/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-505"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "",
    "date_of_designation_or_refusal": "16/01/2014",
    "intended_use": "Treatment of acute lymphoblastic leukaemia",
    "eu_designation_number": "EU/3/13/1231",
    "status": "Positive",
    "first_published_date": "24/03/2014",
    "last_updated_date": "11/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1231"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "",
    "date_of_designation_or_refusal": "16/01/2014",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/13/1230",
    "status": "Withdrawn",
    "first_published_date": "24/03/2014",
    "last_updated_date": "11/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1230"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "branaplam",
    "date_of_designation_or_refusal": "16/04/2018",
    "intended_use": "Treatment of spinal muscular atrophy",
    "eu_designation_number": "EU/3/18/2010",
    "status": "Withdrawn",
    "first_published_date": "17/05/2018",
    "last_updated_date": "11/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2010"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "antisense oligonucleotide targeting exon 73 in the COL7A1 gene",
    "date_of_designation_or_refusal": "12/10/2017",
    "intended_use": "Treatment of epidermolysis bullosa",
    "eu_designation_number": "EU/3/17/1938",
    "status": "Withdrawn",
    "first_published_date": "15/01/2018",
    "last_updated_date": "11/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1938"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant adeno-associated viral vector serotype S3 containing codon-optimised expression cassette encoding human coagulation factor IX variant",
    "date_of_designation_or_refusal": "26/10/2018",
    "intended_use": "Treatment of haemophilia B",
    "eu_designation_number": "EU/3/18/2080",
    "status": "Withdrawn",
    "first_published_date": "11/01/2019",
    "last_updated_date": "11/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2080"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "repagermanium",
    "date_of_designation_or_refusal": "19/02/2024",
    "intended_use": "Treatment of focal segmental glomerulosclerosis",
    "eu_designation_number": "EU/3/24/2897",
    "status": "Positive",
    "first_published_date": "11/04/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2897"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "andecaliximab",
    "date_of_designation_or_refusal": "19/02/2024",
    "intended_use": "Treatment of fibrodysplasia ossificans progressiva",
    "eu_designation_number": "EU/3/24/2901",
    "status": "Positive",
    "first_published_date": "11/04/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2901"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "raludotatug deruxtecan",
    "date_of_designation_or_refusal": "19/02/2024",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/24/2890",
    "status": "Positive",
    "first_published_date": "11/04/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2890"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "",
    "date_of_designation_or_refusal": "19/02/2024",
    "intended_use": "Treatment of small cell lung cancer",
    "eu_designation_number": "EU/3/24/2892",
    "status": "Positive",
    "first_published_date": "11/04/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2892"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "carboplatin",
    "date_of_designation_or_refusal": "19/02/2024",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/24/2891",
    "status": "Positive",
    "first_published_date": "11/04/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2891"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Plerixafor",
    "date_of_designation_or_refusal": "19/02/2024",
    "intended_use": "Treatment of acute respiratory distress syndrome (ARDS)",
    "eu_designation_number": "EU/3/24/2899",
    "status": "Positive",
    "first_published_date": "11/04/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2899"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous CD3-positive T-cells expressing a chimeric antigen receptor against B cell maturation agent",
    "date_of_designation_or_refusal": "19/02/2024",
    "intended_use": "Treatment of AL amyloidosis",
    "eu_designation_number": "EU/3/24/2900",
    "status": "Positive",
    "first_published_date": "11/04/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2900"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human IgG1 monoclonal antibody targeting amyloid transthyretin",
    "date_of_designation_or_refusal": "19/02/2024",
    "intended_use": "Treatment of ATTR amyloidosis",
    "eu_designation_number": "EU/3/24/2896",
    "status": "Positive",
    "first_published_date": "11/04/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2896"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "paclitaxel",
    "date_of_designation_or_refusal": "19/02/2024",
    "intended_use": "Treatment of gastric cancer",
    "eu_designation_number": "EU/3/24/2893",
    "status": "Positive",
    "first_published_date": "11/04/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2893"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adenine",
    "date_of_designation_or_refusal": "12/01/2024",
    "intended_use": "Treatment of epidermolysis bullosa",
    "eu_designation_number": "EU/3/23/2880",
    "status": "Positive",
    "first_published_date": "11/04/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2880"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human heparan-N-sulfatase",
    "date_of_designation_or_refusal": "12/01/2024",
    "intended_use": "Treatment of mucopolysaccharidosis type IIIA (Sanfilippo A syndrome)",
    "eu_designation_number": "EU/3/23/2888",
    "status": "Positive",
    "first_published_date": "11/04/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2888"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ziftomenib",
    "date_of_designation_or_refusal": "12/01/2024",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/23/2881",
    "status": "Positive",
    "first_published_date": "11/04/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2881"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "apilimod dimesilate",
    "date_of_designation_or_refusal": "12/01/2024",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/23/2877",
    "status": "Positive",
    "first_published_date": "11/04/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2877"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 9 containing the human MECP2 gene, an intron encoding a miRNA generating sequence, and complementary miRNA binding sites",
    "date_of_designation_or_refusal": "12/01/2024",
    "intended_use": "Treatment of Rett syndrome",
    "eu_designation_number": "EU/3/23/2884",
    "status": "Positive",
    "first_published_date": "11/04/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2884"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "cutamesine",
    "date_of_designation_or_refusal": "12/01/2024",
    "intended_use": "alpha-thalassaemia X-linked intellectual disability syndrome (due to mutations in the ATRX gene)",
    "eu_designation_number": "EU/3/23/2883",
    "status": "Positive",
    "first_published_date": "11/04/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2883"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tarlatamab",
    "date_of_designation_or_refusal": "12/01/2024",
    "intended_use": "Treatment of small cell lung cancer",
    "eu_designation_number": "EU/3/23/2876",
    "status": "Positive",
    "first_published_date": "11/04/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2876"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "motixafortide",
    "date_of_designation_or_refusal": "12/01/2024",
    "intended_use": "Treatment of patients undergoing haematopoietic stem cell transplantation",
    "eu_designation_number": "EU/3/23/2885",
    "status": "Positive",
    "first_published_date": "11/04/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2885"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "mitapivat sulfate",
    "date_of_designation_or_refusal": "12/01/2024",
    "intended_use": "Treatment of thalassaemia intermedia and major",
    "eu_designation_number": "EU/3/23/2889",
    "status": "Positive",
    "first_published_date": "11/04/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2889"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "thiophene methylimidazole pentahydrogen",
    "date_of_designation_or_refusal": "12/01/2024",
    "intended_use": "Diagnosis of glioma",
    "eu_designation_number": "EU/3/23/2875",
    "status": "Positive",
    "first_published_date": "11/04/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2875"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Ersodetug",
    "date_of_designation_or_refusal": "12/01/2024",
    "intended_use": "Treatment of insulinoma",
    "eu_designation_number": "EU/3/23/2879",
    "status": "Positive",
    "first_published_date": "11/04/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2879"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Methyl-(1-{[6-{[(1S)-1-cyclopropylethyl]amino}-2-(pyrazolo[5,1-b][1,3]thiazol-7-yl)-pyrimidin-4-yl]carbonyl}piperidin-4-yl)carbamate mono(4-methylbenzenesulfonate)",
    "date_of_designation_or_refusal": "12/01/2024",
    "intended_use": "Treatment of eosinophilic granulomatosis with polyangiitis",
    "eu_designation_number": "EU/3/23/2882",
    "status": "Positive",
    "first_published_date": "11/04/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2882"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "golcadomide hydrochloride",
    "date_of_designation_or_refusal": "12/01/2024",
    "intended_use": "Treatment of diffuse large B-cell lymphoma",
    "eu_designation_number": "EU/3/23/2878",
    "status": "Positive",
    "first_published_date": "11/04/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2878"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human coagulation factor X",
    "date_of_designation_or_refusal": "12/01/2024",
    "intended_use": "Treatment of acquired factor X deficiency",
    "eu_designation_number": "EU/3/23/2886",
    "status": "Positive",
    "first_published_date": "11/04/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2886"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(4R)-3-(4-fluoro-2-hydroxyphenyl)-4-methyl-4,5-dihydro-1H-pyrazole-1-carboximidamide hydrochloride",
    "date_of_designation_or_refusal": "12/01/2024",
    "intended_use": "Treatment of systemic sclerosis",
    "eu_designation_number": "EU/3/23/2874",
    "status": "Positive",
    "first_published_date": "11/04/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2874"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "mRNA encoding the human CFTR gene",
    "date_of_designation_or_refusal": "19/02/2024",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/24/2894",
    "status": "Positive",
    "first_published_date": "11/04/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2894"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "fidanacogene elaparvovec",
    "date_of_designation_or_refusal": "19/11/2018",
    "intended_use": "Treatment of haemophilia B",
    "eu_designation_number": "EU/3/18/2090",
    "status": "Withdrawn",
    "first_published_date": "19/02/2019",
    "last_updated_date": "09/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2090"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "veliparib",
    "date_of_designation_or_refusal": "17/12/2010",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/10/830",
    "status": "Withdrawn",
    "first_published_date": "20/01/2011",
    "last_updated_date": "09/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-830"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "eflornithine",
    "date_of_designation_or_refusal": "27/09/2011",
    "intended_use": "Treatment of neuroblastoma",
    "eu_designation_number": "EU/3/11/902",
    "status": "Withdrawn",
    "first_published_date": "17/10/2011",
    "last_updated_date": "09/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-902"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "genetically modified serotype 5/3 adenovirus coding for granulocyte macrophage colony-stimulating factor for the treatment of ovarian cancer",
    "date_of_designation_or_refusal": "29/04/2014",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/14/1265",
    "status": "Withdrawn",
    "first_published_date": "04/06/2014",
    "last_updated_date": "09/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1265"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(6aR, 10aR)-3-(1',1'-dimethylheptyl)-delta-8-tetrahydro-cannabinol-9-carboxylic acid",
    "date_of_designation_or_refusal": "12/01/2017",
    "intended_use": "Treatment of systemic sclerosis",
    "eu_designation_number": "EU/3/16/1808",
    "status": "Withdrawn",
    "first_published_date": "14/07/2017",
    "last_updated_date": "09/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1808"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 9 encoding a codon-optimised human aspartylglucosaminidase transgene",
    "date_of_designation_or_refusal": "19/10/2020",
    "intended_use": "Treatment of aspartylglucosaminuria",
    "eu_designation_number": "EU/3/20/2334",
    "status": "Withdrawn",
    "first_published_date": "12/02/2021",
    "last_updated_date": "09/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2334"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(6aR,10aR)-3-(1,1-dimethylheptyl)-delta8-tetrahydro-cannabinol-9-carboxylic acid",
    "date_of_designation_or_refusal": "14/10/2016",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/16/1736",
    "status": "Withdrawn",
    "first_published_date": "15/11/2016",
    "last_updated_date": "09/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1736"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(6aR,10aR)-3-(1,1-dimethylheptyl)-delta8-tetrahydro-cannabinol-9-carboxylic acid",
    "date_of_designation_or_refusal": "",
    "intended_use": "Treatment of dermatomyositis",
    "eu_designation_number": "EU/3/18/2070",
    "status": "Withdrawn",
    "first_published_date": "10/01/2019",
    "last_updated_date": "09/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2070"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "3-(((1S,2S,3R)-2,3-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile",
    "date_of_designation_or_refusal": "21/08/2020",
    "intended_use": "Treatment of von Hippel-Lindau disease",
    "eu_designation_number": "EU/3/20/2324",
    "status": "Withdrawn",
    "first_published_date": "25/11/2020",
    "last_updated_date": "09/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2324"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Bis-(3-deoxy-3-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-beta-D-galactopyranosyl) sulfane",
    "date_of_designation_or_refusal": "21/08/2020",
    "intended_use": "Treatment of idiopathic pulmonary fibrosis",
    "eu_designation_number": "EU/3/20/2309",
    "status": "Withdrawn",
    "first_published_date": "25/11/2020",
    "last_updated_date": "09/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2309"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector containing porphobilinogen deaminase gene",
    "date_of_designation_or_refusal": "29/04/2009",
    "intended_use": "Treatment of acute intermittent porphyria",
    "eu_designation_number": "EU/3/09/632",
    "status": "Withdrawn",
    "first_published_date": "12/05/2009",
    "last_updated_date": "09/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-632"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector of serotype 5 containing the human alanine-glyoxylate-aminotransferase gene",
    "date_of_designation_or_refusal": "21/03/2012",
    "intended_use": "Treatment of primary hyperoxaluria type 1",
    "eu_designation_number": "EU/3/12/974",
    "status": "Withdrawn",
    "first_published_date": "19/04/2012",
    "last_updated_date": "09/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-974"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector containing modified U1 snRNA",
    "date_of_designation_or_refusal": "08/10/2009",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/09/663",
    "status": "Positive",
    "first_published_date": "20/10/2009",
    "last_updated_date": "09/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-663"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Florilglutamic acid (18F)",
    "date_of_designation_or_refusal": "21/03/2016",
    "intended_use": "Diagnosis of glioma",
    "eu_designation_number": "EU/3/16/1631",
    "status": "Withdrawn",
    "first_published_date": "02/05/2016",
    "last_updated_date": "09/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1631"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Florilglutamic acid (18F)",
    "date_of_designation_or_refusal": "21/03/2016",
    "intended_use": "Diagnosis of hepatocellular carcinoma",
    "eu_designation_number": "EU/3/16/1632",
    "status": "Withdrawn",
    "first_published_date": "02/05/2016",
    "last_updated_date": "09/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1632"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous CD34+ cells transduced with a lentiviral vector encoding galactosidase alpha",
    "date_of_designation_or_refusal": "19/10/2020",
    "intended_use": "Treatment of Fabry disease",
    "eu_designation_number": "EU/3/20/2341",
    "status": "Withdrawn",
    "first_published_date": "16/02/2021",
    "last_updated_date": "09/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2341"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus serotype HSC15, containing human homology arms, expressing human phenylalanine hydroxylase",
    "date_of_designation_or_refusal": "16/03/2022",
    "intended_use": "Treatment of phenylalanine hydroxylase deficiency",
    "eu_designation_number": "EU/3/22/2593",
    "status": "Withdrawn",
    "first_published_date": "20/06/2022",
    "last_updated_date": "09/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2593"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 8 containing a functional copy of the codon-optimised F8 cDNA encoding the B-domain deleted human coagulation factor VIII",
    "date_of_designation_or_refusal": "25/05/2018",
    "intended_use": "Treatment of haemophilia A",
    "eu_designation_number": "EU/3/18/2015",
    "status": "Withdrawn",
    "first_published_date": "18/07/2018",
    "last_updated_date": "09/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2015"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous CD34+ cells transduced with a lentiviral vector encoding glucosylceramidase beta",
    "date_of_designation_or_refusal": "21/08/2020",
    "intended_use": "Treatment of Gaucher disease",
    "eu_designation_number": "EU/3/20/2326",
    "status": "Positive",
    "first_published_date": "25/11/2020",
    "last_updated_date": "09/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2326"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic cultured postnatal thymus-derived tissue",
    "date_of_designation_or_refusal": "26/02/2019",
    "intended_use": "Treatment of DiGeorge syndrome",
    "eu_designation_number": "EU/3/19/2135",
    "status": "Positive",
    "first_published_date": "09/04/2019",
    "last_updated_date": "08/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2135"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic cultured postnatal thymus-derived tissue",
    "date_of_designation_or_refusal": "26/02/2019",
    "intended_use": "Treatment of CHARGE syndrome",
    "eu_designation_number": "EU/3/19/2136",
    "status": "Positive",
    "first_published_date": "09/04/2019",
    "last_updated_date": "08/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2136"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "azithromycin dihydrate",
    "date_of_designation_or_refusal": "14/01/2022",
    "intended_use": "Prevention of bronchopulmonary dysplasia",
    "eu_designation_number": "EU/3/21/2568",
    "status": "Positive",
    "first_published_date": "15/06/2022",
    "last_updated_date": "08/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2568"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Mavorixafor",
    "date_of_designation_or_refusal": "25/07/2019",
    "intended_use": "Treatment of WHIM syndrome",
    "eu_designation_number": "EU/3/19/2183",
    "status": "Positive",
    "first_published_date": "24/09/2019",
    "last_updated_date": "08/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2183"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Glycyl-L-2-methylprolyl-L-glutamic acid",
    "date_of_designation_or_refusal": "28/07/2015",
    "intended_use": "Treatment of fragile X syndrome",
    "eu_designation_number": "EU/3/15/1529",
    "status": "Positive",
    "first_published_date": "18/08/2015",
    "last_updated_date": "08/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1529"
  },
  {
    "medicine_name": "Ogsiveo",
    "related_ema_product_number": "EMEA/H/C/006071",
    "active_substance": "nirogacestat",
    "date_of_designation_or_refusal": "17/10/2019",
    "intended_use": "Treatment of soft tissue sarcoma",
    "eu_designation_number": "EU/3/19/2214",
    "status": "Positive",
    "first_published_date": "23/01/2020",
    "last_updated_date": "08/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2214"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus serotype rh10 containing the human GALC gene",
    "date_of_designation_or_refusal": "15/10/2021",
    "intended_use": "Treatment of Krabbe disease",
    "eu_designation_number": "EU/3/21/2511",
    "status": "Positive",
    "first_published_date": "21/01/2022",
    "last_updated_date": "08/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2511"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Oxygen, sodium chloride solution 0.9%",
    "date_of_designation_or_refusal": "11/10/2022",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/22/2692",
    "status": "Positive",
    "first_published_date": "24/01/2023",
    "last_updated_date": "08/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2692"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant adeno-associated viral vector encoding a human micro-dystrophin gene under the control of a muscle specific promoter",
    "date_of_designation_or_refusal": "14/10/2016",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/16/1759",
    "status": "Positive",
    "first_published_date": "15/11/2016",
    "last_updated_date": "08/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1759"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "olorofim",
    "date_of_designation_or_refusal": "14/01/2022",
    "intended_use": "Treatment of invasive Scopulariopsis",
    "eu_designation_number": "EU/3/21/2563",
    "status": "Positive",
    "first_published_date": "09/06/2022",
    "last_updated_date": "08/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2563"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-{4-[4-(5-fluoro-pyrimidin-2-yl)piperazin-1-yl]-phenyl}-2-oxo-acetamide (also known as F901318) (olorofim)",
    "date_of_designation_or_refusal": "29/08/2016",
    "intended_use": "Treatment of scedosporiosis",
    "eu_designation_number": "EU/3/16/1713",
    "status": "Positive",
    "first_published_date": "03/10/2016",
    "last_updated_date": "08/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1713"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "melatonin",
    "date_of_designation_or_refusal": "02/04/2012",
    "intended_use": "Treatment of perinatal asphyxia",
    "eu_designation_number": "EU/3/12/978",
    "status": "Positive",
    "first_published_date": "30/04/2012",
    "last_updated_date": "08/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-978"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous CD34+ cells transduced with a lentiviral RNA vector that results in integrated cDNA encoding for functional cystinosin",
    "date_of_designation_or_refusal": "19/02/2021",
    "intended_use": "Treatment of cystinosis",
    "eu_designation_number": "EU/3/21/2407",
    "status": "Positive",
    "first_published_date": "23/02/2022",
    "last_updated_date": "08/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2407"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "imatinib",
    "date_of_designation_or_refusal": "21/06/2021",
    "intended_use": "Treatment of  pulmonary arterial hypertension",
    "eu_designation_number": "EU/3/21/2449",
    "status": "Positive",
    "first_published_date": "11/05/2022",
    "last_updated_date": "08/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2449"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "alisitol;retinol palmitate;zinc gluconate",
    "date_of_designation_or_refusal": "13/11/2020",
    "intended_use": "Treatment of microvillus inclusion disease",
    "eu_designation_number": "EU/3/20/2354",
    "status": "Positive",
    "first_published_date": "15/02/2021",
    "last_updated_date": "08/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2354"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 8 encoding B-domain deleted liver specific codon optimized bioengineered chimeric human porcine factor VIII, under a synthetic hepatic combinatorial bundle promoter",
    "date_of_designation_or_refusal": "13/04/2022",
    "intended_use": "Treatment of  haemophilia A",
    "eu_designation_number": "EU/3/22/2606",
    "status": "Positive",
    "first_published_date": "19/07/2022",
    "last_updated_date": "08/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2606"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic placenta-derived decidual stromal cells",
    "date_of_designation_or_refusal": "10/08/2022",
    "intended_use": "Treatment of graft-versus-host-disease",
    "eu_designation_number": "EU/3/22/2679",
    "status": "Positive",
    "first_published_date": "15/12/2022",
    "last_updated_date": "08/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2679"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "rovatirelin",
    "date_of_designation_or_refusal": "11/11/2022",
    "intended_use": "Treatment of spinocerebellar ataxia",
    "eu_designation_number": "EU/3/22/2715",
    "status": "Positive",
    "first_published_date": "23/01/2023",
    "last_updated_date": "08/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2715"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide, (L)-malate salt (cabozantinib)",
    "date_of_designation_or_refusal": "06/02/2009",
    "intended_use": "Treatment of medullary thyroid carcinoma",
    "eu_designation_number": "EU/3/08/610",
    "status": "Positive",
    "first_published_date": "29/06/2009",
    "last_updated_date": "02/04/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-610"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tislelizumab",
    "date_of_designation_or_refusal": "06/03/2024",
    "intended_use": "Treatment of hepatocellular carcinoma",
    "eu_designation_number": "EU/3/20/2269",
    "status": "Withdrawn",
    "first_published_date": "15/03/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2269"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(1R,2S) 6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-(1-naphthyl)-beta-phenyl-3-quinolineethanol bedaquiline",
    "date_of_designation_or_refusal": "26/08/2005",
    "intended_use": "Treatment of tuberculosis",
    "eu_designation_number": "EU/3/05/314",
    "status": "Withdrawn",
    "first_published_date": "17/09/2009",
    "last_updated_date": "13/03/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-314"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "selumetinib",
    "date_of_designation_or_refusal": "13/12/2023",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/23/2870",
    "status": "Positive",
    "first_published_date": "08/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2870"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous T lymphocytes containing a T-cell receptor against Epstein–Barr virus",
    "date_of_designation_or_refusal": "13/12/2023",
    "intended_use": "Treatment of peripheral T-cell lymphoma",
    "eu_designation_number": "EU/3/23/2868",
    "status": "Positive",
    "first_published_date": "02/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2868"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2'-O, 4'-C-Methylene-P-thio-adenylyl-(3'->5')-2'-O, 4'-C-methylene-P-thioguanylyl-(3'->5')-2'-O, 4'-C-methylene-P-thio-adenylyl-(3'->5')-2'-deoxy-P-thioadenylyl-(3'->5')-2'-deoxy-P-thio-thymidylyl-(3'->5')-2'-deoxy-P-thio-guanylyl-(3'->5')-2'-deoxy-P-thio-guanylyl-(3'->5')-2'-deoxy-P-thio-cytidylyl-(3'->5')-2'-deoxy-P-thio-adenylyl-(3'->5')-2'-deoxy-P-thio-cytidylyl-(3'->5')-2'-deoxy-P-thio-adenylyl-(3'->5')-2'-deoxy-P-thio-thymidylyl-(3'->5')-2'-deoxy-P-thio-cytidylyl-(3'->5')-2'-deoxy-P-thio-thymidylyl-(3'->5')-2'-O, 4'-C-methylene-5-methyl-P-thio-cytidylyl-(3'->5')-2'-O, 4'-C-methylene-5-methyl-P-thio-uridylyl-(3'->5')-2'-O, 4'-C-methylene-5-methyl-P-thio-uridylyl-(3'->5')-2'-O, 4'-C-methyleneguanosine",
    "date_of_designation_or_refusal": "13/12/2023",
    "intended_use": "Treatment of Angelman syndrome",
    "eu_designation_number": "EU/3/23/2869",
    "status": "Positive",
    "first_published_date": "02/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2869"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "brogidirsen",
    "date_of_designation_or_refusal": "13/12/2023",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/23/2863",
    "status": "Positive",
    "first_published_date": "02/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2863"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised IgG1 kappa fragment antibody targeting TfR1 conjugated to P125 oligonucleotide",
    "date_of_designation_or_refusal": "22/05/2023",
    "intended_use": "Treatment of myotonic disorders",
    "eu_designation_number": "EU/3/23/2781",
    "status": "Positive",
    "first_published_date": "02/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2781"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "govorestat",
    "date_of_designation_or_refusal": "22/05/2023",
    "intended_use": "Treatment of Charcot-Marie-Tooth disease",
    "eu_designation_number": "EU/3/23/2783",
    "status": "Positive",
    "first_published_date": "02/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2783"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-((2-fluoro-4-iodophenyl)amino)-N-(2-hydroxyethoxy)-1-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamide",
    "date_of_designation_or_refusal": "22/05/2023",
    "intended_use": "Treatment of neurofibromatosis type 1",
    "eu_designation_number": "EU/3/23/2779",
    "status": "Positive",
    "first_published_date": "02/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2779"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "aspacytarabine",
    "date_of_designation_or_refusal": "22/05/2023",
    "intended_use": "Treatment of myelodysplastic syndromes",
    "eu_designation_number": "EU/3/23/2782",
    "status": "Positive",
    "first_published_date": "02/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2782"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Fingolimod",
    "date_of_designation_or_refusal": "22/05/2023",
    "intended_use": "Treatment of hypomyelinating leukodystrophy-18",
    "eu_designation_number": "EU/3/23/2776",
    "status": "Positive",
    "first_published_date": "02/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2776"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Efzofitimod",
    "date_of_designation_or_refusal": "20/06/2023",
    "intended_use": "Treatment of systemic sclerosis",
    "eu_designation_number": "EU/3/23/2795",
    "status": "Positive",
    "first_published_date": "02/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2795"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "fasudil hydrochloride",
    "date_of_designation_or_refusal": "20/06/2023",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/23/2789",
    "status": "Positive",
    "first_published_date": "02/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2789"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus vector serotype 8 encoding the ABCA4 protein, C-region, adeno-associated virus vector serotype 8 encoding the ABCA4 protein, N-region",
    "date_of_designation_or_refusal": "20/06/2023",
    "intended_use": "Treatment of inherited retinal dystrophies",
    "eu_designation_number": "EU/3/23/2788",
    "status": "Positive",
    "first_published_date": "02/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2788"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(3S,3'S,3a'S,10a'S)-6-chloro-3'-(3-chloro-2-fluorophenyl)-1'-(cyclopropylmethyl)-6'-methyl-2-oxo-1,2,3',3a',10',10a'-hexahydro-1'H-spiro[indole-3,2'-pyrrolo[2',3':4,5]pyrrolo[1,2-b]indazole]-7'-carboxylic acid",
    "date_of_designation_or_refusal": "20/06/2023",
    "intended_use": "Treatment of soft tissue sarcoma",
    "eu_designation_number": "EU/3/23/2792",
    "status": "Positive",
    "first_published_date": "02/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2792"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Evorpacept",
    "date_of_designation_or_refusal": "20/06/2023",
    "intended_use": "Treatment of gastric cancer",
    "eu_designation_number": "EU/3/23/2787",
    "status": "Positive",
    "first_published_date": "02/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2787"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous CD34+ haematopoietic stem and progenitor cells transduced with a lentiviral vector encoding the interferon alpha-2 gene",
    "date_of_designation_or_refusal": "20/06/2023",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/23/2794",
    "status": "Positive",
    "first_published_date": "02/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2794"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous dendritic cells pulsed with allogeneic tumour cell lysate",
    "date_of_designation_or_refusal": "20/06/2023",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/23/2790",
    "status": "Positive",
    "first_published_date": "02/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2790"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "exenatide",
    "date_of_designation_or_refusal": "20/06/2023",
    "intended_use": "Treatment of moderate and severe closed traumatic brain injury",
    "eu_designation_number": "EU/3/23/2793",
    "status": "Positive",
    "first_published_date": "02/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2793"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus vector serotype 9 containing the PKP2 gene",
    "date_of_designation_or_refusal": "16/08/2023",
    "intended_use": "Treatment of arrhythmogenic right ventricular cardiomyopathy due to plakophilin-2 gene mutations",
    "eu_designation_number": "EU/3/23/2824",
    "status": "Positive",
    "first_published_date": "02/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2824"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2'-O-(2-methoxyethyl) modified antisense oligonucleotide targeting PLP1 pre-mRNA",
    "date_of_designation_or_refusal": "16/08/2023",
    "intended_use": "Treatment of Pelizaeus-Merzbacher disease",
    "eu_designation_number": "EU/3/23/2823",
    "status": "Positive",
    "first_published_date": "02/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2823"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Herpes simplex virus-1, derived from strain F, with deletions on genes gamma (1) 34.5 and UL39",
    "date_of_designation_or_refusal": "16/08/2023",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/23/2820",
    "status": "Positive",
    "first_published_date": "02/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2820"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "virus-like particle containing Cas9/gRNA ribonucleoprotein targeting the human HTT gene",
    "date_of_designation_or_refusal": "16/08/2023",
    "intended_use": "Treatment of Huntington’s disease",
    "eu_designation_number": "EU/3/23/2819",
    "status": "Positive",
    "first_published_date": "02/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2819"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "cedazuridine;decitabine",
    "date_of_designation_or_refusal": "16/08/2023",
    "intended_use": "Treatment of myelodysplastic syndromes",
    "eu_designation_number": "EU/3/23/2825",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2825"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Mitazalimab",
    "date_of_designation_or_refusal": "16/08/2023",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/23/2821",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2821"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic faecal microbiota, pooled",
    "date_of_designation_or_refusal": "16/08/2023",
    "intended_use": "Treatment in haematopoietic stem cell transplantation",
    "eu_designation_number": "EU/3/23/2818",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2818"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "alprostadil",
    "date_of_designation_or_refusal": "16/08/2023",
    "intended_use": "Treatment of in solid organ transplantation",
    "eu_designation_number": "EU/3/23/2817",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2817"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Adeno-associated viral vector serotype rh10 encoding miRNA against SOD1 mRNA",
    "date_of_designation_or_refusal": "08/11/2023",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/23/2859",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2859"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "oregovomab",
    "date_of_designation_or_refusal": "08/11/2023",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/23/2857",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2857"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "rucosopasem manganese",
    "date_of_designation_or_refusal": "08/11/2023",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/23/2852",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2852"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "5-bromo-N-(prop-2-yn-1-yl)-2-(1H-1,2,4-triazol-1-yl)pyrimidine-4,6-diamine",
    "date_of_designation_or_refusal": "08/11/2023",
    "intended_use": "Treatment of Prader-Willi syndrome",
    "eu_designation_number": "EU/3/23/2855",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2855"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ambroxol hydrochloride",
    "date_of_designation_or_refusal": "08/11/2023",
    "intended_use": "Treatment of Gaucher disease",
    "eu_designation_number": "EU/3/23/2849",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2849"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "bortezomib",
    "date_of_designation_or_refusal": "08/11/2023",
    "intended_use": "Treatment of patients with light chain (AL) amyloidosis",
    "eu_designation_number": "EU/3/23/2848",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2848"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "setanaxib",
    "date_of_designation_or_refusal": "08/11/2023",
    "intended_use": "Treatment of Alport syndrome",
    "eu_designation_number": "EU/3/23/2850",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2850"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "bersiporocin",
    "date_of_designation_or_refusal": "13/12/2023",
    "intended_use": "Treatment of idiopathic pulmonary fibrosis",
    "eu_designation_number": "EU/3/23/2871",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2871"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Methyl 4-(2-acetamidoethylsulfanyl)-4-oxobutanoate",
    "date_of_designation_or_refusal": "13/12/2023",
    "intended_use": "Treatment of Leigh syndrome",
    "eu_designation_number": "EU/3/23/2867",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2867"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic amniotic fluid-derived mesenchymal stem cells with lung specificity",
    "date_of_designation_or_refusal": "13/12/2023",
    "intended_use": "Prevention of primary graft dysfunction following lung transplantation",
    "eu_designation_number": "EU/3/23/2860",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2860"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "golcadomide hydrochloride",
    "date_of_designation_or_refusal": "13/12/2023",
    "intended_use": "Treatment of follicular lymphoma",
    "eu_designation_number": "EU/3/23/2864",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2864"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "selumetinib",
    "date_of_designation_or_refusal": "13/12/2023",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/23/2865",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2865"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "cutamesine",
    "date_of_designation_or_refusal": "13/12/2023",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EMA/OD/0000149115",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/ema-od-0000149115"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ovine polyclonal fragment antigen-binding against ricin",
    "date_of_designation_or_refusal": "13/12/2023",
    "intended_use": "Treatment of ricin poisoning",
    "eu_designation_number": "EU/3/23/2872",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2872"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "vactosertib",
    "date_of_designation_or_refusal": "25/07/2023",
    "intended_use": "Treatment of osteosarcoma",
    "eu_designation_number": "EU/3/23/2797",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2797"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ulefnersen",
    "date_of_designation_or_refusal": "",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/23/2839",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2839"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised IgG1 monoclonal antibody against TfR1 conjugated to exon 44 specific phosphorodiamidate morpholino oligonucleotide via a non-cleavable linker",
    "date_of_designation_or_refusal": "13/10/2023",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/23/2838",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2838"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-(3-(3,5-Dimethyltriazol-4-yl)-5-((S)-oxan-4-yl(phenyl)methyl)pyrido(3,2-b)indol-7-yl)propan-2-ol",
    "date_of_designation_or_refusal": "13/10/2023",
    "intended_use": "Treatment of myelofibrosis",
    "eu_designation_number": "EU/3/23/2844",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2844"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "zedenoleucel",
    "date_of_designation_or_refusal": "25/02/2023",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/23/2806",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2806"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous adipose-derived mesenchymal stem cells",
    "date_of_designation_or_refusal": "21/04/2023",
    "intended_use": "Treatment of oesophageal atresia",
    "eu_designation_number": "EU/3/23/2772",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2772"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "setmelanotide",
    "date_of_designation_or_refusal": "13/10/2023",
    "intended_use": "Treatment of acquired hypothalamic obesity",
    "eu_designation_number": "EU/3/23/2833",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2833"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(R)-(3-(2'-cyclopropyl-3-(hydroxymethyl)-[1,1'-biphenyl]-4-yl) pyrrolidin-1-yl)(5-fluoropyridin-2-yl)methanone",
    "date_of_designation_or_refusal": "13/10/2023",
    "intended_use": "Treatment of Olmsted syndrome",
    "eu_designation_number": "EU/3/23/2840",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2840"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium oxybate",
    "date_of_designation_or_refusal": "13/10/2023",
    "intended_use": "Treatment of narcolepsy",
    "eu_designation_number": "EU/3/23/2846",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2846"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "chimeric human-murine IgG1 kappa monoclonal antibody against TNF alfa",
    "date_of_designation_or_refusal": "25/07/2023",
    "intended_use": "Treatment of sarcoidosis",
    "eu_designation_number": "EU/3/23/2809",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2809"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tarperprumig",
    "date_of_designation_or_refusal": "25/07/2023",
    "intended_use": "Treatment of sickle cell disease",
    "eu_designation_number": "EU/3/23/2814",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2814"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "mitapivat sulfate",
    "date_of_designation_or_refusal": "13/10/2023",
    "intended_use": "Treatment of thalassaemia intermedia and major",
    "eu_designation_number": "EU/3/23/2827",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2827"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "alpelisib",
    "date_of_designation_or_refusal": "13/10/2023",
    "intended_use": "Treatment of lymphatic malformations",
    "eu_designation_number": "EU/3/23/2841",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2841"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "paclitaxel obaluronate",
    "date_of_designation_or_refusal": "25/07/2023",
    "intended_use": "Treatment of malignant mesothelioma",
    "eu_designation_number": "EU/3/23/2807",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2807"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "anagrelide hydrochloride monohydrate",
    "date_of_designation_or_refusal": "20/03/2023",
    "intended_use": "Treatment of gastrointestinal stromal tumours",
    "eu_designation_number": "EU/3/23/2765",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2765"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "6-(4-(1-amino-3-hydroxycyclobutyl)phenyl)-1-ethyl-7-phenyl-1H-pyrido[2,3-b][1,4]oxazin-2(3H)-one, L-tartrate salt",
    "date_of_designation_or_refusal": "20/03/2023",
    "intended_use": "Treatment of hereditary haemorrhagic telangiectasia",
    "eu_designation_number": "EU/3/23/2766",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2766"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium selenate",
    "date_of_designation_or_refusal": "13/10/2023",
    "intended_use": "Treatment of progressive supranuclear palsy",
    "eu_designation_number": "EU/3/23/2829",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2829"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "messenger ribonucleic acid coding for coiled-coil domain-containing protein 40",
    "date_of_designation_or_refusal": "25/07/2023",
    "intended_use": "Treatment of primary ciliary dyskinesia",
    "eu_designation_number": "EU/3/23/2812",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2812"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "nomacopan",
    "date_of_designation_or_refusal": "25/07/2023",
    "intended_use": "Treatment in haematopoietic stem cell transplantation",
    "eu_designation_number": "EU/3/23/2810",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2810"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "bezuclastinib",
    "date_of_designation_or_refusal": "20/03/2023",
    "intended_use": "Treatment of gastrointestinal stromal tumours",
    "eu_designation_number": "EU/3/23/2767",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2767"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "rhizobium rhizogenes;lipopolysaccharide",
    "date_of_designation_or_refusal": "25/07/2023",
    "intended_use": "Treatment of congenital diaphragmatic hernia",
    "eu_designation_number": "EU/3/23/2801",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2801"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "vonafexor",
    "date_of_designation_or_refusal": "25/07/2023",
    "intended_use": "Treatment of Alport syndrome",
    "eu_designation_number": "EU/3/23/2808",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2808"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "certepetide",
    "date_of_designation_or_refusal": "13/10/2023",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/23/2834",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2834"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "taldefgrobep alfa",
    "date_of_designation_or_refusal": "25/07/2023",
    "intended_use": "Treatment of spinal muscular atrophy",
    "eu_designation_number": "EU/3/23/2813",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2813"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Indole-3-carboxaldehyde",
    "date_of_designation_or_refusal": "20/03/2023",
    "intended_use": "Treatment of primary CTLA-4 checkpoint related immunodeficiencies",
    "eu_designation_number": "EU/3/23/2769",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2769"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sildenafil citrate",
    "date_of_designation_or_refusal": "13/10/2023",
    "intended_use": "Treatment of Leigh syndrome",
    "eu_designation_number": "EU/3/23/2831",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2831"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic peripheral blood-derived haematopoietic stem and progenitor cells, regulatory T cells and conventional T cells",
    "date_of_designation_or_refusal": "25/07/2023",
    "intended_use": "Treatment in haematopoietic stem cell transplantation",
    "eu_designation_number": "EU/3/23/2815",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2815"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "omadacycline",
    "date_of_designation_or_refusal": "25/07/2024",
    "intended_use": "Treatment of nontuberculous mycobacterial lung disease",
    "eu_designation_number": "EU/3/23/2804",
    "status": "Positive",
    "first_published_date": "01/02/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2804"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "rituximab",
    "date_of_designation_or_refusal": "25/07/2023",
    "intended_use": "Treatment of primary membranous nephropathy",
    "eu_designation_number": "EU/3/23/2816",
    "status": "Positive",
    "first_published_date": "31/01/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2816"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "humanised IgG1 monoclonal antibody against muscle specific kinase",
    "date_of_designation_or_refusal": "25/07/2023",
    "intended_use": "Treatment of congenital myasthenic syndromes",
    "eu_designation_number": "EU/3/23/2799",
    "status": "Positive",
    "first_published_date": "31/01/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2799"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Ilginatinib maleate",
    "date_of_designation_or_refusal": "25/07/2023",
    "intended_use": "Treatment of myelofibrosis",
    "eu_designation_number": "EU/3/23/2803",
    "status": "Positive",
    "first_published_date": "31/01/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2803"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tasimelteon",
    "date_of_designation_or_refusal": "13/10/2023",
    "intended_use": "Treatment of Smith-Magenis syndrome",
    "eu_designation_number": "EU/3/23/2832",
    "status": "Positive",
    "first_published_date": "31/01/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2832"
  },
  {
    "medicine_name": "Fintepla",
    "related_ema_product_number": "EMEA/H/C/003933",
    "active_substance": "fenfluramine hydrochloride",
    "date_of_designation_or_refusal": "20/03/2023",
    "intended_use": "Treatment of CDKL5 deficiency disorder",
    "eu_designation_number": "EU/3/23/2768",
    "status": "Positive",
    "first_published_date": "31/01/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2768"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "guanabenz acetate",
    "date_of_designation_or_refusal": "20/03/2023",
    "intended_use": "Treatment of vanishing white matter disease",
    "eu_designation_number": "EU/3/23/2764",
    "status": "Positive",
    "first_published_date": "31/01/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2764"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "5,5-dimethyl-3-[2-(7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione",
    "date_of_designation_or_refusal": "20/03/2023",
    "intended_use": "Treatment of fragile X syndrome",
    "eu_designation_number": "EU/3/23/2770",
    "status": "Positive",
    "first_published_date": "31/01/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2770"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Lurbinectedin",
    "date_of_designation_or_refusal": "21/04/2023",
    "intended_use": "Treatment of soft tissue sarcoma",
    "eu_designation_number": "EU/3/23/2774",
    "status": "Positive",
    "first_published_date": "31/01/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2774"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "riboflavin",
    "date_of_designation_or_refusal": "08/11/2023",
    "intended_use": "Treatment of medium-chain acyl-coenzyme A dehydrogenase deficiency",
    "eu_designation_number": "EU/3/23/2853",
    "status": "Positive",
    "first_published_date": "31/01/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2853"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Elesclomol-copper",
    "date_of_designation_or_refusal": "08/11/2023",
    "intended_use": "Treatment of Menkes disease",
    "eu_designation_number": "EU/3/23/2858",
    "status": "Positive",
    "first_published_date": "31/01/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2858"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-{(2S,3R)-4,4-Difluoro-1-(2-hydroxy-2-methylpropanoyl)-2-[(2,3',5'-trifluoro[1,1'-biphenyl]-3-yl)methyl]pyrrolidin-3-yl}ethanesulfonamide",
    "date_of_designation_or_refusal": "08/11/2023",
    "intended_use": "Treatment of narcolepsy",
    "eu_designation_number": "EU/3/23/2851",
    "status": "Positive",
    "first_published_date": "31/01/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2851"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised IgG1 monoclonal antibody against CLDN6 conjugated to monomethyl auristatin E via a cathepsin hydrolysable dipeptide VC linker",
    "date_of_designation_or_refusal": "08/11/2023",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/23/2854",
    "status": "Positive",
    "first_published_date": "31/01/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2854"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "5-(3,4-Dichloro-phenyl)-N-((1R,2R)-2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-ethoxy)-nicotinamide",
    "date_of_designation_or_refusal": "20/06/2023",
    "intended_use": "Treatment of Alport syndrome",
    "eu_designation_number": "EU/3/23/2791",
    "status": "Positive",
    "first_published_date": "30/01/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2791"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "nicotinamide mononucleotide",
    "date_of_designation_or_refusal": "20/06/2023",
    "intended_use": "Treatment of sickle cell disease",
    "eu_designation_number": "EU/3/23/2786",
    "status": "Positive",
    "first_published_date": "30/01/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2786"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "cannabidiol",
    "date_of_designation_or_refusal": "25/07/2023",
    "intended_use": "Treatment of Leigh syndrome",
    "eu_designation_number": "EU/3/23/2800",
    "status": "Positive",
    "first_published_date": "30/01/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2800"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pemafibrate",
    "date_of_designation_or_refusal": "25/07/2023",
    "intended_use": "Treatment of primary biliary cholangitis",
    "eu_designation_number": "EU/3/23/2798",
    "status": "Positive",
    "first_published_date": "30/01/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2798"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ulviprubart",
    "date_of_designation_or_refusal": "25/07/2023",
    "intended_use": "Treatment of inclusion body myositis",
    "eu_designation_number": "EU/3/23/2805",
    "status": "Positive",
    "first_published_date": "30/01/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2805"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus serotype 9 vector containing the human LAMP2 isoform B transgene",
    "date_of_designation_or_refusal": "16/08/2023",
    "intended_use": "Treatment of Danon disease",
    "eu_designation_number": "EU/3/23/2826",
    "status": "Positive",
    "first_published_date": "30/01/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2826"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "lusvertikimab",
    "date_of_designation_or_refusal": "25/07/2023",
    "intended_use": "Treatment of acute lymphoblastic leukaemia",
    "eu_designation_number": "EU/3/23/2802",
    "status": "Positive",
    "first_published_date": "26/01/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2802"
  },
  {
    "medicine_name": "Nezglyal",
    "related_ema_product_number": "EMEA/H/C/005757",
    "active_substance": "5-[4-[2-(5-(1-hydroxyethyl)-2-pyridinyl)ethoxy]benzyl]-2,4-thiazolidinedione hydrochloride",
    "date_of_designation_or_refusal": "18/11/2016",
    "intended_use": "Treatment of adrenoleukodystrophy",
    "eu_designation_number": "EU/3/16/1770",
    "status": "Positive",
    "first_published_date": "13/12/2016",
    "last_updated_date": "26/01/2024",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1770"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Lithium carbonate",
    "date_of_designation_or_refusal": "16/08/2023",
    "intended_use": "Treatment of Kleine Levin syndrome",
    "eu_designation_number": "EU/3/23/2822",
    "status": "Positive",
    "first_published_date": "25/01/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2822"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-{4-[4-(4-{5-[(1S)-1-amino-1-(4-fluorophenyl) ethyl]pyrimidin-2-yl}piperazin-1-yl)pyrrolo[2,1-f] [1,2,4]triazin-6-yl]-1H-pyrazol-1-yl}ethan-1-ol",
    "date_of_designation_or_refusal": "21/04/2023",
    "intended_use": "Treatment of mastocytosis",
    "eu_designation_number": "EU/3/23/2775",
    "status": "Positive",
    "first_published_date": "25/01/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2775"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Escherichia coli, strain Nissle 1917, expressing high affinity phenylalanine transporter, phenylalanine ammonia lyase and L-amino acid deaminase",
    "date_of_designation_or_refusal": "21/04/2023",
    "intended_use": "Treatment of hyperphenylalaninaemia",
    "eu_designation_number": "EU/3/23/2773",
    "status": "Positive",
    "first_published_date": "25/01/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2773"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous blood-derived tumour and hypoxia educated macrophages",
    "date_of_designation_or_refusal": "22/05/2023",
    "intended_use": "Treatment of spinal cord injury",
    "eu_designation_number": "EU/3/23/2777",
    "status": "Positive",
    "first_published_date": "25/01/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2777"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "doruxapapogene ralaplasmid",
    "date_of_designation_or_refusal": "22/05/2023",
    "intended_use": "Treatment of recurrent respiratory papillomatosis",
    "eu_designation_number": "EU/3/23/2785",
    "status": "Positive",
    "first_published_date": "25/01/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2785"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "H-L-tryphophanyl-L-seryl-glycyl-L-tryptophanyl-L-seryl-L-seryl-L-cysteinyl-L-seryl-L-arginyl-L-seryl-L-cysteinyl-glycyl-OH (disulfide bond), acetate salt",
    "date_of_designation_or_refusal": "15/02/2023",
    "intended_use": "Treatment of spinal cord injury",
    "eu_designation_number": "EU/3/23/2758",
    "status": "Positive",
    "first_published_date": "25/01/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2758"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 9 expressing fukutin-related protein",
    "date_of_designation_or_refusal": "15/02/2023",
    "intended_use": "Treatment of limb girdle muscular dystrophy",
    "eu_designation_number": "EU/3/23/2755",
    "status": "Positive",
    "first_published_date": "25/01/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2755"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "patidistrogene bexoparvovec",
    "date_of_designation_or_refusal": "15/02/2023",
    "intended_use": "Treatment of limb girdle muscular dystrophy",
    "eu_designation_number": "EU/3/23/2753",
    "status": "Positive",
    "first_published_date": "25/01/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2753"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Glycerol phenylbutyrate",
    "date_of_designation_or_refusal": "13/10/2023",
    "intended_use": "Treatment of STXBP1 developmental and epileptic encephalopathy",
    "eu_designation_number": "EU/3/23/2842",
    "status": "Positive",
    "first_published_date": "24/01/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2842"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 9 containing the human PLA2G6 gene",
    "date_of_designation_or_refusal": "10/12/2023",
    "intended_use": "Treatment of infantile neuroaxonal dystrophy",
    "eu_designation_number": "EU/3/23/2845",
    "status": "Positive",
    "first_published_date": "24/01/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2845"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus vector serotype 9/rh74 containing the human CAPN3 gene and a target sequence of cardiac-specific microRNA",
    "date_of_designation_or_refusal": "13/10/2023",
    "intended_use": "Treatment of limb-girdle muscular dystrophy",
    "eu_designation_number": "EU/3/23/2837",
    "status": "Positive",
    "first_published_date": "24/01/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2837"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "1-(4-((1R,2S,3R)-1,2,3,4-Tetrahydroxybutyl)-1H-imidazol-2-yl) ethanone oxime",
    "date_of_designation_or_refusal": "13/10/2024",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/23/2830",
    "status": "Positive",
    "first_published_date": "24/01/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2830"
  },
  {
    "medicine_name": "Kinselby",
    "related_ema_product_number": "EMEA/H/C/006259",
    "active_substance": "resminostat",
    "date_of_designation_or_refusal": "13/10/2024",
    "intended_use": "Treatment of cutaneous T-cell lymphoma",
    "eu_designation_number": "EU/3/23/2835",
    "status": "Positive",
    "first_published_date": "24/01/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2835"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "melatonin",
    "date_of_designation_or_refusal": "15/02/2023",
    "intended_use": "Treatment of perinatal asphyxia",
    "eu_designation_number": "EU/3/23/2757",
    "status": "Positive",
    "first_published_date": "24/01/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2757"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "messenger RNA encoding Cas9, single guide RNA targeting the human KLKB1 gene",
    "date_of_designation_or_refusal": "08/11/2023",
    "intended_use": "Treatment of hereditary angioedema",
    "eu_designation_number": "EU/3/23/2856",
    "status": "Positive",
    "first_published_date": "24/01/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2856"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Idronoxil",
    "date_of_designation_or_refusal": "22/05/2023",
    "intended_use": "Treatment of soft tissue sarcoma",
    "eu_designation_number": "EU/3/23/2778",
    "status": "Positive",
    "first_published_date": "24/01/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2778"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised IgG4 monoclonal antibody against active complement component 1, subcomponent s",
    "date_of_designation_or_refusal": "22/05/2023",
    "intended_use": "Treatment of chronic inflammatory demyelinating polyneuropathy",
    "eu_designation_number": "EU/3/23/2784",
    "status": "Positive",
    "first_published_date": "24/01/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2784"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus serotype 9 expressing a transcription factor for the SCN1A gene",
    "date_of_designation_or_refusal": "22/05/2023",
    "intended_use": "Treatment of Dravet syndrome",
    "eu_designation_number": "EU/3/23/2780",
    "status": "Positive",
    "first_published_date": "24/01/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2780"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 9 containing the human NPC1 gene",
    "date_of_designation_or_refusal": "13/10/2023",
    "intended_use": "Treatment of Niemann-Pick's disease, type C",
    "eu_designation_number": "EU/3/23/2843",
    "status": "Positive",
    "first_published_date": "24/01/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2843"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "bitopertin",
    "date_of_designation_or_refusal": "15/02/2023",
    "intended_use": "Treatment of erythropoietic protoporphyria",
    "eu_designation_number": "EU/3/23/2761",
    "status": "Positive",
    "first_published_date": "19/01/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2761"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "",
    "date_of_designation_or_refusal": "15/02/2023",
    "intended_use": "Treatment of GM2 gangliosidosis",
    "eu_designation_number": "EU/3/23/2762",
    "status": "Positive",
    "first_published_date": "19/01/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2762"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous CD34+ cells transduced with a lentiviral vector containing the human GAA gene",
    "date_of_designation_or_refusal": "15/02/2024",
    "intended_use": "Treatment of glycogen storage disease type II (Pompe's disease)",
    "eu_designation_number": "EU/3/23/2751",
    "status": "Positive",
    "first_published_date": "19/01/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2751"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "crisdesalazine",
    "date_of_designation_or_refusal": "15/02/2023",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/23/2759",
    "status": "Positive",
    "first_published_date": "19/01/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2759"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "humanised IgG1 monoclonal antibody against TfR1 conjugated to double stranded siRNA oligonucleotide against DUX4 mRNA via a non-cleavable linker",
    "date_of_designation_or_refusal": "15/02/2023",
    "intended_use": "treatment of facioscapulohumeral muscular dystrophy",
    "eu_designation_number": "EU/3/23/2756",
    "status": "Positive",
    "first_published_date": "19/01/2024",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2756"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "dersimelagon",
    "date_of_designation_or_refusal": "16/03/2022",
    "intended_use": "Treatment of erythropoietic protoporphyria",
    "eu_designation_number": "EU/3/22/2585",
    "status": "Positive",
    "first_published_date": "16/06/2022",
    "last_updated_date": "07/12/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2585"
  },
  {
    "medicine_name": "Finlee",
    "related_ema_product_number": "EMEA/H/C/005885",
    "active_substance": "dabrafenib mesilate",
    "date_of_designation_or_refusal": "09/12/2020",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/20/2372",
    "status": "Positive",
    "first_published_date": "25/05/2021",
    "last_updated_date": "05/12/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2372"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "cholic acid",
    "date_of_designation_or_refusal": "18/12/2002",
    "intended_use": "Treatment of inborn errors in primary bile acid synthesis",
    "eu_designation_number": "EU/3/02/127",
    "status": "Positive",
    "first_published_date": "18/08/2008",
    "last_updated_date": "25/09/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-127"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "7-beta-hydroxy cholesteryl-3-beta-oleate",
    "date_of_designation_or_refusal": "17/12/2010",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/10/816",
    "status": "Positive",
    "first_published_date": "19/01/2011",
    "last_updated_date": "22/09/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-816"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroxy-2-phenylpropan-1-one",
    "date_of_designation_or_refusal": "19/10/2020",
    "intended_use": "Treatment of sickle cell disease",
    "eu_designation_number": "EU/3/20/2335",
    "status": "Positive",
    "first_published_date": "15/02/2021",
    "last_updated_date": "22/09/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2335"
  },
  {
    "medicine_name": "Talvey",
    "related_ema_product_number": "EMEA/H/C/005864",
    "active_substance": "talquetamab",
    "date_of_designation_or_refusal": "20/08/2021",
    "intended_use": "Treatment of multiple myeloma",
    "eu_designation_number": "EU/3/21/2486",
    "status": "Positive",
    "first_published_date": "25/02/2022",
    "last_updated_date": "21/09/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2486"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "belzupacap sarotalocan",
    "date_of_designation_or_refusal": "13/04/2022",
    "intended_use": "Treatment of uveal melanoma",
    "eu_designation_number": "EU/3/22/2599",
    "status": "Positive",
    "first_published_date": "19/07/2022",
    "last_updated_date": "20/09/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2599"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "celecoxib;ciprofloxacin",
    "date_of_designation_or_refusal": "06/01/2021",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/20/2395",
    "status": "Positive",
    "first_published_date": "18/05/2021",
    "last_updated_date": "19/09/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2395"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "3-{[2,3,5,6-tetrafluoro-3'-(trifluoromethoxy)biphenyl-4-yl]carbamoyl}thiophene-2-carboxylic acid",
    "date_of_designation_or_refusal": "19/06/2015",
    "intended_use": "Treatment of non-infectious uveitis",
    "eu_designation_number": "EU/3/15/1507",
    "status": "Positive",
    "first_published_date": "27/07/2015",
    "last_updated_date": "18/09/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1507"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-(5-tert-Butylisoxazol-3-yl)-N'-{4-[7-(2-(morpholin-4-yl)ethoxy) imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea di-hydrochloride salt",
    "date_of_designation_or_refusal": "23/03/2009",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/09/622",
    "status": "Positive",
    "first_published_date": "08/04/2009",
    "last_updated_date": "15/09/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-622"
  },
  {
    "medicine_name": "Yorvipath",
    "related_ema_product_number": "EMEA/H/C/005934",
    "active_substance": "Poly(oxy-1,2-ethanediyl), alpha-hydro-omega-methoxy, ether with N-[[[2-[[6-[[1-[3-[[3-(2,3-dihydroxypropoxy)propyl]amino]-3-oxopropyl]-2,5-dioxo-3-pyrrolidinyl]thio]hexyl]amino]ethyl]amino]carbonyl]-2-methylalanyl-teriparatide (2:1)",
    "date_of_designation_or_refusal": "19/10/2020",
    "intended_use": "Treatment of hypoparathyroidism",
    "eu_designation_number": "EU/3/20/2350",
    "status": "Positive",
    "first_published_date": "18/02/2021",
    "last_updated_date": "15/09/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2350"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "everolimus",
    "date_of_designation_or_refusal": "04/08/2010",
    "intended_use": "Treatment of tuberous sclerosis",
    "eu_designation_number": "EU/3/10/764",
    "status": "Expired",
    "first_published_date": "11/08/2010",
    "last_updated_date": "15/09/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-764"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "zilucoplan",
    "date_of_designation_or_refusal": "18/07/2022",
    "intended_use": "Treatment of myasthenia gravis",
    "eu_designation_number": "EU/3/22/2650",
    "status": "Positive",
    "first_published_date": "25/01/2023",
    "last_updated_date": "15/09/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2650"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "asunercept",
    "date_of_designation_or_refusal": "23/08/2017",
    "intended_use": "Treatment of myelodysplastic syndromes",
    "eu_designation_number": "EU/3/17/1900",
    "status": "Positive",
    "first_published_date": "17/10/2017",
    "last_updated_date": "15/09/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1900"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant fusion protein consisting of the extracellular portion of CD95 fused to the Fc part of a human IgG1 molecule",
    "date_of_designation_or_refusal": "28/01/2010",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/09/709",
    "status": "Positive",
    "first_published_date": "25/02/2010",
    "last_updated_date": "15/09/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-709"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant fusion protein consisting of the extracellular portion of CD95 fused to the Fc part of a human IgG1 molecule",
    "date_of_designation_or_refusal": "31/10/2006",
    "intended_use": "Prevention of graft-versus-host disease",
    "eu_designation_number": "EU/3/06/411",
    "status": "Positive",
    "first_published_date": "02/04/2009",
    "last_updated_date": "15/09/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-411"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Entinostat",
    "date_of_designation_or_refusal": "10/06/2010",
    "intended_use": "Treatment of Hodgkin's lymphoma",
    "eu_designation_number": "EU/3/10/732",
    "status": "Positive",
    "first_published_date": "24/06/2010",
    "last_updated_date": "13/09/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-732"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "mixture of seven synthetic fragments consisting of p21 RAS peptides",
    "date_of_designation_or_refusal": "05/08/2011",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/11/885",
    "status": "Positive",
    "first_published_date": "16/08/2011",
    "last_updated_date": "13/09/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-885"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Pomalidomide",
    "date_of_designation_or_refusal": "08/10/2009",
    "intended_use": "Treatment of multiple myeloma",
    "eu_designation_number": "EU/3/09/672",
    "status": "Expired",
    "first_published_date": "20/10/2009",
    "last_updated_date": "13/09/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-672"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "enzastaurin hydrochloride",
    "date_of_designation_or_refusal": "20/03/2007",
    "intended_use": "Treatment of diffuse large B-cell lymphoma",
    "eu_designation_number": "EU/3/07/442",
    "status": "Withdrawn",
    "first_published_date": "10/07/2008",
    "last_updated_date": "12/09/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-442"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "risdiplam",
    "date_of_designation_or_refusal": "26/02/2019",
    "intended_use": "Treatment of spinal muscular atrophy",
    "eu_designation_number": "EU/3/19/2145",
    "status": "Withdrawn",
    "first_published_date": "09/04/2019",
    "last_updated_date": "12/09/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2145"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 2/6 encoding zinc-finger nucleases and the human iduronate 2-sulfatase gene",
    "date_of_designation_or_refusal": "17/01/2018",
    "intended_use": "Treatment of mucopolysaccharidosis type II (Hunter's syndrome)",
    "eu_designation_number": "EU/3/17/1956",
    "status": "Withdrawn",
    "first_published_date": "13/03/2018",
    "last_updated_date": "12/09/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1956"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 2/6 encoding zinc-finger nucleases and the human alpha L-iduronidase gene (devafidugene civaparvovec)",
    "date_of_designation_or_refusal": "17/01/2018",
    "intended_use": "Treatment of mucopolysaccharidosis type I",
    "eu_designation_number": "EU/3/17/1955",
    "status": "Withdrawn",
    "first_published_date": "12/03/2018",
    "last_updated_date": "12/09/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1955"
  },
  {
    "medicine_name": "Fanskya",
    "related_ema_product_number": "EMEA/H/C/005537",
    "active_substance": "Lentiviral vector carrying the Fanconi anaemia-A (FANCA) gene",
    "date_of_designation_or_refusal": "17/12/2010",
    "intended_use": "Treatment of Fanconi anaemia type A",
    "eu_designation_number": "EU/3/10/822",
    "status": "Positive",
    "first_published_date": "20/01/2011",
    "last_updated_date": "11/09/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-822"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2',3',5'-Tri-O-acetyluridine",
    "date_of_designation_or_refusal": "15/05/2009",
    "intended_use": "Treatment of 5-fluorouracil overdose",
    "eu_designation_number": "EU/3/09/637",
    "status": "Positive",
    "first_published_date": "09/06/2009",
    "last_updated_date": "11/09/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-637"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "4-Amino-(6R,S)-5,6,7,8-tetrahydro-L-biopterin dihydrochloride (ronopterin)",
    "date_of_designation_or_refusal": "28/08/2006",
    "intended_use": "Treatment of moderate and severe traumatic brain injury",
    "eu_designation_number": "EU/3/06/390",
    "status": "Positive",
    "first_published_date": "24/02/2009",
    "last_updated_date": "11/08/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-390"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus serotype HSC 15 expressing human iduronate 2-sulfatase (Bevufenogene nofeparvovec)",
    "date_of_designation_or_refusal": "16/03/2022",
    "intended_use": "Treatment of mucopolysaccharidosis type II (Hunter Syndrome)",
    "eu_designation_number": "EU/3/22/2592",
    "status": "Withdrawn",
    "first_published_date": "20/06/2022",
    "last_updated_date": "08/08/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2592"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus serotype HSC15 expressing human phenylalanine hydroxylase",
    "date_of_designation_or_refusal": "14/12/2018",
    "intended_use": "Treatment of phenylalanine hydroxylase deficiency",
    "eu_designation_number": "EU/3/18/2109",
    "status": "Withdrawn",
    "first_published_date": "08/03/2019",
    "last_updated_date": "08/08/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2109"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Human telomerase reverse transcriptase peptide (611-626) (tertomotide)",
    "date_of_designation_or_refusal": "25/07/2006",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/06/384",
    "status": "Withdrawn",
    "first_published_date": "21/09/2009",
    "last_updated_date": "08/08/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-384"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human factor IX protein modified with three point mutations (dalcinonacog alfa)",
    "date_of_designation_or_refusal": "20/06/2017",
    "intended_use": "Treatment of haemophilia B",
    "eu_designation_number": "EU/3/17/1884",
    "status": "Positive",
    "first_published_date": "17/07/2017",
    "last_updated_date": "03/08/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1884"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Marzeptacog alfa (activated)",
    "date_of_designation_or_refusal": "01/04/2019",
    "intended_use": "Treatment of haemophilia B",
    "eu_designation_number": "EU/3/19/2151",
    "status": "Positive",
    "first_published_date": "07/05/2019",
    "last_updated_date": "03/08/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2151"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised IgG1 monoclonal antibody against SEZ6 linked to N-acetyl-calicheamicin",
    "date_of_designation_or_refusal": "15/10/2021",
    "intended_use": "Treatment of small cell lung cancer",
    "eu_designation_number": "EU/3/21/2502",
    "status": "Withdrawn",
    "first_published_date": "20/01/2022",
    "last_updated_date": "31/07/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2502"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tobramycin",
    "date_of_designation_or_refusal": "17/03/2003",
    "intended_use": "Treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis",
    "eu_designation_number": "EU/3/03/140",
    "status": "Expired",
    "first_published_date": "07/03/2007",
    "last_updated_date": "31/07/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-140"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Itraconazole",
    "date_of_designation_or_refusal": "23/08/2017",
    "intended_use": "Treatment of naevoid basal-cell carcinoma syndrome (Gorlin syndrome)",
    "eu_designation_number": "EU/3/17/1901",
    "status": "Withdrawn",
    "first_published_date": "17/10/2017",
    "last_updated_date": "27/07/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1901"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Fusion protein composed of the first 2 immunoglobulin-like domains of the human Roundabout guidance receptor 2 fused to a human IgG1 crystallised fragment",
    "date_of_designation_or_refusal": "16/05/2022",
    "intended_use": "Treatment of focal segmental glomerulosclerosis",
    "eu_designation_number": "EU/3/22/2611",
    "status": "Withdrawn",
    "first_published_date": "14/12/2022",
    "last_updated_date": "27/07/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2611"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Iodine (124I) evuzamitide",
    "date_of_designation_or_refusal": "09/12/2022",
    "intended_use": "Diagnosis of ATTR amyloidosis",
    "eu_designation_number": "EU/3/22/2725",
    "status": "Positive",
    "first_published_date": "13/03/2023",
    "last_updated_date": "25/07/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2725"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Iodine (124I) evuzamitide",
    "date_of_designation_or_refusal": "11/11/2022",
    "intended_use": "Diagnosis of AL amyloidosis",
    "eu_designation_number": "EU/3/22/2712",
    "status": "Positive",
    "first_published_date": "23/01/2023",
    "last_updated_date": "25/07/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2712"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "codon-optimised human cystic fibrosis transmembrane conductance regulator messenger ribonucleic acid complexed with lipid-based nanoparticles;pomulmeran",
    "date_of_designation_or_refusal": "01/04/2019",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/19/2150",
    "status": "Withdrawn",
    "first_published_date": "07/05/2019",
    "last_updated_date": "21/07/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2150"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus serotype HSC15 expressing human arylsulfatase A gene",
    "date_of_designation_or_refusal": "26/06/2020",
    "intended_use": "treatment of metachromatic leukodystrophy",
    "eu_designation_number": "EU/3/20/2297",
    "status": "Withdrawn",
    "first_published_date": "24/09/2020",
    "last_updated_date": "21/07/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2297"
  },
  {
    "medicine_name": "Radicava",
    "related_ema_product_number": "EMEA/H/C/004938",
    "active_substance": "edaravone",
    "date_of_designation_or_refusal": "19/06/2015",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/15/1510",
    "status": "Positive",
    "first_published_date": "27/07/2015",
    "last_updated_date": "21/07/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1510"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Benzamide, 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl] (ponatinib)",
    "date_of_designation_or_refusal": "02/02/2010",
    "intended_use": "Treatment of acute lymphoblastic leukaemia",
    "eu_designation_number": "EU/3/09/715",
    "status": "Expired",
    "first_published_date": "04/03/2010",
    "last_updated_date": "20/07/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-715"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Benzamide, 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl] (ponatinib)",
    "date_of_designation_or_refusal": "02/02/2010",
    "intended_use": "Treatment of chronic myeloid leukaemia",
    "eu_designation_number": "EU/3/09/716",
    "status": "Expired",
    "first_published_date": "04/03/2010",
    "last_updated_date": "20/07/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-716"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human embryonic stem-cell-derived retinal pigment epithelial cells",
    "date_of_designation_or_refusal": "21/06/2011",
    "intended_use": "Treatment of Stargardt's disease",
    "eu_designation_number": "EU/3/11/874",
    "status": "Withdrawn",
    "first_published_date": "12/07/2011",
    "last_updated_date": "19/07/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-874"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]-2-propen-1-one (futibatinib)",
    "date_of_designation_or_refusal": "01/04/2019",
    "intended_use": "Treatment of biliary tract cancer",
    "eu_designation_number": "EU/3/19/2146",
    "status": "Positive",
    "first_published_date": "07/05/2019",
    "last_updated_date": "18/07/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2146"
  },
  {
    "medicine_name": "Xenpozyme",
    "related_ema_product_number": "EMEA/H/C/004850",
    "active_substance": "recombinant human acid sphingomyelinase (also known as olipudase alfa)",
    "date_of_designation_or_refusal": "24/06/2022",
    "intended_use": "Treatment of Niemann-Pick disease",
    "eu_designation_number": "EU/3/01/056",
    "status": "Positive",
    "first_published_date": "15/06/2009",
    "last_updated_date": "18/07/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-056"
  },
  {
    "medicine_name": "Cerdelga",
    "related_ema_product_number": "EMEA/H/C/003724",
    "active_substance": "",
    "date_of_designation_or_refusal": "04/12/2007",
    "intended_use": "Treatment of Gaucher disease",
    "eu_designation_number": "EU/3/07/514",
    "status": "Positive",
    "first_published_date": "02/07/2008",
    "last_updated_date": "18/07/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-514"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "synthetic double-stranded siRNA oligonucleotide directed against antithrombin mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues (fitusiran)",
    "date_of_designation_or_refusal": "29/07/2014",
    "intended_use": "Treatment of haemophilia A",
    "eu_designation_number": "EU/3/14/1297",
    "status": "Positive",
    "first_published_date": "01/09/2014",
    "last_updated_date": "18/07/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1297"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "synthetic double-stranded siRNA oligonucleotide directed against antithrombin mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues (fitusiran)",
    "date_of_designation_or_refusal": "29/07/2014",
    "intended_use": "Treatment of haemophilia B",
    "eu_designation_number": "EU/3/14/1298",
    "status": "Positive",
    "first_published_date": "01/09/2014",
    "last_updated_date": "18/07/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1298"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "",
    "date_of_designation_or_refusal": "22/08/2014",
    "intended_use": "Treatment of Fabry disease",
    "eu_designation_number": "EU/3/14/1310",
    "status": "Positive",
    "first_published_date": "30/09/2014",
    "last_updated_date": "18/07/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1310"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(3S)-1-azabicyclo[2.2.2]oct-3-yl{2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl}carbaNmate (venglustat)",
    "date_of_designation_or_refusal": "19/11/2014",
    "intended_use": "Treatment of Gaucher disease",
    "eu_designation_number": "EU/3/14/1374",
    "status": "Positive",
    "first_published_date": "15/01/2015",
    "last_updated_date": "18/07/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1374"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sutimlimab",
    "date_of_designation_or_refusal": "28/02/2020",
    "intended_use": "Treatment of immune thrombocytopenia",
    "eu_designation_number": "EU/3/20/2258",
    "status": "Positive",
    "first_published_date": "06/05/2020",
    "last_updated_date": "18/07/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2258"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "rilzabrutinib",
    "date_of_designation_or_refusal": "04/06/2020",
    "intended_use": "Treatment of immune thrombocytopenia",
    "eu_designation_number": "EU/3/20/2278",
    "status": "Positive",
    "first_published_date": "19/08/2020",
    "last_updated_date": "18/07/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2278"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "venglustat",
    "date_of_designation_or_refusal": "21/08/2020",
    "intended_use": "Treatment of GM2 gangliosidosis",
    "eu_designation_number": "EU/3/20/2325",
    "status": "Positive",
    "first_published_date": "25/11/2020",
    "last_updated_date": "18/07/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2325"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised monoclonal antibody derivative against fibroblast growth factor receptor 3",
    "date_of_designation_or_refusal": "21/06/2021",
    "intended_use": "Treatment of achondroplasia",
    "eu_designation_number": "EU/3/21/2454",
    "status": "Positive",
    "first_published_date": "11/05/2022",
    "last_updated_date": "18/07/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2454"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised IgG4 monoclonal antibody against active complement component 1, subcomponent s",
    "date_of_designation_or_refusal": "18/07/2022",
    "intended_use": "Treatment of autoimmune haemolytic anaemia",
    "eu_designation_number": "EU/3/22/2643",
    "status": "Positive",
    "first_published_date": "25/01/2023",
    "last_updated_date": "18/07/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2643"
  },
  {
    "medicine_name": "Nulibry",
    "related_ema_product_number": "EMEA/H/C/005378",
    "active_substance": "cyclic pyranopterin monophosphate (fosdenopterin)",
    "date_of_designation_or_refusal": "20/09/2010",
    "intended_use": "Treatment of molybdenum-cofactor deficiency type A",
    "eu_designation_number": "EU/3/10/777",
    "status": "Positive",
    "first_published_date": "18/10/2010",
    "last_updated_date": "17/07/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-777"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "cedazuridine;decitabine",
    "date_of_designation_or_refusal": "10/12/2021",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/21/2548",
    "status": "Withdrawn",
    "first_published_date": "28/04/2022",
    "last_updated_date": "06/07/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2548"
  },
  {
    "medicine_name": "Strimvelis",
    "related_ema_product_number": "EMEA/H/C/003854",
    "active_substance": "autologous CD34+ cells transfected with retroviral vector containing adenosine deaminase gene",
    "date_of_designation_or_refusal": "26/08/2005",
    "intended_use": "Treatment of severe combined immunodeficiency (SCID) due to adenosine deaminase (ADA) deficiency",
    "eu_designation_number": "EU/3/05/313",
    "status": "Positive",
    "first_published_date": "04/01/2006",
    "last_updated_date": "27/06/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-313"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(S)-N-(5-(4-(1-(benzo[d][1,3]dioxol-5-yl)ethyl)piperazin-1-yl)-1,3,4-thiadiazol-2-yl)acetamide, hydrochloride salt",
    "date_of_designation_or_refusal": "09/12/2020",
    "intended_use": "Treatment of progressive supranuclear palsy",
    "eu_designation_number": "EU/3/20/2381",
    "status": "Positive",
    "first_published_date": "27/05/2021",
    "last_updated_date": "27/06/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2381"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant adeno-associated viral vector expressing the human CNGA3 gene",
    "date_of_designation_or_refusal": "09/10/2015",
    "intended_use": "Treatment of achromatopsia caused by mutations in the CNGA3 gene",
    "eu_designation_number": "EU/3/15/1556",
    "status": "Positive",
    "first_published_date": "16/11/2015",
    "last_updated_date": "27/06/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1556"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "zanidatamab",
    "date_of_designation_or_refusal": "13/11/2020",
    "intended_use": "Treatment of gastric cancer",
    "eu_designation_number": "EU/3/20/2353",
    "status": "Positive",
    "first_published_date": "15/02/2021",
    "last_updated_date": "27/06/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2353"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "modified mRNA encoding human methylmalonyl-coenzyme A mutase encapsulated into lipid nanoparticles",
    "date_of_designation_or_refusal": "25/05/2018",
    "intended_use": "Treatment of methylmalonic acidaemia",
    "eu_designation_number": "EU/3/18/2025",
    "status": "Withdrawn",
    "first_published_date": "23/07/2018",
    "last_updated_date": "26/06/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2025"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant self-complementary adeno-associated viral vector serotype 9 containing the human CLN3 gene",
    "date_of_designation_or_refusal": "08/10/2009",
    "intended_use": "Treatment of neuronal ceroid lipofuscinosis",
    "eu_designation_number": "EU/3/16/1806",
    "status": "Withdrawn",
    "first_published_date": "09/01/2017",
    "last_updated_date": "20/06/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1806"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human elafin",
    "date_of_designation_or_refusal": "28/01/2010",
    "intended_use": "Treatment of oesophagus carcinoma",
    "eu_designation_number": "EU/3/09/710",
    "status": "Positive",
    "first_published_date": "25/02/2010",
    "last_updated_date": "20/06/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-710"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Elafin",
    "date_of_designation_or_refusal": "20/03/2007",
    "intended_use": "Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension",
    "eu_designation_number": "EU/3/07/443",
    "status": "Positive",
    "first_published_date": "02/07/2008",
    "last_updated_date": "20/06/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-443"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "cannabidiol",
    "date_of_designation_or_refusal": "13/04/2022",
    "intended_use": "Treatment of epilepsy with myoclonic-atonic seizures",
    "eu_designation_number": "EU/3/22/2600",
    "status": "Positive",
    "first_published_date": "19/07/2022",
    "last_updated_date": "16/06/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2600"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant adeno-associated viral vector containing the human CNGB3 gene",
    "date_of_designation_or_refusal": "08/02/2013",
    "intended_use": "Treatment of achromatopsia caused by mutations in the CNGB3 gene",
    "eu_designation_number": "EU/3/13/1099",
    "status": "Positive",
    "first_published_date": "04/03/2013",
    "last_updated_date": "16/06/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1099"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "imetelstat sodium",
    "date_of_designation_or_refusal": "14/12/2015",
    "intended_use": "Treatment of myelofibrosis",
    "eu_designation_number": "EU/3/15/1593",
    "status": "Positive",
    "first_published_date": "03/02/2016",
    "last_updated_date": "16/06/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1593"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "cannabidivarin",
    "date_of_designation_or_refusal": "22/02/2018",
    "intended_use": "Treatment of fragile X syndrome",
    "eu_designation_number": "EU/3/18/1977",
    "status": "Positive",
    "first_published_date": "11/04/2018",
    "last_updated_date": "15/06/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1977"
  },
  {
    "medicine_name": "Epidyolex",
    "related_ema_product_number": "EMEA/H/C/004675",
    "active_substance": "cannabidiol",
    "date_of_designation_or_refusal": "17/01/2018",
    "intended_use": "Treatment of tuberous sclerosis",
    "eu_designation_number": "EU/3/17/1959",
    "status": "Positive",
    "first_published_date": "12/03/2018",
    "last_updated_date": "15/06/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1959"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "cannabidivarin",
    "date_of_designation_or_refusal": "16/10/2017",
    "intended_use": "Treatment of Rett syndrome",
    "eu_designation_number": "EU/3/17/1921",
    "status": "Positive",
    "first_published_date": "08/01/2018",
    "last_updated_date": "15/06/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1921"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Delta-9-tetrahydrocannabinol and cannabidiol from extracts of the Cannabis sativa L. plant",
    "date_of_designation_or_refusal": "17/02/2016",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/16/1621",
    "status": "Positive",
    "first_published_date": "07/04/2016",
    "last_updated_date": "15/06/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1621"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "cannabidiol",
    "date_of_designation_or_refusal": "16/10/2017",
    "intended_use": "Treatment of West syndrome",
    "eu_designation_number": "EU/3/17/1920",
    "status": "Positive",
    "first_published_date": "08/01/2018",
    "last_updated_date": "15/06/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1920"
  },
  {
    "medicine_name": "Epidyolex",
    "related_ema_product_number": "EMEA/H/C/004675",
    "active_substance": "cannabidiol",
    "date_of_designation_or_refusal": "20/03/2017",
    "intended_use": "Treatment of Lennox-Gastaut syndrome",
    "eu_designation_number": "EU/3/17/1855",
    "status": "Positive",
    "first_published_date": "05/05/2017",
    "last_updated_date": "14/06/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1855"
  },
  {
    "medicine_name": "Epidyolex",
    "related_ema_product_number": "EMEA/H/C/004675",
    "active_substance": "cannabidiol",
    "date_of_designation_or_refusal": "15/10/2014",
    "intended_use": "Treatment of Dravet syndrome",
    "eu_designation_number": "EU/3/14/1339",
    "status": "Positive",
    "first_published_date": "12/11/2014",
    "last_updated_date": "14/06/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1339"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "cannabidiol",
    "date_of_designation_or_refusal": "28/07/2015",
    "intended_use": "Treatment of perinatal asphyxia",
    "eu_designation_number": "EU/3/15/1520",
    "status": "Positive",
    "first_published_date": "18/08/2015",
    "last_updated_date": "14/06/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1520"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "rifapentine",
    "date_of_designation_or_refusal": "09/06/2010",
    "intended_use": "Treatment of tuberculosis",
    "eu_designation_number": "EU/3/10/750",
    "status": "Positive",
    "first_published_date": "23/06/2010",
    "last_updated_date": "12/06/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-750"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "7-ethyl-10-hydroxy-camptothecin",
    "date_of_designation_or_refusal": "25/07/2019",
    "intended_use": "Treatment of soft tissue sarcoma",
    "eu_designation_number": "EU/3/19/2181",
    "status": "Positive",
    "first_published_date": "24/09/2019",
    "last_updated_date": "09/06/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2181"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sirolimus",
    "date_of_designation_or_refusal": "13/11/2013",
    "intended_use": "Prevention of arteriovenous access dysfunction in haemodialysis patients",
    "eu_designation_number": "EU/3/13/1204",
    "status": "Positive",
    "first_published_date": "02/12/2013",
    "last_updated_date": "09/06/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1204"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Glucagon",
    "date_of_designation_or_refusal": "19/11/2018",
    "intended_use": "Treatment of noninsulinoma pancreatogenous hypoglycaemia syndrome",
    "eu_designation_number": "EU/3/18/2091",
    "status": "Positive",
    "first_published_date": "19/02/2019",
    "last_updated_date": "09/06/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2091"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sulfonated monophosphorylated mannose oligosaccharide",
    "date_of_designation_or_refusal": "21/06/2011",
    "intended_use": "Treatment of hepatocellular carcinoma",
    "eu_designation_number": "EU/3/11/872",
    "status": "Positive",
    "first_published_date": "12/07/2011",
    "last_updated_date": "09/06/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-872"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Glucagon",
    "date_of_designation_or_refusal": "08/10/2009",
    "intended_use": "Treatment of congenital hyperinsulinism",
    "eu_designation_number": "EU/3/14/1342",
    "status": "Positive",
    "first_published_date": "12/11/2014",
    "last_updated_date": "09/06/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1342"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "triamcinolone acetonide",
    "date_of_designation_or_refusal": "21/05/2015",
    "intended_use": "Treatment of non-infectious uveitis",
    "eu_designation_number": "EU/3/15/1490",
    "status": "Positive",
    "first_published_date": "30/06/2015",
    "last_updated_date": "09/06/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1490"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "26 base synthetic single-stranded fully phosphorothioated 2'-O-methyl-RNA and DNA mixmer oligonucleotide-based compound",
    "date_of_designation_or_refusal": "27/02/2017",
    "intended_use": "Treatment of Dravet syndrome",
    "eu_designation_number": "EU/3/17/1829",
    "status": "Positive",
    "first_published_date": "31/03/2017",
    "last_updated_date": "09/06/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1829"
  },
  {
    "medicine_name": "Hyftor",
    "related_ema_product_number": "EMEA/H/C/005896",
    "active_substance": "sirolimus",
    "date_of_designation_or_refusal": "23/08/2017",
    "intended_use": "Treatment of tuberous sclerosis",
    "eu_designation_number": "EU/3/17/1910",
    "status": "Positive",
    "first_published_date": "17/10/2017",
    "last_updated_date": "09/06/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1910"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus",
    "date_of_designation_or_refusal": "24/03/2020",
    "intended_use": "Treatment in haematopoietic stem cell transplantation",
    "eu_designation_number": "EU/3/20/2260",
    "status": "Positive",
    "first_published_date": "12/08/2020",
    "last_updated_date": "08/06/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2260"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Doxorubicin(6-maleimidocaproyl)hydrazone (aldoxorubicin)",
    "date_of_designation_or_refusal": "26/03/2014",
    "intended_use": "Treatment of soft tissue sarcoma",
    "eu_designation_number": "EU/3/14/1258",
    "status": "Withdrawn",
    "first_published_date": "07/05/2014",
    "last_updated_date": "06/06/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1258"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "citric acid monohydrate",
    "date_of_designation_or_refusal": "27/06/2016",
    "intended_use": "Treatment of acute liver failure",
    "eu_designation_number": "EU/3/16/1675",
    "status": "Positive",
    "first_published_date": "26/07/2016",
    "last_updated_date": "05/06/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1675"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "4,7,10,13,16,19-docosahexaenoic acid",
    "date_of_designation_or_refusal": "04/11/2006",
    "intended_use": "Treatment of retinitis pigmentosa",
    "eu_designation_number": "EU/3/06/412",
    "status": "Positive",
    "first_published_date": "02/04/2009",
    "last_updated_date": "05/06/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-412"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "5'-ASCSASTSCSASGSTSCSTSGSASUSASASGSCSTSA-3' (lademirsen)",
    "date_of_designation_or_refusal": "19/03/2015",
    "intended_use": "Treatment of Alport syndrome",
    "eu_designation_number": "EU/3/15/1451",
    "status": "Withdrawn",
    "first_published_date": "11/05/2015",
    "last_updated_date": "05/06/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1451"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "viltolarsen",
    "date_of_designation_or_refusal": "04/06/2020",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/20/2282",
    "status": "Positive",
    "first_published_date": "19/08/2020",
    "last_updated_date": "01/06/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2282"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human acid alpha-glucosidase",
    "date_of_designation_or_refusal": "21/03/2018",
    "intended_use": "Treatment of glycogen storage disease type II (Pompe's disease)",
    "eu_designation_number": "EU/3/18/2000",
    "status": "Withdrawn",
    "first_published_date": "15/05/2018",
    "last_updated_date": "30/05/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2000"
  },
  {
    "medicine_name": "Tibsovo",
    "related_ema_product_number": "EMEA/H/C/005936",
    "active_substance": "Ivosidenib",
    "date_of_designation_or_refusal": "21/03/2018",
    "intended_use": "Treatment of biliary tract cancer",
    "eu_designation_number": "EU/3/18/1994",
    "status": "Positive",
    "first_published_date": "08/05/2018",
    "last_updated_date": "12/05/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1994"
  },
  {
    "medicine_name": "Tibsovo; Tidhesco",
    "related_ema_product_number": "EMEA/H/C/005936; EMEA/H/C/006174",
    "active_substance": "Ivosidenib",
    "date_of_designation_or_refusal": "12/12/2016",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/16/1802",
    "status": "Positive",
    "first_published_date": "09/01/2017",
    "last_updated_date": "12/05/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1802"
  },
  {
    "medicine_name": "Nugalviq",
    "related_ema_product_number": "EMEA/H/C/006270",
    "active_substance": "govorestat",
    "date_of_designation_or_refusal": "21/06/2022",
    "intended_use": "Treatment of galactosaemia",
    "eu_designation_number": "EU/3/22/2642",
    "status": "Positive",
    "first_published_date": "22/09/2022",
    "last_updated_date": "10/05/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2642"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pegunigalsidase alfa",
    "date_of_designation_or_refusal": "12/12/2017",
    "intended_use": "Treatment of Fabry disease",
    "eu_designation_number": "EU/3/17/1953",
    "status": "Withdrawn",
    "first_published_date": "23/01/2018",
    "last_updated_date": "08/05/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1953"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-[(2S)-5-{[(1R, 2S)-2-(4-fluorophenyl)cyclopropyl]amino}-1-(4-methylpiperazin-1-yl)-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide, bis-tosilate salt (Bomedemstat ditosilate)",
    "date_of_designation_or_refusal": "14/10/2016",
    "intended_use": "Treatment of myelofibrosis",
    "eu_designation_number": "EU/3/16/1757",
    "status": "Positive",
    "first_published_date": "15/11/2016",
    "last_updated_date": "08/05/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1757"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "nimorazole",
    "date_of_designation_or_refusal": "23/02/2011",
    "intended_use": "Treatment of squamous-cell carcinoma of the head and neck in patients undergoing radiotherapy",
    "eu_designation_number": "EU/3/10/842",
    "status": "Positive",
    "first_published_date": "04/03/2011",
    "last_updated_date": "08/05/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-842"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "troriluzole hydrochloride",
    "date_of_designation_or_refusal": "10/12/2021",
    "intended_use": "Treatment of spinocerebellar ataxia",
    "eu_designation_number": "EU/3/21/2553",
    "status": "Positive",
    "first_published_date": "05/05/2022",
    "last_updated_date": "08/05/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2553"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "rozanolixizumab",
    "date_of_designation_or_refusal": "11/01/2019",
    "intended_use": "Treatment of immune thrombocytopenia",
    "eu_designation_number": "EU/3/18/2131",
    "status": "Withdrawn",
    "first_published_date": "27/03/2019",
    "last_updated_date": "08/05/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2131"
  },
  {
    "medicine_name": "Oxbryta",
    "related_ema_product_number": "EMEA/H/C/004869",
    "active_substance": "2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (voxelotor)",
    "date_of_designation_or_refusal": "18/11/2016",
    "intended_use": "Treatment of sickle cell disease",
    "eu_designation_number": "EU/3/16/1769",
    "status": "Positive",
    "first_published_date": "14/12/2016",
    "last_updated_date": "04/05/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1769"
  },
  {
    "medicine_name": "SomaKit TOC",
    "related_ema_product_number": "EMEA/H/C/004140",
    "active_substance": "Gallium (68Ga)-edotreotide",
    "date_of_designation_or_refusal": "19/03/2015",
    "intended_use": "Diagnosis of gastro-entero-pancreatic neuroendocrine tumours",
    "eu_designation_number": "EU/3/15/1450",
    "status": "Positive",
    "first_published_date": "11/05/2015",
    "last_updated_date": "03/05/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1450"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "68Ga-DOTA-pABzA-DIG-dPhe-Gln-Trp-Ala-Val-Gly-His-NHCH[(CH2-CH(CH3)2]2",
    "date_of_designation_or_refusal": "12/12/2016",
    "intended_use": "Diagnosis of gastrointestinal stromal tumours",
    "eu_designation_number": "EU/3/16/1794",
    "status": "Positive",
    "first_published_date": "09/01/2017",
    "last_updated_date": "03/05/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1794"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Gallium [Ga-68]-N-[(4,7,10-Tricarboxymethyl-1,4,7,10-tetraazacyclododec-1-yl)acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophanyl-L-lysyl-L-threoninyl-Lcysteinyl-L-threonine-cyclic(2-7)disulfide",
    "date_of_designation_or_refusal": "19/02/2014",
    "intended_use": "Diagnosis of gastro-entero-pancreatic neuroendocrine tumours",
    "eu_designation_number": "EU/3/14/1237",
    "status": "Positive",
    "first_published_date": "01/04/2014",
    "last_updated_date": "03/05/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1237"
  },
  {
    "medicine_name": "Lutathera",
    "related_ema_product_number": "EMEA/H/C/004123",
    "active_substance": "Lutetium (177Lu)-N-[(4,7,10-Tricarboxymethyl-1,4,7,10-tetraazacyclododec-1-yl)acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophanyl-L-lysyl-L-threoninyl-L-cysteinyl-L-threonine-cyclic(2-7)disulfide (lutetium (177Lu) oxodotreotide)",
    "date_of_designation_or_refusal": "31/01/2008",
    "intended_use": "Treatment of gastro-entero-pancreatic neuroendocrine tumours",
    "eu_designation_number": "EU/3/07/523",
    "status": "Positive",
    "first_published_date": "10/07/2008",
    "last_updated_date": "03/05/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-523"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Bomedemstat ditosilate",
    "date_of_designation_or_refusal": "21/06/2021",
    "intended_use": "Treatment of essential thrombocythaemia",
    "eu_designation_number": "EU/3/21/2451",
    "status": "Positive",
    "first_published_date": "11/05/2022",
    "last_updated_date": "02/05/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2451"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ex-vivo fused autologous human bone marrow-derived mesenchymal stem cell with allogenic human myoblast",
    "date_of_designation_or_refusal": "31/07/2018",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/18/2045",
    "status": "Positive",
    "first_published_date": "10/10/2018",
    "last_updated_date": "28/04/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2045"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Ex vivo fused normal allogeneic human myoblast with another normal allogeneic human myoblast",
    "date_of_designation_or_refusal": "19/11/2018",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/18/2088",
    "status": "Positive",
    "first_published_date": "25/02/2019",
    "last_updated_date": "28/04/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2088"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Ile-Ser-Ile-Thr-Glu-Ile-Lys-Gly-Val-Ile-Val-His-Arg-Ile-Glu-Thr-Ile-Leu-Phe-Lys-Lys-Lys-Lys-Glu-Met-Pro-Ser-Glu-Glu-Gly-Tyr-Gln-Asp",
    "date_of_designation_or_refusal": "19/11/2018",
    "intended_use": "Treatment of multiple system atrophy",
    "eu_designation_number": "EU/3/18/2095",
    "status": "Positive",
    "first_published_date": "25/02/2019",
    "last_updated_date": "28/04/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2095"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Ex vivo fused normal allogeneic human myoblast with autologous human myoblast derived from Duchenne muscular dystrophy affected donor",
    "date_of_designation_or_refusal": "19/11/2019",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/18/2089",
    "status": "Positive",
    "first_published_date": "25/02/2019",
    "last_updated_date": "28/04/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2089"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tazemetostat",
    "date_of_designation_or_refusal": "21/03/2018",
    "intended_use": "Treatment of follicular lymphoma",
    "eu_designation_number": "EU/3/18/2005",
    "status": "Positive",
    "first_published_date": "15/05/2018",
    "last_updated_date": "28/04/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2005"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tazemetostat",
    "date_of_designation_or_refusal": "21/03/2018",
    "intended_use": "Treatment of diffuse large B-cell lymphoma",
    "eu_designation_number": "EU/3/18/2004",
    "status": "Positive",
    "first_published_date": "08/05/2018",
    "last_updated_date": "28/04/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2004"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tazemetostat",
    "date_of_designation_or_refusal": "21/03/2018",
    "intended_use": "Treatment of malignant mesothelioma",
    "eu_designation_number": "EU/3/18/2006",
    "status": "Positive",
    "first_published_date": "17/05/2018",
    "last_updated_date": "28/04/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2006"
  },
  {
    "medicine_name": "Kygevvi",
    "related_ema_product_number": "EMEA/H/C/005119",
    "active_substance": "thymidine;deoxycytidine",
    "date_of_designation_or_refusal": "20/04/2017",
    "intended_use": "Treatment of mitochondrial DNA depletion syndrome, myopathic form",
    "eu_designation_number": "EU/3/17/1870",
    "status": "Positive",
    "first_published_date": "15/05/2017",
    "last_updated_date": "25/04/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1870"
  },
  {
    "medicine_name": "Fintepla",
    "related_ema_product_number": "EMEA/H/C/003933",
    "active_substance": "fenfluramine hydrochloride",
    "date_of_designation_or_refusal": "27/02/2017",
    "intended_use": "Treatment of Lennox-Gastaut syndrome",
    "eu_designation_number": "EU/3/17/1836",
    "status": "Positive",
    "first_published_date": "31/03/2017",
    "last_updated_date": "25/04/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1836"
  },
  {
    "medicine_name": "Fintepla",
    "related_ema_product_number": "EMEA/H/C/003933",
    "active_substance": "fenfluramine hydrochloride",
    "date_of_designation_or_refusal": "18/12/2013",
    "intended_use": "Treatment of Dravet syndrome",
    "eu_designation_number": "EU/3/13/1219",
    "status": "Positive",
    "first_published_date": "23/01/2014",
    "last_updated_date": "25/04/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1219"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "3-(3-(3,5-bis(trifluoromethyl)phenyl)-1h-pyrazol-1-yl)propanoic acid",
    "date_of_designation_or_refusal": "24/04/2019",
    "intended_use": "Treatment of Stargardt's disease",
    "eu_designation_number": "EU/3/19/2152",
    "status": "Withdrawn",
    "first_published_date": "14/06/2019",
    "last_updated_date": "13/04/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2152"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tripotassium citrate monohydrate;potassium hydrogen carbonate",
    "date_of_designation_or_refusal": "09/01/2020",
    "intended_use": "Treatment of cystinuria",
    "eu_designation_number": "EU/3/19/2239",
    "status": "Positive",
    "first_published_date": "19/05/2020",
    "last_updated_date": "13/04/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2239"
  },
  {
    "medicine_name": "Miplyffa",
    "related_ema_product_number": "EMEA/H/C/005203",
    "active_substance": "arimoclomol citrate",
    "date_of_designation_or_refusal": "19/11/2014",
    "intended_use": "Treatment of Niemann-Pick's disease, type C",
    "eu_designation_number": "EU/3/14/1376",
    "status": "Positive",
    "first_published_date": "16/01/2015",
    "last_updated_date": "11/04/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1376"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(R)-1-[1-(4-acetoxy-3,3-dimethyl-2-oxo-butyl)-2-oxo-5-(pyridin-2-yl)-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-3-(3-methylamino-phenyl)-urea (ceclazepide)",
    "date_of_designation_or_refusal": "14/12/2015",
    "intended_use": "Treatment of gastro-entero-pancreatic neuroendocrine tumours",
    "eu_designation_number": "EU/3/15/1588",
    "status": "Withdrawn",
    "first_published_date": "02/02/2016",
    "last_updated_date": "04/04/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1588"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "streptococcus pyogenes, group A, type 3, strain Su, inactivated",
    "date_of_designation_or_refusal": "16/05/2022",
    "intended_use": "Treatment of lymphatic malformations",
    "eu_designation_number": "EU/3/22/2613",
    "status": "Positive",
    "first_published_date": "14/12/2022",
    "last_updated_date": "04/04/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2613"
  },
  {
    "medicine_name": "Qalsody",
    "related_ema_product_number": "EMEA/H/C/005493",
    "active_substance": "synthetic ribonucleic acid oligonucleotide directed against superoxide dismutase 1 messenger ribonucleic acid (tofersen)",
    "date_of_designation_or_refusal": "29/08/2016",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/16/1732",
    "status": "Positive",
    "first_published_date": "03/10/2016",
    "last_updated_date": "03/04/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1732"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised anti-alpha ν beta 6 monoclonal antibody",
    "date_of_designation_or_refusal": "29/07/2014",
    "intended_use": "Treatment of idiopathic pulmonary fibrosis",
    "eu_designation_number": "EU/3/14/1301",
    "status": "Positive",
    "first_published_date": "01/09/2014",
    "last_updated_date": "03/04/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1301"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous CD34+ cells transduced with a lentiviral vector containing the human ADA gene",
    "date_of_designation_or_refusal": "07/06/2013",
    "intended_use": "Treatment of adenosine-deaminase-deficient severe combined immunodeficiency",
    "eu_designation_number": "EU/3/13/1134",
    "status": "Positive",
    "first_published_date": "25/06/2013",
    "last_updated_date": "03/04/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1134"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Iodine (131I) iobenguane",
    "date_of_designation_or_refusal": "31/01/2008",
    "intended_use": "Treatment of neuroblastoma",
    "eu_designation_number": "EU/3/07/525",
    "status": "Positive",
    "first_published_date": "10/07/2008",
    "last_updated_date": "29/03/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-525"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant adeno-associated viral vector containing the human RPGR gene",
    "date_of_designation_or_refusal": "30/05/2016",
    "intended_use": "Treatment of retinitis pigmentosa caused by mutations in the RPGR gene",
    "eu_designation_number": "EU/3/16/1665",
    "status": "Positive",
    "first_published_date": "22/06/2016",
    "last_updated_date": "27/03/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1665"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidine-3-yl)chroman-2-carboxamide hydrochloride",
    "date_of_designation_or_refusal": "28/06/2019",
    "intended_use": "Treatment of maternally-inherited diabetes and deafness",
    "eu_designation_number": "EU/3/19/2168",
    "status": "Positive",
    "first_published_date": "02/10/2019",
    "last_updated_date": "27/03/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2168"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride",
    "date_of_designation_or_refusal": "10/08/2015",
    "intended_use": "Treatment of mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes",
    "eu_designation_number": "EU/3/15/1543",
    "status": "Positive",
    "first_published_date": "02/10/2015",
    "last_updated_date": "27/03/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1543"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride",
    "date_of_designation_or_refusal": "15/10/2014",
    "intended_use": "Treatment of Leigh syndrome",
    "eu_designation_number": "EU/3/14/1336",
    "status": "Positive",
    "first_published_date": "12/11/2014",
    "last_updated_date": "27/03/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1336"
  },
  {
    "medicine_name": "Waskyra",
    "related_ema_product_number": "EMEA/H/C/006525",
    "active_substance": "autologous CD34+ cells transfected with lentiviral vector containing the Wiskott-Aldrich syndrome protein gene (etuvetidigene autotemcel)",
    "date_of_designation_or_refusal": "06/06/2012",
    "intended_use": "Treatment of Wiskott-Aldrich syndrome",
    "eu_designation_number": "EU/3/12/998",
    "status": "Positive",
    "first_published_date": "04/07/2012",
    "last_updated_date": "27/03/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-998"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Adeno-associated viral vector serotype LK03 encoding human ornithine transcarbamylase",
    "date_of_designation_or_refusal": "20/03/2017",
    "intended_use": "Treatment of ornithine transcarbamylase deficiency",
    "eu_designation_number": "EU/3/17/1850",
    "status": "Positive",
    "first_published_date": "05/05/2017",
    "last_updated_date": "27/03/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1850"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "soluble recombinant human fibroblast growth factor receptor 3",
    "date_of_designation_or_refusal": "27/02/2017",
    "intended_use": "Treatment of achondroplasia",
    "eu_designation_number": "EU/3/17/1843",
    "status": "Withdrawn",
    "first_published_date": "31/03/2017",
    "last_updated_date": "24/03/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1843"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "miglustat",
    "date_of_designation_or_refusal": "11/01/2019",
    "intended_use": "Treatment of glycogen storage disease type II (Pompe's disease)",
    "eu_designation_number": "EU/3/18/2129",
    "status": "Withdrawn",
    "first_published_date": "27/03/2019",
    "last_updated_date": "24/03/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2129"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous haematopoietic stem cells transduced with lentiviral vector encoding the human beta-globin gene",
    "date_of_designation_or_refusal": "29/04/2009",
    "intended_use": "Treatment of beta thalassaemia intermedia and major",
    "eu_designation_number": "EU/3/09/623",
    "status": "Positive",
    "first_published_date": "12/05/2009",
    "last_updated_date": "24/03/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-623"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 2 containing the human SLC6A3 gene",
    "date_of_designation_or_refusal": "13/01/2023",
    "intended_use": "Treatment of dopamine transporter deficiency syndrome",
    "eu_designation_number": "EU/3/22/2746",
    "status": "Positive",
    "first_published_date": "23/03/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2746"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous CD34+ cells transduced with a lentiviral vector encoding the human NCF1 gene",
    "date_of_designation_or_refusal": "13/01/2023",
    "intended_use": "Treatment of chronic granulomatous disease",
    "eu_designation_number": "EU/3/22/2747",
    "status": "Positive",
    "first_published_date": "23/03/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2747"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Efzofitimod",
    "date_of_designation_or_refusal": "13/01/2023",
    "intended_use": "Treatment of sarcoidosis",
    "eu_designation_number": "EU/3/22/2744",
    "status": "Positive",
    "first_published_date": "23/03/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2744"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "opelconazole",
    "date_of_designation_or_refusal": "13/01/2023",
    "intended_use": "Treatment of invasive aspergillosis",
    "eu_designation_number": "EU/3/22/2745",
    "status": "Positive",
    "first_published_date": "23/03/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2745"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous hematopoietic cells genetically modified with a lentiviral vector containing the human RAG2 gene",
    "date_of_designation_or_refusal": "13/01/2023",
    "intended_use": "Treatment of recombination-activating gene 2 deficient severe combined immunodeficiency",
    "eu_designation_number": "EU/3/22/2741",
    "status": "Positive",
    "first_published_date": "23/03/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2741"
  },
  {
    "medicine_name": "Zynyz",
    "related_ema_product_number": "EMEA/H/C/006194",
    "active_substance": "retifanlimab",
    "date_of_designation_or_refusal": "13/01/2023",
    "intended_use": "Treatment of Merkel cell carcinoma",
    "eu_designation_number": "EU/3/22/2743",
    "status": "Positive",
    "first_published_date": "23/03/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2743"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N1,N14-diethyl-3S,12S-dihydroxyhomospermine tetrahydrochloride",
    "date_of_designation_or_refusal": "13/01/2023",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/22/2740",
    "status": "Positive",
    "first_published_date": "23/03/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2740"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "octreotide acetate",
    "date_of_designation_or_refusal": "13/01/2023",
    "intended_use": "Treatment of carcinoid syndrome",
    "eu_designation_number": "EU/3/22/2738",
    "status": "Positive",
    "first_published_date": "23/03/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2738"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "3-(1-(2',3'-dimethoxy-[1,1'-biphenyl]-4-yl)-1H-1,2,3-triazol-4-yl)benzoic acid",
    "date_of_designation_or_refusal": "13/01/2023",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/22/2739",
    "status": "Positive",
    "first_published_date": "23/03/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2739"
  },
  {
    "medicine_name": "Voranigo",
    "related_ema_product_number": "EMEA/H/C/006284",
    "active_substance": "vorasidenib hemicitrate hemihydrate",
    "date_of_designation_or_refusal": "13/01/2023",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/22/2737",
    "status": "Positive",
    "first_published_date": "23/03/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2737"
  },
  {
    "medicine_name": "Reblozyl",
    "related_ema_product_number": "EMEA/H/C/004444",
    "active_substance": "recombinant fusion protein consisting of a modified form of the extracellular domain of human activin receptor IIB linked to the human IgG1 Fc domain (luspatercept)",
    "date_of_designation_or_refusal": "29/07/2014",
    "intended_use": "Treatment of beta thalassaemia intermedia and major",
    "eu_designation_number": "EU/3/14/1300",
    "status": "Positive",
    "first_published_date": "01/09/2014",
    "last_updated_date": "21/03/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1300"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous T-cells transduced with a lentiviral vector encoding a chimeric antigen receptor against CD7",
    "date_of_designation_or_refusal": "09/12/2022",
    "intended_use": "Treatment of acute lymphoblastic leukaemia",
    "eu_designation_number": "EU/3/22/2732",
    "status": "Positive",
    "first_published_date": "13/03/2023",
    "last_updated_date": "14/03/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2732"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "briquilimab",
    "date_of_designation_or_refusal": "09/12/2022",
    "intended_use": "Treatment in haematopoietic stem cell transplantation",
    "eu_designation_number": "EU/3/22/2733",
    "status": "Positive",
    "first_published_date": "13/03/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2733"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(2S)-4-[2-methoxyethyl-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-(quinazolin-4-ylamino)butanoic acid",
    "date_of_designation_or_refusal": "09/12/2022",
    "intended_use": "Treatment of idiopathic pulmonary fibrosis",
    "eu_designation_number": "EU/3/22/2735",
    "status": "Positive",
    "first_published_date": "13/03/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2735"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "potassium 2-chloro-3-(1-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)-6-oxo-5-phenyl-6,7-dihydrothieno[2,3-b]pyridin-4-olate monohydrate",
    "date_of_designation_or_refusal": "09/12/2022",
    "intended_use": "Treatment of adrenoleukodystrophy",
    "eu_designation_number": "EU/3/22/2734",
    "status": "Positive",
    "first_published_date": "13/03/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2734"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Duvelisib",
    "date_of_designation_or_refusal": "09/12/2022",
    "intended_use": "Treatment of peripheral T-cell lymphoma",
    "eu_designation_number": "EU/3/22/2730",
    "status": "Positive",
    "first_published_date": "13/03/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2730"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant adeno-associated virus Olig001 containing human aspartoacylase cDNA",
    "date_of_designation_or_refusal": "09/12/2022",
    "intended_use": "Treatment of Canavan disease",
    "eu_designation_number": "EU/3/22/2729",
    "status": "Positive",
    "first_published_date": "13/03/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2729"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Mebendazole",
    "date_of_designation_or_refusal": "09/12/2022",
    "intended_use": "Treatment of autosomal dominant polycystic kidney disease",
    "eu_designation_number": "EU/3/22/2726",
    "status": "Positive",
    "first_published_date": "13/03/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2726"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "16-base single stranded RNA targeting miR-23b linked to oleic acid",
    "date_of_designation_or_refusal": "09/12/2022",
    "intended_use": "Treatment of myotonic disorders",
    "eu_designation_number": "EU/3/22/2724",
    "status": "Positive",
    "first_published_date": "13/03/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2724"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Lentiviral vector containing the human MYO7A gene",
    "date_of_designation_or_refusal": "23/03/2010",
    "intended_use": "Treatment of retinitis pigmentosa in Usher syndrome 1B",
    "eu_designation_number": "EU/3/10/727",
    "status": "Positive",
    "first_published_date": "26/03/2010",
    "last_updated_date": "13/03/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-727"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Lentiviral vector containing the human ABCA4 gene",
    "date_of_designation_or_refusal": "02/02/2010",
    "intended_use": "Treatment of Stargardt's disease",
    "eu_designation_number": "EU/3/09/720",
    "status": "Positive",
    "first_published_date": "04/03/2010",
    "last_updated_date": "13/03/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-720"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "clofazimine",
    "date_of_designation_or_refusal": "21/08/2019",
    "intended_use": "Treatment of nontuberculous mycobacterial lung disease",
    "eu_designation_number": "EU/3/19/2200",
    "status": "Positive",
    "first_published_date": "16/01/2020",
    "last_updated_date": "13/03/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2200"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "5-aminolevulinic acid",
    "date_of_designation_or_refusal": "12/01/2017",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/16/1811",
    "status": "Positive",
    "first_published_date": "13/07/2017",
    "last_updated_date": "10/03/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1811"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "cannabidiol",
    "date_of_designation_or_refusal": "11/11/2022",
    "intended_use": "Treatment of 22q11.2 deletion syndrome",
    "eu_designation_number": "EU/3/22/2718",
    "status": "Positive",
    "first_published_date": "23/01/2023",
    "last_updated_date": "07/03/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2718"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "cannabidiol",
    "date_of_designation_or_refusal": "25/02/2022",
    "intended_use": "Treatment of fragile X syndrome (FXS)",
    "eu_designation_number": "EU/3/22/2583",
    "status": "Positive",
    "first_published_date": "13/05/2022",
    "last_updated_date": "07/03/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2583"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)-carbamimidoyl)pyrazine-2-carboxamide, Sodium chloride solution 4.2% (w/v)",
    "date_of_designation_or_refusal": "16/11/2020",
    "intended_use": "Treatment of primary ciliary dyskinesia",
    "eu_designation_number": "EU/3/20/2363",
    "status": "Positive",
    "first_published_date": "15/02/2021",
    "last_updated_date": "07/03/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2363"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "apomorphine hydrochloride",
    "date_of_designation_or_refusal": "16/02/2006",
    "intended_use": "Treatment of off-periods in Parkinson's disease not responding to oral treatment",
    "eu_designation_number": "EU/3/06/349",
    "status": "Positive",
    "first_published_date": "24/08/2006",
    "last_updated_date": "28/02/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-349"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ribitol",
    "date_of_designation_or_refusal": "19/10/2020",
    "intended_use": "Treatment of limb-girdle muscular dystrophy",
    "eu_designation_number": "EU/3/20/2337",
    "status": "Positive",
    "first_published_date": "25/05/2021",
    "last_updated_date": "27/02/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2337"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "synthetic double-stranded siRNA oligonucleotide directed against SERPINA1 mRNA and containing four modified nucleosides which form a ligand cluster of four N-acetylgalactosamine residues",
    "date_of_designation_or_refusal": "16/12/2019",
    "intended_use": "Treatment of congenital alpha-1 antitrypsin deficiency",
    "eu_designation_number": "EU/3/19/2235",
    "status": "Positive",
    "first_published_date": "25/02/2020",
    "last_updated_date": "24/02/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2235"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "synthetic double-stranded siRNA oligonucleotide directed against lactate dehydrogenase A mRNA and containing four modified nucleosides which form a ligand cluster of four N-acetylgalactosamine residues",
    "date_of_designation_or_refusal": "31/07/2018",
    "intended_use": "Treatment of primary hyperoxaluria",
    "eu_designation_number": "EU/3/18/2052",
    "status": "Positive",
    "first_published_date": "11/10/2018",
    "last_updated_date": "24/02/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2052-0"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "patidegib",
    "date_of_designation_or_refusal": "21/03/2018",
    "intended_use": "Treatment of naevoid basal-cell carcinoma syndrome (Gorlin syndrome)",
    "eu_designation_number": "EU/3/18/1998",
    "status": "Positive",
    "first_published_date": "08/05/2017",
    "last_updated_date": "24/02/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1998"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-hydroxy-N,N,N-trimethylethan-1-aminium (Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoate",
    "date_of_designation_or_refusal": "24/03/2020",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/20/2259",
    "status": "Withdrawn",
    "first_published_date": "12/08/2020",
    "last_updated_date": "16/02/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2259"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "proteolytic enzymes enriched in bromelain",
    "date_of_designation_or_refusal": "30/07/2002",
    "intended_use": "Treatment of partial deep dermal and full-thickness burns",
    "eu_designation_number": "EU/3/02/107",
    "status": "Expired",
    "first_published_date": "08/01/2003",
    "last_updated_date": "15/02/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-107"
  },
  {
    "medicine_name": "Tyvaso; Tyvaso",
    "related_ema_product_number": "EMEA/H/C/001115; EMEA/H/C/001115",
    "active_substance": "treprostinil sodium",
    "date_of_designation_or_refusal": "14/04/2004",
    "intended_use": "Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension",
    "eu_designation_number": "EU/3/04/197",
    "status": "Positive",
    "first_published_date": "23/09/2009",
    "last_updated_date": "13/02/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-197"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "treprostinil diethanolamine",
    "date_of_designation_or_refusal": "15/05/2009",
    "intended_use": "Treatment of systemic sclerosis",
    "eu_designation_number": "EU/3/09/635",
    "status": "Positive",
    "first_published_date": "09/06/2009",
    "last_updated_date": "13/02/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-635"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ralinepag",
    "date_of_designation_or_refusal": "11/01/2019",
    "intended_use": "Treatment of pulmonary arterial hypertension",
    "eu_designation_number": "EU/3/18/2130",
    "status": "Positive",
    "first_published_date": "27/03/2019",
    "last_updated_date": "13/02/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2130"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "berzosertib",
    "date_of_designation_or_refusal": "18/07/2022",
    "intended_use": "Treatment of small cell lung cancer",
    "eu_designation_number": "EU/3/22/2655",
    "status": "Withdrawn",
    "first_published_date": "23/01/2023",
    "last_updated_date": "07/02/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2655"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "rebastinib",
    "date_of_designation_or_refusal": "12/11/2021",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/21/2524",
    "status": "Positive",
    "first_published_date": "09/06/2022",
    "last_updated_date": "07/02/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2524"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Dodecyl creatine ester, dodecyl creatine ester hydrochloride",
    "date_of_designation_or_refusal": "19/02/2021",
    "intended_use": "Treatment of creatine deficiency syndromes",
    "eu_designation_number": "EU/3/21/2409",
    "status": "Positive",
    "first_published_date": "23/02/2022",
    "last_updated_date": "06/02/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2409"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "polyethylene glycol-modified human recombinant truncated cystathionine beta-synthase (pegtibatinase)",
    "date_of_designation_or_refusal": "30/05/2016",
    "intended_use": "Treatment of homocystinuria",
    "eu_designation_number": "EU/3/16/1664",
    "status": "Positive",
    "first_published_date": "23/06/2016",
    "last_updated_date": "06/02/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1664"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "volanesorsen sodium",
    "date_of_designation_or_refusal": "14/07/2016",
    "intended_use": "Treatment of familial partial lipodystrophy",
    "eu_designation_number": "EU/3/16/1711",
    "status": "Positive",
    "first_published_date": "06/09/2016",
    "last_updated_date": "02/02/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1711"
  },
  {
    "medicine_name": "Waylivra",
    "related_ema_product_number": "EMEA/H/C/004538",
    "active_substance": "phosphorothioate oligonucleotide targeted to apolipoprotein C-III (volanesorsen)",
    "date_of_designation_or_refusal": "19/02/2014",
    "intended_use": "Treatment of familial chylomicronaemia syndrome",
    "eu_designation_number": "EU/3/14/1249",
    "status": "Positive",
    "first_published_date": "03/04/2014",
    "last_updated_date": "02/02/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1249"
  },
  {
    "medicine_name": "Ebvallo",
    "related_ema_product_number": "EMEA/H/C/004577",
    "active_substance": "allogeneic Epstein-Barr virus specific cytotoxic T lymphocytes (Tabelecleucel)",
    "date_of_designation_or_refusal": "21/03/2016",
    "intended_use": "Treatment of post-transplantation lymphoproliferative disorders",
    "eu_designation_number": "EU/3/16/1627",
    "status": "Positive",
    "first_published_date": "03/05/2016",
    "last_updated_date": "30/01/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1627"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ex-vivo-expanded autologous keratinocytes transduced with retroviral vector containing the COL7A1 gene (prademagene zamikeracel)",
    "date_of_designation_or_refusal": "27/02/2017",
    "intended_use": "Treatment of epidermolysis bullosa",
    "eu_designation_number": "EU/3/17/1835",
    "status": "Positive",
    "first_published_date": "31/03/2017",
    "last_updated_date": "30/01/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1835"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Bardoxolone methyl",
    "date_of_designation_or_refusal": "20/08/2021",
    "intended_use": "Treatment of autosomal dominant polycystic kidney disease",
    "eu_designation_number": "EU/3/21/2480",
    "status": "Positive",
    "first_published_date": "25/02/2022",
    "last_updated_date": "30/01/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2480"
  },
  {
    "medicine_name": "Imbarkyd",
    "related_ema_product_number": "EMEA/H/C/005869",
    "active_substance": "Bardoxolone methyl",
    "date_of_designation_or_refusal": "25/05/2018",
    "intended_use": "Treatment of Alport syndrome",
    "eu_designation_number": "EU/3/18/2019",
    "status": "Positive",
    "first_published_date": "23/07/2018",
    "last_updated_date": "30/01/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2019"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "idursulfase",
    "date_of_designation_or_refusal": "06/01/2021",
    "intended_use": "Treatment of mucopolysaccharidosis type II (Hunter's syndrome)",
    "eu_designation_number": "EU/3/20/2391",
    "status": "Withdrawn",
    "first_published_date": "18/10/2021",
    "last_updated_date": "27/01/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2391"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Loncastuximab tesirine",
    "date_of_designation_or_refusal": "20/08/2021",
    "intended_use": "Treatment of diffuse large B-cell lymphoma",
    "eu_designation_number": "EU/3/21/2481",
    "status": "Withdrawn",
    "first_published_date": "25/02/2022",
    "last_updated_date": "26/01/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2481"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2,4,6,7,8,9-hexahydro-4-((2-methylphenyl)methyl)-7-(phenylmethyl)imidazo(1,2-a)pyrido(3,4-e)pyrimidin-5(1H)-one",
    "date_of_designation_or_refusal": "18/07/2022",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/22/2661",
    "status": "Positive",
    "first_published_date": "25/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2661"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 9 containing the human ABCD1 gene",
    "date_of_designation_or_refusal": "11/11/2022",
    "intended_use": "Treatment of adrenoleukodystrophy",
    "eu_designation_number": "EU/3/22/2719",
    "status": "Positive",
    "first_published_date": "25/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2719"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous naive regulatory T cells transduced with a lentiviral vector encoding for a chimeric antigen receptor to recognise the HLA-A*02 antigen",
    "date_of_designation_or_refusal": "18/07/2022",
    "intended_use": "Treatment in solid organ transplantation",
    "eu_designation_number": "EU/3/22/2647",
    "status": "Positive",
    "first_published_date": "25/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2647"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "crofelemer",
    "date_of_designation_or_refusal": "11/10/2022",
    "intended_use": "Treatment of microvillus inclusion disease",
    "eu_designation_number": "EU/3/22/2693",
    "status": "Positive",
    "first_published_date": "24/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2693"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous T cells transduced with a lentiviral vector expressing a chimeric antigen receptor against CLL-1",
    "date_of_designation_or_refusal": "11/10/2022",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/22/2694",
    "status": "Positive",
    "first_published_date": "24/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2694"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Epeleuton",
    "date_of_designation_or_refusal": "11/10/2022",
    "intended_use": "Treatment of sickle cell disease",
    "eu_designation_number": "EU/3/22/2695",
    "status": "Positive",
    "first_published_date": "24/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2695"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "velusetrag",
    "date_of_designation_or_refusal": "11/10/2022",
    "intended_use": "Treatment of intestinal pseudo-obstruction",
    "eu_designation_number": "EU/3/22/2696",
    "status": "Positive",
    "first_published_date": "24/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2696"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Inaxaplin",
    "date_of_designation_or_refusal": "11/10/2022",
    "intended_use": "Treatment of apolipoprotein L1-mediated kidney disease",
    "eu_designation_number": "EU/3/22/2697",
    "status": "Positive",
    "first_published_date": "24/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2697"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 8 containing the 3' human otoferlin coding sequence, adeno?associated viral vector serotype 8 containing the 5' human otoferlin coding sequenceAdeno‐associated viral vector serotype 8 containing the 3' human otoferlin coding sequence, adeno‐associated viral vector serotype 8 containing the 5' human otoferlin coding sequence",
    "date_of_designation_or_refusal": "11/10/2022",
    "intended_use": "Treatment of otoferlin gene-mediated hearing loss",
    "eu_designation_number": "EU/3/22/2698",
    "status": "Positive",
    "first_published_date": "24/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2698"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human IgG4k monoclonal antibody against CD89",
    "date_of_designation_or_refusal": "11/10/2022",
    "intended_use": "Treatment of linear IgA bullous dermatosis",
    "eu_designation_number": "EU/3/22/2702",
    "status": "Positive",
    "first_published_date": "24/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2702"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Etidronate disodium",
    "date_of_designation_or_refusal": "11/10/2022",
    "intended_use": "Treatment of pseudoxanthoma elasticum",
    "eu_designation_number": "EU/3/22/2703",
    "status": "Positive",
    "first_published_date": "24/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2703"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium ({(2S)-1,4-bis[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[2.2.2]octan-2-yl}oxy)methyl hydrogen phosphate-2-amino-2-(hydroxymethyl)propane-1,3-diol (1/1/1)",
    "date_of_designation_or_refusal": "11/10/2022",
    "intended_use": "Treatment of vanishing white matter disease",
    "eu_designation_number": "EU/3/22/2704",
    "status": "Positive",
    "first_published_date": "24/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2704"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "selinexor",
    "date_of_designation_or_refusal": "11/10/2022",
    "intended_use": "Treatment of myelofibrosis",
    "eu_designation_number": "EU/3/22/2705",
    "status": "Positive",
    "first_published_date": "24/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2705"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Methyl(R)-4-((3S,5R,7R,8R,9S,10S,13R,14S,17R)-7-hydroxy-10,13-dimethyl-3-((4-((pyridin-3-ylmethyl)amino)butyl)amino)hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate",
    "date_of_designation_or_refusal": "11/10/2022",
    "intended_use": "Treatment of Rett syndrome",
    "eu_designation_number": "EU/3/22/2706",
    "status": "Positive",
    "first_published_date": "24/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2706"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Eculizumab",
    "date_of_designation_or_refusal": "11/10/2022",
    "intended_use": "Treatment of Guillain-Barré syndrome",
    "eu_designation_number": "EU/3/22/2707",
    "status": "Positive",
    "first_published_date": "24/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2707"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "acetylleucine",
    "date_of_designation_or_refusal": "11/10/2022",
    "intended_use": "Treatment of GM1 gangliosidosis",
    "eu_designation_number": "EU/3/22/2708",
    "status": "Positive",
    "first_published_date": "24/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2708"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ropeginterferon alfa-2b",
    "date_of_designation_or_refusal": "11/10/2022",
    "intended_use": "Treatment of essential thrombocythaemia",
    "eu_designation_number": "EU/3/22/2709",
    "status": "Positive",
    "first_published_date": "24/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2709"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human mesencephalic astrocyte-derived neurotrophic factor",
    "date_of_designation_or_refusal": "24/04/2015",
    "intended_use": "Treatment of retinitis pigmentosa",
    "eu_designation_number": "EU/3/15/1486",
    "status": "Positive",
    "first_published_date": "22/05/2015",
    "last_updated_date": "24/01/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1486"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(R)-deuteropioglitazone hydrochloride",
    "date_of_designation_or_refusal": "11/11/2022",
    "intended_use": "Treatment of adrenoleukodystrophy",
    "eu_designation_number": "EU/3/22/2720",
    "status": "Positive",
    "first_published_date": "23/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2720"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(S)-5-(1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethylamino-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile (olutasidenib)",
    "date_of_designation_or_refusal": "29/05/2019",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/19/2159",
    "status": "Positive",
    "first_published_date": "09/08/2019",
    "last_updated_date": "23/01/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2159"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tricaprilin",
    "date_of_designation_or_refusal": "11/11/2022",
    "intended_use": "Treatment of West syndrome",
    "eu_designation_number": "EU/3/22/2717",
    "status": "Positive",
    "first_published_date": "23/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2717"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "melatonin",
    "date_of_designation_or_refusal": "28/11/2022",
    "intended_use": "Treatment of retinopathy of prematurity",
    "eu_designation_number": "-",
    "status": "Negative",
    "first_published_date": "23/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-retinopathy-prematurity"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pegcetacoplan",
    "date_of_designation_or_refusal": "11/11/2022",
    "intended_use": "Treatment of C3 glomerulopathy with or without immune complexes",
    "eu_designation_number": "EU/3/22/2716",
    "status": "Positive",
    "first_published_date": "23/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2716"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "copper nanocluster conjugated to acetate, histidinate and ascorbate",
    "date_of_designation_or_refusal": "11/11/2022",
    "intended_use": "Treatment of Menkes disease",
    "eu_designation_number": "EU/3/22/2711",
    "status": "Positive",
    "first_published_date": "23/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2711"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Delpazolid",
    "date_of_designation_or_refusal": "10/11/2022",
    "intended_use": "Treatment of tuberculosis",
    "eu_designation_number": "EU/3/22/2710",
    "status": "Positive",
    "first_published_date": "23/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2710"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "atorvastatin",
    "date_of_designation_or_refusal": "11/11/2022",
    "intended_use": "Treatment of familial cerebral cavernous malformations",
    "eu_designation_number": "EU/3/22/2714",
    "status": "Positive",
    "first_published_date": "23/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2714"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "thiostrepton",
    "date_of_designation_or_refusal": "18/07/2022",
    "intended_use": "Treatment of  malignant mesothelioma",
    "eu_designation_number": "EU/3/22/2648",
    "status": "Positive",
    "first_published_date": "23/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2648"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "propranolol",
    "date_of_designation_or_refusal": "11/11/2022",
    "intended_use": "Treatment of familial cerebral cavernous malformations",
    "eu_designation_number": "EU/3/22/2713",
    "status": "Positive",
    "first_published_date": "23/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2713"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione",
    "date_of_designation_or_refusal": "18/07/2022",
    "intended_use": "Treatment of familial adenomatous polyposis (FAP)",
    "eu_designation_number": "EU/3/22/2670",
    "status": "Positive",
    "first_published_date": "23/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2670"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "toripalimab",
    "date_of_designation_or_refusal": "18/07/2022",
    "intended_use": "Treatment of nasopharyngeal cancer",
    "eu_designation_number": "EU/3/22/2669",
    "status": "Withdrawn",
    "first_published_date": "23/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2669"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "liraglutide",
    "date_of_designation_or_refusal": "18/07/2022",
    "intended_use": "Treatment of Wolfram syndrome",
    "eu_designation_number": "EU/3/22/2667",
    "status": "Positive",
    "first_published_date": "23/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2667"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "mRNA encoding modified human ornithine transcarbamylase",
    "date_of_designation_or_refusal": "18/07/2022",
    "intended_use": "Treatment of ornithine transcarbamylase deficiency",
    "eu_designation_number": "EU/3/22/2646",
    "status": "Positive",
    "first_published_date": "23/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2646"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "W253R/R275S tissue plasminogen activator",
    "date_of_designation_or_refusal": "18/07/2022",
    "intended_use": "Treatment of non-traumatic spontaneous intracerebral haemorrhage",
    "eu_designation_number": "EU/3/22/2666",
    "status": "Positive",
    "first_published_date": "23/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2666"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pyridoxal 5'-phosphate",
    "date_of_designation_or_refusal": "18/07/2022",
    "intended_use": "Treatment of pyridoxal 5'‐phosphate homeostasis protein deficiency",
    "eu_designation_number": "EU/3/22/2665",
    "status": "Positive",
    "first_published_date": "23/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2665"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "hydroquinidine hydrochloride",
    "date_of_designation_or_refusal": "18/07/2022",
    "intended_use": "Treatment of Brugada syndrome",
    "eu_designation_number": "EU/3/22/2651",
    "status": "Positive",
    "first_published_date": "23/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2651"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole",
    "date_of_designation_or_refusal": "18/07/2022",
    "intended_use": "Treatment of multiple system atrophy",
    "eu_designation_number": "EU/3/22/2652",
    "status": "Positive",
    "first_published_date": "23/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2652"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "melatonin",
    "date_of_designation_or_refusal": "14/10/2022",
    "intended_use": "Prevention of spaceflight-related radiation and microgravity",
    "eu_designation_number": "N/A",
    "status": "Negative",
    "first_published_date": "23/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-prevention-spaceflight-related-radiation-and-microgravity"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium phenylbutyrate",
    "date_of_designation_or_refusal": "18/07/2022",
    "intended_use": "Treatment of maple syrup urine disease",
    "eu_designation_number": "EU/3/22/2663",
    "status": "Positive",
    "first_published_date": "23/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2663"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(S)-1-(4-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-ylamino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide",
    "date_of_designation_or_refusal": "18/07/2022",
    "intended_use": "Treatment of fibrodysplasia ossificans progressiva",
    "eu_designation_number": "EU/3/22/2654",
    "status": "Positive",
    "first_published_date": "23/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2654"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "vilobelimab",
    "date_of_designation_or_refusal": "18/07/2022",
    "intended_use": "Treatment of pyoderma gangrenosum",
    "eu_designation_number": "EU/3/22/2662",
    "status": "Positive",
    "first_published_date": "23/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2662"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Efgartigimod alfa",
    "date_of_designation_or_refusal": "18/07/2022",
    "intended_use": "Treatment of pemphigus",
    "eu_designation_number": "EU/3/22/2653",
    "status": "Positive",
    "first_published_date": "23/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2653"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "panobinostat",
    "date_of_designation_or_refusal": "18/07/2022",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/22/2660",
    "status": "Positive",
    "first_published_date": "23/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2660"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Parsaclisib",
    "date_of_designation_or_refusal": "18/07/2022",
    "intended_use": "Treatment of autoimmune haemolytic anaemia",
    "eu_designation_number": "EU/3/22/2659",
    "status": "Positive",
    "first_published_date": "23/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2659"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "heterologous swine glyco-humanised polyclonal antibody against T lymphocytes",
    "date_of_designation_or_refusal": "18/07/2022",
    "intended_use": "Treatment in solid organ transplantation",
    "eu_designation_number": "EU/3/22/2658",
    "status": "Positive",
    "first_published_date": "23/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2658"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Salmonella enterica, subsp. enterica, serovar Typhimurium, strain YS1646, live",
    "date_of_designation_or_refusal": "18/07/2022",
    "intended_use": "Treatment of schwannoma",
    "eu_designation_number": "EU/3/22/2657",
    "status": "Positive",
    "first_published_date": "23/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2657"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Herpes simplex virus 1 expressing the human CFTR gene",
    "date_of_designation_or_refusal": "26/03/2021",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/21/2421",
    "status": "Positive",
    "first_published_date": "19/01/2022",
    "last_updated_date": "17/01/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2421"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "replication-incompetent, non-integrating, herpes simplex virus 1 vector expressing the human transglutaminase-1 enzyme (Inetagugene geperpavec)",
    "date_of_designation_or_refusal": "13/11/2019",
    "intended_use": "Treatment of autosomal recessive congenital ichthyosis",
    "eu_designation_number": "EU/3/19/2225",
    "status": "Positive",
    "first_published_date": "13/02/2020",
    "last_updated_date": "13/01/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2225"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised IgG1 monoclonal antibody against TfR1 conjugated to double stranded siRNA oligonucleotide against DMPK via a non-cleavable linker",
    "date_of_designation_or_refusal": "20/08/2021",
    "intended_use": "Treatment of myotonic disorders",
    "eu_designation_number": "EU/3/21/2485",
    "status": "Positive",
    "first_published_date": "09/01/2023",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2485"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "zanubrutinib",
    "date_of_designation_or_refusal": "20/05/2021",
    "intended_use": "Treatment of marginal zone lymphoma",
    "eu_designation_number": "EU/3/21/2438",
    "status": "Withdrawn",
    "first_published_date": "18/03/2022",
    "last_updated_date": "05/01/2023",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2438"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pegylated adrenomedullin",
    "date_of_designation_or_refusal": "27/07/2020",
    "intended_use": "Treatment of acute respiratory distress syndrome (ARDS)",
    "eu_designation_number": "EU/3/20/2301",
    "status": "Positive",
    "first_published_date": "19/11/2020",
    "last_updated_date": "22/12/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2301"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human allogeneic bone-marrow-derived osteoblastic-like cells",
    "date_of_designation_or_refusal": "05/08/2013",
    "intended_use": "Treatment of non-traumatic osteonecrosis",
    "eu_designation_number": "EU/3/13/1176",
    "status": "Positive",
    "first_published_date": "13/09/2013",
    "last_updated_date": "22/12/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1176"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human allogeneic bone-marrow-derived osteoblastic cells",
    "date_of_designation_or_refusal": "10/08/2015",
    "intended_use": "Treatment of osteogenesis imperfecta",
    "eu_designation_number": "EU/3/15/1533",
    "status": "Positive",
    "first_published_date": "02/10/2015",
    "last_updated_date": "22/12/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1533"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "regorafenib",
    "date_of_designation_or_refusal": "28/06/2019",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/19/2177",
    "status": "Withdrawn",
    "first_published_date": "14/10/2019",
    "last_updated_date": "20/12/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2177"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic retinal pigment epithelial cells genetically modified with a non-viral vector to express human alpha-L-iduronidase",
    "date_of_designation_or_refusal": "15/10/2021",
    "intended_use": "Treatment of mucopolysaccharidosis type I",
    "eu_designation_number": "EU/3/21/2505",
    "status": "Withdrawn",
    "first_published_date": "20/01/2022",
    "last_updated_date": "20/12/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2505"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "bevacizumab",
    "date_of_designation_or_refusal": "16/12/2014",
    "intended_use": "Treatment of hereditary haemorrhagic telangiectasia",
    "eu_designation_number": "EU/3/14/1390",
    "status": "Positive",
    "first_published_date": "26/02/2015",
    "last_updated_date": "19/12/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1390"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "4-[131I] Iodo-L-phenylalanine",
    "date_of_designation_or_refusal": "11/04/2006",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/06/363",
    "status": "Positive",
    "first_published_date": "24/04/2009",
    "last_updated_date": "19/12/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-363"
  },
  {
    "medicine_name": "Yescarta",
    "related_ema_product_number": "EMEA/H/C/004480",
    "active_substance": "autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3 zeta chimeric antigen receptor (axicabtagene ciloleucel)",
    "date_of_designation_or_refusal": "16/12/2014",
    "intended_use": "Treatment of diffuse large B-cell lymphoma",
    "eu_designation_number": "EU/3/14/1393",
    "status": "Positive",
    "first_published_date": "26/02/2015",
    "last_updated_date": "16/12/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1393"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "amphotericin B",
    "date_of_designation_or_refusal": "10/08/2022",
    "intended_use": "Treatment of cryptococcosis",
    "eu_designation_number": "EU/3/22/2691",
    "status": "Positive",
    "first_published_date": "15/12/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2691"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tamibarotene",
    "date_of_designation_or_refusal": "10/08/2022",
    "intended_use": "Treatment of myelodysplastic syndromes",
    "eu_designation_number": "EU/3/22/2688",
    "status": "Positive",
    "first_published_date": "15/12/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2688"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(7S)-8,8-dimethyl-7-{[(2E)-3-phenyl-2-propen-1-yl]oxy}-7,8-dihydro-2H,6H-pyrano[3,2-g]chromen-2-one",
    "date_of_designation_or_refusal": "10/08/2022",
    "intended_use": "Treatment of Hutchinson-Gilford progeria syndrome",
    "eu_designation_number": "EU/3/22/2689",
    "status": "Positive",
    "first_published_date": "15/12/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2689"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised IgG1 tetravalent monoclonal antibody against death receptor 5",
    "date_of_designation_or_refusal": "10/08/2022",
    "intended_use": "Treatment of chondrosarcoma",
    "eu_designation_number": "EU/3/22/2690",
    "status": "Positive",
    "first_published_date": "15/12/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2690"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic adult liver-derived stem cells",
    "date_of_designation_or_refusal": "10/08/2022",
    "intended_use": "Treatment of urea cycle disorders",
    "eu_designation_number": "EU/3/22/2685",
    "status": "Positive",
    "first_published_date": "15/12/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2685"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Gold",
    "date_of_designation_or_refusal": "10/08/2022",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/22/2686",
    "status": "Positive",
    "first_published_date": "15/12/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2686"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "clarithromycin;clofazimine;rifabutin",
    "date_of_designation_or_refusal": "10/08/2022",
    "intended_use": "Treatment of nontuberculous mycobacterial lung disease",
    "eu_designation_number": "EU/3/22/2687",
    "status": "Positive",
    "first_published_date": "15/12/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2687"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "vutrisiran",
    "date_of_designation_or_refusal": "10/08/2022",
    "intended_use": "Treatment of Stargardt's disease",
    "eu_designation_number": "EU/3/22/2682",
    "status": "Positive",
    "first_published_date": "15/12/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2682"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sotuletinib",
    "date_of_designation_or_refusal": "10/08/2022",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/22/2683",
    "status": "Positive",
    "first_published_date": "15/12/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2683"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous human bone marrow-derived haematopoietic and mesenchymal stem cells depleted of erythrocytes, monocytes and lymphocytes",
    "date_of_designation_or_refusal": "10/08/2022",
    "intended_use": "Treatment of frontotemporal dementia",
    "eu_designation_number": "EU/3/22/2681",
    "status": "Positive",
    "first_published_date": "15/12/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2681"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Mazindol",
    "date_of_designation_or_refusal": "10/08/2022",
    "intended_use": "Treatment of idiopathic hypersomnia",
    "eu_designation_number": "EU/3/22/2676",
    "status": "Positive",
    "first_published_date": "15/12/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2676"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "calmangafodipir",
    "date_of_designation_or_refusal": "10/08/2022",
    "intended_use": "Prevention of acute liver failure",
    "eu_designation_number": "EU/3/22/2678",
    "status": "Positive",
    "first_published_date": "15/12/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2678"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Lithium carbonate",
    "date_of_designation_or_refusal": "10/08/2022",
    "intended_use": "Treatment of familial adenomatous polyposis (FAP)",
    "eu_designation_number": "EU/3/22/2674",
    "status": "Positive",
    "first_published_date": "15/12/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2674"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Bezafibrate",
    "date_of_designation_or_refusal": "10/08/2022",
    "intended_use": "Treatment of primary sclerosing cholangitis",
    "eu_designation_number": "EU/3/22/2675",
    "status": "Positive",
    "first_published_date": "15/12/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2675"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "toll-like receptor 4 agonist",
    "date_of_designation_or_refusal": "10/08/2022",
    "intended_use": "Treatment of osteosarcoma",
    "eu_designation_number": "EU/3/22/2672",
    "status": "Positive",
    "first_published_date": "15/12/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2672"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous CD34+ haematopoietic stem and progenitor cells genetically modified with a lentiviral vector encoding for the N-acetylgalactosamine 6-sulfatase cDNA",
    "date_of_designation_or_refusal": "10/08/2022",
    "intended_use": "Treatment of mucopolysaccharidosis type IV A (Morquio A syndrome)",
    "eu_designation_number": "EU/3/22/2671",
    "status": "Positive",
    "first_published_date": "15/12/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2671"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pentosan polysulfate sodium",
    "date_of_designation_or_refusal": "21/08/2020",
    "intended_use": "Treatment of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)",
    "eu_designation_number": "EU/3/20/2315",
    "status": "Positive",
    "first_published_date": "25/11/2020",
    "last_updated_date": "15/12/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2315"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pentosan polysulfate sodium",
    "date_of_designation_or_refusal": "19/11/2014",
    "intended_use": "Treatment of mucopolysaccharidosis type I",
    "eu_designation_number": "EU/3/14/1359",
    "status": "Positive",
    "first_published_date": "15/01/2015",
    "last_updated_date": "15/12/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1359"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "concizumab",
    "date_of_designation_or_refusal": "12/10/2017",
    "intended_use": "Treatment of haemophilia B",
    "eu_designation_number": "EU/3/17/1940",
    "status": "Withdrawn",
    "first_published_date": "15/01/2018",
    "last_updated_date": "14/12/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1940"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised monoclonal IgG4 antibody against tissue-factor-pathway inhibitor (concizumab)",
    "date_of_designation_or_refusal": "10/10/2012",
    "intended_use": "Treatment of haemophilia A",
    "eu_designation_number": "EU/3/12/1052",
    "status": "Withdrawn",
    "first_published_date": "16/11/2012",
    "last_updated_date": "14/12/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1052"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "alisporivir",
    "date_of_designation_or_refusal": "16/03/2022",
    "intended_use": "Treatment of collagen VI-related myopathies",
    "eu_designation_number": "EU/3/22/2590",
    "status": "Positive",
    "first_published_date": "20/06/2022",
    "last_updated_date": "14/12/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2590"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "besilesomab",
    "date_of_designation_or_refusal": "17/10/2019",
    "intended_use": "Treatment in haematopoietic stem cell transplantation",
    "eu_designation_number": "EU/3/19/2211",
    "status": "Positive",
    "first_published_date": "22/01/2020",
    "last_updated_date": "14/12/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2211"
  },
  {
    "medicine_name": "Livmarli",
    "related_ema_product_number": "EMEA/H/C/005857",
    "active_substance": "(4R,5R)-1-[[4-[[4-[3,3-dibutyl-7-(dimethylamino)-2,3,4,5- tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-1-azoniabicyclo[2.2.2]octane chloride (maralixibat chloride)",
    "date_of_designation_or_refusal": "18/12/2013",
    "intended_use": "Treatment of Alagille syndrome",
    "eu_designation_number": "EU/3/13/1214",
    "status": "Positive",
    "first_published_date": "22/01/2014",
    "last_updated_date": "14/12/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1214"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "chimeric peptide of human glucagon-like peptide-1, glucagon and gastric inhibitory polypeptide analogues linked to a human immunoglobulin Fc fragment",
    "date_of_designation_or_refusal": "16/05/2022",
    "intended_use": "Treatment of idiopathic pulmonary fibrosis",
    "eu_designation_number": "EU/3/22/2619",
    "status": "Positive",
    "first_published_date": "14/12/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2619"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pasireotide",
    "date_of_designation_or_refusal": "16/05/2022",
    "intended_use": "Treatment of noninsulinoma pancreatogenous hypoglycemia syndrome",
    "eu_designation_number": "EU/3/22/2620",
    "status": "Positive",
    "first_published_date": "14/12/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2620"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous peripheral blood-derived CD4 T-cells CRISPR-edited at the CD40LG locus",
    "date_of_designation_or_refusal": "16/05/2022",
    "intended_use": "Treatment of hyper IgM syndromes",
    "eu_designation_number": "EU/3/22/2617",
    "status": "Positive",
    "first_published_date": "14/12/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2617"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Icerguastat acetate",
    "date_of_designation_or_refusal": "16/05/2022",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/22/2618",
    "status": "Positive",
    "first_published_date": "14/12/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2618"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Ibudilast",
    "date_of_designation_or_refusal": "16/05/2022",
    "intended_use": "Treatment of fragile X syndrome",
    "eu_designation_number": "EU/3/22/2615",
    "status": "Positive",
    "first_published_date": "14/12/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2615"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus serotype 8 expressing the human gamma-sarcoglycan gene",
    "date_of_designation_or_refusal": "16/05/2022",
    "intended_use": "Treatment of limb-girdle muscular dystrophy",
    "eu_designation_number": "EU/3/22/2616",
    "status": "Positive",
    "first_published_date": "14/12/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2616"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "elamipretide",
    "date_of_designation_or_refusal": "16/05/2022",
    "intended_use": "Treatment of myopathic mitochondrial DNA depletion syndrome",
    "eu_designation_number": "EU/3/22/2614",
    "status": "Positive",
    "first_published_date": "14/12/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2614"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Elezanumab",
    "date_of_designation_or_refusal": "16/05/2022",
    "intended_use": "Treatment of spinal cord injury",
    "eu_designation_number": "EU/3/22/2612",
    "status": "Positive",
    "first_published_date": "14/12/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2612"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD123",
    "date_of_designation_or_refusal": "16/05/2022",
    "intended_use": "Treatment of blastic plasmacytoid dendritic cell neoplasm",
    "eu_designation_number": "EU/3/22/2610",
    "status": "Positive",
    "first_published_date": "14/12/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2610"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "cannabidiol",
    "date_of_designation_or_refusal": "16/05/2022",
    "intended_use": "Treatment of epidermolysis bullosa",
    "eu_designation_number": "EU/3/22/2609",
    "status": "Positive",
    "first_published_date": "14/12/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2609"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus serotype R100 containing the human RPGRorf15 gene isoform",
    "date_of_designation_or_refusal": "16/05/2022",
    "intended_use": "Treatment of inherited retinal dystrophies due to defects in the RPGR gene",
    "eu_designation_number": "EU/3/22/2608",
    "status": "Positive",
    "first_published_date": "14/12/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2608"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Parsaclisib",
    "date_of_designation_or_refusal": "25/07/2019",
    "intended_use": "Treatment of marginal zone lymphoma",
    "eu_designation_number": "EU/3/19/2185",
    "status": "Withdrawn",
    "first_published_date": "24/09/2019",
    "last_updated_date": "13/12/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2185"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tremelimumab",
    "date_of_designation_or_refusal": "09/12/2020",
    "intended_use": "Treatment of hepatocellular carcinoma",
    "eu_designation_number": "EU/3/20/2370",
    "status": "Withdrawn",
    "first_published_date": "21/05/2021",
    "last_updated_date": "09/12/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2370"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "3-[4-(1H-imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophene-2-[(N-butyloxylcarbamate)-sulphonamide] sodium salt",
    "date_of_designation_or_refusal": "14/07/2016",
    "intended_use": "Treatment of idiopathic pulmonary fibrosis",
    "eu_designation_number": "EU/3/16/1692",
    "status": "Positive",
    "first_published_date": "06/09/2016",
    "last_updated_date": "08/12/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1692"
  },
  {
    "medicine_name": "Pyrukynd",
    "related_ema_product_number": "EMEA/H/C/005540",
    "active_substance": "mitapivat sulfate",
    "date_of_designation_or_refusal": "22/04/2020",
    "intended_use": "Treatment of pyruvate kinase deficiency",
    "eu_designation_number": "EU/3/20/2270",
    "status": "Positive",
    "first_published_date": "12/08/2020",
    "last_updated_date": "07/12/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2270"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic retinal pigment epithelial cells genetically modified with a non-viral vector to express beta-domain deleted human factor VIII",
    "date_of_designation_or_refusal": "09/12/2020",
    "intended_use": "Treatment of  haemophilia A",
    "eu_designation_number": "EU/3/20/2380",
    "status": "Withdrawn",
    "first_published_date": "27/05/2021",
    "last_updated_date": "05/12/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2380"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Lentiviral vector encoding human coagulation factor IX",
    "date_of_designation_or_refusal": "26/02/2019",
    "intended_use": "Treatment of haemophilia B",
    "eu_designation_number": "EU/3/19/2141",
    "status": "Positive",
    "first_published_date": "09/04/2019",
    "last_updated_date": "02/12/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2141"
  },
  {
    "medicine_name": "Tecartus",
    "related_ema_product_number": "EMEA/H/C/005102",
    "active_substance": "autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti-CD19 CD28/CD3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel)",
    "date_of_designation_or_refusal": "19/10/2020",
    "intended_use": "Treatment of acute lymphoblastic leukaemia",
    "eu_designation_number": "EU/3/20/2344",
    "status": "Positive",
    "first_published_date": "16/02/2021",
    "last_updated_date": "02/12/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2344"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "1-(3-{4-[3,4-difluoro-2-(trifluoromethyl)phenyl]piperidine-1-carbonyl}-1H,4H,5H,6H,7H-pyrazolo[3,4- c]pyridin-6-yl)ethan-1-one (Tinlarebant)",
    "date_of_designation_or_refusal": "25/05/2018",
    "intended_use": "Treatment of Stargardt's disease",
    "eu_designation_number": "EU/3/18/2014",
    "status": "Positive",
    "first_published_date": "23/07/2018",
    "last_updated_date": "01/12/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2014"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous CD34+ haematopoietic stem cells transduced with lentiviral vector encoding the human betaA-T87Q-globin gene (betibeglogene autotemcel)",
    "date_of_designation_or_refusal": "24/01/2013",
    "intended_use": "Treatment of beta thalassaemia intermedia and major",
    "eu_designation_number": "EU/3/12/1091",
    "status": "Withdrawn",
    "first_published_date": "01/03/2013",
    "last_updated_date": "30/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1091"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Linerixibat",
    "date_of_designation_or_refusal": "12/11/2021",
    "intended_use": "Treatment of primary biliary cholangitis",
    "eu_designation_number": "EU/3/21/2515",
    "status": "Positive",
    "first_published_date": "07/06/2022",
    "last_updated_date": "29/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2515"
  },
  {
    "medicine_name": "Livtencity",
    "related_ema_product_number": "EMEA/H/C/005787",
    "active_substance": "Maribavir",
    "date_of_designation_or_refusal": "07/06/2013",
    "intended_use": "Treatment of cytomegalovirus disease in patients with impaired cell-mediated immunity",
    "eu_designation_number": "EU/3/13/1133",
    "status": "Positive",
    "first_published_date": "25/06/2013",
    "last_updated_date": "24/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1133"
  },
  {
    "medicine_name": "Livtencity",
    "related_ema_product_number": "EMEA/H/C/005787",
    "active_substance": "Maribavir",
    "date_of_designation_or_refusal": "18/12/2007",
    "intended_use": "Prevention of cytomegalovirus disease in patients with impaired cell-mediated immunity",
    "eu_designation_number": "EU/3/07/519",
    "status": "Positive",
    "first_published_date": "23/09/2009",
    "last_updated_date": "24/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-519"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "1-(2-hydroxyethyl)-8-{[5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy) phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide fumarate salt (onvansertib)",
    "date_of_designation_or_refusal": "24/08/2018",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/18/2057",
    "status": "Withdrawn",
    "first_published_date": "19/12/2018",
    "last_updated_date": "22/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2057"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "5-{(1R,2R)-2-[(cyclopropylmethyl)amino]cyclopropyl}-N-(tetrahydro-2H-pyran-4-yl)thiophene-3-carboxamide monohydrochloride",
    "date_of_designation_or_refusal": "19/11/2018",
    "intended_use": "Treatment of Kabuki syndrome",
    "eu_designation_number": "EU/3/18/2082",
    "status": "Withdrawn",
    "first_published_date": "19/02/2019",
    "last_updated_date": "22/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2082"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Hexasodium phytate",
    "date_of_designation_or_refusal": "17/07/2012",
    "intended_use": "Treatment of calciphylaxis",
    "eu_designation_number": "EU/3/12/1026",
    "status": "Positive",
    "first_published_date": "31/08/2012",
    "last_updated_date": "22/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1026"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant chimeric monoclonal antibody against CD20 (ublituximab)",
    "date_of_designation_or_refusal": "26/11/2009",
    "intended_use": "Treatment of chronic lymphocytic leukaemia",
    "eu_designation_number": "EU/3/09/699",
    "status": "Positive",
    "first_published_date": "09/12/2009",
    "last_updated_date": "22/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-699"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "6alpha-ethyl-chenodeoxycholic acid",
    "date_of_designation_or_refusal": "27/07/2010",
    "intended_use": "Treatment of primary biliary cirrhosis",
    "eu_designation_number": "EU/3/10/753",
    "status": "Positive",
    "first_published_date": "05/08/2010",
    "last_updated_date": "21/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-753"
  },
  {
    "medicine_name": "Loargys",
    "related_ema_product_number": "EMEA/H/C/005484",
    "active_substance": "poly(oxy-1,2-ethanediyl), alpha-(carboxymethyl)-omega-methoxy-, amide with arginase 1 [cobalt cofactor] (synthetic human) (1:10), trimer (pegzilarginase)",
    "date_of_designation_or_refusal": "14/07/2016",
    "intended_use": "Treatment of hyperargininaemia",
    "eu_designation_number": "EU/3/16/1701",
    "status": "Positive",
    "first_published_date": "06/09/2016",
    "last_updated_date": "18/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1701"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Glyceryl tri-(4-phenylbutyrate)",
    "date_of_designation_or_refusal": "10/06/2010",
    "intended_use": "Treatment of citrullinaemia type 2",
    "eu_designation_number": "EU/3/10/739",
    "status": "Positive",
    "first_published_date": "24/06/2010",
    "last_updated_date": "18/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-739"
  },
  {
    "medicine_name": "Ravicti",
    "related_ema_product_number": "EMEA/H/C/003822",
    "active_substance": "Glyceryl tri-(4-phenylbutyrate)",
    "date_of_designation_or_refusal": "10/06/2010",
    "intended_use": "Ornithine translocase deficiency (hyperornithinaemia-hyperammonaemia homocitrullinuria (HHH) syndrom",
    "eu_designation_number": "EU/3/10/738",
    "status": "Positive",
    "first_published_date": "24/06/2010",
    "last_updated_date": "18/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-738"
  },
  {
    "medicine_name": "Ravicti",
    "related_ema_product_number": "EMEA/H/C/003822",
    "active_substance": "Glyceryl tri-(4-phenylbutyrate)",
    "date_of_designation_or_refusal": "10/06/2010",
    "intended_use": "Treatment of hyperargininaemia",
    "eu_designation_number": "EU/3/10/737",
    "status": "Positive",
    "first_published_date": "24/06/2010",
    "last_updated_date": "18/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-737"
  },
  {
    "medicine_name": "Ravicti",
    "related_ema_product_number": "EMEA/H/C/003822",
    "active_substance": "Glyceryl tri-(4-phenylbutyrate)",
    "date_of_designation_or_refusal": "10/06/2010",
    "intended_use": "Treatment of argininosuccinic aciduria",
    "eu_designation_number": "EU/3/10/736",
    "status": "Positive",
    "first_published_date": "24/06/2010",
    "last_updated_date": "18/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-736"
  },
  {
    "medicine_name": "Ravicti",
    "related_ema_product_number": "EMEA/H/C/003822",
    "active_substance": "Glyceryl tri-(4-phenylbutyrate)",
    "date_of_designation_or_refusal": "10/06/2010",
    "intended_use": "Treatment of citrullinaemia type 1",
    "eu_designation_number": "EU/3/10/735",
    "status": "Positive",
    "first_published_date": "28/06/2010",
    "last_updated_date": "18/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-735"
  },
  {
    "medicine_name": "Ravicti",
    "related_ema_product_number": "EMEA/H/C/003822",
    "active_substance": "Glyceryl tri-(4-phenylbutyrate)",
    "date_of_designation_or_refusal": "10/06/2010",
    "intended_use": "Treatment of ornithine carbamoyltransferase deficiency",
    "eu_designation_number": "EU/3/10/734",
    "status": "Positive",
    "first_published_date": "24/06/2010",
    "last_updated_date": "18/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-734"
  },
  {
    "medicine_name": "Ravicti",
    "related_ema_product_number": "EMEA/H/C/003822",
    "active_substance": "Glyceryl tri-(4-phenylbutyrate)",
    "date_of_designation_or_refusal": "03/02/2010",
    "intended_use": "Treatment of carbamoyl-phosphate synthase-1 deficiency",
    "eu_designation_number": "EU/3/10/733",
    "status": "Positive",
    "first_published_date": "24/06/2010",
    "last_updated_date": "18/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-733"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "gefinitib",
    "date_of_designation_or_refusal": "26/10/2018",
    "intended_use": "Treatment of Fanconi anaemia type A",
    "eu_designation_number": "EU/3/18/2075",
    "status": "Positive",
    "first_published_date": "10/01/2019",
    "last_updated_date": "11/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2075"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Metformin",
    "date_of_designation_or_refusal": "12/12/2016",
    "intended_use": "Treatment of progressive myoclonic epilepsy type 2 (Lafora disease)",
    "eu_designation_number": "EU/3/16/1803",
    "status": "Positive",
    "first_published_date": "09/01/2017",
    "last_updated_date": "11/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1803"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "temsirolimus",
    "date_of_designation_or_refusal": "30/05/2016",
    "intended_use": "Treatment of adrenoleukodystrophy",
    "eu_designation_number": "EU/3/16/1669",
    "status": "Positive",
    "first_published_date": "24/06/2016",
    "last_updated_date": "11/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1669"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ubiquinol",
    "date_of_designation_or_refusal": "20/09/2016",
    "intended_use": "Treatment of primary coenzyme Q10 deficiency syndrome",
    "eu_designation_number": "EU/3/16/1765",
    "status": "Positive",
    "first_published_date": "15/11/2016",
    "last_updated_date": "11/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1765"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Haematopoietic stem cells modified with a lentiviral vector containing the CD18 gene",
    "date_of_designation_or_refusal": "20/09/2016",
    "intended_use": "Treatment of leukocyte adhesion deficiency type I",
    "eu_designation_number": "EU/3/16/1753",
    "status": "Positive",
    "first_published_date": "15/11/2016",
    "last_updated_date": "11/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1753"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Lentiviral vector containing the human liver and erythroid pyruvate kinase (PKLR) gene",
    "date_of_designation_or_refusal": "22/08/2014",
    "intended_use": "Treatment of pyruvate kinase deficiency",
    "eu_designation_number": "EU/3/14/1330",
    "status": "Positive",
    "first_published_date": "02/10/2014",
    "last_updated_date": "11/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1330"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "afatinib",
    "date_of_designation_or_refusal": "14/12/2018",
    "intended_use": "Treatment of Fanconi anaemia",
    "eu_designation_number": "EU/3/18/2110",
    "status": "Positive",
    "first_published_date": "08/03/2019",
    "last_updated_date": "11/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2110"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "dimethyl fumarate",
    "date_of_designation_or_refusal": "09/01/2020",
    "intended_use": "Treatment of adrenoleukodystrophy",
    "eu_designation_number": "EU/3/19/2236",
    "status": "Positive",
    "first_published_date": "14/05/2020",
    "last_updated_date": "11/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2236"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous skin equivalent graft composed of keratinocytes and fibroblasts genetically corrected by CRISPR/Cas9-mediated excision of mutation-carrying COL7A1 exon 80",
    "date_of_designation_or_refusal": "28/02/2020",
    "intended_use": "Treatment of epidermolysis bullosa",
    "eu_designation_number": "EU/3/20/2253",
    "status": "Positive",
    "first_published_date": "06/05/2020",
    "last_updated_date": "11/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2253"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Adeno-associated virus of serotype rh10 encoding Human MLC1 under the control of GFAP promoter",
    "date_of_designation_or_refusal": "15/10/2021",
    "intended_use": "Treatment of megalencephalic leukoencephalopathy with subcortical cysts",
    "eu_designation_number": "EU/3/21/2500",
    "status": "Positive",
    "first_published_date": "20/01/2022",
    "last_updated_date": "11/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2500"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous CD34+ enriched cells transduced with a self-inactivating lentiviral vector containing the codon-optimized RPS19 gene",
    "date_of_designation_or_refusal": "12/11/2021",
    "intended_use": "Treatment of Diamond-Blackfan anaemia",
    "eu_designation_number": "EU/3/21/2519",
    "status": "Positive",
    "first_published_date": "08/06/2022",
    "last_updated_date": "11/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2519"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Fingolimod",
    "date_of_designation_or_refusal": "12/11/2021",
    "intended_use": "Treatment of adrenoleukodystrophy",
    "eu_designation_number": "EU/3/21/2520",
    "status": "Positive",
    "first_published_date": "08/06/2022",
    "last_updated_date": "11/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2520"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous CD34+ cells edited with CRISPR/Cas9 and transduced with an adeno-associated virus vector serotype 6 containing the codon-optimized version of PKLR gene",
    "date_of_designation_or_refusal": "24/02/2022",
    "intended_use": "Treatment of pyruvate kinase deficiency",
    "eu_designation_number": "EU/3/22/2580",
    "status": "Positive",
    "first_published_date": "13/05/2022",
    "last_updated_date": "11/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2580"
  },
  {
    "medicine_name": "Crysvita",
    "related_ema_product_number": "EMEA/H/C/004275",
    "active_substance": "burosumab",
    "date_of_designation_or_refusal": "16/04/2018",
    "intended_use": "Treatment of phosphaturic mesenchymal tumour",
    "eu_designation_number": "EU/3/18/2011",
    "status": "Positive",
    "first_published_date": "17/05/2018",
    "last_updated_date": "08/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2011"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "6-((3S,4S)-4-methyl-1-(pyrimidin-2-yl-methyl)pyrrolidin-3-yl)-3-tetrahydropyran-4-yl-7H-imidazo(1,5-a)pyrazin-8-one (Tovinontrine)",
    "date_of_designation_or_refusal": "21/08/2020",
    "intended_use": "Treatment of sickle cell disease",
    "eu_designation_number": "EU/3/20/2322",
    "status": "Withdrawn",
    "first_published_date": "25/11/2020",
    "last_updated_date": "08/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2322"
  },
  {
    "medicine_name": "Febseltiq",
    "related_ema_product_number": "EMEA/H/C/005361",
    "active_substance": "Infigratinib",
    "date_of_designation_or_refusal": "21/08/2020",
    "intended_use": "Treatment of cholangiocarcinoma",
    "eu_designation_number": "EU/3/20/2329",
    "status": "Withdrawn",
    "first_published_date": "25/11/2020",
    "last_updated_date": "08/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2329"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "",
    "date_of_designation_or_refusal": "26/08/2005",
    "intended_use": "Treatment of progressive myoclonic epilepsies",
    "eu_designation_number": "EU/3/05/315",
    "status": "Withdrawn",
    "first_published_date": "18/08/2008",
    "last_updated_date": "08/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-315"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium phenylbutyrate",
    "date_of_designation_or_refusal": "11/11/2015",
    "intended_use": "Treatment of pyruvate dehydrogenase complex deficiency",
    "eu_designation_number": "EU/3/15/1581",
    "status": "Positive",
    "first_published_date": "06/01/2016",
    "last_updated_date": "07/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1581"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous haematopoietic stem and progenitor cell population containing CD34+ cells transduced with a lentiviral vector encoding the TCIRG1 cDNA ex vivo expanded",
    "date_of_designation_or_refusal": "15/10/2021",
    "intended_use": "Treatment of osteopetrosis",
    "eu_designation_number": "EU/3/21/2507",
    "status": "Positive",
    "first_published_date": "21/01/2022",
    "last_updated_date": "07/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2507"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tamoxifen citrate",
    "date_of_designation_or_refusal": "",
    "intended_use": "Treatment of neuronal ceroid lipofuscinosis",
    "eu_designation_number": "EU/3/22/2635",
    "status": "Positive",
    "first_published_date": "22/09/2022",
    "last_updated_date": "07/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2635"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Combination of two adeno-associated viral vectors of serotype 8 containing the 5'- and the 3'- half coding sequences of human ABCA4 fused to inteins",
    "date_of_designation_or_refusal": "17/10/2019",
    "intended_use": "Treatment of Stargardt's disease",
    "eu_designation_number": "EU/3/19/2208",
    "status": "Positive",
    "first_published_date": "22/01/2020",
    "last_updated_date": "07/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2208"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Combination of three adeno-associated viral vectors of serotype 8 containing the 5'-, the body- and the 3'-  coding sequences of human CEP290 fused to inteins",
    "date_of_designation_or_refusal": "28/02/2020",
    "intended_use": "Treatment of inherited retinal dystrophies",
    "eu_designation_number": "EU/3/20/2254",
    "status": "Positive",
    "first_published_date": "06/05/2020",
    "last_updated_date": "07/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2254"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous CD34+ cell enriched population containing haematopoietic stem and progenitor cells transduced ex vivo with a lentiviral vector encoding the human ADA2 gene",
    "date_of_designation_or_refusal": "20/08/2021",
    "intended_use": "Treatment of adenosine deaminase 2 deficiency (DADA2)",
    "eu_designation_number": "EU/3/21/2496",
    "status": "Positive",
    "first_published_date": "04/03/2022",
    "last_updated_date": "07/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2496"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "mixture of two adeno-associated viral vectors serotype 8 containing the 5'-half sequence of human MYO7A gene and the 3'-half sequence of human MYO7A gene",
    "date_of_designation_or_refusal": "04/07/2014",
    "intended_use": "Treatment of Usher syndrome",
    "eu_designation_number": "EU/3/14/1282",
    "status": "Positive",
    "first_published_date": "16/07/2014",
    "last_updated_date": "07/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1282"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "mixture of two adeno-associated viral vectors of serotye 8 containing the 5'-half sequence of human ABCA4 gene and the 3'-half sequence of human ABCA4 gene",
    "date_of_designation_or_refusal": "04/07/2014",
    "intended_use": "Treatment of Stargardt's disease",
    "eu_designation_number": "EU/3/14/1283",
    "status": "Positive",
    "first_published_date": "16/07/2014",
    "last_updated_date": "07/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1283"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector containing the human ARSB gene",
    "date_of_designation_or_refusal": "13/05/2011",
    "intended_use": "Treatment of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)",
    "eu_designation_number": "EU/3/11/864",
    "status": "Positive",
    "first_published_date": "27/05/2011",
    "last_updated_date": "07/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-864"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 8 containing the human GUCY2D gene",
    "date_of_designation_or_refusal": "26/03/2014",
    "intended_use": "Treatment of Leber's congenital amaurosis",
    "eu_designation_number": "EU/3/14/1256",
    "status": "Positive",
    "first_published_date": "07/05/2014",
    "last_updated_date": "07/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1256"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 8 encoding engineered rhodopsin DNA-binding repressor and human rhodopsin expression cassettes",
    "date_of_designation_or_refusal": "12/12/2016",
    "intended_use": "Treatment of retinitis pigmentosa",
    "eu_designation_number": "EU/3/16/1796",
    "status": "Positive",
    "first_published_date": "09/01/2017",
    "last_updated_date": "07/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1796"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "acamprosate calcium",
    "date_of_designation_or_refusal": "15/10/2014",
    "intended_use": "Treatment of fragile X syndrome",
    "eu_designation_number": "EU/3/14/1337",
    "status": "Positive",
    "first_published_date": "12/11/2014",
    "last_updated_date": "03/11/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1337"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-({Carbamoylmethyl-[3-(2-oxo-pyrrolidin-1-yl)-propyl]-carbamoyl}-methyl)-2-[2-(2-fluoro-phenyl)-ethylamino]-N-isobutyl-acetamide",
    "date_of_designation_or_refusal": "31/03/2014",
    "intended_use": "Treatment of optic neuritis",
    "eu_designation_number": "EU/3/14/1248",
    "status": "Positive",
    "first_published_date": "03/04/2014",
    "last_updated_date": "31/10/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1248"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ovine specific immunoglobulin (Fab) fragments raised against Vipera berus veno",
    "date_of_designation_or_refusal": "09/10/2015",
    "intended_use": "Treatment of snakebite envenomation",
    "eu_designation_number": "EU/3/15/1548",
    "status": "Positive",
    "first_published_date": "16/11/2015",
    "last_updated_date": "21/10/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1548"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "variant of recombinant human fibroblast growth factor 19",
    "date_of_designation_or_refusal": "22/08/2014",
    "intended_use": "Treatment of primary biliary cirrhosis",
    "eu_designation_number": "EU/3/14/1329",
    "status": "Positive",
    "first_published_date": "02/10/2014",
    "last_updated_date": "21/10/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1329"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "1-(3-methylbutanoyl)-L-aspartyl-L-threonyl-L-histidyl-L-phenylalanyl-L-prolyl-(L-cystinyl-L-isoleucyl-[(N6-(S)-4-carboxy-4-palmitamidobutanoyl)-L-lysinyl]-L-phenylalanyl-L-glutamyl-L-prolyl-L-arginyl-L-serinyl-L-lysinyl-L-glycinyl-L-cystinyl)-L-lysinamide, disulfide, acetate salt",
    "date_of_designation_or_refusal": "24/08/2018",
    "intended_use": "Treatment of beta thalassaemia intermedia and major",
    "eu_designation_number": "EU/3/18/2058",
    "status": "Withdrawn",
    "first_published_date": "20/12/2018",
    "last_updated_date": "21/10/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2058"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "teclistamab",
    "date_of_designation_or_refusal": "19/07/2022",
    "intended_use": "Treatment of multiple myeloma",
    "eu_designation_number": "EU/3/20/2331",
    "status": "Withdrawn",
    "first_published_date": "11/02/2021",
    "last_updated_date": "13/10/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2331"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-Hydroxy-4-(3-methyl-2-(S)-phenyl-butyrylamino) benzamide",
    "date_of_designation_or_refusal": "06/06/2012",
    "intended_use": "Treatment of meningioma",
    "eu_designation_number": "EU/3/12/996",
    "status": "Positive",
    "first_published_date": "04/07/2012",
    "last_updated_date": "12/10/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-996"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-Hydroxy-4-(3-methyl-2-(S)-phenyl-butyrylamino) benzamide",
    "date_of_designation_or_refusal": "06/06/2012",
    "intended_use": "Treatment of schwannoma",
    "eu_designation_number": "EU/3/12/997",
    "status": "Positive",
    "first_published_date": "04/07/2012",
    "last_updated_date": "12/10/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-997"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "[Gly2]-recombinant human glucagon-like peptide",
    "date_of_designation_or_refusal": "12/12/2001",
    "intended_use": "Treatment of short bowel syndrome",
    "eu_designation_number": "EU/3/01/077",
    "status": "Positive",
    "first_published_date": "15/05/2009",
    "last_updated_date": "12/10/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-077"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl",
    "date_of_designation_or_refusal": "12/12/2017",
    "intended_use": "Treatment of familial cerebral cavernous malformations",
    "eu_designation_number": "EU/3/17/1948",
    "status": "Positive",
    "first_published_date": "23/01/2018",
    "last_updated_date": "11/10/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1948"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Adeno-associated viral vector serotype rh10 containing the human factor IX gene for the treatment of haemophilia B-",
    "date_of_designation_or_refusal": "14/12/2015",
    "intended_use": "Treatment of haemophilia B",
    "eu_designation_number": "EU/3/15/1599",
    "status": "Withdrawn",
    "first_published_date": "03/02/2016",
    "last_updated_date": "11/10/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1599"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant adeno-associated viral vector containing the human retinoschisin gene",
    "date_of_designation_or_refusal": "12/03/2013",
    "intended_use": "Treatment of X-linked juvenile retinoschisis",
    "eu_designation_number": "EU/3/13/1107",
    "status": "Positive",
    "first_published_date": "05/04/2013",
    "last_updated_date": "06/10/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1107"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant adeno-associated viral vector containing human alpha-1 antitrypsin gene",
    "date_of_designation_or_refusal": "20/03/2007",
    "intended_use": "Treatment of congenital alpha-1 antitrypsin deficiency",
    "eu_designation_number": "EU/3/07/440",
    "status": "Positive",
    "first_published_date": "19/07/2007",
    "last_updated_date": "06/10/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-440"
  },
  {
    "medicine_name": "Omjjara",
    "related_ema_product_number": "EMEA/H/C/005768",
    "active_substance": "N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt (momelotinib)",
    "date_of_designation_or_refusal": "05/08/2011",
    "intended_use": "Treatment of primary myelofibrosis",
    "eu_designation_number": "EU/3/11/888",
    "status": "Positive",
    "first_published_date": "16/08/2011",
    "last_updated_date": "04/10/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-888"
  },
  {
    "medicine_name": "Omjjara",
    "related_ema_product_number": "EMEA/H/C/005768",
    "active_substance": "N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt (momelotinib)",
    "date_of_designation_or_refusal": "05/08/2011",
    "intended_use": "Treatment of post-polycythaemia vera myelofibrosis",
    "eu_designation_number": "EU/3/11/886",
    "status": "Positive",
    "first_published_date": "16/08/2011",
    "last_updated_date": "04/10/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-886"
  },
  {
    "medicine_name": "Omjjara",
    "related_ema_product_number": "EMEA/H/C/005768",
    "active_substance": "N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt (momelotinib)",
    "date_of_designation_or_refusal": "05/08/2011",
    "intended_use": "Treatment of post-essential thrombocythaemia myelofibrosis",
    "eu_designation_number": "EU/3/11/887",
    "status": "Positive",
    "first_published_date": "16/08/2011",
    "last_updated_date": "04/10/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-887"
  },
  {
    "medicine_name": "Takhzyro",
    "related_ema_product_number": "EMEA/H/C/004806",
    "active_substance": "recombinant human IgG1 kappa light chain monoclonal antibody targeting plasma kallikrein (lanadelumab)",
    "date_of_designation_or_refusal": "09/10/2015",
    "intended_use": "Treatment of hereditary angioedema",
    "eu_designation_number": "EU/3/15/1551",
    "status": "Positive",
    "first_published_date": "16/11/2015",
    "last_updated_date": "04/10/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1551"
  },
  {
    "medicine_name": "Natpar",
    "related_ema_product_number": "EMEA/H/C/003861",
    "active_substance": "recombinant human parathyroid hormone",
    "date_of_designation_or_refusal": "16/01/2014",
    "intended_use": "Treatment of hypoparathyroidism",
    "eu_designation_number": "EU/3/13/1210",
    "status": "Positive",
    "first_published_date": "23/01/2014",
    "last_updated_date": "04/10/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1210"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human arylsulfatase A",
    "date_of_designation_or_refusal": "26/11/2010",
    "intended_use": "treatment of metachromatic leukodystrophy",
    "eu_designation_number": "EU/3/10/813",
    "status": "Positive",
    "first_published_date": "17/12/2010",
    "last_updated_date": "04/10/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-813"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(S)-3-((3-(1-((6-(3,4-dimethoxyphenyl)pryazin-2-yl)amino)ethyl)phenyl)carbamoyl)-5-methylpridin-1-ium (seralutinib)",
    "date_of_designation_or_refusal": "29/05/2019",
    "intended_use": "Treatment of  pulmonary arterial hypertension",
    "eu_designation_number": "EU/3/19/2158",
    "status": "Positive",
    "first_published_date": "09/08/2019",
    "last_updated_date": "30/09/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2158"
  },
  {
    "medicine_name": "Imcivree",
    "related_ema_product_number": "EMEA/H/C/005089",
    "active_substance": "setmelanotide",
    "date_of_designation_or_refusal": "21/08/2019",
    "intended_use": "Treatment of Bardet-Biedl syndrome",
    "eu_designation_number": "EU/3/19/2192",
    "status": "Positive",
    "first_published_date": "14/01/2020",
    "last_updated_date": "30/09/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2192"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "variant of recombinant human fibroblast growth factor 19",
    "date_of_designation_or_refusal": "14/12/2015",
    "intended_use": "Treatment of primary sclerosing cholangitis",
    "eu_designation_number": "EU/3/15/1584",
    "status": "Positive",
    "first_published_date": "02/02/2016",
    "last_updated_date": "28/09/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1584"
  },
  {
    "medicine_name": "Roctavian; Roctavian",
    "related_ema_product_number": "EMEA/H/C/004749; EMEA/H/C/005830",
    "active_substance": "adeno-associated viral vector serotype 5 containing a B-domain deleted variant of human coagulation factor VIII gene",
    "date_of_designation_or_refusal": "21/03/2016",
    "intended_use": "Treatment of haemophilia A",
    "eu_designation_number": "EU/3/16/1622",
    "status": "Positive",
    "first_published_date": "04/05/2016",
    "last_updated_date": "28/09/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1622"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Combretastatin A1 diphosphate",
    "date_of_designation_or_refusal": "14/12/2015",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/15/1587",
    "status": "Positive",
    "first_published_date": "02/02/2016",
    "last_updated_date": "28/09/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1587"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Ilixadencel",
    "date_of_designation_or_refusal": "26/03/2021",
    "intended_use": "Treatment of gastrointestinal stromal tumours",
    "eu_designation_number": "EU/3/21/2418",
    "status": "Positive",
    "first_published_date": "19/01/2022",
    "last_updated_date": "28/09/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2418"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous CD34+ cells transduced with lentiviral vector encoding the human beta globin gene",
    "date_of_designation_or_refusal": "30/05/2016",
    "intended_use": "Treatment of beta thalassaemia intermedia and major",
    "eu_designation_number": "EU/3/16/1660",
    "status": "Positive",
    "first_published_date": "23/06/2016",
    "last_updated_date": "26/09/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1660"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ofranergene obadenovec",
    "date_of_designation_or_refusal": "16/10/2017",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/17/1926",
    "status": "Withdrawn",
    "first_published_date": "08/01/2018",
    "last_updated_date": "26/09/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1926"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adenovirus-associated vector containing human Fas-c gene (ofranergene obadenovec)",
    "date_of_designation_or_refusal": "06/06/2012",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/12/1002",
    "status": "Withdrawn",
    "first_published_date": "04/07/2012",
    "last_updated_date": "26/09/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1002"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "eltanexor",
    "date_of_designation_or_refusal": "21/06/2022",
    "intended_use": "Treatment of myelodysplastic syndromes",
    "eu_designation_number": "EU/3/22/2641",
    "status": "Positive",
    "first_published_date": "22/09/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2641"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "modified mRNA encoding human methylmalonyl-coenzyme A mutase containing a polymorphism at position 671",
    "date_of_designation_or_refusal": "21/06/2022",
    "intended_use": "Treatment of methylmalonic acidaemia",
    "eu_designation_number": "EU/3/22/2638",
    "status": "Positive",
    "first_published_date": "22/09/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2638"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl -(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl",
    "date_of_designation_or_refusal": "21/06/2022",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/22/2639",
    "status": "Positive",
    "first_published_date": "22/09/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2639"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human allogeneic keratinocytes",
    "date_of_designation_or_refusal": "21/06/2022",
    "intended_use": "Treatment of partial deep dermal and full thickness burns",
    "eu_designation_number": "EU/3/22/2637",
    "status": "Positive",
    "first_published_date": "22/09/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2637"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2'-O-(2-methoxyethyl) modified antisense oligonucleotide targeting UBE3A antisense transcript RNA",
    "date_of_designation_or_refusal": "21/06/2022",
    "intended_use": "Treatment of Angelman syndrome",
    "eu_designation_number": "EU/3/22/2636",
    "status": "Positive",
    "first_published_date": "22/09/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2636"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "epcoritamab",
    "date_of_designation_or_refusal": "21/06/2022",
    "intended_use": "Treatment of follicular lymphoma",
    "eu_designation_number": "EU/3/22/2634",
    "status": "Positive",
    "first_published_date": "22/09/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2634"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sirolimus",
    "date_of_designation_or_refusal": "21/06/2022",
    "intended_use": "Treatment of lymphatic malformations",
    "eu_designation_number": "EU/3/22/2633",
    "status": "Positive",
    "first_published_date": "22/09/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2633"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Lithium carbonate",
    "date_of_designation_or_refusal": "21/06/2022",
    "intended_use": "treatment of TBR1-related disorder",
    "eu_designation_number": "EU/3/22/2632",
    "status": "Positive",
    "first_published_date": "22/09/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2632"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogenic cytomegalovirus-specific cytotoxic T lymphocytes (adimlecleucel)",
    "date_of_designation_or_refusal": "18/11/2016",
    "intended_use": "Treatment of cytomegalovirus infection in patients with impaired cell-mediated immunity",
    "eu_designation_number": "EU/3/16/1773",
    "status": "Withdrawn",
    "first_published_date": "13/12/2016",
    "last_updated_date": "16/09/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1773"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic CD34+ cells expanded ex vivo with an aryl hydrocarbon receptor antagonist (spanlecortemlocel)",
    "date_of_designation_or_refusal": "16/12/2014",
    "intended_use": "Treatment of acute lymphoblastic leukaemia",
    "eu_designation_number": "EU/3/14/1382",
    "status": "Withdrawn",
    "first_published_date": "26/02/2015",
    "last_updated_date": "16/09/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1382"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous CD34+ cells transduced ex vivo with a lentiviral vector containing a modified gamma-globin gene",
    "date_of_designation_or_refusal": "13/11/2020",
    "intended_use": "Treatment of sickle cell disease",
    "eu_designation_number": "EU/3/20/2356",
    "status": "Withdrawn",
    "first_published_date": "15/02/2021",
    "last_updated_date": "16/09/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2356"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "self-complementary adeno-associated viral vector serotype 9 containing the SGSH gene",
    "date_of_designation_or_refusal": "20/09/2016",
    "intended_use": "Treatment of mucopolysaccharidosis, type IIIA (Sanfilippo A syndrome)",
    "eu_designation_number": "EU/3/16/1761",
    "status": "Positive",
    "first_published_date": "15/11/2016",
    "last_updated_date": "16/09/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1761"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium (4Z,7Z,10R,11E,13E,15Z,17S,19Z)10,17-dihydroxy-docosa-4,7,11,13,15,19-hexaenoate",
    "date_of_designation_or_refusal": "21/06/2022",
    "intended_use": "Prevention of retinopathy of prematurity",
    "eu_designation_number": "EU/3/22/2631",
    "status": "Positive",
    "first_published_date": "15/09/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2631"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Pirfenidone",
    "date_of_designation_or_refusal": "24/06/2022",
    "intended_use": "Treatment of idiopathic pulmonary fibrosis",
    "eu_designation_number": "EU/3/22/2630",
    "status": "Positive",
    "first_published_date": "15/09/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2630"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "4-[[(3S)-1-benzylpyrrolidin-3-yl]-methylamino]-2-fluoro-5-methyl-N-(1,3-thiazol-4-yl)benzenesulfonamide",
    "date_of_designation_or_refusal": "21/06/2022",
    "intended_use": "Treatment of SCN8A developmental and epileptic encephalopathy",
    "eu_designation_number": "EU/3/22/2629",
    "status": "Positive",
    "first_published_date": "15/09/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2629"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "3-(1-(2',3'-dimethoxy-[1,1'-biphenyl]-4-yl)-1H-1,2,3-triazol-4-yl)benzoic acid",
    "date_of_designation_or_refusal": "21/06/2022",
    "intended_use": "Treatment of gain-of-function mutations of STIM1 and ORAI1 related diseases",
    "eu_designation_number": "EU/3/22/2628",
    "status": "Positive",
    "first_published_date": "15/09/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2628"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ropeginterferon alfa-2b",
    "date_of_designation_or_refusal": "21/06/2022",
    "intended_use": "Treatment of chronic myeloid leukaemia",
    "eu_designation_number": "EU/3/22/2627",
    "status": "Positive",
    "first_published_date": "15/09/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2627"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic human dendritic cells derived from a CD34+ progenitor cell line",
    "date_of_designation_or_refusal": "22/05/2012",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/12/969",
    "status": "Positive",
    "first_published_date": "06/07/2012",
    "last_updated_date": "15/09/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-969"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic faecal microbiota, pooled",
    "date_of_designation_or_refusal": "19/11/2018",
    "intended_use": "Treatment of graft-versus-host disease",
    "eu_designation_number": "EU/3/18/2083",
    "status": "Positive",
    "first_published_date": "25/02/2019",
    "last_updated_date": "15/09/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2083"
  },
  {
    "medicine_name": "Ekterly",
    "related_ema_product_number": "EMEA/H/C/006211",
    "active_substance": "sebetralstat",
    "date_of_designation_or_refusal": "21/06/2022",
    "intended_use": "Treatment of hereditary angioedema",
    "eu_designation_number": "EU/3/22/2625",
    "status": "Positive",
    "first_published_date": "15/09/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2625"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Doxorubicin",
    "date_of_designation_or_refusal": "21/06/2022",
    "intended_use": "Treatment of soft tissue sarcoma",
    "eu_designation_number": "EU/3/22/2624",
    "status": "Positive",
    "first_published_date": "15/09/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2624"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "losartan",
    "date_of_designation_or_refusal": "21/06/2022",
    "intended_use": "Treatment of osteogenesis imperfecta",
    "eu_designation_number": "EU/3/22/2622",
    "status": "Positive",
    "first_published_date": "15/09/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2622"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Escherichia coli, strain Nissle 1917, expressing high affinity phenylalanine transporter, phenylalanine ammonia lyase and L-amino acid deaminase",
    "date_of_designation_or_refusal": "21/06/2022",
    "intended_use": "Treatment of hyperphenylalaninaemia",
    "eu_designation_number": "EU/3/22/2621",
    "status": "Positive",
    "first_published_date": "15/09/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2621"
  },
  {
    "medicine_name": "Kinpeygo",
    "related_ema_product_number": "EMEA/H/C/005653",
    "active_substance": "Budesonide",
    "date_of_designation_or_refusal": "18/11/2016",
    "intended_use": "Treatment of primary IgA nephropathy",
    "eu_designation_number": "EU/3/16/1778",
    "status": "Positive",
    "first_published_date": "13/12/2016",
    "last_updated_date": "14/09/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1778"
  },
  {
    "medicine_name": "Agamree",
    "related_ema_product_number": "EMEA/H/C/005679",
    "active_substance": "17α,21-Dihydroxy-16α-methyl-pregna-1,4,9(11)-triene-3,20-dione (vamorolone)",
    "date_of_designation_or_refusal": "22/08/2014",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/14/1309",
    "status": "Positive",
    "first_published_date": "01/10/2014",
    "last_updated_date": "14/09/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1309"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "modified mRNA encoding the UGT1A1 protein",
    "date_of_designation_or_refusal": "27/06/2016",
    "intended_use": "Treatment of Crigler-Najjar syndrome",
    "eu_designation_number": "EU/3/16/1684",
    "status": "Positive",
    "first_published_date": "26/07/2016",
    "last_updated_date": "14/09/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1684"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "radio-iodinated (131I) anti-CD45 murine monoclonal antibody",
    "date_of_designation_or_refusal": "14/10/2016",
    "intended_use": "Treatment in haematopoietic stem cell transplantation",
    "eu_designation_number": "EU/3/16/1760",
    "status": "Positive",
    "first_published_date": "17/11/2016",
    "last_updated_date": "14/09/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1760"
  },
  {
    "medicine_name": "Vyvgart",
    "related_ema_product_number": "EMEA/H/C/005849",
    "active_substance": "Efgartigimod alfa",
    "date_of_designation_or_refusal": "10/08/2022",
    "intended_use": "Treatment of myasthenia gravis",
    "eu_designation_number": "EU/3/18/1992",
    "status": "Positive",
    "first_published_date": "17/05/2018",
    "last_updated_date": "12/09/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1992"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "velaglucerase alfa",
    "date_of_designation_or_refusal": "06/06/2010",
    "intended_use": "Treatment of Gaucher disease",
    "eu_designation_number": "EU/3/10/752",
    "status": "Expired",
    "first_published_date": "23/06/2010",
    "last_updated_date": "09/09/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-752"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "18‐mer antisense oligonucleotide complementary to SCN1A mRNA;sodium salt",
    "date_of_designation_or_refusal": "24/02/2022",
    "intended_use": "Treatment of Dravet syndrome",
    "eu_designation_number": "EU/3/22/2579",
    "status": "Positive",
    "first_published_date": "13/05/2022",
    "last_updated_date": "08/09/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2579"
  },
  {
    "medicine_name": "Iqirvo",
    "related_ema_product_number": "EMEA/H/C/006231",
    "active_substance": "Elafibranor",
    "date_of_designation_or_refusal": "25/07/2019",
    "intended_use": "Treatment of primary biliary cholangitis",
    "eu_designation_number": "EU/3/19/2182",
    "status": "Positive",
    "first_published_date": "25/09/2019",
    "last_updated_date": "08/09/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2182"
  },
  {
    "medicine_name": "Scemblix",
    "related_ema_product_number": "EMEA/H/C/005605",
    "active_substance": "asciminib",
    "date_of_designation_or_refusal": "24/03/2020",
    "intended_use": "Treatment of chronic myeloid leukaemia",
    "eu_designation_number": "EU/3/20/2261",
    "status": "Positive",
    "first_published_date": "12/08/2020",
    "last_updated_date": "07/09/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2261"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "setanaxib",
    "date_of_designation_or_refusal": "06/01/2021",
    "intended_use": "Treatment of primary biliary cholangitis",
    "eu_designation_number": "EU/3/20/2387",
    "status": "Positive",
    "first_published_date": "18/05/2021",
    "last_updated_date": "30/08/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2387"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-C]pyridine-3,6(2H,5H)-dione",
    "date_of_designation_or_refusal": "09/10/2015",
    "intended_use": "Treatment of systemic sclerosis",
    "eu_designation_number": "EU/3/15/1559",
    "status": "Positive",
    "first_published_date": "18/11/2015",
    "last_updated_date": "30/08/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1559"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-C]pyridine-3,6(2H,5H)-dione",
    "date_of_designation_or_refusal": "26/11/2010",
    "intended_use": "Treatment of idiopathic pulmonary fibrosis",
    "eu_designation_number": "EU/3/10/802",
    "status": "Positive",
    "first_published_date": "15/12/2010",
    "last_updated_date": "30/08/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-802"
  },
  {
    "medicine_name": "Xegafri",
    "related_ema_product_number": "EMEA/H/C/004053",
    "active_substance": "sirolimus",
    "date_of_designation_or_refusal": "30/08/2011",
    "intended_use": "Treatment of chronic non-infectious uveitis",
    "eu_designation_number": "EU/3/11/898",
    "status": "Withdrawn",
    "first_published_date": "21/09/2011",
    "last_updated_date": "30/08/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-898"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human monoclonal antibody against human interleukin 13",
    "date_of_designation_or_refusal": "13/11/2013",
    "intended_use": "Treatment of eosinophilic oesophagitis",
    "eu_designation_number": "EU/3/13/1205",
    "status": "Withdrawn",
    "first_published_date": "02/12/2013",
    "last_updated_date": "30/08/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1205"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Melphalan flufenamide",
    "date_of_designation_or_refusal": "19/03/2015",
    "intended_use": "Treatment of plasma cell myeloma",
    "eu_designation_number": "EU/3/15/1463",
    "status": "Withdrawn",
    "first_published_date": "11/05/2015",
    "last_updated_date": "22/08/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1463"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous dendritic cells pulsed with killed ovarian cancer cells and matured by TLR3 ligand ex vivo",
    "date_of_designation_or_refusal": "16/04/2018",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/18/2009",
    "status": "Withdrawn",
    "first_published_date": "17/05/2018",
    "last_updated_date": "17/08/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2009"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant truncated N-terminal fragment of human lens epithelium-derived growth factor",
    "date_of_designation_or_refusal": "23/08/2017",
    "intended_use": "Treatment of retinitis pigmentosa",
    "eu_designation_number": "EU/3/17/1908",
    "status": "Withdrawn",
    "first_published_date": "17/10/2017",
    "last_updated_date": "12/08/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1908"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic peripheral blood mononuclear cells incubated ex-vivo with 16, 16-dimethyl prostaglandin E2;dexamethasone",
    "date_of_designation_or_refusal": "18/11/2016",
    "intended_use": "Treatment in haematopoietic stem cell transplantation",
    "eu_designation_number": "EU/3/16/1774",
    "status": "Withdrawn",
    "first_published_date": "13/12/2016",
    "last_updated_date": "10/08/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1774"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-(2,4-di-tert-butyl-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide (ivacaftor)",
    "date_of_designation_or_refusal": "08/07/2008",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/08/556",
    "status": "Expired",
    "first_published_date": "02/04/2009",
    "last_updated_date": "10/08/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-556"
  },
  {
    "medicine_name": "Upstaza",
    "related_ema_product_number": "EMEA/H/C/005352",
    "active_substance": "recombinant adeno-associated viral vector serotype 2 carrying the gene for the human aromatic L-amino acid decarboxylase protein;Eladocagene exuparvovec",
    "date_of_designation_or_refusal": "18/11/2016",
    "intended_use": "Treatment of aromatic L-amino acid decarboxylase deficiency",
    "eu_designation_number": "EU/3/16/1786",
    "status": "Positive",
    "first_published_date": "14/12/2016",
    "last_updated_date": "10/08/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1786"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-Chloro-N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide (namodenoson)",
    "date_of_designation_or_refusal": "09/10/2015",
    "intended_use": "Treatment of hepatocellular carcinoma",
    "eu_designation_number": "EU/3/15/1565",
    "status": "Positive",
    "first_published_date": "18/11/2015",
    "last_updated_date": "10/08/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1565"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adenovirus associated viral vector serotype 4 containing the human RPE65 gene",
    "date_of_designation_or_refusal": "14/11/2007",
    "intended_use": "Treatment of retinitis pigmentosa",
    "eu_designation_number": "EU/3/07/486",
    "status": "Positive",
    "first_published_date": "02/07/2008",
    "last_updated_date": "09/08/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-486"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adenovirus associated viral vector serotype 4 containing the human RPE65 gene",
    "date_of_designation_or_refusal": "22/10/2007",
    "intended_use": "Treatment of Leber's congenital amaurosis",
    "eu_designation_number": "EU/3/07/484",
    "status": "Positive",
    "first_published_date": "22/01/2008",
    "last_updated_date": "09/08/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-484"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 5 containing the human RLBP1 gene",
    "date_of_designation_or_refusal": "14/10/2016",
    "intended_use": "Treatment of retinitis pigmentosa",
    "eu_designation_number": "EU/3/16/1741",
    "status": "Positive",
    "first_published_date": "15/11/2016",
    "last_updated_date": "09/08/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1741"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Mazindol",
    "date_of_designation_or_refusal": "09/10/2015",
    "intended_use": "Treatment of narcolepsy",
    "eu_designation_number": "EU/3/15/1547",
    "status": "Positive",
    "first_published_date": "16/11/2015",
    "last_updated_date": "03/08/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1547"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "bilayer engineered collagen hydrogel-based skin graft composed of autologous keratinocytes and fibroblasts",
    "date_of_designation_or_refusal": "14/12/2015",
    "intended_use": "Treatment of partial deep dermal and full-thickness burns",
    "eu_designation_number": "EU/3/15/1596",
    "status": "Positive",
    "first_published_date": "03/02/2016",
    "last_updated_date": "03/08/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1596"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human alpha-glucosidase conjugated with multiple copies of synthetic bismannose-6-phosphate-tetra-mannose glycan (avalglucosidase alfa)",
    "date_of_designation_or_refusal": "26/03/2014",
    "intended_use": "Treatment of glycogen storage disease type II (Pompe's disease)",
    "eu_designation_number": "EU/3/14/1251",
    "status": "Withdrawn",
    "first_published_date": "06/05/2014",
    "last_updated_date": "02/08/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1251"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pegylated recombinant arginine deiminase (pegargiminase)",
    "date_of_designation_or_refusal": "15/01/2015",
    "intended_use": "Treatment of malignant mesothelioma",
    "eu_designation_number": "EU/3/14/1409",
    "status": "Positive",
    "first_published_date": "05/03/2015",
    "last_updated_date": "02/08/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1409"
  },
  {
    "medicine_name": "Xermelo",
    "related_ema_product_number": "EMEA/H/C/003937",
    "active_substance": "(S)-ethyl 2-amino-3-(4-(2-amino-6((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate",
    "date_of_designation_or_refusal": "30/05/2016",
    "intended_use": "Treatment of carcinoid syndrome",
    "eu_designation_number": "EU/3/09/661",
    "status": "Positive",
    "first_published_date": "20/10/2009",
    "last_updated_date": "28/07/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-661"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "moxetumomab pasudotox",
    "date_of_designation_or_refusal": "19/07/2022",
    "intended_use": "Treatment of B-lymphoblastic leukaemia/lymphoma",
    "eu_designation_number": "EU/3/13/1150",
    "status": "Withdrawn",
    "first_published_date": "22/08/2013",
    "last_updated_date": "25/07/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1150"
  },
  {
    "medicine_name": "Zolgensma",
    "related_ema_product_number": "EMEA/H/C/004750",
    "active_substance": "adeno-associated viral vector serotype 9 containing the human SMN gene (onasemnogene abeparvovec)",
    "date_of_designation_or_refusal": "19/06/2015",
    "intended_use": "Treatment of spinal muscular atrophy",
    "eu_designation_number": "EU/3/15/1509",
    "status": "Positive",
    "first_published_date": "27/07/2015",
    "last_updated_date": "25/07/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1509"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "",
    "date_of_designation_or_refusal": "13/04/2022",
    "intended_use": "Treatment of primary sclerosing cholangitis",
    "eu_designation_number": "EU/3/22/2604",
    "status": "Positive",
    "first_published_date": "19/07/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2604"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tiratricol",
    "date_of_designation_or_refusal": "13/04/2022",
    "intended_use": "Treatment of resistance to thyroid hormone type beta",
    "eu_designation_number": "EU/3/22/2603",
    "status": "Positive",
    "first_published_date": "19/07/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2603"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Devimistat",
    "date_of_designation_or_refusal": "13/04/2022",
    "intended_use": "Treatment of biliary tract cancer",
    "eu_designation_number": "EU/3/22/2602",
    "status": "Positive",
    "first_published_date": "19/07/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2602"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-(methoxypolyethylene glycol 5000 carbamoyl)-1,2-dipalmitoyl-sn-glycero-3-phosphatidylethanolamine",
    "date_of_designation_or_refusal": "13/04/2022",
    "intended_use": "Treatment in solid organ transplantation",
    "eu_designation_number": "EU/3/22/2601",
    "status": "Positive",
    "first_published_date": "19/07/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2601"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "arimoclomol citrate",
    "date_of_designation_or_refusal": "18/07/2022",
    "intended_use": "Treatment of inclusion body myositis",
    "eu_designation_number": "EU/3/16/1659",
    "status": "Withdrawn",
    "first_published_date": "28/06/2016",
    "last_updated_date": "19/07/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1659"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "arimoclomol",
    "date_of_designation_or_refusal": "18/07/2022",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/06/406",
    "status": "Withdrawn",
    "first_published_date": "02/04/2009",
    "last_updated_date": "19/07/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-406"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised anti-CD37 monoclonal antibody conjugated to maytansinoid DM1 (naratuximab emtansine)",
    "date_of_designation_or_refusal": "18/07/2022",
    "intended_use": "Treatment of diffuse large B-cell lymphoma",
    "eu_designation_number": "EU/3/15/1494",
    "status": "Withdrawn",
    "first_published_date": "30/06/2015",
    "last_updated_date": "19/07/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1494"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "norucholic acid",
    "date_of_designation_or_refusal": "13/04/2022",
    "intended_use": "Treatment of primary biliary cholangitis",
    "eu_designation_number": "EU/3/22/2597",
    "status": "Positive",
    "first_published_date": "19/07/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2597"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sirolimus",
    "date_of_designation_or_refusal": "20/06/2017",
    "intended_use": "Treatment of tuberous sclerosis",
    "eu_designation_number": "EU/3/17/1886",
    "status": "Positive",
    "first_published_date": "17/07/2017",
    "last_updated_date": "19/07/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1886"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus serotype 9 containing human MYBPC3 gene",
    "date_of_designation_or_refusal": "13/04/2022",
    "intended_use": "Treatment of Hypertrophic cardiomyopathy due to mutations in the MYBPC3 gene encoding cardiac myosin-binding protein C",
    "eu_designation_number": "EU/3/22/2596",
    "status": "Positive",
    "first_published_date": "18/07/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2596"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Glofitamab",
    "date_of_designation_or_refusal": "13/04/2022",
    "intended_use": "Treatment of mantle cell lymphoma",
    "eu_designation_number": "EU/3/22/2595",
    "status": "Positive",
    "first_published_date": "18/07/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2595"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous CD34+ haematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the alpha-L-iduronidase cDNA",
    "date_of_designation_or_refusal": "26/10/2018",
    "intended_use": "Treatment of mucopolysaccharidosis type I",
    "eu_designation_number": "EU/3/18/2073",
    "status": "Positive",
    "first_published_date": "10/01/2019",
    "last_updated_date": "14/07/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2073"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous CD34+ cells transduced with a lentiviral vector containing the human SGSH gene",
    "date_of_designation_or_refusal": "10/06/2014",
    "intended_use": "Treatment of mucopolysaccharidosis, type IIIA (Sanfilippo A syndrome)",
    "eu_designation_number": "EU/3/14/1280",
    "status": "Positive",
    "first_published_date": "09/07/2014",
    "last_updated_date": "14/07/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1280"
  },
  {
    "medicine_name": "Libmeldy",
    "related_ema_product_number": "EMEA/H/C/005321",
    "active_substance": "autologous CD34+ cells transfected with lentiviral vector containing the human arylsulfatase A cDNA",
    "date_of_designation_or_refusal": "13/04/2007",
    "intended_use": "treatment of metachromatic leukodystrophy",
    "eu_designation_number": "EU/3/07/446",
    "status": "Positive",
    "first_published_date": "29/07/2008",
    "last_updated_date": "14/07/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-446"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Darinaparsin",
    "date_of_designation_or_refusal": "15/04/2011",
    "intended_use": "Treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)",
    "eu_designation_number": "EU/3/11/850",
    "status": "Positive",
    "first_published_date": "26/04/2011",
    "last_updated_date": "14/07/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-850"
  },
  {
    "medicine_name": "Yescarta",
    "related_ema_product_number": "EMEA/H/C/004480",
    "active_substance": "autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor (axicabtagene ciloleucel)",
    "date_of_designation_or_refusal": "11/11/2015",
    "intended_use": "Treatment of follicular lymphoma",
    "eu_designation_number": "EU/3/15/1579",
    "status": "Positive",
    "first_published_date": "06/01/2016",
    "last_updated_date": "12/07/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1579"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus serotype 9 vector containing human n-acetylgalactosamine-6-sulfate sulfatase gene",
    "date_of_designation_or_refusal": "09/01/2020",
    "intended_use": "Treatment of mucopolysaccharidosis type IVA (Morquio A Syndrome)",
    "eu_designation_number": "EU/3/19/2238",
    "status": "Positive",
    "first_published_date": "19/05/2020",
    "last_updated_date": "08/07/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2238"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 9 containing the human sulfamidase gene",
    "date_of_designation_or_refusal": "21/06/2011",
    "intended_use": "Treatment of mucopolysaccharidosis, type IIIA (Sanfilippo A syndrome)",
    "eu_designation_number": "EU/3/11/877",
    "status": "Positive",
    "first_published_date": "12/07/2011",
    "last_updated_date": "08/07/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-877"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human monoclonal antibody binding to vascular adhesion protein-1",
    "date_of_designation_or_refusal": "19/03/2015",
    "intended_use": "Treatment of primary sclerosing cholangitis",
    "eu_designation_number": "EU/3/15/1461",
    "status": "Positive",
    "first_published_date": "11/05/2015",
    "last_updated_date": "08/07/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1461"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-Hydroxy-4-(3-methyl-2-(S)-phenyl-butyrylamino) benzamide",
    "date_of_designation_or_refusal": "26/04/2012",
    "intended_use": "Treatment of neurofibromatosis type 2",
    "eu_designation_number": "EU/3/12/993",
    "status": "Positive",
    "first_published_date": "18/06/2012",
    "last_updated_date": "05/07/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-993"
  },
  {
    "medicine_name": "Vynpenta (previously AvacopanChemoCentryx); Tavneos",
    "related_ema_product_number": "EMEA/H/C/004487; EMEA/H/C/005523",
    "active_substance": "(2R,3S)-2-(4-cyclopentylaminophenyl)-1-(2-fluoro-6-methylbenzoyl)piperidine-3-carboxylic acid(4-methyl-3-trifluoromethylphenyl)amNide",
    "date_of_designation_or_refusal": "19/11/2014",
    "intended_use": "Treatment of microscopic polyangiitis (avacopan)",
    "eu_designation_number": "EU/3/14/1372",
    "status": "Positive",
    "first_published_date": "15/01/2015",
    "last_updated_date": "04/07/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1372"
  },
  {
    "medicine_name": "Vynpenta (previously AvacopanChemoCentryx); Tavneos",
    "related_ema_product_number": "EMEA/H/C/004487; EMEA/H/C/005523",
    "active_substance": "",
    "date_of_designation_or_refusal": "19/11/2014",
    "intended_use": "Treatment of granulomatosis with polyangiitis",
    "eu_designation_number": "EU/3/14/1373",
    "status": "Positive",
    "first_published_date": "15/01/2015",
    "last_updated_date": "04/07/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1373"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human autologous mesenchymal adult stem cells extracted from adipose tissue",
    "date_of_designation_or_refusal": "26/08/2005",
    "intended_use": "Treatment of anal fistula",
    "eu_designation_number": "EU/3/05/303",
    "status": "Withdrawn",
    "first_published_date": "22/10/2009",
    "last_updated_date": "01/07/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-303"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "setmelanotide",
    "date_of_designation_or_refusal": "09/01/2020",
    "intended_use": "Treatment of Alström syndrome",
    "eu_designation_number": "EU/3/19/2245",
    "status": "Positive",
    "first_published_date": "20/05/2020",
    "last_updated_date": "01/07/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2245"
  },
  {
    "medicine_name": "Imcivree",
    "related_ema_product_number": "EMEA/H/C/005089",
    "active_substance": "setmelanotide",
    "date_of_designation_or_refusal": "19/11/2018",
    "intended_use": "Treatment of leptin receptor deficiency",
    "eu_designation_number": "EU/3/18/2101",
    "status": "Positive",
    "first_published_date": "25/02/2019",
    "last_updated_date": "01/07/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2101"
  },
  {
    "medicine_name": "Imcivree",
    "related_ema_product_number": "EMEA/H/C/005089",
    "active_substance": "setmelanotide",
    "date_of_designation_or_refusal": "14/07/2016",
    "intended_use": "Treatment of pro-opiomelanocortin deficiency",
    "eu_designation_number": "EU/3/16/1703",
    "status": "Positive",
    "first_published_date": "06/09/2016",
    "last_updated_date": "01/07/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1703"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "setmelanotide",
    "date_of_designation_or_refusal": "27/06/2016",
    "intended_use": "Treatment of Prader-Willi syndrome",
    "eu_designation_number": "EU/3/16/1688",
    "status": "Positive",
    "first_published_date": "26/07/2016",
    "last_updated_date": "01/07/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1688"
  },
  {
    "medicine_name": "Rezzayo",
    "related_ema_product_number": "EMEA/H/C/005900",
    "active_substance": "rezafungin acetate",
    "date_of_designation_or_refusal": "06/01/2021",
    "intended_use": "Treatment of invasive candidiasis",
    "eu_designation_number": "EU/3/20/2385",
    "status": "Positive",
    "first_published_date": "18/05/2021",
    "last_updated_date": "30/06/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2385"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human monoclonal antibody to insulin receptor",
    "date_of_designation_or_refusal": "14/07/2016",
    "intended_use": "Treatment of congenital hyperinsulinism",
    "eu_designation_number": "EU/3/16/1702",
    "status": "Positive",
    "first_published_date": "06/09/2016",
    "last_updated_date": "30/06/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1702"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol methanesulfonate (enasidenib)",
    "date_of_designation_or_refusal": "28/04/2016",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/16/1640",
    "status": "Positive",
    "first_published_date": "31/05/2016",
    "last_updated_date": "29/06/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1640"
  },
  {
    "medicine_name": "Lunsumio",
    "related_ema_product_number": "EMEA/H/C/005680",
    "active_substance": "mosunetuzumab",
    "date_of_designation_or_refusal": "12/11/2021",
    "intended_use": "Treatment of follicular lymphoma",
    "eu_designation_number": "EU/3/21/2517",
    "status": "Positive",
    "first_published_date": "08/06/2022",
    "last_updated_date": "23/06/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2517"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "chimeric locked nucleic acid deoxynucleoside phosphorothioate-linked oligonucleotide inhibitor directed against microRNA-155-5p",
    "date_of_designation_or_refusal": "22/05/2017",
    "intended_use": "Treatment of cutaneous T-cell lymphoma",
    "eu_designation_number": "EU/3/17/1872",
    "status": "Withdrawn",
    "first_published_date": "29/06/2017",
    "last_updated_date": "22/06/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1872"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "protein-based delivery vector carrying a DNA payload encoding an RNA-guided nuclease that targets stx genes of Shiga toxin-producing Escherichia coli",
    "date_of_designation_or_refusal": "21/08/2020",
    "intended_use": "Prevention of haemolytic uraemic syndrome",
    "eu_designation_number": "EU/3/20/2316",
    "status": "Positive",
    "first_published_date": "25/11/2020",
    "last_updated_date": "22/06/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2316"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "modified messenger ribonucleic acid encoding human propionyl-coenzyme A carboxylase alpha and beta subunits encapsulated into lipid nanoparticle",
    "date_of_designation_or_refusal": "24/04/2019",
    "intended_use": "Treatment of propionic acidaemia",
    "eu_designation_number": "EU/3/19/2156",
    "status": "Positive",
    "first_published_date": "14/06/2019",
    "last_updated_date": "22/06/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2156"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "synthetic signal peptide of human mucin-1 (amino acids 1-21)",
    "date_of_designation_or_refusal": "15/01/2015",
    "intended_use": "Treatment of plasma cell myeloma",
    "eu_designation_number": "EU/3/14/1423",
    "status": "Positive",
    "first_published_date": "06/03/2015",
    "last_updated_date": "22/06/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1423"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "heterologous human adult liver-derived stem cells",
    "date_of_designation_or_refusal": "16/03/2022",
    "intended_use": "Treatment of argininosuccinic aciduria",
    "eu_designation_number": "EU/3/22/2594",
    "status": "Positive",
    "first_published_date": "20/06/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2594"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "emactuzumab",
    "date_of_designation_or_refusal": "16/03/2022",
    "intended_use": "Treatment of tenosynovial giant cell tumour, localised and diffuse type",
    "eu_designation_number": "EU/3/22/2591",
    "status": "Positive",
    "first_published_date": "20/06/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2591"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "",
    "date_of_designation_or_refusal": "14/01/2022",
    "intended_use": "Treatment of Leber’s hereditary optic neuropathy",
    "eu_designation_number": "EU/3/21/2571",
    "status": "Positive",
    "first_published_date": "16/06/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2571"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(S)-12-fluoro-4-(2-methylpyridin-3-yl)-7a,8,13,14-tetrahydro-7H-[1,2,4]triazolo[4',3':1,6]pyrido[3,2-b]benzofuro[4,3-fg][1,4]oxazonine",
    "date_of_designation_or_refusal": "16/03/2022",
    "intended_use": "Treatment of sickle cell disease",
    "eu_designation_number": "EU/3/22/2589",
    "status": "Positive",
    "first_published_date": "16/06/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2589"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tropatepine hydrochloride",
    "date_of_designation_or_refusal": "16/03/2022",
    "intended_use": "Treatment of narcolepsy",
    "eu_designation_number": "EU/3/22/2587",
    "status": "Positive",
    "first_published_date": "16/06/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2587"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "codergocrine mesilate;oxitriptan",
    "date_of_designation_or_refusal": "16/03/2022",
    "intended_use": "Treatment of fragile X syndrome",
    "eu_designation_number": "EU/3/22/2586",
    "status": "Positive",
    "first_published_date": "16/06/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2586"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Hymecromone",
    "date_of_designation_or_refusal": "16/03/2022",
    "intended_use": "Treatment of spinal cord injury",
    "eu_designation_number": "EU/3/22/2584",
    "status": "Positive",
    "first_published_date": "16/06/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2584"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "chimeric peptide of human glucagon-like peptide-1, glucagon and gastric inhibitory polypeptide analogues linked to a human immunoglobulin Fc fragment",
    "date_of_designation_or_refusal": "14/01/2022",
    "intended_use": "Treatment of primary biliary cholangitis",
    "eu_designation_number": "EU/3/21/2561",
    "status": "Positive",
    "first_published_date": "15/06/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2561"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sirolimus",
    "date_of_designation_or_refusal": "14/01/2022",
    "intended_use": "Treatment of bronchiolitis obliterans syndrome (BOS)",
    "eu_designation_number": "EU/3/21/2570",
    "status": "Positive",
    "first_published_date": "15/06/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2570"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "trans N-ethyl-2-((4-(7-((4-(ethylsulfonamido)cyclohexyl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)pyrimidin-5-yl)oxy)-5-fluoro-N-isopropylbenzamide sesquifumarate",
    "date_of_designation_or_refusal": "14/01/2022",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/21/2569",
    "status": "Positive",
    "first_published_date": "15/06/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2569"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "melatonin",
    "date_of_designation_or_refusal": "14/01/2022",
    "intended_use": "Treatment of pre-eclampsia",
    "eu_designation_number": "EU/3/21/2567",
    "status": "Positive",
    "first_published_date": "15/06/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2567"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 9 containing the human SURF1 gene",
    "date_of_designation_or_refusal": "12/11/2021",
    "intended_use": "Treatment of Leigh syndrome",
    "eu_designation_number": "EU/3/21/2531",
    "status": "Positive",
    "first_published_date": "15/06/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2531"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "olverembatinib",
    "date_of_designation_or_refusal": "12/11/2021",
    "intended_use": "Treatment of chronic myeloid leukaemia",
    "eu_designation_number": "EU/3/21/2530",
    "status": "Positive",
    "first_published_date": "15/06/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2530"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]-5-pyrimidinyl(methyl)carbamate (riociguat)  ",
    "date_of_designation_or_refusal": "20/12/2007",
    "intended_use": "Treatment of pulmonary arterial hypertension",
    "eu_designation_number": "EU/3/07/518",
    "status": "Withdrawn",
    "first_published_date": "23/09/2009",
    "last_updated_date": "14/06/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-518"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(4R,5R)-1-[[4-[[4-[3,3-dibutyl-7-(dimethylamino)-2,3,4,5- tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-1-azoniabicyclo[2.2.2]octane chloride (maralixibat chloride)",
    "date_of_designation_or_refusal": "16/01/2014",
    "intended_use": "Treatment of primary sclerosing cholangitis",
    "eu_designation_number": "EU/3/13/1217",
    "status": "Withdrawn",
    "first_published_date": "22/01/2014",
    "last_updated_date": "14/06/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1217"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(4R,5R)-1-[[4-[[4-[3,3-dibutyl-7-(dimethylamino)-2,3,4,5- tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-1-azoniabicyclo[2.2.2]octane chloride (maralixibat chloride)",
    "date_of_designation_or_refusal": "16/01/2014",
    "intended_use": "Treatment of primary biliary cirrhosis",
    "eu_designation_number": "EU/3/13/1215",
    "status": "Withdrawn",
    "first_published_date": "22/01/2014",
    "last_updated_date": "14/06/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1215"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 8 containing the human acid alpha-glucosidase gene",
    "date_of_designation_or_refusal": "16/04/2018",
    "intended_use": "Treatment of glycogen storage disease type II (Pompe's disease)",
    "eu_designation_number": "EU/3/18/2007",
    "status": "Positive",
    "first_published_date": "17/05/2017",
    "last_updated_date": "14/06/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2007"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pasireotide",
    "date_of_designation_or_refusal": "08/10/2009",
    "intended_use": "Treatment of Cushing's disease",
    "eu_designation_number": "EU/3/09/671",
    "status": "Expired",
    "first_published_date": "20/10/2009",
    "last_updated_date": "14/06/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-671"
  },
  {
    "medicine_name": "Carvykti",
    "related_ema_product_number": "EMEA/H/C/005095",
    "active_substance": "autologous human T cells genetically modified ex-vivo with a lentiviral vector encoding a chimeric antigen receptor for B-cell maturation antigen",
    "date_of_designation_or_refusal": "28/02/2020",
    "intended_use": "Treatment of multiple myeloma",
    "eu_designation_number": "EU/3/20/2252",
    "status": "Positive",
    "first_published_date": "06/05/2020",
    "last_updated_date": "13/06/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2252"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus serotype 9 expressing the human fukutin related protein and target sequence of the miR-208a",
    "date_of_designation_or_refusal": "14/01/2022",
    "intended_use": "Treatment of limb girdle muscular dystrophy",
    "eu_designation_number": "EU/3/21/2566",
    "status": "Positive",
    "first_published_date": "09/06/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2566"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "5' moemC-(sp)-moemC-(p)-moeA-(p)-moemC-(p)-moeG-(p)-moeA-(p)-dmC-(sp)-dA-(sp)-dT-(sp)-dA-(sp)-dT-(sp)-dT-(sp)-dT-(sp)-dT-(sp)-dT-(sp)-dmC-(sp)-moeT-(p)-moeA-(sp)-moemC-(sp)-moeA 3'",
    "date_of_designation_or_refusal": "14/01/2022",
    "intended_use": "Treatment of SCN2A developmental and epileptic encephalopathy",
    "eu_designation_number": "EU/3/21/2565",
    "status": "Positive",
    "first_published_date": "09/06/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2565"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "5-((4'-(3,3-difluorocyclobutyl)-[1,1'-biphenyl]-4-yl)oxy)-1H-1,2,3-triazole-4-carboxylic acid",
    "date_of_designation_or_refusal": "14/01/2022",
    "intended_use": "Treatment of primary hyperoxaluria",
    "eu_designation_number": "EU/3/21/2564",
    "status": "Positive",
    "first_published_date": "09/06/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2564"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Gadolinium-chelated polysiloxane nanoparticles",
    "date_of_designation_or_refusal": "14/01/2022",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/21/2562",
    "status": "Positive",
    "first_published_date": "09/06/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2562"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "fasudil hydrochloride",
    "date_of_designation_or_refusal": "14/01/2022",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/21/2559",
    "status": "Positive",
    "first_published_date": "09/06/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2559"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "mRNA encoding human glucose-6-phosphatase variant S298C",
    "date_of_designation_or_refusal": "14/01/2022",
    "intended_use": "treatment of glycogen storage disease type Ia",
    "eu_designation_number": "EU/3/21/2558",
    "status": "Positive",
    "first_published_date": "09/06/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2558"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Insulin human",
    "date_of_designation_or_refusal": "14/01/2022",
    "intended_use": "Prevention of retinopathy of prematurity",
    "eu_designation_number": "EU/3/21/2557",
    "status": "Positive",
    "first_published_date": "09/06/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2557"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "navtemadlin",
    "date_of_designation_or_refusal": "14/01/2022",
    "intended_use": "Treatment of Merkel cell carcinoma",
    "eu_designation_number": "EU/3/21/2556",
    "status": "Positive",
    "first_published_date": "09/06/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2556"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Efgartigimod alfa",
    "date_of_designation_or_refusal": "14/01/2022",
    "intended_use": "Treatment of chronic inflammatory demyelinating polyneuropathy",
    "eu_designation_number": "EU/3/21/2555",
    "status": "Positive",
    "first_published_date": "09/06/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2555"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Enterovirus B, echovirus 7, live",
    "date_of_designation_or_refusal": "11/01/2022",
    "intended_use": "Treatment of uveal melanoma",
    "eu_designation_number": "-",
    "status": "Negative",
    "first_published_date": "09/06/2022",
    "last_updated_date": "09/06/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-uveal-melanoma"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-[(S-methylsulfonimidoyl)methyl] pyridin-2-yl}pyridin-2-amine",
    "date_of_designation_or_refusal": "12/11/2021",
    "intended_use": "Treatment of diffuse large B-cell lymphoma",
    "eu_designation_number": "EU/3/21/2523",
    "status": "Positive",
    "first_published_date": "09/06/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2523"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "cannabidiol;Dronabinol",
    "date_of_designation_or_refusal": "12/11/2021",
    "intended_use": "Treatment of complex regional pain syndrome",
    "eu_designation_number": "EU/3/21/2522",
    "status": "Positive",
    "first_published_date": "08/06/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2522"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "udonitrectag lysine",
    "date_of_designation_or_refusal": "12/11/2021",
    "intended_use": "Treatment in solid organ transplantation",
    "eu_designation_number": "EU/3/21/2521",
    "status": "Positive",
    "first_published_date": "08/06/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2521"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sirolimus",
    "date_of_designation_or_refusal": "14/12/2015",
    "intended_use": "Treatment of beta thalassaemia intermedia and major",
    "eu_designation_number": "EU/3/15/1585",
    "status": "Positive",
    "first_published_date": "02/02/2016",
    "last_updated_date": "08/06/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1585"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "paclitaxel;polyoligo(ethylene glycol)methacrylate-co-poly(vinylbenzyldithiodibutyric acid-gemcitabine)",
    "date_of_designation_or_refusal": "12/11/2021",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/21/2518",
    "status": "Positive",
    "first_published_date": "08/06/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2518"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "nadunolimab",
    "date_of_designation_or_refusal": "12/11/2021",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/21/2516",
    "status": "Positive",
    "first_published_date": "08/06/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2516"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous CD34+ cells transfected with a lentiviral vector containing codon optimised RPS19 gene",
    "date_of_designation_or_refusal": "20/08/2021",
    "intended_use": "Treatment of Diamond-Blackfan anaemia",
    "eu_designation_number": "EU/3/21/2488",
    "status": "Positive",
    "first_published_date": "25/02/2022",
    "last_updated_date": "08/06/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2488"
  },
  {
    "medicine_name": "Polivy",
    "related_ema_product_number": "EMEA/H/C/004870",
    "active_substance": "polatuzumab vedotin",
    "date_of_designation_or_refusal": "16/04/2018",
    "intended_use": "Treatment of diffuse large B-cell lymphoma",
    "eu_designation_number": "EU/3/18/2013",
    "status": "Positive",
    "first_published_date": "17/05/2018",
    "last_updated_date": "08/06/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2013"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "D-lactic acid, glycolic acid",
    "date_of_designation_or_refusal": "12/11/2021",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/21/2528",
    "status": "Positive",
    "first_published_date": "07/06/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2528"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-[1-(3-{6-[(1E)-(hydroxyimino)methyl]-5-methyl-4-oxo-7-propyl-3H,4H-pyrrolo[2,1-f][1,2,4]triazin-2-yl}-4-propoxybenzenesulfonyl)piperidin-4-yl]ethyl nitrate",
    "date_of_designation_or_refusal": "12/11/2021",
    "intended_use": "Treatment of systemic sclerosis",
    "eu_designation_number": "EU/3/21/2526",
    "status": "Positive",
    "first_published_date": "07/06/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2526"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "anti-CD38 IgG4 human monoclonal antibody",
    "date_of_designation_or_refusal": "12/11/2021",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/21/2514",
    "status": "Positive",
    "first_published_date": "07/06/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2514"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "trifarotene",
    "date_of_designation_or_refusal": "24/03/2020",
    "intended_use": "Treatment of autosomal recessive congenital ichthyosis",
    "eu_designation_number": "EU/3/20/2264",
    "status": "Withdrawn",
    "first_published_date": "12/08/2020",
    "last_updated_date": "07/06/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2264"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tipifarnib",
    "date_of_designation_or_refusal": "19/10/2020",
    "intended_use": "Treatment of peripheral T-cell lymphoma",
    "eu_designation_number": "EU/3/20/2333",
    "status": "Positive",
    "first_published_date": "12/02/2021",
    "last_updated_date": "24/05/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2333"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "6-(R)-methyl-5-O-(5-amino-5,6-dideoxy-alpha-L-talofuranosyl)-paromamine sulfate",
    "date_of_designation_or_refusal": "26/10/2018",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/18/2072",
    "status": "Positive",
    "first_published_date": "11/01/2019",
    "last_updated_date": "24/05/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2072"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-methyl-4-({4-[({3-methyl(methylsulfonyl)aminopyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride (defactinib)",
    "date_of_designation_or_refusal": "15/01/2015",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/14/1429",
    "status": "Positive",
    "first_published_date": "06/03/2015",
    "last_updated_date": "24/05/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1429"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tipifarnib",
    "date_of_designation_or_refusal": "10/03/2005",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/05/269",
    "status": "Positive",
    "first_published_date": "01/06/2005",
    "last_updated_date": "24/05/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-269"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tisagenlecleucel",
    "date_of_designation_or_refusal": "19/07/2021",
    "intended_use": "Treatment of follicular lymphoma",
    "eu_designation_number": "EU/3/21/2464",
    "status": "Positive",
    "first_published_date": "12/11/2021",
    "last_updated_date": "19/05/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2464"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "inebilizumab",
    "date_of_designation_or_refusal": "20/03/2017",
    "intended_use": "Treatment of neuromyelitis optica spectrum disorders",
    "eu_designation_number": "EU/3/17/1856",
    "status": "Withdrawn",
    "first_published_date": "05/05/2017",
    "last_updated_date": "19/05/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1856"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Lefitolimod",
    "date_of_designation_or_refusal": "26/03/2021",
    "intended_use": "Treatment of small cell lung cancer",
    "eu_designation_number": "EU/3/21/2415",
    "status": "Positive",
    "first_published_date": "19/01/2022",
    "last_updated_date": "19/05/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2415"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "avapritinib",
    "date_of_designation_or_refusal": "26/10/2018",
    "intended_use": "Treatment of mastocytosis",
    "eu_designation_number": "EU/3/18/2074",
    "status": "Positive",
    "first_published_date": "04/01/2019",
    "last_updated_date": "18/05/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2074"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "synthetic human hepcidin",
    "date_of_designation_or_refusal": "18/11/2016",
    "intended_use": "Treatment of sickle cell disease",
    "eu_designation_number": "EU/3/16/1789",
    "status": "Withdrawn",
    "first_published_date": "13/12/2016",
    "last_updated_date": "18/05/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1789"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "synthetic hepcidin",
    "date_of_designation_or_refusal": "09/10/2015",
    "intended_use": "Treatment of beta thalassaemia intermedia and major",
    "eu_designation_number": "EU/3/15/1555",
    "status": "Withdrawn",
    "first_published_date": "16/11/2015",
    "last_updated_date": "18/05/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1555"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "6-{[(1R,2S)-2-aminocyclohexyl]amino}-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one monocitrate (also known as mivavotinib)",
    "date_of_designation_or_refusal": "22/02/2018",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/18/1974",
    "status": "Positive",
    "first_published_date": "10/04/2018",
    "last_updated_date": "16/05/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1974"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pentosan polysulfate sodium",
    "date_of_designation_or_refusal": "30/05/2016",
    "intended_use": "Treatment of interstitial cystitis",
    "eu_designation_number": "EU/3/16/1663",
    "status": "Positive",
    "first_published_date": "22/06/2016",
    "last_updated_date": "16/05/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1663"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Epcoritamab",
    "date_of_designation_or_refusal": "24/02/2022",
    "intended_use": "Treatment of diffuse large B-cell lymphoma",
    "eu_designation_number": "EU/3/22/2581",
    "status": "Positive",
    "first_published_date": "13/05/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2581"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector LK03 encoding human methylmalonyl-CoA mutase",
    "date_of_designation_or_refusal": "21/06/2021",
    "intended_use": "Treatment of methylmalonic acidaemia",
    "eu_designation_number": "EU/3/21/2457",
    "status": "Positive",
    "first_published_date": "11/05/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2457"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "H-D-valyl1-D-alanyl-D-glutamyl-D-alanyl-D-arginyl5-D-glutamyl-D-glutamyl-D-leucyl-D-glutamyl-D-arginyl10-D-leucyl-D-glutamyl-D-alanyl-D-arginyl-D-leucyl15-glycyl-D-glutaminyl-D-alanyl-D-arginyl-glycyl20-D-glutamyl-D-leucyl-D-lysyl-D-lysyl-D-tryptophyl25-D-lysyl-D-methionyl-D-arginyl-D-arginyl-D-asparaginyl30-D-glutaminyl-D-phenylalanyl-D-tryptophyl-D-leucyl-D-lysyl35-D-leucyl-D-glutaminyl-D-arginine",
    "date_of_designation_or_refusal": "21/06/2021",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/21/2455",
    "status": "Positive",
    "first_published_date": "11/05/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2455"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "melatonin",
    "date_of_designation_or_refusal": "21/06/2021",
    "intended_use": "Prevention of retinopathy of prematurity",
    "eu_designation_number": "EU/3/21/2453",
    "status": "Positive",
    "first_published_date": "11/05/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2453"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Hydrocortisone hydrogen succinate",
    "date_of_designation_or_refusal": "21/06/2021",
    "intended_use": "Prevention of bronchopulmonary dysplasia",
    "eu_designation_number": "EU/3/21/2452",
    "status": "Positive",
    "first_published_date": "11/05/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2452"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus serotype 9 containing the human FXN gene isoform 1",
    "date_of_designation_or_refusal": "21/06/2021",
    "intended_use": "Treatment of Friedreich's ataxia",
    "eu_designation_number": "EU/3/21/2456",
    "status": "Withdrawn",
    "first_published_date": "11/05/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2456"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropane-2-yl)-1H-pyrazole-4-carboxamide",
    "date_of_designation_or_refusal": "21/06/2021",
    "intended_use": "Treatment of mantle cell lymphoma",
    "eu_designation_number": "EU/3/21/2450",
    "status": "Positive",
    "first_published_date": "11/05/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2450"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogenic placenta-derived mesenchymal stromal cells secretome",
    "date_of_designation_or_refusal": "21/06/2021",
    "intended_use": "Treatment of pre-eclampsia",
    "eu_designation_number": "EU/3/21/2448",
    "status": "Positive",
    "first_published_date": "11/05/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2448"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus serotype 9 expressing human CLN5",
    "date_of_designation_or_refusal": "21/06/2021",
    "intended_use": "Treatment of neuronal ceroid lipofuscinosis",
    "eu_designation_number": "EU/3/21/2447",
    "status": "Positive",
    "first_published_date": "11/05/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2447"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tislelizumab",
    "date_of_designation_or_refusal": "21/06/2021",
    "intended_use": "Treatment of nasopharyngeal cancer",
    "eu_designation_number": "EU/3/21/2446",
    "status": "Positive",
    "first_published_date": "11/05/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2446"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised IgG2 monoclonal antibody against TNFSF13",
    "date_of_designation_or_refusal": "21/06/2021",
    "intended_use": "Treatment of primary IgA nephropathy",
    "eu_designation_number": "EU/3/21/2444",
    "status": "Positive",
    "first_published_date": "11/05/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2444"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "L-ergothioneine",
    "date_of_designation_or_refusal": "21/06/2021",
    "intended_use": "Treatment of cystinuria",
    "eu_designation_number": "EU/3/21/2445",
    "status": "Positive",
    "first_published_date": "11/05/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2445"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "obeticholic acid",
    "date_of_designation_or_refusal": "16/03/2014",
    "intended_use": "Treatment of primary sclerosing cholangitis",
    "eu_designation_number": "EU/3/13/1228",
    "status": "Withdrawn",
    "first_published_date": "24/03/2014",
    "last_updated_date": "10/05/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1228"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-(2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide (mocetinostat)",
    "date_of_designation_or_refusal": "14/09/2007",
    "intended_use": "Treatment of Hodgkin's lymphoma",
    "eu_designation_number": "EU/3/07/478",
    "status": "Withdrawn",
    "first_published_date": "23/09/2009",
    "last_updated_date": "10/05/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-478"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Mannitolum",
    "date_of_designation_or_refusal": "07/11/2005",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/05/325",
    "status": "Expired",
    "first_published_date": "29/07/2008",
    "last_updated_date": "05/05/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-325"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Mercaptopurine",
    "date_of_designation_or_refusal": "30/04/2009",
    "intended_use": "Treatment of acute lymphoblastic leukaemia",
    "eu_designation_number": "EU/3/09/628",
    "status": "Expired",
    "first_published_date": "12/05/2009",
    "last_updated_date": "05/05/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-628"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogenic fetal mesenchymal stem cells",
    "date_of_designation_or_refusal": "10/12/2021",
    "intended_use": "Treatment of osteogenesis imperfecta",
    "eu_designation_number": "EU/3/21/2534",
    "status": "Positive",
    "first_published_date": "05/05/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2534"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "octreotide acetate",
    "date_of_designation_or_refusal": "10/12/2021",
    "intended_use": "Treatment of idiopathic intracranial hypertension",
    "eu_designation_number": "EU/3/21/2554",
    "status": "Positive",
    "first_published_date": "05/05/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2554"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2’-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3’-O->5’-O)-2’-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3’-O->5’-O)-2’-O-(2-methoxyethyl)-P-thioguanylyl-(3’-O->5’-O)-2’-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3’-O->5’-O)-2’-O-(2-methoxyethyl)-P-thioadenylyl-(3’-O->5’-O)-2’-O-(2-methoxyethyl)-P-thioadenylyl-(3’-O->5’-O)-2’-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3’-O->5’-O)-2’-O-(2-methoxyethyl)-P-thioadenylyl-(3’-O->5’-O)-2’-O-(2-methoxyethyl)-P-thioguanoylyl-(3’-O->5’-O)-2’-O-(2-methoxyethyl)-P-thioadenylyl-(3’-O->5’-O)-2’-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3’-O->5’-O)-2’-O-(2-methoxyethyl)-P-thioguanylyl-(3’-O->5’-O)-2’-O-(2-methoxyethyl)-P-thioguanylyl ...",
    "date_of_designation_or_refusal": "10/12/2021",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/21/2552",
    "status": "Positive",
    "first_published_date": "05/05/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2552"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N- (2-Amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide (mocetinostat)",
    "date_of_designation_or_refusal": "31/01/2008",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/07/526",
    "status": "Withdrawn",
    "first_published_date": "23/09/2009",
    "last_updated_date": "04/05/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-526"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "lisocabtagene maraleucel",
    "date_of_designation_or_refusal": "19/11/2018",
    "intended_use": "Treatment of primary mediastinal large B-cell lymphoma",
    "eu_designation_number": "EU/3/18/2099",
    "status": "Withdrawn",
    "first_published_date": "25/02/2019",
    "last_updated_date": "04/05/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2099"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous CD4+ and CD8+ T cells expressing a CD19-specific chimeric antigen receptor (lisocabtagene maraleucel)",
    "date_of_designation_or_refusal": "25/05/2018",
    "intended_use": "Treatment of follicular lymphoma",
    "eu_designation_number": "EU/3/18/2018",
    "status": "Withdrawn",
    "first_published_date": "24/07/2018",
    "last_updated_date": "04/05/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2018"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous CD4+ and CD8+ T cells expressing a CD19-specific chimeric antigen receptor (lisocabtagene maraleucel)",
    "date_of_designation_or_refusal": "17/07/2017",
    "intended_use": "Treatment of diffuse large B-cell lymphoma",
    "eu_designation_number": "EU/3/17/1890",
    "status": "Withdrawn",
    "first_published_date": "14/08/2017",
    "last_updated_date": "04/05/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1890"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human culture expanded autologous mesenchymal stromal cells",
    "date_of_designation_or_refusal": "24/04/2019",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/19/2155",
    "status": "Positive",
    "first_published_date": "14/06/2019",
    "last_updated_date": "03/05/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2155"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus vector serotype 9 encoding the human GRN gene",
    "date_of_designation_or_refusal": "10/12/2021",
    "intended_use": "Treatment of frontotemporal dementia",
    "eu_designation_number": "EU/3/21/2551",
    "status": "Positive",
    "first_published_date": "03/05/2022",
    "last_updated_date": "03/05/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2551"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Norrin (25-133), Lys86Pro",
    "date_of_designation_or_refusal": "10/12/2021",
    "intended_use": "Treatment of familial exudative vitreoretinopathy",
    "eu_designation_number": "EU/3/21/2549",
    "status": "Positive",
    "first_published_date": "03/05/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2549"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Gadolinium-chelated polysiloxane nanoparticles",
    "date_of_designation_or_refusal": "24/02/2022",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/22/2576",
    "status": "Positive",
    "first_published_date": "29/04/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2576"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "aldesleukin",
    "date_of_designation_or_refusal": "24/02/2022",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/22/2578",
    "status": "Positive",
    "first_published_date": "29/04/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2578"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "[Ala1,3,12,Gln10,Arg11,Trp14]PTH(1-14)/[Ala18,22, Lys26]PTHrP(15-36)COOH",
    "date_of_designation_or_refusal": "24/02/2022",
    "intended_use": "Treatment of hypoparathyroidism",
    "eu_designation_number": "EU/3/22/2577",
    "status": "Positive",
    "first_published_date": "29/04/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2577"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "bovactant",
    "date_of_designation_or_refusal": "24/02/2022",
    "intended_use": "Treatment of respiratory distress syndrome",
    "eu_designation_number": "EU/3/22/2575",
    "status": "Positive",
    "first_published_date": "29/04/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2575"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pyridoxal 5'-phosphate",
    "date_of_designation_or_refusal": "24/02/2022",
    "intended_use": "Treatment of pyridoxamine 5'-phosphate oxidase deficiency",
    "eu_designation_number": "EU/3/22/2574",
    "status": "Positive",
    "first_published_date": "28/04/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2574"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "vatiquinone",
    "date_of_designation_or_refusal": "24/02/2022",
    "intended_use": "Treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes",
    "eu_designation_number": "EU/3/22/2573",
    "status": "Positive",
    "first_published_date": "28/04/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2573"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "valemetostat tosilate",
    "date_of_designation_or_refusal": "24/02/2022",
    "intended_use": "Treatment of peripheral T-cell lymphoma",
    "eu_designation_number": "EU/3/22/2572",
    "status": "Positive",
    "first_published_date": "28/04/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2572"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "chimeric peptide of human glucagon-like peptide-1, glucagon and gastric inhibitory polypeptide analogues linked to a human immunoglobulin Fc fragment",
    "date_of_designation_or_refusal": "10/12/2021",
    "intended_use": "Treatment of primary sclerosing cholangitis",
    "eu_designation_number": "EU/3/21/2547",
    "status": "Positive",
    "first_published_date": "28/04/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2547"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human interleukin-3 truncated diphtheria toxin fusion protein",
    "date_of_designation_or_refusal": "09/10/2015",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/15/1563",
    "status": "Positive",
    "first_published_date": "18/11/2015",
    "last_updated_date": "25/04/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1563"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous CD34+ hematopoietic stem and progenitor cells transfected with zinc finger nuclease mRNAs SB-mRENH1 and SB-mRENH2",
    "date_of_designation_or_refusal": "19/02/2021",
    "intended_use": "Treatment of sickle cell disease",
    "eu_designation_number": "EU/3/21/2406",
    "status": "Positive",
    "first_published_date": "23/02/2022",
    "last_updated_date": "25/04/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2406"
  },
  {
    "medicine_name": "Kimmtrak",
    "related_ema_product_number": "EMEA/H/C/004929",
    "active_substance": "tebentafusp",
    "date_of_designation_or_refusal": "19/02/2021",
    "intended_use": "Treatment of uveal melanoma",
    "eu_designation_number": "EU/3/21/2397",
    "status": "Positive",
    "first_published_date": "22/02/2022",
    "last_updated_date": "22/04/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2397"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-[1-((5-cyanopyridin-2-yl)methyl)-1H-pyrazol- 3-yl]-2-[4-(1-(trifluoromethyl)cyclopropyl)  phenyl]acetamide",
    "date_of_designation_or_refusal": "10/12/2021",
    "intended_use": "Treatment of epileptic encephalopathy with continuous spike-and-wave during sleep",
    "eu_designation_number": "EU/3/21/2545",
    "status": "Positive",
    "first_published_date": "21/04/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2545"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ribonucleoprotein complex composed of two sgRNA and a Cas9 nuclease targeting the human COL7A1 gene",
    "date_of_designation_or_refusal": "10/12/2021",
    "intended_use": "Treatment of epidermolysis bullosa",
    "eu_designation_number": "EU/3/21/2544",
    "status": "Positive",
    "first_published_date": "20/04/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2544"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "copper (64Cu) chloride",
    "date_of_designation_or_refusal": "10/12/2021",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/21/2543",
    "status": "Positive",
    "first_published_date": "20/04/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2543"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "crofelemer",
    "date_of_designation_or_refusal": "10/12/2021",
    "intended_use": "Treatment of short bowel syndrome",
    "eu_designation_number": "EU/3/21/2541",
    "status": "Positive",
    "first_published_date": "19/04/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2541"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyrazine",
    "date_of_designation_or_refusal": "10/12/2021",
    "intended_use": "Treatment of SCN8A developmental and epileptic encephalopathy",
    "eu_designation_number": "EU/3/21/2540",
    "status": "Positive",
    "first_published_date": "19/04/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2540"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyrazine",
    "date_of_designation_or_refusal": "10/12/2021",
    "intended_use": "Treatment of SCN2A developmental and epileptic encephalopathy",
    "eu_designation_number": "EU/3/21/2539",
    "status": "Positive",
    "first_published_date": "13/04/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2539"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "anti-(endothelin-1 receptor subtype A) IgG4 humanised monoclonal antibody",
    "date_of_designation_or_refusal": "10/12/2021",
    "intended_use": "Treatment of  pulmonary arterial hypertension",
    "eu_designation_number": "EU/3/21/2538",
    "status": "Positive",
    "first_published_date": "13/04/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2538"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "retinol palmitate",
    "date_of_designation_or_refusal": "10/12/2021",
    "intended_use": "Prevention of bronchopulmonary dysplasia",
    "eu_designation_number": "EU/3/21/2537",
    "status": "Positive",
    "first_published_date": "13/04/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2537"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "vatiquinone",
    "date_of_designation_or_refusal": "10/12/2021",
    "intended_use": "Treatment of Alpers-Huttenlocher syndrome",
    "eu_designation_number": "EU/3/21/2536",
    "status": "Positive",
    "first_published_date": "13/04/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2536"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "mocravimod",
    "date_of_designation_or_refusal": "15/10/2021",
    "intended_use": "Treatment in haematopoietic stem cell transplantation",
    "eu_designation_number": "EU/3/21/2504",
    "status": "Positive",
    "first_published_date": "20/01/2022",
    "last_updated_date": "13/04/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2504"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous T cells ex vivo modified with a lentiviral vector encoding a chimeric antigen receptor specific for CD1a",
    "date_of_designation_or_refusal": "10/12/2021",
    "intended_use": "Treatment of acute lymphoblastic leukaemia",
    "eu_designation_number": "EU/3/21/2535",
    "status": "Positive",
    "first_published_date": "13/04/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2535"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "macitentan",
    "date_of_designation_or_refusal": "10/12/2021",
    "intended_use": "Treatment of chronic thromboembolic pulmonary hypertension",
    "eu_designation_number": "EU/3/21/2533",
    "status": "Positive",
    "first_published_date": "13/04/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2533"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Encapsulated human retinal pigment epithelial cell line transfected with plasmid vector expressing human ciliary neurotrophic factor",
    "date_of_designation_or_refusal": "24/01/2013",
    "intended_use": "Treatment of retinitis pigmentosa",
    "eu_designation_number": "EU/3/12/1098",
    "status": "Positive",
    "first_published_date": "01/03/2013",
    "last_updated_date": "12/04/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1098"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Encapsulated human retinal pigment epithelial cell line transfected with plasmid vector expressing human ciliary neurotropic factor",
    "date_of_designation_or_refusal": "08/11/2012",
    "intended_use": "Treatment of macular telangiectasia type 2",
    "eu_designation_number": "EU/3/12/1072",
    "status": "Positive",
    "first_published_date": "12/12/2012",
    "last_updated_date": "12/04/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1072"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Leniolisib",
    "date_of_designation_or_refusal": "19/10/2020",
    "intended_use": "Treatment of activated phosphoinositide 3-kinase delta syndrome",
    "eu_designation_number": "EU/3/20/2339",
    "status": "Positive",
    "first_published_date": "25/05/2021",
    "last_updated_date": "11/04/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2339"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(5R,5aR,8aR,9S)-9-[[4,6-O-[(R)-Ethylidene]-β-D-glucopyranosyl]-oxy]-5-(4-({[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]carbonyl}oxy)-3,5-dimethoxyphenyl)-5,8,8a,9-tetrahydroisobenzofuro[5,6-f][1,3]benzodioxol-6(5aH)-one (etoposide toniribate)",
    "date_of_designation_or_refusal": "04/06/2014",
    "intended_use": "Treatment of biliary tract cancer",
    "eu_designation_number": "EU/3/14/1270",
    "status": "Positive",
    "first_published_date": "10/07/2014",
    "last_updated_date": "08/04/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1270"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic donor-derived ex-vivo expanded T lymphocytes transduced with a retroviral vector containing inducible caspase 9 and truncated CD19",
    "date_of_designation_or_refusal": "27/06/2016",
    "intended_use": "Treatment in haematopoietic stem cell transplantation",
    "eu_designation_number": "EU/3/16/1674",
    "status": "Withdrawn",
    "first_published_date": "26/07/2016",
    "last_updated_date": "07/04/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1674"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "rimiducid",
    "date_of_designation_or_refusal": "30/05/2016",
    "intended_use": "Treatment of graft-versus-host disease",
    "eu_designation_number": "EU/3/16/1666",
    "status": "Withdrawn",
    "first_published_date": "23/06/2016",
    "last_updated_date": "07/04/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1666"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "molgramostim",
    "date_of_designation_or_refusal": "27/06/2016",
    "intended_use": "Treatment of acute respiratory distress syndrome (ARDS)",
    "eu_designation_number": "EU/3/16/1685",
    "status": "Positive",
    "first_published_date": "26/07/2016",
    "last_updated_date": "06/04/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1685"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Granulocyte-macrophage colony-stimulating factor",
    "date_of_designation_or_refusal": "17/07/2013",
    "intended_use": "Treatment of pulmonary alveolar proteinosis",
    "eu_designation_number": "EU/3/13/1147",
    "status": "Positive",
    "first_published_date": "21/08/2013",
    "last_updated_date": "06/04/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1147"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ciprofloxacin",
    "date_of_designation_or_refusal": "24/07/2009",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/09/652",
    "status": "Positive",
    "first_published_date": "11/09/2009",
    "last_updated_date": "06/04/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-652"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "multilamellar microvesicle comprising phosphatidylcholine, sphingomyelin, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol and cholesterol",
    "date_of_designation_or_refusal": "30/08/2011",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/11/896",
    "status": "Withdrawn",
    "first_published_date": "21/09/2011",
    "last_updated_date": "06/04/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-896"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous haematopoietic stem cells transduced with lentiviral vector Lenti-D encoding the human ABCD1 cDNA (elivaldogene autotemcel)",
    "date_of_designation_or_refusal": "06/06/2012",
    "intended_use": "Treatment of adrenoleukodystrophy",
    "eu_designation_number": "EU/3/12/1003",
    "status": "Withdrawn",
    "first_published_date": "04/07/2012",
    "last_updated_date": "04/04/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1003"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus serotype 9 expressing the cDNA for human MECP2",
    "date_of_designation_or_refusal": "20/05/2021",
    "intended_use": "Treatment of Rett syndrome",
    "eu_designation_number": "EU/3/21/2442",
    "status": "Withdrawn",
    "first_published_date": "18/03/2022",
    "last_updated_date": "30/03/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2442"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "dantrolene sodium, hemiheptahydrate",
    "date_of_designation_or_refusal": "20/05/2021",
    "intended_use": "Treatment of malignant hyperthermia",
    "eu_designation_number": "EU/3/21/2443",
    "status": "Withdrawn",
    "first_published_date": "24/03/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2443"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "veledimex",
    "date_of_designation_or_refusal": "21/08/2019",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/19/2199",
    "status": "Withdrawn",
    "first_published_date": "16/01/2020",
    "last_updated_date": "21/03/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2199"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adenoviral vector serotype 5 encoding the human interleukin-12 p70 transgene under the control of activator ligand veledimex",
    "date_of_designation_or_refusal": "21/08/2019",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/19/2198",
    "status": "Withdrawn",
    "first_published_date": "16/01/2020",
    "last_updated_date": "21/03/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2198"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 5 expressing the human Cone-Rod Homeobox gene",
    "date_of_designation_or_refusal": "20/05/2021",
    "intended_use": "Treatment of Leber's congenital amaurosis",
    "eu_designation_number": "EU/3/21/2441",
    "status": "Positive",
    "first_published_date": "18/03/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2441"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "melatonin",
    "date_of_designation_or_refusal": "20/05/2021",
    "intended_use": "Treatment of retinitis pigmentosa",
    "eu_designation_number": "EU/3/21/2439",
    "status": "Positive",
    "first_published_date": "18/03/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2439"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "synthetic 2′-O-(2-methoxyethyl)-modified antisense oligonucleotide linked to a triantennary cluster of N-acetyl galactosamine sugars targeting transmembrane protease, serine 6 mRNA",
    "date_of_designation_or_refusal": "20/05/2021",
    "intended_use": "Treatment of beta thalassaemia intermedia and major",
    "eu_designation_number": "EU/3/21/2437",
    "status": "Positive",
    "first_published_date": "18/03/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2437"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ribonucleotide reductase R2 specific phosphorothioate oligonucleotide",
    "date_of_designation_or_refusal": "08/05/2008",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/08/542",
    "status": "Positive",
    "first_published_date": "29/07/2008",
    "last_updated_date": "18/03/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-542"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human surfactant protein D",
    "date_of_designation_or_refusal": "11/04/2014",
    "intended_use": "Prevention of bronchopulmonary dysplasia",
    "eu_designation_number": "EU/3/14/1262",
    "status": "Positive",
    "first_published_date": "05/06/2014",
    "last_updated_date": "18/03/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1262"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-terminal hexaglutamine-tagged recombinant human N-acetylgalactosamine-6-sulfate sulfatase",
    "date_of_designation_or_refusal": "27/02/2009",
    "intended_use": "Treatment of mucopolysaccharidosis, type IVA (Morquio A syndrome)",
    "eu_designation_number": "EU/3/09/615",
    "status": "Positive",
    "first_published_date": "30/10/2009",
    "last_updated_date": "18/03/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-615"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "bovine bile extract",
    "date_of_designation_or_refusal": "20/06/2005",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/05/287",
    "status": "Positive",
    "first_published_date": "07/03/2007",
    "last_updated_date": "18/03/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-287"
  },
  {
    "medicine_name": "Corluxin",
    "related_ema_product_number": "EMEA/H/C/002830",
    "active_substance": "mifepristone",
    "date_of_designation_or_refusal": "27/10/2011",
    "intended_use": "Treatment of hypercortisolism (Cushing's syndrome) of endogenous origin",
    "eu_designation_number": "EU/3/11/925",
    "status": "Positive",
    "first_published_date": "23/11/2011",
    "last_updated_date": "18/03/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-925"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "trabedersen",
    "date_of_designation_or_refusal": "24/07/2009",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/09/660",
    "status": "Positive",
    "first_published_date": "11/09/2009",
    "last_updated_date": "18/03/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-660"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "TGF-ß2-specific phosphorothioate antisense oligodeoxynucleotide",
    "date_of_designation_or_refusal": "22/03/2002",
    "intended_use": "Treatment of high-grade glioma",
    "eu_designation_number": "EU/3/02/091",
    "status": "Positive",
    "first_published_date": "08/01/2003",
    "last_updated_date": "18/03/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-091"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Gly-Gly-Asp-Leu-Leu-Pro-Arg-Gly-Ser",
    "date_of_designation_or_refusal": "18/11/2016",
    "intended_use": "Treatment of Huntington’s disease",
    "eu_designation_number": "EU/3/16/1790",
    "status": "Positive",
    "first_published_date": "14/12/2016",
    "last_updated_date": "18/03/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1790"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-(2-phenylvinyl)-4-[4- methylpiperazin-1-yl)]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt",
    "date_of_designation_or_refusal": "10/08/2015",
    "intended_use": "Treatment of hepatocellular carcinoma",
    "eu_designation_number": "EU/3/15/1544",
    "status": "Positive",
    "first_published_date": "02/10/2015",
    "last_updated_date": "18/03/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1544"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "carboplatin;sodium valproate",
    "date_of_designation_or_refusal": "31/07/2018",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/18/2043",
    "status": "Positive",
    "first_published_date": "11/10/2018",
    "last_updated_date": "18/03/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2043"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "trehalose",
    "date_of_designation_or_refusal": "20/05/2021",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/21/2436",
    "status": "Positive",
    "first_published_date": "18/03/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2436"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 2.5T encoding the human cystic fibrosis transmembrane conductance regulator with a partial deletion in the R domain",
    "date_of_designation_or_refusal": "20/05/2021",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/21/2433",
    "status": "Positive",
    "first_published_date": "18/03/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2433"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ponatinib hydrochloride",
    "date_of_designation_or_refusal": "15/01/2015",
    "intended_use": "Treatment of gastrointestinal stromal tumours",
    "eu_designation_number": "EU/3/14/1421",
    "status": "Withdrawn",
    "first_published_date": "06/03/2015",
    "last_updated_date": "18/03/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1421"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "C1 esterase inhibitor (human)",
    "date_of_designation_or_refusal": "14/12/2018",
    "intended_use": "Treatment in solid organ transplantation",
    "eu_designation_number": "EU/3/18/2114",
    "status": "Positive",
    "first_published_date": "12/03/2019",
    "last_updated_date": "17/03/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2114"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-[4-[3-(methylamino)-1-phenylpropoxy]phenyl]ethanol hydrochloride",
    "date_of_designation_or_refusal": "20/05/2021",
    "intended_use": "Treatment of fragile X syndrome",
    "eu_designation_number": "EU/3/21/2432",
    "status": "Positive",
    "first_published_date": "17/03/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2432"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human IgG1 monoclonal antibody against alpha-synuclein",
    "date_of_designation_or_refusal": "20/05/2021",
    "intended_use": "Treatment of multiple system atrophy",
    "eu_designation_number": "EU/3/21/2431",
    "status": "Positive",
    "first_published_date": "17/03/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2431"
  },
  {
    "medicine_name": "Ifinwil",
    "related_ema_product_number": "EMEA/H/C/006067",
    "active_substance": "eflornithine",
    "date_of_designation_or_refusal": "20/05/2021",
    "intended_use": "Treatment of neuroblastoma",
    "eu_designation_number": "EU/3/21/2429",
    "status": "Positive",
    "first_published_date": "17/03/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2429"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "macitentan",
    "date_of_designation_or_refusal": "20/05/2021",
    "intended_use": "Treatment of functional single ventricle congenital heart disease",
    "eu_designation_number": "EU/3/21/2428",
    "status": "Positive",
    "first_published_date": "16/03/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2428"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "begelomab",
    "date_of_designation_or_refusal": "20/05/2021",
    "intended_use": "Treatment of dermatomyositis",
    "eu_designation_number": "EU/3/21/2427",
    "status": "Positive",
    "first_published_date": "16/03/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2427"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Heat-killed Mycobacterium obuense (whole cell)",
    "date_of_designation_or_refusal": "16/12/2014",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/14/1385",
    "status": "Positive",
    "first_published_date": "26/02/2015",
    "last_updated_date": "08/03/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1385"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Heat-killed Mycobacterium vaccae (whole cell)",
    "date_of_designation_or_refusal": "20/09/2010",
    "intended_use": "Treatment of tuberculosis",
    "eu_designation_number": "EU/3/10/786",
    "status": "Positive",
    "first_published_date": "18/10/2010",
    "last_updated_date": "08/03/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-786"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "losartan",
    "date_of_designation_or_refusal": "26/02/2019",
    "intended_use": "Treatment of epidermolysis bullosa",
    "eu_designation_number": "EU/3/19/2142",
    "status": "Positive",
    "first_published_date": "09/04/2019",
    "last_updated_date": "07/03/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2142"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "alvocidib",
    "date_of_designation_or_refusal": "12/02/2015",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/15/1437",
    "status": "Positive",
    "first_published_date": "09/04/2015",
    "last_updated_date": "07/03/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1437"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "alvocidib",
    "date_of_designation_or_refusal": "23/10/2007",
    "intended_use": "Treatment of chronic lymphocytic leukaemia",
    "eu_designation_number": "EU/3/07/485",
    "status": "Positive",
    "first_published_date": "18/08/2008",
    "last_updated_date": "07/03/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-485"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Lurbinectedin",
    "date_of_designation_or_refusal": "20/08/2021",
    "intended_use": "Treatment of  malignant mesothelioma",
    "eu_designation_number": "EU/3/21/2495",
    "status": "Positive",
    "first_published_date": "04/03/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2495"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus serotype 9 encoding human NGLY1 gene",
    "date_of_designation_or_refusal": "20/08/2021",
    "intended_use": "Treatment of NGLY1 deficiency",
    "eu_designation_number": "EU/3/21/2492",
    "status": "Positive",
    "first_published_date": "03/03/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2492"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human apolipoprotein A-I",
    "date_of_designation_or_refusal": "20/08/2021",
    "intended_use": "Treatment of lecithin-cholesterol acyltransferase deficiency",
    "eu_designation_number": "EU/3/21/2490",
    "status": "Positive",
    "first_published_date": "03/03/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2490"
  },
  {
    "medicine_name": "Ngenla",
    "related_ema_product_number": "EMEA/H/C/005633",
    "active_substance": "recombinant modified human growth hormone",
    "date_of_designation_or_refusal": "24/01/2013",
    "intended_use": "Treatment of growth hormone deficiency",
    "eu_designation_number": "EU/3/12/1087",
    "status": "Positive",
    "first_published_date": "01/03/2013",
    "last_updated_date": "03/03/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1087"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 9 expressing codon-optimized human GBA gene",
    "date_of_designation_or_refusal": "19/02/2021",
    "intended_use": "Treatment of Gaucher disease",
    "eu_designation_number": "EU/3/21/2413",
    "status": "Positive",
    "first_published_date": "02/03/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2413"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sabatolimab",
    "date_of_designation_or_refusal": "20/08/2021",
    "intended_use": "Treatment of myelodysplastic syndromes",
    "eu_designation_number": "EU/3/21/2494",
    "status": "Positive",
    "first_published_date": "02/03/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2494"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous CD34+ haematopoietic stem and progenitor cells genetically modified with the lentiviral vector encoding for the human iduronate 2-sulfatase gene",
    "date_of_designation_or_refusal": "20/08/2021",
    "intended_use": "Treatment of mucopolysaccharidosis type II (Hunter's syndrome)",
    "eu_designation_number": "EU/3/21/2493",
    "status": "Positive",
    "first_published_date": "02/03/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2493"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "fluticasone propionate",
    "date_of_designation_or_refusal": "12/01/2017",
    "intended_use": "Treatment of eosinophilic oesophagitis",
    "eu_designation_number": "EU/3/16/1815",
    "status": "Positive",
    "first_published_date": "14/07/2017",
    "last_updated_date": "01/03/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1815"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Adeno-associated viral vector serotype S3 containing codon-optimised expression cassette encoding human beta-glucocerebrosidase variant",
    "date_of_designation_or_refusal": "20/08/2021",
    "intended_use": "Treatment of Gaucher disease",
    "eu_designation_number": "EU/3/21/2491",
    "status": "Positive",
    "first_published_date": "01/03/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2491"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "3-pentylbenzeneacetic acid sodium salt",
    "date_of_designation_or_refusal": "09/10/2015",
    "intended_use": "Treatment of idiopathic pulmonary fibrosis",
    "eu_designation_number": "EU/3/15/1550",
    "status": "Withdrawn",
    "first_published_date": "16/11/2015",
    "last_updated_date": "28/02/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1550"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "3-pentylbenzeneacetic acid sodium salt",
    "date_of_designation_or_refusal": "12/01/2017",
    "intended_use": "Treatment of Alström syndrome",
    "eu_designation_number": "EU/3/16/1810",
    "status": "Withdrawn",
    "first_published_date": "14/07/2017",
    "last_updated_date": "28/02/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1810"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-methyl-4-({4-[({3-methyl(methylsulfonyl)aminopyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride (defactinib)",
    "date_of_designation_or_refusal": "07/06/2013",
    "intended_use": "Treatment of malignant mesothelioma",
    "eu_designation_number": "EU/3/13/1132",
    "status": "Withdrawn",
    "first_published_date": "25/06/2013",
    "last_updated_date": "28/02/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1132"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "synthetic double-stranded siRNA oligonucleotide directed against p53 mRNA (teprasiran)",
    "date_of_designation_or_refusal": "06/06/2010",
    "intended_use": "Prevention of delayed graft function after renal transplantation",
    "eu_designation_number": "EU/3/10/751",
    "status": "Withdrawn",
    "first_published_date": "23/06/2010",
    "last_updated_date": "28/02/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-751"
  },
  {
    "medicine_name": "Luxceptar",
    "related_ema_product_number": "EMEA/H/C/002397",
    "active_substance": "Donor T lymphocytes depleted ex vivo of host alloreactive T cells using photodynamic treatment-",
    "date_of_designation_or_refusal": "27/06/2016",
    "intended_use": "Treatment in haematopoietic stem cell transplantation",
    "eu_designation_number": "EU/3/16/1678",
    "status": "Withdrawn",
    "first_published_date": "26/07/2016",
    "last_updated_date": "28/02/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1678"
  },
  {
    "medicine_name": "Luxceptar",
    "related_ema_product_number": "EMEA/H/C/002397",
    "active_substance": "Donor T lymphocytes depleted ex-vivo of host alloreactive T cells using photodynamic treatment",
    "date_of_designation_or_refusal": "19/11/2014",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/14/1356",
    "status": "Withdrawn",
    "first_published_date": "15/01/2015",
    "last_updated_date": "28/02/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1356"
  },
  {
    "medicine_name": "Luxceptar",
    "related_ema_product_number": "EMEA/H/C/002397",
    "active_substance": "Donor lymphocyte preparation depleted of functional alloreactive T-cells",
    "date_of_designation_or_refusal": "05/09/2008",
    "intended_use": "Prevention of graft-versus-host disease",
    "eu_designation_number": "EU/3/08/561",
    "status": "Withdrawn",
    "first_published_date": "24/04/2009",
    "last_updated_date": "28/02/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-561"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic peripheral blood mononuclear cells induced to an early apoptotic state",
    "date_of_designation_or_refusal": "15/01/2015",
    "intended_use": "Prevention of graft-versus-host disease",
    "eu_designation_number": "EU/3/14/1426",
    "status": "Withdrawn",
    "first_published_date": "06/03/2015",
    "last_updated_date": "28/02/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1426"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus serotype PTC3 expressing the human UBE3A gene",
    "date_of_designation_or_refusal": "20/08/2021",
    "intended_use": "Treatment of Angelman syndrome",
    "eu_designation_number": "EU/3/21/2487",
    "status": "Positive",
    "first_published_date": "25/02/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2487"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 9 containing the human MECP2 gene",
    "date_of_designation_or_refusal": "20/08/2021",
    "intended_use": "Treatment of Rett syndrome",
    "eu_designation_number": "EU/3/21/2484",
    "status": "Positive",
    "first_published_date": "25/02/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2484"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human keratinocytes",
    "date_of_designation_or_refusal": "20/08/2021",
    "intended_use": "Treatment of partial deep dermal and full thickness burns",
    "eu_designation_number": "EU/3/21/2483",
    "status": "Positive",
    "first_published_date": "25/02/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2483"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 9 containing the human HEXA and HEXB genes",
    "date_of_designation_or_refusal": "20/08/2021",
    "intended_use": "Treatment of GM2 gangliosidosis",
    "eu_designation_number": "EU/3/21/2482",
    "status": "Positive",
    "first_published_date": "25/02/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2482"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Pro-Pro-Thr-Val-Pro-Thr-Arg",
    "date_of_designation_or_refusal": "19/11/2014",
    "intended_use": "Treatment of xeroderma pigmentosum",
    "eu_designation_number": "EU/3/14/1375",
    "status": "Withdrawn",
    "first_published_date": "16/01/2015",
    "last_updated_date": "25/02/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1375"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Dinaciclib",
    "date_of_designation_or_refusal": "27/09/2011",
    "intended_use": "Treatment of chronic lymphocytic leukaemia",
    "eu_designation_number": "EU/3/11/901",
    "status": "Withdrawn",
    "first_published_date": "17/10/2011",
    "last_updated_date": "25/02/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-901"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Adeno-associated virus serotype 5 containing the human NR2E3 gene",
    "date_of_designation_or_refusal": "19/02/2021",
    "intended_use": "Treatment of Leber's congenital amaurosis",
    "eu_designation_number": "EU/3/21/2412",
    "status": "Positive",
    "first_published_date": "24/02/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2412"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Cys-Asp-Met-Ala-Glu-His-Thr-Glu-Arg-Leu-Lys-Ala-Asn-Asp-Ser-Leu-Lys-Leu-Ser-Gln-Glu-Tyr-Glu-Ser-Ile-NH2",
    "date_of_designation_or_refusal": "19/02/2021",
    "intended_use": "Treatment of spinal cord injury",
    "eu_designation_number": "EU/3/21/2411",
    "status": "Positive",
    "first_published_date": "23/02/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2411"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Adeno-associated virus serotype 5 containing the human NR2E3 gene",
    "date_of_designation_or_refusal": "19/02/2021",
    "intended_use": "Treatment of retinitis pigmentosa",
    "eu_designation_number": "EU/3/21/2408",
    "status": "Positive",
    "first_published_date": "23/02/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2408"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "",
    "date_of_designation_or_refusal": "19/02/2021",
    "intended_use": "Treatment of leishmaniasis",
    "eu_designation_number": "EU/3/21/2404",
    "status": "Positive",
    "first_published_date": "22/02/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2404"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "rintatolimod",
    "date_of_designation_or_refusal": "19/02/2022",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/21/2403",
    "status": "Positive",
    "first_published_date": "22/02/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2403"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-(2-{[2-(1h-benzimidazol-2-yl)ethyl]amino}ethyl)-n-[(3-fluoropyridin-2-yl)methyl]-1,3-oxazole-4-carboxamide trihydrochloride",
    "date_of_designation_or_refusal": "19/02/2021",
    "intended_use": "Treatment of sickle cell disease",
    "eu_designation_number": "EU/3/21/2402",
    "status": "Positive",
    "first_published_date": "22/02/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2402"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "",
    "date_of_designation_or_refusal": "19/02/2021",
    "intended_use": "Treatment of paroxysmal nocturnal haemoglobinuria",
    "eu_designation_number": "EU/3/21/2401",
    "status": "Positive",
    "first_published_date": "22/02/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2401"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "anti-SIGLEC8 IgG1 humanised monoclonal antibody",
    "date_of_designation_or_refusal": "19/02/2021",
    "intended_use": "Treatment of eosinophilic gastroenteritis",
    "eu_designation_number": "EU/3/21/2400",
    "status": "Positive",
    "first_published_date": "22/02/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2400"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "18-(p-[131I]-iodophenyl)octadecyl phosphocholine",
    "date_of_designation_or_refusal": "19/02/2021",
    "intended_use": "Treatment of lymphoplasmacytic lymphoma",
    "eu_designation_number": "EU/3/21/2399",
    "status": "Positive",
    "first_published_date": "22/02/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2399"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2'-O-methyl phosphorothioate RNA oligonucleotide, 5'-m5CUGm5CUGm5CUGm5CUGm5CUGm5CUGm5CUG-3'",
    "date_of_designation_or_refusal": "19/02/2021",
    "intended_use": "Treatment of spinocerebellar ataxia",
    "eu_designation_number": "EU/3/21/2398",
    "status": "Positive",
    "first_published_date": "22/02/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2398"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sirolimus",
    "date_of_designation_or_refusal": "14/07/2016",
    "intended_use": "Treatment of sporadic lymphangioleiomyomatosis",
    "eu_designation_number": "EU/3/16/1704",
    "status": "Positive",
    "first_published_date": "06/09/2016",
    "last_updated_date": "18/02/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1704"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human insulin receptor monoclonal antibody-fused-α-L-iduronidase",
    "date_of_designation_or_refusal": "15/10/2014",
    "intended_use": "Treatment of mucopolysaccharidosis type I",
    "eu_designation_number": "EU/3/14/1349",
    "status": "Withdrawn",
    "first_published_date": "12/11/2014",
    "last_updated_date": "18/02/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1349"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human insulin receptor monoclonal antibody-fused iduronate 2-sulfatase",
    "date_of_designation_or_refusal": "13/11/2013",
    "intended_use": "Treatment of mucopolysaccharidosis type II (Hunter's syndrome)",
    "eu_designation_number": "EU/3/13/1198",
    "status": "Withdrawn",
    "first_published_date": "02/12/2013",
    "last_updated_date": "18/02/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1198"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pracinostat",
    "date_of_designation_or_refusal": "16/10/2017",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/17/1927",
    "status": "Withdrawn",
    "first_published_date": "09/01/2018",
    "last_updated_date": "18/02/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1927"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pevonedistat",
    "date_of_designation_or_refusal": "25/07/2019",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/19/2186",
    "status": "Withdrawn",
    "first_published_date": "24/09/2019",
    "last_updated_date": "18/02/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2186"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pevonedistat",
    "date_of_designation_or_refusal": "14/12/2018",
    "intended_use": "Treatment of myelodysplastic syndromes",
    "eu_designation_number": "EU/3/18/2120",
    "status": "Withdrawn",
    "first_published_date": "12/03/2019",
    "last_updated_date": "18/02/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2120"
  },
  {
    "medicine_name": "Skytrofa (previously Lonapegsomatropin Ascendis Pharma)",
    "related_ema_product_number": "EMEA/H/C/005367",
    "active_substance": "lonapegsomatropin",
    "date_of_designation_or_refusal": "17/10/2019",
    "intended_use": "Treatment of growth hormone deficiency",
    "eu_designation_number": "EU/3/19/2213",
    "status": "Positive",
    "first_published_date": "22/01/2020",
    "last_updated_date": "17/02/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2213"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pridopidine hydrochloride",
    "date_of_designation_or_refusal": "19/07/2021",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/21/2470",
    "status": "Positive",
    "first_published_date": "12/11/2021",
    "last_updated_date": "17/02/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2470"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Lutetium-177(3+), S2,S7-cyclo[N-{4,7,10-tricarboxymethyl-1,4,7,10-tetraaza-cyclododecan-1-yl-acetyl}-4-chloro-L-phenylalanyl-D-cysteinyl-4-[(4S)-2,6-dioxo-1,3-diazinane-4-carboxamido]-L-phenylalanyl-4-(carbamoylamino)-D-phenylalanyl-L-lysyl-L-threonyl-L-cysteinyl-D-tyrosinamide]-",
    "date_of_designation_or_refusal": "20/09/2016",
    "intended_use": "Treatment of gastro-entero-pancreatic neuroendocrine tumours",
    "eu_designation_number": "EU/3/16/1754",
    "status": "Positive",
    "first_published_date": "14/11/2016",
    "last_updated_date": "09/02/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1754"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Bifunctional fusion protein composed of two extracellular domains of transforming growth factor beta receptor II fused with a human immunoglobulin G1 monoclonal antibody against programmed death ligand 1",
    "date_of_designation_or_refusal": "14/12/2018",
    "intended_use": "Treatment of biliary tract cancer",
    "eu_designation_number": "EU/3/18/2112",
    "status": "Withdrawn",
    "first_published_date": "11/03/2019",
    "last_updated_date": "07/02/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2112"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant anti-CD3-bi-single-chain-Fv-diphtheria toxin fusion protein",
    "date_of_designation_or_refusal": "09/08/2012",
    "intended_use": "Treatment of cutaneous T-cell lymphoma",
    "eu_designation_number": "EU/3/12/1039",
    "status": "Positive",
    "first_published_date": "27/09/2012",
    "last_updated_date": "04/02/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1039"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant anti-CD3-bi-single-chain-Fv-diphtheria toxin fusion protein",
    "date_of_designation_or_refusal": "09/08/2012",
    "intended_use": "Treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)",
    "eu_designation_number": "EU/3/12/1038",
    "status": "Positive",
    "first_published_date": "27/09/2012",
    "last_updated_date": "04/02/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1038"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide (selisistat)",
    "date_of_designation_or_refusal": "08/10/2009",
    "intended_use": "Treatment of Huntington’s disease",
    "eu_designation_number": "EU/3/09/681",
    "status": "Positive",
    "first_published_date": "18/11/2009",
    "last_updated_date": "04/02/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-681"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Dimethyl sulfoxide",
    "date_of_designation_or_refusal": "03/03/2005",
    "intended_use": "Treatment of severe closed traumatic brain injury",
    "eu_designation_number": "EU/3/05/263",
    "status": "Positive",
    "first_published_date": "01/07/2005",
    "last_updated_date": "04/02/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-263"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Duramycin",
    "date_of_designation_or_refusal": "13/11/2002",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/02/120",
    "status": "Positive",
    "first_published_date": "12/12/2005",
    "last_updated_date": "04/02/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-120"
  },
  {
    "medicine_name": "Turalio",
    "related_ema_product_number": "EMEA/H/C/004832",
    "active_substance": "[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine hydrochloride",
    "date_of_designation_or_refusal": "19/03/2015",
    "intended_use": "Treatment of tenosynovial giant cell tumour, localised and diffuse type",
    "eu_designation_number": "EU/3/15/1457",
    "status": "Withdrawn",
    "first_published_date": "11/05/2015",
    "last_updated_date": "02/02/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1457"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "synthetic 15-amino-acid macrocyclic peptide acylated with a polyethyleneglycol palmitoylated linker (zilucoplan)",
    "date_of_designation_or_refusal": "14/10/2016",
    "intended_use": "Treatment of paroxysmal nocturnal haemoglobinuria",
    "eu_designation_number": "EU/3/16/1762",
    "status": "Withdrawn",
    "first_published_date": "15/11/2016",
    "last_updated_date": "01/02/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1762"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "anetumab ravtansine",
    "date_of_designation_or_refusal": "19/11/2018",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/18/2084",
    "status": "Withdrawn",
    "first_published_date": "25/02/2019",
    "last_updated_date": "01/02/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2084"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "L-threo-3,4-dihydroxyphenylserine",
    "date_of_designation_or_refusal": "02/08/2007",
    "intended_use": "Treatment of orthostatic hypotension in patients with multiple system atrophy",
    "eu_designation_number": "EU/3/07/466",
    "status": "Withdrawn",
    "first_published_date": "21/09/2009",
    "last_updated_date": "28/01/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-466"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "L-threo-3,4-dihydroxyphenylserine",
    "date_of_designation_or_refusal": "02/08/2007",
    "intended_use": "Treatment of orthostatic hypotension in patients with pure autonomic failure",
    "eu_designation_number": "EU/3/07/465",
    "status": "Withdrawn",
    "first_published_date": "21/09/2009",
    "last_updated_date": "28/01/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-465"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "chimeric fibril-reactive IgG1k monoclonal antibody 11-1F4",
    "date_of_designation_or_refusal": "13/11/2019",
    "intended_use": "Treatment of AL amyloidosis",
    "eu_designation_number": "EU/3/19/2222",
    "status": "Positive",
    "first_published_date": "13/02/2020",
    "last_updated_date": "28/01/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2222"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "nomacopan",
    "date_of_designation_or_refusal": "26/06/2020",
    "intended_use": "Treatment of bullous pemphigoid",
    "eu_designation_number": "EU/3/20/2289",
    "status": "Positive",
    "first_published_date": "22/09/2020",
    "last_updated_date": "26/01/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2289"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant protein derived from the saliva of the Ornithodoros moubata tick (nomacopan)",
    "date_of_designation_or_refusal": "29/08/2016",
    "intended_use": "Treatment of paroxysmal nocturnal haemoglobinuria",
    "eu_designation_number": "EU/3/16/1725",
    "status": "Positive",
    "first_published_date": "03/10/2016",
    "last_updated_date": "26/01/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1725"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant protein derived from the saliva of the Ornithodoros moubata tick (nomacopan)",
    "date_of_designation_or_refusal": "27/06/2016",
    "intended_use": "Treatment of Guillain-Barré syndrome",
    "eu_designation_number": "EU/3/16/1687",
    "status": "Positive",
    "first_published_date": "26/07/2016",
    "last_updated_date": "26/01/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1687"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant derivative of C3 transferase",
    "date_of_designation_or_refusal": "05/09/2008",
    "intended_use": "Treatment of traumatic spinal cord injury",
    "eu_designation_number": "EU/3/08/563",
    "status": "Positive",
    "first_published_date": "24/04/2009",
    "last_updated_date": "25/01/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-563"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-{1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl}cyclopropanecarboxamide (tezacaftor)",
    "date_of_designation_or_refusal": "04/07/2014",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/14/1281",
    "status": "Positive",
    "first_published_date": "15/07/2014",
    "last_updated_date": "25/01/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1281"
  },
  {
    "medicine_name": "Symkevi",
    "related_ema_product_number": "EMEA/H/C/004682",
    "active_substance": "ivacaftor;tezacaftor",
    "date_of_designation_or_refusal": "27/02/2017",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/17/1828",
    "status": "Positive",
    "first_published_date": "31/03/2017",
    "last_updated_date": "25/01/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1828"
  },
  {
    "medicine_name": "Kaftrio",
    "related_ema_product_number": "EMEA/H/C/005269",
    "active_substance": "Ivacaftor, N-(1,3-dimethyl-1H-pyrazole-4-sulfonyl)-6-[3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide, tezacaftor (ivacaftor / tezacaftor / elexacaftor)",
    "date_of_designation_or_refusal": "14/12/2018",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/18/2116",
    "status": "Positive",
    "first_published_date": "07/03/2019",
    "last_updated_date": "25/01/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2116"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Ivacaftor, potassium(benzenesulfonyl)({[6-(3-{2-[1-(trifluoromethyl) cyclopropyl]ethoxy}-1H-pyrazol-1-yl)-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridin-3-yl]carbonyl})azanide, tezacaftor",
    "date_of_designation_or_refusal": "14/12/2018",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/18/2117",
    "status": "Positive",
    "first_published_date": "07/03/2019",
    "last_updated_date": "25/01/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2117"
  },
  {
    "medicine_name": "Casgevy",
    "related_ema_product_number": "EMEA/H/C/005763",
    "active_substance": "autologous CD34+ haematopoietic stem cells with a CRISPR-edited erythroid enhancer region of the BCL11A gene",
    "date_of_designation_or_refusal": "17/10/2019",
    "intended_use": "Treatment of beta thalassaemia intermedia and major",
    "eu_designation_number": "EU/3/19/2210",
    "status": "Positive",
    "first_published_date": "22/01/2020",
    "last_updated_date": "25/01/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2210"
  },
  {
    "medicine_name": "Casgevy",
    "related_ema_product_number": "EMEA/H/C/005763",
    "active_substance": "autologous CD34+ hematopoietic stem cells with a CRISPR-edited erythroid enhancer region of the BCL11A gene",
    "date_of_designation_or_refusal": "09/01/2020",
    "intended_use": "Treatment of sickle cell disease",
    "eu_designation_number": "EU/3/19/2242",
    "status": "Positive",
    "first_published_date": "19/05/2020",
    "last_updated_date": "25/01/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2242"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "amivantamab",
    "date_of_designation_or_refusal": "28/06/2021",
    "intended_use": "Treatment of partial deep dermal and full-thickness burns",
    "eu_designation_number": "-",
    "status": "Negative",
    "first_published_date": "24/01/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-partial-deep-dermal-and-full-thickness-burns-0"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "cevostamab",
    "date_of_designation_or_refusal": "13/04/2021",
    "intended_use": "Treatment of multiple myeloma",
    "eu_designation_number": "EU/3/21/2424",
    "status": "Positive",
    "first_published_date": "24/01/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2424"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "psilocybine",
    "date_of_designation_or_refusal": "15/10/2021",
    "intended_use": "Treatment of fragile X syndrome",
    "eu_designation_number": "EU/3/21/2513",
    "status": "Positive",
    "first_published_date": "21/01/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2513"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Idursulfase beta",
    "date_of_designation_or_refusal": "15/10/2021",
    "intended_use": "Treatment of mucopolysaccharidosis type II (Hunter's syndrome)",
    "eu_designation_number": "EU/3/21/2512",
    "status": "Positive",
    "first_published_date": "21/01/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2512"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "encaleret",
    "date_of_designation_or_refusal": "15/10/2021",
    "intended_use": "Treatment of hypoparathyroidism",
    "eu_designation_number": "EU/3/21/2510",
    "status": "Positive",
    "first_published_date": "21/01/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2510"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "selinexor",
    "date_of_designation_or_refusal": "15/10/2021",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/21/2509",
    "status": "Positive",
    "first_published_date": "21/01/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2509"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic umbilical cord mesenchymal cells-derived extracellular vesicles",
    "date_of_designation_or_refusal": "15/10/2021",
    "intended_use": "Prevention of bronchopulmonary dysplasia",
    "eu_designation_number": "EU/3/21/2508",
    "status": "Positive",
    "first_published_date": "21/01/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2508"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 5 expressing the human Cone-Rod Homeobox gene",
    "date_of_designation_or_refusal": "15/10/2021",
    "intended_use": "Treatment of cone-rod dystrophy",
    "eu_designation_number": "EU/3/21/2506",
    "status": "Positive",
    "first_published_date": "21/01/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2506"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "batiraxcept",
    "date_of_designation_or_refusal": "15/10/2021",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/21/2501",
    "status": "Positive",
    "first_published_date": "20/01/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2501"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Devimistat",
    "date_of_designation_or_refusal": "15/10/2021",
    "intended_use": "Treatment of Burkitt's lymphoma",
    "eu_designation_number": "EU/3/21/2499",
    "status": "Positive",
    "first_published_date": "20/01/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2499"
  },
  {
    "medicine_name": "Voraxaze; Voraxaze",
    "related_ema_product_number": "EMEA/H/C/000681; EMEA/H/C/005467",
    "active_substance": "carboxypeptidase G2 (glucarpidase)",
    "date_of_designation_or_refusal": "03/02/2003",
    "intended_use": "Adjunctive treatment in patients at risk of methotrexate toxicity",
    "eu_designation_number": "EU/3/02/128",
    "status": "Positive",
    "first_published_date": "17/02/2003",
    "last_updated_date": "20/01/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-128"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Denileukin diftitox",
    "date_of_designation_or_refusal": "11/12/2001",
    "intended_use": "Treatment of cutaneous T-cell lymphoma",
    "eu_designation_number": "EU/3/01/075",
    "status": "Positive",
    "first_published_date": "21/09/2009",
    "last_updated_date": "19/01/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-075"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "vatiquinone",
    "date_of_designation_or_refusal": "26/03/2021",
    "intended_use": "Treatment of Friedreich's ataxia",
    "eu_designation_number": "EU/3/21/2423",
    "status": "Positive",
    "first_published_date": "19/01/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2423"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Lorcaserin hydrochloride",
    "date_of_designation_or_refusal": "26/03/2021",
    "intended_use": "Treatment of Dravet syndrome",
    "eu_designation_number": "EU/3/21/2422",
    "status": "Positive",
    "first_published_date": "19/01/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2422"
  },
  {
    "medicine_name": "Vijoice",
    "related_ema_product_number": "EMEA/H/C/005468",
    "active_substance": "alpelisib",
    "date_of_designation_or_refusal": "26/03/2021",
    "intended_use": "Treatment of PIK3CA related overgrowth spectrum",
    "eu_designation_number": "EU/3/21/2420",
    "status": "Positive",
    "first_published_date": "19/01/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2420"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus serotype hu68 containing the human GALC gene",
    "date_of_designation_or_refusal": "26/03/2021",
    "intended_use": "Treatment of Krabbe disease",
    "eu_designation_number": "EU/3/21/2417",
    "status": "Positive",
    "first_published_date": "19/01/2022",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2417"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Fenretinide",
    "date_of_designation_or_refusal": "14/10/2016",
    "intended_use": "Treatment of peripheral T-cell lymphoma",
    "eu_designation_number": "EU/3/16/1751",
    "status": "Withdrawn",
    "first_published_date": "15/11/2016",
    "last_updated_date": "19/01/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1751"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Fenretinide",
    "date_of_designation_or_refusal": "21/03/2016",
    "intended_use": "Treatment of cutaneous T-cell lymphoma",
    "eu_designation_number": "EU/3/16/1630",
    "status": "Withdrawn",
    "first_published_date": "03/05/2016",
    "last_updated_date": "19/01/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1630"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "chimeric fusion protein of recombinant human alpha-N-acetylglucosaminidase and human insulin-like growth factor 2 (tralesinidase alfa)",
    "date_of_designation_or_refusal": "15/01/2015",
    "intended_use": "Treatment of mucopolysaccharidosis type IIIB",
    "eu_designation_number": "EU/3/14/1422",
    "status": "Positive",
    "first_published_date": "06/03/2015",
    "last_updated_date": "14/01/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1422"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "resiquimod",
    "date_of_designation_or_refusal": "28/04/2016",
    "intended_use": "Treatment of cutaneous T-cell lymphoma",
    "eu_designation_number": "EU/3/16/1653",
    "status": "Positive",
    "first_published_date": "31/05/2016",
    "last_updated_date": "13/01/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1653"
  },
  {
    "medicine_name": "Orepaxam",
    "related_ema_product_number": "EMEA/H/C/005990",
    "active_substance": "treprostinil diethanolamine",
    "date_of_designation_or_refusal": "26/08/2005",
    "intended_use": "Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension",
    "eu_designation_number": "EU/3/05/310",
    "status": "Positive",
    "first_published_date": "23/09/2009",
    "last_updated_date": "13/01/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-310"
  },
  {
    "medicine_name": "Artesunate Amivas",
    "related_ema_product_number": "EMEA/H/C/005550",
    "active_substance": "artesunate",
    "date_of_designation_or_refusal": "28/02/2020",
    "intended_use": "Treatment of malaria",
    "eu_designation_number": "EU/3/20/2251",
    "status": "Positive",
    "first_published_date": "06/05/2020",
    "last_updated_date": "13/01/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2251"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor (axicabtagene ciloleucel)",
    "date_of_designation_or_refusal": "09/10/2015",
    "intended_use": "Treatment of mantle cell lymphoma",
    "eu_designation_number": "EU/3/15/1552",
    "status": "Withdrawn",
    "first_published_date": "16/11/2015",
    "last_updated_date": "12/01/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1552"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor (axicabtagene ciloleucel)",
    "date_of_designation_or_refusal": "11/11/2015",
    "intended_use": "Treatment of acute lymphoblastic leukaemia",
    "eu_designation_number": "EU/3/15/1571",
    "status": "Withdrawn",
    "first_published_date": "06/01/2016",
    "last_updated_date": "12/01/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1571"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor (axicabtagene ciloleucel)",
    "date_of_designation_or_refusal": "11/11/2015",
    "intended_use": "Treatment of chronic lymphocytic leukaemia / small lymphocytic lymphoma",
    "eu_designation_number": "EU/3/15/1572",
    "status": "Withdrawn",
    "first_published_date": "06/01/2016",
    "last_updated_date": "12/01/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1572"
  },
  {
    "medicine_name": "Filspari",
    "related_ema_product_number": "EMEA/H/C/005783",
    "active_substance": "sparsentan",
    "date_of_designation_or_refusal": "19/10/2020",
    "intended_use": "Treatment of primary IgA nephropathy",
    "eu_designation_number": "EU/3/20/2345",
    "status": "Positive",
    "first_published_date": "16/02/2021",
    "last_updated_date": "12/01/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2345"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide",
    "date_of_designation_or_refusal": "11/11/2015",
    "intended_use": "Treatment of focal segmental glomerulosclerosis",
    "eu_designation_number": "EU/3/15/1574",
    "status": "Positive",
    "first_published_date": "06/01/2016",
    "last_updated_date": "12/01/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1574"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Human plasminogen",
    "date_of_designation_or_refusal": "28/07/2015",
    "intended_use": "Treatment of plasminogen deficiency",
    "eu_designation_number": "EU/3/15/1511",
    "status": "Positive",
    "first_published_date": "18/08/2015",
    "last_updated_date": "06/01/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1511"
  },
  {
    "medicine_name": "Albrioza",
    "related_ema_product_number": "EMEA/H/C/005901",
    "active_substance": "sodium phenylbutyrate;tauroursodeoxycholic acid",
    "date_of_designation_or_refusal": "04/06/2020",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/20/2284",
    "status": "Positive",
    "first_published_date": "19/08/2020",
    "last_updated_date": "05/01/2022",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2284"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sirolimus",
    "date_of_designation_or_refusal": "19/07/2021",
    "intended_use": "Treatment of perivascular epithelioid cell tumours",
    "eu_designation_number": "EU/3/21/2467",
    "status": "Positive",
    "first_published_date": "12/11/2021",
    "last_updated_date": "21/12/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2467"
  },
  {
    "medicine_name": "Aspaveli",
    "related_ema_product_number": "EMEA/H/C/005553",
    "active_substance": "Poly(oxy-1,2-ethanediyl),.alpha.-hydro-.omega.-hydroxy-,15,15'-diester with N-acetyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-.alpha.-aspartyl-L-tryptophylglycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-L-threonyl-2-[2-(2-aminoethoxy)ethoxy]acetyl-N6-carboxy-L-lysinamide cyclic (2.fwdarw.12)-(disulfide); where two identical synthetic peptide domains are covalently linked at the ends of the polyethylene glycol chain",
    "date_of_designation_or_refusal": "22/05/2017",
    "intended_use": "Treatment of paroxysmal nocturnal haemoglobinuria",
    "eu_designation_number": "EU/3/17/1873",
    "status": "Positive",
    "first_published_date": "29/06/2017",
    "last_updated_date": "16/12/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1873"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "zanubrutinib",
    "date_of_designation_or_refusal": "29/05/2019",
    "intended_use": "Treatment of lymphoplasmacytic lymphoma",
    "eu_designation_number": "EU/3/19/2167",
    "status": "Withdrawn",
    "first_published_date": "12/08/2019",
    "last_updated_date": "15/12/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2167"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tislelizumab",
    "date_of_designation_or_refusal": "13/11/2020",
    "intended_use": "Treatment of oesophageal cancer",
    "eu_designation_number": "EU/3/20/2357",
    "status": "Positive",
    "first_published_date": "15/02/2021",
    "last_updated_date": "14/12/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2357"
  },
  {
    "medicine_name": "Folcepri",
    "related_ema_product_number": "EMEA/H/C/002570",
    "active_substance": "N-[4-[[(2-amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-D-gamma-glutamyl-(2S)-2-amino-beta-alanyl-L-alpha-aspartyl-L-cysteine (etarfolatide)",
    "date_of_designation_or_refusal": "10/09/2012",
    "intended_use": "Diagnosis of positive folate-receptor status in ovarian cancer",
    "eu_designation_number": "EU/3/12/1043",
    "status": "Withdrawn",
    "first_published_date": "27/09/2012",
    "last_updated_date": "07/12/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1043"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous CD34+ haematopoietic stem cells transduced with lentiviral vector encoding the human beta A-T87Q-globin gene",
    "date_of_designation_or_refusal": "29/04/2014",
    "intended_use": "The treatment of sickle cell disease",
    "eu_designation_number": "EU/3/14/1263",
    "status": "Withdrawn",
    "first_published_date": "04/06/2014",
    "last_updated_date": "07/12/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1263"
  },
  {
    "medicine_name": "Abecma",
    "related_ema_product_number": "EMEA/H/C/004662",
    "active_substance": "autologous T lymphocyte-enriched population of cells transduced with a lentiviral vector encoding a chimeric antigen receptor targeting human B cell maturation antigen with 4-1BB and CD3-zeta intracellular signalling domains (idecabtagene vicleucel)",
    "date_of_designation_or_refusal": "20/04/2017",
    "intended_use": "Treatment of multiple myeloma",
    "eu_designation_number": "EU/3/17/1863",
    "status": "Positive",
    "first_published_date": "15/05/2017",
    "last_updated_date": "03/12/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1863"
  },
  {
    "medicine_name": "Livmarli",
    "related_ema_product_number": "EMEA/H/C/005551",
    "active_substance": "(4R,5R)-1-[[4-[[4-[3,3-dibutyl-7-(dimethylamino)-2,3,4,5- tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-1-azoniabicyclo[2.2.2]octane chloride (maralixibat chloride)",
    "date_of_designation_or_refusal": "16/01/2014",
    "intended_use": "Treatment of progressive familial intrahepatic cholestasis",
    "eu_designation_number": "EU/3/13/1216",
    "status": "Positive",
    "first_published_date": "22/01/2014",
    "last_updated_date": "03/12/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1216"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Glycosylation independent lysosomal targeting (GILT)-tagged recombinant human acid alpha glucosidase",
    "date_of_designation_or_refusal": "27/10/2011",
    "intended_use": "Treatment of glycogen storage disease type II (Pompe's disease)",
    "eu_designation_number": "EU/3/11/921",
    "status": "Positive",
    "first_published_date": "23/11/2011",
    "last_updated_date": "30/11/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-921"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "CD34+ haematopoietic stem and progenitor cells with CD3+ T-cells",
    "date_of_designation_or_refusal": "24/08/2018",
    "intended_use": "Treatment in solid organ transplantation",
    "eu_designation_number": "EU/3/18/2063",
    "status": "Positive",
    "first_published_date": "20/12/2018",
    "last_updated_date": "30/11/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2063"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-methyl D-(2,3,4,5,6-pentahydroxy-hexyl)-ammonium; 2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylate (tafamidis)",
    "date_of_designation_or_refusal": "28/08/2006",
    "intended_use": "Treatment of familial amyloid polyneuropathy",
    "eu_designation_number": "EU/3/06/401",
    "status": "Expired",
    "first_published_date": "02/04/2009",
    "last_updated_date": "25/11/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-401"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "hydrocortisone",
    "date_of_designation_or_refusal": "22/05/2006",
    "intended_use": "Treatment of adrenal insufficiency",
    "eu_designation_number": "EU/3/06/372",
    "status": "Expired",
    "first_published_date": "21/09/2009",
    "last_updated_date": "25/11/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-372"
  },
  {
    "medicine_name": "Qinlock",
    "related_ema_product_number": "EMEA/H/C/005614",
    "active_substance": "1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea",
    "date_of_designation_or_refusal": "08/11/2017",
    "intended_use": "Treatment of gastrointestinal stromal tumours",
    "eu_designation_number": "EU/3/17/1936",
    "status": "Positive",
    "first_published_date": "15/01/2018",
    "last_updated_date": "23/11/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1936"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Ibrutinib",
    "date_of_designation_or_refusal": "16/01/2014",
    "intended_use": "Treatment of follicular lymphoma",
    "eu_designation_number": "EU/3/13/1212",
    "status": "Withdrawn",
    "first_published_date": "23/01/2014",
    "last_updated_date": "23/11/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1212"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Ibrutinib",
    "date_of_designation_or_refusal": "13/11/2013",
    "intended_use": "Treatment of diffuse large B-cell lymphoma",
    "eu_designation_number": "EU/3/13/1203",
    "status": "Withdrawn",
    "first_published_date": "02/12/2013",
    "last_updated_date": "23/11/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1203"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Ibrutinib",
    "date_of_designation_or_refusal": "18/11/2016",
    "intended_use": "Treatment of graft-versus-host disease",
    "eu_designation_number": "EU/3/16/1780",
    "status": "Withdrawn",
    "first_published_date": "14/12/2016",
    "last_updated_date": "23/11/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1780"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Ibrutinib",
    "date_of_designation_or_refusal": "10/08/2015",
    "intended_use": "Treatment of marginal zone lymphoma",
    "eu_designation_number": "EU/3/15/1541",
    "status": "Withdrawn",
    "first_published_date": "02/10/2015",
    "last_updated_date": "23/11/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1541"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised Fc engineered monoclonal antibody against CD19 (tafasitamab)",
    "date_of_designation_or_refusal": "04/07/2014",
    "intended_use": "Treatment of chronic lymphocytic leukaemia / small lymphocytic lymphoma",
    "eu_designation_number": "EU/3/14/1286",
    "status": "Positive",
    "first_published_date": "16/07/2014",
    "last_updated_date": "18/11/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1286"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human ectonucleotide pyrophosphatase/phosphodiesterase 1 fused to the Fc fragment of IgG1",
    "date_of_designation_or_refusal": "19/07/2021",
    "intended_use": "Treatment of adenosine triphosphate binding cassette transporter protein subfamily C member 6 deficiency",
    "eu_designation_number": "EU/3/21/2479",
    "status": "Positive",
    "first_published_date": "16/11/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2479"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "humanised IgG2k Fc-modified bispecific monoclonal antibody against CD3 and BCMA",
    "date_of_designation_or_refusal": "19/07/2021",
    "intended_use": "Treatment of multiple myeloma",
    "eu_designation_number": "EU/3/21/2471",
    "status": "Positive",
    "first_published_date": "16/11/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2471"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "mRNA encoding the human glycogen debranching enzyme",
    "date_of_designation_or_refusal": "19/07/2021",
    "intended_use": "Treatment of glycogen storage disease type III",
    "eu_designation_number": "EU/3/21/2472",
    "status": "Positive",
    "first_published_date": "16/11/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2472"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 9 containing the human SLC13A5 gene",
    "date_of_designation_or_refusal": "19/07/2021",
    "intended_use": "Treatment of SLC13A5-epileptic encephalopathy deficiencies",
    "eu_designation_number": "EU/3/21/2473",
    "status": "Positive",
    "first_published_date": "16/11/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2473"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous CD34+ hematopoietic stem and progenitor cells genetically modified with the lentiviral vector encoding for the human palmitoyl-protein thioesterase 1 gene",
    "date_of_designation_or_refusal": "19/07/2021",
    "intended_use": "Treatment of neuronal ceroid lipofuscinosis",
    "eu_designation_number": "EU/3/21/2474",
    "status": "Positive",
    "first_published_date": "16/11/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2474"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Infigratinib",
    "date_of_designation_or_refusal": "19/07/2021",
    "intended_use": "Treatment of achondroplasia",
    "eu_designation_number": "EU/3/21/2475",
    "status": "Positive",
    "first_published_date": "16/11/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2475"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "3,5-diiodothyropropionic acid",
    "date_of_designation_or_refusal": "19/07/2021",
    "intended_use": "Treatment of Allan-Herndon-Dudley syndrome",
    "eu_designation_number": "EU/3/21/2476",
    "status": "Positive",
    "first_published_date": "16/11/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2476"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus vector serotype 1 containing the human GRN gene",
    "date_of_designation_or_refusal": "19/07/2021",
    "intended_use": "Treatment of frontotemporal dementia",
    "eu_designation_number": "EU/3/21/2478",
    "status": "Positive",
    "first_published_date": "16/11/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2478"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Adeno-associated viral vector serotype Anc80 containing the 3' portion of human OTOF gene, adeno-associated viral vector serotype Anc80 containing the 5' portion of human OTOF gene",
    "date_of_designation_or_refusal": "19/07/2021",
    "intended_use": "Treatment of otoferlin gene-mediated hearing loss",
    "eu_designation_number": "EU/3/21/2477",
    "status": "Positive",
    "first_published_date": "16/11/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2477"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Polyphenyl(disodium 3-O-sulfo-beta-D-glucopyranuronate)-(1->3)-beta-D-galactopyranoside",
    "date_of_designation_or_refusal": "17/07/2017",
    "intended_use": "Treatment of anti-MAG neuropathy",
    "eu_designation_number": "EU/3/17/1893",
    "status": "Withdrawn",
    "first_published_date": "16/08/2017",
    "last_updated_date": "15/11/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1893"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "agammaglobulinaemia tyrosine kinase",
    "date_of_designation_or_refusal": "12/12/2017",
    "intended_use": "Treatment of pemphigus",
    "eu_designation_number": "EU/3/17/1951",
    "status": "Withdrawn",
    "first_published_date": "24/01/2018",
    "last_updated_date": "15/11/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1951"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "",
    "date_of_designation_or_refusal": "19/07/2021",
    "intended_use": "Treatment of chronic myeloid leukaemia",
    "eu_designation_number": "EU/3/21/2469",
    "status": "Positive",
    "first_published_date": "12/11/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2469"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "melatonin",
    "date_of_designation_or_refusal": "19/07/2021",
    "intended_use": "Treatment of non-traumatic spontaneous intracerebral haemorrhage",
    "eu_designation_number": "EU/3/21/2468",
    "status": "Positive",
    "first_published_date": "12/11/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2468"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Lutetium (177Lu) omburtamab barzuxetan",
    "date_of_designation_or_refusal": "19/07/2021",
    "intended_use": "Treatment of medulloblastoma",
    "eu_designation_number": "EU/3/21/2466",
    "status": "Positive",
    "first_published_date": "12/11/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2466"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Eftansomatropin alfa",
    "date_of_designation_or_refusal": "19/07/2021",
    "intended_use": "Treatment of growth hormone deficiency",
    "eu_designation_number": "EU/3/21/2465",
    "status": "Positive",
    "first_published_date": "12/11/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2465"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Itolizumab",
    "date_of_designation_or_refusal": "19/07/2021",
    "intended_use": "Treatment of graft-versus-host disease",
    "eu_designation_number": "EU/3/21/2463",
    "status": "Positive",
    "first_published_date": "12/11/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2463"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "saroglitazar magnesium",
    "date_of_designation_or_refusal": "19/07/2021",
    "intended_use": "Treatment of primary biliary cholangitis",
    "eu_designation_number": "EU/3/21/2460",
    "status": "Positive",
    "first_published_date": "12/11/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2460"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(E)-2,4,6-trimethoxystyryl-3-carboxymethylamino-4-methoxybenzyl-sulfone sodium salt (rigosertib sodium)",
    "date_of_designation_or_refusal": "26/04/2012",
    "intended_use": "Treatment of myelodysplastic syndromes",
    "eu_designation_number": "EU/3/12/987",
    "status": "Withdrawn",
    "first_published_date": "18/06/2012",
    "last_updated_date": "27/10/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-987"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Ibrutinib",
    "date_of_designation_or_refusal": "29/04/2014",
    "intended_use": "Treatment of lymphoplasmacytic lymphoma",
    "eu_designation_number": "EU/3/14/1264",
    "status": "Withdrawn",
    "first_published_date": "04/06/2014",
    "last_updated_date": "22/10/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1264"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4 d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one (ibrutinib)",
    "date_of_designation_or_refusal": "12/03/2013",
    "intended_use": "Treatment of mantle cell lymphoma",
    "eu_designation_number": "EU/3/13/1115",
    "status": "Withdrawn",
    "first_published_date": "05/04/2013",
    "last_updated_date": "22/10/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1115"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4 d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one (ibrutinib)",
    "date_of_designation_or_refusal": "26/04/2012",
    "intended_use": "Treatment of chronic lymphocytic leukaemia",
    "eu_designation_number": "EU/3/12/984",
    "status": "Withdrawn",
    "first_published_date": "18/06/2012",
    "last_updated_date": "21/10/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-984"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "palovarotene",
    "date_of_designation_or_refusal": "27/06/2018",
    "intended_use": "Treatment of multiple osteochondromas",
    "eu_designation_number": "EU/3/18/2038",
    "status": "Withdrawn",
    "first_published_date": "21/08/2018",
    "last_updated_date": "19/10/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2038"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "seletalisib",
    "date_of_designation_or_refusal": "22/02/2018",
    "intended_use": "Treatment of activated phosphoinositide 3-kinase delta syndrome",
    "eu_designation_number": "EU/3/18/1986",
    "status": "Withdrawn",
    "first_published_date": "11/04/2018",
    "last_updated_date": "19/10/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1986"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human alpha 1 chain homotrimer of type VII collagen",
    "date_of_designation_or_refusal": "04/06/2014",
    "intended_use": "Treatment of epidermolysis bullosa",
    "eu_designation_number": "EU/3/14/1272",
    "status": "Positive",
    "first_published_date": "10/07/2014",
    "last_updated_date": "13/10/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1272"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ex-vivo cultured adult human mesenchymal stem cells",
    "date_of_designation_or_refusal": "20/02/2007",
    "intended_use": "Treatment of graft-versus-host disease",
    "eu_designation_number": "EU/3/07/432",
    "status": "Positive",
    "first_published_date": "19/07/2007",
    "last_updated_date": "13/10/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-432"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human hepatocarcinoma-intestine-pancreas;pancreatic associated protein",
    "date_of_designation_or_refusal": "11/02/2009",
    "intended_use": "Treatment of acute liver failure",
    "eu_designation_number": "EU/3/08/611",
    "status": "Positive",
    "first_published_date": "29/06/2009",
    "last_updated_date": "13/10/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-611"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pegylated carboxyhaemoglobin",
    "date_of_designation_or_refusal": "26/11/2009",
    "intended_use": "Treatment of sickle cell disease",
    "eu_designation_number": "EU/3/09/698",
    "status": "Positive",
    "first_published_date": "10/12/2009",
    "last_updated_date": "13/10/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-698"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "carbetocin",
    "date_of_designation_or_refusal": "21/03/2012",
    "intended_use": "Treatment of Prader-Willi syndrome",
    "eu_designation_number": "EU/3/12/975",
    "status": "Positive",
    "first_published_date": "19/04/2012",
    "last_updated_date": "13/10/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-975"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic fetal human retinal progenitor cells expanded ex vivo",
    "date_of_designation_or_refusal": "17/02/2016",
    "intended_use": "Treatment of retinitis pigmentosa",
    "eu_designation_number": "EU/3/16/1620",
    "status": "Positive",
    "first_published_date": "07/04/2016",
    "last_updated_date": "13/10/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1620"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "myriocin",
    "date_of_designation_or_refusal": "12/02/2015",
    "intended_use": "Treatment of retinitis pigmentosa",
    "eu_designation_number": "EU/3/15/1449",
    "status": "Positive",
    "first_published_date": "09/04/2015",
    "last_updated_date": "13/10/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1449"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(E)-(6-((N-methyl-((3-methylbenzofuran-2-yl)methyl)amino)-3-oxoprop-1-en-1-yl)-2-oxo-3,4-dihydro-1,8-naphthyridin-1(2H)-yl)methyl phosphate, bis ethanolamine salt (afabicin)",
    "date_of_designation_or_refusal": "14/10/2016",
    "intended_use": "Treatment of osteomyelitis",
    "eu_designation_number": "EU/3/16/1737",
    "status": "Positive",
    "first_published_date": "15/11/2016",
    "last_updated_date": "13/10/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1737"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adult human bone-marrow-derived, ex-vivo-expanded, pooled allogeneic mesenchymal stromal cells",
    "date_of_designation_or_refusal": "21/05/2015",
    "intended_use": "Treatment of thromboangiitis obliterans (Buerger's disease)",
    "eu_designation_number": "EU/3/15/1499",
    "status": "Positive",
    "first_published_date": "30/06/2015",
    "last_updated_date": "13/10/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1499"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "225Ac-lintuzumab",
    "date_of_designation_or_refusal": "22/05/2017",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/17/1871",
    "status": "Positive",
    "first_published_date": "30/06/2017",
    "last_updated_date": "13/10/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1871"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic ex-vivo-expanded umbilical cord blood-derived haematopoietic CD34+ progenitor cells and allogeneic non-expanded umbilical cord blood-derived haematopoietic mature myeloid and lymphoid cells",
    "date_of_designation_or_refusal": "20/03/2017",
    "intended_use": "Treatment in haematopoietic stem cell transplantation",
    "eu_designation_number": "EU/3/17/1852",
    "status": "Positive",
    "first_published_date": "05/05/2017",
    "last_updated_date": "13/10/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1852"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "venglustat",
    "date_of_designation_or_refusal": "14/12/2018",
    "intended_use": "Treatment of autosomal dominant polycystic kidney disease",
    "eu_designation_number": "EU/3/18/2122",
    "status": "Withdrawn",
    "first_published_date": "08/03/2019",
    "last_updated_date": "12/10/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2122"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sulindac",
    "date_of_designation_or_refusal": "09/12/2020",
    "intended_use": "Treatment of fragile X syndrome",
    "eu_designation_number": "EU/3/20/2384",
    "status": "Positive",
    "first_published_date": "26/05/2021",
    "last_updated_date": "12/10/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2384"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "three human monoclonal antibodies against the EBOV glycoprotein",
    "date_of_designation_or_refusal": "25/05/2018",
    "intended_use": "Treatment of Ebola virus disease",
    "eu_designation_number": "EU/3/18/2027",
    "status": "Positive",
    "first_published_date": "23/07/2018",
    "last_updated_date": "07/10/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2027"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human monoclonal antibody against activin A",
    "date_of_designation_or_refusal": "18/11/2016",
    "intended_use": "Treatment of fibrodysplasia ossificans progressiva",
    "eu_designation_number": "EU/3/16/1779",
    "status": "Positive",
    "first_published_date": "14/12/2016",
    "last_updated_date": "07/10/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1779"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "single-chain urokinase plasminogen activator",
    "date_of_designation_or_refusal": "16/12/2014",
    "intended_use": "Treatment of pleural empyema",
    "eu_designation_number": "EU/3/14/1383",
    "status": "Positive",
    "first_published_date": "26/02/2015",
    "last_updated_date": "27/09/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1383"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Maralixibat chloride",
    "date_of_designation_or_refusal": "27/07/2020",
    "intended_use": "Treatment of biliary atresia",
    "eu_designation_number": "EU/3/20/2304",
    "status": "Positive",
    "first_published_date": "19/11/2020",
    "last_updated_date": "24/09/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2304"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "humanised fusion protein consisting of extracellular domain of CD24 linked to IgG1 Fc domain",
    "date_of_designation_or_refusal": "11/11/2015",
    "intended_use": "Prevention of graft-versus-host disease",
    "eu_designation_number": "EU/3/15/1575",
    "status": "Positive",
    "first_published_date": "06/01/2016",
    "last_updated_date": "24/09/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1575"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "eptacog alfa (activated)",
    "date_of_designation_or_refusal": "14/12/2005",
    "intended_use": "Treatment of diffuse alveolar haemorrhage",
    "eu_designation_number": "EU/3/05/333",
    "status": "Withdrawn",
    "first_published_date": "21/09/2009",
    "last_updated_date": "21/09/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-333"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "drotrecogin alfa (activated)",
    "date_of_designation_or_refusal": "22/09/2008",
    "intended_use": "Treatment of acute respiratory distress syndrome (ARDS)",
    "eu_designation_number": "EU/3/08/565",
    "status": "Withdrawn",
    "first_published_date": "24/02/2009",
    "last_updated_date": "21/09/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-565"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "1-(2-isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d] pyrimidin-4-one (verdiperstat)",
    "date_of_designation_or_refusal": "16/12/2014",
    "intended_use": "Treatment of multiple system atrophy",
    "eu_designation_number": "EU/3/14/1404",
    "status": "Positive",
    "first_published_date": "27/02/2015",
    "last_updated_date": "21/09/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1404"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic CD4+ and CD25+ T lymphocytes ex vivo incubated with GP120",
    "date_of_designation_or_refusal": "22/02/2018",
    "intended_use": "Treatment in haematopoietic stem cell transplantation",
    "eu_designation_number": "EU/3/18/1976",
    "status": "Positive",
    "first_published_date": "11/04/2018",
    "last_updated_date": "17/09/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1976"
  },
  {
    "medicine_name": "Inrebic",
    "related_ema_product_number": "EMEA/H/C/005026",
    "active_substance": "N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate (fedratinib)",
    "date_of_designation_or_refusal": "26/11/2010",
    "intended_use": "Treatment of post-polycythaemia vera myelofibrosis",
    "eu_designation_number": "EU/3/10/811",
    "status": "Positive",
    "first_published_date": "17/12/2010",
    "last_updated_date": "17/09/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-811"
  },
  {
    "medicine_name": "Inrebic",
    "related_ema_product_number": "EMEA/H/C/005026",
    "active_substance": "N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate (fedratinib)",
    "date_of_designation_or_refusal": "26/11/2010",
    "intended_use": "Treatment of post-essential thrombocythaemia myelofibrosis",
    "eu_designation_number": "EU/3/10/810",
    "status": "Positive",
    "first_published_date": "17/12/2010",
    "last_updated_date": "17/09/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-810"
  },
  {
    "medicine_name": "Inrebic",
    "related_ema_product_number": "EMEA/H/C/005026",
    "active_substance": "N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate (fedratinib)",
    "date_of_designation_or_refusal": "01/10/2010",
    "intended_use": "Treatment of primary myelofibrosis",
    "eu_designation_number": "EU/3/10/794",
    "status": "Positive",
    "first_published_date": "14/10/2010",
    "last_updated_date": "17/09/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-794"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "perflubron",
    "date_of_designation_or_refusal": "09/12/2020",
    "intended_use": "Treatment of respiratory distress syndrome",
    "eu_designation_number": "EU/3/20/2383",
    "status": "Positive",
    "first_published_date": "26/05/2021",
    "last_updated_date": "16/09/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2383"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "perflubron",
    "date_of_designation_or_refusal": "13/11/2020",
    "intended_use": "Treatment of congenital pulmonary hypoplasia",
    "eu_designation_number": "EU/3/20/2361",
    "status": "Positive",
    "first_published_date": "15/02/2021",
    "last_updated_date": "16/09/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2361"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "paclitaxel",
    "date_of_designation_or_refusal": "17/10/2019",
    "intended_use": "Treatment of soft tissue sarcoma",
    "eu_designation_number": "EU/3/19/2215",
    "status": "Positive",
    "first_published_date": "23/01/2020",
    "last_updated_date": "16/09/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2215"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "4-oxo-4H-chromene-2-carboxylic acid (2-(2-4-(2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl)-phenyl-2H-tetrazol-5-yl)-4,5-dimethoxy-phenyl)-amide (encequidar)",
    "date_of_designation_or_refusal": "17/10/2019",
    "intended_use": "Treatment of soft tissue sarcoma",
    "eu_designation_number": "EU/3/19/2207",
    "status": "Positive",
    "first_published_date": "21/01/2020",
    "last_updated_date": "16/09/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2207"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Dantrolene sodium",
    "date_of_designation_or_refusal": "12/12/2016",
    "intended_use": "Treatment of Wolfram syndrome",
    "eu_designation_number": "EU/3/16/1800",
    "status": "Positive",
    "first_published_date": "09/01/2017",
    "last_updated_date": "16/09/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1800"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "teriparatide",
    "date_of_designation_or_refusal": "27/06/2016",
    "intended_use": "Treatment of hypoparathyroidism",
    "eu_designation_number": "EU/3/16/1689",
    "status": "Positive",
    "first_published_date": "26/07/2016",
    "last_updated_date": "16/09/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1689"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "exenatide",
    "date_of_designation_or_refusal": "21/03/2016",
    "intended_use": "Treatment of idiopathic intracranial hypertension",
    "eu_designation_number": "EU/3/16/1629",
    "status": "Positive",
    "first_published_date": "02/05/2016",
    "last_updated_date": "16/09/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1629"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium valproate fNor",
    "date_of_designation_or_refusal": "15/01/2015",
    "intended_use": "Treatment of Wolfram syndrome",
    "eu_designation_number": "EU/3/14/1428",
    "status": "Positive",
    "first_published_date": "06/03/2015",
    "last_updated_date": "16/09/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1428"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adenovirus serotype 5 containing partial E1A deletion and an integrin-binding domain (tasadenoturev)",
    "date_of_designation_or_refusal": "16/12/2014",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/14/1396",
    "status": "Positive",
    "first_published_date": "26/02/2015",
    "last_updated_date": "16/09/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1396"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "hydroxy-propyl-beta-cyclodextrin (hydroxypropylbetadex)",
    "date_of_designation_or_refusal": "30/08/2011",
    "intended_use": "Treatment of Niemann-Pick's disease, type C",
    "eu_designation_number": "EU/3/11/895",
    "status": "Positive",
    "first_published_date": "21/09/2011",
    "last_updated_date": "16/09/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-895"
  },
  {
    "medicine_name": "Cerepro; Cerepro; Cerepro",
    "related_ema_product_number": "EMEA/H/C/000694; EMEA/H/C/001103; EMEA/H/C/001103",
    "active_substance": "adenovirus-mediated herpes-simplex-virus thymidine-kinase (HKSV-tk) gene",
    "date_of_designation_or_refusal": "06/02/2002",
    "intended_use": "Treatment of high-grade glioma with subsequent use of ganciclovir sodium",
    "eu_designation_number": "EU/3/01/083",
    "status": "Positive",
    "first_published_date": "06/01/2003",
    "last_updated_date": "16/09/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-083"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant factor VIIa modified with three terminal repeats derived from the β chain of human chorionic gonadotropin",
    "date_of_designation_or_refusal": "22/08/2014",
    "intended_use": "Treatment of haemophilia B",
    "eu_designation_number": "EU/3/14/1319",
    "status": "Positive",
    "first_published_date": "01/10/2014",
    "last_updated_date": "16/09/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1319"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant factor VIIa modified with three terminal repeats derived from the β chain of human chorionic gonadotropin",
    "date_of_designation_or_refusal": "22/08/2014",
    "intended_use": "Treatment of congenital factor VII deficiency",
    "eu_designation_number": "EU/3/14/1312",
    "status": "Positive",
    "first_published_date": "30/09/2014",
    "last_updated_date": "16/09/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1312"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant factor VIIa modified with three terminal repeats derived from the β chain of human chorionic gonadotropin",
    "date_of_designation_or_refusal": "22/08/2014",
    "intended_use": "Treatment of haemophilia A",
    "eu_designation_number": "EU/3/14/1316",
    "status": "Positive",
    "first_published_date": "01/10/2014",
    "last_updated_date": "16/09/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1316"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "axicabtagene ciloleucel",
    "date_of_designation_or_refusal": "26/06/2020",
    "intended_use": "Treatment of marginal zone lymphoma",
    "eu_designation_number": "EU/3/20/2296",
    "status": "Positive",
    "first_published_date": "24/09/2020",
    "last_updated_date": "15/09/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2296"
  },
  {
    "medicine_name": "Tecartus",
    "related_ema_product_number": "EMEA/H/C/005102",
    "active_substance": "autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti CD19 CD28/CD3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel)",
    "date_of_designation_or_refusal": "13/11/2019",
    "intended_use": "Treatment of mantle cell lymphoma",
    "eu_designation_number": "EU/3/19/2220",
    "status": "Positive",
    "first_published_date": "13/02/2020",
    "last_updated_date": "15/09/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2220"
  },
  {
    "medicine_name": "Yescarta",
    "related_ema_product_number": "EMEA/H/C/004480",
    "active_substance": "autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor (axicabtagene ciloleucel)",
    "date_of_designation_or_refusal": "09/10/2015",
    "intended_use": "Treatment of primary mediastinal large B-cell lymphoma",
    "eu_designation_number": "EU/3/15/1553",
    "status": "Positive",
    "first_published_date": "16/11/2015",
    "last_updated_date": "15/09/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1553"
  },
  {
    "medicine_name": "Koselugo",
    "related_ema_product_number": "EMEA/H/C/005244",
    "active_substance": "selumetinib",
    "date_of_designation_or_refusal": "31/07/2018",
    "intended_use": "Treatment of neurofibromatosis type 1",
    "eu_designation_number": "EU/3/18/2050",
    "status": "Positive",
    "first_published_date": "11/10/2018",
    "last_updated_date": "15/09/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2050"
  },
  {
    "medicine_name": "Voxzogo",
    "related_ema_product_number": "EMEA/H/C/005475",
    "active_substance": "modified recombinant human C-type natriuretic peptide (Vosoritide)",
    "date_of_designation_or_refusal": "24/01/2013",
    "intended_use": "Treatment of achondroplasia",
    "eu_designation_number": "EU/3/12/1094",
    "status": "Positive",
    "first_published_date": "01/03/2013",
    "last_updated_date": "09/09/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1094"
  },
  {
    "medicine_name": "Minjuvi",
    "related_ema_product_number": "EMEA/H/C/005436",
    "active_substance": "Humanised Fc engineered monoclonal antibody against CD19 (tafasitamab)",
    "date_of_designation_or_refusal": "15/01/2015",
    "intended_use": "Treatment of diffuse large B-cell lymphoma",
    "eu_designation_number": "EU/3/14/1424",
    "status": "Positive",
    "first_published_date": "06/03/2015",
    "last_updated_date": "08/09/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1424"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human heparan-N-sulfatase",
    "date_of_designation_or_refusal": "07/11/2008",
    "intended_use": "Treatment of mucopolysaccharidosis, type IIIA (Sanfilippo A syndrome)",
    "eu_designation_number": "EU/3/08/582",
    "status": "Withdrawn",
    "first_published_date": "29/06/2009",
    "last_updated_date": "02/09/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-582"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "chimeric IgG monoclonal antibody cG250 (girentuximab)",
    "date_of_designation_or_refusal": "19/03/2002",
    "intended_use": "Treatment of renal-cell carcinoma",
    "eu_designation_number": "EU/3/02/094",
    "status": "Withdrawn",
    "first_published_date": "08/01/2003",
    "last_updated_date": "02/09/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-094"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Fosbretabulin tromethamine",
    "date_of_designation_or_refusal": "17/07/2013",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/13/1154",
    "status": "Withdrawn",
    "first_published_date": "21/08/2013",
    "last_updated_date": "02/09/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1154"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "reduced oxidised N-acetyl heparin (roneparstat)",
    "date_of_designation_or_refusal": "21/05/2015",
    "intended_use": "Treatment of plasma cell myeloma",
    "eu_designation_number": "EU/3/15/1487",
    "status": "Withdrawn",
    "first_published_date": "30/06/2015",
    "last_updated_date": "02/09/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1487"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-(2-((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenamido)ethyl)-2-hydroxybenzamide (edasalonexent)",
    "date_of_designation_or_refusal": "09/10/2015",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/15/1560",
    "status": "Withdrawn",
    "first_published_date": "18/11/2015",
    "last_updated_date": "02/09/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1560"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Fosbretabulin tromethamine",
    "date_of_designation_or_refusal": "21/03/2016",
    "intended_use": "Treatment of gastro-entero-pancreatic neuroendocrine tumours",
    "eu_designation_number": "EU/3/16/1633",
    "status": "Withdrawn",
    "first_published_date": "04/05/2016",
    "last_updated_date": "02/09/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1633"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Efgartigimod alfa",
    "date_of_designation_or_refusal": "16/12/2019",
    "intended_use": "Treatment of immune thrombocytopenia",
    "eu_designation_number": "EU/3/19/2230",
    "status": "Positive",
    "first_published_date": "25/02/2020",
    "last_updated_date": "02/09/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2230"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Enoxacin",
    "date_of_designation_or_refusal": "19/03/2015",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/15/1459",
    "status": "Positive",
    "first_published_date": "11/05/2015",
    "last_updated_date": "02/09/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1459"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "4-hydroxyandrostenedione;serenoa serrulata;alpha lipoic acid",
    "date_of_designation_or_refusal": "28/04/2016",
    "intended_use": "Treatment of multiple symmetric lipomatosis",
    "eu_designation_number": "EU/3/16/1646",
    "status": "Positive",
    "first_published_date": "31/05/2016",
    "last_updated_date": "02/09/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1646"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Ibutamoren mesilate",
    "date_of_designation_or_refusal": "20/06/2017",
    "intended_use": "Treatment of growth hormone deficiency",
    "eu_designation_number": "EU/3/17/1882",
    "status": "Positive",
    "first_published_date": "17/07/2017",
    "last_updated_date": "02/09/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1882"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "heterologous human adult liver-derived stem cells",
    "date_of_designation_or_refusal": "05/03/2012",
    "intended_use": "Treatment of carbamoyl-phosphate synthase-1 deficiency",
    "eu_designation_number": "EU/3/12/971",
    "status": "Positive",
    "first_published_date": "19/04/2012",
    "last_updated_date": "26/08/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-971"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "heterologous human adult liver-derived stem cells",
    "date_of_designation_or_refusal": "27/09/2011",
    "intended_use": "Treatment of ornithine transcarbamylase deficiency",
    "eu_designation_number": "EU/3/11/904",
    "status": "Positive",
    "first_published_date": "17/10/2011",
    "last_updated_date": "26/08/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-904"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "heterologous human adult liver-derived stem cells",
    "date_of_designation_or_refusal": "26/04/2012",
    "intended_use": "Treatment of acute liver failure",
    "eu_designation_number": "EU/3/12/983",
    "status": "Positive",
    "first_published_date": "18/06/2012",
    "last_updated_date": "26/08/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-983"
  },
  {
    "medicine_name": "Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron)",
    "related_ema_product_number": "EMEA/H/C/003918",
    "active_substance": "chimeric monoclonal antibody against GD2",
    "date_of_designation_or_refusal": "08/11/2012",
    "intended_use": "Treatment of neuroblastoma",
    "eu_designation_number": "EU/3/12/1062",
    "status": "Positive",
    "first_published_date": "13/12/2012",
    "last_updated_date": "26/08/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1062"
  },
  {
    "medicine_name": "Romvimza",
    "related_ema_product_number": "EMEA/H/C/006363",
    "active_substance": "2-(isopropylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one",
    "date_of_designation_or_refusal": "16/12/2019",
    "intended_use": "Treatment of tenosynovial giant cell tumour, localised and diffuse type",
    "eu_designation_number": "EU/3/19/2227",
    "status": "Positive",
    "first_published_date": "24/02/2020",
    "last_updated_date": "25/08/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2227"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "murine anti-CD22 antibody variable region fused to truncated Pseudomonas exotoxin 38 ( Moxetumomab pasudotox)",
    "date_of_designation_or_refusal": "05/12/2008",
    "intended_use": "Treatment of hairy cell leukaemia",
    "eu_designation_number": "EU/3/08/592",
    "status": "Withdrawn",
    "first_published_date": "17/09/2009",
    "last_updated_date": "19/08/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-592"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "1, 1'-[1,4-Phenylenebis (methylene)]-bis-1,4,8,11-tetraazacyclotetradecane (plerixafor)",
    "date_of_designation_or_refusal": "20/10/2004",
    "intended_use": "Treatment to mobilize progenitor cells prior to stem cell transplantation",
    "eu_designation_number": "EU/3/04/227",
    "status": "Expired",
    "first_published_date": "18/08/2008",
    "last_updated_date": "10/08/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-227"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "imatinib",
    "date_of_designation_or_refusal": "19/11/2014",
    "intended_use": "Treatment of acute respiratory distress syndrome (ARDS)",
    "eu_designation_number": "EU/3/14/1357",
    "status": "Positive",
    "first_published_date": "15/01/2015",
    "last_updated_date": "06/08/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1357"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector containing the human factor IX gene",
    "date_of_designation_or_refusal": "11/01/2012",
    "intended_use": "Treatment of haemophilia B",
    "eu_designation_number": "EU/3/11/938",
    "status": "Positive",
    "first_published_date": "01/02/2012",
    "last_updated_date": "06/08/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-938"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus serotype 2/6 encoding human alpha-galactosidase A cDNA",
    "date_of_designation_or_refusal": "09/01/2020",
    "intended_use": "Treatment of Fabry disease",
    "eu_designation_number": "EU/3/19/2241",
    "status": "Positive",
    "first_published_date": "19/05/2020",
    "last_updated_date": "04/08/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2241"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "daratumumab",
    "date_of_designation_or_refusal": "25/05/2018",
    "intended_use": "Treatment of AL amyloidosis",
    "eu_designation_number": "EU/3/18/2020",
    "status": "Positive",
    "first_published_date": "23/07/2018",
    "last_updated_date": "03/08/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2020"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-(trans-3-(5-((R)-1-hydroxyethyl)-1,3,4-oxadiazol-2-yl)cyclobutyl)-3-phenylisoxazole-5-carboxamide",
    "date_of_designation_or_refusal": "29/05/2019",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/19/2163",
    "status": "Withdrawn",
    "first_published_date": "09/08/2019",
    "last_updated_date": "30/07/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2163"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Immunoglobulin G1, anti-(human tumour-associated calcium signal transducer 2)(human-Mus musculus monoclonal hRS7 heavy chain), disulfide with human-Mus musculus monoclonal hRS7 κ-chain, dimer, hexakis(thioether) with (4S)-4-[[[[4-[[(2S)-2-(4-aminobutyl)-2-[[2-[2-[[26-[4-[[[[4-[(3-mercapto-2,5-dioxo-1-pyrrolidinyl)methyl]cyclohexyl]carbonyl]amino]methyl]-1H-1,2,3-triazol-1-yl]-3,6,9,12,15,18,21,24-octaoxahexacos-1-yl]amino]-2-oxoethoxy]acetyl]amino]-1-oxoethyl]amino]phenyl]methoxy]carbonyl]oxy]-4,11-diethyl-9-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione (sacituzumab govitecan)",
    "date_of_designation_or_refusal": "15/10/2014",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/14/1343",
    "status": "Positive",
    "first_published_date": "12/11/2014",
    "last_updated_date": "28/07/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1343"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic anti-Epstein Barr virus cytotoxic T lymphocytes expanded ex vivo",
    "date_of_designation_or_refusal": "21/07/2021",
    "intended_use": "Treatment of post-transplant lymphoproliferative disorder",
    "eu_designation_number": "EU/3/19/2138",
    "status": "Withdrawn",
    "first_published_date": "02/10/2019",
    "last_updated_date": "21/07/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2138"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-Methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-phenol (fosbretabulin tromethamine)",
    "date_of_designation_or_refusal": "21/07/2021",
    "intended_use": "Treatment of anaplastic thyroid cancer",
    "eu_designation_number": "EU/3/04/195",
    "status": "Withdrawn",
    "first_published_date": "05/11/2004",
    "last_updated_date": "21/07/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-195"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(RS)-Bacoflen;naltrexone hydrochloride;D-sorbitol",
    "date_of_designation_or_refusal": "26/03/2014",
    "intended_use": "Treatment of Charcot-Marie-Tooth disease type 1A",
    "eu_designation_number": "EU/3/14/1260",
    "status": "Positive",
    "first_published_date": "07/05/2014",
    "last_updated_date": "16/07/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1260"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human monoclonal antibody targeting Staphylococcus aureus alpha-toxin (tosatoxumab)",
    "date_of_designation_or_refusal": "05/03/2012",
    "intended_use": "Treatment of pneumonia caused by Staphylococcus aureus",
    "eu_designation_number": "EU/3/12/968",
    "status": "Positive",
    "first_published_date": "06/07/2012",
    "last_updated_date": "13/07/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-968"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "gallium citrate",
    "date_of_designation_or_refusal": "21/08/2019",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/19/2189",
    "status": "Positive",
    "first_published_date": "14/01/2020",
    "last_updated_date": "13/07/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2189"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human monoclonal antibody against Pseudomonas aeruginosa serotype O11 (Panobacumab)",
    "date_of_designation_or_refusal": "29/06/2006",
    "intended_use": "Treatment of pneumonia caused by serotype O11 Pseudomonas aeruginosa",
    "eu_designation_number": "EU/3/06/381",
    "status": "Positive",
    "first_published_date": "15/05/2009",
    "last_updated_date": "13/07/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-381"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "dimethyl fumarate",
    "date_of_designation_or_refusal": "21/03/2018",
    "intended_use": "Treatment of Friedreich’s ataxia",
    "eu_designation_number": "EU/3/18/1990",
    "status": "Positive",
    "first_published_date": "15/05/2018",
    "last_updated_date": "08/07/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1990"
  },
  {
    "medicine_name": "Hemgenix",
    "related_ema_product_number": "EMEA/H/C/004827",
    "active_substance": "recombinant adeno-associated viral vector containing a codon-optimized Padua derivative of human coagulation factor IX cDNA (etranacogene dezaparvovec)",
    "date_of_designation_or_refusal": "21/03/2018",
    "intended_use": "Treatment of haemophilia B",
    "eu_designation_number": "EU/3/18/1999",
    "status": "Positive",
    "first_published_date": "17/05/2018",
    "last_updated_date": "01/07/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1999"
  },
  {
    "medicine_name": "Hepcludex",
    "related_ema_product_number": "EMEA/H/C/004854",
    "active_substance": "",
    "date_of_designation_or_refusal": "19/06/2015",
    "intended_use": "Treatment of hepatitis delta virus infection",
    "eu_designation_number": "EU/3/15/1500",
    "status": "Positive",
    "first_published_date": "27/07/2015",
    "last_updated_date": "30/06/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1500"
  },
  {
    "medicine_name": "Enspryng",
    "related_ema_product_number": "EMEA/H/C/004788",
    "active_substance": "Humanised anti-IL-6 receptor monoclonal antibody (satralizumab)",
    "date_of_designation_or_refusal": "27/06/2016",
    "intended_use": "Treatment of neuromyelitis optica spectrum disorders",
    "eu_designation_number": "EU/3/16/1680",
    "status": "Positive",
    "first_published_date": "26/07/2016",
    "last_updated_date": "30/06/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1680"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human acid ceramidase",
    "date_of_designation_or_refusal": "10/08/2015",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/15/1536",
    "status": "Positive",
    "first_published_date": "02/10/2015",
    "last_updated_date": "25/06/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1536"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human acid ceramidase",
    "date_of_designation_or_refusal": "19/02/2014",
    "intended_use": "Treatment of Farber disease",
    "eu_designation_number": "EU/3/14/1243",
    "status": "Positive",
    "first_published_date": "02/04/2014",
    "last_updated_date": "25/06/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1243"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human aspartylglucosaminidase",
    "date_of_designation_or_refusal": "15/01/2015",
    "intended_use": "Treatment of aspartylglucosaminuria",
    "eu_designation_number": "EU/3/14/1410",
    "status": "Withdrawn",
    "first_published_date": "05/03/2015",
    "last_updated_date": "25/06/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1410"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "chimeric group B adenovirus (11p/3) with deletions in the E3 and E4 regions (enadenotucirev)",
    "date_of_designation_or_refusal": "12/02/2015",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/15/1434",
    "status": "Withdrawn",
    "first_published_date": "08/04/2015",
    "last_updated_date": "25/06/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1434"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic hepatoblastoma cells encapsulated in alginate, ex vivo expanded",
    "date_of_designation_or_refusal": "21/08/2020",
    "intended_use": "Treatment of acute liver failure",
    "eu_designation_number": "EU/3/20/2312",
    "status": "Positive",
    "first_published_date": "25/11/2020",
    "last_updated_date": "24/06/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2312"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "bacterial lipase (burlulipase)",
    "date_of_designation_or_refusal": "07/11/2005",
    "intended_use": "Treatment of malabsorption due to exocrine pancreatic enzyme insufficiency",
    "eu_designation_number": "EU/3/05/323",
    "status": "Positive",
    "first_published_date": "09/02/2006",
    "last_updated_date": "21/06/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-323"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "hydrocortisone",
    "date_of_designation_or_refusal": "27/07/2005",
    "intended_use": "Treatment of congenital adrenal hyperplasia",
    "eu_designation_number": "EU/3/05/296",
    "status": "Positive",
    "first_published_date": "21/09/2009",
    "last_updated_date": "14/06/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-296"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 2/2 containing a gene encoding the channelrhodopsin-2 protein",
    "date_of_designation_or_refusal": "14/10/2016",
    "intended_use": "Treatment of retinitis pigmentosa",
    "eu_designation_number": "EU/3/16/1740",
    "status": "Withdrawn",
    "first_published_date": "15/11/2016",
    "last_updated_date": "11/06/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1740"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (bimiralisib)",
    "date_of_designation_or_refusal": "27/02/2017",
    "intended_use": "Treatment of diffuse large B-cell lymphoma",
    "eu_designation_number": "EU/3/17/1830",
    "status": "Positive",
    "first_published_date": "31/03/2017",
    "last_updated_date": "10/06/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1830"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "carglumic acid",
    "date_of_designation_or_refusal": "07/11/2008",
    "intended_use": "Treatment of propionic acidaemia",
    "eu_designation_number": "EU/3/08/577",
    "status": "Expired",
    "first_published_date": "02/04/2009",
    "last_updated_date": "09/06/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-577"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "carglumic acid",
    "date_of_designation_or_refusal": "07/11/2008",
    "intended_use": "Treatment of isovaleric acidaemia",
    "eu_designation_number": "EU/3/08/575",
    "status": "Expired",
    "first_published_date": "02/04/2009",
    "last_updated_date": "09/06/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-575"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "carglumic acid",
    "date_of_designation_or_refusal": "07/11/2008",
    "intended_use": "Treatment of methylmalonic acidaemia",
    "eu_designation_number": "EU/3/08/576",
    "status": "Expired",
    "first_published_date": "02/04/2009",
    "last_updated_date": "09/06/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-576"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "selinexor",
    "date_of_designation_or_refusal": "19/11/2014",
    "intended_use": "Treatment of plasma cell myeloma",
    "eu_designation_number": "EU/3/14/1355",
    "status": "Positive",
    "first_published_date": "15/01/2015",
    "last_updated_date": "07/06/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1355"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "R)-1-(3-(aminomethyl) phenyl)-N-(5-((3-cyanophenyl)(cyclopropylmethylamino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide dihydrochloride (berotralstat)",
    "date_of_designation_or_refusal": "27/06/2018",
    "intended_use": "Treatment of hereditary angioedema",
    "eu_designation_number": "EU/3/18/2028",
    "status": "Positive",
    "first_published_date": "21/08/2018",
    "last_updated_date": "01/06/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2028"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one",
    "date_of_designation_or_refusal": "17/07/2013",
    "intended_use": "Treatment of follicular lymphoma",
    "eu_designation_number": "EU/3/13/1157",
    "status": "Positive",
    "first_published_date": "16/08/2013",
    "last_updated_date": "31/05/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1157"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one (duvelisib)",
    "date_of_designation_or_refusal": "26/04/2013",
    "intended_use": "Treatment of chronic lymphocytic leukaemia / small lymphocytic lymphoma",
    "eu_designation_number": "EU/3/13/1125",
    "status": "Positive",
    "first_published_date": "14/05/2013",
    "last_updated_date": "31/05/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1125"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector expressing lipoprotein lipase (alipogene tiparvovec)",
    "date_of_designation_or_refusal": "09/03/2004",
    "intended_use": "Treatment of lipoprotein-lipase deficiency",
    "eu_designation_number": "EU/3/04/194",
    "status": "Withdrawn",
    "first_published_date": "07/03/2007",
    "last_updated_date": "31/05/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-194"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "4-[(3S)-3-aminopyrrolidin-1-yl]-6-cyano-5-(3,5-difluorophenyl)-N-[(2S)-1,1,1-trifluoropropan-2-yl]pyridine-3-carboxamide",
    "date_of_designation_or_refusal": "09/12/2020",
    "intended_use": "Treatment of congenital hyperinsulinism",
    "eu_designation_number": "EU/3/20/2376",
    "status": "Positive",
    "first_published_date": "27/05/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2376"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 9 encoding human ATP7B",
    "date_of_designation_or_refusal": "09/12/2020",
    "intended_use": "Treatment of Wilson's disease",
    "eu_designation_number": "EU/3/20/2378",
    "status": "Positive",
    "first_published_date": "27/05/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2378"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2’-O-(2-methoxyethyl) modified antisense oligonucleotide targeting glycogen synthase 1 pre‑mRNA",
    "date_of_designation_or_refusal": "09/12/2020",
    "intended_use": "Treatment of progressive myoclonic epilepsy type 2 (Lafora disease)",
    "eu_designation_number": "EU/3/20/2377",
    "status": "Positive",
    "first_published_date": "27/05/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2377"
  },
  {
    "medicine_name": "Nurzigma",
    "related_ema_product_number": "EMEA/H/C/006261",
    "active_substance": "4-[3-(Methylsulfonyl)phenyl]-1-propylpiperidine x HC1 (pridopidine hydrochloride)",
    "date_of_designation_or_refusal": "20/06/2005",
    "intended_use": "Treatment of Huntington’s disease",
    "eu_designation_number": "EU/3/05/288",
    "status": "Positive",
    "first_published_date": "04/07/2007",
    "last_updated_date": "26/05/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-288"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous CD4+ and CD8+ T cells genetically modified with a lentiviral vector encoding a B-cell maturation antigen-specific chimeric antigen receptor",
    "date_of_designation_or_refusal": "09/12/2020",
    "intended_use": "Treatment of multiple myeloma",
    "eu_designation_number": "EU/3/20/2366",
    "status": "Withdrawn",
    "first_published_date": "26/05/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2366"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised IgG1 monoclonal antibody against the extracellular domain of receptor tyrosine kinase-like orphan receptor 1 coupled via a proteolytically cleavable maleimidocaproyl-valine-citrulline-para-aminobenzoate linker to monomethyl auristatin E",
    "date_of_designation_or_refusal": "09/12/2020",
    "intended_use": "Treatment of mantle cell lymphoma",
    "eu_designation_number": "EU/3/20/2373",
    "status": "Positive",
    "first_published_date": "25/05/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2373"
  },
  {
    "medicine_name": "Spexotras",
    "related_ema_product_number": "EMEA/H/C/005886",
    "active_substance": "trametinib dimethyl sulfoxide",
    "date_of_designation_or_refusal": "09/12/2020",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/20/2374",
    "status": "Positive",
    "first_published_date": "25/05/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2374"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2'-O-(2-methoxyethyl) phosphorothioate antisense oligonucleotide targeting CD49d RNA",
    "date_of_designation_or_refusal": "09/12/2020",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/20/2375",
    "status": "Positive",
    "first_published_date": "25/05/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2375"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "aspacytarabine",
    "date_of_designation_or_refusal": "09/12/2020",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/20/2371",
    "status": "Positive",
    "first_published_date": "21/05/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2371"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus serotype rh74 containing the human sarcoglycan beta gene",
    "date_of_designation_or_refusal": "09/12/2020",
    "intended_use": "Treatment of limb-girdle muscular dystrophy",
    "eu_designation_number": "EU/3/20/2365",
    "status": "Positive",
    "first_published_date": "19/05/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2365"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea fumarate",
    "date_of_designation_or_refusal": "09/12/2020",
    "intended_use": "Treatment of Prader-Willi syndrome",
    "eu_designation_number": "EU/3/20/2367",
    "status": "Positive",
    "first_published_date": "19/05/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2367"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human interleukin 12 fused with immunoglobulin G4 C-terminal Fc fragment",
    "date_of_designation_or_refusal": "09/12/2020",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/20/2368",
    "status": "Positive",
    "first_published_date": "19/05/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2368"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "alpha galactosidase A",
    "date_of_designation_or_refusal": "06/01/2021",
    "intended_use": "Treatment of Fabry disease",
    "eu_designation_number": "EU/3/20/2396",
    "status": "Positive",
    "first_published_date": "18/05/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2396"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised IgG1K monoclonal antibody against interferon beta",
    "date_of_designation_or_refusal": "06/01/2021",
    "intended_use": "Treatment of dermatomyositis",
    "eu_designation_number": "EU/3/20/2392",
    "status": "Positive",
    "first_published_date": "18/05/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2392"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human laminin-111, recombinant",
    "date_of_designation_or_refusal": "06/01/2021",
    "intended_use": "Treatment of congenital muscular dystrophy",
    "eu_designation_number": "EU/3/20/2388",
    "status": "Positive",
    "first_published_date": "18/05/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2388"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium oxybate;calcium oxybate;magnesium oxybate;potassium oxybate",
    "date_of_designation_or_refusal": "06/01/2021",
    "intended_use": "Treatment of idiopathic hypersomnia",
    "eu_designation_number": "EU/3/20/2386",
    "status": "Positive",
    "first_published_date": "18/05/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2386"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "18-(p-(131I)-iodophenyl)octadecyl phosphocholine",
    "date_of_designation_or_refusal": "17/10/2019",
    "intended_use": "Treatment of multiple myeloma",
    "eu_designation_number": "EU/3/19/2204",
    "status": "Positive",
    "first_published_date": "21/01/2020",
    "last_updated_date": "11/05/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2204"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human alpha-1-microglobulin",
    "date_of_designation_or_refusal": "04/07/2014",
    "intended_use": "Treatment of pre-eclampsia",
    "eu_designation_number": "EU/3/14/1289",
    "status": "Withdrawn",
    "first_published_date": "16/07/2014",
    "last_updated_date": "11/05/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1289"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "teicoplanin",
    "date_of_designation_or_refusal": "23/08/2017",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/17/1913",
    "status": "Positive",
    "first_published_date": "17/10/2017",
    "last_updated_date": "06/05/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1913"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "anti-neonatal Fc receptor human monoclonal antibody",
    "date_of_designation_or_refusal": "17/10/2019",
    "intended_use": "Prevention of haemolytic disease of the foetus and newborn",
    "eu_designation_number": "EU/3/19/2209",
    "status": "Positive",
    "first_published_date": "22/01/2020",
    "last_updated_date": "05/05/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2209"
  },
  {
    "medicine_name": "Pemazyre",
    "related_ema_product_number": "EMEA/H/C/005266",
    "active_substance": "pemigatinib",
    "date_of_designation_or_refusal": "24/08/2018",
    "intended_use": "Treatment of biliary tract cancer",
    "eu_designation_number": "EU/3/18/2066",
    "status": "Positive",
    "first_published_date": "19/12/2018",
    "last_updated_date": "04/05/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2066"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tripotassium citrate monohydrate;potassium hydrogen carbonate",
    "date_of_designation_or_refusal": "20/06/2017",
    "intended_use": "Treatment of distal renal tubular acidosis",
    "eu_designation_number": "EU/3/17/1888",
    "status": "Withdrawn",
    "first_published_date": "17/07/2017",
    "last_updated_date": "03/05/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1888"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "L-cystine bis(N-methylpiperazide)",
    "date_of_designation_or_refusal": "27/06/2018",
    "intended_use": "Treatment of cystinuria",
    "eu_designation_number": "EU/3/18/2036",
    "status": "Positive",
    "first_published_date": "21/08/2018",
    "last_updated_date": "30/04/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2036"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Mexiletine hydrochloride",
    "date_of_designation_or_refusal": "07/06/2013",
    "intended_use": "Treatment of non-dystrophic myotonia",
    "eu_designation_number": "EU/3/13/1126",
    "status": "Positive",
    "first_published_date": "25/06/2013",
    "last_updated_date": "30/04/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1126"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "1,2:5,6-Dianhydrogalactitol",
    "date_of_designation_or_refusal": "24/01/2013",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/12/1093",
    "status": "Positive",
    "first_published_date": "01/03/2013",
    "last_updated_date": "28/04/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1093"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "codon-optimised human ornithine transcarbamylase mRNA complexed with lipid-based nanoparticles",
    "date_of_designation_or_refusal": "27/06/2018",
    "intended_use": "Treatment of ornithine transcarbamylase deficiency",
    "eu_designation_number": "EU/3/18/2033",
    "status": "Withdrawn",
    "first_published_date": "21/08/2018",
    "last_updated_date": "28/04/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2033"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "diclofenamide",
    "date_of_designation_or_refusal": "17/02/2016",
    "intended_use": "Treatment of periodic paralysis",
    "eu_designation_number": "EU/3/16/1616",
    "status": "Positive",
    "first_published_date": "07/04/2016",
    "last_updated_date": "26/04/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1616"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Eicosapentaenoic acid",
    "date_of_designation_or_refusal": "08/10/2009",
    "intended_use": "Treatment of familial adenomatous polyposis (FAP)",
    "eu_designation_number": "EU/3/09/666",
    "status": "Positive",
    "first_published_date": "20/10/2009",
    "last_updated_date": "22/04/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-666"
  },
  {
    "medicine_name": "Sogroya",
    "related_ema_product_number": "EMEA/H/C/005030",
    "active_substance": "somapacitan",
    "date_of_designation_or_refusal": "24/08/2018",
    "intended_use": "Treatment of growth hormone deficiency",
    "eu_designation_number": "EU/3/18/2068",
    "status": "Positive",
    "first_published_date": "19/12/2018",
    "last_updated_date": "15/04/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2068"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ribavirin",
    "date_of_designation_or_refusal": "21/02/2018",
    "intended_use": "Treatment of Lassa fever",
    "eu_designation_number": "EU/3/18/2003",
    "status": "Positive",
    "first_published_date": "15/05/2018",
    "last_updated_date": "12/04/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2003"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ribavirin",
    "date_of_designation_or_refusal": "21/03/2018",
    "intended_use": "Treatment of Crimean-Congo haemorrhagic fever",
    "eu_designation_number": "EU/3/18/2002",
    "status": "Positive",
    "first_published_date": "15/05/2018",
    "last_updated_date": "12/04/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2002"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Ixazomib",
    "date_of_designation_or_refusal": "08/11/2012",
    "intended_use": "Treatment of systemic light chain amyloidosis",
    "eu_designation_number": "EU/3/12/1060",
    "status": "Withdrawn",
    "first_published_date": "12/12/2012",
    "last_updated_date": "09/04/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1060"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 9 containing the human cardiac calsequestrin gene",
    "date_of_designation_or_refusal": "29/07/2014",
    "intended_use": "Treatment of catecholaminergic polymorphic ventricular tachycardia",
    "eu_designation_number": "EU/3/14/1296",
    "status": "Positive",
    "first_published_date": "01/09/2014",
    "last_updated_date": "09/04/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1296"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-((2-ethyl-6-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)-piperazin-1-yl)-8-methylimidazo[1,2-alpha]pyridin-3-yl)-(methyl)amino)-4-(4-fluorophenyl)-thiazole-5-carbonitrile (ziritaxestat)",
    "date_of_designation_or_refusal": "29/08/2016",
    "intended_use": "Treatment of idiopathic pulmonary fibrosis",
    "eu_designation_number": "EU/3/16/1712",
    "status": "Withdrawn",
    "first_published_date": "04/10/2016",
    "last_updated_date": "09/04/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1712"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "chimeric monoclonal antibody against claudin 6",
    "date_of_designation_or_refusal": "24/01/2013",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/12/1092",
    "status": "Withdrawn",
    "first_published_date": "01/03/2013",
    "last_updated_date": "08/04/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1092"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human glutamate oxaloacetate transaminase 1",
    "date_of_designation_or_refusal": "12/02/2015",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/15/1443",
    "status": "Withdrawn",
    "first_published_date": "09/04/2015",
    "last_updated_date": "07/04/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1443"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "synthetic 12 amino acid peptide designed after subcommissural organ-spondin",
    "date_of_designation_or_refusal": "13/11/2013",
    "intended_use": "Treatment of spinal cord injury",
    "eu_designation_number": "EU/3/13/1206",
    "status": "Positive",
    "first_published_date": "02/12/2013",
    "last_updated_date": "07/04/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1206"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "romilkimab",
    "date_of_designation_or_refusal": "09/01/2020",
    "intended_use": "Treatment of systemic sclerosis",
    "eu_designation_number": "EU/3/19/2246",
    "status": "Withdrawn",
    "first_published_date": "20/05/2020",
    "last_updated_date": "06/04/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2246"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ziritaxestat",
    "date_of_designation_or_refusal": "09/01/2020",
    "intended_use": "Treatment of systemic sclerosis",
    "eu_designation_number": "EU/3/19/2244",
    "status": "Withdrawn",
    "first_published_date": "20/05/2020",
    "last_updated_date": "06/04/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2244"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus serotype 9 containing the human ASPA gene",
    "date_of_designation_or_refusal": "04/06/2020",
    "intended_use": "Treatment of Canavan disease",
    "eu_designation_number": "EU/3/20/2287",
    "status": "Positive",
    "first_published_date": "19/08/2020",
    "last_updated_date": "06/04/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2287"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "terguride",
    "date_of_designation_or_refusal": "24/01/2013",
    "intended_use": "Treatment of systemic sclerosis",
    "eu_designation_number": "EU/3/12/1096",
    "status": "Withdrawn",
    "first_published_date": "01/03/2013",
    "last_updated_date": "22/03/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1096"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Salmonella typhi Ty21a strain transfected with a plasmid vector encoding the human vascular endothelial growth factor receptor 2",
    "date_of_designation_or_refusal": "23/08/2017",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/17/1909",
    "status": "Positive",
    "first_published_date": "17/10/2017",
    "last_updated_date": "22/03/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1909"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Pirfenidone",
    "date_of_designation_or_refusal": "16/11/2004",
    "intended_use": "Treatment of idiopathic pulmonary fibrosis",
    "eu_designation_number": "EU/3/04/241",
    "status": "Expired",
    "first_published_date": "23/09/2009",
    "last_updated_date": "22/03/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-241"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "milciclib maleate",
    "date_of_designation_or_refusal": "08/11/2012",
    "intended_use": "Treatment of malignant thymoma",
    "eu_designation_number": "EU/3/12/1059",
    "status": "Withdrawn",
    "first_published_date": "09/07/2013",
    "last_updated_date": "22/03/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1059"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic umbilical cord blood CD34+ cells cultured ex vivo with Notch ligand Delta1 (dilanubicel)",
    "date_of_designation_or_refusal": "17/01/2018",
    "intended_use": "Treatment in haematopoietic stem cell transplantation",
    "eu_designation_number": "EU/3/17/1958",
    "status": "Withdrawn",
    "first_published_date": "14/03/2018",
    "last_updated_date": "22/03/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1958"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "genetically modified serotype 5/3 adenovirus coding for granulocyte macrophage colony-stimulating factor",
    "date_of_designation_or_refusal": "16/12/2014",
    "intended_use": "Treatment of malignant mesothelioma",
    "eu_designation_number": "EU/3/14/1398",
    "status": "Positive",
    "first_published_date": "26/02/2015",
    "last_updated_date": "19/03/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1398"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "genetically modified serotype 5/3 adenovirus coding for granulocyte-macrophage colony-stimulating factor",
    "date_of_designation_or_refusal": "19/06/2013",
    "intended_use": "Treatment of soft tissue sarcoma",
    "eu_designation_number": "EU/3/13/1145",
    "status": "Positive",
    "first_published_date": "11/07/2013",
    "last_updated_date": "19/03/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1145"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Levosimendan",
    "date_of_designation_or_refusal": "22/02/2018",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/18/1980",
    "status": "Withdrawn",
    "first_published_date": "11/04/2018",
    "last_updated_date": "19/03/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1980"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised single-chain monoclonal antibody against CD37 (otlertuzumab)",
    "date_of_designation_or_refusal": "06/12/2012",
    "intended_use": "Treatment chronic lymphocytic leukaemia",
    "eu_designation_number": "EU/3/12/1083",
    "status": "Withdrawn",
    "first_published_date": "25/01/2013",
    "last_updated_date": "19/03/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1083"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 8 containing the human UGT1A1 gene (volrubigene ralaparvovec)",
    "date_of_designation_or_refusal": "22/08/2014",
    "intended_use": "Treatment of Crigler-Najjar syndrome",
    "eu_designation_number": "EU/3/14/1321",
    "status": "Withdrawn",
    "first_published_date": "01/10/2014",
    "last_updated_date": "19/03/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1321"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "nimorazole maleate",
    "date_of_designation_or_refusal": "09/02/2012",
    "intended_use": "Treatment of squamous-cell carcinoma of the head and neck in patients undergoing radiotherapy",
    "eu_designation_number": "EU/3/12/952",
    "status": "Withdrawn",
    "first_published_date": "01/03/2012",
    "last_updated_date": "19/03/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-952"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "three chimeric human/murine monoclonal antibodies against the Ebola (Zaire) surface glycoprotein (porgaviximab)",
    "date_of_designation_or_refusal": "09/10/2015",
    "intended_use": "Treatment for Ebola virus disease",
    "eu_designation_number": "EU/3/15/1558",
    "status": "Withdrawn",
    "first_published_date": "18/11/2015",
    "last_updated_date": "19/03/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1558"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "R-1-[2,3-dihydro-2-oxo-1-pivaloylmethyl-5-(2-pyridyl)-1 H-1,4-benzodiazepin-3-yl]-3-(3-methylaminophenyl)urea (netazepide)",
    "date_of_designation_or_refusal": "14/06/2007",
    "intended_use": "Treatment of gastric carcinoid",
    "eu_designation_number": "EU/3/07/452",
    "status": "Positive",
    "first_published_date": "19/07/2007",
    "last_updated_date": "02/03/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-452"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-(4-(1-cyanocyclopentyl)phenyl)-2-(4-pyridinylmethyl)amino-3-pyridinecarboxamide methanesulfonate",
    "date_of_designation_or_refusal": "27/02/2017",
    "intended_use": "Treatment of gastric cancer",
    "eu_designation_number": "EU/3/17/1840",
    "status": "Positive",
    "first_published_date": "31/03/2017",
    "last_updated_date": "02/03/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1840"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-acetylgalactosamine-conjugated synthetic double-stranded oligomer specific to serpin family A member 1 gene",
    "date_of_designation_or_refusal": "31/07/2018",
    "intended_use": "Treatment of congenital alpha-1 antitrypsin deficiency",
    "eu_designation_number": "EU/3/18/2048",
    "status": "Positive",
    "first_published_date": "11/10/2018",
    "last_updated_date": "02/03/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2048"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tadekinig alfa",
    "date_of_designation_or_refusal": "14/10/2016",
    "intended_use": "Treatment of haemophagocytic lymphohistiocytosis",
    "eu_designation_number": "EU/3/16/1763",
    "status": "Positive",
    "first_published_date": "15/11/2016",
    "last_updated_date": "19/02/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1763"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "miglustat",
    "date_of_designation_or_refusal": "19/10/2020",
    "intended_use": "Treatment of neuronal ceroid lipofuscinosis",
    "eu_designation_number": "EU/3/20/2349",
    "status": "Positive",
    "first_published_date": "18/02/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2349"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "poly(oxy-1,2-ethanediyl), alpha-(carboxymethyl)-omega-methoxy-, amide with cystathionine γ-lyase [Pyridoxal 5’-phosphate cofactor] (synthetic engineered human), tetramer",
    "date_of_designation_or_refusal": "19/10/2020",
    "intended_use": "Treatment of homocystinuria",
    "eu_designation_number": "EU/3/20/2348",
    "status": "Positive",
    "first_published_date": "18/02/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2348"
  },
  {
    "medicine_name": "Reblozyl",
    "related_ema_product_number": "EMEA/H/C/004444",
    "active_substance": "recombinant fusion protein consisting of a modified form of the extracellular domain of human activin receptor IIB linked to the human IgG1 Fc domain (luspatercept)",
    "date_of_designation_or_refusal": "22/08/2014",
    "intended_use": "Treatment of myelodysplastic syndromes",
    "eu_designation_number": "EU/3/14/1331",
    "status": "Positive",
    "first_published_date": "29/09/2014",
    "last_updated_date": "18/02/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1331"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Luspatercept",
    "date_of_designation_or_refusal": "28/02/2020",
    "intended_use": "Treatment of myelofibrosis",
    "eu_designation_number": "EU/3/20/2255",
    "status": "Positive",
    "first_published_date": "06/05/2020",
    "last_updated_date": "18/02/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2255"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus serotype hu68 containing the human GLB1 gene",
    "date_of_designation_or_refusal": "19/10/2020",
    "intended_use": "Treatment of GM1 gangliosidosis",
    "eu_designation_number": "EU/3/20/2346",
    "status": "Positive",
    "first_published_date": "16/02/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2346"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "retifanlimab",
    "date_of_designation_or_refusal": "19/10/2020",
    "intended_use": "Treatment of anal cancer",
    "eu_designation_number": "EU/3/20/2343",
    "status": "Positive",
    "first_published_date": "16/02/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2343"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Highly branched poly (beta-amino ester) complexed with a nanoplasmid containing the human COL7A1 gene",
    "date_of_designation_or_refusal": "19/10/2020",
    "intended_use": "Treatment of epidermolysis bullosa",
    "eu_designation_number": "EU/3/20/2342",
    "status": "Positive",
    "first_published_date": "16/02/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2342"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-(2-(18F)fluoropyridin-4-yl)-9H-pyrrolo[2,3-b:4,5-c']dipyridine",
    "date_of_designation_or_refusal": "19/10/2020",
    "intended_use": "Diagnosis of corticobasal degeneration",
    "eu_designation_number": "EU/3/20/2340",
    "status": "Positive",
    "first_published_date": "15/02/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2340"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "DNA plasmid encoding human transferrin gene",
    "date_of_designation_or_refusal": "13/11/2020",
    "intended_use": "Treatment of retinitis pigmentosa",
    "eu_designation_number": "EU/3/20/2364",
    "status": "Positive",
    "first_published_date": "15/02/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2364"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "decitabine;tetrahydrouridine",
    "date_of_designation_or_refusal": "19/10/2020",
    "intended_use": "Treatment of sickle cell disease",
    "eu_designation_number": "EU/3/20/2338",
    "status": "Positive",
    "first_published_date": "15/02/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2338"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(4-{(2S,4S)-4-ethoxy-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]piperidin-2-yl}benzoic acid-hydrogen chloride(1/1))",
    "date_of_designation_or_refusal": "19/10/2020",
    "intended_use": "Treatment of primary IgA nephropathy",
    "eu_designation_number": "EU/3/20/2336",
    "status": "Positive",
    "first_published_date": "15/02/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2336"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "triheptanoin",
    "date_of_designation_or_refusal": "13/11/2020",
    "intended_use": "Treatment of carnitine palmitoyltransferase I deficiency",
    "eu_designation_number": "EU/3/20/2360",
    "status": "Positive",
    "first_published_date": "15/02/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2360"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 9 expressing codon-optimized human GBA gene",
    "date_of_designation_or_refusal": "13/11/2020",
    "intended_use": "Treatment of frontotemporal dementia",
    "eu_designation_number": "EU/3/20/2359",
    "status": "Positive",
    "first_published_date": "15/02/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2359"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "L-pyroglutamyl-L-asparaginyl-L-prolyl-D-tyrosyl-D-tryptophan amide",
    "date_of_designation_or_refusal": "13/11/2020",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/20/2358",
    "status": "Positive",
    "first_published_date": "15/02/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2358"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "anti-(pancreatic adenocarcinoma upregulated factor) IgG1 humanised monoclonal antibody",
    "date_of_designation_or_refusal": "13/11/2020",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/20/2355",
    "status": "Positive",
    "first_published_date": "15/02/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2355"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(R)‑tetrahydrofuran‑3‑yl 4‑(6‑(5‑(4‑ethoxy‑1‑isopropylpiperidin‑4‑yl)pyridin-2-yl)pyrrolo[1,2-b]pyridazin-4-yl)piperazine-1-carboxylate sesquisuccinate",
    "date_of_designation_or_refusal": "13/11/2020",
    "intended_use": "Treatment of fibrodysplasia ossificans progressiva",
    "eu_designation_number": "EU/3/20/2352",
    "status": "Positive",
    "first_published_date": "15/02/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2352"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "retigabine",
    "date_of_designation_or_refusal": "19/10/2020",
    "intended_use": "Treatment of KCNQ2 developmental and epileptic encephalopathy",
    "eu_designation_number": "EU/3/20/2332",
    "status": "Positive",
    "first_published_date": "12/02/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2332"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "5-(Ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole (ezutromid)",
    "date_of_designation_or_refusal": "04/12/2008",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/08/591",
    "status": "Withdrawn",
    "first_published_date": "29/06/2009",
    "last_updated_date": "10/02/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-591"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "1-(3-methylbutanoyl)-L-aspartyl-L-threonyl-L-histidyl-L-phenylalanyl-L-prolyl-(L-cystinyl-L-isoleucyl-[(N6-(S)-4-carboxy-4-palmitamidobutanoyl)-L-lysinyl]-L-phenylalanyl-L-glutamyl-L-prolyl-L-arginyl-L-serinyl-L-lysinyl-L-glycinyl-L-cystinyl)-L-lysinamide, disulfide, acetate salt",
    "date_of_designation_or_refusal": "19/10/2020",
    "intended_use": "Treatment of polycythaemia vera",
    "eu_designation_number": "EU/3/20/2330",
    "status": "Positive",
    "first_published_date": "10/02/2021",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2330"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human monoclonal antibody against Pseudomonas aeruginosa IATS-O1",
    "date_of_designation_or_refusal": "28/01/2010",
    "intended_use": "Treatment of pneumonia caused by serotype O1 Pseudomonas aeruginosa",
    "eu_designation_number": "EU/3/09/705",
    "status": "Withdrawn",
    "first_published_date": "25/02/2010",
    "last_updated_date": "03/02/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-705"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "RNA, [P-deoxy-P-(dimethylamino)] (2',3'-dideoxy-2',3'-imino-2',3'-seco) (2'a→5') (C-m5U-m5U-A-C-A-G-G-C-m5U-C-C-A-A-m5U-A-G-m5U-G-G-m5U-C-A-G-m5U), 5' [P-[4-[[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]carbonyl]-1-piperazinyl]-N,N-dimethylaminophosphonamidate], 3'-[2'a-[N2-acetyl-L-arginyl-6-aminohexanoyl-L-arginyl-L-arginyl-β-alanyl-L-arginyl-L-arginyl-6-aminohexanoyl-L-arginyl-L-arginyl-β-alanyl-L-arginyl-6-aminohexanoyl-β-alanyl], octahydrochloride",
    "date_of_designation_or_refusal": "02/02/2010",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/09/725",
    "status": "Withdrawn",
    "first_published_date": "04/03/2010",
    "last_updated_date": "03/02/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-725"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium thiosulfate",
    "date_of_designation_or_refusal": "23/02/2011",
    "intended_use": "Treatment of calciphylaxis",
    "eu_designation_number": "EU/3/10/848",
    "status": "Withdrawn",
    "first_published_date": "07/03/2011",
    "last_updated_date": "03/02/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-848"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 8 containing the human UGT1A1 gene (volrubigene ralaparvovec)",
    "date_of_designation_or_refusal": "18/11/2016",
    "intended_use": "Treatment of Crigler-Najjar syndrome",
    "eu_designation_number": "EU/3/16/1772",
    "status": "Withdrawn",
    "first_published_date": "13/12/2016",
    "last_updated_date": "03/02/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1772"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "heparin-activated recombinant human fibroblast growth factor 1 (on a biodegradable device made from alpha-calcium sulfate hemihydrate)",
    "date_of_designation_or_refusal": "27/07/2010",
    "intended_use": "Treatment of traumatic spinal cord injury",
    "eu_designation_number": "EU/3/10/754",
    "status": "Withdrawn",
    "first_published_date": "05/08/2010",
    "last_updated_date": "03/02/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-754"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Poly(oxy-1,2-ethanediyl), alpha-hydro-omega-hydroxy-,15,15'-diester with N-acetyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-alpha-aspartyl-L-tryptophylglycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-L-threonyl-2-[2-(2-aminoethoxy)ethoxy]acetyl-N6-carboxy-L-lysinamide cyclic (2.fwdarw.12)-(disulfide); where two identical synthetic peptide domains are covalently linked at the ends of the polyethylene glycol chain (pegcetacoplan)",
    "date_of_designation_or_refusal": "21/08/2019",
    "intended_use": "Treatment of C3 glomerulopathy",
    "eu_designation_number": "EU/3/19/2201",
    "status": "Positive",
    "first_published_date": "16/01/2020",
    "last_updated_date": "03/02/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2201"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-isopropyl-3H-naphtho[1,2-d]imidazole-4,5-dione",
    "date_of_designation_or_refusal": "12/12/2017",
    "intended_use": "Treatment of mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes",
    "eu_designation_number": "EU/3/17/1947",
    "status": "Positive",
    "first_published_date": "23/01/2018",
    "last_updated_date": "03/02/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1947"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ciclosporin",
    "date_of_designation_or_refusal": "01/10/2010",
    "intended_use": "Treatment of moderate and severe closed traumatic brain injury",
    "eu_designation_number": "EU/3/10/791",
    "status": "Positive",
    "first_published_date": "14/10/2010",
    "last_updated_date": "03/02/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-791"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-Hydroxyoleic acid",
    "date_of_designation_or_refusal": "27/10/2011",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/11/916",
    "status": "Positive",
    "first_published_date": "23/11/2011",
    "last_updated_date": "03/02/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-916"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "",
    "date_of_designation_or_refusal": "09/02/2012",
    "intended_use": "Treatment of West syndrome",
    "eu_designation_number": "EU/3/12/953",
    "status": "Withdrawn",
    "first_published_date": "01/03/2012",
    "last_updated_date": "03/02/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-953"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "rovalpituzumab tesirine",
    "date_of_designation_or_refusal": "30/05/2016",
    "intended_use": "Treatment of small cell lung cancer",
    "eu_designation_number": "EU/3/16/1667",
    "status": "Withdrawn",
    "first_published_date": "23/06/2016",
    "last_updated_date": "03/02/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1667"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "oxalobacter formigenes strain HC-1",
    "date_of_designation_or_refusal": "17/02/2006",
    "intended_use": "Treatment of primary hyperoxaluria",
    "eu_designation_number": "EU/3/06/354",
    "status": "Positive",
    "first_published_date": "15/05/2009",
    "last_updated_date": "02/02/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-354"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "oxalobacter formigenes strain HC-1",
    "date_of_designation_or_refusal": "15/10/2014",
    "intended_use": "Treatment of short bowel syndrome",
    "eu_designation_number": "EU/3/14/1346",
    "status": "Positive",
    "first_published_date": "12/11/2014",
    "last_updated_date": "02/02/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1346"
  },
  {
    "medicine_name": "Pemazyre",
    "related_ema_product_number": "EMEA/H/C/005266",
    "active_substance": "pemigatinib",
    "date_of_designation_or_refusal": "17/10/2019",
    "intended_use": "Treatment of myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK",
    "eu_designation_number": "EU/3/19/2216",
    "status": "Positive",
    "first_published_date": "23/01/2020",
    "last_updated_date": "01/02/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2216"
  },
  {
    "medicine_name": "Elzonris",
    "related_ema_product_number": "EMEA/H/C/005031",
    "active_substance": "recombinant human interleukin-3 truncated diphtheria toxin fusion protein",
    "date_of_designation_or_refusal": "11/11/2015",
    "intended_use": "Treatment of blastic plasmacytoid dendritic cell neoplasm",
    "eu_designation_number": "EU/3/15/1567",
    "status": "Positive",
    "first_published_date": "05/01/2016",
    "last_updated_date": "25/01/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1567"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Oxytocin",
    "date_of_designation_or_refusal": "29/07/2014",
    "intended_use": "Treatment of Prader-Willi syndrome",
    "eu_designation_number": "EU/3/14/1302",
    "status": "Positive",
    "first_published_date": "01/09/2014",
    "last_updated_date": "25/01/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1302"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "rasagiline",
    "date_of_designation_or_refusal": "28/06/2019",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/19/2174",
    "status": "Withdrawn",
    "first_published_date": "10/10/2019",
    "last_updated_date": "12/01/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2174"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tetrahydrobiopterin",
    "date_of_designation_or_refusal": "08/06/2004",
    "intended_use": "Treatment of hyperphenylalaninaemia",
    "eu_designation_number": "EU/3/04/199",
    "status": "Withdrawn",
    "first_published_date": "18/08/2008",
    "last_updated_date": "11/01/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-199"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 2 containing the human REP1 gene (timrepigene emparvovec)",
    "date_of_designation_or_refusal": "24/08/2018",
    "intended_use": "Treatment of spinal muscular atrophy",
    "eu_designation_number": "EU/3/18/2060",
    "status": "Withdrawn",
    "first_published_date": "19/12/2018",
    "last_updated_date": "07/01/2021",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2060"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Miransertib",
    "date_of_designation_or_refusal": "21/03/2018",
    "intended_use": "Treatment of Proteus syndrome",
    "eu_designation_number": "EU/3/18/1997",
    "status": "Positive",
    "first_published_date": "15/05/2018",
    "last_updated_date": "22/12/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1997"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "antisense oligonucleotide targeting the F508delta mutation of CFTR (eluforsen)",
    "date_of_designation_or_refusal": "07/10/2013",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/13/1195",
    "status": "Withdrawn",
    "first_published_date": "31/10/2013",
    "last_updated_date": "18/12/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1195"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "1-(6-benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic acid (lanifibranor)",
    "date_of_designation_or_refusal": "19/11/2014",
    "intended_use": "Treatment of systemic sclerosis",
    "eu_designation_number": "EU/3/14/1361",
    "status": "Withdrawn",
    "first_published_date": "15/01/2015",
    "last_updated_date": "14/12/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1361"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "5-amino-1-(2-methyl-1H-benzo[d]imidazol-5-yl)-1H-pyrazol-4-yl 1H-indol-2-yl ketone mono[(S)-2-hydroxysuccinate]",
    "date_of_designation_or_refusal": "16/10/2017",
    "intended_use": "Treatment of biliary tract cancer",
    "eu_designation_number": "EU/3/17/1916",
    "status": "Withdrawn",
    "first_published_date": "10/01/2018",
    "last_updated_date": "11/12/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1916"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant antibody derivative against human CD19 and CD3 (blinatumomab)",
    "date_of_designation_or_refusal": "01/12/2003",
    "intended_use": "Treatment of chronic lymphocytic leukaemia",
    "eu_designation_number": "EU/3/03/176",
    "status": "Withdrawn",
    "first_published_date": "04/01/2006",
    "last_updated_date": "11/12/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-176"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant antibody derivative against human CD19 and CD3 (blinatumomab)",
    "date_of_designation_or_refusal": "01/12/2003",
    "intended_use": "Treatment of mantle cell lymphoma",
    "eu_designation_number": "EU/3/03/175",
    "status": "Withdrawn",
    "first_published_date": "05/11/2004",
    "last_updated_date": "11/12/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-175"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "treosulfan",
    "date_of_designation_or_refusal": "22/02/2004",
    "intended_use": "Conditioning treatment prior to haematopoietic-progenitor-cell transplantation",
    "eu_designation_number": "EU/3/04/186",
    "status": "Positive",
    "first_published_date": "22/11/2004",
    "last_updated_date": "11/12/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-186"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pentetrazol",
    "date_of_designation_or_refusal": "11/11/2015",
    "intended_use": "Treatment of idiopathic hypersomnia",
    "eu_designation_number": "EU/3/15/1569",
    "status": "Withdrawn",
    "first_published_date": "06/01/2016",
    "last_updated_date": "10/12/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1569"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "copper meso-5,15-bis[3-[(1,2-dicarba-closo-dodecaboranyl)methoxy]phenyl]-meso-10,20-dinitroporphyrin",
    "date_of_designation_or_refusal": "27/06/2013",
    "intended_use": "Treatment of squamous-cell carcinoma of the head and neck in patients undergoing radiotherapy",
    "eu_designation_number": "EU/3/13/1138",
    "status": "Withdrawn",
    "first_published_date": "11/07/2013",
    "last_updated_date": "10/12/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1138"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Ecothiopate iodide",
    "date_of_designation_or_refusal": "24/04/2015",
    "intended_use": "Treatment of Stargardt's disease",
    "eu_designation_number": "EU/3/15/1474",
    "status": "Withdrawn",
    "first_published_date": "21/05/2015",
    "last_updated_date": "10/12/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1474"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allantoin",
    "date_of_designation_or_refusal": "16/01/2014",
    "intended_use": "Treatment of epidermolysis bullosa",
    "eu_designation_number": "EU/3/13/1232",
    "status": "Withdrawn",
    "first_published_date": "24/03/2014",
    "last_updated_date": "10/12/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1232"
  },
  {
    "medicine_name": "Dovprela (previously Pretomanid FGK)",
    "related_ema_product_number": "EMEA/H/C/005167",
    "active_substance": "(S)-2-nitro-6-(4-trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo[2,1-b] [1,3] oxazine (pretomanid)",
    "date_of_designation_or_refusal": "29/11/2007",
    "intended_use": "Treatment of tuberculosis",
    "eu_designation_number": "EU/3/07/513",
    "status": "Positive",
    "first_published_date": "02/07/2008",
    "last_updated_date": "09/12/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-513"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "alpha-1 proteinase inhibitor",
    "date_of_designation_or_refusal": "14/09/2007",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/07/474",
    "status": "Withdrawn",
    "first_published_date": "17/01/2008",
    "last_updated_date": "08/12/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-474"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium cromoglicate",
    "date_of_designation_or_refusal": "26/06/2020",
    "intended_use": "Treatment of idiopathic pulmonary fibrosis",
    "eu_designation_number": "EU/3/20/2294",
    "status": "Withdrawn",
    "first_published_date": "23/09/2020",
    "last_updated_date": "08/12/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2294"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector expressing acid alpha-glucosidase gene",
    "date_of_designation_or_refusal": "27/07/2020",
    "intended_use": "Treatment of glycogen storage disease type II (Pompe's disease)",
    "eu_designation_number": "EU/3/20/2303",
    "status": "Positive",
    "first_published_date": "19/11/2020",
    "last_updated_date": "08/12/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2303"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "L-cysteine, L-leucyl-L-alpha-glutamyl-L-alpha-glutamyl-L-lysyl-L-lysylglycyl-L-asparaginyl-L-tyrosyl-L-valyl-L-valyl-L-threonyl-L-alpha-aspartyl-L-histidyl-S-[1-[(4-carboxycyclohexyl)methyl]-2,5-dioxo-3-pyrrolidinyl]-complex with keyhole limpet haemocyanin",
    "date_of_designation_or_refusal": "27/10/2011",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/11/923",
    "status": "Withdrawn",
    "first_published_date": "23/11/2011",
    "last_updated_date": "04/12/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-923"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Adeno-associated viral vector serotype Anc80 containing the truncated human ATP7B gene under the control of the human alpha-1 antitrypsin promoter",
    "date_of_designation_or_refusal": "23/08/2017",
    "intended_use": "Treatment of Wilson's disease",
    "eu_designation_number": "EU/3/17/1898",
    "status": "Withdrawn",
    "first_published_date": "17/10/2017",
    "last_updated_date": "03/12/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1898"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium (2R,3S,5R)-5-(4-amino-2-oxo-1,3,5-triazin-1(2H)-yl)-2-(hydroxymethyl)tetrahydrofuran-3-yl ((2R,3S,5R)-5-(2-amino-6-oxo-1H-purin-9(6H)-yl)-3-hydroxytetrahydrofuran-2-yl)methyl phosphate (guadecitabine)",
    "date_of_designation_or_refusal": "14/12/2015",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/15/1597",
    "status": "Withdrawn",
    "first_published_date": "03/02/2016",
    "last_updated_date": "01/12/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1597"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human bone morphogenetic protein 4",
    "date_of_designation_or_refusal": "15/10/2014",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/14/1348",
    "status": "Positive",
    "first_published_date": "12/11/2014",
    "last_updated_date": "30/11/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1348"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "obiltoxaximab",
    "date_of_designation_or_refusal": "24/08/2018",
    "intended_use": "Treatment of anthrax",
    "eu_designation_number": "EU/3/18/2065",
    "status": "Withdrawn",
    "first_published_date": "19/12/2018",
    "last_updated_date": "27/11/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2065"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Picropodophyllin",
    "date_of_designation_or_refusal": "23/08/2017",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/17/1904",
    "status": "Positive",
    "first_published_date": "17/10/2017",
    "last_updated_date": "27/11/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1904"
  },
  {
    "medicine_name": "Oxlumo",
    "related_ema_product_number": "EMEA/H/C/005040",
    "active_substance": "synthetic double-stranded siRNA oligonucleotide directed against hydroxyacid oxidase 1 mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues (lumasiran)",
    "date_of_designation_or_refusal": "21/03/2016",
    "intended_use": "Treatment of primary hyperoxaluria",
    "eu_designation_number": "EU/3/16/1637",
    "status": "Positive",
    "first_published_date": "02/05/2016",
    "last_updated_date": "25/11/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1637"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "dextran sulfate low molecular weight",
    "date_of_designation_or_refusal": "21/08/2020",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/20/2318",
    "status": "Positive",
    "first_published_date": "25/11/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2318"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "copper histidinate",
    "date_of_designation_or_refusal": "21/08/2020",
    "intended_use": "Treatment of Menkes disease",
    "eu_designation_number": "EU/3/20/2320",
    "status": "Positive",
    "first_published_date": "25/11/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2320"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 3B encoding shortened human ATP7B",
    "date_of_designation_or_refusal": "21/08/2020",
    "intended_use": "Treatment of Wilson's disease",
    "eu_designation_number": "EU/3/20/2321",
    "status": "Positive",
    "first_published_date": "25/11/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2321"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "trehalose",
    "date_of_designation_or_refusal": "21/08/2020",
    "intended_use": "Treatment of mucopolysaccharidosis type III (Sanfilippo syndrome)",
    "eu_designation_number": "EU/3/20/2323",
    "status": "Positive",
    "first_published_date": "25/11/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2323"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous T cells transduced with lentiviral vector containing a tandem chimeric antigen receptor directed against CD20 and CD19",
    "date_of_designation_or_refusal": "21/08/2020",
    "intended_use": "Treatment of diffuse large B-cell lymphoma",
    "eu_designation_number": "EU/3/20/2327",
    "status": "Positive",
    "first_published_date": "25/11/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2327"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human frataxin fused to TAT cell-penetrating peptide",
    "date_of_designation_or_refusal": "21/08/2020",
    "intended_use": "Treatment of Friedreich’s ataxia",
    "eu_designation_number": "EU/3/20/2328",
    "status": "Positive",
    "first_published_date": "25/11/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2328"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic T-cell precursors, mobilised peripheral blood-derived, ex vivo cultured",
    "date_of_designation_or_refusal": "21/08/2020",
    "intended_use": "Treatment in haematopoietic stem cell transplantation",
    "eu_designation_number": "EU/3/20/2317",
    "status": "Positive",
    "first_published_date": "25/11/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2317"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-(2-(18F)fluoropyridin-4-yl)-9H-pyrrolo[2,3-b:4,5-c']dipyridine",
    "date_of_designation_or_refusal": "21/08/2020",
    "intended_use": "Diagnosis of progressive supranuclear palsy",
    "eu_designation_number": "EU/3/20/2313",
    "status": "Positive",
    "first_published_date": "25/11/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2313"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Adeno-associated virus serotype 2/8 vector containing the human PDE6A gene",
    "date_of_designation_or_refusal": "21/08/2020",
    "intended_use": "Treatment of retinitis pigmentosa",
    "eu_designation_number": "EU/3/20/2310",
    "status": "Positive",
    "first_published_date": "25/11/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2310"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "hydroxychloroquine",
    "date_of_designation_or_refusal": "12/01/2017",
    "intended_use": "Treatment of antiphospholipid syndrome",
    "eu_designation_number": "EU/3/16/1820",
    "status": "Positive",
    "first_published_date": "13/07/2017",
    "last_updated_date": "24/11/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1820"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic umbilical cord tissue-derived mesenchymal stromal cells ex vivo expanded",
    "date_of_designation_or_refusal": "21/08/2020",
    "intended_use": "Prevention of bronchopulmonary dysplasia",
    "eu_designation_number": "EU/3/20/2308",
    "status": "Positive",
    "first_published_date": "24/11/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2308"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised monoclonal antibody against P-selectin (crizanlizumab)",
    "date_of_designation_or_refusal": "09/08/2012",
    "intended_use": "Treatment of sickle cell disease",
    "eu_designation_number": "EU/3/12/1034",
    "status": "Positive",
    "first_published_date": "26/09/2012",
    "last_updated_date": "24/11/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1034"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "retinol palmitate",
    "date_of_designation_or_refusal": "27/07/2020",
    "intended_use": "Prevention of bronchopulmonary dysplasia",
    "eu_designation_number": "EU/3/20/2306",
    "status": "Positive",
    "first_published_date": "19/11/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2306"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tinostamustine",
    "date_of_designation_or_refusal": "27/07/2020",
    "intended_use": "Treatment of T-cell prolymphocytic leukaemia",
    "eu_designation_number": "EU/3/20/2307",
    "status": "Positive",
    "first_published_date": "19/11/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2307"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "benzyl benzoate;beta-caryophyllene;cineole;cinnamaldehyde;cinnamyl acetate;linalool;trans-2-methoxycinnamaldehyde",
    "date_of_designation_or_refusal": "18/06/2020",
    "intended_use": "Treatment of eumycetoma",
    "eu_designation_number": "-",
    "status": "Negative",
    "first_published_date": "19/11/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-eumycetoma"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "melatonin",
    "date_of_designation_or_refusal": "06/07/2020",
    "intended_use": "Treatment of intracerebral haemorrhage",
    "eu_designation_number": "-",
    "status": "Negative",
    "first_published_date": "19/11/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-intracerebral-haemorrhage"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "triheptanoin",
    "date_of_designation_or_refusal": "27/07/2020",
    "intended_use": "Treatment of carnitine-acylcarnitine translocase deficiency",
    "eu_designation_number": "EU/3/20/2302",
    "status": "Positive",
    "first_published_date": "19/11/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2302"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "fasudil hydrochloride",
    "date_of_designation_or_refusal": "27/07/2020",
    "intended_use": "Treatment of non-traumatic subarachnoid haemorrhage",
    "eu_designation_number": "EU/3/20/2300",
    "status": "Positive",
    "first_published_date": "19/11/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2300"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "C-type natriuretic peptide conjugated to multi-arm polyethylene glycol carrier through a cleavable linker",
    "date_of_designation_or_refusal": "27/07/2020",
    "intended_use": "Treatment of achondroplasia",
    "eu_designation_number": "EU/3/20/2299",
    "status": "Positive",
    "first_published_date": "19/11/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2299"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Hemopexin",
    "date_of_designation_or_refusal": "27/07/2020",
    "intended_use": "Treatment of sickle cell disease",
    "eu_designation_number": "EU/3/20/2298",
    "status": "Positive",
    "first_published_date": "19/11/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2298"
  },
  {
    "medicine_name": "Mepsevii",
    "related_ema_product_number": "EMEA/H/C/004438",
    "active_substance": "recombinant human beta-glucuronidase (vestronidase alfa)",
    "date_of_designation_or_refusal": "21/03/2012",
    "intended_use": "Treatment of mucopolysaccharidosis type VII (Sly syndrome)",
    "eu_designation_number": "EU/3/12/973",
    "status": "Positive",
    "first_published_date": "19/04/2012",
    "last_updated_date": "11/11/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-973"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "acalabrutinib",
    "date_of_designation_or_refusal": "21/03/2016",
    "intended_use": "Treatment of chronic lymphocytic leukaemia / small lymphocytic lymphoma",
    "eu_designation_number": "EU/3/16/1624",
    "status": "Withdrawn",
    "first_published_date": "02/05/2016",
    "last_updated_date": "11/11/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1624"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "triheptanoin",
    "date_of_designation_or_refusal": "28/07/2015",
    "intended_use": "Treatment of carnitine palmitoyltransferase II deficiency",
    "eu_designation_number": "EU/3/15/1526",
    "status": "Positive",
    "first_published_date": "18/08/2015",
    "last_updated_date": "11/11/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1526"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "triheptanoin",
    "date_of_designation_or_refusal": "28/07/2015",
    "intended_use": "Treatment of mitochondrial trifunctional protein deficiency",
    "eu_designation_number": "EU/3/15/1525",
    "status": "Positive",
    "first_published_date": "18/12/2015",
    "last_updated_date": "11/11/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1525"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "triheptanoin",
    "date_of_designation_or_refusal": "28/07/2015",
    "intended_use": "Treatment of long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency",
    "eu_designation_number": "EU/3/15/1524",
    "status": "Positive",
    "first_published_date": "18/08/2015",
    "last_updated_date": "11/11/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1524"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "triheptanoin",
    "date_of_designation_or_refusal": "19/06/2015",
    "intended_use": "Treatment of very long-chain acyl-CoA dehydrogenase deficiency",
    "eu_designation_number": "EU/3/15/1508",
    "status": "Positive",
    "first_published_date": "27/07/2015",
    "last_updated_date": "11/11/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1508"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 8 containing the human glucose-6-phosphatase gene (pariglasgene brecaparvovec)",
    "date_of_designation_or_refusal": "18/11/2016",
    "intended_use": "treatment of glycogen storage disease type Ia",
    "eu_designation_number": "EU/3/16/1771",
    "status": "Positive",
    "first_published_date": "14/12/2016",
    "last_updated_date": "11/11/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1771"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 8 encoding human ornithine transcarbamylase (avalotcagene ontaparvovec)",
    "date_of_designation_or_refusal": "21/03/2016",
    "intended_use": "Treatment of ornithine transcarbamylase deficiency",
    "eu_designation_number": "EU/3/16/1623",
    "status": "Positive",
    "first_published_date": "04/05/2016",
    "last_updated_date": "11/11/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1623"
  },
  {
    "medicine_name": "Zejula",
    "related_ema_product_number": "EMEA/H/C/004249",
    "active_substance": "(3S)-3-{4-[7-(aminocarbonyl)-2H-indazol-2-yl] phenyl} piperidine tosilate monohydrate salt (niraparib)",
    "date_of_designation_or_refusal": "04/08/2010",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/10/760",
    "status": "Positive",
    "first_published_date": "11/08/2010",
    "last_updated_date": "06/11/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-760"
  },
  {
    "medicine_name": "Arikayce liposomal",
    "related_ema_product_number": "EMEA/H/C/005264",
    "active_substance": "amikacin sulfate",
    "date_of_designation_or_refusal": "08/04/2014",
    "intended_use": "Treatment of nontuberculous mycobacterial lung disease",
    "eu_designation_number": "EU/3/14/1259",
    "status": "Positive",
    "first_published_date": "07/05/2014",
    "last_updated_date": "03/11/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1259"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "amikacin sulfate",
    "date_of_designation_or_refusal": "25/07/2006",
    "intended_use": "Treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis",
    "eu_designation_number": "EU/3/06/387",
    "status": "Positive",
    "first_published_date": "02/04/2009",
    "last_updated_date": "03/11/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-387"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "5,7-dichloro-2-((ethylamino)methyl)-8-hydroxy-3-methylquinazolin-4(3H)-one mesilate",
    "date_of_designation_or_refusal": "16/12/2019",
    "intended_use": "Treatment of multiple system atrophy",
    "eu_designation_number": "EU/3/19/2228",
    "status": "Positive",
    "first_published_date": "25/02/2020",
    "last_updated_date": "27/10/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2228"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised monoclonal antibody against myostatin (domagrozumab)",
    "date_of_designation_or_refusal": "08/02/2013",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/13/1105",
    "status": "Withdrawn",
    "first_published_date": "04/03/2013",
    "last_updated_date": "23/10/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1105"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Mepolizumab",
    "date_of_designation_or_refusal": "12/03/2013",
    "intended_use": "Treatment of Churg-Strauss syndrome",
    "eu_designation_number": "EU/3/13/1116",
    "status": "Withdrawn",
    "first_published_date": "05/04/2013",
    "last_updated_date": "23/10/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1116"
  },
  {
    "medicine_name": "Bosatria; Bosatria",
    "related_ema_product_number": "EMEA/H/C/001069; EMEA/H/C/001069",
    "active_substance": "Mepolizumab",
    "date_of_designation_or_refusal": "29/07/2004",
    "intended_use": "Treatment of hypereosinophilic syndrome",
    "eu_designation_number": "EU/3/04/213",
    "status": "Withdrawn",
    "first_published_date": "23/09/2009",
    "last_updated_date": "23/10/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-213"
  },
  {
    "medicine_name": "Elevidys",
    "related_ema_product_number": "EMEA/H/C/005293",
    "active_substance": "adeno-associated virus serotype rh74 containing the human micro-dystrophin gene",
    "date_of_designation_or_refusal": "28/02/2020",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/20/2250",
    "status": "Positive",
    "first_published_date": "05/05/2020",
    "last_updated_date": "22/10/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2250"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "somatropin",
    "date_of_designation_or_refusal": "08/08/2000",
    "intended_use": "AIDS wasting",
    "eu_designation_number": "EU/3/00/001",
    "status": "Withdrawn",
    "first_published_date": "03/03/2009",
    "last_updated_date": "15/10/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-00-001"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-hydroxymethyl-2-methoxymethyl-1-azabicyclo[2,2,2]octan-3-one",
    "date_of_designation_or_refusal": "16/12/2014",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/14/1386",
    "status": "Positive",
    "first_published_date": "26/02/2015",
    "last_updated_date": "13/10/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1386"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-(hydroxymethyl)-2-(methoxymethyl)-1-azabicyclo[2.2.2]octan-3-one",
    "date_of_designation_or_refusal": "25/07/2019",
    "intended_use": "Treatment of myelodysplastic syndromes",
    "eu_designation_number": "EU/3/19/2180",
    "status": "Positive",
    "first_published_date": "24/09/2019",
    "last_updated_date": "13/10/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2180"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-Methoxymethyl-2-hydroxymethyl-1-azabicyclo[2,2,2]octan-3-one",
    "date_of_designation_or_refusal": "10/06/2010",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/10/742",
    "status": "Positive",
    "first_published_date": "25/06/2010",
    "last_updated_date": "13/10/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-742"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2ʹ-O-(2-methoxyethyl) antisense oligonucleotide targeting microtubule-associated protein tau pre-mRNA",
    "date_of_designation_or_refusal": "31/07/2018",
    "intended_use": "treatment of behavioural variant frontotemporal dementia",
    "eu_designation_number": "EU/3/18/2041",
    "status": "Positive",
    "first_published_date": "11/10/2018",
    "last_updated_date": "13/10/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2041"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "DNA plasmid encoding a recombinant fusion protein consisting of the extracellular domain of human TNFα p55 receptor linked to the human IgG1 Fc domain",
    "date_of_designation_or_refusal": "17/02/2016",
    "intended_use": "Treatment of non-infectious uveitis",
    "eu_designation_number": "EU/3/16/1619",
    "status": "Positive",
    "first_published_date": "07/04/2016",
    "last_updated_date": "29/09/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1619"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "synthetic glucagon analogue modified to contain 7 amino acid substitutions",
    "date_of_designation_or_refusal": "20/06/2017",
    "intended_use": "Treatment of congenital hyperinsulinism",
    "eu_designation_number": "EU/3/17/1887",
    "status": "Positive",
    "first_published_date": "17/07/2017",
    "last_updated_date": "25/09/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1887"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Lys40(NODAGA-68Ga)NH2-exendin-4",
    "date_of_designation_or_refusal": "26/06/2020",
    "intended_use": "Diagnosis of insulinoma",
    "eu_designation_number": "EU/3/20/2295",
    "status": "Positive",
    "first_published_date": "24/09/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2295"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "stiripentol",
    "date_of_designation_or_refusal": "26/06/2020",
    "intended_use": "Treatment of primary hyperoxaluria",
    "eu_designation_number": "EU/3/20/2290",
    "status": "Positive",
    "first_published_date": "22/09/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2290"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "onfekafusp alfa",
    "date_of_designation_or_refusal": "26/06/2020",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/20/2291",
    "status": "Positive",
    "first_published_date": "22/09/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2291"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 8 containing the human MTM1 gene (resamirigene bilparvovec)",
    "date_of_designation_or_refusal": "10/08/2015",
    "intended_use": "Treatment of X-linked myotubular myopathy",
    "eu_designation_number": "EU/3/15/1539",
    "status": "Positive",
    "first_published_date": "02/10/2015",
    "last_updated_date": "18/09/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1539"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-[4-Methoxy-3-(2-m-tolyl-ethoxy)-benzoylamino]-indan-2-carboxylic acid",
    "date_of_designation_or_refusal": "12/03/2013",
    "intended_use": "Treatment of systemic sclerosis",
    "eu_designation_number": "EU/3/13/1108",
    "status": "Positive",
    "first_published_date": "05/04/2013",
    "last_updated_date": "18/09/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1108"
  },
  {
    "medicine_name": "Idefirix",
    "related_ema_product_number": "EMEA/H/C/004849",
    "active_substance": "recombinant IgG degrading enzyme of Streptococcus pyogenes (imlifidase)",
    "date_of_designation_or_refusal": "12/01/2017",
    "intended_use": "Prevention of graft rejection following solid organ transplantation",
    "eu_designation_number": "EU/3/16/1826",
    "status": "Positive",
    "first_published_date": "14/07/2017",
    "last_updated_date": "28/08/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1826"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(16E)-14-methyl-20-oxa-5,7,14,26-tetraaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene–citric acid",
    "date_of_designation_or_refusal": "17/10/2019",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/19/2202",
    "status": "Positive",
    "first_published_date": "21/01/2020",
    "last_updated_date": "27/08/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2202"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous stromal vascular cell fraction from adipose tissue",
    "date_of_designation_or_refusal": "28/04/2016",
    "intended_use": "Treatment of systemic sclerosis",
    "eu_designation_number": "EU/3/16/1643",
    "status": "Withdrawn",
    "first_published_date": "31/05/2016",
    "last_updated_date": "27/08/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1643"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous adult live cultured osteoblasts",
    "date_of_designation_or_refusal": "26/02/2019",
    "intended_use": "Treatment of non-traumatic osteonecrosis",
    "eu_designation_number": "EU/3/19/2139",
    "status": "Positive",
    "first_published_date": "09/04/2019",
    "last_updated_date": "27/08/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2139"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "P-ethoxy growth factor receptor-bound protein 2 antisense oligonucleotide",
    "date_of_designation_or_refusal": "14/10/2016",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/16/1758",
    "status": "Positive",
    "first_published_date": "15/11/2016",
    "last_updated_date": "27/08/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1758"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "balipodect",
    "date_of_designation_or_refusal": "14/04/2019",
    "intended_use": "Treatment of fragile X syndrome",
    "eu_designation_number": "EU/3/19/2154",
    "status": "Positive",
    "first_published_date": "14/06/2019",
    "last_updated_date": "26/08/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2154"
  },
  {
    "medicine_name": "Ninlaro",
    "related_ema_product_number": "EMEA/H/C/003844",
    "active_substance": "2,2'-{2-[(1R)-1-({[(2,5-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]-5-oxo-1,3,2-dioxaborolane-4,4-diyl}diacetic acid",
    "date_of_designation_or_refusal": "27/09/2011",
    "intended_use": "Treatment of multiple myeloma",
    "eu_designation_number": "EU/3/11/899",
    "status": "Positive",
    "first_published_date": "07/12/2016",
    "last_updated_date": "26/08/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-899"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Ile-Ala-Leu-Ile-Leu-Glu-Pro-Ile-Cys-Cys-Gln-Glu-Arg-Ala-Ala-(discrete-polyethylene glycol)24",
    "date_of_designation_or_refusal": "04/06/2020",
    "intended_use": "Treatment of neonatal encephalopathy",
    "eu_designation_number": "EU/3/20/2283",
    "status": "Positive",
    "first_published_date": "19/08/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2283"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "1-((2S,4S)-2-((((S)-(4-bromophenoxy)(((S)-1-oxo-1-(((S)-pentan-2-yl)oxy)propan-2-yl)amino)phosphoryl)oxy)methyl)-1,3-dioxolan-4-yl)-2-oxo-1,2-dihydropyrimidin-4-aminium chloride",
    "date_of_designation_or_refusal": "04/06/2020",
    "intended_use": "Treatment of hepatocellular carcinoma",
    "eu_designation_number": "EU/3/20/2285",
    "status": "Positive",
    "first_published_date": "19/08/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2285"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous CD4+ and CD8+ T cells transduced with a lentiviral vector encoding an affinity enhanced T cell receptor specific to MAGE-A4",
    "date_of_designation_or_refusal": "04/06/2020",
    "intended_use": "Treatment of soft tissue sarcoma",
    "eu_designation_number": "EU/3/20/2286",
    "status": "Positive",
    "first_published_date": "19/08/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2286"
  },
  {
    "medicine_name": "Fabhalta",
    "related_ema_product_number": "EMEA/H/C/005764",
    "active_substance": "(4-{(2S,4S)-4-ethoxy-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]piperidin-2-yl}benzoic acid-hydrogen chloride(1/1))",
    "date_of_designation_or_refusal": "04/06/2020",
    "intended_use": "Treatment of paroxysmal nocturnal haemoglobinuria",
    "eu_designation_number": "EU/3/20/2281",
    "status": "Positive",
    "first_published_date": "19/08/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2281"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Lutetium (177Lu) lilotomab satetraxetan",
    "date_of_designation_or_refusal": "04/06/2020",
    "intended_use": "Treatment of marginal zone lymphoma",
    "eu_designation_number": "EU/3/20/2280",
    "status": "Positive",
    "first_published_date": "19/08/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2280"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Lumacaftor",
    "date_of_designation_or_refusal": "04/06/2020",
    "intended_use": "Treatment of non-traumatic subarachnoid haemorrhage",
    "eu_designation_number": "EU/3/20/2279",
    "status": "Positive",
    "first_published_date": "19/08/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2279"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "methotrexate",
    "date_of_designation_or_refusal": "04/06/2020",
    "intended_use": "Treatment of retinal detachment",
    "eu_designation_number": "EU/3/20/2276",
    "status": "Positive",
    "first_published_date": "19/08/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2276"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Glucagon analogue linked to a human immunoglobulin Fc fragment",
    "date_of_designation_or_refusal": "22/04/2020",
    "intended_use": "Treatment of insulin autoimmune syndrome",
    "eu_designation_number": "EU/3/20/2275",
    "status": "Positive",
    "first_published_date": "13/08/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2275"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus vector serotype hu37 encoding human factor VIII",
    "date_of_designation_or_refusal": "22/04/2020",
    "intended_use": "Treatment of  haemophilia A",
    "eu_designation_number": "EU/3/20/2274",
    "status": "Positive",
    "first_published_date": "13/08/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2274"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "anti-(integrin beta-3) human monoclonal antibody",
    "date_of_designation_or_refusal": "22/04/2020",
    "intended_use": "Prevention of fetal and neonatal alloimmune thrombocytopenia due to human platelet antigen-1a incompatibility",
    "eu_designation_number": "EU/3/20/2273",
    "status": "Positive",
    "first_published_date": "13/08/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2273"
  },
  {
    "medicine_name": "Rystiggo",
    "related_ema_product_number": "EMEA/H/C/005824",
    "active_substance": "rozanolixizumab",
    "date_of_designation_or_refusal": "22/04/2020",
    "intended_use": "Treatment of myasthenia gravis",
    "eu_designation_number": "EU/3/20/2272",
    "status": "Positive",
    "first_published_date": "13/08/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2272"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Methyl 3-((2R)-2-hydroxy-4-(((((S)-1-methoxy-1-oxopropan-2-yl) amino)(phenoxy)phosphoryl)oxy)-3,3-dimethylbutanamido)propanoate",
    "date_of_designation_or_refusal": "17/02/2016",
    "intended_use": "Treatment of pantothenate-kinase-associated neurodegeneration",
    "eu_designation_number": "EU/3/16/1612",
    "status": "Withdrawn",
    "first_published_date": "06/04/2016",
    "last_updated_date": "13/08/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1612"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "florbetaben (18F)",
    "date_of_designation_or_refusal": "22/04/2020",
    "intended_use": "Diagnosis of AL amyloidosis",
    "eu_designation_number": "EU/3/20/2268",
    "status": "Positive",
    "first_published_date": "12/08/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2268"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "icatibant acetate",
    "date_of_designation_or_refusal": "18/02/2003",
    "intended_use": "Treatment of angioedema",
    "eu_designation_number": "EU/3/03/133",
    "status": "Expired",
    "first_published_date": "09/04/2003",
    "last_updated_date": "12/08/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-133"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human galactocerebrosidase",
    "date_of_designation_or_refusal": "27/09/2011",
    "intended_use": "Treatment of globoid cell leukodystrophy (Krabbe disease)",
    "eu_designation_number": "EU/3/11/911",
    "status": "Withdrawn",
    "first_published_date": "17/10/2011",
    "last_updated_date": "12/08/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-911"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human porphobilinogen deaminase",
    "date_of_designation_or_refusal": "12/06/2002",
    "intended_use": "Treatment of acute intermittent porphyria",
    "eu_designation_number": "EU/3/02/103",
    "status": "Withdrawn",
    "first_published_date": "08/01/2003",
    "last_updated_date": "12/08/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-103"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "fosgemcitabine palabenamide",
    "date_of_designation_or_refusal": "24/03/2020",
    "intended_use": "Treatment of biliary tract cancer",
    "eu_designation_number": "EU/3/20/2262",
    "status": "Withdrawn",
    "first_published_date": "12/08/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2262"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "cabiralizumab",
    "date_of_designation_or_refusal": "12/12/2016",
    "intended_use": "Treatment of tenosynovial giant cell tumour, localised and diffuse type",
    "eu_designation_number": "EU/3/16/1799",
    "status": "Withdrawn",
    "first_published_date": "09/01/2017",
    "last_updated_date": "12/08/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1799"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino]isonicotinamide hydrochloride",
    "date_of_designation_or_refusal": "08/10/2009",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/09/685",
    "status": "Withdrawn",
    "first_published_date": "19/11/2009",
    "last_updated_date": "12/08/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-685"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino]isonicotinamide hydrochloride",
    "date_of_designation_or_refusal": "17/12/2010",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/10/824",
    "status": "Withdrawn",
    "first_published_date": "20/01/2011",
    "last_updated_date": "12/08/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-824"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "DNA plasmid encoding IL-12 p35 and p40 genes",
    "date_of_designation_or_refusal": "22/04/2020",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/20/2266",
    "status": "Positive",
    "first_published_date": "11/08/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2266"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised monoclonal antibody to the folate receptor alpha",
    "date_of_designation_or_refusal": "01/04/2008",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/08/535",
    "status": "Positive",
    "first_published_date": "10/07/2008",
    "last_updated_date": "11/08/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-535"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "amatuximab",
    "date_of_designation_or_refusal": "16/01/2014",
    "intended_use": "Treatment of malignant mesothelioma",
    "eu_designation_number": "EU/3/13/1222",
    "status": "Positive",
    "first_published_date": "21/03/2014",
    "last_updated_date": "11/08/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1222"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-{2-[(6-{[(2,6-dichloro-3,5-dimethoxyphenyl)carbamoyl](methyl)amino}pyrimidin-4-yl)amino]-5-(4-ethylpiperazin-1-yl)phenyl}prop-2-enamide",
    "date_of_designation_or_refusal": "23/08/2017",
    "intended_use": "Treatment of hepatocellular carcinoma",
    "eu_designation_number": "EU/3/17/1902",
    "status": "Positive",
    "first_published_date": "17/10/2017",
    "last_updated_date": "11/08/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1902"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "cholic acid",
    "date_of_designation_or_refusal": "29/10/2009",
    "intended_use": "Treatment of inborn errors in primary bile acid synthesis responsive to treatment with cholic acid",
    "eu_designation_number": "EU/3/09/683",
    "status": "Withdrawn",
    "first_published_date": "18/11/2009",
    "last_updated_date": "29/07/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-683"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "oleylphosphocholine",
    "date_of_designation_or_refusal": "23/04/2012",
    "intended_use": "Treatment of leishmaniasis",
    "eu_designation_number": "EU/3/12/964",
    "status": "Positive",
    "first_published_date": "03/05/2012",
    "last_updated_date": "10/07/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-964"
  },
  {
    "medicine_name": "Isturisa",
    "related_ema_product_number": "EMEA/H/C/004821",
    "active_substance": "osilodrostat",
    "date_of_designation_or_refusal": "15/10/2014",
    "intended_use": "Treatment of Cushing's syndrome",
    "eu_designation_number": "EU/3/14/1345",
    "status": "Positive",
    "first_published_date": "12/11/2014",
    "last_updated_date": "07/07/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1345"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2'-O-methyl phosphorothioate RNA oligonucleotide, 5'-m5CUGm5CUGm5CUGm5CUGm5CUGm5CUGm5CUG-3'",
    "date_of_designation_or_refusal": "12/02/2015",
    "intended_use": "Treatment of Huntington’s disease",
    "eu_designation_number": "EU/3/15/1432",
    "status": "Positive",
    "first_published_date": "08/04/2015",
    "last_updated_date": "23/06/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1432"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised monoclonal antibody against CD38 for the treatment of plasma cell myeloma (isatuximab)",
    "date_of_designation_or_refusal": "29/04/2014",
    "intended_use": "Treatment of plasma cell myeloma",
    "eu_designation_number": "EU/3/14/1268",
    "status": "Withdrawn",
    "first_published_date": "04/06/2014",
    "last_updated_date": "12/06/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1268"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "modified adenovirus serotype 5/35 containing a CMV promoter-driven transgene cassette with the human transgenes for a membrane-bound CD40 ligand and full length 4-1BBL",
    "date_of_designation_or_refusal": "28/07/2015",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/15/1516",
    "status": "Positive",
    "first_published_date": "18/08/2015",
    "last_updated_date": "11/06/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1516"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human monoclonal antibody against Fas ligand",
    "date_of_designation_or_refusal": "09/02/2012",
    "intended_use": "Treatment of pemphigus",
    "eu_designation_number": "EU/3/12/956",
    "status": "Positive",
    "first_published_date": "01/03/2012",
    "last_updated_date": "11/06/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-956"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "nintedanib",
    "date_of_designation_or_refusal": "26/04/2013",
    "intended_use": "Treatment of idiopathic pulmonary fibrosis",
    "eu_designation_number": "EU/3/13/1123",
    "status": "Withdrawn",
    "first_published_date": "14/05/2013",
    "last_updated_date": "09/06/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1123"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sirolimus",
    "date_of_designation_or_refusal": "17/01/2018",
    "intended_use": "Treatment of sickle cell disease",
    "eu_designation_number": "EU/3/17/1970",
    "status": "Positive",
    "first_published_date": "14/03/2018",
    "last_updated_date": "08/06/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1970"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "trehalose",
    "date_of_designation_or_refusal": "19/06/2015",
    "intended_use": "Treatment of spinocerebellar ataxia",
    "eu_designation_number": "EU/3/15/1502",
    "status": "Positive",
    "first_published_date": "27/07/2015",
    "last_updated_date": "08/06/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1502"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Etamsylate",
    "date_of_designation_or_refusal": "19/11/2018",
    "intended_use": "Treatment of hereditary haemorrhagic telangiectasia",
    "eu_designation_number": "EU/3/18/2087",
    "status": "Positive",
    "first_published_date": "25/02/2019",
    "last_updated_date": "08/06/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2087"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "4,6,4'-trimethylangelicin",
    "date_of_designation_or_refusal": "19/06/2013",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/13/1137",
    "status": "Positive",
    "first_published_date": "11/07/2013",
    "last_updated_date": "08/06/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1137"
  },
  {
    "medicine_name": "Garsun",
    "related_ema_product_number": "EMEA/H/C/005718",
    "active_substance": "artesunate",
    "date_of_designation_or_refusal": "28/07/2015",
    "intended_use": "Treatment of malaria",
    "eu_designation_number": "EU/3/15/1521",
    "status": "Positive",
    "first_published_date": "18/08/2015",
    "last_updated_date": "08/06/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1521"
  },
  {
    "medicine_name": "Voydeya",
    "related_ema_product_number": "EMEA/H/C/005517",
    "active_substance": "(2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidine-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridine-2-yl)-4-fluoropyrrolidine-2-carboxamide",
    "date_of_designation_or_refusal": "12/12/2017",
    "intended_use": "Treatment of paroxysmal nocturnal haemoglobinuria",
    "eu_designation_number": "EU/3/17/1946",
    "status": "Positive",
    "first_published_date": "24/01/2018",
    "last_updated_date": "08/06/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1946"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant modified ricin toxin A-chain subunit",
    "date_of_designation_or_refusal": "21/03/2018",
    "intended_use": "Prevention of ricin poisoning",
    "eu_designation_number": "EU/3/18/2001",
    "status": "Positive",
    "first_published_date": "17/05/2018",
    "last_updated_date": "08/06/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2001"
  },
  {
    "medicine_name": "orBec",
    "related_ema_product_number": "EMEA/H/C/000803",
    "active_substance": "beclomethasone 17, 21-dipropionate",
    "date_of_designation_or_refusal": "13/03/2002",
    "intended_use": "Treatment of intestinal graft-versus-host disease",
    "eu_designation_number": "EU/3/02/093",
    "status": "Positive",
    "first_published_date": "18/08/2008",
    "last_updated_date": "08/06/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-093"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "trehalose",
    "date_of_designation_or_refusal": "21/05/2015",
    "intended_use": "Treatment of oculopharyngeal muscular dystrophy",
    "eu_designation_number": "EU/3/15/1496",
    "status": "Positive",
    "first_published_date": "30/06/2015",
    "last_updated_date": "08/06/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1496"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "vaccine consisting of 5 survivin peptides with different human leukocyte antigen restrictions",
    "date_of_designation_or_refusal": "18/11/2016",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/16/1791",
    "status": "Positive",
    "first_published_date": "14/12/2016",
    "last_updated_date": "08/06/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1791"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human pentraxin-2",
    "date_of_designation_or_refusal": "19/11/2014",
    "intended_use": "Treatment of post-essential thrombocythaemia myelofibrosis",
    "eu_designation_number": "EU/3/14/1358",
    "status": "Positive",
    "first_published_date": "15/01/2015",
    "last_updated_date": "08/06/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1358"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human pentraxin-2",
    "date_of_designation_or_refusal": "19/11/2014",
    "intended_use": "Treatment of primary myelofibrosis",
    "eu_designation_number": "EU/3/14/1366",
    "status": "Positive",
    "first_published_date": "15/01/2015",
    "last_updated_date": "08/06/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1366"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human pentraxin-2",
    "date_of_designation_or_refusal": "19/11/2014",
    "intended_use": "Treatment of post-polycythaemia vera myelofibrosis",
    "eu_designation_number": "EU/3/14/1365",
    "status": "Positive",
    "first_published_date": "15/01/2015",
    "last_updated_date": "08/06/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1365"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous Epstein-Barr virus specific T cells derived from peripheral blood mononuclear cells, expanded ex vivo",
    "date_of_designation_or_refusal": "14/07/2016",
    "intended_use": "Treatment of post-transplantation lymphoproliferative disorders",
    "eu_designation_number": "EU/3/16/1696",
    "status": "Withdrawn",
    "first_published_date": "06/09/2016",
    "last_updated_date": "25/05/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1696"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous Epstein-Barr virus specific T cells derived from peripheral blood mononuclear cells, expanded ex vivo",
    "date_of_designation_or_refusal": "14/07/2016",
    "intended_use": "Treatment of extranodal NK/T-cell lymphoma, nasal type",
    "eu_designation_number": "EU/3/16/1695",
    "status": "Withdrawn",
    "first_published_date": "06/09/2016",
    "last_updated_date": "25/05/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1695"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Mertansine functionalised gold nanoconjugate",
    "date_of_designation_or_refusal": "22/02/2018",
    "intended_use": "Treatment of hepatocellular carcinoma",
    "eu_designation_number": "EU/3/18/1981",
    "status": "Withdrawn",
    "first_published_date": "11/04/2018",
    "last_updated_date": "20/05/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1981"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "motixafortide",
    "date_of_designation_or_refusal": "09/01/2020",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/19/2243",
    "status": "Positive",
    "first_published_date": "19/05/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2243"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "nicardipine",
    "date_of_designation_or_refusal": "09/01/2020",
    "intended_use": "Treatment of non-traumatic subarachnoid haemorrhage",
    "eu_designation_number": "EU/3/19/2240",
    "status": "Positive",
    "first_published_date": "19/05/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2240"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Itraconazole",
    "date_of_designation_or_refusal": "25/05/2018",
    "intended_use": "Prevention of invasive aspergillosis",
    "eu_designation_number": "EU/3/18/2024",
    "status": "Positive",
    "first_published_date": "24/07/2018",
    "last_updated_date": "15/05/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2024"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-(3,7-Dimethyl-octa-2, 6-dienyl)-6-ethylamino-3-hydroxy-5-pentyl-[1,4]benzoquinone",
    "date_of_designation_or_refusal": "09/01/2020",
    "intended_use": "Treatment of Huntington's disease",
    "eu_designation_number": "EU/3/19/2237",
    "status": "Positive",
    "first_published_date": "15/05/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2237"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "liposomal mannose-1-phosphate",
    "date_of_designation_or_refusal": "31/07/2018",
    "intended_use": "treatment of phosphomannomutase 2-congenital disorder of glycosylation",
    "eu_designation_number": "EU/3/18/2047",
    "status": "Positive",
    "first_published_date": "11/10/2018",
    "last_updated_date": "07/05/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2047"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sirolimus",
    "date_of_designation_or_refusal": "17/07/2017",
    "intended_use": "Treatment of pachyonychia congenita",
    "eu_designation_number": "EU/3/17/1896",
    "status": "Positive",
    "first_published_date": "14/08/2017",
    "last_updated_date": "07/05/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1896"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "rusalatide acetate",
    "date_of_designation_or_refusal": "22/02/2018",
    "intended_use": "Treatment of acute radiation syndrome",
    "eu_designation_number": "EU/3/18/1985",
    "status": "Positive",
    "first_published_date": "11/04/2018",
    "last_updated_date": "07/05/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1985"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Entolimod",
    "date_of_designation_or_refusal": "11/01/2016",
    "intended_use": "Treatment of acute radiation syndrome",
    "eu_designation_number": "EU/3/15/1607",
    "status": "Withdrawn",
    "first_published_date": "05/02/2016",
    "last_updated_date": "07/05/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1607"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "melatonin;sorafenib",
    "date_of_designation_or_refusal": "23/09/2019",
    "intended_use": "Treatment of hepatocellular carcinoma",
    "eu_designation_number": "-",
    "status": "Negative",
    "first_published_date": "06/05/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-hepatocellular-carcinoma"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sintilimab",
    "date_of_designation_or_refusal": "28/02/2020",
    "intended_use": "Treatment of peripheral T-cell lymphoma",
    "eu_designation_number": "EU/3/20/2257",
    "status": "Positive",
    "first_published_date": "06/05/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2257"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus serotype 8 containing the human RdCVF sequence and the human RdCVFL sequence",
    "date_of_designation_or_refusal": "28/02/2020",
    "intended_use": "Treatment of inherited retinal dystrophies",
    "eu_designation_number": "EU/3/20/2249",
    "status": "Positive",
    "first_published_date": "05/05/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2249"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Adeno-associated viral vector serotype S3 encoding human alpha-galactosidase A cDNA",
    "date_of_designation_or_refusal": "28/02/2020",
    "intended_use": "Treatment of Fabry disease",
    "eu_designation_number": "EU/3/20/2248",
    "status": "Positive",
    "first_published_date": "05/05/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2248"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Imidazolyl ethanamide pentandioic acid",
    "date_of_designation_or_refusal": "28/06/2019",
    "intended_use": "Treatment of acute radiation syndrome",
    "eu_designation_number": "EU/3/19/2173",
    "status": "Positive",
    "first_published_date": "07/10/2019",
    "last_updated_date": "04/05/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2173"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human pentraxin-2",
    "date_of_designation_or_refusal": "17/07/2012",
    "intended_use": "Treatment of idiopathic pulmonary fibrosis",
    "eu_designation_number": "EU/3/12/1020",
    "status": "Positive",
    "first_published_date": "30/08/2012",
    "last_updated_date": "24/04/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1020"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "",
    "date_of_designation_or_refusal": "05/08/2013",
    "intended_use": "Treatment of sickle cell disease",
    "eu_designation_number": "EU/3/13/1184",
    "status": "Positive",
    "first_published_date": "16/09/2013",
    "last_updated_date": "23/04/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1184"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "thiotepa",
    "date_of_designation_or_refusal": "29/01/2007",
    "intended_use": "Conditioning treatment prior to haematopoietic-progenitor-cell transplantation",
    "eu_designation_number": "EU/3/06/424",
    "status": "Withdrawn",
    "first_published_date": "19/07/2007",
    "last_updated_date": "20/04/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-424"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-(7-ethoxy-4-(3-fluorophenyl)-1-oxophthalazin-2(1H)-yl)-N-methyl-N-(2-methylbenzo[d]oxazol-6-yl) acetamide",
    "date_of_designation_or_refusal": "21/05/2015",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/15/1498",
    "status": "Withdrawn",
    "first_published_date": "30/06/2015",
    "last_updated_date": "16/04/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1498"
  },
  {
    "medicine_name": "Trepulmix",
    "related_ema_product_number": "EMEA/H/C/005207",
    "active_substance": "treprostinil sodium",
    "date_of_designation_or_refusal": "08/02/2013",
    "intended_use": "Treatment of chronic thromboembolic pulmonary hypertension",
    "eu_designation_number": "EU/3/13/1103",
    "status": "Positive",
    "first_published_date": "04/03/2013",
    "last_updated_date": "08/04/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1103"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-(tert-butylcarbamoyl)-5-cyano-2-((4'-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)oxy)benzenesulfonamide",
    "date_of_designation_or_refusal": "22/02/2018",
    "intended_use": "Treatment of pulmonary arterial hypertension",
    "eu_designation_number": "EU/3/18/1982",
    "status": "Positive",
    "first_published_date": "11/04/2018",
    "last_updated_date": "08/04/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1982"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "nitisinone",
    "date_of_designation_or_refusal": "13/03/2002",
    "intended_use": "Treatment of alkaptonuria",
    "eu_designation_number": "EU/3/02/096",
    "status": "Withdrawn",
    "first_published_date": "06/01/2003",
    "last_updated_date": "01/04/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-096"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised recombinant IgG4 anti-human tau antibody (tilavonemab)",
    "date_of_designation_or_refusal": "28/04/2016",
    "intended_use": "Treatment of progressive supranuclear palsy",
    "eu_designation_number": "EU/3/16/1649",
    "status": "Withdrawn",
    "first_published_date": "30/05/2016",
    "last_updated_date": "01/04/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1649"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous adult bone marrow-derived non-expanded CD133+ haematopoietic stem cells",
    "date_of_designation_or_refusal": "20/04/2017",
    "intended_use": "Treatment of Asherman's syndrome",
    "eu_designation_number": "EU/3/17/1862",
    "status": "Positive",
    "first_published_date": "15/05/2017",
    "last_updated_date": "31/03/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1862"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human monoclonal IgG2 antibody against tissue factor pathway inhibitor",
    "date_of_designation_or_refusal": "22/02/2018",
    "intended_use": "Treatment of haemophilia A",
    "eu_designation_number": "EU/3/18/1979",
    "status": "Withdrawn",
    "first_published_date": "11/04/2018",
    "last_updated_date": "26/03/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1979"
  },
  {
    "medicine_name": "Givlaari",
    "related_ema_product_number": "EMEA/H/C/004775",
    "active_substance": "synthetic double-stranded siRNA oligonucleotide directed against delta-aminolevulinic acid synthase 1 mRNA, covalently linked to a ligand containing three N-acetylgalactosamine residues (givosiran)",
    "date_of_designation_or_refusal": "29/08/2016",
    "intended_use": "Treatment of acute hepatic porphyria",
    "eu_designation_number": "EU/3/16/1731",
    "status": "Positive",
    "first_published_date": "11/10/2016",
    "last_updated_date": "09/03/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1731"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "yttrium (90Y)-DOTA-radiolabelled humanized monoclonal antibody against mucin 1",
    "date_of_designation_or_refusal": "06/02/2009",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/08/608",
    "status": "Withdrawn",
    "first_published_date": "29/06/2009",
    "last_updated_date": "06/03/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-608"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "veltuzumab",
    "date_of_designation_or_refusal": "29/01/2010",
    "intended_use": "Treatment of chronic lymphocytic leukaemia",
    "eu_designation_number": "EU/3/09/713",
    "status": "Withdrawn",
    "first_published_date": "25/02/2010",
    "last_updated_date": "06/03/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-713"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 8 containing the human factor-VII gene",
    "date_of_designation_or_refusal": "15/01/2015",
    "intended_use": "Treatment of congenital factor VII deficiency",
    "eu_designation_number": "EU/3/14/1430",
    "status": "Positive",
    "first_published_date": "06/03/2015",
    "last_updated_date": "05/03/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1430"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "3,4-diaminopyridine phosphate (amifampridine)",
    "date_of_designation_or_refusal": "19/12/2002",
    "intended_use": "Treatment of Lambert-Eaton myasthenic syndrome",
    "eu_designation_number": "EU/3/02/124",
    "status": "Withdrawn",
    "first_published_date": "18/08/2008",
    "last_updated_date": "04/03/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-124"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "dimethyl fumarate",
    "date_of_designation_or_refusal": "14/07/2016",
    "intended_use": "Treatment of bullous pemphigoid",
    "eu_designation_number": "EU/3/16/1698",
    "status": "Positive",
    "first_published_date": "06/09/2016",
    "last_updated_date": "02/03/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1698"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Human platelet antigen-1a immunoglobulin",
    "date_of_designation_or_refusal": "27/10/2011",
    "intended_use": "Prevention of fetal and neonatal alloimmune thrombocytopenia",
    "eu_designation_number": "EU/3/11/922",
    "status": "Positive",
    "first_published_date": "23/11/2011",
    "last_updated_date": "02/03/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-922"
  },
  {
    "medicine_name": "Vyndaqel",
    "related_ema_product_number": "EMEA/H/C/002294",
    "active_substance": "tafamidis",
    "date_of_designation_or_refusal": "08/11/2012",
    "intended_use": "Treatment of senile systemic amyloidosis",
    "eu_designation_number": "EU/3/12/1066",
    "status": "Positive",
    "first_published_date": "13/12/2012",
    "last_updated_date": "25/02/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1066"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "navitoclax",
    "date_of_designation_or_refusal": "16/12/2019",
    "intended_use": "Treatment of myelofibrosis",
    "eu_designation_number": "EU/3/19/2233",
    "status": "Positive",
    "first_published_date": "25/02/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2233"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "H-Leu-Pro-Pro-Leu-Pro-Tyr-Pro-OH",
    "date_of_designation_or_refusal": "16/12/2019",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/19/2231",
    "status": "Positive",
    "first_published_date": "25/02/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2231"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated virus vector encoding human phenylalanine hydroxylase",
    "date_of_designation_or_refusal": "16/12/2019",
    "intended_use": "Treatment of phenylalanine hydroxylase deficiency",
    "eu_designation_number": "EU/3/19/2229",
    "status": "Positive",
    "first_published_date": "25/02/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2229"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(E)-2-((2S,4S)-4-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-2-yl)-10-(carboxymethyl)-1-hydroxy-13-(2-(2-(2-((E)-3-(3-((3-hydroxy-3,3 diphosphonopropyl)(methyl)amino)propoxy)benzylidene)hydrazine-1-carbonothioyl)hydrazineyl)-2-oxoethyl)-8-oxo-5-thioxo-3,4,6,7,10,13-hexaazapentadec-2-en-15-oic acid",
    "date_of_designation_or_refusal": "16/12/2019",
    "intended_use": "Treatment of osteosarcoma",
    "eu_designation_number": "EU/3/19/2226",
    "status": "Positive",
    "first_published_date": "24/02/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2226"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "naltrexone",
    "date_of_designation_or_refusal": "07/11/2020",
    "intended_use": "Treatment of fibromyalgia",
    "eu_designation_number": "-",
    "status": "Negative",
    "first_published_date": "24/02/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-fibromyalgia-0"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous dendritic cells pulsed with tumour antigen-derived synthetic peptides (MAGE-1, HER-2, AIM-2, TRP-2, gp-100, and interleukin-13 receptor alpha)",
    "date_of_designation_or_refusal": "19/02/2014",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/14/1247",
    "status": "Positive",
    "first_published_date": "02/04/2014",
    "last_updated_date": "19/02/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1247"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Milatuzumab",
    "date_of_designation_or_refusal": "19/01/2009",
    "intended_use": "Treatment of chronic lymphocytic leukaemia",
    "eu_designation_number": "EU/3/08/602",
    "status": "Withdrawn",
    "first_published_date": "29/06/2009",
    "last_updated_date": "18/02/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-602"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Milatuzumab",
    "date_of_designation_or_refusal": "19/01/2009",
    "intended_use": "Treatment of multiple myeloma",
    "eu_designation_number": "EU/3/08/601",
    "status": "Withdrawn",
    "first_published_date": "29/06/2009",
    "last_updated_date": "18/02/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-601"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Exendin (9-39)",
    "date_of_designation_or_refusal": "13/11/2019",
    "intended_use": "Treatment of congenital hyperinsulinism",
    "eu_designation_number": "EU/3/19/2223",
    "status": "Positive",
    "first_published_date": "13/02/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2223"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "camsirubicin",
    "date_of_designation_or_refusal": "13/11/2019",
    "intended_use": "Treatment of soft tissue sarcoma",
    "eu_designation_number": "EU/3/19/2221",
    "status": "Positive",
    "first_published_date": "13/02/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2221"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "",
    "date_of_designation_or_refusal": "13/11/2019",
    "intended_use": "Treatment of GM2 gangliosidosis",
    "eu_designation_number": "EU/3/19/2218",
    "status": "Positive",
    "first_published_date": "12/02/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2218"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "4-((E)-(5-(2-(2-((S)-2-((S)-1-(L-threonyl-L-lysyl)pyrrolidine-2-carboxamido)-5-guanidinopentanamido)acetamido)-2-carboxyethyl)-2-hydroxyphenyl)diazenyl)phenyl (2-(trimethylammonio)ethyl) phosphate",
    "date_of_designation_or_refusal": "13/11/2019",
    "intended_use": "Treatment of non-infectious uveitis",
    "eu_designation_number": "EU/3/19/2219",
    "status": "Positive",
    "first_published_date": "12/02/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2219"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "505 amino acid protein, corresponding to amino acids 2-506 of the wild type human histidyl-tRNA synthetase",
    "date_of_designation_or_refusal": "27/02/2017",
    "intended_use": "Treatment of limb-girdle muscular dystrophy",
    "eu_designation_number": "EU/3/17/1831",
    "status": "Withdrawn",
    "first_published_date": "13/03/2017",
    "last_updated_date": "12/02/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1831"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "505 amino acid protein, corresponding to amino acids 2-506 of the wild type human histidyl-tRNA synthetase",
    "date_of_designation_or_refusal": "12/02/2015",
    "intended_use": "treatment of facioscapulohumeral muscular dystrophy",
    "eu_designation_number": "EU/3/15/1448",
    "status": "Withdrawn",
    "first_published_date": "09/04/2015",
    "last_updated_date": "12/02/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1448"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adenovirus-specific T-cells derived from allogeneic donor leukocytes, expanded ex vivo",
    "date_of_designation_or_refusal": "16/01/2014",
    "intended_use": "Treatment of adenovirus infection in allogeneic haematopoietic stem cell transplant recipients",
    "eu_designation_number": "EU/3/13/1227",
    "status": "Withdrawn",
    "first_published_date": "21/03/2014",
    "last_updated_date": "12/02/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1227"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "lenalidomide",
    "date_of_designation_or_refusal": "24/01/2013",
    "intended_use": "Treatment of follicular lymphoma",
    "eu_designation_number": "EU/3/12/1097",
    "status": "Withdrawn",
    "first_published_date": "01/03/2013",
    "last_updated_date": "11/02/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1097"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "beraprost sodium",
    "date_of_designation_or_refusal": "10/07/2008",
    "intended_use": "Treatment of pulmonary arterial hypertension",
    "eu_designation_number": "EU/3/08/554",
    "status": "Withdrawn",
    "first_published_date": "24/04/2009",
    "last_updated_date": "11/02/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-554"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "bromelain",
    "date_of_designation_or_refusal": "14/12/2018",
    "intended_use": "Treatment of pseudomyxoma peritonei",
    "eu_designation_number": "EU/3/18/2113",
    "status": "Positive",
    "first_published_date": "08/03/2019",
    "last_updated_date": "05/02/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2113"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "acetylcysteine",
    "date_of_designation_or_refusal": "14/12/2018",
    "intended_use": "Treatment of pseudomyxoma peritonei",
    "eu_designation_number": "EU/3/18/2107",
    "status": "Positive",
    "first_published_date": "08/03/2019",
    "last_updated_date": "05/02/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2107"
  },
  {
    "medicine_name": "Upkanz",
    "related_ema_product_number": "EMEA/H/C/005004",
    "active_substance": "Deferiprone",
    "date_of_designation_or_refusal": "27/06/2018",
    "intended_use": "Treatment of neurodegeneration with brain iron accumulation",
    "eu_designation_number": "EU/3/18/2034",
    "status": "Positive",
    "first_published_date": "21/08/2018",
    "last_updated_date": "04/02/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2034"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Deferiprone",
    "date_of_designation_or_refusal": "23/02/2011",
    "intended_use": "Treatment of sickle cell disease",
    "eu_designation_number": "EU/3/10/832",
    "status": "Positive",
    "first_published_date": "04/03/2011",
    "last_updated_date": "04/02/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-832"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human monoclonal antibody against hepatitis-B virus (active ingredient lenvervimab)",
    "date_of_designation_or_refusal": "15/08/2013",
    "intended_use": "Prevention of hepatitis-B re-infection following liver transplantation",
    "eu_designation_number": "EU/3/13/1156",
    "status": "Positive",
    "first_published_date": "22/08/2013",
    "last_updated_date": "04/02/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1156"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "glycine;L-alanine;L-arginine;L-aspartic acid;L-cysteine;L-glutamic acid;L-histidine;L-lysine monohydrate;L-methionine;L-phenylalanine;L-proline;L-serine;L-threonine;L-tryptophan;L-tyrosine;taurine",
    "date_of_designation_or_refusal": "26/10/2018",
    "intended_use": "Treatment of maple syrup urine disease",
    "eu_designation_number": "EU/3/18/2076",
    "status": "Positive",
    "first_published_date": "10/01/2019",
    "last_updated_date": "03/02/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2076"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "propranolol hydrochloride",
    "date_of_designation_or_refusal": "17/10/2019",
    "intended_use": "Treatment of retinopathy of prematurity",
    "eu_designation_number": "EU/3/19/2217",
    "status": "Positive",
    "first_published_date": "23/01/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2217"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "leriglitazone",
    "date_of_designation_or_refusal": "17/10/2019",
    "intended_use": "Treatment of Friedreich’s ataxia",
    "eu_designation_number": "EU/3/19/2212",
    "status": "Positive",
    "first_published_date": "22/01/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2212"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2'-O-(2-methoxyethyl)-D-ribose antisense oligonucleotide targeting glial fibrillary acidic protein messenger ribonucleic acid",
    "date_of_designation_or_refusal": "17/10/2019",
    "intended_use": "Treatment of Alexander disease",
    "eu_designation_number": "EU/3/19/2206",
    "status": "Positive",
    "first_published_date": "21/01/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2206"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "nilotinib",
    "date_of_designation_or_refusal": "22/05/2006",
    "intended_use": "Treatment of chronic myeloid leukaemia",
    "eu_designation_number": "EU/3/06/375",
    "status": "Expired",
    "first_published_date": "04/12/2007",
    "last_updated_date": "20/01/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-375"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "1-(2,2-diphenyltetrahydrofuran-3-yl)-N,N-dimethylmethanamine hydrochloride",
    "date_of_designation_or_refusal": "21/08/2019",
    "intended_use": "Treatment of Rett syndrome",
    "eu_designation_number": "EU/3/19/2195",
    "status": "Positive",
    "first_published_date": "16/01/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2195"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Herpes simplex 1 virus-thymidine kinase and truncated low affinity nerve growth factor receptor transfected donor lymphocytes",
    "date_of_designation_or_refusal": "20/10/2003",
    "intended_use": "Adjunctive treatment in haematopoietic cell transplantation",
    "eu_designation_number": "EU/3/03/168",
    "status": "Withdrawn",
    "first_published_date": "04/01/2006",
    "last_updated_date": "16/01/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-168"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "triheptanoin",
    "date_of_designation_or_refusal": "21/05/2015",
    "intended_use": "Treatment of glucose transporter type-1 deficiency syndrome",
    "eu_designation_number": "EU/3/15/1495",
    "status": "Withdrawn",
    "first_published_date": "30/06/2015",
    "last_updated_date": "16/01/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1495"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile",
    "date_of_designation_or_refusal": "26/10/2018",
    "intended_use": "Treatment of medullary thyroid carcinoma",
    "eu_designation_number": "EU/3/18/2071",
    "status": "Withdrawn",
    "first_published_date": "11/01/2019",
    "last_updated_date": "16/01/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2071"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "olaratumab",
    "date_of_designation_or_refusal": "12/02/2015",
    "intended_use": "Treatment of soft tissue sarcoma",
    "eu_designation_number": "EU/3/15/1447",
    "status": "Withdrawn",
    "first_published_date": "09/04/2015",
    "last_updated_date": "15/01/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1447"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine",
    "date_of_designation_or_refusal": "21/08/2019",
    "intended_use": "Treatment of congenital adrenal hyperplasia",
    "eu_designation_number": "EU/3/19/2194",
    "status": "Positive",
    "first_published_date": "14/01/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2194"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "acetazolamide",
    "date_of_designation_or_refusal": "21/08/2019",
    "intended_use": "Treatment of periodic paralysis",
    "eu_designation_number": "EU/3/19/2193",
    "status": "Positive",
    "first_published_date": "14/01/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2193"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "peginterferon lambda-1a",
    "date_of_designation_or_refusal": "21/08/2019",
    "intended_use": "Treatment of hepatitis D virus infection",
    "eu_designation_number": "EU/3/19/2190",
    "status": "Positive",
    "first_published_date": "14/01/2020",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2190"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "lenalidomide",
    "date_of_designation_or_refusal": "24/04/2015",
    "intended_use": "Treatment of marginal zone lymphoma",
    "eu_designation_number": "EU/3/15/1473",
    "status": "Withdrawn",
    "first_published_date": "21/05/2015",
    "last_updated_date": "13/01/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1473"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "lenalidomide",
    "date_of_designation_or_refusal": "13/05/2011",
    "intended_use": "Treatment of diffuse large B-cell lymphoma",
    "eu_designation_number": "EU/3/11/868",
    "status": "Withdrawn",
    "first_published_date": "30/05/2011",
    "last_updated_date": "13/01/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-868"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "lenalidomide",
    "date_of_designation_or_refusal": "19/11/2007",
    "intended_use": "Treatment of chronic lymphocytic leukaemia",
    "eu_designation_number": "EU/3/07/494",
    "status": "Withdrawn",
    "first_published_date": "21/09/2009",
    "last_updated_date": "13/01/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-494"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "lenalidomide",
    "date_of_designation_or_refusal": "27/10/2011",
    "intended_use": "Treatment of mantle cell lymphoma",
    "eu_designation_number": "EU/3/11/924",
    "status": "Withdrawn",
    "first_published_date": "23/11/2011",
    "last_updated_date": "13/01/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-924"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "",
    "date_of_designation_or_refusal": "08/03/2004",
    "intended_use": "Treatment of myelodysplastic syndromes",
    "eu_designation_number": "EU/3/04/192",
    "status": "Withdrawn",
    "first_published_date": "29/07/2008",
    "last_updated_date": "13/01/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-192"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "two allogeneic irradiated pancreatic tumour cell lines",
    "date_of_designation_or_refusal": "11/01/2016",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/15/1604",
    "status": "Withdrawn",
    "first_published_date": "05/02/2016",
    "last_updated_date": "13/01/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1604"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Live attenuated Listeria monocytogenes delta actA/delta inlB strain expressing human mesothelin",
    "date_of_designation_or_refusal": "11/01/2016",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/15/1603",
    "status": "Withdrawn",
    "first_published_date": "05/02/2016",
    "last_updated_date": "13/01/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1603"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Live attenuated Listeria monocytogenes delta actA/delta inlB strain expressing human mesothelin",
    "date_of_designation_or_refusal": "14/12/2015",
    "intended_use": "Treatment of malignant mesothelioma",
    "eu_designation_number": "EU/3/15/1594",
    "status": "Withdrawn",
    "first_published_date": "03/02/2016",
    "last_updated_date": "13/01/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1594"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ulocuplumab",
    "date_of_designation_or_refusal": "12/02/2015",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/15/1445",
    "status": "Withdrawn",
    "first_published_date": "09/04/2015",
    "last_updated_date": "13/01/2020",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1445"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "vatiquinone",
    "date_of_designation_or_refusal": "17/01/2018",
    "intended_use": "Treatment of RARS2 syndrome",
    "eu_designation_number": "EU/3/17/1971",
    "status": "Positive",
    "first_published_date": "12/03/2018",
    "last_updated_date": "03/12/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1971"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(R)-troloxamide quinone",
    "date_of_designation_or_refusal": "12/10/2017",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/17/1934",
    "status": "Positive",
    "first_published_date": "15/01/2018",
    "last_updated_date": "03/12/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1934"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "alpha-tocotrienol quinone",
    "date_of_designation_or_refusal": "09/12/2011",
    "intended_use": "Treatment of Leigh syndrome",
    "eu_designation_number": "EU/3/11/937",
    "status": "Positive",
    "first_published_date": "20/12/2011",
    "last_updated_date": "03/12/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-937"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "S-acetyl-(S)-4'-phosphopantetheine, calcium salt",
    "date_of_designation_or_refusal": "28/04/2016",
    "intended_use": "Treatment of pantothenate-kinase-associated neurodegeneration",
    "eu_designation_number": "EU/3/16/1654",
    "status": "Positive",
    "first_published_date": "31/05/2016",
    "last_updated_date": "02/12/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1654"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "trabectedin",
    "date_of_designation_or_refusal": "17/10/2003",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/03/171",
    "status": "Expired",
    "first_published_date": "01/10/2004",
    "last_updated_date": "27/11/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-171"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N2'-Deacetyl-N2'-[4-methyl-4-(oxobuthyldithio)-1-oxopentyl]-maytansine-chimerized anti-CD138 IgG4 monoclonal antibody",
    "date_of_designation_or_refusal": "03/12/2008",
    "intended_use": "Treatment of multiple myeloma",
    "eu_designation_number": "EU/3/08/593",
    "status": "Withdrawn",
    "first_published_date": "29/06/2009",
    "last_updated_date": "20/11/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-593"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "4-hydroxy-6-{2-[4-(trifluoromethyl)phenyl]ethyl}pyridazin-3(2H)-one",
    "date_of_designation_or_refusal": "01/04/2019",
    "intended_use": "Treatment of Friedreich’s ataxia",
    "eu_designation_number": "EU/3/19/2148",
    "status": "Withdrawn",
    "first_published_date": "07/05/2019",
    "last_updated_date": "20/11/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2148"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human autologous bone-forming cells derived from bone marrow stem cells",
    "date_of_designation_or_refusal": "29/10/2007",
    "intended_use": "Treatment of non-traumatic osteonecrosis",
    "eu_designation_number": "EU/3/07/490",
    "status": "Withdrawn",
    "first_published_date": "17/01/2008",
    "last_updated_date": "20/11/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-490"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "5,7-dichloro-2-dimethylaminomethyl-8-hydroxyquinoline hydrochloride",
    "date_of_designation_or_refusal": "21/05/2015",
    "intended_use": "Treatment of Huntington’s disease",
    "eu_designation_number": "EU/3/15/1497",
    "status": "Withdrawn",
    "first_published_date": "30/06/2015",
    "last_updated_date": "20/11/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1497"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Halofuginone hydrobromide",
    "date_of_designation_or_refusal": "11/12/2001",
    "intended_use": "Treatment of systemic sclerosis",
    "eu_designation_number": "EU/3/01/074",
    "status": "Withdrawn",
    "first_published_date": "15/06/2009",
    "last_updated_date": "20/11/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-074"
  },
  {
    "medicine_name": "Strensiq",
    "related_ema_product_number": "EMEA/H/C/003794",
    "active_substance": "recombinant human tissue non-specific alkaline phosphatase - Fc - deca-aspartate fusion protein",
    "date_of_designation_or_refusal": "04/12/2008",
    "intended_use": "Treatment of hypophosphatasia",
    "eu_designation_number": "EU/3/08/594",
    "status": "Positive",
    "first_published_date": "24/04/2009",
    "last_updated_date": "20/11/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-594"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "choline tetrathiomolybdate",
    "date_of_designation_or_refusal": "24/01/2013",
    "intended_use": "Treatment of Wilson's disease",
    "eu_designation_number": "EU/3/12/1089",
    "status": "Positive",
    "first_published_date": "01/03/2013",
    "last_updated_date": "20/11/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1089"
  },
  {
    "medicine_name": "Kanuma",
    "related_ema_product_number": "EMEA/H/C/004004",
    "active_substance": "recombinant human lysosomal acid lipase",
    "date_of_designation_or_refusal": "17/12/2010",
    "intended_use": "Treatment of lysosomal acid lipase deficiency",
    "eu_designation_number": "EU/3/10/827",
    "status": "Positive",
    "first_published_date": "20/01/2011",
    "last_updated_date": "20/11/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-827"
  },
  {
    "medicine_name": "Soliris",
    "related_ema_product_number": "EMEA/H/C/000791",
    "active_substance": "Eculizumab",
    "date_of_designation_or_refusal": "29/07/2014",
    "intended_use": "Treatment myasthenia gravis",
    "eu_designation_number": "EU/3/14/1304",
    "status": "Positive",
    "first_published_date": "01/09/2014",
    "last_updated_date": "20/11/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1304"
  },
  {
    "medicine_name": "Soliris",
    "related_ema_product_number": "EMEA/H/C/000791",
    "active_substance": "Eculizumab",
    "date_of_designation_or_refusal": "05/08/2013",
    "intended_use": "Treatment of neuromyelitis optica spectrum disorders",
    "eu_designation_number": "EU/3/13/1185",
    "status": "Positive",
    "first_published_date": "16/09/2013",
    "last_updated_date": "20/11/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1185"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Eculizumab",
    "date_of_designation_or_refusal": "17/10/2003",
    "intended_use": "Treatment of paroxysmal nocturnal haemoglobinuria",
    "eu_designation_number": "EU/3/03/166",
    "status": "Expired",
    "first_published_date": "21/09/2009",
    "last_updated_date": "20/11/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-166"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Eculizumab",
    "date_of_designation_or_refusal": "24/07/2009",
    "intended_use": "Treatment of atypical haemolytic uraemic syndrome (aHUS)",
    "eu_designation_number": "EU/3/09/653",
    "status": "Positive",
    "first_published_date": "11/09/2009",
    "last_updated_date": "20/11/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-653"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous collagen type II-specific regulatory T cells",
    "date_of_designation_or_refusal": "16/12/2014",
    "intended_use": "Treatment of non-infectious uveitis",
    "eu_designation_number": "EU/3/14/1405",
    "status": "Withdrawn",
    "first_published_date": "27/02/2015",
    "last_updated_date": "19/11/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1405"
  },
  {
    "medicine_name": "Xospata",
    "related_ema_product_number": "EMEA/H/C/004752",
    "active_substance": "Gilteritinib",
    "date_of_designation_or_refusal": "17/01/2018",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/17/1961",
    "status": "Positive",
    "first_published_date": "13/03/2018",
    "last_updated_date": "08/11/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1961"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Larotrectinib",
    "date_of_designation_or_refusal": "21/03/2018",
    "intended_use": "Treatment of salivary gland cancer",
    "eu_designation_number": "EU/3/18/1995",
    "status": "Withdrawn",
    "first_published_date": "08/05/2018",
    "last_updated_date": "24/10/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1995"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate (larotrectinib)",
    "date_of_designation_or_refusal": "11/01/2016",
    "intended_use": "Treatment of soft tissue sarcoma",
    "eu_designation_number": "EU/3/15/1606",
    "status": "Withdrawn",
    "first_published_date": "05/02/2016",
    "last_updated_date": "24/10/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1606"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Larotrectinib",
    "date_of_designation_or_refusal": "19/11/2018",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/18/2097",
    "status": "Withdrawn",
    "first_published_date": "19/02/2019",
    "last_updated_date": "24/10/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2097"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Larotrectinib",
    "date_of_designation_or_refusal": "19/11/2018",
    "intended_use": "Treatment of papillary thyroid cancer",
    "eu_designation_number": "EU/3/18/2098",
    "status": "Withdrawn",
    "first_published_date": "22/02/2019",
    "last_updated_date": "24/10/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2098"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human monoclonal antibody to human Nogo-A protein of the IgG4/kappa class (atinumab)",
    "date_of_designation_or_refusal": "19/01/2009",
    "intended_use": "Treatment of spinal cord injury",
    "eu_designation_number": "EU/3/08/605",
    "status": "Withdrawn",
    "first_published_date": "15/05/2009",
    "last_updated_date": "16/10/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-605"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "aztreonam lysinate",
    "date_of_designation_or_refusal": "21/06/2004",
    "intended_use": "Treatment of Gram-negative bacterial lung infection in cystic fibrosis",
    "eu_designation_number": "EU/3/04/204",
    "status": "Expired",
    "first_published_date": "30/05/2007",
    "last_updated_date": "16/10/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-204"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human soluble Fc-gamma receptor II b",
    "date_of_designation_or_refusal": "02/08/2007",
    "intended_use": "Treatment of idiopathic thrombocytopenic purpura",
    "eu_designation_number": "EU/3/07/462",
    "status": "Withdrawn",
    "first_published_date": "29/07/2008",
    "last_updated_date": "16/10/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-462"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Ibudilast",
    "date_of_designation_or_refusal": "12/12/2016",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/16/1801",
    "status": "Positive",
    "first_published_date": "09/01/2017",
    "last_updated_date": "16/10/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1801"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human monoclonal IgG1 antibody against programmed death ligand-1 (avelumab)",
    "date_of_designation_or_refusal": "14/12/2015",
    "intended_use": "Treatment of Merkel cell carcinoma",
    "eu_designation_number": "EU/3/15/1590",
    "status": "Withdrawn",
    "first_published_date": "03/02/2016",
    "last_updated_date": "15/10/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1590"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "avelumab",
    "date_of_designation_or_refusal": "12/12/2016",
    "intended_use": "Treatment of gastric cancer",
    "eu_designation_number": "EU/3/16/1798",
    "status": "Withdrawn",
    "first_published_date": "09/01/2017",
    "last_updated_date": "15/10/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1798"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised recombinant monoclonal antibody against epidermal growth factor receptor conjugated to maleimidocaproyl monomethylauristatin F(depatuxizumab mafodotin",
    "date_of_designation_or_refusal": "29/07/2014",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/14/1305",
    "status": "Withdrawn",
    "first_published_date": "01/09/2014",
    "last_updated_date": "15/10/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1305"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Glucopyranosyl lipid A",
    "date_of_designation_or_refusal": "16/10/2017",
    "intended_use": "Treatment of follicular lymphoma",
    "eu_designation_number": "EU/3/17/1924",
    "status": "Withdrawn",
    "first_published_date": "09/01/2018",
    "last_updated_date": "15/10/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1924"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Glucopyranosyl lipid A stable emulsion and recombinant New York oesophageal squamous cell carcinoma-1 protein",
    "date_of_designation_or_refusal": "21/03/2016",
    "intended_use": "Treatment of soft tissue sarcoma",
    "eu_designation_number": "EU/3/16/1634",
    "status": "Withdrawn",
    "first_published_date": "02/05/2016",
    "last_updated_date": "15/10/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1634"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sindbis virus envelope pseudotyped lentiviral vector encoding New York oesophageal squamous cell carcinoma-1 protein",
    "date_of_designation_or_refusal": "21/03/2016",
    "intended_use": "Treatment of soft tissue sarcoma",
    "eu_designation_number": "EU/3/16/1636",
    "status": "Withdrawn",
    "first_published_date": "04/05/2016",
    "last_updated_date": "15/10/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1636"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium benzoate;sodium phenylacetate",
    "date_of_designation_or_refusal": "28/06/2019",
    "intended_use": "Treatment of hyperargininaemia",
    "eu_designation_number": "EU/3/19/2179",
    "status": "Positive",
    "first_published_date": "14/10/2019",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2179"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium benzoate;sodium phenylacetate",
    "date_of_designation_or_refusal": "28/06/2019",
    "intended_use": "Treatment of argininosuccinic aciduria",
    "eu_designation_number": "EU/3/19/2178",
    "status": "Positive",
    "first_published_date": "14/10/2019",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2178"
  },
  {
    "medicine_name": "Altuvoct",
    "related_ema_product_number": "EMEA/H/C/005968",
    "active_substance": "recombinant human coagulation factor VIII Fc - von Willebrand factor - XTEN fusion protein",
    "date_of_designation_or_refusal": "28/06/2019",
    "intended_use": "Treatment of  haemophilia A",
    "eu_designation_number": "EU/3/19/2176",
    "status": "Positive",
    "first_published_date": "14/10/2019",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2176"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant adeno-associated viral vector containing a bioengineered capsid serotype AAV-rh74 and a codon-optimised expression cassette to drive the expression of a secretable form of human acid alpha-glucosidase",
    "date_of_designation_or_refusal": "28/06/2019",
    "intended_use": "Treatment of glycogen storage disease type II (Pompe's disease)",
    "eu_designation_number": "EU/3/19/2175",
    "status": "Positive",
    "first_published_date": "10/10/2019",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2175"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Gaboxadol monohydrate",
    "date_of_designation_or_refusal": "28/06/2019",
    "intended_use": "Treatment of Angelman syndrome",
    "eu_designation_number": "EU/3/19/2172",
    "status": "Positive",
    "first_published_date": "07/10/2019",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2172"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "S[+] apomorphine",
    "date_of_designation_or_refusal": "09/02/2012",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/12/954",
    "status": "Positive",
    "first_published_date": "01/03/2012",
    "last_updated_date": "03/10/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-954"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "5'-cEtG-sp-cEt5MeU-sp-cEt5MeU-sp-dT-sp-dA-sp-dT-sp-dT-sp-dA-sp-dT-sp-dA-sp-dG-sp-dG-sp-dG-sp-cEt5MeC-sp-cEt5MeU-sp-cEt5MeU-3' (also known as DYN101)",
    "date_of_designation_or_refusal": "28/06/2019",
    "intended_use": "Treatment of centronuclear myopathies",
    "eu_designation_number": "EU/3/19/2171",
    "status": "Positive",
    "first_published_date": "03/10/2019",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2171"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-(2-{[2-(1H-benzimidazol-2-yl)ethyl]amino}ethyl)-N-[(3-fluoropyridine-2-yl)methyl]-1,3-oxazole-4-carboxamide trihydrochloride",
    "date_of_designation_or_refusal": "28/06/2019",
    "intended_use": "Treatment of beta thalassaemia intermedia and major",
    "eu_designation_number": "EU/3/19/2170",
    "status": "Positive",
    "first_published_date": "02/10/2019",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2170"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Diaspirin cross-linked haemoglobin",
    "date_of_designation_or_refusal": "19/11/2014",
    "intended_use": "Treatment of hepatocellular carcinoma",
    "eu_designation_number": "EU/3/14/1378",
    "status": "Positive",
    "first_published_date": "16/01/2015",
    "last_updated_date": "30/09/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1378"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Diaspirin cross-linked haemoglobin",
    "date_of_designation_or_refusal": "21/03/2016",
    "intended_use": "Treatment of oesophageal cancer",
    "eu_designation_number": "EU/3/16/1628",
    "status": "Positive",
    "first_published_date": "02/05/2016",
    "last_updated_date": "30/09/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1628"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant mutated extracellular domain of the human acetylcholine receptor subunit alpha1",
    "date_of_designation_or_refusal": "25/07/2019",
    "intended_use": "Treatment of myasthenia gravis",
    "eu_designation_number": "EU/3/19/2187",
    "status": "Positive",
    "first_published_date": "24/09/2019",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2187"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic umbilical cord blood cells treated ex vivo with 16,16-dimethyl prostaglandin E2",
    "date_of_designation_or_refusal": "13/05/2011",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/11/867",
    "status": "Withdrawn",
    "first_published_date": "30/05/2011",
    "last_updated_date": "30/08/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-867"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-[[3-({4-[(5-{2-[(3-Fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-quinazolin-7-yl}oxy)propyl](ethyl)amino]ethyl dihydrogen phosphate trihydrate",
    "date_of_designation_or_refusal": "05/12/2008",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/08/590",
    "status": "Withdrawn",
    "first_published_date": "24/04/2009",
    "last_updated_date": "30/08/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-590"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "5'-CTG CCA CGT TCT CCT GC-(2' methoxy)A-(2' methoxy)C-(2' methoxy)C-3'",
    "date_of_designation_or_refusal": "21/06/2004",
    "intended_use": "Treatment of myasthenia gravis",
    "eu_designation_number": "EU/3/04/203",
    "status": "Withdrawn",
    "first_published_date": "06/09/2005",
    "last_updated_date": "30/08/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-203"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Exendin (9-39)",
    "date_of_designation_or_refusal": "14/10/2016",
    "intended_use": "Treatment of noninsulinoma pancreatogenous hypoglycaemia syndrome",
    "eu_designation_number": "EU/3/16/1750",
    "status": "Positive",
    "first_published_date": "14/11/2016",
    "last_updated_date": "19/08/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1750"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ubenimex",
    "date_of_designation_or_refusal": "21/03/2016",
    "intended_use": "Treatment of pulmonary arterial hypertension",
    "eu_designation_number": "EU/3/16/1638",
    "status": "Positive",
    "first_published_date": "02/05/2016",
    "last_updated_date": "19/08/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1638"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Lonafarnib",
    "date_of_designation_or_refusal": "16/01/2014",
    "intended_use": "Treatment of hepatitis delta virus infection",
    "eu_designation_number": "EU/3/13/1225",
    "status": "Positive",
    "first_published_date": "21/03/2014",
    "last_updated_date": "19/08/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1225"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium benzoate",
    "date_of_designation_or_refusal": "11/01/2016",
    "intended_use": "Treatment of hyperargininaemia",
    "eu_designation_number": "EU/3/15/1600",
    "status": "Positive",
    "first_published_date": "05/02/2016",
    "last_updated_date": "19/08/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1600"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium benzoate",
    "date_of_designation_or_refusal": "11/01/2016",
    "intended_use": "Treatment of argininosuccinic aciduria",
    "eu_designation_number": "EU/3/15/1601",
    "status": "Positive",
    "first_published_date": "05/02/2016",
    "last_updated_date": "19/08/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1601"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium thiosulfate",
    "date_of_designation_or_refusal": "15/01/2015",
    "intended_use": "Treatment for calciphylaxis",
    "eu_designation_number": "EU/3/14/1414",
    "status": "Positive",
    "first_published_date": "05/03/2015",
    "last_updated_date": "19/08/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1414"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium nitrite",
    "date_of_designation_or_refusal": "16/01/2014",
    "intended_use": "Treatment of aneurysmal subarachnoid haemorrhage",
    "eu_designation_number": "EU/3/13/1224",
    "status": "Positive",
    "first_published_date": "21/03/2014",
    "last_updated_date": "19/08/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1224"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Diacerein",
    "date_of_designation_or_refusal": "29/05/2019",
    "intended_use": "Treatment of epidermolysis bullosa",
    "eu_designation_number": "EU/3/19/2161",
    "status": "Positive",
    "first_published_date": "09/08/2019",
    "last_updated_date": "19/08/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2161"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant fragment of human surfactant protein-D",
    "date_of_designation_or_refusal": "23/08/2017",
    "intended_use": "Prevention of bronchopulmonary dysplasia",
    "eu_designation_number": "EU/3/17/1907",
    "status": "Positive",
    "first_published_date": "17/10/2017",
    "last_updated_date": "19/08/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1907"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium benzoate",
    "date_of_designation_or_refusal": "29/05/2019",
    "intended_use": "Treatment of carbamoyl-phosphate synthase-1 deficiency",
    "eu_designation_number": "EU/3/19/2166",
    "status": "Positive",
    "first_published_date": "12/08/2019",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2166"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium phenylacetate;sodium benzoate",
    "date_of_designation_or_refusal": "29/05/2019",
    "intended_use": "Treatment of citrullinaemia type 1",
    "eu_designation_number": "EU/3/19/2165",
    "status": "Positive",
    "first_published_date": "12/08/2019",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2165"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "emixustat hydrochloride",
    "date_of_designation_or_refusal": "29/05/2019",
    "intended_use": "Treatment of Stargardt's disease",
    "eu_designation_number": "EU/3/19/2162",
    "status": "Positive",
    "first_published_date": "09/08/2019",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2162"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic skin-derived ABCB5-positive mesenchymal stem cells",
    "date_of_designation_or_refusal": "29/05/2019",
    "intended_use": "Treatment of epidermolysis bullosa",
    "eu_designation_number": "EU/3/19/2160",
    "status": "Positive",
    "first_published_date": "09/08/2019",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2160"
  },
  {
    "medicine_name": "Zokinvy",
    "related_ema_product_number": "EMEA/H/C/005271",
    "active_substance": "Lonafarnib",
    "date_of_designation_or_refusal": "14/12/2018",
    "intended_use": "Treatment of Hutchinson-Gilford progeria",
    "eu_designation_number": "EU/3/18/2118",
    "status": "Positive",
    "first_published_date": "11/03/2019",
    "last_updated_date": "01/08/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2118"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tamoxifen citrate",
    "date_of_designation_or_refusal": "12/10/2017",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/17/1944",
    "status": "Positive",
    "first_published_date": "15/01/2018",
    "last_updated_date": "30/07/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1944"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "metformin;l-citrulline",
    "date_of_designation_or_refusal": "17/01/2018",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/17/1965",
    "status": "Positive",
    "first_published_date": "12/03/2018",
    "last_updated_date": "30/07/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1965"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant adeno-associated viral vector serotype 6 encoding the B-domain-deleted human factor VIII",
    "date_of_designation_or_refusal": "22/05/2017",
    "intended_use": "Treatment of haemophilia A",
    "eu_designation_number": "EU/3/17/1874",
    "status": "Positive",
    "first_published_date": "29/06/2017",
    "last_updated_date": "30/07/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1874"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "trientine dihydrochloride",
    "date_of_designation_or_refusal": "24/10/2003",
    "intended_use": "Treatment of Wilson's disease",
    "eu_designation_number": "EU/3/03/172",
    "status": "Withdrawn",
    "first_published_date": "26/04/2004",
    "last_updated_date": "29/07/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-172"
  },
  {
    "medicine_name": "Sohonos",
    "related_ema_product_number": "EMEA/H/C/004867",
    "active_substance": "palovarotene",
    "date_of_designation_or_refusal": "19/11/2014",
    "intended_use": "Treatment of fibrodysplasia ossificans progressiva",
    "eu_designation_number": "EU/3/14/1368",
    "status": "Positive",
    "first_published_date": "15/01/2015",
    "last_updated_date": "18/07/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1368"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "diazoxide choline",
    "date_of_designation_or_refusal": "12/10/2017",
    "intended_use": "Treatment of Prader-Willi syndrome",
    "eu_designation_number": "EU/3/17/1941",
    "status": "Positive",
    "first_published_date": "12/01/2018",
    "last_updated_date": "17/07/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1941"
  },
  {
    "medicine_name": "Xyndari",
    "related_ema_product_number": "EMEA/H/C/004734",
    "active_substance": "Levoglutamide",
    "date_of_designation_or_refusal": "04/07/2012",
    "intended_use": "Treatment of sickle cell disease",
    "eu_designation_number": "EU/3/12/1011",
    "status": "Positive",
    "first_published_date": "24/07/2012",
    "last_updated_date": "12/07/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1011"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "muramyl tripeptide phosphatidyl ethanolamine",
    "date_of_designation_or_refusal": "21/06/2004",
    "intended_use": "Treatment of osteosarcoma",
    "eu_designation_number": "EU/3/04/206",
    "status": "Expired",
    "first_published_date": "23/09/2009",
    "last_updated_date": "11/07/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-206"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Caffeine citrate",
    "date_of_designation_or_refusal": "18/02/2003",
    "intended_use": "Treatment of primary apnoea of premature newborns",
    "eu_designation_number": "EU/3/03/132",
    "status": "Expired",
    "first_published_date": "07/03/2007",
    "last_updated_date": "11/07/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-132"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Fc- and CDR-modified humanised monoclonal antibody against C5 (ravulizumab)",
    "date_of_designation_or_refusal": "30/05/2016",
    "intended_use": "Treatment of paroxysmal nocturnal haemoglobinuria",
    "eu_designation_number": "EU/3/16/1661",
    "status": "Withdrawn",
    "first_published_date": "28/06/2016",
    "last_updated_date": "11/07/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1661"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ciclosporin",
    "date_of_designation_or_refusal": "29/07/2004",
    "intended_use": "Prevention of graft rejection after lung transplantation",
    "eu_designation_number": "EU/3/04/209",
    "status": "Positive",
    "first_published_date": "13/12/2007",
    "last_updated_date": "10/07/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-209"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine disulfate salt",
    "date_of_designation_or_refusal": "12/02/2015",
    "intended_use": "Treatment of progressive supranuclear palsy",
    "eu_designation_number": "EU/3/15/1446",
    "status": "Positive",
    "first_published_date": "09/04/2015",
    "last_updated_date": "10/07/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1446"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ciclosporin",
    "date_of_designation_or_refusal": "24/05/2017",
    "intended_use": "Treatment of bronchiolitis obliterans syndrome",
    "eu_designation_number": "EU/3/04/210",
    "status": "Positive",
    "first_published_date": "13/12/2007",
    "last_updated_date": "10/07/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-210"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant monoclonal antibody to human serum amyloid P component (dezamizumab)",
    "date_of_designation_or_refusal": "29/07/2014",
    "intended_use": "Treatment of AL amyloidosis",
    "eu_designation_number": "EU/3/14/1293",
    "status": "Withdrawn",
    "first_published_date": "01/09/2014",
    "last_updated_date": "09/07/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1293"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "carboxy pyrrolidine hexanoyl pyrrolidine carboxylate (miridesap)",
    "date_of_designation_or_refusal": "29/07/2014",
    "intended_use": "Treatment of AL amyloidosis",
    "eu_designation_number": "EU/3/14/1292",
    "status": "Withdrawn",
    "first_published_date": "01/09/2014",
    "last_updated_date": "09/07/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1292"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Cyclocreatine",
    "date_of_designation_or_refusal": "27/06/2016",
    "intended_use": "Treatment of creatine deficiency syndromes",
    "eu_designation_number": "EU/3/16/1676",
    "status": "Withdrawn",
    "first_published_date": "26/07/2016",
    "last_updated_date": "09/07/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1676"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "CD33-directed antibody-drug conjugate consisting of an antibody conjugated to a DNA cross-linking pyrrolobenzodiazepine dimer drug (vadastuximab talirine)",
    "date_of_designation_or_refusal": "10/08/2015",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/15/1545",
    "status": "Withdrawn",
    "first_published_date": "02/10/2015",
    "last_updated_date": "09/07/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1545"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Doxorubicine polyisohexylcyanoacrylate nanoparticles",
    "date_of_designation_or_refusal": "21/10/2004",
    "intended_use": "Treatment of hepatocellular carcinoma",
    "eu_designation_number": "EU/3/04/229",
    "status": "Withdrawn",
    "first_published_date": "21/09/2009",
    "last_updated_date": "09/07/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-229"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human type I pancreatic elastase for the prevention of arteriovenous access dysfunction in haemodialysis patients (vonapanitase)",
    "date_of_designation_or_refusal": "16/01/2014",
    "intended_use": "Prevention of arteriovenous access dysfunction in haemodialysis patients",
    "eu_designation_number": "EU/3/13/1218",
    "status": "Withdrawn",
    "first_published_date": "23/01/2014",
    "last_updated_date": "09/07/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1218"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pegylated recombinant factor VIII (turoctocog alfa pegol)",
    "date_of_designation_or_refusal": "26/04/2012",
    "intended_use": "Treatment of haemophilia A",
    "eu_designation_number": "EU/3/12/995",
    "status": "Withdrawn",
    "first_published_date": "18/06/2012",
    "last_updated_date": "28/06/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-995"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "melatonin",
    "date_of_designation_or_refusal": "11/01/2019",
    "intended_use": "Treatment of perinatal asphyxia",
    "eu_designation_number": "EU/3/18/2127",
    "status": "Positive",
    "first_published_date": "27/03/2019",
    "last_updated_date": "28/06/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2127"
  },
  {
    "medicine_name": "Gamifant",
    "related_ema_product_number": "EMEA/H/C/004386",
    "active_substance": "recombinant human anti-interferon gamma monoclonal antibody (emapalumab)",
    "date_of_designation_or_refusal": "09/06/2010",
    "intended_use": "Treatment of haemophagocytic lymphohistiocytosis",
    "eu_designation_number": "EU/3/10/749",
    "status": "Positive",
    "first_published_date": "23/06/2010",
    "last_updated_date": "19/06/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-749"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous mesenchymal stromal cells on a decellularised tracheal scaffold from a cadaveric donor",
    "date_of_designation_or_refusal": "29/08/2016",
    "intended_use": "Treatment of tracheal stenosis",
    "eu_designation_number": "EU/3/16/1717",
    "status": "Positive",
    "first_published_date": "03/10/2016",
    "last_updated_date": "19/06/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1717"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant adeno-associated viral vector containing human acid alfa-glucosidase-gene",
    "date_of_designation_or_refusal": "04/07/2012",
    "intended_use": "Treatment of glycogen storage disease type II (Pompe's disease)",
    "eu_designation_number": "EU/3/12/1018",
    "status": "Positive",
    "first_published_date": "24/07/2012",
    "last_updated_date": "18/06/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1018"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-quinoline-6-carboxamide monohydrate",
    "date_of_designation_or_refusal": "26/04/2013",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/13/1120",
    "status": "Withdrawn",
    "first_published_date": "14/05/2013",
    "last_updated_date": "17/06/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1120"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-quinoline-6-carboxamide monohydrate",
    "date_of_designation_or_refusal": "12/03/2013",
    "intended_use": "Treatment of hepatocellular carcinoma",
    "eu_designation_number": "EU/3/13/1109",
    "status": "Withdrawn",
    "first_published_date": "05/04/2013",
    "last_updated_date": "17/06/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1109"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Human/murine chimeric monoclonal antibody against endoglin (carotuximab)",
    "date_of_designation_or_refusal": "28/04/2016",
    "intended_use": "Treatment of soft tissue sarcoma",
    "eu_designation_number": "EU/3/16/1648",
    "status": "Withdrawn",
    "first_published_date": "30/05/2016",
    "last_updated_date": "17/06/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1648"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Diacerein",
    "date_of_designation_or_refusal": "08/11/2018",
    "intended_use": "Treatment of epidermolysis bullosa",
    "eu_designation_number": "-",
    "status": "Negative",
    "first_published_date": "14/06/2019",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-epidermolysis-bullosa"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium benzoate;sodium phenylacetate",
    "date_of_designation_or_refusal": "24/04/2019",
    "intended_use": "Treatment of ornithine transcarbamylase deficiency",
    "eu_designation_number": "EU/3/19/2157",
    "status": "Positive",
    "first_published_date": "14/06/2019",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2157"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous human bone marrow-derived haematopoietic and mesenchymal stem cells depleted of erythrocytes, monocytes and lymphocytes",
    "date_of_designation_or_refusal": "24/04/2019",
    "intended_use": "Treatment of spinal cord injury",
    "eu_designation_number": "EU/3/19/2153",
    "status": "Positive",
    "first_published_date": "14/06/2019",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2153"
  },
  {
    "medicine_name": "Palynziq",
    "related_ema_product_number": "EMEA/H/C/004744",
    "active_substance": "pegylated recombinant phenylalanine ammonia lyase (pegvaliase)",
    "date_of_designation_or_refusal": "28/01/2010",
    "intended_use": "Treatment of hyperphenylalaninaemia",
    "eu_designation_number": "EU/3/09/708",
    "status": "Positive",
    "first_published_date": "25/02/2010",
    "last_updated_date": "29/05/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-708"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Human plasma-derived alpha-1 proteinase inhibitor",
    "date_of_designation_or_refusal": "19/03/2015",
    "intended_use": "Treatment of graft-versus-host disease",
    "eu_designation_number": "EU/3/15/1455",
    "status": "Positive",
    "first_published_date": "11/05/2015",
    "last_updated_date": "27/05/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1455"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant protein consisting of modified human growth hormone releasing hormone and the translocation and endopeptidase domains of botulinum toxin serotype D",
    "date_of_designation_or_refusal": "11/01/2012",
    "intended_use": "Treatment of acromegaly",
    "eu_designation_number": "EU/3/11/947",
    "status": "Withdrawn",
    "first_published_date": "01/02/2012",
    "last_updated_date": "23/05/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-947"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Glucagon analogue linked to a human immunoglobulin Fc fragment",
    "date_of_designation_or_refusal": "25/05/2018",
    "intended_use": "Treatment of congenital hyperinsulinism",
    "eu_designation_number": "EU/3/18/2022",
    "status": "Positive",
    "first_published_date": "24/07/2018",
    "last_updated_date": "23/05/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2022"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Efpegsomatropin",
    "date_of_designation_or_refusal": "27/06/2018",
    "intended_use": "Treatment of growth hormone deficiency",
    "eu_designation_number": "EU/3/18/2035",
    "status": "Positive",
    "first_published_date": "21/08/2018",
    "last_updated_date": "23/05/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2035"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "siplizumab",
    "date_of_designation_or_refusal": "16/10/2017",
    "intended_use": "Treatment in solid organ transplantation",
    "eu_designation_number": "EU/3/17/1931",
    "status": "Positive",
    "first_published_date": "09/01/2018",
    "last_updated_date": "23/05/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1931"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "brincidofovir",
    "date_of_designation_or_refusal": "18/11/2016",
    "intended_use": "Treatment of smallpox",
    "eu_designation_number": "EU/3/16/1777",
    "status": "Positive",
    "first_published_date": "14/12/2016",
    "last_updated_date": "23/05/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1777"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "fibrinogen-coated albumin spheres",
    "date_of_designation_or_refusal": "10/08/2015",
    "intended_use": "Treatment of acute radiation syndrome",
    "eu_designation_number": "EU/3/15/1535",
    "status": "Positive",
    "first_published_date": "02/10/2015",
    "last_updated_date": "22/05/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1535"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "fibrinogen-coated albumin spheres",
    "date_of_designation_or_refusal": "12/02/2015",
    "intended_use": "Treatment of Ebola virus disease",
    "eu_designation_number": "EU/3/15/1442",
    "status": "Positive",
    "first_published_date": "09/04/2015",
    "last_updated_date": "22/05/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1442"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Gemfibrozil",
    "date_of_designation_or_refusal": "21/03/2018",
    "intended_use": "Treatment of neuronal ceroid lipofuscinosis",
    "eu_designation_number": "EU/3/18/1993",
    "status": "Positive",
    "first_published_date": "14/05/2018",
    "last_updated_date": "22/05/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1993"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sinapultide;Dipalmitoylphosphatidylcholine;palmitoyl-oleoyl phosphatidylglycerol sodium salt;palmitic acid",
    "date_of_designation_or_refusal": "27/10/2011",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/11/927",
    "status": "Positive",
    "first_published_date": "23/11/2011",
    "last_updated_date": "22/05/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-927"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sinapultide;Dipalmitoylphosphatidylcholine;palmitoyloleoyl phosphatidylglycerol;palmitic acid",
    "date_of_designation_or_refusal": "29/07/2004",
    "intended_use": "Respiratory distress syndrome in premature neonates of less then 37 weeks of gestational age",
    "eu_designation_number": "EU/3/04/217",
    "status": "Positive",
    "first_published_date": "02/09/2009",
    "last_updated_date": "22/05/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-217"
  },
  {
    "medicine_name": "Ayvakyt",
    "related_ema_product_number": "EMEA/H/C/005208",
    "active_substance": "(S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-yl)pyrimidin-5-yl)ethan-1-amine",
    "date_of_designation_or_refusal": "17/07/2017",
    "intended_use": "Treatment of gastrointestinal stromal tumours",
    "eu_designation_number": "EU/3/17/1889",
    "status": "Positive",
    "first_published_date": "14/07/2017",
    "last_updated_date": "22/05/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1889"
  },
  {
    "medicine_name": "Surfaxin; Surfaxin",
    "related_ema_product_number": "EMEA/H/C/000625; EMEA/H/C/000625",
    "active_substance": "sinapultide;Dipalmitoylphosphatidylcholine;palmitoyloleoyl phosphatidylglycerol;palmitic acid",
    "date_of_designation_or_refusal": "29/07/2004",
    "intended_use": "Respiratory distress syndrome in  premature neonates of less than 32 weeks of gestational age",
    "eu_designation_number": "EU/3/04/216",
    "status": "Positive",
    "first_published_date": "23/09/2009",
    "last_updated_date": "22/05/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-216"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sinapultide;Dipalmitoylphosphatidylcholine;palmitoyloleoyl phosphatidylglycerol;palmitic acid",
    "date_of_designation_or_refusal": "04/02/2002",
    "intended_use": "Treatment of acute lung Injury",
    "eu_designation_number": "EU/3/01/079",
    "status": "Positive",
    "first_published_date": "30/05/2007",
    "last_updated_date": "22/05/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-079"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 9 containing the human HGSNAT gene",
    "date_of_designation_or_refusal": "21/05/2015",
    "intended_use": "Treatment of mucopolysaccharidosis IIIC (Sanfilippo C syndrome)",
    "eu_designation_number": "EU/3/15/1491",
    "status": "Positive",
    "first_published_date": "30/06/2015",
    "last_updated_date": "21/05/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1491"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tamibarotene",
    "date_of_designation_or_refusal": "31/07/2018",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/18/2053",
    "status": "Positive",
    "first_published_date": "10/10/2018",
    "last_updated_date": "21/05/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2053"
  },
  {
    "medicine_name": "Cresemba",
    "related_ema_product_number": "EMEA/H/C/002734",
    "active_substance": "Isavuconazonium sulfate",
    "date_of_designation_or_refusal": "04/07/2014",
    "intended_use": "Treatment of invasive aspergillosis",
    "eu_designation_number": "EU/3/14/1284",
    "status": "Positive",
    "first_published_date": "16/07/2014",
    "last_updated_date": "21/05/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1284"
  },
  {
    "medicine_name": "Cresemba",
    "related_ema_product_number": "EMEA/H/C/002734",
    "active_substance": "Isavuconazonium sulfate",
    "date_of_designation_or_refusal": "04/06/2014",
    "intended_use": "Treatment of mucormycosis",
    "eu_designation_number": "EU/3/14/1276",
    "status": "Positive",
    "first_published_date": "10/07/2014",
    "last_updated_date": "21/05/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1276"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Forodesine",
    "date_of_designation_or_refusal": "20/09/2010",
    "intended_use": "Treatment of chronic lymphocytic leukaemia",
    "eu_designation_number": "EU/3/10/780",
    "status": "Positive",
    "first_published_date": "18/10/2010",
    "last_updated_date": "21/05/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-780"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "cysteamine",
    "date_of_designation_or_refusal": "09/12/2011",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/11/928",
    "status": "Positive",
    "first_published_date": "20/12/2011",
    "last_updated_date": "21/05/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-928"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "forodesine hydrochloride",
    "date_of_designation_or_refusal": "29/01/2007",
    "intended_use": "Treatment of cutaneous T-cell lymphoma",
    "eu_designation_number": "EU/3/06/428",
    "status": "Positive",
    "first_published_date": "13/12/2007",
    "last_updated_date": "21/05/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-428"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "forodesine hydrochloride",
    "date_of_designation_or_refusal": "18/12/2006",
    "intended_use": "Treatment of acute lymphoblastic leukaemia",
    "eu_designation_number": "EU/3/06/421",
    "status": "Positive",
    "first_published_date": "13/12/2007",
    "last_updated_date": "21/05/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-421"
  },
  {
    "medicine_name": "Galafold",
    "related_ema_product_number": "EMEA/H/C/004059",
    "active_substance": "1-Deoxygalactonojirimycin hydrochloride",
    "date_of_designation_or_refusal": "22/05/2006",
    "intended_use": "Treatment of Fabry disease",
    "eu_designation_number": "EU/3/06/368",
    "status": "Positive",
    "first_published_date": "15/05/2009",
    "last_updated_date": "21/05/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-368"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Methoxsalen",
    "date_of_designation_or_refusal": "22/05/2006",
    "intended_use": "Treatment of graft-versus-host disease",
    "eu_designation_number": "EU/3/06/374",
    "status": "Positive",
    "first_published_date": "24/04/2009",
    "last_updated_date": "21/05/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-374"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(Manganese, dichloro [(4aR, 13aR, 17aR, 21aR)-1, 2, 3, 4, 4a, 5, 6, 12, 13, 13a, 14, 15, 16, 17, 17a, 18, 19, 20, 21, 21a-eicosahydro-11, 7-nitrilo-7H-dibenzo[ b,h] [1,4,7,10] tetraazacycloheptadecine-κN5, κN13, κN18, κN21, κN22]-) (misopasem manganese)",
    "date_of_designation_or_refusal": "31/01/2008",
    "intended_use": "Prevention of oral mucositis in head and neck cancer patients undergoing radiation therapy",
    "eu_designation_number": "EU/3/07/522",
    "status": "Positive",
    "first_published_date": "10/07/2008",
    "last_updated_date": "17/05/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-522"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "heparin (sodium)",
    "date_of_designation_or_refusal": "22/05/2006",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/06/371",
    "status": "Positive",
    "first_published_date": "15/05/2009",
    "last_updated_date": "17/05/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-371"
  },
  {
    "medicine_name": "Tegsedi",
    "related_ema_product_number": "EMEA/H/C/004782",
    "active_substance": "phosphorothioate oligonucleotide targeted to transthyretin (inotersen)",
    "date_of_designation_or_refusal": "26/03/2014",
    "intended_use": "Treatment of ATTR amyloidosis",
    "eu_designation_number": "EU/3/14/1250",
    "status": "Positive",
    "first_published_date": "06/05/2014",
    "last_updated_date": "17/05/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1250"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 8 containing the human alpha-galactosidase A gene",
    "date_of_designation_or_refusal": "20/03/2017",
    "intended_use": "Treatment of Fabry disease",
    "eu_designation_number": "EU/3/17/1849",
    "status": "Positive",
    "first_published_date": "05/05/2017",
    "last_updated_date": "13/05/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1849"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "9-cis-Retinyl acetate",
    "date_of_designation_or_refusal": "13/05/2011",
    "intended_use": "Treatment of Leber's congenital amaurosis",
    "eu_designation_number": "EU/3/11/861",
    "status": "Positive",
    "first_published_date": "27/05/2011",
    "last_updated_date": "13/05/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-861"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "9-cis-Retinyl acetate",
    "date_of_designation_or_refusal": "13/05/2011",
    "intended_use": "Treatment of retinitis pigmentosa",
    "eu_designation_number": "EU/3/11/865",
    "status": "Positive",
    "first_published_date": "27/05/2011",
    "last_updated_date": "13/05/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-865"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(R)-6-(2-fluorophenyl)-N-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine dihydrochloride (derazantinib)",
    "date_of_designation_or_refusal": "30/05/2016",
    "intended_use": "Treatment of biliary tract cancer",
    "eu_designation_number": "EU/3/16/1657",
    "status": "Positive",
    "first_published_date": "28/06/2016",
    "last_updated_date": "13/05/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1657"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "S-Nitrosoglutathione",
    "date_of_designation_or_refusal": "13/05/2011",
    "intended_use": "Treatment of pre-eclampsia",
    "eu_designation_number": "EU/3/11/870",
    "status": "Positive",
    "first_published_date": "31/05/2011",
    "last_updated_date": "13/05/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-870"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pegylated proline-interferon alpha-2b (ropeginterferon alfa-2b)",
    "date_of_designation_or_refusal": "09/12/2011",
    "intended_use": "Treatment of polycythaemia vera",
    "eu_designation_number": "EU/3/11/932",
    "status": "Withdrawn",
    "first_published_date": "20/12/2011",
    "last_updated_date": "08/05/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-932"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-[3-(2-chloro-4-{[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy}phenyl)-3-hydroxyazetidin-1-yl]pyridine-4-carboxylic acid-2-amino-2-(hydroxymethyl)propane-1,3-diol (1/1)",
    "date_of_designation_or_refusal": "01/04/2019",
    "intended_use": "Treatment of primary sclerosing cholangitis",
    "eu_designation_number": "EU/3/19/2147",
    "status": "Positive",
    "first_published_date": "07/05/2019",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2147"
  },
  {
    "medicine_name": "Infinia",
    "related_ema_product_number": "EMEA/H/C/003934",
    "active_substance": "alpha-1 antitrypsin",
    "date_of_designation_or_refusal": "16/11/2004",
    "intended_use": "Treatment of emphysema secondary to congenital alpha-1 antitrypsin deficiency",
    "eu_designation_number": "EU/3/04/244",
    "status": "Positive",
    "first_published_date": "17/09/2009",
    "last_updated_date": "07/05/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-244"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "eflornithine",
    "date_of_designation_or_refusal": "20/09/2010",
    "intended_use": "Treatment of familial adenomatous polyposis (FAP)",
    "eu_designation_number": "EU/3/10/779",
    "status": "Positive",
    "first_published_date": "18/10/2010",
    "last_updated_date": "29/04/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-779"
  },
  {
    "medicine_name": "Flynpovi",
    "related_ema_product_number": "EMEA/H/C/005043",
    "active_substance": "eflornithine",
    "date_of_designation_or_refusal": "24/01/2013",
    "intended_use": "Treatment of familial adenomatous polyposis (FAP)",
    "eu_designation_number": "EU/3/12/1086",
    "status": "Positive",
    "first_published_date": "01/03/2013",
    "last_updated_date": "29/04/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1086"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised IgG4 monoclonal antibody against extracellular tau",
    "date_of_designation_or_refusal": "28/07/2015",
    "intended_use": "Treatment of progressive supranuclear palsy",
    "eu_designation_number": "EU/3/15/1522",
    "status": "Positive",
    "first_published_date": "18/08/2015",
    "last_updated_date": "29/04/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1522"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-[2,6-bis(1-methylethyl)phenyl]-N'-[[1-[4-(dimethylamino)phenyl]cyclopentyl]methyl]urea, hydrochloride salt",
    "date_of_designation_or_refusal": "17/01/2018",
    "intended_use": "Treatment of congenital adrenal hyperplasia",
    "eu_designation_number": "EU/3/17/1967",
    "status": "Positive",
    "first_published_date": "13/03/2018",
    "last_updated_date": "26/04/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1967"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "alpha-1 antitrypsin",
    "date_of_designation_or_refusal": "16/11/2004",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/04/243",
    "status": "Positive",
    "first_published_date": "17/09/2009",
    "last_updated_date": "25/04/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-243"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "acetylleucine",
    "date_of_designation_or_refusal": "22/11/2018",
    "intended_use": "Treatment of spinocerebellar ataxia",
    "eu_designation_number": "EU/3/18/2059",
    "status": "Positive",
    "first_published_date": "20/12/2018",
    "last_updated_date": "25/04/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2059"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "acetylleucine",
    "date_of_designation_or_refusal": "11/01/2019",
    "intended_use": "Treatment of ataxia telangiectasia",
    "eu_designation_number": "EU/3/18/2124",
    "status": "Positive",
    "first_published_date": "27/03/2019",
    "last_updated_date": "25/04/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2124"
  },
  {
    "medicine_name": "Aqneursa",
    "related_ema_product_number": "EMEA/H/C/006327",
    "active_substance": "acetylleucine",
    "date_of_designation_or_refusal": "20/03/2017",
    "intended_use": "Treatment of Niemann-Pick disease",
    "eu_designation_number": "EU/3/17/1848",
    "status": "Positive",
    "first_published_date": "05/05/2017",
    "last_updated_date": "25/04/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1848"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ursodeoxycholic acid",
    "date_of_designation_or_refusal": "22/05/2017",
    "intended_use": "Treatment of Niemann-Pick disease",
    "eu_designation_number": "EU/3/17/1878",
    "status": "Positive",
    "first_published_date": "29/06/2017",
    "last_updated_date": "25/04/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1878"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "acetylleucine",
    "date_of_designation_or_refusal": "12/12/2017",
    "intended_use": "Treatment of GM2 gangliosidosis",
    "eu_designation_number": "EU/3/17/1949",
    "status": "Positive",
    "first_published_date": "24/01/2018",
    "last_updated_date": "25/04/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1949"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 2 containing the human CHM gene encoding human Rab escort protein 1",
    "date_of_designation_or_refusal": "04/06/2014",
    "intended_use": "Treatment of choroideraemia",
    "eu_designation_number": "EU/3/14/1278",
    "status": "Positive",
    "first_published_date": "10/07/2014",
    "last_updated_date": "24/04/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1278"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant adeno-associated viral vector containing a bioengineered capsid and a codon-optimised expression cassette to drive the expression of the SQ form of a B-domain deleted human coagulation factor VIII",
    "date_of_designation_or_refusal": "26/10/2018",
    "intended_use": "Treatment of haemophilia A",
    "eu_designation_number": "EU/3/18/2079",
    "status": "Positive",
    "first_published_date": "10/01/2019",
    "last_updated_date": "24/04/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2079"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "chimeric monoclonal antibody to shiga toxin 1 and 2",
    "date_of_designation_or_refusal": "26/08/2005",
    "intended_use": "Treatment of shiga-toxin-producing bacterial infection",
    "eu_designation_number": "EU/3/05/301",
    "status": "Positive",
    "first_published_date": "09/02/2006",
    "last_updated_date": "12/04/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-301"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 2 containing the human REP1 gene",
    "date_of_designation_or_refusal": "04/07/2014",
    "intended_use": "Treatment of choroideraemia",
    "eu_designation_number": "EU/3/14/1290",
    "status": "Positive",
    "first_published_date": "15/07/2014",
    "last_updated_date": "12/04/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1290"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Tyr-Met-Phe-Pro-Asn-Ala-Pro-Tyr-Leu, Ser-Gly-Gln-Ala-Tyr-Met-Phe-Pro-Asn-Ala-Pro-Tyr-Leu-Pro-Ser-Cys-Leu-Glu-Ser, Arg-Ser-Asp-Glu-Leu-Val-Arg-His-His-Asn-Met-His-Gln-Arg-Asn-Met-Thr-Lys-Leu and Pro-Gly-Cys-Asn-Lys-Arg-Tyr-Phe-Lys-Leu-Ser-His-Leu-Gln-Met-His-Ser-Arg-Lys-His-Thr-Gly",
    "date_of_designation_or_refusal": "28/04/2016",
    "intended_use": "Treatment of  malignant mesothelioma",
    "eu_designation_number": "EU/3/16/1656",
    "status": "Positive",
    "first_published_date": "30/05/2016",
    "last_updated_date": "12/04/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1656"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Tyr-Met-Phe-Pro-Asn-Ala-Pro-Tyr-Leu, Ser-Gly-Gln-Ala-Tyr-Met-Phe-Pro-Asn-Ala-Pro-Tyr-Leu-Pro-Ser-Cys-Leu-Glu-Ser, Arg-Ser-Asp-Glu-Leu-Val-Arg-His-His-Asn-Met-His-Gln-Arg-Asn-Met-Thr-Lys-Leu and Pro-Gly-Cys-Asn-Lys-Arg-Tyr-Phe-Lys-Leu-Ser-His-Leu-Gln-Met-His-Ser-Arg-Lys-His-Thr-Gly",
    "date_of_designation_or_refusal": "28/04/2016",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/16/1655",
    "status": "Positive",
    "first_published_date": "30/05/2016",
    "last_updated_date": "12/04/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1655"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human minibody against complement component C5 fused with RGD-motif",
    "date_of_designation_or_refusal": "20/01/2009",
    "intended_use": "Prevention of ischaemia/reperfusion injury associated with solid organ transplantation",
    "eu_designation_number": "EU/3/08/604",
    "status": "Withdrawn",
    "first_published_date": "29/06/2009",
    "last_updated_date": "12/04/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-604"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human minibody against complement component C5",
    "date_of_designation_or_refusal": "27/10/2011",
    "intended_use": "Treatment of primary membranoproliferative glomerulonephritis",
    "eu_designation_number": "EU/3/11/926",
    "status": "Withdrawn",
    "first_published_date": "23/11/2011",
    "last_updated_date": "12/04/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-926"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human minibody against complement component C5",
    "date_of_designation_or_refusal": "22/09/2008",
    "intended_use": "Treatment of atypical haemolytic uraemic syndrome (aHUS)",
    "eu_designation_number": "EU/3/08/571",
    "status": "Withdrawn",
    "first_published_date": "02/04/2009",
    "last_updated_date": "12/04/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-571"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "cholest-4-en-3-one, oxime",
    "date_of_designation_or_refusal": "10/03/2005",
    "intended_use": "Treatment of 5q spinal muscular atrophy",
    "eu_designation_number": "EU/3/05/264",
    "status": "Withdrawn",
    "first_published_date": "11/10/2005",
    "last_updated_date": "12/04/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-264"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Fusion proteins composed by a genetically modified cholera toxin subunit A1, peptides from the acetylcholine receptor alpha chain and a dimer of the D fragment from Staphylococcus aureus protein A",
    "date_of_designation_or_refusal": "21/05/2015",
    "intended_use": "Treatment of myasthenia gravis",
    "eu_designation_number": "EU/3/15/1489",
    "status": "Withdrawn",
    "first_published_date": "30/06/2015",
    "last_updated_date": "12/04/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1489"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "venetoclax",
    "date_of_designation_or_refusal": "17/02/2016",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/16/1617",
    "status": "Withdrawn",
    "first_published_date": "07/04/2016",
    "last_updated_date": "12/04/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1617"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "nitric oxide",
    "date_of_designation_or_refusal": "24/04/2015",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/15/1484",
    "status": "Withdrawn",
    "first_published_date": "22/05/2015",
    "last_updated_date": "12/04/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1484"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tosedostat",
    "date_of_designation_or_refusal": "24/07/2009",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/09/659",
    "status": "Withdrawn",
    "first_published_date": "11/09/2009",
    "last_updated_date": "12/04/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-659"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic cultured postnatal thymus-derived tissue",
    "date_of_designation_or_refusal": "26/02/2019",
    "intended_use": "Treatment of severe combined immunodeficiency due to FOXN1 deficiency",
    "eu_designation_number": "EU/3/19/2137",
    "status": "Positive",
    "first_published_date": "09/04/2019",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2137"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Poly(N-acetyl, N-arginyl)glucosamine",
    "date_of_designation_or_refusal": "26/02/2019",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/19/2144",
    "status": "Positive",
    "first_published_date": "09/04/2019",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2144"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "9-cis, 12-cis-11,11-D2-linoleic acid ethyl ester",
    "date_of_designation_or_refusal": "26/02/2019",
    "intended_use": "Treatment of infantile neuroaxonal dystrophy",
    "eu_designation_number": "EU/3/19/2134",
    "status": "Positive",
    "first_published_date": "09/04/2019",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2134"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Lurbinectedin",
    "date_of_designation_or_refusal": "26/02/2019",
    "intended_use": "Treatment of small cell lung cancer",
    "eu_designation_number": "EU/3/19/2143",
    "status": "Positive",
    "first_published_date": "09/04/2019",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2143"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human club cell 10 KDa protein",
    "date_of_designation_or_refusal": "27/02/2017",
    "intended_use": "Treatment of bronchiolitis obliterans syndrome",
    "eu_designation_number": "EU/3/17/1842",
    "status": "Positive",
    "first_published_date": "31/03/2017",
    "last_updated_date": "08/04/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1842"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Methylthioninium",
    "date_of_designation_or_refusal": "26/11/2010",
    "intended_use": "treatment of frontotemporal dementia with parkinsonism-17",
    "eu_designation_number": "EU/3/10/807",
    "status": "Positive",
    "first_published_date": "15/12/2010",
    "last_updated_date": "28/03/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-807"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Methylthioninium",
    "date_of_designation_or_refusal": "26/11/2010",
    "intended_use": "treatment of progressive non-fluent aphasia",
    "eu_designation_number": "EU/3/10/806",
    "status": "Positive",
    "first_published_date": "15/12/2010",
    "last_updated_date": "28/03/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-806"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Methylthioninium",
    "date_of_designation_or_refusal": "26/11/2010",
    "intended_use": "treatment of behavioural variant frontotemporal dementia",
    "eu_designation_number": "EU/3/10/805",
    "status": "Positive",
    "first_published_date": "15/12/2010",
    "last_updated_date": "28/03/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-805"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Methylthioninium",
    "date_of_designation_or_refusal": "26/11/2010",
    "intended_use": "Treatment of progressive supranuclear palsy",
    "eu_designation_number": "EU/3/10/804",
    "status": "Positive",
    "first_published_date": "15/12/2010",
    "last_updated_date": "28/03/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-804"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Mercaptamine-pantetheine disulfide",
    "date_of_designation_or_refusal": "11/01/2019",
    "intended_use": "Treatment of Rett syndrome",
    "eu_designation_number": "EU/3/18/2128",
    "status": "Positive",
    "first_published_date": "27/03/2019",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2128"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "vinorelbine tartrate",
    "date_of_designation_or_refusal": "11/01/2019",
    "intended_use": "Treatment of soft tissue sarcoma",
    "eu_designation_number": "EU/3/18/2133",
    "status": "Positive",
    "first_published_date": "27/03/2019",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2133"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "synthetic double-stranded siRNA oligonucleotide directed against TMPRSS6 mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues",
    "date_of_designation_or_refusal": "11/01/2019",
    "intended_use": "Treatment of beta thalassaemia intermedia and major",
    "eu_designation_number": "EU/3/18/2132",
    "status": "Positive",
    "first_published_date": "27/03/2019",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2132"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "benserazide hydrochloride",
    "date_of_designation_or_refusal": "11/01/2019",
    "intended_use": "The treatment of sickle cell disease",
    "eu_designation_number": "EU/3/18/2125",
    "status": "Positive",
    "first_published_date": "27/03/2019",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2125"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human glucagon-like peptide-2 analogue linked to a human immunoglobulin Fc fragment",
    "date_of_designation_or_refusal": "11/01/2019",
    "intended_use": "Treatment of short bowel syndrome",
    "eu_designation_number": "EU/3/18/2126",
    "status": "Positive",
    "first_published_date": "27/03/2019",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2126"
  },
  {
    "medicine_name": "Coagadex",
    "related_ema_product_number": "EMEA/H/C/003855",
    "active_substance": "human coagulation factor X",
    "date_of_designation_or_refusal": "14/09/2007",
    "intended_use": "Treatment of hereditary factor X deficiency",
    "eu_designation_number": "EU/3/07/471",
    "status": "Positive",
    "first_published_date": "29/07/2008",
    "last_updated_date": "26/03/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-471"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "acebutolol hydrochloride",
    "date_of_designation_or_refusal": "14/10/2016",
    "intended_use": "Treatment of Smith-Magenis syndrome",
    "eu_designation_number": "EU/3/16/1742",
    "status": "Positive",
    "first_published_date": "15/11/2016",
    "last_updated_date": "18/03/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1742"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human haptoglobin",
    "date_of_designation_or_refusal": "09/12/2011",
    "intended_use": "Treatment of sickle cell disease",
    "eu_designation_number": "EU/3/11/936",
    "status": "Positive",
    "first_published_date": "20/12/2011",
    "last_updated_date": "18/03/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-936"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "6-fluoro-9-methyl-9H-pyrido[3,4-b]-indole",
    "date_of_designation_or_refusal": "14/12/2018",
    "intended_use": "Treatment of sudden sensorineural hearing loss",
    "eu_designation_number": "EU/3/18/2106",
    "status": "Positive",
    "first_published_date": "12/03/2019",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2106"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "6,8-bis(benzylthio)octanoic acid",
    "date_of_designation_or_refusal": "14/12/2018",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/18/2123",
    "status": "Positive",
    "first_published_date": "12/03/2019",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2123"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "6,8-bis(benzylthio)octanoic acid",
    "date_of_designation_or_refusal": "14/12/2018",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/18/2105",
    "status": "Positive",
    "first_published_date": "12/03/2019",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2105"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "",
    "date_of_designation_or_refusal": "14/12/2018",
    "intended_use": "Treatment of biliary atresia",
    "eu_designation_number": "EU/3/18/2103",
    "status": "Positive",
    "first_published_date": "12/03/2019",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2103"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Marizomib",
    "date_of_designation_or_refusal": "14/12/2018",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/18/2119",
    "status": "Positive",
    "first_published_date": "12/03/2019",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2119"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(4-{(2S,4S)-4-ethoxy-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]piperidin-2-yl}benzoic acid-hydrogen chloride(1/1))",
    "date_of_designation_or_refusal": "14/12/2018",
    "intended_use": "Treatment of C3 glomerulopathy",
    "eu_designation_number": "EU/3/18/2104",
    "status": "Positive",
    "first_published_date": "11/03/2019",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2104"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic ABCB5-positive limbal stem cells",
    "date_of_designation_or_refusal": "14/12/2018",
    "intended_use": "Treatment of limbal stem cell deficiency",
    "eu_designation_number": "EU/3/18/2111",
    "status": "Positive",
    "first_published_date": "11/03/2019",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2111"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium 2-hydroxylinoleate",
    "date_of_designation_or_refusal": "14/12/2018",
    "intended_use": "Treatment of biliary tract cancer",
    "eu_designation_number": "EU/3/18/2121",
    "status": "Positive",
    "first_published_date": "08/03/2019",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2121"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector expressing human 21- hydroxylase",
    "date_of_designation_or_refusal": "14/12/2018",
    "intended_use": "Treatment of congenital adrenal hyperplasia",
    "eu_designation_number": "EU/3/18/2108",
    "status": "Positive",
    "first_published_date": "07/03/2019",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2108"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "avacopan",
    "date_of_designation_or_refusal": "20/06/2017",
    "intended_use": "Treatment of C3 glomerulopathy",
    "eu_designation_number": "EU/3/17/1880",
    "status": "Positive",
    "first_published_date": "17/07/2017",
    "last_updated_date": "06/03/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1880"
  },
  {
    "medicine_name": "Luxturna",
    "related_ema_product_number": "EMEA/H/C/004451",
    "active_substance": "adenovirus-associated viral vector serotype 2 containing the human RPE65 gene (voretigene neparvovec)",
    "date_of_designation_or_refusal": "28/07/2015",
    "intended_use": "Treatment of retinitis pigmentosa",
    "eu_designation_number": "EU/3/15/1518",
    "status": "Positive",
    "first_published_date": "18/08/2015",
    "last_updated_date": "04/03/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1518"
  },
  {
    "medicine_name": "Luxturna",
    "related_ema_product_number": "EMEA/H/C/004451",
    "active_substance": "adenovirus-associated viral vector serotype 2 containing the human RPE65 gene (voretigene neparvovec)",
    "date_of_designation_or_refusal": "02/04/2012",
    "intended_use": "Treatment of Leber's congenital amaurosis",
    "eu_designation_number": "EU/3/12/981",
    "status": "Positive",
    "first_published_date": "30/04/2012",
    "last_updated_date": "04/03/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-981"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-2Thi-Gly-Leu-Met(O2)-NH2-DOTA-213-bismuth",
    "date_of_designation_or_refusal": "19/11/2018",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/18/2092",
    "status": "Positive",
    "first_published_date": "25/02/2019",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2092"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "anti-GD2 monoclonal antibody 3F8 humanised",
    "date_of_designation_or_refusal": "19/11/2018",
    "intended_use": "Treatment of neuroblastoma",
    "eu_designation_number": "EU/3/18/2094",
    "status": "Positive",
    "first_published_date": "25/02/2019",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2094"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "smilagenin",
    "date_of_designation_or_refusal": "27/09/2011",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/11/914",
    "status": "Positive",
    "first_published_date": "17/10/2011",
    "last_updated_date": "22/02/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-914"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pegylated recombinant human hyaluronidase PH20(pegvorhyaluronidase alfa)",
    "date_of_designation_or_refusal": "16/12/2014",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/14/1394",
    "status": "Positive",
    "first_published_date": "26/02/2015",
    "last_updated_date": "22/02/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1394"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ciprofloxacin",
    "date_of_designation_or_refusal": "03/08/2007",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/07/469",
    "status": "Withdrawn",
    "first_published_date": "15/06/2009",
    "last_updated_date": "21/02/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-469"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "chimeric monoclonal antibody against GD2 (dinutuximab)",
    "date_of_designation_or_refusal": "21/06/2011",
    "intended_use": "Treatment of neuroblastoma",
    "eu_designation_number": "EU/3/11/879",
    "status": "Withdrawn",
    "first_published_date": "12/07/2011",
    "last_updated_date": "21/02/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-879"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "celecoxib",
    "date_of_designation_or_refusal": "21/11/2001",
    "intended_use": "Treatment of familial adenomatous polyposis (FAP)",
    "eu_designation_number": "EU/3/01/070",
    "status": "Withdrawn",
    "first_published_date": "15/06/2009",
    "last_updated_date": "21/02/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-070"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "rilonacept",
    "date_of_designation_or_refusal": "10/07/2007",
    "intended_use": "Treatment of cryopirin-associated periodic syndromes",
    "eu_designation_number": "EU/3/07/456",
    "status": "Withdrawn",
    "first_published_date": "29/07/2008",
    "last_updated_date": "21/02/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-456"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-Allyl-1-[6-(1-hydroxy-1-methylethyl)pyridin-2-yl]-6-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one",
    "date_of_designation_or_refusal": "26/04/2012",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/12/989",
    "status": "Withdrawn",
    "first_published_date": "18/03/2012",
    "last_updated_date": "21/02/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-989"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "amphotericin B",
    "date_of_designation_or_refusal": "28/08/2006",
    "intended_use": "Prevention of pulmonary fungal infection in patients deemed at risk",
    "eu_designation_number": "EU/3/06/391",
    "status": "Withdrawn",
    "first_published_date": "02/04/2009",
    "last_updated_date": "21/02/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-391"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Halofuginone hydrobromide",
    "date_of_designation_or_refusal": "26/04/2012",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/12/988",
    "status": "Withdrawn",
    "first_published_date": "18/06/2012",
    "last_updated_date": "21/02/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-988"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "riociguat",
    "date_of_designation_or_refusal": "29/07/2014",
    "intended_use": "Treatment of systemic sclerosis",
    "eu_designation_number": "EU/3/14/1299",
    "status": "Withdrawn",
    "first_published_date": "01/09/2014",
    "last_updated_date": "21/02/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1299"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "alpha-1 proteinase inhibitor",
    "date_of_designation_or_refusal": "16/02/2006",
    "intended_use": "Treatment of emphysema secondary to congenital alpha-1 antitrypsin deficiency",
    "eu_designation_number": "EU/3/06/350",
    "status": "Withdrawn",
    "first_published_date": "17/09/2009",
    "last_updated_date": "21/02/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-350"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human growth hormone modified by fusion with two hydrophilic polypeptide chains (somavaratan)",
    "date_of_designation_or_refusal": "05/08/2013",
    "intended_use": "Treatment of growth hormone deficiency",
    "eu_designation_number": "EU/3/13/1179",
    "status": "Withdrawn",
    "first_published_date": "13/09/2013",
    "last_updated_date": "21/02/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1179"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector containing DNA encoding an RNAi targeting rhodopsin;adeno-associated viral vector containing a rhodopsin gene",
    "date_of_designation_or_refusal": "17/12/2010",
    "intended_use": "Treatment of rhodopsin-linked retinitis pigmentosa",
    "eu_designation_number": "EU/3/10/817",
    "status": "Withdrawn",
    "first_published_date": "19/01/2011",
    "last_updated_date": "21/02/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-817"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "becatecarin",
    "date_of_designation_or_refusal": "25/07/2006",
    "intended_use": "Treatment of cancers of the biliary tree",
    "eu_designation_number": "EU/3/06/388",
    "status": "Withdrawn",
    "first_published_date": "24/04/2009",
    "last_updated_date": "21/02/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-388"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4 methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino) benzamide (entrectinib)",
    "date_of_designation_or_refusal": "11/11/2015",
    "intended_use": "Treatment of neuroblastoma",
    "eu_designation_number": "EU/3/15/1580",
    "status": "Withdrawn",
    "first_published_date": "06/01/2016",
    "last_updated_date": "21/02/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1580"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Covalently closed DNA plasmids coding for cytomegalovirus phosphoprotein 65 and glycoprotein B genes",
    "date_of_designation_or_refusal": "09/08/2012",
    "intended_use": "Prevention of cytomegalovirus disease in patients with impaired cell-mediated immunity",
    "eu_designation_number": "EU/3/12/1042",
    "status": "Withdrawn",
    "first_published_date": "26/09/2012",
    "last_updated_date": "21/02/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1042"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(3S)-3-{4-[7-(aminocarbonyl)-2H-indazol-2-yl] phenyl} piperidine tosilate monohydrate salt",
    "date_of_designation_or_refusal": "01/10/2010",
    "intended_use": "Treatment of mantle cell lymphoma",
    "eu_designation_number": "EU/3/10/787",
    "status": "Withdrawn",
    "first_published_date": "14/10/2010",
    "last_updated_date": "21/02/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-787"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "trans-4-[4-[5-[[6-(trifluoromethyl)-3-pyridinyl]amino]-2-pyridinyl]phenyl] cyclohexane acetic acid sodium salt",
    "date_of_designation_or_refusal": "14/09/2012",
    "intended_use": "Treatment of familial chylomicronaemia syndrome (type-I hyperlipoproteinaemia)",
    "eu_designation_number": "EU/3/12/1036",
    "status": "Withdrawn",
    "first_published_date": "05/12/2012",
    "last_updated_date": "21/02/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1036"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tideglusib",
    "date_of_designation_or_refusal": "19/03/2015",
    "intended_use": "Treatment of fragile X syndrome",
    "eu_designation_number": "EU/3/15/1452",
    "status": "Withdrawn",
    "first_published_date": "11/05/2015",
    "last_updated_date": "21/02/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1452"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Iodine (131I) chlorotoxin",
    "date_of_designation_or_refusal": "22/10/2007",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/07/492",
    "status": "Withdrawn",
    "first_published_date": "21/09/2009",
    "last_updated_date": "21/02/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-492"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Isofagomine tartrate",
    "date_of_designation_or_refusal": "23/10/2007",
    "intended_use": "Treatment of Gaucher disease",
    "eu_designation_number": "EU/3/07/493",
    "status": "Withdrawn",
    "first_published_date": "21/09/2009",
    "last_updated_date": "21/02/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-493"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "1-Cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea",
    "date_of_designation_or_refusal": "26/11/2009",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/09/693",
    "status": "Withdrawn",
    "first_published_date": "10/12/2009",
    "last_updated_date": "21/02/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-693"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "obinutuzumab",
    "date_of_designation_or_refusal": "22/08/2014",
    "intended_use": "Treatment of diffuse large B-cell lymphoma",
    "eu_designation_number": "EU/3/14/1325",
    "status": "Withdrawn",
    "first_published_date": "02/10/2014",
    "last_updated_date": "21/02/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1325"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naphthyridin-3(2H)-one mono-hydrochloride",
    "date_of_designation_or_refusal": "30/11/2009",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/09/695",
    "status": "Withdrawn",
    "first_published_date": "10/12/2009",
    "last_updated_date": "21/02/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-695"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "histamine dihydrochloride",
    "date_of_designation_or_refusal": "11/04/2005",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/05/272",
    "status": "Expired",
    "first_published_date": "07/03/2007",
    "last_updated_date": "20/02/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-272"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "miglustat",
    "date_of_designation_or_refusal": "16/02/2006",
    "intended_use": "Treatment of Niemann-Pick's disease, type C",
    "eu_designation_number": "EU/3/06/351",
    "status": "Expired",
    "first_published_date": "24/08/2006",
    "last_updated_date": "20/02/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-351"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "azacitidine",
    "date_of_designation_or_refusal": "06/02/2002",
    "intended_use": "Treatment of myelodysplastic syndromes",
    "eu_designation_number": "EU/3/01/084",
    "status": "Expired",
    "first_published_date": "17/09/2009",
    "last_updated_date": "20/02/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-084"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "azacitidine",
    "date_of_designation_or_refusal": "29/11/2007",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/07/509",
    "status": "Expired",
    "first_published_date": "17/09/2009",
    "last_updated_date": "20/02/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-509"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "rufinamide",
    "date_of_designation_or_refusal": "20/10/2004",
    "intended_use": "Treatment of Lennox-Gastaut syndrome",
    "eu_designation_number": "EU/3/04/240",
    "status": "Expired",
    "first_published_date": "28/02/2007",
    "last_updated_date": "20/02/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-240"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant megakaryopoiesis-stimulating protein",
    "date_of_designation_or_refusal": "27/05/2005",
    "intended_use": "Treatment of idiopathic thrombocytopenic purpura",
    "eu_designation_number": "EU/3/05/283",
    "status": "Expired",
    "first_published_date": "29/06/2005",
    "last_updated_date": "20/02/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-283"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand",
    "date_of_designation_or_refusal": "19/11/2018",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/18/2085",
    "status": "Positive",
    "first_published_date": "20/02/2019",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2085"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "apraglutide",
    "date_of_designation_or_refusal": "19/11/2018",
    "intended_use": "Treatment of short bowel syndrome",
    "eu_designation_number": "EU/3/18/2102",
    "status": "Positive",
    "first_published_date": "19/02/2019",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2102"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "4-[[(1S,4S)-5-[[4-[4-(oxazol-2-yl)phenoxy]phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]benzoic acid (acebilustat)",
    "date_of_designation_or_refusal": "19/11/2014",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/14/1363",
    "status": "Positive",
    "first_published_date": "15/01/2015",
    "last_updated_date": "19/02/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1363"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human apotransferrin",
    "date_of_designation_or_refusal": "19/11/2018",
    "intended_use": "Treatment of beta thalassaemia intermedia and major",
    "eu_designation_number": "EU/3/18/2093",
    "status": "Positive",
    "first_published_date": "19/02/2019",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2093"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "cyclo[L-alanyl-L-seryl-L-isoleucyl-L-prolyl-L-prolyl-L-glutaminyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-(2S)-2-aminodecanoyl-L-alpha-glutamyl-L-threonyl]acetate",
    "date_of_designation_or_refusal": "19/11/2018",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/18/2086",
    "status": "Positive",
    "first_published_date": "19/02/2019",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2086"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "rucaparib",
    "date_of_designation_or_refusal": "10/10/2012",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/12/1049",
    "status": "Withdrawn",
    "first_published_date": "16/11/2012",
    "last_updated_date": "19/02/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1049"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "imlifidase",
    "date_of_designation_or_refusal": "19/11/2018",
    "intended_use": "Treatment of anti-glomerular basement membrane disease",
    "eu_designation_number": "EU/3/18/2096",
    "status": "Positive",
    "first_published_date": "13/02/2019",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2096"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pegylated B-domain-deleted sequence-modified recombinant human factor VIII (damoctocog alfa pegol)",
    "date_of_designation_or_refusal": "23/02/2011",
    "intended_use": "Treatment of haemophilia A",
    "eu_designation_number": "EU/3/10/847",
    "status": "Withdrawn",
    "first_published_date": "07/03/2011",
    "last_updated_date": "28/01/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-847"
  },
  {
    "medicine_name": "Poteligeo",
    "related_ema_product_number": "EMEA/H/C/004232",
    "active_substance": "mogamulizumab",
    "date_of_designation_or_refusal": "14/10/2016",
    "intended_use": "Treatment of cutaneous T-cell lymphoma",
    "eu_designation_number": "EU/3/16/1756",
    "status": "Positive",
    "first_published_date": "14/11/2016",
    "last_updated_date": "28/01/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1756"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "3-(5-Amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride",
    "date_of_designation_or_refusal": "27/06/2016",
    "intended_use": "Treatment of diffuse large B-cell lymphoma",
    "eu_designation_number": "EU/3/16/1672",
    "status": "Positive",
    "first_published_date": "26/07/2016",
    "last_updated_date": "23/01/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1672"
  },
  {
    "medicine_name": "Exondys",
    "related_ema_product_number": "EMEA/H/C/004355",
    "active_substance": "RNA, [P-deoxy-P-(dimethylamino)] (2',3'-dideoxy-2',3'-imino-2',3'-seco) (2'a→5') (C-m5U-C-C-A-A-C-A-m5U-C-A-A-G-G-A-A-G-A-m5U-G-G-C-A-m5U-m5U-m5U-C-m5U-A-G), P-[4-[[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]carbonyl]-1-piperazinyl]-N,N dimethylaminophosphonamidate (Eteplirsen)",
    "date_of_designation_or_refusal": "03/12/2008",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/08/586",
    "status": "Positive",
    "first_published_date": "29/06/2009",
    "last_updated_date": "22/01/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-586"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "doxorubicin hydrochloride",
    "date_of_designation_or_refusal": "23/02/2011",
    "intended_use": "Treatment of hepatocellular carcinoma",
    "eu_designation_number": "EU/3/10/833",
    "status": "Positive",
    "first_published_date": "04/03/2011",
    "last_updated_date": "22/01/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-833"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous skeletal myoblasts expanded ex vivo",
    "date_of_designation_or_refusal": "13/04/2018",
    "intended_use": "Treatment of oculopharyngeal muscular dystrophy",
    "eu_designation_number": "-",
    "status": "Negative",
    "first_published_date": "11/01/2019",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-oculopharyngeal-muscular-dystrophy"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Peptides YMFPNAPYL, SGQAYMFPNAPYLPSCLES, RSDELVRHHNMHQRNMTKL and PGCNKRYFKLSHLQMHSRKHTG",
    "date_of_designation_or_refusal": "26/10/2018",
    "intended_use": "Treatment of multiple myeloma",
    "eu_designation_number": "EU/3/18/2078",
    "status": "Positive",
    "first_published_date": "10/01/2019",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2078"
  },
  {
    "medicine_name": "Amglidia",
    "related_ema_product_number": "EMEA/H/C/004379",
    "active_substance": "glibenclamide",
    "date_of_designation_or_refusal": "15/01/2016",
    "intended_use": "Treatment of neonatal diabetes",
    "eu_designation_number": "EU/3/15/1589",
    "status": "Positive",
    "first_published_date": "02/02/2016",
    "last_updated_date": "04/01/2019",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1589"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "bertilimumab",
    "date_of_designation_or_refusal": "24/11/2018",
    "intended_use": "Treatment of bullous pemphigoid",
    "eu_designation_number": "EU/3/18/2062",
    "status": "Positive",
    "first_published_date": "20/12/2018",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2062"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(S)-(−)-3-(4-aminophenyl)-2-methoxypropanoic acid",
    "date_of_designation_or_refusal": "24/08/2018",
    "intended_use": "Treatment of idiopathic pulmonary fibrosis",
    "eu_designation_number": "EU/3/18/2056",
    "status": "Positive",
    "first_published_date": "19/12/2018",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2056"
  },
  {
    "medicine_name": "Aliqopa",
    "related_ema_product_number": "EMEA/H/C/004334",
    "active_substance": "Copanlisib",
    "date_of_designation_or_refusal": "24/08/2018",
    "intended_use": "Treatment of marginal zone lymphoma",
    "eu_designation_number": "EU/3/18/2064",
    "status": "Positive",
    "first_published_date": "19/12/2018",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2064"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "",
    "date_of_designation_or_refusal": "24/08/2018",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/18/2055",
    "status": "Positive",
    "first_published_date": "19/12/2018",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2055"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous glioma tumour cells treated with antisense molecule directed against the insulin-like growth factor type 1 receptor",
    "date_of_designation_or_refusal": "24/08/2018",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/18/2061",
    "status": "Positive",
    "first_published_date": "19/12/2018",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2061"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human monoclonal antibody against mannan-binding lectin-associated serine protease-2",
    "date_of_designation_or_refusal": "24/08/2018",
    "intended_use": "Treatment in haematopoietic stem cell transplantation",
    "eu_designation_number": "EU/3/18/2067",
    "status": "Positive",
    "first_published_date": "19/12/2018",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2067"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tilorone",
    "date_of_designation_or_refusal": "24/08/2018",
    "intended_use": "Treatment of idiopathic pulmonary fibrosis",
    "eu_designation_number": "EU/3/18/2069",
    "status": "Positive",
    "first_published_date": "19/12/2018",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2069"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "melatonin",
    "date_of_designation_or_refusal": "26/10/2018",
    "intended_use": "Treatment of acute radiation syndrome",
    "eu_designation_number": "EU/3/18/2077",
    "status": "Positive",
    "first_published_date": "19/12/2018",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2077"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant adeno-associated viral vector serotype 9 carrying the gene for the human E6-AP ubiquitin protein ligase",
    "date_of_designation_or_refusal": "28/04/2016",
    "intended_use": "Treatment of Angelman syndrome",
    "eu_designation_number": "EU/3/16/1651",
    "status": "Positive",
    "first_published_date": "30/05/2016",
    "last_updated_date": "18/12/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1651"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant adeno-associated viral vector serotype 5 carrying the gene for the human frataxin protein",
    "date_of_designation_or_refusal": "23/08/2017",
    "intended_use": "Treatment of Friedreich's ataxia",
    "eu_designation_number": "EU/3/17/1906",
    "status": "Positive",
    "first_published_date": "17/10/2017",
    "last_updated_date": "18/12/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1906"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "H-Phe-Ser-Arg-Tyr-Ala-Arg-OH acetate (Alirinetide)",
    "date_of_designation_or_refusal": "30/05/2016",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/16/1662",
    "status": "Positive",
    "first_published_date": "22/06/2016",
    "last_updated_date": "18/12/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1662"
  },
  {
    "medicine_name": "Onivyde pegylated liposomal (previously Onivyde)",
    "related_ema_product_number": "EMEA/H/C/004125",
    "active_substance": "nanoliposomal irinotecan",
    "date_of_designation_or_refusal": "09/12/2011",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/11/933",
    "status": "Positive",
    "first_published_date": "20/12/2011",
    "last_updated_date": "17/12/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-933"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "",
    "date_of_designation_or_refusal": "12/10/2017",
    "intended_use": "Treatment of systemic sclerosis",
    "eu_designation_number": "EU/3/17/1933",
    "status": "Positive",
    "first_published_date": "15/01/2018",
    "last_updated_date": "07/12/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1933"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "paclitaxel",
    "date_of_designation_or_refusal": "17/12/2006",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/06/422",
    "status": "Withdrawn",
    "first_published_date": "02/04/2009",
    "last_updated_date": "05/12/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-422"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "4-(4-{[2-(4-Chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide (venetoclax)",
    "date_of_designation_or_refusal": "06/12/2012",
    "intended_use": "Treatment of chronic lymphocytic leukaemia",
    "eu_designation_number": "EU/3/12/1080",
    "status": "Withdrawn",
    "first_published_date": "25/01/2013",
    "last_updated_date": "22/11/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1080"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human monoclonal antibody against activin receptor type IIB",
    "date_of_designation_or_refusal": "09/08/2012",
    "intended_use": "Treatment of inclusion body myositis",
    "eu_designation_number": "EU/3/12/1035",
    "status": "Withdrawn",
    "first_published_date": "27/09/2012",
    "last_updated_date": "24/10/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1035"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Maytansinoid-conjugated human monoclonal antibody against mesothelin (anetumab ravtansine)",
    "date_of_designation_or_refusal": "06/12/2012",
    "intended_use": "Treatment of malignant mesothelioma",
    "eu_designation_number": "EU/3/12/1073",
    "status": "Withdrawn",
    "first_published_date": "24/01/2013",
    "last_updated_date": "24/10/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1073"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adenovirus-associated viral vector serotype 8 containing the human RPGR gene",
    "date_of_designation_or_refusal": "22/02/2018",
    "intended_use": "Treatment of retinitis pigmentosa",
    "eu_designation_number": "EU/3/18/1975",
    "status": "Positive",
    "first_published_date": "11/04/2018",
    "last_updated_date": "24/10/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1975"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "bitopertin",
    "date_of_designation_or_refusal": "16/10/2017",
    "intended_use": "Treatment of beta thalassaemia intermedia and major",
    "eu_designation_number": "EU/3/17/1919",
    "status": "Withdrawn",
    "first_published_date": "10/01/2018",
    "last_updated_date": "24/10/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1919"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "melatonin",
    "date_of_designation_or_refusal": "14/10/2016",
    "intended_use": "Treatment of Smith-Magenis syndrome",
    "eu_designation_number": "EU/3/16/1755",
    "status": "Positive",
    "first_published_date": "15/11/2016",
    "last_updated_date": "23/10/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1755"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "melatonin",
    "date_of_designation_or_refusal": "01/08/2016",
    "intended_use": "Treatment of necrotising enterocolitis",
    "eu_designation_number": "EU/3/16/1682",
    "status": "Positive",
    "first_published_date": "02/08/2016",
    "last_updated_date": "23/10/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1682"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "melatonin",
    "date_of_designation_or_refusal": "27/06/2016",
    "intended_use": "Treatment of neonatal sepsis",
    "eu_designation_number": "EU/3/16/1683",
    "status": "Positive",
    "first_published_date": "26/07/2016",
    "last_updated_date": "23/10/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1683"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sildenafil citrate",
    "date_of_designation_or_refusal": "26/11/2010",
    "intended_use": "treatment of postcardiotomy right ventricular failure",
    "eu_designation_number": "EU/3/10/815",
    "status": "Positive",
    "first_published_date": "17/12/2010",
    "last_updated_date": "23/10/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-815"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pegylated recombinant human interleukin-10",
    "date_of_designation_or_refusal": "12/12/2016",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/16/1804",
    "status": "Positive",
    "first_published_date": "09/01/2017",
    "last_updated_date": "23/10/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1804"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "lenvatinib",
    "date_of_designation_or_refusal": "19/03/2015",
    "intended_use": "Treatment of hepatocellular carcinoma",
    "eu_designation_number": "EU/3/15/1460",
    "status": "Withdrawn",
    "first_published_date": "11/05/2015",
    "last_updated_date": "22/10/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1460"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "lenvatinib",
    "date_of_designation_or_refusal": "26/04/2013",
    "intended_use": "Treatment of papillary thyroid cancer",
    "eu_designation_number": "EU/3/13/1121",
    "status": "Withdrawn",
    "first_published_date": "14/05/2013",
    "last_updated_date": "22/10/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1121"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "lenvatinib",
    "date_of_designation_or_refusal": "26/04/2013",
    "intended_use": "Treatment of follicular thyroid cancer",
    "eu_designation_number": "EU/3/13/1119",
    "status": "Withdrawn",
    "first_published_date": "14/05/2013",
    "last_updated_date": "22/10/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1119"
  },
  {
    "medicine_name": "Crysvita",
    "related_ema_product_number": "EMEA/H/C/004275",
    "active_substance": "recombinant human monoclonal IgG1 antibody for fibroblast growth factor 23 (burosumab)",
    "date_of_designation_or_refusal": "15/10/2014",
    "intended_use": "Treatment of X-linked hypophosphataemia",
    "eu_designation_number": "EU/3/14/1351",
    "status": "Positive",
    "first_published_date": "12/11/2014",
    "last_updated_date": "22/10/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1351"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "mogamulizumab",
    "date_of_designation_or_refusal": "11/01/2012",
    "intended_use": "Treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)",
    "eu_designation_number": "EU/3/11/943",
    "status": "Positive",
    "first_published_date": "01/02/2012",
    "last_updated_date": "18/10/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-943"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "3-Chloro-4-fluorophenyl-[4-fluoro-4-{[(5-methylpyrimidin-2-ylmethyl) amino]methyl}piperidin-1-yl]methanone",
    "date_of_designation_or_refusal": "19/02/2014",
    "intended_use": "Treatment of Rett syndrome",
    "eu_designation_number": "EU/3/14/1242",
    "status": "Positive",
    "first_published_date": "02/04/2014",
    "last_updated_date": "18/10/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1242"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ofatumumab",
    "date_of_designation_or_refusal": "07/11/2008",
    "intended_use": "Treatment of chronic lymphocytic leukaemia",
    "eu_designation_number": "EU/3/08/581",
    "status": "Withdrawn",
    "first_published_date": "02/04/2009",
    "last_updated_date": "18/10/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-581"
  },
  {
    "medicine_name": "Spinraza",
    "related_ema_product_number": "EMEA/H/C/004312",
    "active_substance": "antisense oligonucleotide targeted to the SMN2 gene (nusinersen)",
    "date_of_designation_or_refusal": "02/04/2012",
    "intended_use": "Treatment of 5q spinal muscular atrophy",
    "eu_designation_number": "EU/3/12/976",
    "status": "Positive",
    "first_published_date": "30/04/2012",
    "last_updated_date": "16/10/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-976"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "macitentan",
    "date_of_designation_or_refusal": "27/09/2011",
    "intended_use": "Treatment of pulmonary arterial hypertension",
    "eu_designation_number": "EU/3/11/909",
    "status": "Positive",
    "first_published_date": "17/10/2011",
    "last_updated_date": "12/10/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-909"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "macitentan",
    "date_of_designation_or_refusal": "28/01/2010",
    "intended_use": "Treatment of idiopathic pulmonary fibrosis",
    "eu_designation_number": "EU/3/09/707",
    "status": "Positive",
    "first_published_date": "25/02/2010",
    "last_updated_date": "12/10/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-707"
  },
  {
    "medicine_name": "Theraloc; Theraloc",
    "related_ema_product_number": "EMEA/H/C/000931; EMEA/H/C/000931",
    "active_substance": "anti epidermal growth factor receptor antibody h-R3",
    "date_of_designation_or_refusal": "02/09/2004",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/04/220",
    "status": "Positive",
    "first_published_date": "01/10/2004",
    "last_updated_date": "12/10/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-220"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "nimotuzumab",
    "date_of_designation_or_refusal": "03/06/2008",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/08/550",
    "status": "Positive",
    "first_published_date": "18/08/2008",
    "last_updated_date": "12/10/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-550"
  },
  {
    "medicine_name": "Istodax",
    "related_ema_product_number": "EMEA/H/C/002122",
    "active_substance": "(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23- tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone",
    "date_of_designation_or_refusal": "28/10/2005",
    "intended_use": "Treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)",
    "eu_designation_number": "EU/3/05/328",
    "status": "Positive",
    "first_published_date": "17/09/2009",
    "last_updated_date": "12/10/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-328"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23- tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone",
    "date_of_designation_or_refusal": "27/05/2005",
    "intended_use": "Treatment of cutaneous T-cell lymphoma",
    "eu_designation_number": "EU/3/05/279",
    "status": "Positive",
    "first_published_date": "17/09/2009",
    "last_updated_date": "12/10/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-279"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "melatonin",
    "date_of_designation_or_refusal": "15/03/2018",
    "intended_use": "Treatment of non-traumatic subarachnoid haemorrhage",
    "eu_designation_number": "-",
    "status": "Negative",
    "first_published_date": "11/10/2018",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-non-traumatic-subarachnoid-haemorrhage"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Givinostat",
    "date_of_designation_or_refusal": "31/07/2018",
    "intended_use": "Treatment of Becker muscular dystrophy",
    "eu_designation_number": "EU/3/18/2046",
    "status": "Positive",
    "first_published_date": "11/10/2018",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2046"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "",
    "date_of_designation_or_refusal": "31/07/2018",
    "intended_use": "Treatment of primary hyperoxaluria",
    "eu_designation_number": "EU/3/18/2052",
    "status": "Positive",
    "first_published_date": "11/10/2018",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2052"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human ectonucleotide pyrophosphatase/phosphodiesterase 1 fused to the Fc fragment of IgG1",
    "date_of_designation_or_refusal": "31/07/2018",
    "intended_use": "treatment of ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency",
    "eu_designation_number": "EU/3/18/2049",
    "status": "Positive",
    "first_published_date": "11/10/2018",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2049"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tetracosactide",
    "date_of_designation_or_refusal": "31/07/2018",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/18/2054",
    "status": "Positive",
    "first_published_date": "11/10/2018",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2054"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "synthetic antisense oligonucleotide directed against human dystrophin pre-mRNA",
    "date_of_designation_or_refusal": "31/07/2018",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/18/2051",
    "status": "Positive",
    "first_published_date": "10/10/2018",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2051"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic bone marrow derived mesenchymal stromal cells, ex-vivo expanded",
    "date_of_designation_or_refusal": "31/07/2018",
    "intended_use": "Treatment of graft-versus-host disease",
    "eu_designation_number": "EU/3/18/2044",
    "status": "Positive",
    "first_published_date": "10/10/2018",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2044"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Imexon",
    "date_of_designation_or_refusal": "23/12/2005",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/05/341",
    "status": "Positive",
    "first_published_date": "08/08/2006",
    "last_updated_date": "04/10/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-341"
  },
  {
    "medicine_name": "Darzalex",
    "related_ema_product_number": "EMEA/H/C/004077",
    "active_substance": "daratumumab",
    "date_of_designation_or_refusal": "17/07/2013",
    "intended_use": "Treatment of plasma-cell myeloma",
    "eu_designation_number": "EU/3/13/1153",
    "status": "Positive",
    "first_published_date": "16/08/2013",
    "last_updated_date": "02/10/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1153"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human von Willebrand factor",
    "date_of_designation_or_refusal": "26/11/2010",
    "intended_use": "Treatment of von Willebrand disease",
    "eu_designation_number": "EU/3/10/814",
    "status": "Withdrawn",
    "first_published_date": "17/12/2010",
    "last_updated_date": "21/09/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-814"
  },
  {
    "medicine_name": "Cablivi",
    "related_ema_product_number": "EMEA/H/C/004426",
    "active_substance": "nanobody directed towards the human A1 domain of von Willebrand factor (caplacizumab) ",
    "date_of_designation_or_refusal": "30/04/2009",
    "intended_use": "Treatment of thrombotic thrombocytopenic purpura",
    "eu_designation_number": "EU/3/09/629",
    "status": "Positive",
    "first_published_date": "12/05/2009",
    "last_updated_date": "10/09/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-629"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human placental growth factor",
    "date_of_designation_or_refusal": "27/06/2018",
    "intended_use": "Treatment of pre-eclampsia",
    "eu_designation_number": "EU/3/18/2040",
    "status": "Positive",
    "first_published_date": "22/08/2018",
    "last_updated_date": "22/08/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2040"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "argon",
    "date_of_designation_or_refusal": "27/06/2018",
    "intended_use": "Treatment of perinatal asphyxia",
    "eu_designation_number": "EU/3/18/2031",
    "status": "Positive",
    "first_published_date": "22/08/2018",
    "last_updated_date": "22/08/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2031"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant adeno-associated viral vector serotype 9 containing human iduronidase gene",
    "date_of_designation_or_refusal": "27/06/2018",
    "intended_use": "Treatment of mucopolysaccharidosis type I",
    "eu_designation_number": "EU/3/18/2039",
    "status": "Positive",
    "first_published_date": "22/08/2018",
    "last_updated_date": "22/08/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2039"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "20-hydroxyecdysone",
    "date_of_designation_or_refusal": "27/06/2018",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/18/2030",
    "status": "Positive",
    "first_published_date": "21/08/2018",
    "last_updated_date": "21/08/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2030"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "carmustine",
    "date_of_designation_or_refusal": "27/06/2018",
    "intended_use": "Treatment in haematopoietic stem cell transplantation",
    "eu_designation_number": "EU/3/18/2032",
    "status": "Positive",
    "first_published_date": "21/08/2018",
    "last_updated_date": "21/08/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2032"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-[(2S)-2-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl]-8-nitro-6-trifluoromethyl-4H-1,3-benzothiazin-4-one",
    "date_of_designation_or_refusal": "27/06/2018",
    "intended_use": "Treatment of tuberculosis",
    "eu_designation_number": "EU/3/18/2029",
    "status": "Positive",
    "first_published_date": "21/08/2018",
    "last_updated_date": "21/08/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2029"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "peretinoin",
    "date_of_designation_or_refusal": "05/08/2011",
    "intended_use": "Treatment of hepatocellular carcinoma",
    "eu_designation_number": "EU/3/11/890",
    "status": "Positive",
    "first_published_date": "16/08/2011",
    "last_updated_date": "26/07/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-890"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-2Thi-Gly-Leu-Met(O2)-NH2-DOTA-225-Actinium",
    "date_of_designation_or_refusal": "25/05/2018",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/18/2023",
    "status": "Positive",
    "first_published_date": "24/07/2018",
    "last_updated_date": "24/07/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2023"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Equine immunoglobulin F(ab')2 fragments targeting Shiga toxin",
    "date_of_designation_or_refusal": "25/05/2018",
    "intended_use": "Prevention of haemolytic uraemic syndrome",
    "eu_designation_number": "EU/3/18/2021",
    "status": "Positive",
    "first_published_date": "24/07/2018",
    "last_updated_date": "24/07/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2021"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ambroxol hydrochloride",
    "date_of_designation_or_refusal": "25/05/2018",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/18/2017",
    "status": "Positive",
    "first_published_date": "24/07/2018",
    "last_updated_date": "24/07/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2017"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 9 containing the human CLN1 gene",
    "date_of_designation_or_refusal": "25/05/2018",
    "intended_use": "Treatment of neuronal ceroid lipofuscinosis",
    "eu_designation_number": "EU/3/18/2016",
    "status": "Positive",
    "first_published_date": "23/07/2018",
    "last_updated_date": "23/07/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2016"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-(5-(6-chloro-2,2-difluorobenzo[d][1,3]dioxol-5-yl)pyrazin-2-yl)-2-fluoro-6-methylbenzamide",
    "date_of_designation_or_refusal": "18/11/2016",
    "intended_use": "Treatment of acute pancreatitis",
    "eu_designation_number": "EU/3/16/1783",
    "status": "Positive",
    "first_published_date": "13/12/2016",
    "last_updated_date": "20/07/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1783"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Gevokizumab",
    "date_of_designation_or_refusal": "22/08/2014",
    "intended_use": "Treatment of Schnitzler syndrome",
    "eu_designation_number": "EU/3/14/1311",
    "status": "Withdrawn",
    "first_published_date": "30/09/2014",
    "last_updated_date": "18/07/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1311"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Gevokizumab",
    "date_of_designation_or_refusal": "12/03/2013",
    "intended_use": "Treatment of chronic non-infectious uveitis",
    "eu_designation_number": "EU/3/13/1111",
    "status": "Withdrawn",
    "first_published_date": "05/04/2013",
    "last_updated_date": "18/07/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1111"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant humanised anti-human interleukin-1 beta monoclonal antibody",
    "date_of_designation_or_refusal": "01/10/2010",
    "intended_use": "Treatment of Behçet's Disease",
    "eu_designation_number": "EU/3/10/796",
    "status": "Withdrawn",
    "first_published_date": "14/10/2010",
    "last_updated_date": "18/07/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-796"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ambrisentan",
    "date_of_designation_or_refusal": "11/04/2005",
    "intended_use": "Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension",
    "eu_designation_number": "EU/3/05/273",
    "status": "Withdrawn",
    "first_published_date": "29/07/2008",
    "last_updated_date": "18/07/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-273"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "thalidomide",
    "date_of_designation_or_refusal": "20/11/2001",
    "intended_use": "Treatment of multiple myeloma",
    "eu_designation_number": "EU/3/01/067",
    "status": "Withdrawn",
    "first_published_date": "29/07/2008",
    "last_updated_date": "18/07/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-067"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "arsenic trioxide",
    "date_of_designation_or_refusal": "12/12/2016",
    "intended_use": "Treatment of graft-versus-host disease",
    "eu_designation_number": "EU/3/16/1797",
    "status": "Positive",
    "first_published_date": "10/01/2017",
    "last_updated_date": "16/07/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1797"
  },
  {
    "medicine_name": "Verkazia; Vekacia; Vekacia",
    "related_ema_product_number": "EMEA/H/C/004411; EMEA/H/C/000904; EMEA/H/C/000904",
    "active_substance": "ciclosporin",
    "date_of_designation_or_refusal": "06/04/2006",
    "intended_use": "Treatment of vernal keratoconjunctivitis",
    "eu_designation_number": "EU/3/06/360",
    "status": "Positive",
    "first_published_date": "24/02/2009",
    "last_updated_date": "12/07/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-360"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Letermovir",
    "date_of_designation_or_refusal": "06/06/2012",
    "intended_use": "Treatment of cytomegalovirus disease in patients with impaired cell-mediated immunity",
    "eu_designation_number": "EU/3/12/999",
    "status": "Positive",
    "first_published_date": "04/07/2012",
    "last_updated_date": "28/06/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-999"
  },
  {
    "medicine_name": "Prevymis",
    "related_ema_product_number": "EMEA/H/C/004536",
    "active_substance": "(S)-{8-Fluoro-2-2[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)-phenyl]-3, 4-dihydro-4-quinazolinyl} acetic acid (letermovir)",
    "date_of_designation_or_refusal": "15/04/2011",
    "intended_use": "Prevention of cytomegalovirus disease in patients with impaired cell-mediated immunity",
    "eu_designation_number": "EU/3/11/849",
    "status": "Positive",
    "first_published_date": "26/04/2011",
    "last_updated_date": "28/06/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-849"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Cyclo[L-alanyl-L-seryl-L-isoleucyl-L-prolyl-L-prolyl-L-glutaminyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-(2S)-2-aminodecanoyl-L-alpha-glutamyl-L-threonyl]acetate salt",
    "date_of_designation_or_refusal": "20/03/2013",
    "intended_use": "Treatment of congenital alpha-1 antitrypsin deficiency",
    "eu_designation_number": "EU/3/13/1114",
    "status": "Positive",
    "first_published_date": "08/04/2013",
    "last_updated_date": "14/06/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1114"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Cyclo[L-alanyl-L-seryl-L-isoleucyl-L-prolyl-L-prolyl-L-glutaminyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-(2S)-2-aminodecanoyl-L-alpha-glutamyl-L-threonyl]acetate salt",
    "date_of_designation_or_refusal": "27/02/2017",
    "intended_use": "Treatment of primary ciliary dyskinesia",
    "eu_designation_number": "EU/3/17/1834",
    "status": "Positive",
    "first_published_date": "31/03/2017",
    "last_updated_date": "14/06/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1834"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-Ethylbutyl (2S)-2-{[(S)-{[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl]methoxy}(phenoxy)phosphoryl]amino}propanoate (remdesivir)",
    "date_of_designation_or_refusal": "17/02/2016",
    "intended_use": "Treatment of Ebola virus disease",
    "eu_designation_number": "EU/3/16/1615",
    "status": "Positive",
    "first_published_date": "17/04/2018",
    "last_updated_date": "13/06/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1615"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sialic acid (also known as aceneuramic acid)",
    "date_of_designation_or_refusal": "16/10/2015",
    "intended_use": "Treatment of GNE myopathy",
    "eu_designation_number": "EU/3/12/972",
    "status": "Withdrawn",
    "first_published_date": "19/04/2012",
    "last_updated_date": "13/06/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-972"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "synthetic double-stranded RNA oligonucleotide specific to hydroxyacid oxidase 1 gene",
    "date_of_designation_or_refusal": "28/07/2015",
    "intended_use": "Treatment of primary hyperoxaluria type 1",
    "eu_designation_number": "EU/3/15/1528",
    "status": "Withdrawn",
    "first_published_date": "18/08/2015",
    "last_updated_date": "13/06/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1528"
  },
  {
    "medicine_name": "Kymriah",
    "related_ema_product_number": "EMEA/H/C/004090",
    "active_substance": "autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19 (tisagenlecleucel)",
    "date_of_designation_or_refusal": "29/04/2014",
    "intended_use": "Treatment of B-lymphoblastic leukaemia/lymphoma",
    "eu_designation_number": "EU/3/14/1266",
    "status": "Positive",
    "first_published_date": "04/06/2014",
    "last_updated_date": "13/06/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1266"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19 (tisagenlecleucel)",
    "date_of_designation_or_refusal": "14/10/2016",
    "intended_use": "Treatment of diffuse large B-cell lymphoma",
    "eu_designation_number": "EU/3/16/1745",
    "status": "Positive",
    "first_published_date": "14/11/2016",
    "last_updated_date": "13/06/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1745"
  },
  {
    "medicine_name": "Namuscla",
    "related_ema_product_number": "EMEA/H/C/004584",
    "active_substance": "Mexiletine hydrochloride",
    "date_of_designation_or_refusal": "19/11/2014",
    "intended_use": "Treatment of myotonic disorders",
    "eu_designation_number": "EU/3/14/1353",
    "status": "Positive",
    "first_published_date": "15/01/2015",
    "last_updated_date": "13/06/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1353"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "staphylococcus aureus protein A",
    "date_of_designation_or_refusal": "09/10/2015",
    "intended_use": "Treatment of immune thrombocytopenia",
    "eu_designation_number": "EU/3/15/1562",
    "status": "Positive",
    "first_published_date": "18/11/2015",
    "last_updated_date": "12/06/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1562"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Poly[2-[(4-{[1-carboxy-2-(hexadecylcarbamoyl)ethyl]sulfanyl}-2,3-bis({2-[((2S)-2-(2-{[(2R)-2-carbamoyl-(2-{[(2S)-1-ethoxy-3-(3-hydroxy-4oxo-1,4-dihydropyridin-1-yl)-1-oxopropan-2-yl]carbamoyl}ethyl]sulfanyl}-3-{[(2S)-1-ethoxy-3-(3-hydroxy-4-oxo-1,4-dihydropyridin-1-yl)-1-oxopropan-2-yl]carbamoyl}propanamido)-3-(3-hydroxy-4-oxo-1,4-dihydropyridin-1-yl)propanoyl ethyl ester))-methoxy]acetyl}oxy)butyl)sulfanyl]-3-(hexadecylcarbamoyl)propanoic acid]-PEG1500-ester]",
    "date_of_designation_or_refusal": "16/01/2014",
    "intended_use": "Treatment of dengue",
    "eu_designation_number": "EU/3/13/1220",
    "status": "Positive",
    "first_published_date": "23/01/2014",
    "last_updated_date": "12/06/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1220"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human donor haematopoietic stem and progenitor cells that have been treated ex vivo with the protein transduction domain of the HIV-1 transactivation protein fused to MYC transcription factor",
    "date_of_designation_or_refusal": "12/01/2017",
    "intended_use": "Treatment in haematopoietic stem cell transplantation",
    "eu_designation_number": "EU/3/16/1817",
    "status": "Positive",
    "first_published_date": "11/07/2017",
    "last_updated_date": "12/06/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1817"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "para-aminosalicylic acid",
    "date_of_designation_or_refusal": "17/12/2010",
    "intended_use": "Treatment of tuberculosis",
    "eu_designation_number": "EU/3/10/826",
    "status": "Positive",
    "first_published_date": "20/01/2011",
    "last_updated_date": "08/06/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-826"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(1S,4R,5R,7S)-3,4-dibenzyl-2-oxo-6,8-dioxa-3-azabyciclo[3.2.1]octane-7-carboxylic acid-L-lysine",
    "date_of_designation_or_refusal": "16/12/2014",
    "intended_use": "Treatment of neurotrophic keratitis",
    "eu_designation_number": "EU/3/14/1400",
    "status": "Positive",
    "first_published_date": "26/02/2015",
    "last_updated_date": "08/06/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1400"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Mavoglurant ",
    "date_of_designation_or_refusal": "10/10/2012",
    "intended_use": "Treatment of fragile X syndrome",
    "eu_designation_number": "EU/3/12/1046",
    "status": "Positive",
    "first_published_date": "16/11/2012",
    "last_updated_date": "04/06/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1046"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human monoclonal antibody of the IgG1 kappa class against human macrophage colony-stimulating factor (lacnotuzumab)",
    "date_of_designation_or_refusal": "15/10/2014",
    "intended_use": "Treatment of tenosynovial giant cell tumour, localised and diffuse type",
    "eu_designation_number": "EU/3/14/1350",
    "status": "Positive",
    "first_published_date": "12/11/2014",
    "last_updated_date": "04/06/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1350"
  },
  {
    "medicine_name": "Onpattro",
    "related_ema_product_number": "EMEA/H/C/004699",
    "active_substance": "synthetic double-stranded siRNA oligonucleotide directed against transthyretin mRNA (also known as patisiran)",
    "date_of_designation_or_refusal": "06/04/2017",
    "intended_use": "Treatment of transthyretin-mediated amyloidosis",
    "eu_designation_number": "EU/3/11/857",
    "status": "Positive",
    "first_published_date": "26/04/2011",
    "last_updated_date": "30/05/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-857"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "chimeric 2'-O-(2-methoxyethyl) modified oligonucleotide targeted to huntingtin RNA",
    "date_of_designation_or_refusal": "19/03/2015",
    "intended_use": "Treatment of Huntington’s disease",
    "eu_designation_number": "EU/3/15/1453",
    "status": "Positive",
    "first_published_date": "11/05/2015",
    "last_updated_date": "30/05/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1453"
  },
  {
    "medicine_name": "Rydapt",
    "related_ema_product_number": "EMEA/H/C/004095",
    "active_substance": "Midostaurin",
    "date_of_designation_or_refusal": "04/08/2010",
    "intended_use": "Treatment of mastocytosis",
    "eu_designation_number": "EU/3/10/765",
    "status": "Positive",
    "first_published_date": "11/08/2010",
    "last_updated_date": "29/05/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-765"
  },
  {
    "medicine_name": "Rydapt",
    "related_ema_product_number": "EMEA/H/C/004095",
    "active_substance": "Midostaurin",
    "date_of_designation_or_refusal": "29/07/2004",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/04/214",
    "status": "Positive",
    "first_published_date": "11/10/2005",
    "last_updated_date": "29/05/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-214"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "venetoclax",
    "date_of_designation_or_refusal": "14/10/2016",
    "intended_use": "Treatment of multiple myeloma",
    "eu_designation_number": "EU/3/16/1767",
    "status": "Positive",
    "first_published_date": "15/11/2016",
    "last_updated_date": "29/05/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1767"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Mazindol",
    "date_of_designation_or_refusal": "12/02/2015",
    "intended_use": "Treatment of narcolepsy",
    "eu_designation_number": "EU/3/15/1444",
    "status": "Withdrawn",
    "first_published_date": "09/04/2015",
    "last_updated_date": "29/05/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1444"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline succinic acid",
    "date_of_designation_or_refusal": "14/07/2016",
    "intended_use": "Treatment of Huntington’s disease",
    "eu_designation_number": "EU/3/16/1691",
    "status": "Withdrawn",
    "first_published_date": "06/09/2016",
    "last_updated_date": "29/05/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1691"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "yttrium (90Y) edotreotide",
    "date_of_designation_or_refusal": "04/08/2008",
    "intended_use": "Treatment of gastro-entero-pancreatic neuroendocrine tumours",
    "eu_designation_number": "EU/3/08/589",
    "status": "Withdrawn",
    "first_published_date": "20/04/2009",
    "last_updated_date": "29/05/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-589"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "olaparib",
    "date_of_designation_or_refusal": "06/12/2007",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/07/501",
    "status": "Withdrawn",
    "first_published_date": "02/07/2008",
    "last_updated_date": "28/05/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-501"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 9 encoding miRNA against human superoxide dismutase 1",
    "date_of_designation_or_refusal": "16/04/2018",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/18/2008",
    "status": "Positive",
    "first_published_date": "17/05/2018",
    "last_updated_date": "17/05/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2008"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Docosahexaenoic acid ethyl ester",
    "date_of_designation_or_refusal": "21/03/2018",
    "intended_use": "Treatment of sickle cell disease",
    "eu_designation_number": "EU/3/18/1991",
    "status": "Positive",
    "first_published_date": "17/05/2018",
    "last_updated_date": "17/05/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1991"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "melatonin",
    "date_of_designation_or_refusal": "21/03/2018",
    "intended_use": "Treatment of neonatal encephalopathy",
    "eu_designation_number": "EU/3/18/1996",
    "status": "Positive",
    "first_published_date": "15/05/2018",
    "last_updated_date": "23/10/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1996"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Bosutinib",
    "date_of_designation_or_refusal": "04/08/2010",
    "intended_use": "Treatment of chronic myeloid leukaemia",
    "eu_designation_number": "EU/3/10/762",
    "status": "Withdrawn",
    "first_published_date": "11/08/2010",
    "last_updated_date": "07/05/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-762"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human interleukin-12",
    "date_of_designation_or_refusal": "29/08/2016",
    "intended_use": "Treatment of acute radiation syndrome",
    "eu_designation_number": "EU/3/16/1727",
    "status": "Positive",
    "first_published_date": "03/10/2016",
    "last_updated_date": "03/05/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1727"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "4-amino-1-[(1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]pyrimidin-2-one",
    "date_of_designation_or_refusal": "12/10/2017",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/17/1937",
    "status": "Positive",
    "first_published_date": "15/01/2018",
    "last_updated_date": "03/05/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1937"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2'-O-(2-Methoxyethyl) phosphorothioate antisense oligonucleotide targeting the growth hormone receptor",
    "date_of_designation_or_refusal": "27/06/2016",
    "intended_use": "Treatment of acromegaly",
    "eu_designation_number": "EU/3/16/1671",
    "status": "Positive",
    "first_published_date": "26/07/2016",
    "last_updated_date": "03/05/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1671"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(1E,6E)-1,7-bis(3,4-dimethoxyphenyl)-4-cyclobutylmethyl-1,6-heptadiene-3,5-dione",
    "date_of_designation_or_refusal": "28/04/2016",
    "intended_use": "Treatment of X-linked spinal and bulbar muscular atrophy (Kennedy's disease)",
    "eu_designation_number": "EU/3/16/1639",
    "status": "Positive",
    "first_published_date": "31/05/2016",
    "last_updated_date": "03/05/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1639"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "live attenuated Listeria monocytogenes bioengineered with a chimeric human epidermal growth factor receptor 2 fused to a truncated form of the Lm protein listeriolysin O",
    "date_of_designation_or_refusal": "14/12/2015",
    "intended_use": "Treatment of osteosarcoma",
    "eu_designation_number": "EU/3/15/1595",
    "status": "Positive",
    "first_published_date": "03/02/2016",
    "last_updated_date": "03/05/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1595"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human monoclonal antibody against mannan-binding lectin-associated serine protease-2",
    "date_of_designation_or_refusal": "22/02/2018",
    "intended_use": "Treatment of primary IgA nephropathy",
    "eu_designation_number": "EU/3/18/1984",
    "status": "Positive",
    "first_published_date": "11/04/2018",
    "last_updated_date": "11/04/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1984"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(R)-2-(5-cyano-2-(6-(methoxycarbonyl)-7-methyl-3-oxo-8-(3-(trifluoromethyl)phenyl)-2,3,5,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrimidine-5-yl)phenyl)-N,N,N-trimethylethanaminium methanesulfonate dehydrate",
    "date_of_designation_or_refusal": "22/02/2018",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/18/1988",
    "status": "Positive",
    "first_published_date": "11/04/2018",
    "last_updated_date": "11/04/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1988"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pyridoxal 5'-phosphate",
    "date_of_designation_or_refusal": "22/02/2018",
    "intended_use": "Treatment of pyridoxamine 5'-phosphate oxidase deficiency",
    "eu_designation_number": "EU/3/18/1983",
    "status": "Positive",
    "first_published_date": "11/04/2018",
    "last_updated_date": "11/04/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1983"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "melatonin",
    "date_of_designation_or_refusal": "13/03/2018",
    "intended_use": "Treatment of partial deep dermal and full-thickness burns",
    "eu_designation_number": "-",
    "status": "Negative",
    "first_published_date": "11/04/2018",
    "last_updated_date": "11/04/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-partial-deep-dermal-full-thickness-burns"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "1-[[[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropanamine-dihydrochloride",
    "date_of_designation_or_refusal": "22/02/2018",
    "intended_use": "Treatment of soft tissue sarcoma",
    "eu_designation_number": "EU/3/18/1972",
    "status": "Positive",
    "first_published_date": "11/04/2018",
    "last_updated_date": "11/04/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-1972"
  },
  {
    "medicine_name": "Lamzede",
    "related_ema_product_number": "EMEA/H/C/003922",
    "active_substance": "recombinant human alpha-Mannosidase (velmanase alfa)",
    "date_of_designation_or_refusal": "26/01/2005",
    "intended_use": "Treatment of alpha-mannosidosis",
    "eu_designation_number": "EU/3/04/260",
    "status": "Positive",
    "first_published_date": "01/07/2005",
    "last_updated_date": "10/04/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-260"
  },
  {
    "medicine_name": "Vyloy",
    "related_ema_product_number": "EMEA/H/C/005868",
    "active_substance": "chimeric monoclonal antibody against claudin-18 splice variant 2",
    "date_of_designation_or_refusal": "26/11/2010",
    "intended_use": "Treatment of gastric cancer",
    "eu_designation_number": "EU/3/10/803",
    "status": "Positive",
    "first_published_date": "15/12/2010",
    "last_updated_date": "03/04/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-803"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium (1R,3R,4R,5S)-3-({2-N-acetylamino-2-deoxy-3-O-[(1S)-1-carboxylato-2-cyclohexylethyl]-beta-D-galactopyranosyl}oxy)-4-({6-deoxy-alpha-L-galactopyranosyl}oxy)-5-ethyl-cyclohexan-1-yl-(38-oxo-2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxa-39-azahentetracontan-41-yl)carboxamide",
    "date_of_designation_or_refusal": "22/05/2017",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/17/1876",
    "status": "Positive",
    "first_published_date": "29/06/2017",
    "last_updated_date": "03/04/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1876"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant fusion protein linking coagulation factor VIIa with albumin",
    "date_of_designation_or_refusal": "07/10/2013",
    "intended_use": "Treatment of congenital factor VII deficiency",
    "eu_designation_number": "EU/3/13/1188",
    "status": "Positive",
    "first_published_date": "31/10/2013",
    "last_updated_date": "28/03/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1188"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human alpha1-proteinase inhibitor",
    "date_of_designation_or_refusal": "09/07/2001",
    "intended_use": "Treatment of emphysema secondary to congenital alpha-1 antitrypsin deficiency",
    "eu_designation_number": "EU/3/01/044",
    "status": "Positive",
    "first_published_date": "24/02/2009",
    "last_updated_date": "28/03/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-044"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "C1-esterase-inhibitor human",
    "date_of_designation_or_refusal": "12/10/2017",
    "intended_use": "Treatment in solid organ transplantation",
    "eu_designation_number": "EU/3/17/1939",
    "status": "Positive",
    "first_published_date": "12/01/2018",
    "last_updated_date": "28/03/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1939"
  },
  {
    "medicine_name": "Idelvion",
    "related_ema_product_number": "EMEA/H/C/003955",
    "active_substance": "recombinant fusion protein linking human coagulation factor IX with human albumin",
    "date_of_designation_or_refusal": "04/02/2010",
    "intended_use": "Treatment of haemophilia B",
    "eu_designation_number": "EU/3/09/723",
    "status": "Positive",
    "first_published_date": "04/03/2010",
    "last_updated_date": "28/03/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-723"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant fusion protein linking human coagulation factor VIIa with human albumin",
    "date_of_designation_or_refusal": "15/04/2011",
    "intended_use": "Treatment of haemophilia A",
    "eu_designation_number": "EU/3/11/855",
    "status": "Positive",
    "first_published_date": "26/04/2011",
    "last_updated_date": "28/03/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-855"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant fusion protein linking human coagulation factor VIIa with human albumin",
    "date_of_designation_or_refusal": "13/05/2011",
    "intended_use": "Treatment of haemophilia B",
    "eu_designation_number": "EU/3/11/863",
    "status": "Positive",
    "first_published_date": "31/05/2011",
    "last_updated_date": "28/03/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-863"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(S)-3'-(OH)-desazadesferrithiocin-polyether, magnesium salt (deferitazole)",
    "date_of_designation_or_refusal": "24/07/2009",
    "intended_use": "Treatment of chronic iron overload requiring chelation therapy",
    "eu_designation_number": "EU/3/09/647",
    "status": "Withdrawn",
    "first_published_date": "11/09/2009",
    "last_updated_date": "26/03/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-647"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ciclopirox",
    "date_of_designation_or_refusal": "17/01/2018",
    "intended_use": "Treatment of congenital erythropoietic porphyria",
    "eu_designation_number": "EU/3/17/1960",
    "status": "Positive",
    "first_published_date": "14/03/2018",
    "last_updated_date": "14/03/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1960"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Itacitinib",
    "date_of_designation_or_refusal": "17/01/2018",
    "intended_use": "Treatment of graft-versus-host disease",
    "eu_designation_number": "EU/3/17/1964",
    "status": "Positive",
    "first_published_date": "13/03/2018",
    "last_updated_date": "13/03/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1964"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant adeno-associated viral vector serotype 2/1 encoding human beta-hexosaminidase alpha and beta subunits",
    "date_of_designation_or_refusal": "17/01/2018",
    "intended_use": "Treatment of GM2 gangliosidosis",
    "eu_designation_number": "EU/3/17/1969",
    "status": "Positive",
    "first_published_date": "13/03/2018",
    "last_updated_date": "13/03/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1969"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-(bromoacetyl)-3,3-dinitroazetidine",
    "date_of_designation_or_refusal": "17/01/2018",
    "intended_use": "Treatment of small cell lung cancer",
    "eu_designation_number": "EU/3/17/1966",
    "status": "Positive",
    "first_published_date": "12/03/2018",
    "last_updated_date": "12/03/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1966"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 5 encoding a microRNA targeted to human huntingtin gene",
    "date_of_designation_or_refusal": "17/01/2018",
    "intended_use": "Treatment of Huntington’s disease",
    "eu_designation_number": "EU/3/17/1957",
    "status": "Positive",
    "first_published_date": "12/03/2018",
    "last_updated_date": "12/03/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1957"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pyrazolo[1,5-a]pyrimidine, 3-[4-chloro-2-(4-morpholinyl)-5-thiazolyl]-7-(1-ethylpropyl)-2,5-dimethyl-pyrazolo[1,3-a]pyrimidine",
    "date_of_designation_or_refusal": "17/01/2018",
    "intended_use": "Treatment of congenital adrenal hyperplasia",
    "eu_designation_number": "EU/3/17/1968",
    "status": "Positive",
    "first_published_date": "12/03/2018",
    "last_updated_date": "12/03/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1968"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised Fc-engineered monoclonal antibody against CD19",
    "date_of_designation_or_refusal": "17/01/2018",
    "intended_use": "Treatment of IgG4-related disease",
    "eu_designation_number": "EU/3/17/1962",
    "status": "Positive",
    "first_published_date": "12/03/2018",
    "last_updated_date": "12/03/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1962"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "siponimod",
    "date_of_designation_or_refusal": "19/11/2014",
    "intended_use": "Treatment of dermatomyositis",
    "eu_designation_number": "EU/3/14/1369",
    "status": "Withdrawn",
    "first_published_date": "16/01/2015",
    "last_updated_date": "12/03/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1369"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "siponimod",
    "date_of_designation_or_refusal": "19/11/2014",
    "intended_use": "Treatment of polymyositis",
    "eu_designation_number": "EU/3/14/1370",
    "status": "Withdrawn",
    "first_published_date": "16/01/2015",
    "last_updated_date": "12/03/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1370"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Human plasmin",
    "date_of_designation_or_refusal": "23/02/2011",
    "intended_use": "Treatment of acute peripheral arterial occlusion",
    "eu_designation_number": "EU/3/10/834",
    "status": "Withdrawn",
    "first_published_date": "04/03/2011",
    "last_updated_date": "12/03/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-834"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ataluren",
    "date_of_designation_or_refusal": "19/11/2014",
    "intended_use": "Treatment of mucopolysaccharidosis type I",
    "eu_designation_number": "EU/3/14/1380",
    "status": "Withdrawn",
    "first_published_date": "16/01/2015",
    "last_updated_date": "22/02/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1380"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(S)-2-(1-((6-amino-5-cyanopyrimidin-4-yl)amino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-5-carbonitrile (tanziertib)",
    "date_of_designation_or_refusal": "15/10/2014",
    "intended_use": "Treatment of pemphigus",
    "eu_designation_number": "EU/3/14/1335",
    "status": "Withdrawn",
    "first_published_date": "12/11/2014",
    "last_updated_date": "22/02/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1335"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "4-[[9-[(3S)-tetrahydro-3-furanyl]-8-[(2,4,6-trifluorophenyl)amino]-9H-purin-2-yl]amino]-trans-cyclohexanol (tanzisertib)",
    "date_of_designation_or_refusal": "09/12/2011",
    "intended_use": "Treatment of idiopathic pulmonary fibrosis",
    "eu_designation_number": "EU/3/11/934",
    "status": "Withdrawn",
    "first_published_date": "20/12/2011",
    "last_updated_date": "22/02/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-934"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "obinutuzumab",
    "date_of_designation_or_refusal": "10/10/2012",
    "intended_use": "Treatment of chronic lymphocytic leukaemia",
    "eu_designation_number": "EU/3/12/1054",
    "status": "Positive",
    "first_published_date": "16/11/2012",
    "last_updated_date": "21/02/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1054"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Marizomib",
    "date_of_designation_or_refusal": "29/07/2014",
    "intended_use": "Treatment of plasma cell myeloma",
    "eu_designation_number": "EU/3/14/1295",
    "status": "Positive",
    "first_published_date": "01/09/2014",
    "last_updated_date": "13/02/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1295"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-{4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide",
    "date_of_designation_or_refusal": "26/08/2005",
    "intended_use": "Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension",
    "eu_designation_number": "EU/3/05/316",
    "status": "Withdrawn",
    "first_published_date": "17/09/2009",
    "last_updated_date": "12/02/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-316"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "dexamethasone",
    "date_of_designation_or_refusal": "09/06/2010",
    "intended_use": "Treatment of multiple myeloma",
    "eu_designation_number": "EU/3/10/745",
    "status": "Withdrawn",
    "first_published_date": "23/06/2010",
    "last_updated_date": "12/02/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-745"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "L-Asparaginase",
    "date_of_designation_or_refusal": "26/01/2005",
    "intended_use": "Treatment of acute lymphoblastic leukaemia",
    "eu_designation_number": "EU/3/04/258",
    "status": "Withdrawn",
    "first_published_date": "26/07/2005",
    "last_updated_date": "12/02/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-258"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Lumacaftor;ivacaftor",
    "date_of_designation_or_refusal": "22/08/2014",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/14/1333",
    "status": "Withdrawn",
    "first_published_date": "29/09/2014",
    "last_updated_date": "12/02/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1333"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant fusion protein consisting of human coagulation factor VIII attached to the Fc domain of human IgG1 (efmoroctocog alfa)",
    "date_of_designation_or_refusal": "20/09/2010",
    "intended_use": "Treatment of haemophilia A",
    "eu_designation_number": "EU/3/10/783",
    "status": "Withdrawn",
    "first_published_date": "18/10/2010",
    "last_updated_date": "12/02/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-783"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tolvaptan",
    "date_of_designation_or_refusal": "05/08/2013",
    "intended_use": "Treatment of autosomal dominant polycystic kidney disease",
    "eu_designation_number": "EU/3/13/1175",
    "status": "Withdrawn",
    "first_published_date": "13/09/2013",
    "last_updated_date": "12/02/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1175"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tobramycin",
    "date_of_designation_or_refusal": "28/02/2009",
    "intended_use": "Treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis",
    "eu_designation_number": "EU/3/09/613",
    "status": "Withdrawn",
    "first_published_date": "29/06/2009",
    "last_updated_date": "09/02/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-613"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Levofloxacin hemihydrate",
    "date_of_designation_or_refusal": "23/09/2008",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/08/566",
    "status": "Withdrawn",
    "first_published_date": "24/04/2009",
    "last_updated_date": "09/02/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-566"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "trans-N1-((1R,2S)-2-phenylcyclopropyl)cyclohexane-1,4-diamine bis-hydrochloride",
    "date_of_designation_or_refusal": "05/08/2013",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/13/1174",
    "status": "Positive",
    "first_published_date": "13/09/2013",
    "last_updated_date": "05/02/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1174"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sorafenib tosilate",
    "date_of_designation_or_refusal": "11/04/2006",
    "intended_use": "Treatment of hepatocellular carcinoma",
    "eu_designation_number": "EU/3/06/364",
    "status": "Expired",
    "first_published_date": "23/09/2009",
    "last_updated_date": "31/01/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-364"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "modified messenger ribonucleic acid encoding human argininosuccinate lyase enzyme encapsulated into lipid nanoparticles",
    "date_of_designation_or_refusal": "12/12/2017",
    "intended_use": "Treatment of argininosuccinic aciduria",
    "eu_designation_number": "EU/3/17/1952",
    "status": "Positive",
    "first_published_date": "23/01/2018",
    "last_updated_date": "23/01/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1952"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tivantinib",
    "date_of_designation_or_refusal": "13/11/2013",
    "intended_use": "Treatment of hepatocellular carcinoma",
    "eu_designation_number": "EU/3/13/1202",
    "status": "Withdrawn",
    "first_published_date": "02/12/2013",
    "last_updated_date": "23/01/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1202"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "naproxcinod",
    "date_of_designation_or_refusal": "07/10/2013",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/13/1194",
    "status": "Withdrawn",
    "first_published_date": "31/10/2013",
    "last_updated_date": "23/01/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1194"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "mixture of two allogeneic human pancreatic cancer cell lines stably transduced with a retroviral vector encoding the murine alpha-(1,3)-galactosyltransferase gene",
    "date_of_designation_or_refusal": "10/10/2012",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/12/1048",
    "status": "Withdrawn",
    "first_published_date": "16/11/2012",
    "last_updated_date": "23/01/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1048"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic, umbilical cord blood-derived, ex vivo-expanded, haematopoietic CD133+ cells;allogeneic, umbilical cord blood-derived, non-expanded, haematopoietic CD133- cells",
    "date_of_designation_or_refusal": "15/01/2015",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/14/1413",
    "status": "Withdrawn",
    "first_published_date": "05/03/2015",
    "last_updated_date": "23/01/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1413"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-amino-2-[2-[2-chloro-4-[[3-(phenylmethoxy)phenyl]thio]phenyl]ethyl]-1,3-propanediol hydrochloride",
    "date_of_designation_or_refusal": "14/12/2015",
    "intended_use": "Prevention of graft-versus-host disease",
    "eu_designation_number": "EU/3/15/1583",
    "status": "Withdrawn",
    "first_published_date": "02/02/2016",
    "last_updated_date": "22/01/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1583"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "temsirolimus",
    "date_of_designation_or_refusal": "06/04/2006",
    "intended_use": "Treatment of renal-cell carcinoma",
    "eu_designation_number": "EU/3/06/365",
    "status": "Expired",
    "first_published_date": "02/04/2009",
    "last_updated_date": "22/01/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-365"
  },
  {
    "medicine_name": "Jorveza",
    "related_ema_product_number": "EMEA/H/C/004655",
    "active_substance": "Budesonide",
    "date_of_designation_or_refusal": "05/08/2013",
    "intended_use": "Treatment of eosinophilic oesophagitis",
    "eu_designation_number": "EU/3/13/1181",
    "status": "Positive",
    "first_published_date": "13/09/2013",
    "last_updated_date": "18/01/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1181"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "hydroxychloroquine sulfate",
    "date_of_designation_or_refusal": "08/10/2009",
    "intended_use": "Treatment of LIPIN1 disease",
    "eu_designation_number": "EU/3/17/1963",
    "status": "Positive",
    "first_published_date": "17/01/2018",
    "last_updated_date": "17/01/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1963"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant adeno-associated viral vector serotype 9 containing human iduronate-2-sulfatase gene",
    "date_of_designation_or_refusal": "12/10/2017",
    "intended_use": "Treatment of mucopolysaccharidosis type II (Hunter's syndrome)",
    "eu_designation_number": "EU/3/17/1943",
    "status": "Positive",
    "first_published_date": "15/01/2018",
    "last_updated_date": "15/01/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1943"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-(2-aminophenyl)-4-(1-[(1,3-dimethyl-1H-pyrazol-4-yl)methyl]piperidin)benzamide",
    "date_of_designation_or_refusal": "12/10/2017",
    "intended_use": "Treatment of peripheral T-cell lymphoma",
    "eu_designation_number": "EU/3/17/1942",
    "status": "Positive",
    "first_published_date": "15/01/2018",
    "last_updated_date": "15/01/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1942"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio] butadiene",
    "date_of_designation_or_refusal": "12/10/2017",
    "intended_use": "Treatment of non-traumatic subarachnoid haemorrhage",
    "eu_designation_number": "EU/3/17/1935",
    "status": "Positive",
    "first_published_date": "15/01/2018",
    "last_updated_date": "15/01/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1935"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous ex-vivo-expanded peripheral polyclonal lymphocytes enriched in activated natural killer cells",
    "date_of_designation_or_refusal": "16/10/2017",
    "intended_use": "Treatment of multiple myeloma",
    "eu_designation_number": "EU/3/17/1918",
    "status": "Positive",
    "first_published_date": "10/01/2018",
    "last_updated_date": "10/01/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1918"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adenoviral vector of serotype 5 modified to contain a chimeric sequence consisting of a minimal urokinase-type plasminogen activator receptor promoter preceded by three Notch-responsive elements, and coated with oligopeptide end-modified poly (beta-amino) esters",
    "date_of_designation_or_refusal": "16/10/2017",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/17/1917",
    "status": "Positive",
    "first_published_date": "09/01/2018",
    "last_updated_date": "09/01/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1917"
  },
  {
    "medicine_name": "Daurismo",
    "related_ema_product_number": "EMEA/H/C/004878",
    "active_substance": "Glasdegib maleate",
    "date_of_designation_or_refusal": "16/10/2017",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/17/1923",
    "status": "Positive",
    "first_published_date": "09/01/2018",
    "last_updated_date": "09/01/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1923"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant monoclonal antibody to sialic acid-binding Ig-like lectin 8",
    "date_of_designation_or_refusal": "16/10/2017",
    "intended_use": "Treatment of mastocytosis",
    "eu_designation_number": "EU/3/17/1929",
    "status": "Positive",
    "first_published_date": "08/01/2018",
    "last_updated_date": "08/01/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1929"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "S)-3-((S)-2-(2-((2,6-difluorophenyl)amino)-2-oxoacetamido)propanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid",
    "date_of_designation_or_refusal": "16/10/2017",
    "intended_use": "Treatment of primary sclerosing cholangitis",
    "eu_designation_number": "EU/3/17/1914",
    "status": "Positive",
    "first_published_date": "08/01/2018",
    "last_updated_date": "08/01/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1914"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "synthetic cyclic 8 amino acid analogue of human unacylated ghrelin",
    "date_of_designation_or_refusal": "16/10/2017",
    "intended_use": "Treatment of Prader-Willi syndrome",
    "eu_designation_number": "EU/3/17/1932",
    "status": "Positive",
    "first_published_date": "08/01/2018",
    "last_updated_date": "08/01/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1932"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-[N-(2-hydroxyethyl)]-N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine",
    "date_of_designation_or_refusal": "16/10/2017",
    "intended_use": "Treatment of Charcot-Marie-Tooth disease",
    "eu_designation_number": "EU/3/17/1915",
    "status": "Positive",
    "first_published_date": "08/01/2018",
    "last_updated_date": "08/01/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1915"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium chlorite",
    "date_of_designation_or_refusal": "19/06/2013",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/13/1139",
    "status": "Positive",
    "first_published_date": "11/07/2013",
    "last_updated_date": "03/01/2018",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1139"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "alicaforsen",
    "date_of_designation_or_refusal": "15/05/2009",
    "intended_use": "Treatment of pouchitis",
    "eu_designation_number": "EU/3/09/641",
    "status": "Positive",
    "first_published_date": "09/06/2009",
    "last_updated_date": "18/12/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-641"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-[2,6-bis(1-methylethyl)phenyl]-N'-[[1-[4-(dimethylamino) phenyl]cyclopentyl]methyl]urea, hydrochloride salt",
    "date_of_designation_or_refusal": "07/06/2013",
    "intended_use": "Treatment of adrenocortical carcinoma",
    "eu_designation_number": "EU/3/13/1128",
    "status": "Positive",
    "first_published_date": "25/06/2013",
    "last_updated_date": "13/11/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1128"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Inolimomab",
    "date_of_designation_or_refusal": "05/03/2001",
    "intended_use": "Treatment of graft-versus-host disease",
    "eu_designation_number": "EU/3/01/028",
    "status": "Positive",
    "first_published_date": "18/08/2008",
    "last_updated_date": "26/10/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-028"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant humanised monoclonal antibody against human complement component C5a",
    "date_of_designation_or_refusal": "29/08/2016",
    "intended_use": "Treatment of graft-versus-host disease",
    "eu_designation_number": "EU/3/16/1728",
    "status": "Withdrawn",
    "first_published_date": "03/10/2016",
    "last_updated_date": "19/10/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1728"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human alpha-N-acetylglucosaminidase",
    "date_of_designation_or_refusal": "19/06/2013",
    "intended_use": "Treatment of mucopolysaccharidosis type IIIB (Sanfilippo B syndrome)",
    "eu_designation_number": "EU/3/13/1144",
    "status": "Withdrawn",
    "first_published_date": "11/07/2013",
    "last_updated_date": "19/10/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1144"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl)diamidophosphate",
    "date_of_designation_or_refusal": "17/07/2013",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/13/1152",
    "status": "Withdrawn",
    "first_published_date": "16/08/2013",
    "last_updated_date": "19/10/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1152"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "phenol, 4-[2-(aminomethyl)-4-thiazolyl]-2,6-bis(1,1-dimethylethyl) monohydrochloride",
    "date_of_designation_or_refusal": "24/04/2015",
    "intended_use": "Treatment of Huntington’s disease",
    "eu_designation_number": "EU/3/15/1481",
    "status": "Withdrawn",
    "first_published_date": "22/05/2015",
    "last_updated_date": "19/10/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1481"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector containing the human factor IX gene",
    "date_of_designation_or_refusal": "19/06/2015",
    "intended_use": "Treatment of haemophilia B",
    "eu_designation_number": "EU/3/15/1501",
    "status": "Withdrawn",
    "first_published_date": "27/07/2015",
    "last_updated_date": "19/10/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1501"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "salirasib",
    "date_of_designation_or_refusal": "21/06/2011",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/11/871",
    "status": "Withdrawn",
    "first_published_date": "12/07/2011",
    "last_updated_date": "19/10/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-871"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tacrolimus",
    "date_of_designation_or_refusal": "23/08/2017",
    "intended_use": "Treatment of pulmonary arterial hypertension",
    "eu_designation_number": "EU/3/17/1912",
    "status": "Positive",
    "first_published_date": "17/10/2017",
    "last_updated_date": "17/10/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1912"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "purified pasteurised and freeze-dried cell-wall fragments from Mycobacterium tuberculosis strain RUTI",
    "date_of_designation_or_refusal": "23/08/2017",
    "intended_use": "Treatment of tuberculosis",
    "eu_designation_number": "EU/3/17/1905",
    "status": "Positive",
    "first_published_date": "17/10/2017",
    "last_updated_date": "17/10/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1905"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "antisense oligonucleotide targeting exon 13 in the USH2A gene",
    "date_of_designation_or_refusal": "23/08/2017",
    "intended_use": "Treatment of retinitis pigmentosa",
    "eu_designation_number": "EU/3/17/1899",
    "status": "Positive",
    "first_published_date": "17/10/2017",
    "last_updated_date": "17/10/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1899"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium 2-hydroxylinoleate",
    "date_of_designation_or_refusal": "23/08/2017",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/17/1911",
    "status": "Positive",
    "first_published_date": "17/10/2017",
    "last_updated_date": "17/10/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1911"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "odiparcil",
    "date_of_designation_or_refusal": "23/08/2017",
    "intended_use": "Treatment of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)",
    "eu_designation_number": "EU/3/17/1903",
    "status": "Positive",
    "first_published_date": "17/10/2017",
    "last_updated_date": "17/10/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1903"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "trientine tetrahydrochloride",
    "date_of_designation_or_refusal": "19/03/2015",
    "intended_use": "Treatment of Wilson's disease",
    "eu_designation_number": "EU/3/15/1471",
    "status": "Withdrawn",
    "first_published_date": "19/05/2015",
    "last_updated_date": "03/10/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1471"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Ecteinascidin 743 (trabectedin)",
    "date_of_designation_or_refusal": "30/05/2001",
    "intended_use": "Treatment of soft tissue sarcoma",
    "eu_designation_number": "EU/3/01/039",
    "status": "Expired",
    "first_published_date": "04/12/2007",
    "last_updated_date": "03/10/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-039"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "5-aminolevulinic acid hydrochloride",
    "date_of_designation_or_refusal": "14/11/2002",
    "intended_use": "Intra-operative photodynamic diagnosis of residual glioma",
    "eu_designation_number": "EU/3/02/121",
    "status": "Expired",
    "first_published_date": "04/12/2007",
    "last_updated_date": "03/10/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-121"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "nelarabine",
    "date_of_designation_or_refusal": "16/06/2005",
    "intended_use": "Treatment of acute lymphoblastic leukaemia",
    "eu_designation_number": "EU/3/05/293",
    "status": "Expired",
    "first_published_date": "29/07/2008",
    "last_updated_date": "03/10/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-293"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Mecasermin",
    "date_of_designation_or_refusal": "22/05/2006",
    "intended_use": "Treatment of primary insulin-like growth factor-1 deficiency due to molecular or genetic defects",
    "eu_designation_number": "EU/3/06/373",
    "status": "Expired",
    "first_published_date": "24/04/2009",
    "last_updated_date": "03/10/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-373"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Lutetium (177Lu) edotreotide",
    "date_of_designation_or_refusal": "04/06/2014",
    "intended_use": "Treatment of gastro-entero-pancreatic neuroendocrine tumours",
    "eu_designation_number": "EU/3/14/1269",
    "status": "Positive",
    "first_published_date": "10/07/2014",
    "last_updated_date": "05/09/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1269"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 5 containing the human CHM gene",
    "date_of_designation_or_refusal": "24/04/2015",
    "intended_use": "Treatment of choroideraemia",
    "eu_designation_number": "EU/3/15/1482",
    "status": "Positive",
    "first_published_date": "22/05/2015",
    "last_updated_date": "16/08/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1482"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant humanised monoclonal IgG2 lambda antibody against human sclerostin",
    "date_of_designation_or_refusal": "27/06/2016",
    "intended_use": "Treatment of osteogenesis imperfecta",
    "eu_designation_number": "EU/3/16/1686",
    "status": "Positive",
    "first_published_date": "26/07/2016",
    "last_updated_date": "16/08/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1686"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N,N'-bis(2-mercaptoethyl)isophthalamide (emeramide)",
    "date_of_designation_or_refusal": "11/01/2012",
    "intended_use": "Treatment of mercury toxicity",
    "eu_designation_number": "EU/3/11/944",
    "status": "Positive",
    "first_published_date": "01/02/2012",
    "last_updated_date": "16/08/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-944"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "emeramide",
    "date_of_designation_or_refusal": "20/04/2017",
    "intended_use": "Prevention of mercury toxicity",
    "eu_designation_number": "EU/3/17/1864",
    "status": "Positive",
    "first_published_date": "15/05/2017",
    "last_updated_date": "16/08/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1864"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Fluocinolone acetonide",
    "date_of_designation_or_refusal": "28/04/2016",
    "intended_use": "Treatment of non-infectious uveitis",
    "eu_designation_number": "EU/3/16/1647",
    "status": "Withdrawn",
    "first_published_date": "30/05/2016",
    "last_updated_date": "16/08/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1647"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "4-[(2E)-1-oxo-3-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2-propen-1-yl]-1-piperazinecarboxamide",
    "date_of_designation_or_refusal": "30/05/2016",
    "intended_use": "Treatment of retinitis pigmentosa",
    "eu_designation_number": "EU/3/16/1658",
    "status": "Withdrawn",
    "first_published_date": "28/06/2016",
    "last_updated_date": "16/08/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1658"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Pyr-His-Trp-Ser-Tyr-D-Lys(doxorubicinylglutarate)-Leu-Arg-Pro-Gly-NH2, acetate salt",
    "date_of_designation_or_refusal": "04/08/2010",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/10/766",
    "status": "Withdrawn",
    "first_published_date": "11/08/2010",
    "last_updated_date": "16/08/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-766"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Desipramine chlorhydrate",
    "date_of_designation_or_refusal": "12/06/2009",
    "intended_use": "Treatment of Rett syndrome",
    "eu_designation_number": "EU/3/09/643",
    "status": "Withdrawn",
    "first_published_date": "01/07/2009",
    "last_updated_date": "16/08/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-643"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(2-aminoethyl) carbamic acid (2R,5S,8S,11S,14R,17S,19aS)-11-(4-aminobutyl)-5-benzyl-8-(4-benzyloxy benzyl)-14-(1H-indol-3-ylmethyl)-4,7,10,13,16,19-hexaoxo-17-phenyloctadecahydro-3a,6,9,12,15,18-hexaazacyclopentacyclooctadecen-2-yl ester, di[(S)-2-aminosu (pasireotide)",
    "date_of_designation_or_refusal": "08/06/2004",
    "intended_use": "Treatment of functional gastro-entero-pancreatic endocrine tumours",
    "eu_designation_number": "EU/3/04/200",
    "status": "Withdrawn",
    "first_published_date": "03/09/2006",
    "last_updated_date": "16/08/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-200"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Oxymetazoline hydrochloride",
    "date_of_designation_or_refusal": "17/07/2017",
    "intended_use": "Treatment of spinal cord injury",
    "eu_designation_number": "EU/3/17/1892",
    "status": "Positive",
    "first_published_date": "15/08/2017",
    "last_updated_date": "15/08/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1892"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Bacillus subtilis oxalate decarboxylase",
    "date_of_designation_or_refusal": "17/07/2017",
    "intended_use": "Treatment of primary hyperoxaluria",
    "eu_designation_number": "EU/3/17/1891",
    "status": "Positive",
    "first_published_date": "15/08/2017",
    "last_updated_date": "15/08/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1891"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "retinol",
    "date_of_designation_or_refusal": "17/07/2017",
    "intended_use": "Prevention of retinopathy of prematurity",
    "eu_designation_number": "EU/3/17/1895",
    "status": "Positive",
    "first_published_date": "15/08/2017",
    "last_updated_date": "15/08/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1895"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "5(S)-(2'-hydroxy ethoxy)-20(S)-Camptothecin",
    "date_of_designation_or_refusal": "08/06/2007",
    "intended_use": "Treatment of osteosarcoma",
    "eu_designation_number": "EU/3/07/450",
    "status": "Withdrawn",
    "first_published_date": "29/07/2008",
    "last_updated_date": "14/08/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-450"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tirapazamine",
    "date_of_designation_or_refusal": "17/07/2017",
    "intended_use": "Treatment of hepatocellular carcinoma",
    "eu_designation_number": "EU/3/17/1897",
    "status": "Positive",
    "first_published_date": "14/08/2017",
    "last_updated_date": "14/08/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1897"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human heat-shock protein 70",
    "date_of_designation_or_refusal": "12/03/2013",
    "intended_use": "Treatment of Niemann-Pick's disease, type C",
    "eu_designation_number": "EU/3/13/1110",
    "status": "Withdrawn",
    "first_published_date": "05/04/2013",
    "last_updated_date": "14/08/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1110"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human antibody directed against misfolded human superoxide dismutase 1",
    "date_of_designation_or_refusal": "17/07/2017",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/17/1894",
    "status": "Positive",
    "first_published_date": "14/08/2017",
    "last_updated_date": "14/08/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1894"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-carboxymethyl-glycyl-L-threonyl-L-histidyl-L-3,3-diphenylalanyl-L-piperidincarboxy-3-yl-L-arginyl-L-S-methylthio-cystyl-L-arginyl-L-tryptophyl-aminohexanyl-N-carboxamidomethyl-glycine N-hexadecylamide",
    "date_of_designation_or_refusal": "28/04/2016",
    "intended_use": "Treatment of beta thalassaemia intermedia and major",
    "eu_designation_number": "EU/3/16/1650",
    "status": "Withdrawn",
    "first_published_date": "30/05/2016",
    "last_updated_date": "10/08/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1650"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "{2-amino-8-[4-(pyrrolidinylcarbonyl)phenyl]-(3H-benzo[f]azepin-4-yl)}-N,N-dipropylcarboxamide",
    "date_of_designation_or_refusal": "21/05/2015",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/15/1488",
    "status": "Withdrawn",
    "first_published_date": "30/06/2015",
    "last_updated_date": "10/08/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1488"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Hydroxyurea",
    "date_of_designation_or_refusal": "09/07/2003",
    "intended_use": "Treatment of sickle cell syndrome",
    "eu_designation_number": "EU/3/03/154",
    "status": "Expired",
    "first_published_date": "29/07/2008",
    "last_updated_date": "06/08/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-154"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pegylated recombinant human factor IX (nonacog beta pegol)",
    "date_of_designation_or_refusal": "15/05/2009",
    "intended_use": "Treatment of haemophilia B",
    "eu_designation_number": "EU/3/09/640",
    "status": "Expired",
    "first_published_date": "09/06/2009",
    "last_updated_date": "03/08/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-640"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "decitabine;tetrahydrouridine",
    "date_of_designation_or_refusal": "20/06/2017",
    "intended_use": "Treatment of sickle cell disease",
    "eu_designation_number": "EU/3/17/1881",
    "status": "Positive",
    "first_published_date": "17/07/2017",
    "last_updated_date": "17/07/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1881"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pentamer formyl thiophene acetic acid",
    "date_of_designation_or_refusal": "20/06/2017",
    "intended_use": "Treatment of Creutzfeldt-Jakob disease",
    "eu_designation_number": "EU/3/17/1883",
    "status": "Positive",
    "first_published_date": "17/07/2017",
    "last_updated_date": "17/07/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1883"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sildenafil",
    "date_of_designation_or_refusal": "20/06/2017",
    "intended_use": "Treatment of congenital diaphragmatic hernia",
    "eu_designation_number": "EU/3/17/1885",
    "status": "Positive",
    "first_published_date": "17/07/2017",
    "last_updated_date": "17/07/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1885"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "murine IgM monoclonal antibody binding to alpha beta T-cell receptor",
    "date_of_designation_or_refusal": "12/03/2013",
    "intended_use": "Prevention of graft rejection following solid organ transplantation",
    "eu_designation_number": "EU/3/13/1113",
    "status": "Withdrawn",
    "first_published_date": "05/04/2013",
    "last_updated_date": "17/07/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1113"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 9 containing the human glucocerebrosidase gene",
    "date_of_designation_or_refusal": "19/03/2015",
    "intended_use": "Treatment of Gaucher disease",
    "eu_designation_number": "EU/3/15/1468",
    "status": "Withdrawn",
    "first_published_date": "11/05/2015",
    "last_updated_date": "17/07/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1468"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised monoclonal modified IgG4 antibody with bispecific structure targeting factors IX, IXa, X and Xa (emicizumab)",
    "date_of_designation_or_refusal": "16/01/2014",
    "intended_use": "Treatment of haemophilia A",
    "eu_designation_number": "EU/3/13/1221",
    "status": "Withdrawn",
    "first_published_date": "23/01/2014",
    "last_updated_date": "17/07/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1221"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Poloxamer 188",
    "date_of_designation_or_refusal": "12/03/2013",
    "intended_use": "Treatment of sickle cell disease",
    "eu_designation_number": "EU/3/13/1112",
    "status": "Withdrawn",
    "first_published_date": "05/04/2013",
    "last_updated_date": "17/07/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1112"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium phenylbutyrate",
    "date_of_designation_or_refusal": "11/01/2012",
    "intended_use": "Treatment of 5q spinal muscular atrophy",
    "eu_designation_number": "EU/3/11/948",
    "status": "Withdrawn",
    "first_published_date": "01/02/2012",
    "last_updated_date": "17/07/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-948"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "3-(4'Aminoisoindoline-1'-one)-1-piperidine-2,6-dione (lenalidomide)",
    "date_of_designation_or_refusal": "12/12/2003",
    "intended_use": "Treatment of multiple myeloma",
    "eu_designation_number": "EU/3/03/177",
    "status": "Withdrawn",
    "first_published_date": "29/07/2008",
    "last_updated_date": "17/07/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-177"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "3-(6-(1-(2,2-Difluorobenzo [d] [1,3] dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (lumacaftor)",
    "date_of_designation_or_refusal": "04/08/2010",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/10/761",
    "status": "Withdrawn",
    "first_published_date": "11/08/2010",
    "last_updated_date": "17/07/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-761"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Betaine anhydrous",
    "date_of_designation_or_refusal": "09/07/2001",
    "intended_use": "Treatment of homocystinuria",
    "eu_designation_number": "EU/3/01/045",
    "status": "Withdrawn",
    "first_published_date": "15/05/2009",
    "last_updated_date": "17/07/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-045"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "doxorubicin hydrochloride in a lipid-based pegylated nanoparticle modified with a 31-aminoacid peptide targeting nucleolin",
    "date_of_designation_or_refusal": "12/01/2017",
    "intended_use": "Treatment of malignant mesothelioma",
    "eu_designation_number": "EU/3/16/1814",
    "status": "Positive",
    "first_published_date": "14/07/2017",
    "last_updated_date": "14/07/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1814"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "antroquinonol",
    "date_of_designation_or_refusal": "12/01/2017",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/16/1812",
    "status": "Positive",
    "first_published_date": "14/07/2017",
    "last_updated_date": "14/07/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1812"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised IgG1 monoclonal antibody against the receptor-binding site of human placental growth factor",
    "date_of_designation_or_refusal": "12/01/2017",
    "intended_use": "Treatment of medulloblastoma",
    "eu_designation_number": "EU/3/16/1819",
    "status": "Positive",
    "first_published_date": "14/07/2017",
    "last_updated_date": "14/07/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1819"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous dendritic cells incubated ex vivo with zebularine and factor VIII",
    "date_of_designation_or_refusal": "12/01/2017",
    "intended_use": "Treatment of haemophilia A",
    "eu_designation_number": "EU/3/16/1813",
    "status": "Positive",
    "first_published_date": "14/07/2017",
    "last_updated_date": "14/07/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1813"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human hepatoma cell line HepaRG in bioartificial liver",
    "date_of_designation_or_refusal": "12/01/2017",
    "intended_use": "Treatment of acute liver failure",
    "eu_designation_number": "EU/3/16/1818",
    "status": "Positive",
    "first_published_date": "14/07/2017",
    "last_updated_date": "14/07/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1818"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Pr-D-Cys-Met-Pip-Arg-Leu-Arg-Sar-Cys-Lys-Arg-Pro-Tyr-Tle-Leu-OH",
    "date_of_designation_or_refusal": "12/01/2017",
    "intended_use": "Treatment of perinatal asphyxia",
    "eu_designation_number": "EU/3/16/1824",
    "status": "Positive",
    "first_published_date": "13/07/2017",
    "last_updated_date": "13/07/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1824"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "trans-resveratrol",
    "date_of_designation_or_refusal": "12/01/2017",
    "intended_use": "Treatment of spinocerebellar ataxia",
    "eu_designation_number": "EU/3/16/1827",
    "status": "Positive",
    "first_published_date": "13/07/2017",
    "last_updated_date": "13/07/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1827"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "[5,10,15,20-tetrakis(4-carboxyphenyl)-21H,23H-porphine]manganese(III) chloride",
    "date_of_designation_or_refusal": "12/01/2017",
    "intended_use": "Treatment of Cockayne syndrome",
    "eu_designation_number": "EU/3/16/1809",
    "status": "Positive",
    "first_published_date": "13/07/2017",
    "last_updated_date": "13/07/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1809"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "genetically modified adeno-associated viral vector serotype 9 expressing shRNA as well as a codon-optimised shRNA-insensitive wildtype PABPN1",
    "date_of_designation_or_refusal": "12/01/2017",
    "intended_use": "Treatment of oculopharyngeal muscular dystrophy",
    "eu_designation_number": "EU/3/16/1816",
    "status": "Positive",
    "first_published_date": "11/07/2017",
    "last_updated_date": "11/07/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1816"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pioglitazone hydrochloride",
    "date_of_designation_or_refusal": "12/01/2017",
    "intended_use": "Treatment of sudden sensorineural hearing loss",
    "eu_designation_number": "EU/3/16/1823",
    "status": "Positive",
    "first_published_date": "11/07/2017",
    "last_updated_date": "11/07/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1823"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pentosan polysulfate sodium",
    "date_of_designation_or_refusal": "12/01/2017",
    "intended_use": "Treatment of interstitial cystitis",
    "eu_designation_number": "EU/3/16/1822",
    "status": "Positive",
    "first_published_date": "11/07/2017",
    "last_updated_date": "11/07/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1822"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "leuprorelin acetate",
    "date_of_designation_or_refusal": "12/01/2017",
    "intended_use": "Treatment of congenital hypogonadotropic hypogonadism",
    "eu_designation_number": "EU/3/16/1821",
    "status": "Positive",
    "first_published_date": "11/07/2017",
    "last_updated_date": "11/07/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1821"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tamoxifen citrate",
    "date_of_designation_or_refusal": "22/05/2017",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/17/1877",
    "status": "Positive",
    "first_published_date": "29/06/2017",
    "last_updated_date": "29/06/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1877"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human interleukin-7 fused to a hybrid crystallisable fragment region of a human antibody-",
    "date_of_designation_or_refusal": "22/05/2017",
    "intended_use": "Treatment of idiopathic CD4 lymphocytopenia",
    "eu_designation_number": "EU/3/17/1875",
    "status": "Positive",
    "first_published_date": "29/06/2017",
    "last_updated_date": "29/06/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1875"
  },
  {
    "medicine_name": "Chenodeoxycholic acid Leadiant (previously Chenodeoxycholic acid sigma-tau)",
    "related_ema_product_number": "EMEA/H/C/004061",
    "active_substance": "chenodeoxycholic acid",
    "date_of_designation_or_refusal": "16/12/2014",
    "intended_use": "Treatment of inborn errors in primary bile acid synthesis",
    "eu_designation_number": "EU/3/14/1406",
    "status": "Positive",
    "first_published_date": "27/02/2015",
    "last_updated_date": "29/06/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1406"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "chimaeric monoclonal antibody against claudin-18 splice variant 2",
    "date_of_designation_or_refusal": "05/08/2013",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/13/1177",
    "status": "Positive",
    "first_published_date": "13/09/2013",
    "last_updated_date": "08/06/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1177"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "chimeric locked nucleic acid-deoxynucleoside phosphorothioate-linked oligonucleotide directed against microRNA-451",
    "date_of_designation_or_refusal": "11/01/2012",
    "intended_use": "Treatment of polycythaemia vera",
    "eu_designation_number": "EU/3/11/940",
    "status": "Withdrawn",
    "first_published_date": "01/02/2012",
    "last_updated_date": "17/05/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-940"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "3-[5-(2-Fluoro-phenyl)-[1,2,4]oxadiazole-3-yl]-benzoic acid",
    "date_of_designation_or_refusal": "27/05/2005",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/05/277",
    "status": "Withdrawn",
    "first_published_date": "04/07/2007",
    "last_updated_date": "17/05/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-277"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Eculizumab",
    "date_of_designation_or_refusal": "19/02/2014",
    "intended_use": "Prevention of delayed graft function after solid organ transplantation",
    "eu_designation_number": "EU/3/14/1238",
    "status": "Withdrawn",
    "first_published_date": "01/04/2014",
    "last_updated_date": "17/05/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1238"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-{2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-isoxazolyl) urea hydrochloride monohydrate",
    "date_of_designation_or_refusal": "09/06/2010",
    "intended_use": "Treatment of renal-cell carcinoma",
    "eu_designation_number": "EU/3/10/747",
    "status": "Withdrawn",
    "first_published_date": "23/06/2010",
    "last_updated_date": "17/05/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-747"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "apremilast",
    "date_of_designation_or_refusal": "05/08/2013",
    "intended_use": "Treatment of Behçet's Disease",
    "eu_designation_number": "EU/3/13/1180",
    "status": "Withdrawn",
    "first_published_date": "13/09/2013",
    "last_updated_date": "17/05/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1180"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "synthetic double-stranded oligomer specific to the SERPINA1 gene and containing a cholesterol-conjugated, acyclic nucleobase analogue",
    "date_of_designation_or_refusal": "11/01/2016",
    "intended_use": "Treatment of congenital alpha-1 antitrypsin deficiency",
    "eu_designation_number": "EU/3/15/1605",
    "status": "Withdrawn",
    "first_published_date": "05/02/2016",
    "last_updated_date": "17/05/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1605"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "beloranib",
    "date_of_designation_or_refusal": "04/07/2014",
    "intended_use": "Treatment of Prader-Willi syndrome",
    "eu_designation_number": "EU/3/14/1287",
    "status": "Withdrawn",
    "first_published_date": "15/07/2014",
    "last_updated_date": "17/05/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1287"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "synthetic double-stranded siRNA oligonucleotide directed against transthyretin mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues for the treatment of ATTR amyloidosis",
    "date_of_designation_or_refusal": "29/04/2014",
    "intended_use": "Treatment of ATTR amyloidosis",
    "eu_designation_number": "EU/3/14/1267",
    "status": "Withdrawn",
    "first_published_date": "04/06/2014",
    "last_updated_date": "17/05/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1267"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "beloranib",
    "date_of_designation_or_refusal": "08/10/2009",
    "intended_use": "Treatment of craniopharyngioma",
    "eu_designation_number": "EU/3/15/1530",
    "status": "Withdrawn",
    "first_published_date": "18/08/2015",
    "last_updated_date": "17/05/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1530"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Doxorubicin",
    "date_of_designation_or_refusal": "28/11/2012",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/12/1006",
    "status": "Withdrawn",
    "first_published_date": "17/12/2012",
    "last_updated_date": "17/05/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1006"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "synthetic double-stranded siRNA oligonucleotide directed against claudin-5 complexed with polyethyleneimine",
    "date_of_designation_or_refusal": "08/11/2012",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/12/1065",
    "status": "Withdrawn",
    "first_published_date": "12/12/2012",
    "last_updated_date": "17/05/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1065"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "20% Intravenous fat emulsion consisting of 20% soybean oil, 1.2% egg yolk phospholipids, 2.25% glycerin, and water for injection",
    "date_of_designation_or_refusal": "03/04/2017",
    "intended_use": "Treatment of poisoning by local anaesthetics",
    "eu_designation_number": "-",
    "status": "Negative",
    "first_published_date": "15/05/2017",
    "last_updated_date": "15/05/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-poisoning-local-anaesthetics"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "rituximab",
    "date_of_designation_or_refusal": "20/04/2017",
    "intended_use": "Treatment in solid organ transplantation",
    "eu_designation_number": "EU/3/17/1869",
    "status": "Positive",
    "first_published_date": "15/05/2017",
    "last_updated_date": "15/05/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1869"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human normal immunoglobulin",
    "date_of_designation_or_refusal": "20/04/2017",
    "intended_use": "Treatment in solid organ transplantation",
    "eu_designation_number": "EU/3/17/1866",
    "status": "Positive",
    "first_published_date": "15/05/2017",
    "last_updated_date": "15/05/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1866"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "modified messenger ribonucleic acid encoding human ornithine transcarbamylase enzyme encapsulated into lipid nanoparticles",
    "date_of_designation_or_refusal": "20/04/2017",
    "intended_use": "Treatment of ornithine transcarbamylase deficiency",
    "eu_designation_number": "EU/3/17/1867",
    "status": "Positive",
    "first_published_date": "15/05/2017",
    "last_updated_date": "15/05/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1867"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Estetrol",
    "date_of_designation_or_refusal": "20/04/2017",
    "intended_use": "Treatment of neonatal encephalopathy",
    "eu_designation_number": "EU/3/17/1865",
    "status": "Positive",
    "first_published_date": "15/05/2017",
    "last_updated_date": "15/05/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1865"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Poly-cyclodextrin-bis-cysteine-PEG3400-camptothecin-conjugate",
    "date_of_designation_or_refusal": "20/03/2017",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/17/1860",
    "status": "Positive",
    "first_published_date": "05/05/2017",
    "last_updated_date": "05/05/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1860"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Phosphoinositide 3-kinase gamma peptide",
    "date_of_designation_or_refusal": "20/03/2017",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/17/1859",
    "status": "Positive",
    "first_published_date": "05/05/2017",
    "last_updated_date": "05/05/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1859"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Ketoconazole",
    "date_of_designation_or_refusal": "20/03/2017",
    "intended_use": "Treatment of granulosa cell tumours",
    "eu_designation_number": "EU/3/17/1857",
    "status": "Positive",
    "first_published_date": "05/05/2017",
    "last_updated_date": "05/05/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1857"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Adeno-associated viral vector serotype rh.10 expressing beta-galactosidase",
    "date_of_designation_or_refusal": "20/03/2017",
    "intended_use": "Treatment of GM1 gangliosidosis",
    "eu_designation_number": "EU/3/17/1851",
    "status": "Positive",
    "first_published_date": "05/05/2017",
    "last_updated_date": "05/05/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1851"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Megestrol acetate",
    "date_of_designation_or_refusal": "20/03/2017",
    "intended_use": "Treatment of granulosa cell tumours",
    "eu_designation_number": "EU/3/17/1858",
    "status": "Positive",
    "first_published_date": "05/05/2017",
    "last_updated_date": "05/05/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1858"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "antisense oligonucleotide targeting the USH2A gene",
    "date_of_designation_or_refusal": "20/03/2017",
    "intended_use": "Treatment of retinitis pigmentosa",
    "eu_designation_number": "EU/3/17/1853",
    "status": "Positive",
    "first_published_date": "05/05/2017",
    "last_updated_date": "05/05/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1853"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous adipose tissue-derived mesenchymal stem cells",
    "date_of_designation_or_refusal": "20/03/2017",
    "intended_use": "Treatment of thromboangiitis obliterans (Buerger's disease)",
    "eu_designation_number": "EU/3/17/1854",
    "status": "Positive",
    "first_published_date": "05/05/2017",
    "last_updated_date": "05/05/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1854"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "3-[2-(4-carbamimidoyl-phenylcarbamoyl)-5-methoxy-4-vinyl-phenyl]-6-(cyclopropylmethyl-carbamoyl)-pyridine-2-carboxylic acid (avoralstat)",
    "date_of_designation_or_refusal": "12/02/2015",
    "intended_use": "Treatment of hereditary angioedema",
    "eu_designation_number": "EU/3/15/1431",
    "status": "Withdrawn",
    "first_published_date": "08/04/2015",
    "last_updated_date": "25/04/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1431"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "irinotecan hydrochloride",
    "date_of_designation_or_refusal": "30/11/2007",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/07/504",
    "status": "Withdrawn",
    "first_published_date": "02/07/2008",
    "last_updated_date": "25/04/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-504"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "doxorubicin hydrochloride",
    "date_of_designation_or_refusal": "30/11/2007",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/07/507",
    "status": "Withdrawn",
    "first_published_date": "02/07/2008",
    "last_updated_date": "25/04/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-507"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "cysteamine",
    "date_of_designation_or_refusal": "19/02/2014",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/14/1240",
    "status": "Positive",
    "first_published_date": "01/04/2014",
    "last_updated_date": "20/04/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1240"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "vemurafenib",
    "date_of_designation_or_refusal": "27/02/2017",
    "intended_use": "Treatment of Erdheim-Chester disease",
    "eu_designation_number": "EU/3/17/1846",
    "status": "Positive",
    "first_published_date": "31/03/2017",
    "last_updated_date": "31/03/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1846"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous T-cells transduced with lentiviral vector encoding an anti-SLAMF7 CD28/CD3-zeta chimeric antigen receptor",
    "date_of_designation_or_refusal": "27/02/2017",
    "intended_use": "Treatment of plasma cell myeloma",
    "eu_designation_number": "EU/3/17/1833",
    "status": "Positive",
    "first_published_date": "31/03/2017",
    "last_updated_date": "31/03/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1833"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised IgG4 monoclonal antibody to the human toll-like receptor type 2",
    "date_of_designation_or_refusal": "27/02/2017",
    "intended_use": "Treatment of myelodysplastic syndromes",
    "eu_designation_number": "EU/3/17/1837",
    "status": "Positive",
    "first_published_date": "31/03/2017",
    "last_updated_date": "31/03/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1837"
  },
  {
    "medicine_name": "Omblastys",
    "related_ema_product_number": "EMEA/H/C/005499",
    "active_substance": "Iodine (131I) murine IgG1 monoclonal antibody against CD276",
    "date_of_designation_or_refusal": "27/02/2017",
    "intended_use": "Treatment of neuroblastoma",
    "eu_designation_number": "EU/3/17/1839",
    "status": "Positive",
    "first_published_date": "31/03/2017",
    "last_updated_date": "31/03/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1839"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "thalidomide",
    "date_of_designation_or_refusal": "27/02/2017",
    "intended_use": "Treatment of hereditary haemorrhagic telangiectasia",
    "eu_designation_number": "EU/3/17/1845",
    "status": "Positive",
    "first_published_date": "31/03/2017",
    "last_updated_date": "31/03/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1845"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "propranolol hydrochloride",
    "date_of_designation_or_refusal": "27/02/2017",
    "intended_use": "Treatment of von Hippel-Lindau disease",
    "eu_designation_number": "EU/3/17/1841",
    "status": "Positive",
    "first_published_date": "31/03/2017",
    "last_updated_date": "31/03/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1841"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tauroursodeoxycholic acid",
    "date_of_designation_or_refusal": "27/02/2017",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/17/1844",
    "status": "Positive",
    "first_published_date": "31/03/2017",
    "last_updated_date": "31/03/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1844"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "alpha-tocopherol;ascorbic acid",
    "date_of_designation_or_refusal": "27/02/2017",
    "intended_use": "Treatment of fragile X syndrome",
    "eu_designation_number": "EU/3/17/1832",
    "status": "Positive",
    "first_published_date": "31/03/2017",
    "last_updated_date": "31/03/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1832"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sevuparin sodium",
    "date_of_designation_or_refusal": "12/02/2015",
    "intended_use": "Treatment of sickle cell disease",
    "eu_designation_number": "EU/3/15/1433",
    "status": "Positive",
    "first_published_date": "08/04/2015",
    "last_updated_date": "17/03/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1433"
  },
  {
    "medicine_name": "Ledaga",
    "related_ema_product_number": "EMEA/H/C/002826",
    "active_substance": "chlormethine",
    "date_of_designation_or_refusal": "22/05/2012",
    "intended_use": "Treatment of cutaneous T-cell lymphoma",
    "eu_designation_number": "EU/3/12/963",
    "status": "Positive",
    "first_published_date": "06/07/2012",
    "last_updated_date": "16/03/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-963"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised IgG4 monoclonal antibody to the human toll-like receptor type 2",
    "date_of_designation_or_refusal": "27/02/2017",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/17/1838",
    "status": "Positive",
    "first_published_date": "13/03/2017",
    "last_updated_date": "13/03/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-17-1838"
  },
  {
    "medicine_name": "Cystadrops",
    "related_ema_product_number": "EMEA/H/C/003769",
    "active_substance": "cysteamine hydrochloride",
    "date_of_designation_or_refusal": "07/11/2008",
    "intended_use": "Treatment of cystinosis",
    "eu_designation_number": "EU/3/08/578",
    "status": "Positive",
    "first_published_date": "29/06/2009",
    "last_updated_date": "22/02/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-578"
  },
  {
    "medicine_name": "Winfuran",
    "related_ema_product_number": "EMEA/H/C/002683",
    "active_substance": "",
    "date_of_designation_or_refusal": "11/09/2002",
    "intended_use": "Treatment of uraemic pruritus",
    "eu_designation_number": "EU/3/02/115",
    "status": "Positive",
    "first_published_date": "10/02/2009",
    "last_updated_date": "14/02/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-115"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "mifepristone",
    "date_of_designation_or_refusal": "27/07/2005",
    "intended_use": "Treatment of Cushing's syndrome secondary to ectopic ACTH secretion",
    "eu_designation_number": "EU/3/05/298",
    "status": "Withdrawn",
    "first_published_date": "11/10/2005",
    "last_updated_date": "10/02/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-298"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Pomalidomide",
    "date_of_designation_or_refusal": "27/07/2010",
    "intended_use": "Treatment of post-essential thrombocythaemia myelofibrosis",
    "eu_designation_number": "EU/3/10/759",
    "status": "Withdrawn",
    "first_published_date": "06/08/2010",
    "last_updated_date": "10/02/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-759"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Pomalidomide",
    "date_of_designation_or_refusal": "27/07/2010",
    "intended_use": "Treatment of post-polycythaemia vera myelofibrosis",
    "eu_designation_number": "EU/3/10/758",
    "status": "Withdrawn",
    "first_published_date": "06/08/2010",
    "last_updated_date": "10/02/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-758"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human factor XIII (composed of two A subunits)",
    "date_of_designation_or_refusal": "12/12/2003",
    "intended_use": "Treatment of hereditary factor-XIII deficiency",
    "eu_designation_number": "EU/3/03/179",
    "status": "Withdrawn",
    "first_published_date": "12/12/2005",
    "last_updated_date": "10/02/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-179"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Pomalidomide",
    "date_of_designation_or_refusal": "27/07/2010",
    "intended_use": "Treatment of primary myelofibrosis",
    "eu_designation_number": "EU/3/10/757",
    "status": "Withdrawn",
    "first_published_date": "06/08/2010",
    "last_updated_date": "10/02/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-757"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "axitinib",
    "date_of_designation_or_refusal": "23/02/2011",
    "intended_use": "Treatment of renal-cell carcinoma",
    "eu_designation_number": "EU/3/10/844",
    "status": "Withdrawn",
    "first_published_date": "04/03/2011",
    "last_updated_date": "10/02/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-844"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "heparin sodium",
    "date_of_designation_or_refusal": "02/09/2004",
    "intended_use": "Treatment of idiopathic pulmonary fibrosis",
    "eu_designation_number": "EU/3/04/223",
    "status": "Withdrawn",
    "first_published_date": "01/07/2005",
    "last_updated_date": "10/02/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-223"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "azacitidine",
    "date_of_designation_or_refusal": "11/11/2015",
    "intended_use": "Treatment of nasopharyngeal carcinoma",
    "eu_designation_number": "EU/3/15/1570",
    "status": "Withdrawn",
    "first_published_date": "06/01/2016",
    "last_updated_date": "08/02/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1570"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "anagrelide hydrochloride",
    "date_of_designation_or_refusal": "30/12/2000",
    "intended_use": "Treatment of essential thrombocythaemia",
    "eu_designation_number": "EU/3/00/010",
    "status": "Expired",
    "first_published_date": "15/06/2009",
    "last_updated_date": "08/02/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-00-010"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "stiripentol",
    "date_of_designation_or_refusal": "06/12/2001",
    "intended_use": "Treatment of severe myoclonic epilepsy in infancy",
    "eu_designation_number": "EU/3/01/071",
    "status": "Expired",
    "first_published_date": "31/07/2007",
    "last_updated_date": "08/02/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-071"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Iduronate-2-sulfatase",
    "date_of_designation_or_refusal": "11/12/2001",
    "intended_use": "Treatment of mucopolysaccharidosis type II (Hunter's syndrome)",
    "eu_designation_number": "EU/3/01/078",
    "status": "Expired",
    "first_published_date": "18/10/2010",
    "last_updated_date": "08/02/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-078"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "dasatinib",
    "date_of_designation_or_refusal": "23/12/2005",
    "intended_use": "Treatment of acute lymphoblastic leukaemia",
    "eu_designation_number": "EU/3/05/338",
    "status": "Expired",
    "first_published_date": "28/02/2007",
    "last_updated_date": "08/02/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-338"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "dasatinib",
    "date_of_designation_or_refusal": "23/12/2005",
    "intended_use": "Treatment of chronic myeloid leukaemia",
    "eu_designation_number": "EU/3/05/339",
    "status": "Expired",
    "first_published_date": "28/02/2007",
    "last_updated_date": "08/02/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-339"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "alisertib",
    "date_of_designation_or_refusal": "06/12/2012",
    "intended_use": "Treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)",
    "eu_designation_number": "EU/3/12/1074",
    "status": "Withdrawn",
    "first_published_date": "24/01/2013",
    "last_updated_date": "07/02/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1074"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "alisertib",
    "date_of_designation_or_refusal": "08/11/2012",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/12/1064",
    "status": "Withdrawn",
    "first_published_date": "13/12/2012",
    "last_updated_date": "07/02/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1064"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "folic acid",
    "date_of_designation_or_refusal": "10/09/2012",
    "intended_use": "Diagnosis of positive folate-receptor status in ovarian cancer",
    "eu_designation_number": "EU/3/12/1044",
    "status": "Withdrawn",
    "first_published_date": "26/09/2012",
    "last_updated_date": "07/02/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1044"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic bone marrow stem cells treated ex vivo with 16,16-dimethyl prostaglandin E2",
    "date_of_designation_or_refusal": "13/05/2011",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/11/866",
    "status": "Withdrawn",
    "first_published_date": "30/05/2011",
    "last_updated_date": "07/02/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-866"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic umbilical cord blood cells treated ex vivo with 16,16-dimethyl prostaglandin E2",
    "date_of_designation_or_refusal": "10/08/2015",
    "intended_use": "Treatment of acute lymphoblastic leukaemia",
    "eu_designation_number": "EU/3/15/1546",
    "status": "Withdrawn",
    "first_published_date": "02/10/2015",
    "last_updated_date": "07/02/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1546"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Fingolimod",
    "date_of_designation_or_refusal": "02/02/2010",
    "intended_use": "Treatment of chronic inflammatory demyelinating polyneuropathy",
    "eu_designation_number": "EU/3/09/718",
    "status": "Withdrawn",
    "first_published_date": "04/03/2010",
    "last_updated_date": "07/02/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-718"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "udenafil",
    "date_of_designation_or_refusal": "12/12/2016",
    "intended_use": "Treatment of functional single ventricle congenital heart disease",
    "eu_designation_number": "EU/3/16/1807",
    "status": "Positive",
    "first_published_date": "10/01/2017",
    "last_updated_date": "10/01/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1807"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "propranolol",
    "date_of_designation_or_refusal": "12/12/2016",
    "intended_use": "Treatment of soft tissue sarcoma",
    "eu_designation_number": "EU/3/16/1805",
    "status": "Positive",
    "first_published_date": "09/01/2017",
    "last_updated_date": "09/01/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1805"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "3-(3-Methanesulfonyl-phenyl)-1-propyl-piperidine hydrochloride",
    "date_of_designation_or_refusal": "13/07/2016",
    "intended_use": "Treatment of narcolepsy",
    "eu_designation_number": "-",
    "status": "Negative",
    "first_published_date": "09/01/2017",
    "last_updated_date": "09/01/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-narcolepsy"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human dyskerin",
    "date_of_designation_or_refusal": "08/11/2012",
    "intended_use": "Treatment of dyskeratosis congenita",
    "eu_designation_number": "EU/3/12/1070",
    "status": "Positive",
    "first_published_date": "12/12/2012",
    "last_updated_date": "05/01/2017",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1070"
  },
  {
    "medicine_name": "Prohippur",
    "related_ema_product_number": "EMEA/H/C/004150",
    "active_substance": "sodium benzoate",
    "date_of_designation_or_refusal": "18/11/2016",
    "intended_use": "Treatment of N-acetylglutamate synthetase (NAGS) deficiency",
    "eu_designation_number": "EU/3/16/1788",
    "status": "Positive",
    "first_published_date": "14/12/2016",
    "last_updated_date": "14/12/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1788"
  },
  {
    "medicine_name": "Prohippur",
    "related_ema_product_number": "EMEA/H/C/004150",
    "active_substance": "sodium benzoate",
    "date_of_designation_or_refusal": "18/11/2016",
    "intended_use": "Treatment of argininosuccinic aciduria",
    "eu_designation_number": "EU/3/16/1787",
    "status": "Positive",
    "first_published_date": "14/12/2016",
    "last_updated_date": "14/12/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1787"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "zinc gluconate",
    "date_of_designation_or_refusal": "18/11/2016",
    "intended_use": "treatment of facioscapulohumeral muscular dystrophy",
    "eu_designation_number": "EU/3/16/1793",
    "status": "Positive",
    "first_published_date": "14/12/2016",
    "last_updated_date": "14/12/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1793"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "alpha-tocopherol",
    "date_of_designation_or_refusal": "18/11/2016",
    "intended_use": "treatment of facioscapulohumeral muscular dystrophy",
    "eu_designation_number": "EU/3/16/1775",
    "status": "Positive",
    "first_published_date": "14/12/2016",
    "last_updated_date": "14/12/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1775"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ascorbic acid",
    "date_of_designation_or_refusal": "18/11/2016",
    "intended_use": "treatment of facioscapulohumeral muscular dystrophy",
    "eu_designation_number": "EU/3/16/1776",
    "status": "Positive",
    "first_published_date": "14/12/2016",
    "last_updated_date": "14/12/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1776"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "L-selenomethionine",
    "date_of_designation_or_refusal": "18/11/2016",
    "intended_use": "treatment of facioscapulohumeral muscular dystrophy",
    "eu_designation_number": "EU/3/16/1782",
    "status": "Positive",
    "first_published_date": "14/12/2016",
    "last_updated_date": "14/12/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1782"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "valproic acid",
    "date_of_designation_or_refusal": "18/11/2016",
    "intended_use": "Treatment of diffuse large B-cell lymphoma",
    "eu_designation_number": "EU/3/16/1792",
    "status": "Positive",
    "first_published_date": "14/12/2016",
    "last_updated_date": "14/12/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1792"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "live-attenuated non-replicative Pseudomonas aeruginosa strain expressing large T antigen of Merkel cell polyomavirus",
    "date_of_designation_or_refusal": "18/11/2016",
    "intended_use": "Treatment of Merkel cell carcinoma",
    "eu_designation_number": "EU/3/16/1781",
    "status": "Positive",
    "first_published_date": "14/12/2016",
    "last_updated_date": "14/12/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1781"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "R-azasetron besilate",
    "date_of_designation_or_refusal": "18/11/2016",
    "intended_use": "Treatment of sudden sensorineural hearing loss",
    "eu_designation_number": "EU/3/16/1785",
    "status": "Positive",
    "first_published_date": "13/12/2016",
    "last_updated_date": "13/12/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1785"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "particles comprised of methacrylic acid based co-polymer, cross-linked with a bi-functional cross-linker, purified to bind L-phenylalanine and L-phenylalanine containing peptides",
    "date_of_designation_or_refusal": "18/11/2016",
    "intended_use": "Treatment of hyperphenylalaninaemia",
    "eu_designation_number": "EU/3/16/1784",
    "status": "Positive",
    "first_published_date": "13/12/2016",
    "last_updated_date": "13/12/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1784"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "naltrexone",
    "date_of_designation_or_refusal": "06/10/2016",
    "intended_use": "Treatment of fibromyalgia",
    "eu_designation_number": "-",
    "status": "Negative",
    "first_published_date": "13/12/2016",
    "last_updated_date": "13/12/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-fibromyalgia"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "exon 52 specific phosphorothioate oligonucleotide",
    "date_of_designation_or_refusal": "06/12/2012",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/12/1077",
    "status": "Positive",
    "first_published_date": "25/01/2013",
    "last_updated_date": "05/12/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1077"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "exon 53 specific phosphorothioate oligonucleotide",
    "date_of_designation_or_refusal": "26/04/2012",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/12/992",
    "status": "Positive",
    "first_published_date": "18/06/2012",
    "last_updated_date": "05/12/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-992"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "exon 55 specific phosphorothioate oligonucleotide",
    "date_of_designation_or_refusal": "06/12/2012",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/12/1078",
    "status": "Positive",
    "first_published_date": "25/01/2013",
    "last_updated_date": "05/12/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1078"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "exon 45 specific phosphorothioate oligonucleotide",
    "date_of_designation_or_refusal": "26/04/2012",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/12/991",
    "status": "Positive",
    "first_published_date": "18/06/2012",
    "last_updated_date": "05/12/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-991"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "exon 44 specific phosphorothioate oligonucleotide",
    "date_of_designation_or_refusal": "27/02/2009",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/08/598",
    "status": "Positive",
    "first_published_date": "29/06/2009",
    "last_updated_date": "02/12/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-598"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human monoclonal IgM antibody targeting glucose regulated protein 78",
    "date_of_designation_or_refusal": "07/10/2013",
    "intended_use": "Treatment of plasma cell myeloma",
    "eu_designation_number": "EU/3/13/1190",
    "status": "Positive",
    "first_published_date": "31/10/2013",
    "last_updated_date": "18/11/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1190"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "carbamazepine",
    "date_of_designation_or_refusal": "14/10/2016",
    "intended_use": "Treatment of metaphyseal chondrodysplasia, Schmid type",
    "eu_designation_number": "EU/3/16/1746",
    "status": "Positive",
    "first_published_date": "15/11/2016",
    "last_updated_date": "15/11/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1746"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "crenolanib besilate",
    "date_of_designation_or_refusal": "14/10/2016",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/16/1748",
    "status": "Positive",
    "first_published_date": "15/11/2016",
    "last_updated_date": "15/11/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1748"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tetrofosmin",
    "date_of_designation_or_refusal": "20/09/2016",
    "intended_use": "Diagnosis of glioma",
    "eu_designation_number": "EU/3/16/1764",
    "status": "Positive",
    "first_published_date": "15/11/2016",
    "last_updated_date": "15/11/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1764"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "chemically modified human recombinant sulfamidase",
    "date_of_designation_or_refusal": "14/10/2016",
    "intended_use": "Treatment of mucopolysaccharidosis, type IIIA (Sanfilippo A syndrome)",
    "eu_designation_number": "EU/3/16/1747",
    "status": "Positive",
    "first_published_date": "15/11/2016",
    "last_updated_date": "15/11/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1747"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous mononuclear cells derived from human cord blood",
    "date_of_designation_or_refusal": "14/10/2016",
    "intended_use": "Treatment of neonatal encephalopathy",
    "eu_designation_number": "EU/3/16/1743",
    "status": "Positive",
    "first_published_date": "15/11/2016",
    "last_updated_date": "15/11/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1743"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "crenolanib besilate",
    "date_of_designation_or_refusal": "20/09/2016",
    "intended_use": "Treatment of soft tissue sarcoma",
    "eu_designation_number": "EU/3/16/1749",
    "status": "Positive",
    "first_published_date": "15/11/2016",
    "last_updated_date": "15/11/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1749"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "xenon",
    "date_of_designation_or_refusal": "14/10/2016",
    "intended_use": "Treatment of ischaemia/reperfusion injury associated with cardiac arrest",
    "eu_designation_number": "EU/3/16/1768",
    "status": "Positive",
    "first_published_date": "15/11/2016",
    "last_updated_date": "15/11/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1768"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "A non-covalent trimer of tumour necrosis factor fused to an antibody specific to the extra-domain B of fibronectin in single-chain variable fragment format",
    "date_of_designation_or_refusal": "20/09/2016",
    "intended_use": "Treatment of soft tissue sarcoma",
    "eu_designation_number": "EU/3/16/1739",
    "status": "Positive",
    "first_published_date": "15/11/2016",
    "last_updated_date": "15/11/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1739"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-{4-[4-(5-fluoro-pyrimidin-2-yl)piperazin-1-yl]-phenyl}-2-oxo-acetamide (also known as F901318)(olorofim)",
    "date_of_designation_or_refusal": "14/10/2016",
    "intended_use": "Treatment of invasive aspergillosis",
    "eu_designation_number": "EU/3/16/1738",
    "status": "Positive",
    "first_published_date": "15/11/2016",
    "last_updated_date": "15/11/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1738"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous mononuclear cells derived from human cord blood",
    "date_of_designation_or_refusal": "14/10/2016",
    "intended_use": "Treatment of periventricular leukomalacia",
    "eu_designation_number": "EU/3/16/1744",
    "status": "Positive",
    "first_published_date": "14/11/2016",
    "last_updated_date": "14/11/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1744"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Dexamethasone phosphate",
    "date_of_designation_or_refusal": "15/05/2009",
    "intended_use": "Treatment of corneal graft rejection",
    "eu_designation_number": "EU/3/09/636",
    "status": "Withdrawn",
    "first_published_date": "09/06/2009",
    "last_updated_date": "21/10/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-636"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector encoding an inducible short hairpin RNA targeting claudin-5",
    "date_of_designation_or_refusal": "08/11/2012",
    "intended_use": "Treatment of retinitis pigmentosa",
    "eu_designation_number": "EU/3/12/1069",
    "status": "Withdrawn",
    "first_published_date": "13/12/2012",
    "last_updated_date": "21/10/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1069"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tralokinumab",
    "date_of_designation_or_refusal": "08/11/2012",
    "intended_use": "Treatment of idiopathic pulmonary fibrosis",
    "eu_designation_number": "EU/3/12/1061",
    "status": "Withdrawn",
    "first_published_date": "13/12/2012",
    "last_updated_date": "21/10/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1061"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Vincaleukoblastin-23-oic acid, O4-deacetyl-, 2-[(2-mercaptoethoxy)carbonyl]hydrazide, disulfide with N-[4-[[(2-amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-γ-glutamyl-L-α-aspartyl-L-arginyl-L-α-aspartyl-L-α-aspartyl-L-cysteine",
    "date_of_designation_or_refusal": "09/02/2012",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/12/959",
    "status": "Withdrawn",
    "first_published_date": "24/02/2012",
    "last_updated_date": "21/10/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-959"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl)diamidophosphate",
    "date_of_designation_or_refusal": "05/03/2012",
    "intended_use": "Treatment of soft tissue sarcoma",
    "eu_designation_number": "EU/3/12/966",
    "status": "Withdrawn",
    "first_published_date": "19/04/2012",
    "last_updated_date": "21/10/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-966"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ciclosporin",
    "date_of_designation_or_refusal": "10/03/2005",
    "intended_use": "Prevention of graft rejection after lung transplantation",
    "eu_designation_number": "EU/3/05/266",
    "status": "Withdrawn",
    "first_published_date": "04/12/2007",
    "last_updated_date": "21/10/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-266"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2'-deoxyguanosylyl-(3',5'-phosphoryl)-2'-deoxythymidylyl-(3',5'-phosphoryl)- 2'-deoxyguanosylyl-(3',5'-phosphoryl)-2'-deoxycytidylyl-(3',5'-phosphoryl)-2'-deoxycytidylyl -(3',5'-phosphoryl)-2'-deoxycytidylyl-(3',5'-phosphoryl)-2'-deoxyguanosylyl...",
    "date_of_designation_or_refusal": "10/08/2015",
    "intended_use": "Treatment of diffuse large B-cell lymphoma",
    "eu_designation_number": "EU/3/15/1542",
    "status": "Withdrawn",
    "first_published_date": "02/10/2015",
    "last_updated_date": "21/10/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1542"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Denufosol tetrasodium",
    "date_of_designation_or_refusal": "23/12/2005",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/05/342",
    "status": "Withdrawn",
    "first_published_date": "04/07/2007",
    "last_updated_date": "21/10/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-342"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pseudomonas exotoxin (domains II/III)-interleukin 13 chimeric protein",
    "date_of_designation_or_refusal": "30/04/2002",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/02/101",
    "status": "Withdrawn",
    "first_published_date": "04/12/2007",
    "last_updated_date": "20/10/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-101"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "HLA class I/II binding tumour associated peptides (ADF-APO-CCN-GUC-K67-MET-MMP-MUC-RGS)",
    "date_of_designation_or_refusal": "15/02/2007",
    "intended_use": "Treatment of renal-cell carcinoma",
    "eu_designation_number": "EU/3/07/433",
    "status": "Withdrawn",
    "first_published_date": "10/07/2008",
    "last_updated_date": "20/10/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-433"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "obinutuzumab",
    "date_of_designation_or_refusal": "19/06/2015",
    "intended_use": "Treatment of marginal zone lymphoma",
    "eu_designation_number": "EU/3/15/1505",
    "status": "Withdrawn",
    "first_published_date": "27/07/2015",
    "last_updated_date": "20/10/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1505"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Iodine (131I) anti-nucleohistone H1 chimeric biotinylated monoclonal antibody",
    "date_of_designation_or_refusal": "13/11/2002",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/02/119",
    "status": "Withdrawn",
    "first_published_date": "26/05/2003",
    "last_updated_date": "20/10/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-119"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Fimaporfin",
    "date_of_designation_or_refusal": "29/08/2016",
    "intended_use": "Treatment of cholangiocarcinoma",
    "eu_designation_number": "EU/3/16/1720",
    "status": "Positive",
    "first_published_date": "10/10/2016",
    "last_updated_date": "10/10/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1720"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "cannabidiol",
    "date_of_designation_or_refusal": "29/08/2016",
    "intended_use": "Treatment of graft-versus-host disease",
    "eu_designation_number": "EU/3/16/1718",
    "status": "Positive",
    "first_published_date": "10/10/2016",
    "last_updated_date": "10/10/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1718"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "methotrexate",
    "date_of_designation_or_refusal": "29/08/2016",
    "intended_use": "Treatment of alkaptonuria",
    "eu_designation_number": "EU/3/16/1723",
    "status": "Positive",
    "first_published_date": "03/10/2016",
    "last_updated_date": "03/10/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1723"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "temozolomide",
    "date_of_designation_or_refusal": "29/08/2016",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/16/1733",
    "status": "Positive",
    "first_published_date": "03/10/2016",
    "last_updated_date": "03/10/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1733"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 9 containing the human mini-dystrophin gene",
    "date_of_designation_or_refusal": "29/08/2016",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/16/1716",
    "status": "Positive",
    "first_published_date": "03/10/2016",
    "last_updated_date": "03/10/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1716"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "L-Pyr-L-Glu-L-Gln-L-Leu-L-Glu-L-Arg-L-Ala-L-Leu-L-Asn-L-Ser-L-Ser (cibinetide)",
    "date_of_designation_or_refusal": "29/08/2016",
    "intended_use": "Prevention of graft loss in pancreatic islet transplantation",
    "eu_designation_number": "EU/3/16/1721",
    "status": "Positive",
    "first_published_date": "03/10/2016",
    "last_updated_date": "03/10/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1721"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "nintedanib",
    "date_of_designation_or_refusal": "29/08/2016",
    "intended_use": "Treatment of systemic sclerosis",
    "eu_designation_number": "EU/3/16/1724",
    "status": "Withdrawn",
    "first_published_date": "03/10/2016",
    "last_updated_date": "03/10/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1724"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human acid alpha-glucosidase conjugated with mannose-6-phosphate analogues",
    "date_of_designation_or_refusal": "29/08/2016",
    "intended_use": "Treatment of glycogen storage disease type II (Pompe's disease)",
    "eu_designation_number": "EU/3/16/1726",
    "status": "Positive",
    "first_published_date": "03/10/2016",
    "last_updated_date": "03/10/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1726"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "cisplatin",
    "date_of_designation_or_refusal": "29/08/2016",
    "intended_use": "Treatment of malignant mesothelioma",
    "eu_designation_number": "EU/3/16/1719",
    "status": "Positive",
    "first_published_date": "03/10/2016",
    "last_updated_date": "03/10/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1719"
  },
  {
    "medicine_name": "Prohippur",
    "related_ema_product_number": "EMEA/H/C/004150",
    "active_substance": "sodium benzoate",
    "date_of_designation_or_refusal": "29/08/2016",
    "intended_use": "Treatment of lysinuric protein intolerance",
    "eu_designation_number": "EU/3/16/1729",
    "status": "Positive",
    "first_published_date": "03/10/2016",
    "last_updated_date": "03/10/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1729"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "valproic acid",
    "date_of_designation_or_refusal": "29/08/2016",
    "intended_use": "Treatment of McArdle's disease",
    "eu_designation_number": "EU/3/16/1734",
    "status": "Positive",
    "first_published_date": "03/10/2016",
    "last_updated_date": "03/10/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1734"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "zoledronic acid",
    "date_of_designation_or_refusal": "29/08/2016",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/16/1735",
    "status": "Positive",
    "first_published_date": "03/10/2016",
    "last_updated_date": "03/10/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1735"
  },
  {
    "medicine_name": "Prohippur",
    "related_ema_product_number": "EMEA/H/C/004150",
    "active_substance": "sodium benzoate",
    "date_of_designation_or_refusal": "29/08/2016",
    "intended_use": "Treatment of ornithine translocase deficiency",
    "eu_designation_number": "EU/3/16/1730",
    "status": "Positive",
    "first_published_date": "03/10/2016",
    "last_updated_date": "03/10/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1730"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "4-(3,5-Bis(hydroxy-phenyl)-1,2,4) triazol-1-yl) benzoic acid",
    "date_of_designation_or_refusal": "13/03/2002",
    "intended_use": "Treatment of chronic iron overload requiring chelation therapy",
    "eu_designation_number": "EU/3/02/092",
    "status": "Expired",
    "first_published_date": "28/02/2007",
    "last_updated_date": "30/09/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-092"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sitaxentan sodium",
    "date_of_designation_or_refusal": "21/10/2004",
    "intended_use": "Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension",
    "eu_designation_number": "EU/3/04/234",
    "status": "Withdrawn",
    "first_published_date": "28/02/2007",
    "last_updated_date": "30/09/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-234"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Dexrazoxane",
    "date_of_designation_or_refusal": "19/09/2001",
    "intended_use": "Treatment of anthracycline extravasations",
    "eu_designation_number": "EU/3/01/059",
    "status": "Expired",
    "first_published_date": "15/06/2009",
    "last_updated_date": "30/09/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-059"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium hypochlorite",
    "date_of_designation_or_refusal": "14/07/2016",
    "intended_use": "Treatment of partial deep dermal and full-thickness burns",
    "eu_designation_number": "EU/3/16/1709",
    "status": "Positive",
    "first_published_date": "06/09/2016",
    "last_updated_date": "06/09/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1709"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 2.7m8 containing the ChrimsonR-tdTomato gene",
    "date_of_designation_or_refusal": "14/07/2016",
    "intended_use": "Treatment of retinitis pigmentosa",
    "eu_designation_number": "EU/3/16/1693",
    "status": "Positive",
    "first_published_date": "06/09/2016",
    "last_updated_date": "06/09/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1693"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "triheptanoin",
    "date_of_designation_or_refusal": "14/07/2016",
    "intended_use": "Treatment of McArdle's disease",
    "eu_designation_number": "EU/3/16/1710",
    "status": "Positive",
    "first_published_date": "06/09/2016",
    "last_updated_date": "06/09/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1710"
  },
  {
    "medicine_name": "Prohippur",
    "related_ema_product_number": "EMEA/H/C/004150",
    "active_substance": "sodium benzoate",
    "date_of_designation_or_refusal": "14/07/2016",
    "intended_use": "Treatment of carbamoyl-phosphate synthase-1 deficiency",
    "eu_designation_number": "EU/3/16/1706",
    "status": "Positive",
    "first_published_date": "06/09/2016",
    "last_updated_date": "06/09/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1706"
  },
  {
    "medicine_name": "Prohippur",
    "related_ema_product_number": "EMEA/H/C/004150",
    "active_substance": "sodium benzoate",
    "date_of_designation_or_refusal": "14/07/2016",
    "intended_use": "Treatment of hyperargininaemia",
    "eu_designation_number": "EU/3/16/1708",
    "status": "Positive",
    "first_published_date": "06/09/2016",
    "last_updated_date": "06/09/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1708"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "mifamurtide",
    "date_of_designation_or_refusal": "14/07/2016",
    "intended_use": "Treatment of echinococcosis",
    "eu_designation_number": "EU/3/16/1699",
    "status": "Positive",
    "first_published_date": "06/09/2016",
    "last_updated_date": "06/09/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1699"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "16-base single-stranded peptide nucleic acid oligonucleotide linked to 7-amino acid peptide",
    "date_of_designation_or_refusal": "14/07/2016",
    "intended_use": "Treatment of soft tissue sarcoma",
    "eu_designation_number": "EU/3/16/1690",
    "status": "Positive",
    "first_published_date": "06/09/2016",
    "last_updated_date": "06/09/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1690"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "mifamurtide",
    "date_of_designation_or_refusal": "14/07/2016",
    "intended_use": "Treatment of hepatocellular carcinoma",
    "eu_designation_number": "EU/3/16/1700",
    "status": "Positive",
    "first_published_date": "06/09/2016",
    "last_updated_date": "06/09/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1700"
  },
  {
    "medicine_name": "Prohippur",
    "related_ema_product_number": "EMEA/H/C/004150",
    "active_substance": "sodium benzoate",
    "date_of_designation_or_refusal": "14/07/2016",
    "intended_use": "Treatment of citrullinaemia type 1",
    "eu_designation_number": "EU/3/16/1707",
    "status": "Positive",
    "first_published_date": "06/09/2016",
    "last_updated_date": "06/09/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1707"
  },
  {
    "medicine_name": "Prohippur",
    "related_ema_product_number": "EMEA/H/C/004150",
    "active_substance": "sodium benzoate",
    "date_of_designation_or_refusal": "14/07/2016",
    "intended_use": "Treatment of ornithine transcarbamylase deficiency",
    "eu_designation_number": "EU/3/16/1705",
    "status": "Positive",
    "first_published_date": "06/09/2016",
    "last_updated_date": "06/09/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1705"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-[4-(3-amino-1H-indazol-4 yl)phenyl]-N'-(2-fluoro-5-methylphenyl) urea",
    "date_of_designation_or_refusal": "20/12/2007",
    "intended_use": "Treatment of hepatocellular carcinoma",
    "eu_designation_number": "EU/3/07/517",
    "status": "Withdrawn",
    "first_published_date": "02/07/2008",
    "last_updated_date": "19/08/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-517"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant antibody construct against human CD30 and CD16A",
    "date_of_designation_or_refusal": "09/10/2009",
    "intended_use": "Treatment of Hodgkin's lymphoma",
    "eu_designation_number": "EU/3/09/673",
    "status": "Positive",
    "first_published_date": "20/10/2009",
    "last_updated_date": "17/08/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-673"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "defibrotide",
    "date_of_designation_or_refusal": "29/07/2004",
    "intended_use": "Treatment of hepatic veno-occlusive disease",
    "eu_designation_number": "EU/3/04/212",
    "status": "Positive",
    "first_published_date": "12/12/2005",
    "last_updated_date": "17/08/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-212"
  },
  {
    "medicine_name": "Heparesc",
    "related_ema_product_number": "EMEA/H/C/003750",
    "active_substance": "human heterologous liver cells",
    "date_of_designation_or_refusal": "17/12/2010",
    "intended_use": "Treatment of argininosuccinic aciduria",
    "eu_designation_number": "EU/3/10/820",
    "status": "Positive",
    "first_published_date": "20/01/2011",
    "last_updated_date": "16/08/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-820"
  },
  {
    "medicine_name": "Heparesc",
    "related_ema_product_number": "EMEA/H/C/003750",
    "active_substance": "human heterologous liver cells",
    "date_of_designation_or_refusal": "17/12/2010",
    "intended_use": "Treatment of carbamoyl-phosphate synthase-1 deficiency",
    "eu_designation_number": "EU/3/10/821",
    "status": "Positive",
    "first_published_date": "20/01/2011",
    "last_updated_date": "16/08/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-821"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium ascorbate;menadione sodium bisulfite",
    "date_of_designation_or_refusal": "22/08/2014",
    "intended_use": "Treatment of autosomal dominant polycystic liver disease",
    "eu_designation_number": "EU/3/14/1308",
    "status": "Positive",
    "first_published_date": "29/09/2014",
    "last_updated_date": "16/08/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1308"
  },
  {
    "medicine_name": "Heparesc",
    "related_ema_product_number": "EMEA/H/C/003750",
    "active_substance": "human heterologous liver cells",
    "date_of_designation_or_refusal": "14/09/2007",
    "intended_use": "Treatment of ornithine-transcarbamylase deficiency",
    "eu_designation_number": "EU/3/07/470",
    "status": "Positive",
    "first_published_date": "22/01/2008",
    "last_updated_date": "16/08/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-470"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "paclitaxel",
    "date_of_designation_or_refusal": "31/10/2006",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/06/419",
    "status": "Positive",
    "first_published_date": "02/04/2009",
    "last_updated_date": "16/08/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-419"
  },
  {
    "medicine_name": "Heparesc",
    "related_ema_product_number": "EMEA/H/C/003750",
    "active_substance": "human heterologous liver cells",
    "date_of_designation_or_refusal": "08/10/2009",
    "intended_use": "Treatment of citrullinaemia type 1",
    "eu_designation_number": "EU/3/10/818",
    "status": "Positive",
    "first_published_date": "19/01/2011",
    "last_updated_date": "16/08/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-818"
  },
  {
    "medicine_name": "Heparesc",
    "related_ema_product_number": "EMEA/H/C/003750",
    "active_substance": "human heterologous liver cells",
    "date_of_designation_or_refusal": "17/12/2010",
    "intended_use": "Treatment of hyperargininaemia",
    "eu_designation_number": "EU/3/10/819",
    "status": "Positive",
    "first_published_date": "19/01/2011",
    "last_updated_date": "16/08/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-819"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human heterologous liver cells",
    "date_of_designation_or_refusal": "11/04/2006",
    "intended_use": "Treatment of acute liver failure",
    "eu_designation_number": "EU/3/06/362",
    "status": "Positive",
    "first_published_date": "24/04/2009",
    "last_updated_date": "15/08/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-362"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human apotransferrin",
    "date_of_designation_or_refusal": "17/07/2012",
    "intended_use": "Treatment of congenital hypotransferrinaemia",
    "eu_designation_number": "EU/3/12/1027",
    "status": "Positive",
    "first_published_date": "31/08/2012",
    "last_updated_date": "15/08/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1027"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "chimeric monoclonal antibody to O-acetyl-GD2 antigen",
    "date_of_designation_or_refusal": "15/01/2015",
    "intended_use": "Treatment of neuroblastoma",
    "eu_designation_number": "EU/3/14/1416",
    "status": "Positive",
    "first_published_date": "05/03/2015",
    "last_updated_date": "15/08/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1416"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Metronidazole",
    "date_of_designation_or_refusal": "21/06/2011",
    "intended_use": "Treatment of pouchitis",
    "eu_designation_number": "EU/3/11/875",
    "status": "Positive",
    "first_published_date": "12/07/2011",
    "last_updated_date": "15/08/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-875"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised IgG1 monoclonal antibody against human eotaxin-2",
    "date_of_designation_or_refusal": "19/11/2014",
    "intended_use": "Treatment of systemic sclerosis",
    "eu_designation_number": "EU/3/14/1371",
    "status": "Positive",
    "first_published_date": "16/01/2015",
    "last_updated_date": "15/08/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1371"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human lecithin cholesterol acyltransferase",
    "date_of_designation_or_refusal": "10/10/2012",
    "intended_use": "Treatment of lecithin-cholesterol-acyltransferase deficiency",
    "eu_designation_number": "EU/3/12/1051",
    "status": "Positive",
    "first_published_date": "16/11/2012",
    "last_updated_date": "15/08/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1051"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "triheptanoin",
    "date_of_designation_or_refusal": "06/12/2012",
    "intended_use": "Treatment of very-long-chain 3-hydroxyacyl-CoA-dehydrogenase deficiency",
    "eu_designation_number": "EU/3/12/1081",
    "status": "Withdrawn",
    "first_published_date": "25/01/2013",
    "last_updated_date": "12/08/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1081"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "unoprostone isopropyl",
    "date_of_designation_or_refusal": "19/06/2013",
    "intended_use": "Treatment of retinitis pigmentosa",
    "eu_designation_number": "EU/3/13/1146",
    "status": "Withdrawn",
    "first_published_date": "11/07/2013",
    "last_updated_date": "11/08/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1146"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "amrubicin hydrochloride",
    "date_of_designation_or_refusal": "02/04/2008",
    "intended_use": "Treatment of small cell lung cancer",
    "eu_designation_number": "EU/3/08/538",
    "status": "Withdrawn",
    "first_published_date": "17/09/2009",
    "last_updated_date": "11/08/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-538"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human anthrax immunoglobulin",
    "date_of_designation_or_refusal": "09/11/2009",
    "intended_use": "Post-exposure prophylaxis of inhalation anthrax disease",
    "eu_designation_number": "EU/3/09/690",
    "status": "Withdrawn",
    "first_published_date": "18/11/2009",
    "last_updated_date": "11/08/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-690"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "17-(Dimethylaminoethylamino)-17-demethoxygeldanamycin",
    "date_of_designation_or_refusal": "28/11/2012",
    "intended_use": "Treatment of retinitis pigmentosa",
    "eu_designation_number": "EU/3/12/1007",
    "status": "Withdrawn",
    "first_published_date": "17/12/2012",
    "last_updated_date": "11/08/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1007"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "chimeric antibody to mesothelin",
    "date_of_designation_or_refusal": "17/03/2008",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/08/536",
    "status": "Withdrawn",
    "first_published_date": "10/07/2008",
    "last_updated_date": "11/08/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-536"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human anthrax monoclonal antibody",
    "date_of_designation_or_refusal": "15/04/2011",
    "intended_use": "Treatment of inhalation anthrax disease",
    "eu_designation_number": "EU/3/11/852",
    "status": "Withdrawn",
    "first_published_date": "26/04/2011",
    "last_updated_date": "11/08/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-852"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human anthrax immunoglobulin",
    "date_of_designation_or_refusal": "18/11/2009",
    "intended_use": "Treatment of inhalation anthrax disease",
    "eu_designation_number": "EU/3/09/691",
    "status": "Withdrawn",
    "first_published_date": "18/11/2009",
    "last_updated_date": "11/08/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-691"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "triheptanoin",
    "date_of_designation_or_refusal": "06/12/2012",
    "intended_use": "Treatment of long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency",
    "eu_designation_number": "EU/3/12/1082",
    "status": "Withdrawn",
    "first_published_date": "25/01/2013",
    "last_updated_date": "11/08/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1082"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ramucirumab",
    "date_of_designation_or_refusal": "04/07/2012",
    "intended_use": "Treatment of hepatocellular carcinoma",
    "eu_designation_number": "EU/3/12/1019",
    "status": "Withdrawn",
    "first_published_date": "24/07/2012",
    "last_updated_date": "11/08/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1019"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human anthrax monoclonal antibody",
    "date_of_designation_or_refusal": "05/08/2011",
    "intended_use": "For post-exposure prophylaxis of inhalation anthrax disease",
    "eu_designation_number": "EU/3/11/891",
    "status": "Withdrawn",
    "first_published_date": "16/08/2011",
    "last_updated_date": "11/08/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-891"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Homoharringtonine",
    "date_of_designation_or_refusal": "20/10/2004",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/04/228",
    "status": "Withdrawn",
    "first_published_date": "21/09/2009",
    "last_updated_date": "10/08/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-228"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Homoharringtonine",
    "date_of_designation_or_refusal": "02/09/2004",
    "intended_use": "Treatment of chronic myeloid leukaemia",
    "eu_designation_number": "EU/3/04/224",
    "status": "Withdrawn",
    "first_published_date": "21/09/2009",
    "last_updated_date": "10/08/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-224"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-Chloro-9-[2-deoxy-2-fluoro-ß-D-arabinofuranosyl]adenine",
    "date_of_designation_or_refusal": "05/02/2002",
    "intended_use": "Treatment of acute lymphoblastic leukaemia",
    "eu_designation_number": "EU/3/01/082",
    "status": "Expired",
    "first_published_date": "18/08/2008",
    "last_updated_date": "10/08/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-082"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human bile-salt-stimulated lipase",
    "date_of_designation_or_refusal": "26/01/2005",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/04/257",
    "status": "Withdrawn",
    "first_published_date": "11/10/2005",
    "last_updated_date": "10/08/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-257"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sorafenib tosilate",
    "date_of_designation_or_refusal": "29/07/2004",
    "intended_use": "Treatment of renal-cell carcinoma",
    "eu_designation_number": "EU/3/04/207",
    "status": "Expired",
    "first_published_date": "23/09/2009",
    "last_updated_date": "10/08/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-207"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Iodine (123I) Serum Amyloid P",
    "date_of_designation_or_refusal": "14/02/2003",
    "intended_use": "Diagnosis of the extent of histologically proven amyloidosis",
    "eu_designation_number": "EU/3/03/134",
    "status": "Withdrawn",
    "first_published_date": "29/07/2008",
    "last_updated_date": "10/08/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-134"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Liarozole",
    "date_of_designation_or_refusal": "10/06/2003",
    "intended_use": "Treatment of congenital ichthyoses",
    "eu_designation_number": "EU/3/03/144",
    "status": "Withdrawn",
    "first_published_date": "26/09/2003",
    "last_updated_date": "10/08/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-144"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Fumagillin",
    "date_of_designation_or_refusal": "05/02/2002",
    "intended_use": "Treatment of diarrhoea associated with intestinal microsporidial infection",
    "eu_designation_number": "EU/3/01/081",
    "status": "Withdrawn",
    "first_published_date": "30/05/2007",
    "last_updated_date": "10/08/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-081"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human acid alpha-glucosidase",
    "date_of_designation_or_refusal": "15/02/2001",
    "intended_use": "Treatment of glycogen storage disease type II (Pompe's disease)",
    "eu_designation_number": "EU/3/01/018",
    "status": "Expired",
    "first_published_date": "15/06/2009",
    "last_updated_date": "10/08/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-018"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pyridoxine;l-pyroglutamic acid",
    "date_of_designation_or_refusal": "27/06/2016",
    "intended_use": "Treatment of fragile X syndrome",
    "eu_designation_number": "EU/3/16/1673",
    "status": "Positive",
    "first_published_date": "26/07/2016",
    "last_updated_date": "26/07/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1673"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "eflornithine",
    "date_of_designation_or_refusal": "27/06/2016",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/16/1679",
    "status": "Positive",
    "first_published_date": "26/07/2016",
    "last_updated_date": "26/07/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1679"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "diclofenamide",
    "date_of_designation_or_refusal": "27/06/2016",
    "intended_use": "Treatment of periodic paralysis",
    "eu_designation_number": "EU/3/16/1677",
    "status": "Positive",
    "first_published_date": "26/07/2016",
    "last_updated_date": "26/07/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1677"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "vemurafenib",
    "date_of_designation_or_refusal": "30/05/2016",
    "intended_use": "Treatment of Langerhans' cell histiocytosis",
    "eu_designation_number": "EU/3/16/1670",
    "status": "Positive",
    "first_published_date": "24/06/2016",
    "last_updated_date": "24/06/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1670"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium nitrite;ethylenediaminetetraacetic acid",
    "date_of_designation_or_refusal": "30/05/2016",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/16/1668",
    "status": "Positive",
    "first_published_date": "22/06/2016",
    "last_updated_date": "22/06/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1668"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "cannabidiol",
    "date_of_designation_or_refusal": "28/04/2016",
    "intended_use": "Prevention of graft-versus-host disease",
    "eu_designation_number": "EU/3/16/1645",
    "status": "Positive",
    "first_published_date": "30/05/2016",
    "last_updated_date": "30/05/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1645"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human cerebral dopamine neurotrophic factor",
    "date_of_designation_or_refusal": "28/04/2016",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/16/1652",
    "status": "Positive",
    "first_published_date": "30/05/2016",
    "last_updated_date": "30/05/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1652"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous dermal fibroblasts genetically modified ex vivo with a lentiviral vector containing the human COL7A1 gene",
    "date_of_designation_or_refusal": "28/04/2016",
    "intended_use": "Treatment of epidermolysis bullosa",
    "eu_designation_number": "EU/3/16/1642",
    "status": "Positive",
    "first_published_date": "30/05/2016",
    "last_updated_date": "30/05/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1642"
  },
  {
    "medicine_name": "Alprolix",
    "related_ema_product_number": "EMEA/H/C/004142",
    "active_substance": "recombinant fusion protein consisting of human coagulation factor IX attached to the Fc domain of human IgG1",
    "date_of_designation_or_refusal": "08/06/2007",
    "intended_use": "Treatment of haemophilia B (congenital factor IX deficiency)",
    "eu_designation_number": "EU/3/07/453",
    "status": "Positive",
    "first_published_date": "29/07/2008",
    "last_updated_date": "30/05/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-453"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Elotuzumab",
    "date_of_designation_or_refusal": "09/08/2012",
    "intended_use": "Treatment of multiple myeloma",
    "eu_designation_number": "EU/3/12/1037",
    "status": "Withdrawn",
    "first_published_date": "26/09/2012",
    "last_updated_date": "23/05/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1037"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allopurinol sodium",
    "date_of_designation_or_refusal": "06/12/2012",
    "intended_use": "Treatment of perinatal asphyxia",
    "eu_designation_number": "EU/3/12/1076",
    "status": "Positive",
    "first_published_date": "25/01/2013",
    "last_updated_date": "23/05/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1076"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "acalabrutinib",
    "date_of_designation_or_refusal": "21/03/2016",
    "intended_use": "Treatment of mantle cell lymphoma",
    "eu_designation_number": "EU/3/16/1625",
    "status": "Positive",
    "first_published_date": "04/05/2016",
    "last_updated_date": "04/05/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1625"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "acalabrutinib",
    "date_of_designation_or_refusal": "21/03/2016",
    "intended_use": "Treatment of lymphoplasmacytic lymphoma",
    "eu_designation_number": "EU/3/16/1626",
    "status": "Positive",
    "first_published_date": "04/05/2016",
    "last_updated_date": "04/05/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1626"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-acetyl-D-mannosamine monohydrate",
    "date_of_designation_or_refusal": "21/03/2016",
    "intended_use": "Treatment of GNE myopathy",
    "eu_designation_number": "EU/3/16/1635",
    "status": "Positive",
    "first_published_date": "04/05/2016",
    "last_updated_date": "04/05/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1635"
  },
  {
    "medicine_name": "Wakix",
    "related_ema_product_number": "EMEA/H/C/002616",
    "active_substance": "1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride",
    "date_of_designation_or_refusal": "10/07/2007",
    "intended_use": "Treatment of narcolepsy",
    "eu_designation_number": "EU/3/07/459",
    "status": "Positive",
    "first_published_date": "04/12/2007",
    "last_updated_date": "20/04/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-459"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "vosaroxin",
    "date_of_designation_or_refusal": "26/04/2012",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/12/990",
    "status": "Positive",
    "first_published_date": "18/06/2012",
    "last_updated_date": "12/04/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-990"
  },
  {
    "medicine_name": "Lumevoq",
    "related_ema_product_number": "EMEA/H/C/005047",
    "active_substance": "adeno-associated viral vector containing the human NADH-dehydrogenase-4 gene",
    "date_of_designation_or_refusal": "13/05/2011",
    "intended_use": "Treatment of Leber's hereditary optic neuropathy",
    "eu_designation_number": "EU/3/11/860",
    "status": "Positive",
    "first_published_date": "27/05/2011",
    "last_updated_date": "11/04/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-860"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "afamelanotide",
    "date_of_designation_or_refusal": "24/07/2009",
    "intended_use": "Treatment of solar urticaria",
    "eu_designation_number": "EU/3/09/648",
    "status": "Positive",
    "first_published_date": "11/09/2009",
    "last_updated_date": "11/04/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-648"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "",
    "date_of_designation_or_refusal": "08/05/2008",
    "intended_use": "Treatment of congenital erythropoietic porphyria",
    "eu_designation_number": "EU/3/08/545",
    "status": "Positive",
    "first_published_date": "17/09/2009",
    "last_updated_date": "11/04/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-545"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human interleukin-2 (glycosylated tetrasaccharide, glycosylated trisaccharide and non-glycosylated)",
    "date_of_designation_or_refusal": "27/10/2006",
    "intended_use": "Treatment of renal-cell carcinoma",
    "eu_designation_number": "EU/3/06/417",
    "status": "Positive",
    "first_published_date": "29/07/2008",
    "last_updated_date": "11/04/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-417"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "afamelanotide",
    "date_of_designation_or_refusal": "04/07/2014",
    "intended_use": "Treatment of familial benign chronic pemphigus (Hailey-Hailey disease)",
    "eu_designation_number": "EU/3/14/1285",
    "status": "Positive",
    "first_published_date": "15/07/2014",
    "last_updated_date": "11/04/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1285"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "H-D-Asp-D-Gln-D-Ser-D-Arg-D-Pro-D-Val-D-Gln-D-Pro-D-Phe-D-Leu-D-Asn-D-Leu-D-Thr-D-Thr-D-Pro-D-Arg-D-Lys-D-Pro-D-Arg-D-Pro-D-Pro-D-Arg-D-Arg-D-Arg-D-Gln-D-Arg-D-Arg-D-Lys-D-Lys-D-Arg-D-Gly-NH2",
    "date_of_designation_or_refusal": "16/06/2005",
    "intended_use": "Hearing loss (acute acoustic trauma, sudden deafness and surgery induced acoustic trauma)",
    "eu_designation_number": "EU/3/05/292",
    "status": "Positive",
    "first_published_date": "21/09/2009",
    "last_updated_date": "11/04/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-292"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-(4-Methoxyphenyl)-N,2,6-trimethylfuro[2,3-d]pyrimidin-4-amine",
    "date_of_designation_or_refusal": "16/02/2016",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/16/1618",
    "status": "Positive",
    "first_published_date": "07/04/2016",
    "last_updated_date": "07/04/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1618"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tolfenamic acid",
    "date_of_designation_or_refusal": "17/02/2016",
    "intended_use": "treatment of behavioural variant frontotemporal dementia",
    "eu_designation_number": "EU/3/16/1614",
    "status": "Positive",
    "first_published_date": "07/04/2016",
    "last_updated_date": "07/04/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1614"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tolfenamic acid",
    "date_of_designation_or_refusal": "17/02/2016",
    "intended_use": "Treatment of progressive supranuclear palsy",
    "eu_designation_number": "EU/3/16/1613",
    "status": "Positive",
    "first_published_date": "07/04/2016",
    "last_updated_date": "07/04/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1613"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ex-vivo-expanded autologous fibroblasts transduced with lentiviral vector containing the COL7A1 gene",
    "date_of_designation_or_refusal": "17/02/2016",
    "intended_use": "Treatment of epidermolysis bullosa",
    "eu_designation_number": "EU/3/16/1611",
    "status": "Positive",
    "first_published_date": "06/04/2016",
    "last_updated_date": "06/04/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1611"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "arsenic trioxide",
    "date_of_designation_or_refusal": "17/02/2016",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/16/1610",
    "status": "Positive",
    "first_published_date": "06/04/2016",
    "last_updated_date": "06/04/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1610"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "S3,S13-cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide)",
    "date_of_designation_or_refusal": "17/02/2016",
    "intended_use": "Treatment of C3 glomerulopathy",
    "eu_designation_number": "EU/3/16/1608",
    "status": "Positive",
    "first_published_date": "06/04/2016",
    "last_updated_date": "06/04/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1608"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Macromolecular conjugate of heparin sodium on a polymer backbone",
    "date_of_designation_or_refusal": "22/08/2014",
    "intended_use": "Prevention of ischaemia/reperfusion injury associated with solid organ transplantation",
    "eu_designation_number": "EU/3/14/1332",
    "status": "Positive",
    "first_published_date": "02/10/2014",
    "last_updated_date": "29/03/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1332"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "genetically modified Lactococcus lactis bacteria containing the human trefoil factor 1 gene",
    "date_of_designation_or_refusal": "27/09/2011",
    "intended_use": "Prevention of oral mucositis in head and neck cancer patients undergoing radiation therapy",
    "eu_designation_number": "EU/3/11/903",
    "status": "Positive",
    "first_published_date": "17/10/2011",
    "last_updated_date": "29/03/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-903"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "5-hydroxymethyl-2-furfural",
    "date_of_designation_or_refusal": "12/02/2015",
    "intended_use": "Treatment of sickle cell disease",
    "eu_designation_number": "EU/3/15/1441",
    "status": "Withdrawn",
    "first_published_date": "09/04/2015",
    "last_updated_date": "10/02/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1441"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "verucerfont",
    "date_of_designation_or_refusal": "10/08/2015",
    "intended_use": "Treatment of congenital adrenal hyperplasia",
    "eu_designation_number": "EU/3/15/1537",
    "status": "Withdrawn",
    "first_published_date": "02/10/2015",
    "last_updated_date": "10/02/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1537"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Iodine (131I) anti-tenascin monoclonal antibody 81C6",
    "date_of_designation_or_refusal": "30/10/2006",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/06/418",
    "status": "Withdrawn",
    "first_published_date": "15/06/2009",
    "last_updated_date": "10/02/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-418"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "5-[8-methyl-9-(1-methylethyl)-2-(4-morpholinyl)-9H-purin-6-yl]-2-pyrimidinamine",
    "date_of_designation_or_refusal": "16/12/2014",
    "intended_use": "Treatment of malignant mesothelioma",
    "eu_designation_number": "EU/3/14/1391",
    "status": "Withdrawn",
    "first_published_date": "26/02/2015",
    "last_updated_date": "10/02/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1391"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-acetylgalactosamine 4-sulfatase",
    "date_of_designation_or_refusal": "15/02/2001",
    "intended_use": "Treatment of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)",
    "eu_designation_number": "EU/3/01/025",
    "status": "Expired",
    "first_published_date": "20/02/2009",
    "last_updated_date": "10/02/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-025"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Miltefosine",
    "date_of_designation_or_refusal": "27/05/2005",
    "intended_use": "Treatment of acanthamoeba keratitis",
    "eu_designation_number": "EU/3/05/282",
    "status": "Positive",
    "first_published_date": "23/09/2009",
    "last_updated_date": "09/02/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-282"
  },
  {
    "medicine_name": "Brineura",
    "related_ema_product_number": "EMEA/H/C/004065",
    "active_substance": "recombinant human tripeptidyl-peptidase 1",
    "date_of_designation_or_refusal": "12/03/2013",
    "intended_use": "Treatment of neuronal ceroid lipofuscinosis type 2",
    "eu_designation_number": "EU/3/13/1118",
    "status": "Positive",
    "first_published_date": "05/04/2013",
    "last_updated_date": "09/02/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1118"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pentosan polysulfate sodium",
    "date_of_designation_or_refusal": "15/01/2015",
    "intended_use": "Treatment of interstitial cystitis",
    "eu_designation_number": "EU/3/14/1411",
    "status": "Withdrawn",
    "first_published_date": "05/03/2015",
    "last_updated_date": "09/02/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1411"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "selinexor",
    "date_of_designation_or_refusal": "19/11/2014",
    "intended_use": "Treatment of chronic lymphocytic leukaemia / small lymphocytic lymphoma",
    "eu_designation_number": "EU/3/14/1354",
    "status": "Positive",
    "first_published_date": "15/01/2015",
    "last_updated_date": "09/02/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1354"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N'-(pyrazin-2-yl)acrylohydrazide",
    "date_of_designation_or_refusal": "22/08/2014",
    "intended_use": "Treatment of diffuse large B-cell lymphoma",
    "eu_designation_number": "EU/3/14/1317",
    "status": "Positive",
    "first_published_date": "01/10/2014",
    "last_updated_date": "09/02/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1317"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-N'-(pyrazin-2-yl)acrylohydrazide",
    "date_of_designation_or_refusal": "22/08/2014",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/14/1313",
    "status": "Positive",
    "first_published_date": "30/09/2014",
    "last_updated_date": "09/02/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1313"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "belinostat",
    "date_of_designation_or_refusal": "17/07/2013",
    "intended_use": "Treatment of malignant thymoma",
    "eu_designation_number": "EU/3/13/1151",
    "status": "Positive",
    "first_published_date": "21/08/2013",
    "last_updated_date": "08/02/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1151"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "belinostat",
    "date_of_designation_or_refusal": "10/10/2012",
    "intended_use": "Treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)",
    "eu_designation_number": "EU/3/12/1055",
    "status": "Positive",
    "first_published_date": "16/11/2012",
    "last_updated_date": "08/02/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1055"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ataluren",
    "date_of_designation_or_refusal": "04/07/2012",
    "intended_use": "Treatment of Becker muscular dystrophy",
    "eu_designation_number": "EU/3/12/1010",
    "status": "Positive",
    "first_published_date": "24/07/2012",
    "last_updated_date": "08/02/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1010"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-(2-Chlorobenzylidene)hydrazinecarboximidamide acetate",
    "date_of_designation_or_refusal": "14/12/2015",
    "intended_use": "Treatment of Charcot-Marie-Tooth disease",
    "eu_designation_number": "EU/3/15/1598",
    "status": "Positive",
    "first_published_date": "03/02/2016",
    "last_updated_date": "03/02/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1598"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "synthetic peptide L-cysteine, L-cysteinylglycyl-L-glutaminyl-L-arginyl-L-.alpha.-glutamyl-L-threonyl-L-prolyl-L-.alpha.-glutamylglycyl-L-alanyl-L-.alpha.-glutamyl-L-alanyl-L-lysyl-L-prolyl-L-tryptophyl-L-tyrosyl-, cyclic (1.fwdarw.17)-disulfide",
    "date_of_designation_or_refusal": "14/12/2015",
    "intended_use": "Treatment of pseudohypoaldosteronism 1B",
    "eu_designation_number": "EU/3/15/1591",
    "status": "Positive",
    "first_published_date": "03/02/2016",
    "last_updated_date": "03/02/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1591"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "-[4-Aminobutanoic acid-glycyl-L-glutaminyl-L-arginyl-L-.alpha.-glutamyl-L-threonyl-L-prolyl-L-.alpha.-glutamylglycyl-L-alanyl-L-.alpha.-glutamyl-L-alanyl-L-lysyl-L-prolyl-L-tryptophyl-L-tyrosyl-L-aspartyl](cyclo 1-Dgamma17)",
    "date_of_designation_or_refusal": "14/12/2015",
    "intended_use": "Treatment of pseudohypoaldosteronism 1B",
    "eu_designation_number": "EU/3/15/1592",
    "status": "Positive",
    "first_published_date": "03/02/2016",
    "last_updated_date": "03/02/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1592"
  },
  {
    "medicine_name": "Oxervate",
    "related_ema_product_number": "EMEA/H/C/004209",
    "active_substance": "recombinant human nerve growth factor (cenegermin)",
    "date_of_designation_or_refusal": "14/12/2015",
    "intended_use": "Treatment of neurotrophic keratitis",
    "eu_designation_number": "EU/3/15/1586",
    "status": "Positive",
    "first_published_date": "02/02/2016",
    "last_updated_date": "02/02/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1586"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ramucirumab",
    "date_of_designation_or_refusal": "04/07/2012",
    "intended_use": "Treatment of gastric cancer",
    "eu_designation_number": "EU/3/12/1004",
    "status": "Withdrawn",
    "first_published_date": "24/07/2012",
    "last_updated_date": "19/01/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1004"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant modified vaccinia virus Ankara expressing tuberculosis antigen 85A",
    "date_of_designation_or_refusal": "28/10/2005",
    "intended_use": "Prevention of tuberculosis disease in Bacille-Calmette-Guerin-vaccinated individuals",
    "eu_designation_number": "EU/3/05/318",
    "status": "Withdrawn",
    "first_published_date": "23/09/2009",
    "last_updated_date": "19/01/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-318"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "liposomal daunorubicin",
    "date_of_designation_or_refusal": "10/10/2012",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/12/1056",
    "status": "Withdrawn",
    "first_published_date": "16/11/2012",
    "last_updated_date": "19/01/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1056"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Asp-Arg-Val-Tyr-Ile-His-Pro",
    "date_of_designation_or_refusal": "10/10/2012",
    "intended_use": "Treatment of acute lung Injury",
    "eu_designation_number": "EU/3/12/1047",
    "status": "Withdrawn",
    "first_published_date": "16/11/2012",
    "last_updated_date": "19/01/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1047"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sequence-modified recombinant human factor VIIa",
    "date_of_designation_or_refusal": "08/10/2009",
    "intended_use": "Treatment of haemophilia B",
    "eu_designation_number": "EU/3/09/676",
    "status": "Withdrawn",
    "first_published_date": "20/10/2009",
    "last_updated_date": "19/01/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-676"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sequence-modified recombinant human factor VIIa",
    "date_of_designation_or_refusal": "09/10/2009",
    "intended_use": "Treatment of haemophilia A",
    "eu_designation_number": "EU/3/09/675",
    "status": "Withdrawn",
    "first_published_date": "20/10/2009",
    "last_updated_date": "19/01/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-675"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Eculizumab",
    "date_of_designation_or_refusal": "04/07/2012",
    "intended_use": "Treatment of infection-associated haemolytic uraemic syndrome",
    "eu_designation_number": "EU/3/12/1015",
    "status": "Withdrawn",
    "first_published_date": "24/07/2012",
    "last_updated_date": "19/01/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1015"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "levodopa;carbidopa",
    "date_of_designation_or_refusal": "10/05/2001",
    "intended_use": "Treatment of advanced idiopathic Parkinson's disease with severe motor fluctuations",
    "eu_designation_number": "EU/3/01/035",
    "status": "Withdrawn",
    "first_published_date": "03/03/2009",
    "last_updated_date": "19/01/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-035"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "talarozole",
    "date_of_designation_or_refusal": "04/07/2012",
    "intended_use": "Treatment of recessive X-linked ichthyosis",
    "eu_designation_number": "EU/3/12/1017",
    "status": "Withdrawn",
    "first_published_date": "24/07/2012",
    "last_updated_date": "19/01/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1017"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sildenafil citrate",
    "date_of_designation_or_refusal": "12/12/2003",
    "intended_use": "Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension",
    "eu_designation_number": "EU/3/03/178",
    "status": "Expired",
    "first_published_date": "28/02/2007",
    "last_updated_date": "19/01/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-178"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "talarozole",
    "date_of_designation_or_refusal": "04/07/2012",
    "intended_use": "Treatment of autosomal recessive congenital ichthyosis",
    "eu_designation_number": "EU/3/12/1005",
    "status": "Withdrawn",
    "first_published_date": "24/07/2012",
    "last_updated_date": "19/01/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1005"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Fampridine",
    "date_of_designation_or_refusal": "10/07/2007",
    "intended_use": "Treatment of Guillain-Barré syndrome",
    "eu_designation_number": "EU/3/07/458",
    "status": "Withdrawn",
    "first_published_date": "17/01/2008",
    "last_updated_date": "19/01/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-458"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant humanised monoclonal antibody to human Nogo-A protein of the IgG1/kappa class",
    "date_of_designation_or_refusal": "01/10/2010",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/10/797",
    "status": "Withdrawn",
    "first_published_date": "14/10/2010",
    "last_updated_date": "19/01/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-797"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human monoclonal antibody against transforming growth factor beta-1, 2 and 3",
    "date_of_designation_or_refusal": "01/04/2008",
    "intended_use": "Treatment of idiopathic pulmonary fibrosis",
    "eu_designation_number": "EU/3/08/533",
    "status": "Withdrawn",
    "first_published_date": "10/07/2008",
    "last_updated_date": "19/01/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-533"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Fresolimumab",
    "date_of_designation_or_refusal": "05/08/2011",
    "intended_use": "Treatment of focal segmental glomerulosclerosis",
    "eu_designation_number": "EU/3/11/882",
    "status": "Withdrawn",
    "first_published_date": "16/08/2011",
    "last_updated_date": "19/01/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-882"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant porcine factor VIII (B-domain-deleted)",
    "date_of_designation_or_refusal": "20/09/2010",
    "intended_use": "Treatment of haemophilia A",
    "eu_designation_number": "EU/3/10/784",
    "status": "Withdrawn",
    "first_published_date": "18/10/2010",
    "last_updated_date": "19/01/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-784"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "talarozole",
    "date_of_designation_or_refusal": "04/07/2012",
    "intended_use": "Treatment of keratinopathic ichthyosis",
    "eu_designation_number": "EU/3/12/1014",
    "status": "Withdrawn",
    "first_published_date": "24/07/2012",
    "last_updated_date": "19/01/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1014"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Ethanol",
    "date_of_designation_or_refusal": "09/03/2004",
    "intended_use": "Treatment of congenital venous malformations",
    "eu_designation_number": "EU/3/04/191",
    "status": "Withdrawn",
    "first_published_date": "28/04/2005",
    "last_updated_date": "18/01/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-191"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Ethanol",
    "date_of_designation_or_refusal": "09/03/2004",
    "intended_use": "Treatment of congenital lymphatic malformations",
    "eu_designation_number": "EU/3/04/190",
    "status": "Withdrawn",
    "first_published_date": "28/04/2005",
    "last_updated_date": "14/01/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-190"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Canakinumab",
    "date_of_designation_or_refusal": "08/11/2012",
    "intended_use": "Treatment of tumour-necrosis-factor-receptor-associated periodic syndrome",
    "eu_designation_number": "EU/3/12/1071",
    "status": "Withdrawn",
    "first_published_date": "17/12/2012",
    "last_updated_date": "14/01/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1071"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "palifosfamide",
    "date_of_designation_or_refusal": "03/12/2008",
    "intended_use": "Treatment of soft tissue sarcoma",
    "eu_designation_number": "EU/3/08/584",
    "status": "Withdrawn",
    "first_published_date": "30/10/2009",
    "last_updated_date": "14/01/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-584"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 8 containing the human CNGA3 gene under the control of a cone arrestin promoter",
    "date_of_designation_or_refusal": "12/12/2016",
    "intended_use": "Treatment of achromatopsia caused by mutations in the CNGA3 gene",
    "eu_designation_number": "EU/3/16/1795",
    "status": "Positive",
    "first_published_date": "09/01/2016",
    "last_updated_date": "09/01/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1795"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 8 encoding the human ATP7B gene under the control of the human alpha-1 antitrypsin promoter",
    "date_of_designation_or_refusal": "11/11/2015",
    "intended_use": "Treatment of Wilson's disease",
    "eu_designation_number": "EU/3/15/1573",
    "status": "Positive",
    "first_published_date": "06/01/2016",
    "last_updated_date": "06/01/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1573"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "interferon alfa-n3",
    "date_of_designation_or_refusal": "11/11/2015",
    "intended_use": "Treatment of Middle East respiratory syndrome",
    "eu_designation_number": "EU/3/15/1568",
    "status": "Positive",
    "first_published_date": "05/01/2016",
    "last_updated_date": "05/01/2016",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1568"
  },
  {
    "medicine_name": "Blincyto",
    "related_ema_product_number": "EMEA/H/C/003731",
    "active_substance": "blinatumomab",
    "date_of_designation_or_refusal": "24/07/2009",
    "intended_use": "Treatment of acute lymphoblastic leukaemia",
    "eu_designation_number": "EU/3/09/650",
    "status": "Positive",
    "first_published_date": "11/09/2009",
    "last_updated_date": "08/12/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-650"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Cytochrome P450 isoform 2B1 gene transfected human embryonic kidney 293 cells encapsulated in polymeric cellulose sulfate",
    "date_of_designation_or_refusal": "30/06/2003",
    "intended_use": "Treatment of pancreatic cancer in combination with ifosfamide",
    "eu_designation_number": "EU/3/03/149",
    "status": "Positive",
    "first_published_date": "21/09/2009",
    "last_updated_date": "26/11/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-149"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sirolimus",
    "date_of_designation_or_refusal": "09/10/2015",
    "intended_use": "Treatment of tuberous sclerosis",
    "eu_designation_number": "EU/3/15/1557",
    "status": "Positive",
    "first_published_date": "18/11/2015",
    "last_updated_date": "18/11/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1557"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ataluren",
    "date_of_designation_or_refusal": "09/10/2015",
    "intended_use": "Treatment of aniridia",
    "eu_designation_number": "EU/3/15/1561",
    "status": "Positive",
    "first_published_date": "18/11/2015",
    "last_updated_date": "18/11/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1561"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Dronabinol;cannabidiol",
    "date_of_designation_or_refusal": "09/10/2015",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/15/1564",
    "status": "Withdrawn",
    "first_published_date": "18/11/2015",
    "last_updated_date": "18/11/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1564"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "nimodipine",
    "date_of_designation_or_refusal": "09/10/2015",
    "intended_use": "Treatment of aneurysmal subarachnoid haemorrhage",
    "eu_designation_number": "EU/3/15/1554",
    "status": "Positive",
    "first_published_date": "16/11/2015",
    "last_updated_date": "16/11/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1554"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous human peripheral blood Vdelta1+ T lymphocytes activated in vitro by cytokine and monoclonal antibody treatment",
    "date_of_designation_or_refusal": "09/10/2015",
    "intended_use": "Treatment of chronic lymphocytic leukaemia / small lymphocytic lymphoma",
    "eu_designation_number": "EU/3/15/1566",
    "status": "Positive",
    "first_published_date": "16/11/2015",
    "last_updated_date": "16/11/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1566"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "synthetic peptide L-cysteine, L-cysteinylglycyl-L-glutaminyl-L-arginyl-L-.alpha.-glutamyl-L-threonyl-L-prolyl-L-.alpha.-glutamylglycyl-L-alanyl-L-.alpha.-glutamyl-L-alanyl-L-lysyl-L-prolyl-L-tryptophyl-L-tyrosyl-, cyclic (1.fwdarw.17)-disulfide",
    "date_of_designation_or_refusal": "09/10/2015",
    "intended_use": "Treatment of primary graft dysfunction following lung transplantation",
    "eu_designation_number": "EU/3/15/1549",
    "status": "Positive",
    "first_published_date": "16/11/2015",
    "last_updated_date": "16/11/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1549"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "nalbuphine hydrochloride",
    "date_of_designation_or_refusal": "27/02/2015",
    "intended_use": "Treatment of uraemic pruritus",
    "eu_designation_number": "-",
    "status": "Negative",
    "first_published_date": "02/10/2015",
    "last_updated_date": "02/10/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-uraemic-pruritus"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Insulin human",
    "date_of_designation_or_refusal": "10/08/2015",
    "intended_use": "Treatment of short bowel syndrome",
    "eu_designation_number": "EU/3/15/1532",
    "status": "Positive",
    "first_published_date": "02/10/2015",
    "last_updated_date": "02/10/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1532"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "fosfomycin disodium;tobramycin",
    "date_of_designation_or_refusal": "10/08/2015",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/15/1538",
    "status": "Positive",
    "first_published_date": "02/10/2015",
    "last_updated_date": "02/10/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1538"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sarizotan hydrochloride",
    "date_of_designation_or_refusal": "28/07/2015",
    "intended_use": "Treatment of Rett syndrome",
    "eu_designation_number": "EU/3/15/1531",
    "status": "Positive",
    "first_published_date": "18/08/2015",
    "last_updated_date": "18/08/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1531"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Hydrocinnamate-[Orn-Pro-dCha-Trp-Arg]acetate",
    "date_of_designation_or_refusal": "28/07/2015",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/15/1527",
    "status": "Positive",
    "first_published_date": "18/08/2015",
    "last_updated_date": "18/08/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1527"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Inecalcitol",
    "date_of_designation_or_refusal": "28/07/2015",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/15/1523",
    "status": "Positive",
    "first_published_date": "18/08/2015",
    "last_updated_date": "18/08/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1523"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic human adult stem cells, isolated from skeletal muscle and expanded ex vivo",
    "date_of_designation_or_refusal": "28/07/2015",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/15/1519",
    "status": "Positive",
    "first_published_date": "18/08/2015",
    "last_updated_date": "18/08/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1519"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-((3-((4-((3-aminopropyl)amino)butyl)amino)propyl)amino)-N-((5S,5aS,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl)acetamide, tetrahydrochloride",
    "date_of_designation_or_refusal": "28/07/2015",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/15/1517",
    "status": "Positive",
    "first_published_date": "18/08/2015",
    "last_updated_date": "18/08/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1517"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Doxorubicin",
    "date_of_designation_or_refusal": "28/07/2015",
    "intended_use": "Treatment of hepatoblastoma",
    "eu_designation_number": "EU/3/15/1513",
    "status": "Positive",
    "first_published_date": "18/08/2015",
    "last_updated_date": "18/08/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1513"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Lanreotide acetate",
    "date_of_designation_or_refusal": "10/08/2015",
    "intended_use": "Treatment of autosomal dominant polycystic kidney disease",
    "eu_designation_number": "EU/3/15/1514",
    "status": "Positive",
    "first_published_date": "18/08/2015",
    "last_updated_date": "18/08/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1514"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "anti-H5N1 equine immunoglobulin F(ab')2 fragments",
    "date_of_designation_or_refusal": "28/07/2015",
    "intended_use": "Treatment of avian influenza",
    "eu_designation_number": "EU/3/15/1512",
    "status": "Positive",
    "first_published_date": "18/08/2015",
    "last_updated_date": "18/08/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1512"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "antisense oligonucleotide directed against TGF-β2 mRNA",
    "date_of_designation_or_refusal": "19/06/2015",
    "intended_use": "Prevention of scarring post glaucoma filtration surgery",
    "eu_designation_number": "EU/3/15/1506",
    "status": "Positive",
    "first_published_date": "27/07/2015",
    "last_updated_date": "27/07/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1506"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic ex-vivo-expanded human umbilical cord blood-derived mesenchymal stem cells",
    "date_of_designation_or_refusal": "19/06/2015",
    "intended_use": "Prevention of bronchopulmonary dysplasia",
    "eu_designation_number": "EU/3/15/1503",
    "status": "Positive",
    "first_published_date": "27/07/2015",
    "last_updated_date": "27/07/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1503"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allopurinol sodium",
    "date_of_designation_or_refusal": "21/05/2015",
    "intended_use": "Treatment of perinatal asphyxia",
    "eu_designation_number": "EU/3/15/1493",
    "status": "Positive",
    "first_published_date": "30/06/2015",
    "last_updated_date": "30/06/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1493"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "AASSGVSTPGSAGHDIITEQPRS",
    "date_of_designation_or_refusal": "12/05/2015",
    "intended_use": "Treatment of Huntington’s disease",
    "eu_designation_number": "EU/3/15/1492",
    "status": "Positive",
    "first_published_date": "30/06/2015",
    "last_updated_date": "30/06/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1492"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "1-(4-{4-Amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-3-(3-fluorophenyl)urea",
    "date_of_designation_or_refusal": "06/06/2012",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/12/1001",
    "status": "Withdrawn",
    "first_published_date": "04/07/2012",
    "last_updated_date": "08/06/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1001"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Pomalidomide",
    "date_of_designation_or_refusal": "26/04/2012",
    "intended_use": "Treatment of systemic sclerosis",
    "eu_designation_number": "EU/3/12/986",
    "status": "Withdrawn",
    "first_published_date": "18/06/2012",
    "last_updated_date": "08/06/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-986"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "chimeric monoclonal antibody against kappa myeloma antigen",
    "date_of_designation_or_refusal": "22/05/2012",
    "intended_use": "Treatment of multiple myeloma",
    "eu_designation_number": "EU/3/12/962",
    "status": "Withdrawn",
    "first_published_date": "06/07/2012",
    "last_updated_date": "08/06/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-962"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "1-(4-{4-Amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-3-(3-fluorophenyl)urea",
    "date_of_designation_or_refusal": "27/10/2011",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/11/915",
    "status": "Withdrawn",
    "first_published_date": "23/11/2011",
    "last_updated_date": "08/06/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-915"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Paclitaxel-succinate-Arg-Arg-Leu-Ser-Tyr-Ser-Arg-Arg-Arg-Phe",
    "date_of_designation_or_refusal": "04/06/2014",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/14/1274",
    "status": "Positive",
    "first_published_date": "10/07/2014",
    "last_updated_date": "27/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1274"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "exon 51 specific phosphorothioate oligonucleotide",
    "date_of_designation_or_refusal": "27/02/2009",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/08/599",
    "status": "Positive",
    "first_published_date": "29/06/2009",
    "last_updated_date": "27/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-599"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium 2-hydroxylinoleate",
    "date_of_designation_or_refusal": "24/04/2015",
    "intended_use": "Treatment of neuroblastoma",
    "eu_designation_number": "EU/3/15/1485",
    "status": "Positive",
    "first_published_date": "22/05/2015",
    "last_updated_date": "22/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1485"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "xenon",
    "date_of_designation_or_refusal": "24/04/2015",
    "intended_use": "Treatment of perinatal asphyxia",
    "eu_designation_number": "EU/3/15/1483",
    "status": "Positive",
    "first_published_date": "22/05/2015",
    "last_updated_date": "22/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1483"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant monoclonal IgG1 antibody against T-cell immune response cDNA 7",
    "date_of_designation_or_refusal": "24/04/2015",
    "intended_use": "Prevention of graft rejection following solid organ transplantation",
    "eu_designation_number": "EU/3/15/1479",
    "status": "Positive",
    "first_published_date": "22/05/2015",
    "last_updated_date": "22/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1479"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "rintatolimod",
    "date_of_designation_or_refusal": "24/04/2015",
    "intended_use": "Treatment of Ebola virus disease",
    "eu_designation_number": "EU/3/15/1480",
    "status": "Positive",
    "first_published_date": "22/05/2015",
    "last_updated_date": "22/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1480"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Human reovirus type 3 Dearing strain",
    "date_of_designation_or_refusal": "24/04/2015",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/15/1477",
    "status": "Positive",
    "first_published_date": "21/05/2015",
    "last_updated_date": "21/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1477"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "1-(4-(N-glycylamido)phenyl)-3-trifluoromethyl-5-(phenanthren-2-yl)-pyrazole-hydrochloride",
    "date_of_designation_or_refusal": "24/04/2015",
    "intended_use": "Treatment of tularaemia",
    "eu_designation_number": "EU/3/15/1476",
    "status": "Positive",
    "first_published_date": "21/05/2015",
    "last_updated_date": "21/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1476"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "1-(4-(N-glycylamido)phenyl)-3-trifluoromethyl-5-(phenanthren-2-yl)-pyrazole-hydrochloride",
    "date_of_designation_or_refusal": "24/04/2015",
    "intended_use": "Treatment of cryptococcosis",
    "eu_designation_number": "EU/3/15/1475",
    "status": "Positive",
    "first_published_date": "21/05/2015",
    "last_updated_date": "21/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1475"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "fluciclovine (18F)",
    "date_of_designation_or_refusal": "24/04/2015",
    "intended_use": "Diagnosis of glioma",
    "eu_designation_number": "EU/3/15/1472",
    "status": "Positive",
    "first_published_date": "21/05/2015",
    "last_updated_date": "21/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1472"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic CD4+ and CD8+ T lymphocytes ex vivo incubated with synthetic peptides of the viral antigens of cytomegalovirus, adenovirus and Epstein-Barr virus",
    "date_of_designation_or_refusal": "19/03/2015",
    "intended_use": "Treatment of adenovirus infection following haematopoietic stem cell transplantation",
    "eu_designation_number": "EU/3/15/1438",
    "status": "Positive",
    "first_published_date": "19/05/2015",
    "last_updated_date": "19/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1438"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic CD4+ and CD8+ T lymphocytes ex vivo incubated with synthetic peptides of the viral antigens of cytomegalovirus, adenovirus and Epstein-Barr virus",
    "date_of_designation_or_refusal": "19/03/2015",
    "intended_use": "Treatment of Epstein-Barr virus infection following haematopoietic stem cell transplantation",
    "eu_designation_number": "EU/3/15/1440",
    "status": "Positive",
    "first_published_date": "19/05/2015",
    "last_updated_date": "19/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1440"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "repertaxin L-lysine salt",
    "date_of_designation_or_refusal": "19/09/2001",
    "intended_use": "Prevention of delayed graft function in organ transplant",
    "eu_designation_number": "EU/3/01/058",
    "status": "Positive",
    "first_published_date": "15/05/2009",
    "last_updated_date": "13/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-058"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human nerve growth factor",
    "date_of_designation_or_refusal": "07/06/2013",
    "intended_use": "Treatment of retinitis pigmentosa",
    "eu_designation_number": "EU/3/13/1135",
    "status": "Positive",
    "first_published_date": "25/06/2013",
    "last_updated_date": "13/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1135"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "reparixin",
    "date_of_designation_or_refusal": "27/09/2011",
    "intended_use": "Prevention of graft loss in pancreatic islet transplantation",
    "eu_designation_number": "EU/3/11/912",
    "status": "Positive",
    "first_published_date": "17/10/2011",
    "last_updated_date": "13/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-912"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium acetate salt of the synthetic peptide H-D-Ala-Ser-Pro-Met-Leu-Val-Ala-Tyr-Asp-D-Ala-OH",
    "date_of_designation_or_refusal": "29/07/2014",
    "intended_use": "Treatment of necrotising soft tissue infections",
    "eu_designation_number": "EU/3/14/1294",
    "status": "Positive",
    "first_published_date": "01/09/2014",
    "last_updated_date": "13/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1294"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ciclosporin",
    "date_of_designation_or_refusal": "29/10/2007",
    "intended_use": "Treatment of herpes simplex virus stromal keratitis",
    "eu_designation_number": "EU/3/07/489",
    "status": "Positive",
    "first_published_date": "02/07/2008",
    "last_updated_date": "13/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-489"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adenovirus-associated viral vector serotype 10 carrying the human N-sulfoglucosamine sulfohydrolase and sulfatase modifying factor 1 cDNAs",
    "date_of_designation_or_refusal": "20/09/2010",
    "intended_use": "Treatment of mucopolysaccharidosis, type IIIA (Sanfilippo A syndrome)",
    "eu_designation_number": "EU/3/10/772",
    "status": "Positive",
    "first_published_date": "18/10/2010",
    "last_updated_date": "13/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-772"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ciclosporin",
    "date_of_designation_or_refusal": "22/10/2007",
    "intended_use": "Prevention of corneal graft rejection",
    "eu_designation_number": "EU/3/07/455",
    "status": "Positive",
    "first_published_date": "02/07/2008",
    "last_updated_date": "13/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-455"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Adeno-associated viral vector serotype rh.rh.10 carrying the human N-sulfoglucosamine sulfohydrolase cDNA",
    "date_of_designation_or_refusal": "16/12/2014",
    "intended_use": "Treatment of mucopolysaccharidosis, type IIIA (Sanfilippo A syndrome)",
    "eu_designation_number": "EU/3/14/1389",
    "status": "Positive",
    "first_published_date": "26/02/2015",
    "last_updated_date": "13/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1389"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-iminobiotin",
    "date_of_designation_or_refusal": "28/01/2010",
    "intended_use": "Treatment of perinatal asphyxia",
    "eu_designation_number": "EU/3/09/701",
    "status": "Positive",
    "first_published_date": "25/02/2010",
    "last_updated_date": "13/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-701"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium 3-[(4aR,6R,7R,7aS)-7-hydroxy-2-oxido-2-sulfanylidene-4a,6,7,7a-tetrahydro-4H-furo [3,2-d][1,3,2] dioxaphosphinin-6-yl]-2-bromo-6-phenyl-5H-imidazo[1,2-a]purin-9-one",
    "date_of_designation_or_refusal": "19/03/2015",
    "intended_use": "Treatment of retinitis pigmentosa",
    "eu_designation_number": "EU/3/15/1462",
    "status": "Positive",
    "first_published_date": "11/05/2015",
    "last_updated_date": "11/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1462"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human club cell 10 KDa protein",
    "date_of_designation_or_refusal": "19/03/2015",
    "intended_use": "Prevention of bronchopulmonary dysplasia",
    "eu_designation_number": "EU/3/15/1456",
    "status": "Positive",
    "first_published_date": "11/05/2015",
    "last_updated_date": "11/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1456"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Human reovirus type 3 Dearing strain",
    "date_of_designation_or_refusal": "19/03/2015",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/15/1469",
    "status": "Positive",
    "first_published_date": "11/05/2015",
    "last_updated_date": "11/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1469"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ex-vivo-expanded autologous human keratinocytes containing epidermal stem cells transduced with a LAMB3-encoding retroviral vector",
    "date_of_designation_or_refusal": "19/03/2015",
    "intended_use": "Treatment of epidermolysis bullosa",
    "eu_designation_number": "EU/3/15/1465",
    "status": "Positive",
    "first_published_date": "11/05/2015",
    "last_updated_date": "11/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1465"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ex-vivo-expanded autologous human keratinocytes containing epidermal stem cells transduced with a COL7A1-encoding retroviral vector",
    "date_of_designation_or_refusal": "19/03/2015",
    "intended_use": "Treatment of epidermolysis bullosa",
    "eu_designation_number": "EU/3/15/1466",
    "status": "Positive",
    "first_published_date": "11/05/2015",
    "last_updated_date": "11/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1466"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous adipose tissue-derived stromal vascular fraction cells",
    "date_of_designation_or_refusal": "19/03/2015",
    "intended_use": "Treatment of systemic sclerosis",
    "eu_designation_number": "EU/3/15/1464",
    "status": "Positive",
    "first_published_date": "11/05/2015",
    "last_updated_date": "11/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1464"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ex-vivo-expanded autologous human keratinocytes containing epidermal stem cells transduced with a COL17A1-encoding retroviral vector",
    "date_of_designation_or_refusal": "19/03/2015",
    "intended_use": "Treatment of epidermolysis bullosa",
    "eu_designation_number": "EU/3/15/1467",
    "status": "Positive",
    "first_published_date": "11/05/2015",
    "last_updated_date": "11/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1467"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "6-ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,1-benzoxazin-4-one",
    "date_of_designation_or_refusal": "19/03/2015",
    "intended_use": "Treatment of Netherton syndrome",
    "eu_designation_number": "EU/3/15/1454",
    "status": "Positive",
    "first_published_date": "11/05/2015",
    "last_updated_date": "11/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1454"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "5,10,15,20-tetrakis(2,6-difluoro-3-N-methylsulfamoylphenyl)bacteriochlorin (redaporfin)",
    "date_of_designation_or_refusal": "19/03/2015",
    "intended_use": "Treatment of biliary tract cancer",
    "eu_designation_number": "EU/3/15/1470",
    "status": "Positive",
    "first_published_date": "11/05/2015",
    "last_updated_date": "11/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1470"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tositumomab",
    "date_of_designation_or_refusal": "14/02/2003",
    "intended_use": "Treatment of follicular lymphoma",
    "eu_designation_number": "EU/3/03/137",
    "status": "Withdrawn",
    "first_published_date": "12/12/2005",
    "last_updated_date": "09/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-137"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "nitisinone",
    "date_of_designation_or_refusal": "30/12/2000",
    "intended_use": "Treatment of tyrosinaemia type 1",
    "eu_designation_number": "EU/3/00/012",
    "status": "Expired",
    "first_published_date": "03/03/2009",
    "last_updated_date": "08/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-00-012"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ruxolitinib",
    "date_of_designation_or_refusal": "19/02/2014",
    "intended_use": "Treatment of polycythaemia vera",
    "eu_designation_number": "EU/3/14/1244",
    "status": "Withdrawn",
    "first_published_date": "02/04/2014",
    "last_updated_date": "08/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1244"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ziconotide",
    "date_of_designation_or_refusal": "09/07/2001",
    "intended_use": "Treatment of chronic pain requiring intraspinal analgesia",
    "eu_designation_number": "EU/3/01/048",
    "status": "Expired",
    "first_published_date": "19/07/2007",
    "last_updated_date": "08/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-048"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Lestaurtinib",
    "date_of_designation_or_refusal": "25/07/2006",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/06/389",
    "status": "Withdrawn",
    "first_published_date": "24/02/2009",
    "last_updated_date": "08/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-389"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Iodine (131I) tositumomab",
    "date_of_designation_or_refusal": "14/02/2003",
    "intended_use": "Treatment of follicular lymphoma",
    "eu_designation_number": "EU/3/03/136",
    "status": "Withdrawn",
    "first_published_date": "12/12/2005",
    "last_updated_date": "08/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-136"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "mixture of recombinant human IgG1 monoclonal antibodies against human cytomegalovirus envelope glycoproteins",
    "date_of_designation_or_refusal": "20/02/2014",
    "intended_use": "Prevention of congenital cytomegalovirus infection following primary cytomegalovirus infection",
    "eu_designation_number": "EU/3/14/1235",
    "status": "Withdrawn",
    "first_published_date": "01/04/2014",
    "last_updated_date": "08/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1235"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "glutathione-pegylated liposomal doxorubicin hydrochloride",
    "date_of_designation_or_refusal": "20/09/2010",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/10/781",
    "status": "Withdrawn",
    "first_published_date": "18/10/2010",
    "last_updated_date": "08/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-781"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic ex-vivo-expanded umbilical-cord blood cells",
    "date_of_designation_or_refusal": "27/02/2009",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/09/619",
    "status": "Withdrawn",
    "first_published_date": "30/10/2009",
    "last_updated_date": "08/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-619"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic ex-vivo-expanded umbilical-cord blood cells",
    "date_of_designation_or_refusal": "27/02/2009",
    "intended_use": "Treatment of acute lymphoblastic leukaemia",
    "eu_designation_number": "EU/3/09/618",
    "status": "Withdrawn",
    "first_published_date": "30/10/2009",
    "last_updated_date": "08/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-618"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic ex-vivo-expanded umbilical-cord blood cells",
    "date_of_designation_or_refusal": "08/10/2009",
    "intended_use": "Treatment of myelodysplastic syndromes",
    "eu_designation_number": "EU/3/09/664",
    "status": "Withdrawn",
    "first_published_date": "20/10/2009",
    "last_updated_date": "08/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-664"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic ex-vivo-expanded umbilical-cord blood cells",
    "date_of_designation_or_refusal": "08/10/2009",
    "intended_use": "Treatment of chronic myeloid leukaemia",
    "eu_designation_number": "EU/3/09/665",
    "status": "Withdrawn",
    "first_published_date": "20/10/2009",
    "last_updated_date": "08/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-665"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic ex-vivo-expanded umbilical-cord blood cells",
    "date_of_designation_or_refusal": "24/07/2009",
    "intended_use": "Treatment of Hodgkin's lymphoma",
    "eu_designation_number": "EU/3/09/649",
    "status": "Withdrawn",
    "first_published_date": "11/09/2009",
    "last_updated_date": "08/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-649"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate",
    "date_of_designation_or_refusal": "03/04/2009",
    "intended_use": "Treatment of myelofibrosis secondary to polycythaemia vera or essential thrombocythaemia",
    "eu_designation_number": "EU/3/09/620",
    "status": "Withdrawn",
    "first_published_date": "28/04/2009",
    "last_updated_date": "08/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-620"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate",
    "date_of_designation_or_refusal": "07/11/2008",
    "intended_use": "Treatment of chronic idiopathic myelofibrosis",
    "eu_designation_number": "EU/3/08/572",
    "status": "Withdrawn",
    "first_published_date": "29/06/2009",
    "last_updated_date": "08/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-572"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "5-(2,6-Difluoro-phenoxy)-3(R,S)-{2(S)-[2(S)-(3-methoxycarbonyl-2(S)-{3-methyl-2(S)-[(quinoline-2-carbonyl)-amino]-butyrylamino}-propionylamino)-3-methyl-butyrylamino]-propionylamino}-4-oxo-pentanoic acid methyl ester",
    "date_of_designation_or_refusal": "23/10/2006",
    "intended_use": "Treatment of neonatal brain injury",
    "eu_designation_number": "EU/3/06/403",
    "status": "Withdrawn",
    "first_published_date": "30/10/2009",
    "last_updated_date": "08/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-403"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2,3,4,5 Tetrahydro-2,8-dimethyl-5-[2-(6-methyl-3-pyridinyl)ethyl]-1H-pyrido[4,3-b]indole dihydrochloride",
    "date_of_designation_or_refusal": "21/01/2009",
    "intended_use": "Treatment of Huntington’s disease",
    "eu_designation_number": "EU/3/08/597",
    "status": "Withdrawn",
    "first_published_date": "15/06/2009",
    "last_updated_date": "08/05/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-597"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Lactobacillus reuteri",
    "date_of_designation_or_refusal": "12/02/2015",
    "intended_use": "Prevention of necrotising enterocolitis",
    "eu_designation_number": "EU/3/15/1436",
    "status": "Positive",
    "first_published_date": "09/04/2015",
    "last_updated_date": "09/04/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1436"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic CD4+ and CD8+ T lymphocytes ex vivo incubated with synthetic peptides of the viral antigens of cytomegalovirus, adenovirus and Epstein-Barr virus",
    "date_of_designation_or_refusal": "12/02/2015",
    "intended_use": "Treatment of cytomegalovirus infection following haematopoietic stem cell transplantation",
    "eu_designation_number": "EU/3/15/1439",
    "status": "Positive",
    "first_published_date": "09/04/2015",
    "last_updated_date": "09/04/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1439"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "nitroglycerin",
    "date_of_designation_or_refusal": "12/02/2015",
    "intended_use": "Treatment of systemic sclerosis",
    "eu_designation_number": "EU/3/15/1435",
    "status": "Positive",
    "first_published_date": "08/04/2015",
    "last_updated_date": "08/04/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1435"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "filgrastim",
    "date_of_designation_or_refusal": "07/11/2008",
    "intended_use": "Treatment of spinal cord injury",
    "eu_designation_number": "EU/3/08/580",
    "status": "Positive",
    "first_published_date": "24/04/2009",
    "last_updated_date": "26/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-580"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Eculizumab",
    "date_of_designation_or_refusal": "26/03/2014",
    "intended_use": "Prevention of graft rejection following solid organ transplantation",
    "eu_designation_number": "EU/3/14/1254",
    "status": "Withdrawn",
    "first_published_date": "06/05/2014",
    "last_updated_date": "26/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1254"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Pancreatic enzymes (cross linked enzyme crystal lipase, protease, amylase)",
    "date_of_designation_or_refusal": "02/09/2004",
    "intended_use": "Treatment of malabsorption due to exocrine pancreatic enzyme insufficiency",
    "eu_designation_number": "EU/3/04/222",
    "status": "Positive",
    "first_published_date": "18/08/2008",
    "last_updated_date": "26/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-222"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "filgrastim",
    "date_of_designation_or_refusal": "01/04/2008",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/08/532",
    "status": "Positive",
    "first_published_date": "10/07/2008",
    "last_updated_date": "26/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-532"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-butyldeoxygalactonojirimycin",
    "date_of_designation_or_refusal": "09/08/2012",
    "intended_use": "Treatment of Fabry disease",
    "eu_designation_number": "EU/3/12/1033",
    "status": "Positive",
    "first_published_date": "27/09/2012",
    "last_updated_date": "24/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1033"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "R,S-O-(3-piperidino-2-hydroxy-1-propyl)-nicotinic acid amidoxime dihydrochloride",
    "date_of_designation_or_refusal": "26/04/2013",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/13/1122",
    "status": "Positive",
    "first_published_date": "14/05/2013",
    "last_updated_date": "24/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1122"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Glufosfamide",
    "date_of_designation_or_refusal": "15/04/2011",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/11/851",
    "status": "Positive",
    "first_published_date": "26/04/2011",
    "last_updated_date": "23/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-851"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ciclosporin",
    "date_of_designation_or_refusal": "10/03/2005",
    "intended_use": "Treatment of graft rejection after lung transplantation",
    "eu_designation_number": "EU/3/05/265",
    "status": "Withdrawn",
    "first_published_date": "04/12/2007",
    "last_updated_date": "23/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-265"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Herpes simplex virus lacking infected cell protein 34.5",
    "date_of_designation_or_refusal": "09/07/2003",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/03/153",
    "status": "Positive",
    "first_published_date": "23/10/2003",
    "last_updated_date": "23/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-153"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous dendritic cells pulsed with allogeneic tumour cell lysate",
    "date_of_designation_or_refusal": "16/01/2014",
    "intended_use": "Treatment of malignant mesothelioma",
    "eu_designation_number": "EU/3/13/1229",
    "status": "Positive",
    "first_published_date": "24/03/2014",
    "last_updated_date": "23/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1229"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "cenersen",
    "date_of_designation_or_refusal": "03/12/2008",
    "intended_use": "Treatment of chronic lymphocytic leukaemia",
    "eu_designation_number": "EU/3/08/587",
    "status": "Positive",
    "first_published_date": "29/06/2009",
    "last_updated_date": "23/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-587"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "5-Methyl-pyridine-2-sulfonic acid{6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-[2-(1H-tetrazol-5-yl)-pyridin-4-yl]-pyrimidin-4-yl}-amide sodium salt",
    "date_of_designation_or_refusal": "12/12/2003",
    "intended_use": "Treatment of aneurysmal subarachnoid haemorrhage",
    "eu_designation_number": "EU/3/03/182",
    "status": "Positive",
    "first_published_date": "12/12/2005",
    "last_updated_date": "23/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-182"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "antisense NF-kBp65 oligonucleotide",
    "date_of_designation_or_refusal": "30/07/2002",
    "intended_use": "Treatment of active ulcerative colitis",
    "eu_designation_number": "EU/3/02/106",
    "status": "Positive",
    "first_published_date": "23/01/2003",
    "last_updated_date": "23/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-106"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "antisense oligonucleotide 5'-d[P-Thio] (CCCTG CTCCC CCCTG GCTCC)-3'",
    "date_of_designation_or_refusal": "03/11/2006",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/06/416",
    "status": "Positive",
    "first_published_date": "02/04/2009",
    "last_updated_date": "23/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-416"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2,2-Dimethylbutyric acid, sodium salt",
    "date_of_designation_or_refusal": "27/02/2009",
    "intended_use": "Treatment of beta thalassaemia intermedia and major",
    "eu_designation_number": "EU/3/09/617",
    "status": "Positive",
    "first_published_date": "29/06/2009",
    "last_updated_date": "20/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-617"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2,2-Dimethylbutyric acid, sodium salt",
    "date_of_designation_or_refusal": "18/03/2009",
    "intended_use": "Treatment of sickle cell disease",
    "eu_designation_number": "EU/3/09/621",
    "status": "Positive",
    "first_published_date": "08/04/2009",
    "last_updated_date": "20/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-621"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-{[(5S)-3-(3-fluoro-4-thiomorpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide",
    "date_of_designation_or_refusal": "30/08/2011",
    "intended_use": "Treatment of tuberculosis",
    "eu_designation_number": "EU/3/11/897",
    "status": "Positive",
    "first_published_date": "21/09/2011",
    "last_updated_date": "12/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-897"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "clonidine hydrochloride",
    "date_of_designation_or_refusal": "27/10/2011",
    "intended_use": "Prevention of oral mucositis in head and neck cancer patients undergoing radiation therapy",
    "eu_designation_number": "EU/3/11/919",
    "status": "Positive",
    "first_published_date": "23/11/2011",
    "last_updated_date": "12/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-919"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "bilayer engineered skin composed of keratinocytes from the patient (autologous) and fibroblasts from a donor (allogeneic) embedded in a plasma matrix",
    "date_of_designation_or_refusal": "22/05/2006",
    "intended_use": "Treatment of epidermolysis bullosa",
    "eu_designation_number": "EU/3/06/369",
    "status": "Positive",
    "first_published_date": "15/05/2009",
    "last_updated_date": "11/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-369"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "3-[5-(2-Fluoro-phenyl)-[1,2,4]oxadiazole-3-yl]-benzoic acid (ataluren)",
    "date_of_designation_or_refusal": "27/05/2005",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/05/278",
    "status": "Positive",
    "first_published_date": "04/07/2007",
    "last_updated_date": "10/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-278"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "5-chloro-N2-[2-isopropoxy-5-methyl-4-(4-piperidinyl)phenyl]-N4-[2-(isopropylsulfonyl)phenyl]-2,4-pyrimidinediamine",
    "date_of_designation_or_refusal": "28/03/2014",
    "intended_use": "Treatment of non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive",
    "eu_designation_number": "-",
    "status": "Negative",
    "first_published_date": "10/03/2015",
    "last_updated_date": "10/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-non-small-cell-lung-cancer-nsclc-anaplastic-lymphoma-kinase-alk-positive"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium ascorbate;menadione sodium bisulfite",
    "date_of_designation_or_refusal": "11/12/2014",
    "intended_use": "Treatment of autosomal dominant polycystic kidney disease",
    "eu_designation_number": "-",
    "status": "Negative",
    "first_published_date": "10/03/2015",
    "last_updated_date": "10/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-autosomal-dominant-polycystic-kidney-disease"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "vatreptacog alfa (activated)",
    "date_of_designation_or_refusal": "09/08/2012",
    "intended_use": "Treatment of haemophilia B",
    "eu_designation_number": "EU/3/12/1032",
    "status": "Withdrawn",
    "first_published_date": "27/09/2012",
    "last_updated_date": "06/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1032"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Maytansinoid-conjugated humanised monoclonal antibody against CD56",
    "date_of_designation_or_refusal": "09/06/2010",
    "intended_use": "Treatment of Merkel cell carcinoma",
    "eu_designation_number": "EU/3/10/746",
    "status": "Withdrawn",
    "first_published_date": "23/06/2010",
    "last_updated_date": "06/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-746"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pegylated recombinant factor VIIa",
    "date_of_designation_or_refusal": "04/06/2008",
    "intended_use": "Treatment of  haemophilia A",
    "eu_designation_number": "EU/3/08/551",
    "status": "Withdrawn",
    "first_published_date": "18/08/2008",
    "last_updated_date": "06/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-551"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide benzenesulfonic acid salt",
    "date_of_designation_or_refusal": "16/03/2014",
    "intended_use": "Treatment of chronic lymphocytic leukaemia / small lymphocytic lymphoma",
    "eu_designation_number": "EU/3/13/1234",
    "status": "Withdrawn",
    "first_published_date": "24/03/2014",
    "last_updated_date": "06/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1234"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant fusion protein consisting of the extracellular portion of human activin receptor IIB linked to the human IgG1 Fc domain",
    "date_of_designation_or_refusal": "26/11/2010",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/10/812",
    "status": "Withdrawn",
    "first_published_date": "17/12/2010",
    "last_updated_date": "06/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-812"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pegylated recombinant factor VIIa",
    "date_of_designation_or_refusal": "03/06/2008",
    "intended_use": "Treatment of haemophilia B",
    "eu_designation_number": "EU/3/08/552",
    "status": "Withdrawn",
    "first_published_date": "18/08/2008",
    "last_updated_date": "06/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-552"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 8 containing the human AIPL1 gene",
    "date_of_designation_or_refusal": "09/12/2011",
    "intended_use": "Treatment of Leber's congenital amaurosis type 4",
    "eu_designation_number": "EU/3/11/929",
    "status": "Withdrawn",
    "first_published_date": "20/12/2011",
    "last_updated_date": "06/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-929"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "zinc acetate dihydrate",
    "date_of_designation_or_refusal": "31/07/2001",
    "intended_use": "Treatment of Wilson's disease",
    "eu_designation_number": "EU/3/01/050",
    "status": "Expired",
    "first_published_date": "03/03/2009",
    "last_updated_date": "06/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-050"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "chimeric anti-interleukin-6 monoclonal antibody",
    "date_of_designation_or_refusal": "12/06/2009",
    "intended_use": "Treatment of multiple myeloma",
    "eu_designation_number": "EU/3/09/642",
    "status": "Withdrawn",
    "first_published_date": "01/07/2009",
    "last_updated_date": "06/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-642"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human monoclonal antibody to human interleukin (IL)-17A of the IgG1/k class",
    "date_of_designation_or_refusal": "02/02/2010",
    "intended_use": "Treatment of chronic non-infectious uveitis",
    "eu_designation_number": "EU/3/09/724",
    "status": "Withdrawn",
    "first_published_date": "04/03/2010",
    "last_updated_date": "06/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-724"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Maytansinoid-conjugated humanised monoclonal antibody against CD56",
    "date_of_designation_or_refusal": "01/10/2010",
    "intended_use": "Treatment of small cell lung cancer",
    "eu_designation_number": "EU/3/10/792",
    "status": "Withdrawn",
    "first_published_date": "14/10/2010",
    "last_updated_date": "06/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-792"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human rod-derived cone viability factor",
    "date_of_designation_or_refusal": "29/11/2007",
    "intended_use": "Treatment of retinitis pigmentosa",
    "eu_designation_number": "EU/3/07/500",
    "status": "Withdrawn",
    "first_published_date": "23/09/2009",
    "last_updated_date": "06/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-500"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Ibuprofen",
    "date_of_designation_or_refusal": "15/02/2001",
    "intended_use": "Treatment of patent ductus arteriosus",
    "eu_designation_number": "EU/3/01/020",
    "status": "Expired",
    "first_published_date": "15/05/2009",
    "last_updated_date": "06/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-020"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Maytansinoid-conjugated humanised monoclonal antibody against CD56",
    "date_of_designation_or_refusal": "23/02/2011",
    "intended_use": "Treatment of multiple myeloma",
    "eu_designation_number": "EU/3/10/835",
    "status": "Withdrawn",
    "first_published_date": "04/03/2011",
    "last_updated_date": "06/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-835"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Plerixafor",
    "date_of_designation_or_refusal": "09/12/2011",
    "intended_use": "Adjunctive treatment to cytotoxic therapy in acute myeloid leukaemia",
    "eu_designation_number": "EU/3/11/931",
    "status": "Withdrawn",
    "first_published_date": "20/12/2011",
    "last_updated_date": "06/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-931"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pegylated recombinant anti-Pseudomonas aeruginosa antibody",
    "date_of_designation_or_refusal": "05/08/2013",
    "intended_use": "Treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis",
    "eu_designation_number": "EU/3/13/1178",
    "status": "Withdrawn",
    "first_published_date": "13/09/2013",
    "last_updated_date": "06/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1178"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "1-[2-(Benzo[1,2,5]thiadiazol-5-ylamino)-6-(2,6-dichloro-phenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl-urea",
    "date_of_designation_or_refusal": "20/09/2010",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/10/770",
    "status": "Withdrawn",
    "first_published_date": "18/10/2010",
    "last_updated_date": "06/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-770"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "vatreptacog alfa (activated)",
    "date_of_designation_or_refusal": "09/08/2012",
    "intended_use": "Treatment of haemophilia A",
    "eu_designation_number": "EU/3/12/1030",
    "status": "Withdrawn",
    "first_published_date": "27/09/2012",
    "last_updated_date": "06/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1030"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "emtricitabine",
    "date_of_designation_or_refusal": "15/01/2015",
    "intended_use": "Treatment of Aicardi-Goutières syndrome",
    "eu_designation_number": "EU/3/14/1420",
    "status": "Positive",
    "first_published_date": "06/03/2015",
    "last_updated_date": "06/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1420"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ceftriaxone",
    "date_of_designation_or_refusal": "15/01/2015",
    "intended_use": "Treatment of spinocerebellar ataxia",
    "eu_designation_number": "EU/3/14/1425",
    "status": "Positive",
    "first_published_date": "06/03/2015",
    "last_updated_date": "06/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1425"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human alkaline phosphatase",
    "date_of_designation_or_refusal": "15/01/2015",
    "intended_use": "Treatment of hypophosphatasia",
    "eu_designation_number": "EU/3/14/1427",
    "status": "Positive",
    "first_published_date": "06/03/2015",
    "last_updated_date": "06/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1427"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tazarotene",
    "date_of_designation_or_refusal": "18/12/2006",
    "intended_use": "Treatment of congenital ichthyoses",
    "eu_designation_number": "EU/3/06/423",
    "status": "Withdrawn",
    "first_published_date": "02/04/2009",
    "last_updated_date": "06/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-423"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Herpes simplex type 1 virus containing cellular B-myb gene as tumour-specific promoter",
    "date_of_designation_or_refusal": "15/01/2015",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/14/1412",
    "status": "Positive",
    "first_published_date": "05/03/2015",
    "last_updated_date": "05/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1412"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adenoviral vector serotype 5 containing the vascular endothelial growth factor D isoform (preprocessed short form) from a CMV promoter",
    "date_of_designation_or_refusal": "15/01/2015",
    "intended_use": "Treatment of placental insufficiency",
    "eu_designation_number": "EU/3/14/1415",
    "status": "Positive",
    "first_published_date": "05/03/2015",
    "last_updated_date": "05/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1415"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "A lentiviral vector pseudotyped by the Indiana serotype of the vesicular stomatitis virus G protein encoding an antigen derived from the Tax, HBZ, p12I and p30II HTLV-1 proteins",
    "date_of_designation_or_refusal": "15/01/2015",
    "intended_use": "Treatment of adult T-cell leukaemia/lymphoma",
    "eu_designation_number": "EU/3/14/1417",
    "status": "Positive",
    "first_published_date": "05/03/2015",
    "last_updated_date": "05/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1417"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "A lentiviral vector pseudotyped by the New-Jersey serotype of the vesicular stomatitis virus G protein encoding an antigen derived from the Tax, HBZ, p12I and p30II HTLV-1 proteins",
    "date_of_designation_or_refusal": "15/01/2015",
    "intended_use": "Treatment of adult T-cell leukaemia/lymphoma",
    "eu_designation_number": "EU/3/14/1418",
    "status": "Positive",
    "first_published_date": "05/03/2015",
    "last_updated_date": "05/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1418"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tenofovir disoproxil fumarate",
    "date_of_designation_or_refusal": "15/01/2015",
    "intended_use": "Treatment of Aicardi-Goutières syndrome",
    "eu_designation_number": "EU/3/14/1419",
    "status": "Positive",
    "first_published_date": "05/03/2015",
    "last_updated_date": "05/03/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1419"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic adipose-derived adult mesenchymal stem cells contained in a fibrin-based bioengineered dermis",
    "date_of_designation_or_refusal": "16/12/2014",
    "intended_use": "Treatment of epidermolysis bullosa",
    "eu_designation_number": "EU/3/14/1407",
    "status": "Positive",
    "first_published_date": "27/02/2015",
    "last_updated_date": "27/02/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1407"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "5,5'-(4-(trifluromethyl)benzylazanediyl)bis(methylene)diquinolin-8-ol",
    "date_of_designation_or_refusal": "16/12/2014",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/14/1408",
    "status": "Positive",
    "first_published_date": "27/02/2015",
    "last_updated_date": "27/02/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1408"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "benserazide hydrochloride",
    "date_of_designation_or_refusal": "16/12/2014",
    "intended_use": "Treatment of beta thalassaemia intermedia and major",
    "eu_designation_number": "EU/3/14/1402",
    "status": "Positive",
    "first_published_date": "27/02/2015",
    "last_updated_date": "27/02/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1402"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Plerixafor",
    "date_of_designation_or_refusal": "16/12/2014",
    "intended_use": "Treatment of WHIM syndrome",
    "eu_designation_number": "EU/3/14/1403",
    "status": "Positive",
    "first_published_date": "27/02/2015",
    "last_updated_date": "27/02/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1403"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "riluzole",
    "date_of_designation_or_refusal": "16/12/2014",
    "intended_use": "Treatment of traumatic spinal cord injury",
    "eu_designation_number": "EU/3/14/1401",
    "status": "Positive",
    "first_published_date": "27/02/2015",
    "last_updated_date": "27/02/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1401"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "amikacin sulfate",
    "date_of_designation_or_refusal": "16/12/2014",
    "intended_use": "Treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis",
    "eu_designation_number": "EU/3/14/1397",
    "status": "Positive",
    "first_published_date": "26/02/2015",
    "last_updated_date": "26/02/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1397"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic ex vivo-generated natural killer cells from CD34+ umbilical cord blood progenitor cells",
    "date_of_designation_or_refusal": "16/12/2014",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/14/1395",
    "status": "Positive",
    "first_published_date": "26/02/2015",
    "last_updated_date": "26/02/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1395"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic bone marrow derived mesenchymal cells expanded ex vivo in synthetic media",
    "date_of_designation_or_refusal": "16/12/2014",
    "intended_use": "Prevention of graft-versus-host disease",
    "eu_designation_number": "EU/3/14/1388",
    "status": "Positive",
    "first_published_date": "26/02/2015",
    "last_updated_date": "26/02/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1388"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Exisulind",
    "date_of_designation_or_refusal": "16/12/2014",
    "intended_use": "Treatment of familial cerebral cavernous malformations",
    "eu_designation_number": "EU/3/14/1387",
    "status": "Positive",
    "first_published_date": "26/02/2015",
    "last_updated_date": "26/02/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1387"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "5-bromo-N-(prop-2-yn-1-yl)-2-(1H-1,2,4-triazol-1-yl)pyrimidine-4,6-diamine",
    "date_of_designation_or_refusal": "16/12/2014",
    "intended_use": "Treatment of Huntington’s disease",
    "eu_designation_number": "EU/3/14/1392",
    "status": "Positive",
    "first_published_date": "26/02/2015",
    "last_updated_date": "26/02/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1392"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "",
    "date_of_designation_or_refusal": "16/12/2014",
    "intended_use": "Treatment of WHIM syndrome",
    "eu_designation_number": "EU/3/14/1384",
    "status": "Positive",
    "first_published_date": "26/02/2015",
    "last_updated_date": "26/02/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1384"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human monoclonal antibody to human IL-1beta of the IgG1/K class",
    "date_of_designation_or_refusal": "05/02/2008",
    "intended_use": "Treatment of systemic-onset juvenile idiopathic arthritis",
    "eu_designation_number": "EU/3/08/527",
    "status": "Withdrawn",
    "first_published_date": "29/07/2008",
    "last_updated_date": "12/02/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-527"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human monoclonal antibody to human IL-1beta of the IgG1/K class",
    "date_of_designation_or_refusal": "20/03/2007",
    "intended_use": "Treatment of cryopirin-associated periodic syndromes (FCUS, MWS, and NOMID)",
    "eu_designation_number": "EU/3/07/439",
    "status": "Withdrawn",
    "first_published_date": "08/04/2009",
    "last_updated_date": "12/02/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-439"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human monoclonal antibody to hsp90",
    "date_of_designation_or_refusal": "05/12/2001",
    "intended_use": "Treatment of invasive fungal infections",
    "eu_designation_number": "EU/3/01/073",
    "status": "Withdrawn",
    "first_published_date": "12/03/2009",
    "last_updated_date": "12/02/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-073"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "patupilone",
    "date_of_designation_or_refusal": "05/11/2009",
    "intended_use": "Treatment of primary peritoneal cancer",
    "eu_designation_number": "EU/3/09/687",
    "status": "Withdrawn",
    "first_published_date": "18/11/2009",
    "last_updated_date": "11/02/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-687"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "panobinostat lactate",
    "date_of_designation_or_refusal": "02/08/2007",
    "intended_use": "Treatment of cutaneous T-cell lymphoma",
    "eu_designation_number": "EU/3/07/464",
    "status": "Withdrawn",
    "first_published_date": "22/01/2008",
    "last_updated_date": "11/02/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-464"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "panobinostat",
    "date_of_designation_or_refusal": "02/02/2010",
    "intended_use": "Treatment of Hodgkin's lymphoma",
    "eu_designation_number": "EU/3/09/721",
    "status": "Withdrawn",
    "first_published_date": "04/03/2010",
    "last_updated_date": "11/02/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-721"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "nilotinib hydrochloride monohydrate",
    "date_of_designation_or_refusal": "13/04/2007",
    "intended_use": "Treatment of gastrointestinal stromal tumours",
    "eu_designation_number": "EU/3/07/447",
    "status": "Withdrawn",
    "first_published_date": "29/07/2008",
    "last_updated_date": "10/02/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-447"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide",
    "date_of_designation_or_refusal": "25/11/2009",
    "intended_use": "Treatment of naevoid basal-cell carcinoma syndrome (Gorlin syndrome)",
    "eu_designation_number": "EU/3/09/697",
    "status": "Withdrawn",
    "first_published_date": "10/12/2009",
    "last_updated_date": "10/02/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-697"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "imatinib mesilate",
    "date_of_designation_or_refusal": "15/02/2001",
    "intended_use": "Treatment of chronic myeloid leukaemia",
    "eu_designation_number": "EU/3/01/021",
    "status": "Expired",
    "first_published_date": "28/02/2007",
    "last_updated_date": "10/02/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-021"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "imatinib mesilate",
    "date_of_designation_or_refusal": "26/08/2005",
    "intended_use": "Treatment of  mastocytosis",
    "eu_designation_number": "EU/3/05/306",
    "status": "Withdrawn",
    "first_published_date": "04/12/2007",
    "last_updated_date": "10/02/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-306"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "imatinib mesilate",
    "date_of_designation_or_refusal": "26/08/2005",
    "intended_use": "Treatment of acute lymphoblastic leukaemia",
    "eu_designation_number": "EU/3/05/304",
    "status": "Expired",
    "first_published_date": "28/02/2007",
    "last_updated_date": "10/02/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-304"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "imatinib mesilate",
    "date_of_designation_or_refusal": "20/11/2001",
    "intended_use": "Treatment of malignant gastrointestinal stromal tumours",
    "eu_designation_number": "EU/3/01/061",
    "status": "Expired",
    "first_published_date": "29/11/2005",
    "last_updated_date": "09/02/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-061"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "imatinib mesilate",
    "date_of_designation_or_refusal": "23/12/2005",
    "intended_use": "Treatment of myelodysplastic / myeloproliferative diseases",
    "eu_designation_number": "EU/3/05/340",
    "status": "Expired",
    "first_published_date": "28/02/2007",
    "last_updated_date": "09/02/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-340"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "imatinib mesilate",
    "date_of_designation_or_refusal": "28/10/2005",
    "intended_use": "Treatment of chronic eosinophilic leukaemia and the hypereosinophilic syndrome",
    "eu_designation_number": "EU/3/05/320",
    "status": "Expired",
    "first_published_date": "28/02/2007",
    "last_updated_date": "09/02/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-320"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "imatinib mesilate",
    "date_of_designation_or_refusal": "26/08/2005",
    "intended_use": "Treatment of  dermatofibrosarcoma protuberans",
    "eu_designation_number": "EU/3/05/305",
    "status": "Expired",
    "first_published_date": "28/02/2007",
    "last_updated_date": "09/02/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-305"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "everolimus",
    "date_of_designation_or_refusal": "14/11/2007",
    "intended_use": "Treatment of gastro-entero-pancreatic neuroendocrine tumours",
    "eu_designation_number": "EU/3/07/488",
    "status": "Withdrawn",
    "first_published_date": "02/07/2008",
    "last_updated_date": "09/02/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-488"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "everolimus",
    "date_of_designation_or_refusal": "30/08/2011",
    "intended_use": "Treatment of gastric cancer",
    "eu_designation_number": "EU/3/11/894",
    "status": "Withdrawn",
    "first_published_date": "21/09/2011",
    "last_updated_date": "09/02/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-894"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Epothilone B",
    "date_of_designation_or_refusal": "22/03/2002",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/02/098",
    "status": "Withdrawn",
    "first_published_date": "11/06/2003",
    "last_updated_date": "09/02/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-098"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "chloroquine",
    "date_of_designation_or_refusal": "19/11/2014",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/14/1377",
    "status": "Positive",
    "first_published_date": "16/01/2015",
    "last_updated_date": "16/01/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1377"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 8 containing the human MD1 gene",
    "date_of_designation_or_refusal": "19/11/2014",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/14/1381",
    "status": "Positive",
    "first_published_date": "16/01/2015",
    "last_updated_date": "16/01/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1381"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Dantrolene sodium",
    "date_of_designation_or_refusal": "19/11/2014",
    "intended_use": "Treatment of malignant hyperthermia",
    "eu_designation_number": "EU/3/14/1379",
    "status": "Positive",
    "first_published_date": "16/01/2015",
    "last_updated_date": "16/01/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1379"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "olaptesed pegol",
    "date_of_designation_or_refusal": "19/11/2014",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/14/1364",
    "status": "Positive",
    "first_published_date": "15/01/2015",
    "last_updated_date": "15/01/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1364"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "bazedoxifene acetate",
    "date_of_designation_or_refusal": "19/11/2014",
    "intended_use": "Treatment of hereditary haemorrhagic telangiectasia",
    "eu_designation_number": "EU/3/14/1367",
    "status": "Positive",
    "first_published_date": "15/01/2015",
    "last_updated_date": "15/01/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1367"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "1-(6-benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic acid (lanifibranor)",
    "date_of_designation_or_refusal": "19/11/2014",
    "intended_use": "Treatment of idiopathic pulmonary fibrosis",
    "eu_designation_number": "EU/3/14/1362",
    "status": "Positive",
    "first_published_date": "15/01/2015",
    "last_updated_date": "15/01/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1362"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "obinutuzumab",
    "date_of_designation_or_refusal": "22/08/2014",
    "intended_use": "Treatment of diffuse large B-cell lymphoma",
    "eu_designation_number": "EU/3/14/1325",
    "status": "Positive",
    "first_published_date": "02/10/2014",
    "last_updated_date": "01/01/2015",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1325-0"
  },
  {
    "medicine_name": "Dropcys",
    "related_ema_product_number": "EMEA/H/C/004038",
    "active_substance": "cysteamine hydrochloride",
    "date_of_designation_or_refusal": "15/10/2014",
    "intended_use": "Treatment of cystinosis",
    "eu_designation_number": "EU/3/14/1341",
    "status": "Positive",
    "first_published_date": "12/11/2014",
    "last_updated_date": "12/11/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1341"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "",
    "date_of_designation_or_refusal": "15/10/2014",
    "intended_use": "Treatment of fragile X syndrome",
    "eu_designation_number": "EU/3/14/1334",
    "status": "Positive",
    "first_published_date": "12/11/2014",
    "last_updated_date": "12/11/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1334"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 8 containing the human UGT1A1 gene (volrubigene ralaparvovec)",
    "date_of_designation_or_refusal": "15/10/2014",
    "intended_use": "Treatment of Crigler-Najjar syndrome",
    "eu_designation_number": "EU/3/14/1338",
    "status": "Positive",
    "first_published_date": "12/11/2014",
    "last_updated_date": "12/11/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1338"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "cultured allogeneic corneal limbal stem cells",
    "date_of_designation_or_refusal": "15/10/2014",
    "intended_use": "Treatment of limbal stem cell deficiency",
    "eu_designation_number": "EU/3/14/1340",
    "status": "Positive",
    "first_published_date": "12/11/2014",
    "last_updated_date": "12/11/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1340"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "raxibacumab",
    "date_of_designation_or_refusal": "15/10/2014",
    "intended_use": "Treatment of inhalation anthrax disease",
    "eu_designation_number": "EU/3/14/1352",
    "status": "Positive",
    "first_published_date": "12/11/2014",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1352"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "nitric oxide",
    "date_of_designation_or_refusal": "15/10/2014",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/14/1344",
    "status": "Positive",
    "first_published_date": "12/11/2014",
    "last_updated_date": "12/11/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1344"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pyridoxal 5'-phosphate",
    "date_of_designation_or_refusal": "15/10/2014",
    "intended_use": "Treatment of pyridoxamine 5'-phosphate oxidase deficiency",
    "eu_designation_number": "EU/3/14/1347",
    "status": "Positive",
    "first_published_date": "12/11/2014",
    "last_updated_date": "12/11/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1347"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "progesterone",
    "date_of_designation_or_refusal": "08/02/2013",
    "intended_use": "Treatment of moderate and severe traumatic brain injury",
    "eu_designation_number": "EU/3/13/1101",
    "status": "Withdrawn",
    "first_published_date": "04/03/2013",
    "last_updated_date": "16/10/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1101"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human monoclonal antibody of the IgG1 kappa class against prostate stem-cell antigen",
    "date_of_designation_or_refusal": "24/01/2013",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/12/1090",
    "status": "Positive",
    "first_published_date": "01/03/2013",
    "last_updated_date": "16/10/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1090"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Glutathione",
    "date_of_designation_or_refusal": "11/04/2006",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/06/361",
    "status": "Withdrawn",
    "first_published_date": "15/05/2009",
    "last_updated_date": "16/10/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-361"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant inhibitor of human plasma kallikrein",
    "date_of_designation_or_refusal": "18/12/2002",
    "intended_use": "Treatment of angioedema",
    "eu_designation_number": "EU/3/02/126",
    "status": "Withdrawn",
    "first_published_date": "23/09/2009",
    "last_updated_date": "16/10/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-126"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector serotype 5 containing the human ABCA4 gene",
    "date_of_designation_or_refusal": "07/02/2009",
    "intended_use": "Treatment of Stargardt's disease",
    "eu_designation_number": "EU/3/08/609",
    "status": "Withdrawn",
    "first_published_date": "30/10/2009",
    "last_updated_date": "16/10/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-609"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-Chloro-9-[2-deoxy-2-fluoro-ß-D-arabinofuranosyl]adenine",
    "date_of_designation_or_refusal": "08/05/2003",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/03/141",
    "status": "Withdrawn",
    "first_published_date": "18/08/2008",
    "last_updated_date": "16/10/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-141"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human interleukin-21",
    "date_of_designation_or_refusal": "02/09/2004",
    "intended_use": "Treatment of renal-cell carcinoma",
    "eu_designation_number": "EU/3/04/226",
    "status": "Withdrawn",
    "first_published_date": "01/10/2004",
    "last_updated_date": "16/10/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-226"
  },
  {
    "medicine_name": "Vyxeos liposomal (previously Vyxeos)",
    "related_ema_product_number": "EMEA/H/C/004282",
    "active_substance": "cytarabine;daunorubicin",
    "date_of_designation_or_refusal": "11/01/2012",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/11/942",
    "status": "Positive",
    "first_published_date": "01/02/2012",
    "last_updated_date": "08/10/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-942"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Lipopolysaccharide of Ochrobactrum intermedium",
    "date_of_designation_or_refusal": "11/01/2012",
    "intended_use": "Prevention of sepsis in at-risk premature infants of less than or equal to 32 weeks",
    "eu_designation_number": "EU/3/11/941",
    "status": "Positive",
    "first_published_date": "01/02/2012",
    "last_updated_date": "08/10/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-941"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "skin equivalent graft genetically corrected with a COL7A1-encoding SIN retroviral vector",
    "date_of_designation_or_refusal": "30/04/2009",
    "intended_use": "Treatment of dystrophic epidermolysis bullosa",
    "eu_designation_number": "EU/3/09/630",
    "status": "Positive",
    "first_published_date": "12/05/2009",
    "last_updated_date": "07/10/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-630"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Peptides mimicking antigen receptors on autoimmune B cells and autoimmune T cells associated with myasthenia gravis",
    "date_of_designation_or_refusal": "09/11/2009",
    "intended_use": "Treatment of myasthenia gravis",
    "eu_designation_number": "EU/3/09/689",
    "status": "Positive",
    "first_published_date": "18/11/2009",
    "last_updated_date": "07/10/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-689"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "S3,S13-cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide)",
    "date_of_designation_or_refusal": "22/10/2014",
    "intended_use": "Treatment of paroxysmal nocturnal haemoglobinuria",
    "eu_designation_number": "EU/3/14/1327",
    "status": "Positive",
    "first_published_date": "02/10/2014",
    "last_updated_date": "02/10/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1327"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "vector based on an adeno-associated virus serotype 2 backbone, pseudo-serotyped with a type 8 capsid, which carries the coding sequence of the human TYMP gene under the control of the human thyroxine binding globulin promoter",
    "date_of_designation_or_refusal": "22/08/2014",
    "intended_use": "Treatment of mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)",
    "eu_designation_number": "EU/3/14/1326",
    "status": "Positive",
    "first_published_date": "02/10/2014",
    "last_updated_date": "02/10/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1326"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethylsulfamide",
    "date_of_designation_or_refusal": "22/08/2014",
    "intended_use": "Treatment of small cell lung cancer",
    "eu_designation_number": "EU/3/14/1324",
    "status": "Positive",
    "first_published_date": "02/10/2014",
    "last_updated_date": "02/10/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1324"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "[5-Amino-1-(4-fluoro-phenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxy-propoxy)-phenyl]-methanone",
    "date_of_designation_or_refusal": "22/08/2014",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/14/1323",
    "status": "Positive",
    "first_published_date": "02/10/2014",
    "last_updated_date": "02/10/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1323"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised IgG1 monoclonal antibody against human KIR3DL2",
    "date_of_designation_or_refusal": "22/08/2014",
    "intended_use": "Treatment of cutaneous T-cell lymphoma",
    "eu_designation_number": "EU/3/14/1322",
    "status": "Positive",
    "first_published_date": "01/10/2014",
    "last_updated_date": "01/10/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1322"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human diamine oxidase",
    "date_of_designation_or_refusal": "22/08/2014",
    "intended_use": "Treatment of mastocytosis",
    "eu_designation_number": "EU/3/14/1320",
    "status": "Positive",
    "first_published_date": "01/10/2014",
    "last_updated_date": "01/10/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1320"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ulinastatin",
    "date_of_designation_or_refusal": "22/08/2014",
    "intended_use": "Treatment of acute pancreatitis",
    "eu_designation_number": "EU/3/14/1318",
    "status": "Positive",
    "first_published_date": "01/10/2014",
    "last_updated_date": "01/10/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1318"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human apolipoprotein A-I in a complex with phospholipids",
    "date_of_designation_or_refusal": "22/08/2014",
    "intended_use": "Treatment of apolipoprotein A-I deficiency",
    "eu_designation_number": "EU/3/14/1315",
    "status": "Positive",
    "first_published_date": "01/10/2014",
    "last_updated_date": "01/10/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1315"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human apolipoprotein A-I in a complex with phospholipids",
    "date_of_designation_or_refusal": "22/08/2014",
    "intended_use": "Treatment of ATP-binding cassette transporter A1 deficiency",
    "eu_designation_number": "EU/3/14/1314",
    "status": "Positive",
    "first_published_date": "30/09/2014",
    "last_updated_date": "30/09/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1314"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "retinol",
    "date_of_designation_or_refusal": "22/08/2014",
    "intended_use": "Prevention of bronchopulmonary dysplasia",
    "eu_designation_number": "EU/3/14/1307",
    "status": "Positive",
    "first_published_date": "29/09/2014",
    "last_updated_date": "29/09/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1307"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "cysteamine bitartrate (gastroresistant) (mercaptamine)",
    "date_of_designation_or_refusal": "29/07/2014",
    "intended_use": "Treatment of Huntington’s disease",
    "eu_designation_number": "EU/3/14/1306",
    "status": "Positive",
    "first_published_date": "01/09/2014",
    "last_updated_date": "01/09/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1306"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "rilotumumab",
    "date_of_designation_or_refusal": "29/07/2014",
    "intended_use": "Treatment of gastric cancer",
    "eu_designation_number": "EU/3/14/1291",
    "status": "Positive",
    "first_published_date": "01/09/2014",
    "last_updated_date": "01/09/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1291"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "cediranib",
    "date_of_designation_or_refusal": "29/07/2014",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/14/1303",
    "status": "Positive",
    "first_published_date": "01/09/2014",
    "last_updated_date": "01/09/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1303"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-carbamyl-L-glutamic acid",
    "date_of_designation_or_refusal": "18/10/2000",
    "intended_use": "Treatment of N-acetylglutamate synthetase (NAGS) deficiency",
    "eu_designation_number": "EU/3/00/007",
    "status": "Expired",
    "first_published_date": "03/03/2009",
    "last_updated_date": "25/07/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-00-007"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Norursodeoxycholic acid",
    "date_of_designation_or_refusal": "04/07/2014",
    "intended_use": "Treatment of primary sclerosing cholangitis",
    "eu_designation_number": "EU/3/14/1288",
    "status": "Positive",
    "first_published_date": "16/07/2014",
    "last_updated_date": "16/07/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1288"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "temocillin sodium",
    "date_of_designation_or_refusal": "14/01/2004",
    "intended_use": "Treatment of Burkholderia cepacia lung infection in cystic fibrosis",
    "eu_designation_number": "EU/3/03/183",
    "status": "Positive",
    "first_published_date": "23/09/2004",
    "last_updated_date": "14/07/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-183"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human interleukin-7",
    "date_of_designation_or_refusal": "04/07/2012",
    "intended_use": "Treatment of progressive multifocal leukoencephalopathy",
    "eu_designation_number": "EU/3/12/1013",
    "status": "Positive",
    "first_published_date": "24/07/2012",
    "last_updated_date": "14/07/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1013"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "methotrexate",
    "date_of_designation_or_refusal": "24/10/2007",
    "intended_use": "Treatment of acute lymphoblastic leukaemia",
    "eu_designation_number": "EU/3/07/495",
    "status": "Positive",
    "first_published_date": "02/07/2008",
    "last_updated_date": "11/07/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-495"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "aganirsen",
    "date_of_designation_or_refusal": "10/06/2014",
    "intended_use": "Treatment of central retinal vein occlusion",
    "eu_designation_number": "EU/3/14/1275",
    "status": "Positive",
    "first_published_date": "10/07/2014",
    "last_updated_date": "10/07/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1275"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous dendritic cells pulsed with RNA from glioma stem cells",
    "date_of_designation_or_refusal": "04/06/2014",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/14/1273",
    "status": "Positive",
    "first_published_date": "10/07/2014",
    "last_updated_date": "10/07/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1273"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "177Lu-tetraxetan-tetulomab",
    "date_of_designation_or_refusal": "04/06/2014",
    "intended_use": "Treatment of follicular lymphoma",
    "eu_designation_number": "EU/3/14/1271",
    "status": "Positive",
    "first_published_date": "10/07/2014",
    "last_updated_date": "10/07/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1271"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Plasmid DNA encoding the human cystic fibrosis transmembrane conductance regulator gene complexed with a non-viral, cationic lipid based gene transfer agent",
    "date_of_designation_or_refusal": "04/06/2014",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/14/1277",
    "status": "Positive",
    "first_published_date": "10/07/2014",
    "last_updated_date": "10/07/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1277"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "4-(4-Methoxy-phenylamino)-6-methylcarbamyl-quinoline-3-carboxylic acid",
    "date_of_designation_or_refusal": "04/06/2014",
    "intended_use": "Prevention of scarring post glaucoma filtration surgery",
    "eu_designation_number": "EU/3/14/1279",
    "status": "Positive",
    "first_published_date": "10/07/2014",
    "last_updated_date": "10/07/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1279"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "mitotane",
    "date_of_designation_or_refusal": "12/06/2002",
    "intended_use": "Treatment of adrenal cortical carcinoma",
    "eu_designation_number": "EU/3/02/102",
    "status": "Expired",
    "first_published_date": "29/11/2005",
    "last_updated_date": "19/06/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-102"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ombrabulin",
    "date_of_designation_or_refusal": "15/04/2011",
    "intended_use": "Treatment of soft tissue sarcoma",
    "eu_designation_number": "EU/3/11/853",
    "status": "Withdrawn",
    "first_published_date": "26/04/2011",
    "last_updated_date": "19/06/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-853"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "melatonin",
    "date_of_designation_or_refusal": "11/04/2005",
    "intended_use": "Treatment of non-24-hour sleep-wake disorders in blind people with no light perception",
    "eu_designation_number": "EU/3/05/274",
    "status": "Withdrawn",
    "first_published_date": "27/10/2005",
    "last_updated_date": "19/06/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-274"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Lentiviral vector containing the human Wiskott Aldrich Syndrome Protein gene",
    "date_of_designation_or_refusal": "24/01/2006",
    "intended_use": "Treatment of Wiskott-Aldrich syndrome",
    "eu_designation_number": "EU/3/05/345",
    "status": "Withdrawn",
    "first_published_date": "24/04/2009",
    "last_updated_date": "19/06/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-345"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Kifunensine",
    "date_of_designation_or_refusal": "27/09/2011",
    "intended_use": "Treatment of gamma sarcoglycanopathy",
    "eu_designation_number": "EU/3/11/908",
    "status": "Withdrawn",
    "first_published_date": "17/10/2011",
    "last_updated_date": "19/06/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-908"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Kifunensine",
    "date_of_designation_or_refusal": "27/09/2011",
    "intended_use": "Treatment of delta sarcoglycanopathy",
    "eu_designation_number": "EU/3/11/907",
    "status": "Withdrawn",
    "first_published_date": "17/10/2011",
    "last_updated_date": "19/06/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-907"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Kifunensine",
    "date_of_designation_or_refusal": "27/09/2011",
    "intended_use": "Treatment of beta sarcoglycanopathy",
    "eu_designation_number": "EU/3/11/906",
    "status": "Withdrawn",
    "first_published_date": "17/10/2011",
    "last_updated_date": "19/06/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-906"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Kifunensine",
    "date_of_designation_or_refusal": "27/09/2011",
    "intended_use": "Treatment of alpha-sarcoglycanopathy",
    "eu_designation_number": "EU/3/11/905",
    "status": "Withdrawn",
    "first_published_date": "17/10/2011",
    "last_updated_date": "19/06/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-905"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Iodine (131I) chimeric IgG monoclonal antibody cG250",
    "date_of_designation_or_refusal": "19/03/2002",
    "intended_use": "Treatment of renal-cell carcinoma",
    "eu_designation_number": "EU/3/02/095",
    "status": "Withdrawn",
    "first_published_date": "06/01/2003",
    "last_updated_date": "18/06/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-095"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Cladribine",
    "date_of_designation_or_refusal": "18/09/2001",
    "intended_use": "Treatment of indolent non-Hodgkin's lymphoma",
    "eu_designation_number": "EU/3/01/055",
    "status": "Expired",
    "first_published_date": "29/11/2005",
    "last_updated_date": "18/06/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-055"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector containing the human gamma-sarcoglycan gene",
    "date_of_designation_or_refusal": "21/10/2004",
    "intended_use": "Treatment of gamma sarcoglycanopathy",
    "eu_designation_number": "EU/3/04/233",
    "status": "Withdrawn",
    "first_published_date": "11/10/2005",
    "last_updated_date": "18/06/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-233"
  },
  {
    "medicine_name": "Deltyba",
    "related_ema_product_number": "EMEA/H/C/002552",
    "active_substance": "(R)-2-Methyl-6-nitro-2-{4-[4-(4-trifluoromethoxyphenoxy)piperidin-1-yl]phenoxymethyl}-2,3-dihydroimidazo[2,1-b]oxazole (delamanid)",
    "date_of_designation_or_refusal": "02/02/2008",
    "intended_use": "Treatment of tuberculosis",
    "eu_designation_number": "EU/3/07/524",
    "status": "Positive",
    "first_published_date": "10/07/2008",
    "last_updated_date": "18/06/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-524"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector containing the human alpha-sarcoglycan gene",
    "date_of_designation_or_refusal": "07/11/2008",
    "intended_use": "Treatment of alpha-sarcoglycanopathy",
    "eu_designation_number": "EU/3/08/573",
    "status": "Withdrawn",
    "first_published_date": "02/04/2009",
    "last_updated_date": "18/06/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-573"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector containing the human calpain 3 gene",
    "date_of_designation_or_refusal": "06/04/2006",
    "intended_use": "Treatment of calpainopathy",
    "eu_designation_number": "EU/3/06/359",
    "status": "Withdrawn",
    "first_published_date": "24/02/2009",
    "last_updated_date": "18/06/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-359"
  },
  {
    "medicine_name": "Blectifor",
    "related_ema_product_number": "EMEA/H/C/004100",
    "active_substance": "Caffeine citrate",
    "date_of_designation_or_refusal": "11/04/2014",
    "intended_use": "Prevention of bronchopulmonary dysplasia",
    "eu_designation_number": "EU/3/14/1261",
    "status": "Positive",
    "first_published_date": "05/06/2014",
    "last_updated_date": "05/06/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1261"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human vascular endothelial growth factor",
    "date_of_designation_or_refusal": "29/01/2010",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/09/711",
    "status": "Positive",
    "first_published_date": "25/02/2010",
    "last_updated_date": "12/05/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-711"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "5'-O-(trans-9\"-octadecenoyl)-1-ß-D-arabinofuranosyl cytosine",
    "date_of_designation_or_refusal": "14/09/2007",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/07/476",
    "status": "Positive",
    "first_published_date": "29/07/2008",
    "last_updated_date": "08/05/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-476"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Bosentan",
    "date_of_designation_or_refusal": "18/03/2003",
    "intended_use": "Treatment of systemic sclerosis (scleroderma)",
    "eu_designation_number": "EU/3/03/139",
    "status": "Withdrawn",
    "first_published_date": "30/05/2007",
    "last_updated_date": "08/05/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-139"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Bosentan",
    "date_of_designation_or_refusal": "05/09/2008",
    "intended_use": "Treatment of idiopathic pulmonary fibrosis",
    "eu_designation_number": "EU/3/08/559",
    "status": "Withdrawn",
    "first_published_date": "02/04/2009",
    "last_updated_date": "08/05/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-559"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "volasertib",
    "date_of_designation_or_refusal": "26/03/2014",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/14/1255",
    "status": "Positive",
    "first_published_date": "06/05/2014",
    "last_updated_date": "06/05/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1255"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ex-vivo cultured human mesenchymal stromal cells",
    "date_of_designation_or_refusal": "26/03/2014",
    "intended_use": "Prevention of graft rejection following solid organ transplantation",
    "eu_designation_number": "EU/3/14/1253",
    "status": "Positive",
    "first_published_date": "06/05/2014",
    "last_updated_date": "06/05/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1253"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "cysteamine bitartrate (gastroresistant) (mercaptamine)",
    "date_of_designation_or_refusal": "26/03/2014",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/14/1252",
    "status": "Positive",
    "first_published_date": "06/05/2014",
    "last_updated_date": "06/05/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1252"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "vascular endothelial growth factor-D gene in an adenoviral vector for use with a collagen collar",
    "date_of_designation_or_refusal": "08/06/2004",
    "intended_use": "Prevention of stenosis in synthetic grafts used in haemodialysis",
    "eu_designation_number": "EU/3/04/201",
    "status": "Positive",
    "first_published_date": "06/12/2004",
    "last_updated_date": "03/04/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-201"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sacrosidase",
    "date_of_designation_or_refusal": "05/08/2013",
    "intended_use": "Treatment of congenital sucrase-isomaltase deficiency",
    "eu_designation_number": "EU/3/13/1183",
    "status": "Positive",
    "first_published_date": "16/09/2013",
    "last_updated_date": "03/04/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1183"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human serum amyloid P",
    "date_of_designation_or_refusal": "09/10/2009",
    "intended_use": "Prevention of scarring post glaucoma filtration surgery",
    "eu_designation_number": "EU/3/09/674",
    "status": "Withdrawn",
    "first_published_date": "20/10/2009",
    "last_updated_date": "03/04/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-674"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pioglitazone",
    "date_of_designation_or_refusal": "19/02/2014",
    "intended_use": "Treatment of adrenoleukodystrophy",
    "eu_designation_number": "EU/3/14/1245",
    "status": "Positive",
    "first_published_date": "02/04/2014",
    "last_updated_date": "02/04/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1245"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant homodimer of the human annexin V",
    "date_of_designation_or_refusal": "11/01/2012",
    "intended_use": "Prevention of ischaemia/reperfusion injury associated with solid organ transplantation",
    "eu_designation_number": "EU/3/11/946",
    "status": "Withdrawn",
    "first_published_date": "01/02/2012",
    "last_updated_date": "01/04/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-946"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Picoplatin",
    "date_of_designation_or_refusal": "06/12/2007",
    "intended_use": "Treatment of small cell lung cancer",
    "eu_designation_number": "EU/3/07/502",
    "status": "Withdrawn",
    "first_published_date": "02/07/2008",
    "last_updated_date": "01/04/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-502"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human dermal fibroblasts cultured on a bioresorbable polyglactin mesh",
    "date_of_designation_or_refusal": "21/06/2011",
    "intended_use": "Treatment of epidermolysis bullosa",
    "eu_designation_number": "EU/3/11/873",
    "status": "Withdrawn",
    "first_published_date": "12/07/2011",
    "last_updated_date": "01/04/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-873"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ascorbic acid",
    "date_of_designation_or_refusal": "01/04/2008",
    "intended_use": "Treatment of Charcot-Marie-Tooth disease type 1A",
    "eu_designation_number": "EU/3/08/531",
    "status": "Positive",
    "first_published_date": "10/07/2008",
    "last_updated_date": "01/04/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-531"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "16-base single-stranded PNA oligonucleotide linked to a 7-aminoacid peptide",
    "date_of_designation_or_refusal": "25/11/2009",
    "intended_use": "Treatment of neuroblastoma",
    "eu_designation_number": "EU/3/09/692",
    "status": "Positive",
    "first_published_date": "10/12/2009",
    "last_updated_date": "01/04/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-692"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "16-base single-stranded peptide nucleic acid oligonucleotide linked to 7-amino acid peptide",
    "date_of_designation_or_refusal": "01/10/2010",
    "intended_use": "Treatment of medulloblastoma",
    "eu_designation_number": "EU/3/10/789",
    "status": "Positive",
    "first_published_date": "14/10/2010",
    "last_updated_date": "01/04/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-789"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "16-base single-stranded peptide nucleic acid oligonucleotide linked to 7-amino acid peptide",
    "date_of_designation_or_refusal": "04/07/2012",
    "intended_use": "Treatment of neuroblastoma",
    "eu_designation_number": "EU/3/12/1016",
    "status": "Positive",
    "first_published_date": "24/07/2012",
    "last_updated_date": "01/04/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1016"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "11-(4-Dimethylamino-3-hydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-aza-cyclopentadecane-13,15-dione",
    "date_of_designation_or_refusal": "19/02/2014",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/14/1239",
    "status": "Positive",
    "first_published_date": "01/04/2014",
    "last_updated_date": "01/04/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-14-1239"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic bone-marrow-derived ex-vivo-expanded multipotent adult progenitor cells",
    "date_of_designation_or_refusal": "16/01/2014",
    "intended_use": "Prevention of graft-versus-host disease",
    "eu_designation_number": "EU/3/13/1233",
    "status": "Positive",
    "first_published_date": "24/03/2014",
    "last_updated_date": "24/03/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1233"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(6aS)-1,10-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-2,9-diol",
    "date_of_designation_or_refusal": "16/01/2014",
    "intended_use": "Treatment of dystrophic myotonia",
    "eu_designation_number": "EU/3/13/1226",
    "status": "Positive",
    "first_published_date": "21/03/2014",
    "last_updated_date": "21/03/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1226"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Inecalcitol",
    "date_of_designation_or_refusal": "16/01/2014",
    "intended_use": "Treatment of chronic lymphocytic leukaemia / small lymphocytic lymphoma",
    "eu_designation_number": "EU/3/13/1223",
    "status": "Positive",
    "first_published_date": "21/03/2014",
    "last_updated_date": "21/03/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1223"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "perifosine",
    "date_of_designation_or_refusal": "10/06/2010",
    "intended_use": "Treatment of multiple myeloma",
    "eu_designation_number": "EU/3/10/740",
    "status": "Withdrawn",
    "first_published_date": "24/06/2010",
    "last_updated_date": "07/02/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-740"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "catumaxomab",
    "date_of_designation_or_refusal": "03/11/2006",
    "intended_use": "Treatment of gastric cancer",
    "eu_designation_number": "EU/3/06/414",
    "status": "Positive",
    "first_published_date": "24/02/2009",
    "last_updated_date": "07/02/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-414"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "anti-epithelial cell adhesion molecule/anti-CD3 monoclonal antibody",
    "date_of_designation_or_refusal": "08/03/2004",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/04/193",
    "status": "Positive",
    "first_published_date": "27/10/2005",
    "last_updated_date": "07/02/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-193"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "nitric oxide",
    "date_of_designation_or_refusal": "16/01/2014",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/13/1209",
    "status": "Positive",
    "first_published_date": "23/01/2014",
    "last_updated_date": "23/01/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1209"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Lactobacillus acidophilus and Bifidobacterium bifidum",
    "date_of_designation_or_refusal": "16/01/2014",
    "intended_use": "Prevention of necrotising enterocolitis",
    "eu_designation_number": "EU/3/13/1213",
    "status": "Positive",
    "first_published_date": "23/01/2014",
    "last_updated_date": "23/01/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1213"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic and autologous haptenised and irradiated cells and cell lysates derived from glioma",
    "date_of_designation_or_refusal": "16/01/2014",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/13/1211",
    "status": "Positive",
    "first_published_date": "22/01/2014",
    "last_updated_date": "22/01/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1211"
  },
  {
    "medicine_name": "Loulla",
    "related_ema_product_number": "EMEA/H/C/002501",
    "active_substance": "Mercaptopurine",
    "date_of_designation_or_refusal": "22/10/2007",
    "intended_use": "Treatment of acute lymphoblastic leukaemia",
    "eu_designation_number": "EU/3/07/496",
    "status": "Positive",
    "first_published_date": "02/07/2008",
    "last_updated_date": "22/01/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-496"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "heparin sodium",
    "date_of_designation_or_refusal": "23/12/2005",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/05/337",
    "status": "Withdrawn",
    "first_published_date": "08/08/2006",
    "last_updated_date": "22/01/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-337"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "",
    "date_of_designation_or_refusal": "08/10/2009",
    "intended_use": "Treatment of soft tissue sarcoma",
    "eu_designation_number": "EU/3/09/678",
    "status": "Withdrawn",
    "first_published_date": "20/10/2009",
    "last_updated_date": "22/01/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-678"
  },
  {
    "medicine_name": "Begedina",
    "related_ema_product_number": "EMEA/H/C/004144",
    "active_substance": "murine monoclonal antibody against CD26",
    "date_of_designation_or_refusal": "26/11/2010",
    "intended_use": "Treatment of graft-versus-host disease",
    "eu_designation_number": "EU/3/10/808",
    "status": "Positive",
    "first_published_date": "15/12/2010",
    "last_updated_date": "22/01/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-808"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "heparin-binding epidermal growth factor-like growth factor, amino acids 74-148",
    "date_of_designation_or_refusal": "31/10/2006",
    "intended_use": "Prevention of necrotising enterocolitis",
    "eu_designation_number": "EU/3/06/407",
    "status": "Positive",
    "first_published_date": "02/04/2009",
    "last_updated_date": "13/01/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-407"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human monoclonal antibody against inhibitory killer cell lg-like receptors (1-7 F9)",
    "date_of_designation_or_refusal": "28/08/2006",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/06/392",
    "status": "Withdrawn",
    "first_published_date": "24/04/2009",
    "last_updated_date": "13/01/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-392"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "valproic acid",
    "date_of_designation_or_refusal": "30/11/2004",
    "intended_use": "Treatment of familial adenomatous polyposis (FAP)",
    "eu_designation_number": "EU/3/04/246",
    "status": "Withdrawn",
    "first_published_date": "04/01/2006",
    "last_updated_date": "13/01/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-246"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human alpha-1 antitrypsin",
    "date_of_designation_or_refusal": "30/04/2002",
    "intended_use": "Treatment of emphysema secondary to congenital alpha-1 antitrypsin deficiency",
    "eu_designation_number": "EU/3/02/100",
    "status": "Withdrawn",
    "first_published_date": "04/06/2012",
    "last_updated_date": "13/01/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-100"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium valproate",
    "date_of_designation_or_refusal": "26/08/2005",
    "intended_use": "Treatment of 5q spinal muscular atrophy",
    "eu_designation_number": "EU/3/05/309",
    "status": "Withdrawn",
    "first_published_date": "29/11/2005",
    "last_updated_date": "13/01/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-309"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "murine anti-idiotypic antibody against OC125 antibody against CA125 antigen",
    "date_of_designation_or_refusal": "09/07/2003",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/03/155",
    "status": "Withdrawn",
    "first_published_date": "04/01/2006",
    "last_updated_date": "13/01/2014",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-155"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous regulatory T cells with an immunophenotype of CD4+CD25hiFoxP3+",
    "date_of_designation_or_refusal": "08/10/2013",
    "intended_use": "Prevention of rejection following solid organ transplantation",
    "eu_designation_number": "EU/3/13/1171",
    "status": "Positive",
    "first_published_date": "03/12/2013",
    "last_updated_date": "03/12/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1171"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "soraprazan",
    "date_of_designation_or_refusal": "13/11/2013",
    "intended_use": "Treatment of Stargardt's disease",
    "eu_designation_number": "EU/3/13/1208",
    "status": "Positive",
    "first_published_date": "02/12/2013",
    "last_updated_date": "02/12/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1208"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "trebananib",
    "date_of_designation_or_refusal": "13/11/2013",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/13/1207",
    "status": "Positive",
    "first_published_date": "02/12/2013",
    "last_updated_date": "02/12/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1207"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous ex-vivo-expanded leucocytes treated with 5-aza-2'-deoxycytidine",
    "date_of_designation_or_refusal": "13/11/2013",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/13/1197",
    "status": "Positive",
    "first_published_date": "28/11/2013",
    "last_updated_date": "28/11/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1197"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "6-Thioguanine",
    "date_of_designation_or_refusal": "26/11/2009",
    "intended_use": "Treatment of acute lymphoblastic leukaemia",
    "eu_designation_number": "EU/3/09/694",
    "status": "Positive",
    "first_published_date": "10/12/2009",
    "last_updated_date": "28/11/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-694"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "",
    "date_of_designation_or_refusal": "05/09/2008",
    "intended_use": "Treatment of moderate and severe closed traumatic brain injury",
    "eu_designation_number": "EU/3/08/560",
    "status": "Positive",
    "first_published_date": "24/04/2009",
    "last_updated_date": "28/11/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-560"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "terguride",
    "date_of_designation_or_refusal": "08/02/2013",
    "intended_use": "Treatment of systemic sclerosis",
    "eu_designation_number": "EU/3/13/1104",
    "status": "Withdrawn",
    "first_published_date": "04/03/2013",
    "last_updated_date": "25/11/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1104"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Idelalisib",
    "date_of_designation_or_refusal": "05/08/2013",
    "intended_use": "Treatment of splenic marginal-zone lymphoma",
    "eu_designation_number": "EU/3/13/1187",
    "status": "Withdrawn",
    "first_published_date": "16/09/2013",
    "last_updated_date": "18/11/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1187"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Idelalisib",
    "date_of_designation_or_refusal": "05/08/2013",
    "intended_use": "Treatment of extranodal marginal-zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)",
    "eu_designation_number": "EU/3/13/1186",
    "status": "Withdrawn",
    "first_published_date": "16/09/2013",
    "last_updated_date": "18/11/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1186"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Idelalisib",
    "date_of_designation_or_refusal": "17/07/2013",
    "intended_use": "Treatment of lymphoplasmacytic lymphoma",
    "eu_designation_number": "EU/3/13/1160",
    "status": "Withdrawn",
    "first_published_date": "22/08/2013",
    "last_updated_date": "18/11/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1160"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Idelalisib",
    "date_of_designation_or_refusal": "05/08/2013",
    "intended_use": "Treatment of nodal marginal-zone lymphoma",
    "eu_designation_number": "EU/3/13/1172",
    "status": "Withdrawn",
    "first_published_date": "12/09/2013",
    "last_updated_date": "18/11/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1172"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Idelalisib",
    "date_of_designation_or_refusal": "05/08/2013",
    "intended_use": "Treatment of chronic lymphocytic leukaemia / small lymphocytic lymphoma",
    "eu_designation_number": "EU/3/13/1173",
    "status": "Withdrawn",
    "first_published_date": "13/09/2013",
    "last_updated_date": "18/11/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1173"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Idelalisib",
    "date_of_designation_or_refusal": "17/07/2013",
    "intended_use": "Treatment of follicular lymphoma",
    "eu_designation_number": "EU/3/13/1159",
    "status": "Withdrawn",
    "first_published_date": "22/08/2013",
    "last_updated_date": "15/11/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1159"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "3,5-diiodothyropropionic acid",
    "date_of_designation_or_refusal": "07/10/2013",
    "intended_use": "Treatment of Allan-Herndon-Dudley syndrome",
    "eu_designation_number": "EU/3/13/1193",
    "status": "Positive",
    "first_published_date": "31/10/2013",
    "last_updated_date": "31/10/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1193"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "zoledronic acid",
    "date_of_designation_or_refusal": "07/10/2013",
    "intended_use": "Treatment of complex regional pain syndrome",
    "eu_designation_number": "EU/3/13/1192",
    "status": "Positive",
    "first_published_date": "31/10/2013",
    "last_updated_date": "31/10/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1192"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "L-Pyr-L-Glu-L-Gln-L-Leu-L-Glu-L-Arg-L-Ala-L-Leu-L-Asn-L-Ser-L-Ser (cibinetide)",
    "date_of_designation_or_refusal": "07/10/2013",
    "intended_use": "Treatment of sarcoidosis",
    "eu_designation_number": "EU/3/13/1191",
    "status": "Positive",
    "first_published_date": "31/10/2013",
    "last_updated_date": "31/10/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1191"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Mexiletine hydrochloride",
    "date_of_designation_or_refusal": "07/10/2013",
    "intended_use": "Treatment of myotonic disorders",
    "eu_designation_number": "EU/3/13/1189",
    "status": "Positive",
    "first_published_date": "31/10/2013",
    "last_updated_date": "31/10/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1189"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous dendritic cells pulsed with recombinant human-fusion protein (mucin 1 - glutathione S transferase) coupled to oxidised polymannose",
    "date_of_designation_or_refusal": "20/09/2010",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/10/776",
    "status": "Positive",
    "first_published_date": "18/10/2010",
    "last_updated_date": "17/10/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-776"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "carmustine",
    "date_of_designation_or_refusal": "05/03/2002",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/02/085",
    "status": "Withdrawn",
    "first_published_date": "23/01/2003",
    "last_updated_date": "17/10/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-085"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "HLA-B27-derived peptide (amino acid 125-138)",
    "date_of_designation_or_refusal": "02/09/2004",
    "intended_use": "Treatment of autoimmune uveitis",
    "eu_designation_number": "EU/3/04/219",
    "status": "Positive",
    "first_published_date": "09/06/2006",
    "last_updated_date": "17/10/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-219"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Complement factor H",
    "date_of_designation_or_refusal": "27/01/2007",
    "intended_use": "Atypical haemolytic uraemic syndrome",
    "eu_designation_number": "EU/3/06/425",
    "status": "Withdrawn",
    "first_published_date": "29/07/2008",
    "last_updated_date": "17/10/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-425"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Cyclo {{(E,Z)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)nona-6,8-dienoyl}-L-2-aminobutyryl-N-methyl-glycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl}",
    "date_of_designation_or_refusal": "14/09/2007",
    "intended_use": "Treatment of chronic non-infectious uveitis",
    "eu_designation_number": "EU/3/07/472",
    "status": "Withdrawn",
    "first_published_date": "29/07/2008",
    "last_updated_date": "17/10/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-472"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "",
    "date_of_designation_or_refusal": "03/06/2008",
    "intended_use": "Treatment of congenital alpha-1 antitrypsin deficiency",
    "eu_designation_number": "EU/3/08/546",
    "status": "Positive",
    "first_published_date": "18/08/2008",
    "last_updated_date": "17/10/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-546"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "artesunate",
    "date_of_designation_or_refusal": "07/12/2007",
    "intended_use": "Treatment of malaria",
    "eu_designation_number": "EU/3/07/510",
    "status": "Positive",
    "first_published_date": "02/07/2008",
    "last_updated_date": "17/10/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-510"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "arsenic trioxide",
    "date_of_designation_or_refusal": "18/10/2000",
    "intended_use": "Treatment of acute promyelocytic leukaemia",
    "eu_designation_number": "EU/3/00/008",
    "status": "Expired",
    "first_published_date": "04/07/2007",
    "last_updated_date": "17/10/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-00-008"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "abarelix",
    "date_of_designation_or_refusal": "20/09/2010",
    "intended_use": "Treatment of low-flow priapism",
    "eu_designation_number": "EU/3/10/771",
    "status": "Withdrawn",
    "first_published_date": "18/10/2010",
    "last_updated_date": "17/10/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-771"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "4,6,8-Trihydroxy-10-(3,7,11-trimethyldodeca-2,6,10-trienyl)-5,10-dihydrodibenzo[b,e][1,4] diazepin-11-one",
    "date_of_designation_or_refusal": "15/05/2009",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/09/639",
    "status": "Withdrawn",
    "first_published_date": "09/06/2009",
    "last_updated_date": "17/10/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-639"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "cholest-4-en-3-one, oxime",
    "date_of_designation_or_refusal": "28/08/2006",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/06/397",
    "status": "Withdrawn",
    "first_published_date": "24/04/2009",
    "last_updated_date": "17/10/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-397"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "4-Benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione",
    "date_of_designation_or_refusal": "28/10/2009",
    "intended_use": "Treatment of progressive supranuclear palsy",
    "eu_designation_number": "EU/3/09/679",
    "status": "Withdrawn",
    "first_published_date": "18/11/2009",
    "last_updated_date": "17/10/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-679"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "cysteamine bitartrate (gastroresistant) (mercaptamine)",
    "date_of_designation_or_refusal": "20/09/2010",
    "intended_use": "Treatment of cystinosis",
    "eu_designation_number": "EU/3/10/778",
    "status": "Positive",
    "first_published_date": "18/10/2010",
    "last_updated_date": "10/10/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-778"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium phenylbutyrate",
    "date_of_designation_or_refusal": "09/02/2012",
    "intended_use": "Treatment of ornithine-transcarbamylase deficiency",
    "eu_designation_number": "EU/3/12/950",
    "status": "Withdrawn",
    "first_published_date": "01/03/2012",
    "last_updated_date": "09/10/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-950"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "iloprost",
    "date_of_designation_or_refusal": "30/12/2000",
    "intended_use": "Treatment of primary and of the following forms of secondary pulmonary hypertension…",
    "eu_designation_number": "EU/3/00/014",
    "status": "Expired",
    "first_published_date": "12/03/2009",
    "last_updated_date": "08/10/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-00-014"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human immunoglobulin",
    "date_of_designation_or_refusal": "24/10/2003",
    "intended_use": "Treatment of polymyositis",
    "eu_designation_number": "EU/3/03/170",
    "status": "Withdrawn",
    "first_published_date": "26/04/2004",
    "last_updated_date": "08/10/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-170"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human immunoglobulin",
    "date_of_designation_or_refusal": "20/10/2003",
    "intended_use": "Treatment of dermatomyositis",
    "eu_designation_number": "EU/3/03/169",
    "status": "Withdrawn",
    "first_published_date": "26/04/2004",
    "last_updated_date": "08/10/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-169"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Deferoxamine mesilate",
    "date_of_designation_or_refusal": "20/10/2004",
    "intended_use": "Treatment of traumatic spinal cord injury",
    "eu_designation_number": "EU/3/04/231",
    "status": "Withdrawn",
    "first_published_date": "21/09/2009",
    "last_updated_date": "08/10/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-231"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous bone-marrow-derived mononuclear-cell fraction",
    "date_of_designation_or_refusal": "20/09/2010",
    "intended_use": "Treatment of thromboangiitis obliterans (Buerger's disease)",
    "eu_designation_number": "EU/3/10/775",
    "status": "Positive",
    "first_published_date": "18/10/2010",
    "last_updated_date": "08/10/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-775"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "5-[1-(2,6-Dichlorobenzyl)piperidin-4-ylmethoxy]quinazoline-2,4-diamine dihydrochloride",
    "date_of_designation_or_refusal": "07/06/2013",
    "intended_use": "Treatment of 5q spinal muscular atrophy",
    "eu_designation_number": "EU/3/13/1136",
    "status": "Positive",
    "first_published_date": "25/06/2013",
    "last_updated_date": "07/10/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1136"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "polyinosine-polycytidylic acid coupled with the polycationic polyethyleneimine",
    "date_of_designation_or_refusal": "06/06/2012",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/12/1000",
    "status": "Withdrawn",
    "first_published_date": "04/07/2012",
    "last_updated_date": "23/09/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1000"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised monoclonal antibody against epidermal-growth-factor receptor",
    "date_of_designation_or_refusal": "09/08/2012",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/12/1029",
    "status": "Withdrawn",
    "first_published_date": "26/09/2012",
    "last_updated_date": "23/09/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1029"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Diphenylcyclopropenone",
    "date_of_designation_or_refusal": "29/06/2006",
    "intended_use": "Treatment of alopecia universalis",
    "eu_designation_number": "EU/3/06/380",
    "status": "Withdrawn",
    "first_published_date": "24/04/2009",
    "last_updated_date": "23/09/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-380"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Diphenylcyclopropenone",
    "date_of_designation_or_refusal": "29/06/2006",
    "intended_use": "Treatment of alopecia totalis",
    "eu_designation_number": "EU/3/06/379",
    "status": "Withdrawn",
    "first_published_date": "24/04/2009",
    "last_updated_date": "19/09/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-379"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "decitabine",
    "date_of_designation_or_refusal": "08/06/2006",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/06/370",
    "status": "Positive",
    "first_published_date": "19/07/2007",
    "last_updated_date": "19/09/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-370"
  },
  {
    "medicine_name": "Kiacta; Kiacta",
    "related_ema_product_number": "EMEA/H/C/000779; EMEA/H/C/000779",
    "active_substance": "1,3-Propanedisulfonic acid, disodium salt",
    "date_of_designation_or_refusal": "31/07/2001",
    "intended_use": "Treatment of systemic secondary amyloidosis",
    "eu_designation_number": "EU/3/01/051",
    "status": "Positive",
    "first_published_date": "15/05/2009",
    "last_updated_date": "19/09/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-051"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Cladribine",
    "date_of_designation_or_refusal": "05/08/2013",
    "intended_use": "Treatment of mastocytosis",
    "eu_designation_number": "EU/3/13/1182",
    "status": "Positive",
    "first_published_date": "16/09/2013",
    "last_updated_date": "16/09/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1182"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "cisplatin",
    "date_of_designation_or_refusal": "05/08/2013",
    "intended_use": "Treatment of osteosarcoma",
    "eu_designation_number": "EU/3/13/1169",
    "status": "Positive",
    "first_published_date": "12/09/2013",
    "last_updated_date": "12/09/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1169"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human haemin",
    "date_of_designation_or_refusal": "17/07/2013",
    "intended_use": "Prevention of ischaemia/reperfusion injury associated with solid organ transplantation",
    "eu_designation_number": "EU/3/13/1149",
    "status": "Positive",
    "first_published_date": "22/08/2013",
    "last_updated_date": "22/08/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1149"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Dexamethasone sodium phosphate encapsulated in human autologous erythrocytes",
    "date_of_designation_or_refusal": "17/07/2013",
    "intended_use": "Treatment of ataxia telangiectasia",
    "eu_designation_number": "EU/3/13/1158",
    "status": "Positive",
    "first_published_date": "16/08/2013",
    "last_updated_date": "16/08/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1158"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ex-vivo-expanded autologous human corneal epithelium containing stem cells",
    "date_of_designation_or_refusal": "17/07/2013",
    "intended_use": "Treatment of limbal stem cell deficiency",
    "eu_designation_number": "EU/3/13/1168",
    "status": "Positive",
    "first_published_date": "16/08/2013",
    "last_updated_date": "16/08/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1168"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous bone-marrow-derived mesenchymal stromal cells secreting neurotrophic factors",
    "date_of_designation_or_refusal": "17/07/2013",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/13/1148",
    "status": "Positive",
    "first_published_date": "16/08/2013",
    "last_updated_date": "16/08/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1148"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic motor neuron progenitor cells derived from human embryonic stem cells",
    "date_of_designation_or_refusal": "17/07/2013",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/13/1155",
    "status": "Positive",
    "first_published_date": "16/08/2013",
    "last_updated_date": "16/08/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1155"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium phenylbutyrate",
    "date_of_designation_or_refusal": "09/02/2012",
    "intended_use": "Treatment of carbamoyl-phosphate synthase-1 deficiency",
    "eu_designation_number": "EU/3/12/951",
    "status": "Withdrawn",
    "first_published_date": "01/03/2012",
    "last_updated_date": "08/08/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-951"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium phenylbutyrate",
    "date_of_designation_or_refusal": "09/02/2012",
    "intended_use": "Treatment of citrullinaemia type 1",
    "eu_designation_number": "EU/3/12/949",
    "status": "Withdrawn",
    "first_published_date": "01/03/2012",
    "last_updated_date": "08/08/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-949"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "titanium dioxide;bisoctrizole",
    "date_of_designation_or_refusal": "03/03/2005",
    "intended_use": "Treatment of ultraviolet-A- and visible-light-induced photosensitivity disorders",
    "eu_designation_number": "EU/3/05/262",
    "status": "Withdrawn",
    "first_published_date": "01/07/2005",
    "last_updated_date": "31/07/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-262"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tamibarotene",
    "date_of_designation_or_refusal": "24/07/2009",
    "intended_use": "Treatment of acute promyelocytic leukaemia",
    "eu_designation_number": "EU/3/09/658",
    "status": "Withdrawn",
    "first_published_date": "11/09/2009",
    "last_updated_date": "31/07/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-658"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "bafetinib",
    "date_of_designation_or_refusal": "10/06/2010",
    "intended_use": "Treatment of chronic myeloid leukaemia",
    "eu_designation_number": "EU/3/10/731",
    "status": "Withdrawn",
    "first_published_date": "24/06/2010",
    "last_updated_date": "31/07/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-731"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "busulfan",
    "date_of_designation_or_refusal": "30/12/2000",
    "intended_use": "Conditioning treatment prior to haematopoietic-progenitor-cell transplantation",
    "eu_designation_number": "EU/3/00/011",
    "status": "Expired",
    "first_published_date": "15/05/2009",
    "last_updated_date": "31/07/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-00-011"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "acadesine",
    "date_of_designation_or_refusal": "27/05/2005",
    "intended_use": "Treatment of B-cell chronic lymphocytic leukaemia",
    "eu_designation_number": "EU/3/05/280",
    "status": "Positive",
    "first_published_date": "17/09/2009",
    "last_updated_date": "31/07/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-280"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "[N-((2S,3R,3aS,3'R,4a'R,6S,6a'R,6b'S,7aR,12a'S,12b'S,Z)-3,6,11',12b'-tetramethyl-2',3a,3',4,4',4a',5,5',6,6',6a',6b',7,7a,7',8',10',12',12a',12b'-icosahydro-1'H,3H-spiro[furo[3,2-b]pyridine-2,9'-naphtho[2,1-a]azulene]-3'-yl)methanesulfonamide hydrochloride]",
    "date_of_designation_or_refusal": "13/05/2011",
    "intended_use": "Treatment of chondrosarcoma",
    "eu_designation_number": "EU/3/11/859",
    "status": "Withdrawn",
    "first_published_date": "27/05/2011",
    "last_updated_date": "31/07/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-859"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "acadesine",
    "date_of_designation_or_refusal": "05/08/2011",
    "intended_use": "Treatment of multiple myeloma",
    "eu_designation_number": "EU/3/11/881",
    "status": "Positive",
    "first_published_date": "16/08/2011",
    "last_updated_date": "31/07/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-881"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "genetically modified human adenovirus encoding human PH20 hyaluronidase",
    "date_of_designation_or_refusal": "21/06/2011",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/11/880",
    "status": "Positive",
    "first_published_date": "12/07/2011",
    "last_updated_date": "31/07/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-880"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "expanded human allogeneic neural retinal progenitor cells extracted from neural retina",
    "date_of_designation_or_refusal": "19/06/2013",
    "intended_use": "Treatment of retinitis pigmentosa",
    "eu_designation_number": "EU/3/13/1140",
    "status": "Positive",
    "first_published_date": "11/07/2013",
    "last_updated_date": "11/07/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1140"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "synthetic double-stranded siRNA oligonucleotide directed against the keratin 6a N171K mutation",
    "date_of_designation_or_refusal": "19/06/2013",
    "intended_use": "Treatment of pachyonychia congenita",
    "eu_designation_number": "EU/3/13/1141",
    "status": "Positive",
    "first_published_date": "11/07/2013",
    "last_updated_date": "11/07/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1141"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "immortalised human C3A hepatoblastoma cells",
    "date_of_designation_or_refusal": "19/06/2013",
    "intended_use": "Treatment of acute liver failure",
    "eu_designation_number": "EU/3/13/1143",
    "status": "Positive",
    "first_published_date": "11/07/2013",
    "last_updated_date": "11/07/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1143"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic bone-marrow-derived mesenchymal cells expanded ex vivo in synthetic media",
    "date_of_designation_or_refusal": "07/06/2013",
    "intended_use": "Treatment of graft-versus-host disease",
    "eu_designation_number": "EU/3/13/1129",
    "status": "Positive",
    "first_published_date": "25/06/2013",
    "last_updated_date": "09/07/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1129"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "octocog alfa",
    "date_of_designation_or_refusal": "24/07/2009",
    "intended_use": "Treatment of haemophilia A",
    "eu_designation_number": "EU/3/09/655",
    "status": "Withdrawn",
    "first_published_date": "11/09/2009",
    "last_updated_date": "08/07/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-655"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "brostallicin",
    "date_of_designation_or_refusal": "23/12/2005",
    "intended_use": "Treatment of soft tissue sarcoma",
    "eu_designation_number": "EU/3/05/336",
    "status": "Withdrawn",
    "first_published_date": "17/09/2009",
    "last_updated_date": "08/07/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-336"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "laronidase",
    "date_of_designation_or_refusal": "15/02/2001",
    "intended_use": "Treatment of mucopolysaccharidosis type I",
    "eu_designation_number": "EU/3/01/022",
    "status": "Expired",
    "first_published_date": "15/06/2009",
    "last_updated_date": "08/07/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-022"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tretazicar",
    "date_of_designation_or_refusal": "04/02/2008",
    "intended_use": "Treatment of visceral leishmaniasis",
    "eu_designation_number": "EU/3/08/529",
    "status": "Positive",
    "first_published_date": "10/07/2008",
    "last_updated_date": "08/07/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-529"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Human-papilloma-virus-type-16 E6;E7 synthetic long peptides",
    "date_of_designation_or_refusal": "20/12/2007",
    "intended_use": "Treatment of epithelial neoplasia of the vulva positive for human papilloma virus",
    "eu_designation_number": "EU/3/07/520",
    "status": "Positive",
    "first_published_date": "21/09/2009",
    "last_updated_date": "26/06/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-520"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Givinostat",
    "date_of_designation_or_refusal": "28/01/2010",
    "intended_use": "Treatment of systemic-onset juvenile idiopathic arthritis",
    "eu_designation_number": "EU/3/09/704",
    "status": "Withdrawn",
    "first_published_date": "25/02/2010",
    "last_updated_date": "25/06/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-704"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human CXCL8 mutant",
    "date_of_designation_or_refusal": "07/06/2013",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/13/1131",
    "status": "Positive",
    "first_published_date": "25/06/2013",
    "last_updated_date": "25/06/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1131"
  },
  {
    "medicine_name": "Besponsa",
    "related_ema_product_number": "EMEA/H/C/004119",
    "active_substance": "Inotuzumab ozogamicin",
    "date_of_designation_or_refusal": "07/06/2013",
    "intended_use": "Treatment of B-cell acute lymphoblastic leukaemia",
    "eu_designation_number": "EU/3/13/1127",
    "status": "Positive",
    "first_published_date": "25/06/2013",
    "last_updated_date": "25/06/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1127"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human transglutaminase 1 encapsulated into liposomes",
    "date_of_designation_or_refusal": "07/06/2013",
    "intended_use": "Treatment of transglutaminase-1-deficient autosomal recessive congenital ichthyosis",
    "eu_designation_number": "EU/3/13/1130",
    "status": "Positive",
    "first_published_date": "25/06/2013",
    "last_updated_date": "25/06/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1130"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Etilefrine",
    "date_of_designation_or_refusal": "13/11/2002",
    "intended_use": "Treatment of low-flow priapism",
    "eu_designation_number": "EU/3/02/122",
    "status": "Positive",
    "first_published_date": "13/12/2002",
    "last_updated_date": "25/06/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-122"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Davunetide",
    "date_of_designation_or_refusal": "23/03/2010",
    "intended_use": "Treatment of progressive supranuclear palsy",
    "eu_designation_number": "EU/3/10/728",
    "status": "Withdrawn",
    "first_published_date": "26/03/2010",
    "last_updated_date": "25/06/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-728"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "brivanib alaninate",
    "date_of_designation_or_refusal": "27/10/2011",
    "intended_use": "Treatment of hepatocellular carcinoma",
    "eu_designation_number": "EU/3/11/918",
    "status": "Withdrawn",
    "first_published_date": "23/11/2011",
    "last_updated_date": "25/06/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-918"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ovine anti-colchicine polyclonal antibody fragments",
    "date_of_designation_or_refusal": "17/12/2010",
    "intended_use": "Treatment of colchicine poisoning",
    "eu_designation_number": "EU/3/10/825",
    "status": "Positive",
    "first_published_date": "20/01/2011",
    "last_updated_date": "25/06/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-825"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "5'-O-(trans-9''-octadecenoyl)-1-beta-D-2'-deoxy-2',2'-difluorocytidine",
    "date_of_designation_or_refusal": "28/10/2009",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/09/680",
    "status": "Withdrawn",
    "first_published_date": "18/11/2009",
    "last_updated_date": "24/06/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-680"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "porfimer sodium",
    "date_of_designation_or_refusal": "06/03/2002",
    "intended_use": "Treatment of high-grade dysplasia in Barrett's oesophagus",
    "eu_designation_number": "EU/3/02/086",
    "status": "Withdrawn",
    "first_published_date": "28/02/2007",
    "last_updated_date": "20/06/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-086"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "yttrium (90Y) antiferritin polyclonal antibodies",
    "date_of_designation_or_refusal": "02/10/2003",
    "intended_use": "Treatment of Hodgkin's lymphoma",
    "eu_designation_number": "EU/3/03/162",
    "status": "Positive",
    "first_published_date": "30/05/2007",
    "last_updated_date": "20/06/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-162"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human MHC non-restricted cytotoxic T-cell line",
    "date_of_designation_or_refusal": "30/11/2009",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/09/696",
    "status": "Positive",
    "first_published_date": "10/12/2009",
    "last_updated_date": "19/06/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-696"
  },
  {
    "medicine_name": "Mylotarg; Mylotarg",
    "related_ema_product_number": "EMEA/H/C/004204; EMEA/H/C/000705",
    "active_substance": "gemtuzumab ozogamicin",
    "date_of_designation_or_refusal": "18/10/2000",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/00/005",
    "status": "Positive",
    "first_published_date": "08/11/2004",
    "last_updated_date": "19/06/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-00-005"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "zoledronic acid",
    "date_of_designation_or_refusal": "17/04/2013",
    "intended_use": "Treatment of complex regional pain syndrome",
    "eu_designation_number": "-",
    "status": "Negative",
    "first_published_date": "23/04/2013",
    "last_updated_date": "23/04/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-complex-regional-pain-syndrome"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Deoxyribose phosphorothioate (5'-tct-ccc-agc-gtg-cgc-cat-3')",
    "date_of_designation_or_refusal": "21/11/2001",
    "intended_use": "Treatment of chronic lymphocytic leukaemia",
    "eu_designation_number": "EU/3/01/063",
    "status": "Withdrawn",
    "first_published_date": "06/01/2005",
    "last_updated_date": "09/04/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-063"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Deoxyribose phosphorothioate (5'-tct-ccc-agc-gtg-cgc-cat-3')",
    "date_of_designation_or_refusal": "20/11/2001",
    "intended_use": "Treatment of multiple myeloma",
    "eu_designation_number": "EU/3/01/065",
    "status": "Withdrawn",
    "first_published_date": "12/12/2005",
    "last_updated_date": "09/04/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-065"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Lisuride hydrogen maleate",
    "date_of_designation_or_refusal": "13/05/2011",
    "intended_use": "Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension",
    "eu_designation_number": "EU/3/11/869",
    "status": "Positive",
    "first_published_date": "31/05/2011",
    "last_updated_date": "09/04/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-869"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "siplizumab",
    "date_of_designation_or_refusal": "29/06/2006",
    "intended_use": "Treatment of T-cell and NK-cell neoplasms",
    "eu_designation_number": "EU/3/06/383",
    "status": "Withdrawn",
    "first_published_date": "23/09/2009",
    "last_updated_date": "09/04/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-383"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "porfimer sodium",
    "date_of_designation_or_refusal": "29/07/2004",
    "intended_use": "Treatment of cholangiocarcinoma",
    "eu_designation_number": "EU/3/04/215",
    "status": "Withdrawn",
    "first_published_date": "22/11/2004",
    "last_updated_date": "09/04/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-215"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "cilengitide",
    "date_of_designation_or_refusal": "15/01/2004",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/03/184",
    "status": "Withdrawn",
    "first_published_date": "08/07/2004",
    "last_updated_date": "09/04/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-184"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Hypothiocyanite;lactoferrin",
    "date_of_designation_or_refusal": "24/07/2009",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/09/654",
    "status": "Positive",
    "first_published_date": "11/09/2009",
    "last_updated_date": "20/03/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-654"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised IgG4 monoclonal antibody to the human toll-like receptor type 2",
    "date_of_designation_or_refusal": "15/05/2009",
    "intended_use": "Prevention of ischaemia/reperfusion injury associated with solid organ transplantation",
    "eu_designation_number": "EU/3/09/638",
    "status": "Positive",
    "first_published_date": "09/06/2009",
    "last_updated_date": "20/03/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-638"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tobramycin",
    "date_of_designation_or_refusal": "11/04/2006",
    "intended_use": "Treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis",
    "eu_designation_number": "EU/3/06/366",
    "status": "Withdrawn",
    "first_published_date": "15/05/2009",
    "last_updated_date": "14/03/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-366"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human histone H1.3 and recombinant human N-bis-met-histone H1.3",
    "date_of_designation_or_refusal": "20/12/2007",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/07/516",
    "status": "Positive",
    "first_published_date": "10/07/2008",
    "last_updated_date": "13/03/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-516"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pegylated L-asparaginase",
    "date_of_designation_or_refusal": "22/09/2008",
    "intended_use": "Treatment of acute lymphoblastic leukaemia",
    "eu_designation_number": "EU/3/08/569",
    "status": "Positive",
    "first_published_date": "29/06/2009",
    "last_updated_date": "13/03/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-569"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human histone H1.3 and recombinant human N-bis-met-histone H1.3",
    "date_of_designation_or_refusal": "23/02/2011",
    "intended_use": "Treatment of acute lymphoblastic leukaemia",
    "eu_designation_number": "EU/3/10/840",
    "status": "Positive",
    "first_published_date": "07/03/2011",
    "last_updated_date": "13/03/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-840"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "vorinostat",
    "date_of_designation_or_refusal": "15/04/2011",
    "intended_use": "Treatment of multiple myeloma",
    "eu_designation_number": "EU/3/11/854",
    "status": "Withdrawn",
    "first_published_date": "26/04/2011",
    "last_updated_date": "12/03/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-854"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "suberolylanilide hydroxamic acid",
    "date_of_designation_or_refusal": "21/06/2004",
    "intended_use": "Treatment of cutaneous T-cell lymphoma",
    "eu_designation_number": "EU/3/04/205",
    "status": "Withdrawn",
    "first_published_date": "11/10/2005",
    "last_updated_date": "12/03/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-205"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "vorinostat",
    "date_of_designation_or_refusal": "20/09/2010",
    "intended_use": "Treatment of malignant mesothelioma",
    "eu_designation_number": "EU/3/10/785",
    "status": "Withdrawn",
    "first_published_date": "18/10/2010",
    "last_updated_date": "12/03/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-785"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "1-[(2-Chloro-4-methoxyphenoxy)methyl]-4-[(2,6-dichlorophenoxy)methyl]benzene",
    "date_of_designation_or_refusal": "17/07/2012",
    "intended_use": "Prevention of poliomyelitis in patients with immunodeficiencies deemed at risk",
    "eu_designation_number": "EU/3/12/1021",
    "status": "Positive",
    "first_published_date": "31/08/2012",
    "last_updated_date": "12/03/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1021"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "nanoparticle albumin-bound paclitaxel",
    "date_of_designation_or_refusal": "26/11/2010",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/10/809",
    "status": "Withdrawn",
    "first_published_date": "17/12/2010",
    "last_updated_date": "11/03/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-809"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Linsitinib",
    "date_of_designation_or_refusal": "02/04/2012",
    "intended_use": "Treatment of adrenal cortical carcinoma",
    "eu_designation_number": "EU/3/12/977",
    "status": "Withdrawn",
    "first_published_date": "30/04/2012",
    "last_updated_date": "11/03/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-977"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic aortic endothelial cells cultured in a porcine gelatin matrix",
    "date_of_designation_or_refusal": "23/02/2011",
    "intended_use": "Prevention of arteriovenous access failure in haemodialysis patients",
    "eu_designation_number": "EU/3/10/843",
    "status": "Withdrawn",
    "first_published_date": "04/03/2011",
    "last_updated_date": "11/03/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-843"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(1R, 2R, 4S)-4-{(2R)-2-[(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R, 27R,34aS)-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetra-cosahydro-3H-23,2",
    "date_of_designation_or_refusal": "26/08/2005",
    "intended_use": "Treatment of soft tissue sarcoma",
    "eu_designation_number": "EU/3/05/312",
    "status": "Withdrawn",
    "first_published_date": "17/09/2009",
    "last_updated_date": "11/03/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-312"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(1R, 2R, 4S)-4-{(2R)-2-[(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R, 27R,34aS)-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetra-cosahydro-3H-23,2",
    "date_of_designation_or_refusal": "28/10/2005",
    "intended_use": "Treatment of primary malignant bone tumours",
    "eu_designation_number": "EU/3/05/321",
    "status": "Withdrawn",
    "first_published_date": "17/09/2009",
    "last_updated_date": "11/03/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-321"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "L-asparaginase encapsulated in erythrocytes",
    "date_of_designation_or_refusal": "08/02/2013",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/13/1106",
    "status": "Positive",
    "first_published_date": "04/03/2013",
    "last_updated_date": "04/03/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1106"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Cyclo-Cys-Gly-Gln-Arg-Glu-Thr-Pro-Glu-Gly-Ala-Glu-Ala-Lys-Pro-Trp-Tyr-Cys",
    "date_of_designation_or_refusal": "08/02/2013",
    "intended_use": "Treatment of high-altitude pulmonary oedema",
    "eu_designation_number": "EU/3/13/1102",
    "status": "Positive",
    "first_published_date": "04/03/2013",
    "last_updated_date": "04/03/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1102"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous dendritic cells pulsed with autologous tumour cell lysate",
    "date_of_designation_or_refusal": "15/02/2007",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/07/431",
    "status": "Positive",
    "first_published_date": "10/07/2008",
    "last_updated_date": "01/03/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-431"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant microbial lipase",
    "date_of_designation_or_refusal": "28/10/2005",
    "intended_use": "Treatment of malabsorption due to exocrine pancreatic enzyme insufficiency",
    "eu_designation_number": "EU/3/05/331",
    "status": "Withdrawn",
    "first_published_date": "13/03/2006",
    "last_updated_date": "01/03/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-331"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic motor neuron progenitor cells derived from human embryonic stem cells",
    "date_of_designation_or_refusal": "24/01/2013",
    "intended_use": "Treatment of 5q spinal muscular atrophy",
    "eu_designation_number": "EU/3/12/1088",
    "status": "Positive",
    "first_published_date": "01/03/2013",
    "last_updated_date": "01/03/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1088"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Interferon gamma",
    "date_of_designation_or_refusal": "29/10/2007",
    "intended_use": "Treatment of idiopathic pulmonary fibrosis",
    "eu_designation_number": "EU/3/07/491",
    "status": "Positive",
    "first_published_date": "02/07/2008",
    "last_updated_date": "01/03/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-491"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "synthetic double-stranded short interfering RNA oligonucleotide directed against proopiomelanocortin",
    "date_of_designation_or_refusal": "01/10/2010",
    "intended_use": "Treatment of adrenocorticotropin-dependent Cushing's syndrome",
    "eu_designation_number": "EU/3/10/798",
    "status": "Positive",
    "first_published_date": "14/10/2010",
    "last_updated_date": "28/02/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-798"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "1,5-(Butylimino)-1,5-dideoxy, D-glucitol",
    "date_of_designation_or_refusal": "18/10/2000",
    "intended_use": "Treatment of Gaucher disease",
    "eu_designation_number": "EU/3/00/006",
    "status": "Expired",
    "first_published_date": "15/05/2009",
    "last_updated_date": "27/02/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-00-006"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Bosentan",
    "date_of_designation_or_refusal": "15/02/2001",
    "intended_use": "Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension",
    "eu_designation_number": "EU/3/01/019",
    "status": "Expired",
    "first_published_date": "28/02/2007",
    "last_updated_date": "27/02/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-019"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pegvisomant",
    "date_of_designation_or_refusal": "15/02/2001",
    "intended_use": "Treatment of acromegaly",
    "eu_designation_number": "EU/3/01/023",
    "status": "Expired",
    "first_published_date": "29/11/2005",
    "last_updated_date": "27/02/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-023"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Erdosteine",
    "date_of_designation_or_refusal": "06/12/2012",
    "intended_use": "Treatment of lead toxicity",
    "eu_designation_number": "EU/3/12/1084",
    "status": "Positive",
    "first_published_date": "25/01/2013",
    "last_updated_date": "25/01/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1084"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "voclosporin",
    "date_of_designation_or_refusal": "06/12/2012",
    "intended_use": "Treatment of non-infectious uveitis",
    "eu_designation_number": "EU/3/12/1085",
    "status": "Positive",
    "first_published_date": "25/01/2013",
    "last_updated_date": "25/01/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1085"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "artesunate",
    "date_of_designation_or_refusal": "06/12/2012",
    "intended_use": "Treatment of malaria",
    "eu_designation_number": "EU/3/12/1079",
    "status": "Positive",
    "first_published_date": "25/01/2013",
    "last_updated_date": "25/01/2013",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1079"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "naloxone hydrochloride dihydrate",
    "date_of_designation_or_refusal": "08/11/2012",
    "intended_use": "Treatment of cutaneous T-cell lymphoma",
    "eu_designation_number": "EU/3/12/1057",
    "status": "Positive",
    "first_published_date": "13/12/2012",
    "last_updated_date": "13/12/2012",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1057"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "IL-12-secreting dendritic cells, loaded with autologous tumour lysate",
    "date_of_designation_or_refusal": "08/11/2012",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/12/1058",
    "status": "Positive",
    "first_published_date": "13/12/2012",
    "last_updated_date": "13/12/2012",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1058"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Erdosteine",
    "date_of_designation_or_refusal": "08/11/2012",
    "intended_use": "Treatment of mercury toxicity",
    "eu_designation_number": "EU/3/12/1067",
    "status": "Positive",
    "first_published_date": "13/12/2012",
    "last_updated_date": "13/12/2012",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1067"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Melarsoprol",
    "date_of_designation_or_refusal": "08/11/2012",
    "intended_use": "Treatment of African trypanosomiasis",
    "eu_designation_number": "EU/3/12/1068",
    "status": "Positive",
    "first_published_date": "13/12/2012",
    "last_updated_date": "13/12/2012",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1068"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Lurbinectedin",
    "date_of_designation_or_refusal": "10/10/2012",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/12/1053",
    "status": "Positive",
    "first_published_date": "16/11/2012",
    "last_updated_date": "01/01/2012",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1053"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "alpha-1 proteinase inhibitor",
    "date_of_designation_or_refusal": "10/10/2012",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/12/1045",
    "status": "Positive",
    "first_published_date": "16/11/2012",
    "last_updated_date": "16/11/2012",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1045"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "[2-Cyano-3-cyclopropyl-3-hydroxy-N-(3-methyl-4-trifluoromethylphenyl)prop-2-enamide]",
    "date_of_designation_or_refusal": "10/10/2012",
    "intended_use": "Treatment of traumatic spinal cord injury",
    "eu_designation_number": "EU/3/12/1050",
    "status": "Positive",
    "first_published_date": "16/11/2012",
    "last_updated_date": "16/11/2012",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1050"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-[4-[[(2-amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-D-gamma-glutamyl-(2S)-2-amino-beta-alanyl-L-alpha-aspartyl-L-cysteine;folic acid",
    "date_of_designation_or_refusal": "09/02/2012",
    "intended_use": "Diagnosis of positive folate-receptor status in ovarian cancer",
    "eu_designation_number": "EU/3/12/958",
    "status": "Withdrawn",
    "first_published_date": "24/02/2012",
    "last_updated_date": "12/11/2012",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-958"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Ketoconazole",
    "date_of_designation_or_refusal": "09/08/2012",
    "intended_use": "Treatment of Cushing's syndrome",
    "eu_designation_number": "EU/3/12/1031",
    "status": "Positive",
    "first_published_date": "26/09/2012",
    "last_updated_date": "26/09/2012",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1031"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "",
    "date_of_designation_or_refusal": "09/08/2012",
    "intended_use": "Treatment of primary biliary cirrhosis",
    "eu_designation_number": "EU/3/12/1041",
    "status": "Positive",
    "first_published_date": "26/09/2012",
    "last_updated_date": "26/09/2012",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1041"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "",
    "date_of_designation_or_refusal": "09/08/2012",
    "intended_use": "Treatment of Alagille syndrome",
    "eu_designation_number": "EU/3/12/1040",
    "status": "Positive",
    "first_published_date": "26/09/2012",
    "last_updated_date": "26/09/2012",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1040"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tariquidar",
    "date_of_designation_or_refusal": "21/03/2012",
    "intended_use": "treatment of P-gp positive breast cancer",
    "eu_designation_number": "-",
    "status": "Negative",
    "first_published_date": "06/09/2012",
    "last_updated_date": "06/09/2012",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-p-gp-positive-breast-cancer"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sarsasapogenin",
    "date_of_designation_or_refusal": "08/05/2008",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/08/543",
    "status": "Withdrawn",
    "first_published_date": "29/07/2008",
    "last_updated_date": "06/09/2012",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-543"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human erythrocytes encapsulating inositol hexaphosphate",
    "date_of_designation_or_refusal": "04/07/2012",
    "intended_use": "Treatment of sickle cell disease",
    "eu_designation_number": "EU/3/12/1008",
    "status": "Positive",
    "first_published_date": "24/07/2012",
    "last_updated_date": "24/07/2012",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-1008"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium nitrite",
    "date_of_designation_or_refusal": "05/03/2012",
    "intended_use": "Treatment of pulmonary arterial hypertension",
    "eu_designation_number": "EU/3/12/967",
    "status": "Positive",
    "first_published_date": "06/07/2012",
    "last_updated_date": "06/07/2012",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-967"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "yttrium (90Y)-DTPA-radiolabelled chimeric monoclonal antibody against frizzled homologue 10",
    "date_of_designation_or_refusal": "25/05/2012",
    "intended_use": "Treatment of soft tissue sarcoma",
    "eu_designation_number": "EU/3/12/994",
    "status": "Positive",
    "first_published_date": "18/06/2012",
    "last_updated_date": "18/06/2012",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-994"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human methionine proinsulin",
    "date_of_designation_or_refusal": "26/04/2012",
    "intended_use": "Treatment of retinitis pigmentosa",
    "eu_designation_number": "EU/3/12/985",
    "status": "Positive",
    "first_published_date": "18/06/2012",
    "last_updated_date": "18/06/2012",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-985"
  },
  {
    "medicine_name": "Lympreva",
    "related_ema_product_number": "EMEA/H/C/002772",
    "active_substance": "autologous tumour-derived immunoglobulin idiotype coupled to keyhole limpet hemocyanin",
    "date_of_designation_or_refusal": "28/08/2006",
    "intended_use": "Treatment of follicular lymphoma",
    "eu_designation_number": "EU/3/06/394",
    "status": "Positive",
    "first_published_date": "02/04/2009",
    "last_updated_date": "14/06/2012",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-394"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pegylated recombinant Erwinia chrysanthemi L-asparaginase",
    "date_of_designation_or_refusal": "05/08/2011",
    "intended_use": "Treatment of acute lymphoblastic leukaemia",
    "eu_designation_number": "EU/3/11/889",
    "status": "Positive",
    "first_published_date": "16/08/2011",
    "last_updated_date": "24/05/2012",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-889"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Doxycycline hyclate",
    "date_of_designation_or_refusal": "02/04/2012",
    "intended_use": "Treatment of familial amyloid polyneuropathy",
    "eu_designation_number": "EU/3/12/955",
    "status": "Positive",
    "first_published_date": "24/05/2012",
    "last_updated_date": "24/05/2012",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-955"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous urothelial and smooth muscle cells",
    "date_of_designation_or_refusal": "18/03/2008",
    "intended_use": "Treatment of spina bifida",
    "eu_designation_number": "EU/3/08/537",
    "status": "Withdrawn",
    "first_published_date": "10/07/2008",
    "last_updated_date": "24/05/2012",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-537"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous urothelial and smooth muscle cells",
    "date_of_designation_or_refusal": "08/11/2008",
    "intended_use": "Treatment of spinal cord injury",
    "eu_designation_number": "EU/3/08/574",
    "status": "Withdrawn",
    "first_published_date": "24/04/2009",
    "last_updated_date": "24/05/2012",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-574"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium thiosulfate",
    "date_of_designation_or_refusal": "02/04/2012",
    "intended_use": "Treatment of calciphylaxis",
    "eu_designation_number": "EU/3/12/979",
    "status": "Positive",
    "first_published_date": "30/04/2012",
    "last_updated_date": "30/04/2012",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-979"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Genistein sodium salt dihydrate",
    "date_of_designation_or_refusal": "02/04/2012",
    "intended_use": "Treatment of mucopolysaccharidosis type III (Sanfilippo syndrome)",
    "eu_designation_number": "EU/3/12/980",
    "status": "Positive",
    "first_published_date": "30/04/2012",
    "last_updated_date": "30/04/2012",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-980"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Dipalmitoylphosphatidylcholine, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol, sodium salt, synthetic surfactant protein C analogue and synthetic surfactant protein B analogue",
    "date_of_designation_or_refusal": "02/04/2012",
    "intended_use": "Respiratory distress syndrome in premature neonates of less than 37 weeks  of gestational age",
    "eu_designation_number": "EU/3/12/982",
    "status": "Positive",
    "first_published_date": "30/04/2012",
    "last_updated_date": "30/04/2012",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-982"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Glucagon",
    "date_of_designation_or_refusal": "05/03/2012",
    "intended_use": "Treatment of congenital hyperinsulinism",
    "eu_designation_number": "EU/3/12/960",
    "status": "Positive",
    "first_published_date": "19/04/2012",
    "last_updated_date": "19/04/2012",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-960"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Doxycycline hyclate",
    "date_of_designation_or_refusal": "05/03/2012",
    "intended_use": "Treatment of systemic amyloidosis caused by beta-2 microglobulin",
    "eu_designation_number": "EU/3/12/961",
    "status": "Positive",
    "first_published_date": "19/04/2012",
    "last_updated_date": "19/04/2012",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-12-961"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Lentiviral vector expressing the truncated form of human tyrosine hydroxylase gene, human aromatic L amino-acid decarboxylase gene, human GTP-cyclohydrolase 1 gene",
    "date_of_designation_or_refusal": "09/09/2010",
    "intended_use": "Treatment of off-periods in adult patients with advanced Parkinson's disease",
    "eu_designation_number": "-",
    "status": "Negative",
    "first_published_date": "30/03/2012",
    "last_updated_date": "30/03/2012",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-periods-adult-patients-advanced-parkinson039s-disease"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tecovirimat",
    "date_of_designation_or_refusal": "01/10/2010",
    "intended_use": "Treatment of cowpox infection",
    "eu_designation_number": "EU/3/10/799",
    "status": "Withdrawn",
    "first_published_date": "14/10/2010",
    "last_updated_date": "28/03/2012",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-799"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic human dermal fibroblasts",
    "date_of_designation_or_refusal": "20/09/2010",
    "intended_use": "Treatment of epidermolysis bullosa",
    "eu_designation_number": "EU/3/10/774",
    "status": "Positive",
    "first_published_date": "18/10/2010",
    "last_updated_date": "09/02/2012",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-774"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant kallikrein inhibitor",
    "date_of_designation_or_refusal": "29/01/2010",
    "intended_use": "Treatment of Netherton syndrome",
    "eu_designation_number": "EU/3/09/712",
    "status": "Positive",
    "first_published_date": "25/02/2010",
    "last_updated_date": "09/02/2012",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-712"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Pagibaximab",
    "date_of_designation_or_refusal": "09/06/2010",
    "intended_use": "Prevention of sepsis caused by Gram-positive pathogens in premature infants less than or equal to 34",
    "eu_designation_number": "EU/3/10/743",
    "status": "Withdrawn",
    "first_published_date": "23/06/2010",
    "last_updated_date": "02/02/2012",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-743"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "eltrombopag olamine",
    "date_of_designation_or_refusal": "03/08/2007",
    "intended_use": "Treatment of idiopathic thrombocytopenic purpura",
    "eu_designation_number": "EU/3/07/467",
    "status": "Withdrawn",
    "first_published_date": "21/09/2009",
    "last_updated_date": "12/01/2012",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-467"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "nabilone",
    "date_of_designation_or_refusal": "16/01/2011",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "-",
    "status": "Negative",
    "first_published_date": "20/12/2011",
    "last_updated_date": "20/12/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-amyotrophic-lateral-sclerosis"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Gallium (68Ga)-pasireotide tetraxetan",
    "date_of_designation_or_refusal": "27/10/2011",
    "intended_use": "Diagnosis of gastro-entero-pancreatic neuroendocrine tumours",
    "eu_designation_number": "EU/3/11/920",
    "status": "Positive",
    "first_published_date": "23/11/2011",
    "last_updated_date": "23/11/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-920"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adeno-associated viral vector containing the human alpha-N-acetylglucosaminidase gene",
    "date_of_designation_or_refusal": "27/10/2011",
    "intended_use": "Treatment of mucopolysaccharidosis type IIIB (Sanfilippo B syndrome)",
    "eu_designation_number": "EU/3/11/917",
    "status": "Positive",
    "first_published_date": "23/11/2011",
    "last_updated_date": "23/11/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-917"
  },
  {
    "medicine_name": "Spanidin; Spanidin",
    "related_ema_product_number": "EMEA/H/C/000809; EMEA/H/C/000809",
    "active_substance": "gusperimus trihydrochloride",
    "date_of_designation_or_refusal": "29/03/2001",
    "intended_use": "Treatment of Wegener's granulomatosis",
    "eu_designation_number": "EU/3/01/034",
    "status": "Positive",
    "first_published_date": "03/03/2009",
    "last_updated_date": "18/11/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-034"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "dextran sulfate",
    "date_of_designation_or_refusal": "05/08/2011",
    "intended_use": "Treatment for mobilisation of progenitor cells prior to stem cell transplantation",
    "eu_designation_number": "EU/3/11/883",
    "status": "Positive",
    "first_published_date": "16/08/2011",
    "last_updated_date": "18/11/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-883"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "dextran sulfate",
    "date_of_designation_or_refusal": "09/10/2009",
    "intended_use": "Prevention of graft rejection during pancreatic islet transplantation",
    "eu_designation_number": "EU/3/09/669",
    "status": "Positive",
    "first_published_date": "20/10/2009",
    "last_updated_date": "18/11/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-669"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "estradiol hemihydrate;progesterone",
    "date_of_designation_or_refusal": "11/04/2005",
    "intended_use": "Bronchopulmonary dysplasia in premature neonates of less than 30 weeks of gestational age",
    "eu_designation_number": "EU/3/05/275",
    "status": "Positive",
    "first_published_date": "04/01/2006",
    "last_updated_date": "18/11/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-275"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Colistimethate sodium",
    "date_of_designation_or_refusal": "19/02/2002",
    "intended_use": "Treatment of Pseudomonas aeruginosa lung infection (including colonisation) in cystic fibrosis",
    "eu_designation_number": "EU/3/02/088",
    "status": "Withdrawn",
    "first_published_date": "08/01/2003",
    "last_updated_date": "18/11/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-088"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Vaccinia GM-CSF/TK-deactivated virus",
    "date_of_designation_or_refusal": "26/11/2009",
    "intended_use": "Treatment of hepatocellular carcinoma (pexastimogene devacirepvec)",
    "eu_designation_number": "EU/3/09/700",
    "status": "Positive",
    "first_published_date": "10/12/2009",
    "last_updated_date": "18/11/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-700"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human arylsulfatase A",
    "date_of_designation_or_refusal": "09/07/2003",
    "intended_use": "treatment of metachromatic leukodystrophy",
    "eu_designation_number": "EU/3/03/158",
    "status": "Withdrawn",
    "first_published_date": "18/08/2008",
    "last_updated_date": "18/11/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-158"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "temsirolimus",
    "date_of_designation_or_refusal": "07/11/2006",
    "intended_use": "Treatment of mantle cell lymphoma",
    "eu_designation_number": "EU/3/06/420",
    "status": "Expired",
    "first_published_date": "02/04/2009",
    "last_updated_date": "18/11/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-420"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "alpha-galactosidase A",
    "date_of_designation_or_refusal": "08/08/2000",
    "intended_use": "Treatment of Fabry disease",
    "eu_designation_number": "EU/3/00/003",
    "status": "Expired",
    "first_published_date": "19/11/2009",
    "last_updated_date": "18/11/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-00-003"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adrenomedullin",
    "date_of_designation_or_refusal": "09/06/2010",
    "intended_use": "Treatment of acute lung Injury",
    "eu_designation_number": "EU/3/10/744",
    "status": "Positive",
    "first_published_date": "23/06/2010",
    "last_updated_date": "18/11/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-744"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "",
    "date_of_designation_or_refusal": "23/03/2010",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/10/729",
    "status": "Withdrawn",
    "first_published_date": "26/03/2010",
    "last_updated_date": "18/11/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-729"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "alpha-galactosidase A",
    "date_of_designation_or_refusal": "08/08/2000",
    "intended_use": "Treatment of Fabry disease",
    "eu_designation_number": "EU/3/00/002",
    "status": "Expired",
    "first_published_date": "18/10/2010",
    "last_updated_date": "18/11/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-00-002"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "naptumomab estafenatox",
    "date_of_designation_or_refusal": "14/09/2007",
    "intended_use": "Treatment of renal-cell carcinoma",
    "eu_designation_number": "EU/3/07/480",
    "status": "Positive",
    "first_published_date": "22/01/2008",
    "last_updated_date": "11/11/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-480"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Lintuzumab",
    "date_of_designation_or_refusal": "30/04/2009",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/09/627",
    "status": "Withdrawn",
    "first_published_date": "12/05/2009",
    "last_updated_date": "11/11/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-627"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Lintuzumab",
    "date_of_designation_or_refusal": "29/04/2009",
    "intended_use": "Treatment of myelodysplastic syndromes",
    "eu_designation_number": "EU/3/09/626",
    "status": "Withdrawn",
    "first_published_date": "12/05/2009",
    "last_updated_date": "11/11/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-626"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "chimeric anti-interleukin-6 monoclonal antibody",
    "date_of_designation_or_refusal": "30/06/2003",
    "intended_use": "Treatment of renal-cell carcinoma",
    "eu_designation_number": "EU/3/03/148",
    "status": "Withdrawn",
    "first_published_date": "08/07/2003",
    "last_updated_date": "11/11/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-148"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "20-pentaerythritol poly (oxy-1,2-ethanediyl)-carboxymethyl-glycinate-7-ethyl-10-hydroxycamptothecine 10-[1,4'-bipiperidine]-1'-carboxylate",
    "date_of_designation_or_refusal": "27/09/2011",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/11/900",
    "status": "Positive",
    "first_published_date": "17/10/2011",
    "last_updated_date": "17/10/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-900"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "NH2-Cys-Ser-Ser-Val-Thr-Ala-Trp-Thr-Thr-Gly-Cys-Gly-CONH2",
    "date_of_designation_or_refusal": "27/09/2011",
    "intended_use": "Treatment of traumatic spinal cord injury",
    "eu_designation_number": "EU/3/11/910",
    "status": "Positive",
    "first_published_date": "17/10/2011",
    "last_updated_date": "17/10/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-910"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "5-[1-(2,6-Dichlorobenzyl)piperidin-4-ylmethoxy]quinazoline-2,4-diamine dihydrochloride",
    "date_of_designation_or_refusal": "30/08/2011",
    "intended_use": "Treatment of 5q spinal muscular atrophy",
    "eu_designation_number": "EU/3/11/892",
    "status": "Positive",
    "first_published_date": "21/09/2011",
    "last_updated_date": "21/09/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-892"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "cardiotrophin-1",
    "date_of_designation_or_refusal": "30/08/2011",
    "intended_use": "Treatment of acute liver failure",
    "eu_designation_number": "EU/3/11/893",
    "status": "Positive",
    "first_published_date": "21/09/2011",
    "last_updated_date": "21/09/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-893"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Iodine (131I) Anti-CEA sheep-human chimeric monoclonal antibody",
    "date_of_designation_or_refusal": "08/05/2003",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/03/142",
    "status": "Withdrawn",
    "first_published_date": "21/05/2003",
    "last_updated_date": "06/09/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-142"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "plitidepsin",
    "date_of_designation_or_refusal": "23/02/2011",
    "intended_use": "Treatment of post-essential thrombocythaemia myelofibrosis",
    "eu_designation_number": "EU/3/10/838",
    "status": "Withdrawn",
    "first_published_date": "07/03/2011",
    "last_updated_date": "06/09/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-838"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "streptococcus pyogenes Su strain cells treated with benzylpenicillin",
    "date_of_designation_or_refusal": "29/01/2010",
    "intended_use": "Treatment of congenital lymphatic malformations",
    "eu_designation_number": "EU/3/09/714",
    "status": "Withdrawn",
    "first_published_date": "25/02/2010",
    "last_updated_date": "06/09/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-714"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "plitidepsin",
    "date_of_designation_or_refusal": "23/02/2011",
    "intended_use": "Treatment of post-polycythaemia vera myelofibrosis",
    "eu_designation_number": "EU/3/10/839",
    "status": "Withdrawn",
    "first_published_date": "07/03/2011",
    "last_updated_date": "06/09/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-839"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "everolimus",
    "date_of_designation_or_refusal": "05/06/2007",
    "intended_use": "Treatment of renal-cell carcinoma",
    "eu_designation_number": "EU/3/07/449",
    "status": "Withdrawn",
    "first_published_date": "19/07/2007",
    "last_updated_date": "06/09/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-449"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "plitidepsin",
    "date_of_designation_or_refusal": "23/02/2011",
    "intended_use": "Treatment of primary myelofibrosis",
    "eu_designation_number": "EU/3/10/837",
    "status": "Withdrawn",
    "first_published_date": "07/03/2011",
    "last_updated_date": "06/09/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-837"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "eptacog alfa (activated)",
    "date_of_designation_or_refusal": "20/03/2007",
    "intended_use": "Treatment of post-neonatal intracerebral haemorrhage",
    "eu_designation_number": "EU/3/07/436",
    "status": "Withdrawn",
    "first_published_date": "04/12/2007",
    "last_updated_date": "06/09/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-436"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "aplidine",
    "date_of_designation_or_refusal": "09/07/2003",
    "intended_use": "Treatment of acute lymphoblastic leukaemia",
    "eu_designation_number": "EU/3/03/151",
    "status": "Withdrawn",
    "first_published_date": "12/12/2005",
    "last_updated_date": "06/09/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-151"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "dihydroartemisinin;piperaquine",
    "date_of_designation_or_refusal": "03/08/2007",
    "intended_use": "Treatment of malaria",
    "eu_designation_number": "EU/3/07/468",
    "status": "Withdrawn",
    "first_published_date": "29/07/2008",
    "last_updated_date": "05/09/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-468"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ambrisentan",
    "date_of_designation_or_refusal": "01/10/2010",
    "intended_use": "Treatment idiopathic pulmonary fibrosis",
    "eu_designation_number": "EU/3/10/790",
    "status": "Withdrawn",
    "first_published_date": "14/10/2010",
    "last_updated_date": "05/09/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-790"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Methyl O-4-O-[2-[2-[2-[2-[[N-[(1R)-1-[[4-(aminoiminomethyl)phenyl]methyl]-2-oxo-2-(1-piperidinyl)ethyl]-N2-[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]-L-α-asparaginyl-4-aminobutanoyl-N6-[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]-L-lysyl]amino]ethoxy]ethoxy]ethoxy]ethyl]-2,3-di-O-methyl-6-O-sulfo-α-D-glucopyranosyl....",
    "date_of_designation_or_refusal": "05/08/2011",
    "intended_use": "Prevention of ischaemia/reperfusion injury associated with solid organ transplantation",
    "eu_designation_number": "EU/3/11/884",
    "status": "Positive",
    "first_published_date": "16/08/2011",
    "last_updated_date": "16/08/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-884"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "viral vector containing DNA encoding the human SMN protein",
    "date_of_designation_or_refusal": "21/06/2011",
    "intended_use": "Treatment of 5q spinal muscular atrophy",
    "eu_designation_number": "EU/3/11/876",
    "status": "Positive",
    "first_published_date": "12/07/2011",
    "last_updated_date": "12/07/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-876"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic T cells encoding an exogenous TK gene",
    "date_of_designation_or_refusal": "21/06/2011",
    "intended_use": "Treatment of acute lymphoblastic leukaemia",
    "eu_designation_number": "EU/3/11/878)",
    "status": "Positive",
    "first_published_date": "12/07/2011",
    "last_updated_date": "12/07/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-878"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "vincristine sulfate liposomes",
    "date_of_designation_or_refusal": "08/07/2008",
    "intended_use": "Treatment of acute lymphoblastic leukaemia",
    "eu_designation_number": "EU/3/08/555",
    "status": "Positive",
    "first_published_date": "29/06/2009",
    "last_updated_date": "21/06/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-555"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human insulin-like growth factor-I;recombinant human insulin-like growth factor binding protein-3",
    "date_of_designation_or_refusal": "21/10/2004",
    "intended_use": "Treatment of Rabson-Mendenhall syndrome",
    "eu_designation_number": "EU/3/04/237",
    "status": "Withdrawn",
    "first_published_date": "20/02/2009",
    "last_updated_date": "21/06/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-237"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human insulin-like growth factor-I;recombinant human insulin-like growth factor binding protein-3",
    "date_of_designation_or_refusal": "21/10/2004",
    "intended_use": "Treatment of type A extreme insulin resistance syndrome",
    "eu_designation_number": "EU/3/04/236",
    "status": "Withdrawn",
    "first_published_date": "21/06/2011",
    "last_updated_date": "21/06/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-236"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human insulin-like growth factor-I;recombinant human insulin-like growth factor binding protein-3",
    "date_of_designation_or_refusal": "09/07/2003",
    "intended_use": "Treatment of primary growth hormone insensitivity syndrome (laron syndrome)",
    "eu_designation_number": "EU/3/03/159",
    "status": "Withdrawn",
    "first_published_date": "30/05/2007",
    "last_updated_date": "21/06/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-159"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human insulin-like growth factor-I;recombinant human insulin-like growth factor binding protein-3",
    "date_of_designation_or_refusal": "21/10/2004",
    "intended_use": "Treatment of leprechaunism",
    "eu_designation_number": "EU/3/04/238",
    "status": "Withdrawn",
    "first_published_date": "20/02/2009",
    "last_updated_date": "21/06/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-238"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Budesonide",
    "date_of_designation_or_refusal": "03/11/2006",
    "intended_use": "Treatment of graft-versus-host disease",
    "eu_designation_number": "EU/3/06/413",
    "status": "Positive",
    "first_published_date": "20/02/2009",
    "last_updated_date": "21/06/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-413"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant histidine-tagged idiotype immunoglobulin Fab fragment of clonal B-cell receptors",
    "date_of_designation_or_refusal": "21/12/2004",
    "intended_use": "Treatment of multiple myeloma",
    "eu_designation_number": "EU/3/04/248",
    "status": "Positive",
    "first_published_date": "06/01/2006",
    "last_updated_date": "01/06/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-248"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant P-selectin glycoprotein immunoglobulin",
    "date_of_designation_or_refusal": "22/05/2006",
    "intended_use": "Prevention of  post transplantation graft dysfunction",
    "eu_designation_number": "EU/3/06/376",
    "status": "Positive",
    "first_published_date": "24/02/2009",
    "last_updated_date": "01/06/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-376"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant histidine-tagged idiotype immunoglobulin Fab fragment of clonal B-cell receptors",
    "date_of_designation_or_refusal": "21/12/2004",
    "intended_use": "Treatment of mantle cell lymphoma",
    "eu_designation_number": "EU/3/04/250",
    "status": "Positive",
    "first_published_date": "06/01/2006",
    "last_updated_date": "01/06/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-250"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pazopanib hydrochloride",
    "date_of_designation_or_refusal": "29/06/2006",
    "intended_use": "Treatment of renal-cell carcinoma",
    "eu_designation_number": "EU/3/06/382",
    "status": "Withdrawn",
    "first_published_date": "20/02/2009",
    "last_updated_date": "01/06/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-382"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "abetimus sodium",
    "date_of_designation_or_refusal": "20/11/2001",
    "intended_use": "Treatment of lupus nephritis",
    "eu_designation_number": "EU/3/01/064",
    "status": "Withdrawn",
    "first_published_date": "03/03/2009",
    "last_updated_date": "31/05/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-064"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant histidine-tagged idiotype immunoglobulin Fab fragment of clonal B-cell receptors",
    "date_of_designation_or_refusal": "24/07/2009",
    "intended_use": "Treatment of diffuse large B-cell lymphoma",
    "eu_designation_number": "EU/3/09/656",
    "status": "Positive",
    "first_published_date": "11/09/2009",
    "last_updated_date": "31/05/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-656"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant histidine-tagged idiotype immunoglobulin Fab fragment of clonal B-cell receptors",
    "date_of_designation_or_refusal": "23/12/2004",
    "intended_use": "Treatment of follicular lymphoma",
    "eu_designation_number": "EU/3/04/249",
    "status": "Positive",
    "first_published_date": "06/01/2006",
    "last_updated_date": "31/05/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-249"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "apomorphine hydrochloride",
    "date_of_designation_or_refusal": "13/05/2011",
    "intended_use": "Treatment of moderate and severe traumatic brain injury",
    "eu_designation_number": "EU/3/11/862",
    "status": "Positive",
    "first_published_date": "27/05/2011",
    "last_updated_date": "27/05/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-862"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazolediamine dihydrochloride monohydrate",
    "date_of_designation_or_refusal": "27/02/2009",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/09/616",
    "status": "Positive",
    "first_published_date": "30/10/2009",
    "last_updated_date": "19/05/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-616"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human C1 inhibitor",
    "date_of_designation_or_refusal": "08/10/2009",
    "intended_use": "Treatment of angioedema caused by C1 inhibitor deficiency",
    "eu_designation_number": "EU/3/09/668",
    "status": "Withdrawn",
    "first_published_date": "20/10/2009",
    "last_updated_date": "19/05/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-668"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid",
    "date_of_designation_or_refusal": "22/10/2007",
    "intended_use": "Treatment of hepatocellular carcinoma",
    "eu_designation_number": "EU/3/07/497",
    "status": "Withdrawn",
    "first_published_date": "29/07/2008",
    "last_updated_date": "18/05/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-497"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "talampanel",
    "date_of_designation_or_refusal": "29/04/2009",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/09/631",
    "status": "Withdrawn",
    "first_published_date": "12/05/2009",
    "last_updated_date": "18/05/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-631"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Paromomycin sulfate",
    "date_of_designation_or_refusal": "11/04/2005",
    "intended_use": "Treatment of visceral leishmaniasis",
    "eu_designation_number": "EU/3/05/271",
    "status": "Withdrawn",
    "first_published_date": "01/07/2005",
    "last_updated_date": "18/05/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-271"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human residue 41 glutamic acid to glutamine variant of interferon alfa-2b",
    "date_of_designation_or_refusal": "19/01/2009",
    "intended_use": "Treatment of Behçet's Disease",
    "eu_designation_number": "EU/3/08/606",
    "status": "Withdrawn",
    "first_published_date": "29/06/2009",
    "last_updated_date": "18/05/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-606"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "amonafide L-malate",
    "date_of_designation_or_refusal": "22/10/2007",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/07/483",
    "status": "Withdrawn",
    "first_published_date": "17/09/2009",
    "last_updated_date": "18/05/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-483"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "26 base single stranded phosphodiester DNA oligonucleotide",
    "date_of_designation_or_refusal": "08/10/2009",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/09/662",
    "status": "Withdrawn",
    "first_published_date": "20/10/2009",
    "last_updated_date": "18/05/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-662"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pixantrone dimaleate",
    "date_of_designation_or_refusal": "02/02/2010",
    "intended_use": "Treatment of diffuse large B-cell lymphoma",
    "eu_designation_number": "EU/3/09/722",
    "status": "Withdrawn",
    "first_published_date": "04/03/2010",
    "last_updated_date": "18/05/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-722"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "26 base single stranded phosphodiester DNA oligonucleotide",
    "date_of_designation_or_refusal": "16/02/2006",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/06/352",
    "status": "Withdrawn",
    "first_published_date": "17/09/2009",
    "last_updated_date": "18/05/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-352"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "26 base single stranded phosphodiester DNA oligonucleotide",
    "date_of_designation_or_refusal": "16/02/2006",
    "intended_use": "Treatment of renal-cell carcinoma",
    "eu_designation_number": "EU/3/06/353",
    "status": "Withdrawn",
    "first_published_date": "17/09/2009",
    "last_updated_date": "18/05/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-353"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ribavirin",
    "date_of_designation_or_refusal": "08/03/2001",
    "intended_use": "Treatment of adenovirus infection in immunocompromised patients",
    "eu_designation_number": "EU/3/01/029",
    "status": "Withdrawn",
    "first_published_date": "03/03/2009",
    "last_updated_date": "07/05/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-029"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ribavirin",
    "date_of_designation_or_refusal": "14/02/2001",
    "intended_use": "Treatment of haemorrhagic fever with renal syndrome",
    "eu_designation_number": "EU/3/01/024",
    "status": "Withdrawn",
    "first_published_date": "03/03/2009",
    "last_updated_date": "07/05/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-024"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pemetrexed disodium",
    "date_of_designation_or_refusal": "17/09/2001",
    "intended_use": "Treatment of malignant mesothelioma",
    "eu_designation_number": "EU/3/01/060",
    "status": "Withdrawn",
    "first_published_date": "03/03/2009",
    "last_updated_date": "06/05/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-060"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "xaliproden hydrochloride",
    "date_of_designation_or_refusal": "17/01/2001",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/00/015",
    "status": "Withdrawn",
    "first_published_date": "11/03/2009",
    "last_updated_date": "06/05/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-00-015"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Fomepizole",
    "date_of_designation_or_refusal": "30/05/2001",
    "intended_use": "Treatment of methanol poisoning",
    "eu_designation_number": "EU/3/01/040",
    "status": "Withdrawn",
    "first_published_date": "24/02/2009",
    "last_updated_date": "06/05/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-040"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human engineered monoclonal antibody specific for transforming growth factor β2",
    "date_of_designation_or_refusal": "30/05/2001",
    "intended_use": "Prevention of scarring in glaucoma filtration surgical procedures",
    "eu_designation_number": "EU/3/01/042",
    "status": "Withdrawn",
    "first_published_date": "17/09/2009",
    "last_updated_date": "05/05/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-042"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant thymidine phosphorylase encapsulated in autologous erythrocytes",
    "date_of_designation_or_refusal": "15/04/2011",
    "intended_use": "Treatment of mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)",
    "eu_designation_number": "EU/3/11/856",
    "status": "Positive",
    "first_published_date": "26/04/2011",
    "last_updated_date": "26/04/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-856"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "R-baclofen",
    "date_of_designation_or_refusal": "15/04/2011",
    "intended_use": "Treatment of fragile X syndrome",
    "eu_designation_number": "EU/3/11/858",
    "status": "Positive",
    "first_published_date": "26/04/2011",
    "last_updated_date": "26/04/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-858"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Metastable technetium 99 [99mTc] demogastrin 2",
    "date_of_designation_or_refusal": "28/08/2006",
    "intended_use": "Diagnosis of medullary thyroid carcinoma",
    "eu_designation_number": "EU/3/06/400",
    "status": "Positive",
    "first_published_date": "24/04/2009",
    "last_updated_date": "12/04/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-400"
  },
  {
    "medicine_name": "Folotyn; Folotyn",
    "related_ema_product_number": "EMEA/H/C/002096; EMEA/H/C/002096",
    "active_substance": "pralatrexate",
    "date_of_designation_or_refusal": "13/04/2007",
    "intended_use": "Treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)",
    "eu_designation_number": "EU/3/07/444",
    "status": "Positive",
    "first_published_date": "02/07/2008",
    "last_updated_date": "07/04/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-444"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "soluble yeast beta-1,3/1,6-glucan",
    "date_of_designation_or_refusal": "16/06/2005",
    "intended_use": "Prevention of oral mucositis in head and neck cancer patients undergoing radiation therapy",
    "eu_designation_number": "EU/3/05/294",
    "status": "Positive",
    "first_published_date": "26/06/2005",
    "last_updated_date": "07/04/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-294"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant adeno-associated viral vector containing human acid alfa-glucosidase-gene",
    "date_of_designation_or_refusal": "09/07/2007",
    "intended_use": "Treatment of glycogen storage disease type II (Pompe's disease)",
    "eu_designation_number": "EU/3/07/454",
    "status": "Withdrawn",
    "first_published_date": "04/12/2007",
    "last_updated_date": "07/04/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-454"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N'-(5-chloro-2-hydroxy-3-methylbenzylidene)-2,4-dihydroxybenzhydrazide",
    "date_of_designation_or_refusal": "22/09/2008",
    "intended_use": "Treatment of partial deep dermal and full-thickness burns",
    "eu_designation_number": "EU/3/08/568",
    "status": "Positive",
    "first_published_date": "24/04/2009",
    "last_updated_date": "06/04/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-568"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pralatrexate",
    "date_of_designation_or_refusal": "19/01/2009",
    "intended_use": "Treatment of non-papillary transitional cell carcinoma of the urinary bladder",
    "eu_designation_number": "EU/3/08/603",
    "status": "Positive",
    "first_published_date": "29/06/2009",
    "last_updated_date": "06/04/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-603"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "4-Amino-5-oxo-4 (pyridinium-1-ylmethyl) proline",
    "date_of_designation_or_refusal": "16/02/2006",
    "intended_use": "Treatment of renal-cell carcinoma",
    "eu_designation_number": "EU/3/06/356",
    "status": "Positive",
    "first_published_date": "24/08/2006",
    "last_updated_date": "04/04/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-356"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "patupilone",
    "date_of_designation_or_refusal": "05/11/2009",
    "intended_use": "Treatment of fallopian tube cancer",
    "eu_designation_number": "EU/3/09/688",
    "status": "Withdrawn",
    "first_published_date": "18/11/2009",
    "last_updated_date": "29/03/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-688"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sapropterin",
    "date_of_designation_or_refusal": "26/08/2005",
    "intended_use": "Treatment of hyperphenylalaninaemia",
    "eu_designation_number": "EU/3/05/308",
    "status": "Withdrawn",
    "first_published_date": "04/01/2006",
    "last_updated_date": "29/03/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-308"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Murine monoclonal antibody to GD2",
    "date_of_designation_or_refusal": "12/06/2009",
    "intended_use": "Treatment of neuroblastoma",
    "eu_designation_number": "EU/3/09/644",
    "status": "Withdrawn",
    "first_published_date": "01/07/2009",
    "last_updated_date": "28/03/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-644"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tegafur;gimeracil;oteracil potassium",
    "date_of_designation_or_refusal": "20/12/2007",
    "intended_use": "Treatment of gastric cancer",
    "eu_designation_number": "EU/3/07/515",
    "status": "Withdrawn",
    "first_published_date": "23/09/2009",
    "last_updated_date": "28/03/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-515"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Fenretinide",
    "date_of_designation_or_refusal": "30/01/2007",
    "intended_use": "Treatment of soft tissue sarcoma",
    "eu_designation_number": "EU/3/06/427",
    "status": "Withdrawn",
    "first_published_date": "29/07/2008",
    "last_updated_date": "25/03/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-427"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Fenretinide",
    "date_of_designation_or_refusal": "26/01/2007",
    "intended_use": "Treatment of primary malignant bone tumours",
    "eu_designation_number": "EU/3/06/426",
    "status": "Withdrawn",
    "first_published_date": "29/07/2008",
    "last_updated_date": "25/03/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-426"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "17-(Allylamino)-17-demethoxygeldanamycin, hydroquinone hydrochloride",
    "date_of_designation_or_refusal": "29/11/2007",
    "intended_use": "Treatment of malignant gastrointestinal stromal tumours",
    "eu_designation_number": "EU/3/07/512",
    "status": "Withdrawn",
    "first_published_date": "17/09/2009",
    "last_updated_date": "25/03/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-512"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human monoclonal antibody against CD4",
    "date_of_designation_or_refusal": "14/04/2004",
    "intended_use": "Treatment of cutaneous T-cell lymphoma",
    "eu_designation_number": "EU/3/04/198",
    "status": "Positive",
    "first_published_date": "18/08/2008",
    "last_updated_date": "10/03/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-198"
  },
  {
    "medicine_name": "Elelyso",
    "related_ema_product_number": "EMEA/H/C/002250",
    "active_substance": "taliglucerase alfa",
    "date_of_designation_or_refusal": "23/03/2010",
    "intended_use": "Treatment of Gaucher disease",
    "eu_designation_number": "EU/3/10/726",
    "status": "Positive",
    "first_published_date": "26/03/2010",
    "last_updated_date": "10/03/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-726"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "zanolimumab",
    "date_of_designation_or_refusal": "20/03/2007",
    "intended_use": "Treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic/disseminated)",
    "eu_designation_number": "EU/3/07/438",
    "status": "Positive",
    "first_published_date": "18/08/2008",
    "last_updated_date": "10/03/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-438"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pralatrexate",
    "date_of_designation_or_refusal": "10/06/2010",
    "intended_use": "Treatment of cutaneous T-cell lymphoma",
    "eu_designation_number": "EU/3/10/741",
    "status": "Positive",
    "first_published_date": "24/06/2010",
    "last_updated_date": "10/03/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-741"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "paquinimod",
    "date_of_designation_or_refusal": "23/02/2011",
    "intended_use": "Treatment of systemic sclerosis",
    "eu_designation_number": "EU/3/10/836",
    "status": "Positive",
    "first_published_date": "07/03/2011",
    "last_updated_date": "07/03/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-836"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous tumour-derived immunoglobulin idiotype coupled to keyhole limpet hemocyanin",
    "date_of_designation_or_refusal": "23/02/2011",
    "intended_use": "Treatment of mantle cell lymphoma",
    "eu_designation_number": "EU/3/10/831",
    "status": "Positive",
    "first_published_date": "04/03/2011",
    "last_updated_date": "04/03/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-831"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "paclitaxel",
    "date_of_designation_or_refusal": "23/02/2011",
    "intended_use": "Treatment of oesophagus carcinoma",
    "eu_designation_number": "EU/3/10/846",
    "status": "Positive",
    "first_published_date": "04/03/2011",
    "last_updated_date": "04/03/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-846"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "silibinin-C-2',3-dihydrogensuccinate, disodium salt",
    "date_of_designation_or_refusal": "17/12/2010",
    "intended_use": "Prevention of recurrent hepatitis C in liver transplant recipients",
    "eu_designation_number": "EU/3/10/828",
    "status": "Positive",
    "first_published_date": "20/01/2011",
    "last_updated_date": "20/01/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-828"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tesetaxel",
    "date_of_designation_or_refusal": "17/12/2010",
    "intended_use": "Treatment of gastric cancer",
    "eu_designation_number": "EU/3/10/829",
    "status": "Positive",
    "first_published_date": "20/01/2011",
    "last_updated_date": "20/01/2011",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-829"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "dexamethasone",
    "date_of_designation_or_refusal": "04/08/2010",
    "intended_use": "Treatment of non-infectious uveitis affecting the posterior segment of the eye",
    "eu_designation_number": "EU/3/10/763",
    "status": "Withdrawn",
    "first_published_date": "11/08/2010",
    "last_updated_date": "19/11/2010",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-763"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ranpirnase",
    "date_of_designation_or_refusal": "29/03/2001",
    "intended_use": "Treatment of  malignant mesothelioma",
    "eu_designation_number": "EU/3/01/033",
    "status": "Withdrawn",
    "first_published_date": "03/03/2009",
    "last_updated_date": "19/11/2010",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-033"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "anti-EphA2 monoclonal antibody conjugated to maleimidocaproyl monomethylauristatin phenylalanine",
    "date_of_designation_or_refusal": "28/10/2009",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/09/682",
    "status": "Withdrawn",
    "first_published_date": "18/11/2009",
    "last_updated_date": "19/11/2010",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-682"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "talampanel",
    "date_of_designation_or_refusal": "12/06/2009",
    "intended_use": "Treatment of amyotrophic lateral sclerosis",
    "eu_designation_number": "EU/3/09/646",
    "status": "Withdrawn",
    "first_published_date": "01/07/2009",
    "last_updated_date": "18/11/2010",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-646"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "anti-von Willebrand aptamer",
    "date_of_designation_or_refusal": "03/06/2008",
    "intended_use": "Treatment of thrombotic thrombocytopenic purpura",
    "eu_designation_number": "EU/3/08/547",
    "status": "Withdrawn",
    "first_published_date": "29/07/2008",
    "last_updated_date": "18/11/2010",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-547"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "adenovirus-interferon gamma-coding DNA sequence",
    "date_of_designation_or_refusal": "09/07/2003",
    "intended_use": "Treatment of cutaneous T-cell lymphoma",
    "eu_designation_number": "EU/3/03/150",
    "status": "Withdrawn",
    "first_published_date": "23/10/2003",
    "last_updated_date": "18/11/2010",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-150"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human C1-inhibitor",
    "date_of_designation_or_refusal": "11/05/2001",
    "intended_use": "Treatment of angioedema caused by C1 inhibitor deficiency",
    "eu_designation_number": "EU/3/01/036",
    "status": "Withdrawn",
    "first_published_date": "15/05/2009",
    "last_updated_date": "18/11/2010",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-036"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(R, S)-3-(bromomethyl)-3-butanol-1-yl-disphosphate",
    "date_of_designation_or_refusal": "29/07/2004",
    "intended_use": "Treatment of renal-cell carcinoma",
    "eu_designation_number": "EU/3/04/218",
    "status": "Withdrawn",
    "first_published_date": "30/05/2007",
    "last_updated_date": "18/11/2010",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-218"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human monoclonal hepatitis B immunoglobulins",
    "date_of_designation_or_refusal": "23/02/2004",
    "intended_use": "Prevention of hepatitis-B re-infection following liver transplantation",
    "eu_designation_number": "EU/3/04/187",
    "status": "Withdrawn",
    "first_published_date": "10/07/2004",
    "last_updated_date": "18/11/2010",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-187"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "thalidomide",
    "date_of_designation_or_refusal": "20/11/2001",
    "intended_use": "Treatment of erythema nodosum leprosum (ENL) or type II lepra reactions",
    "eu_designation_number": "EU/3/01/066",
    "status": "Withdrawn",
    "first_published_date": "20/02/2009",
    "last_updated_date": "18/11/2010",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-066"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic T cells encoding an exogenous TK gene",
    "date_of_designation_or_refusal": "20/09/2010",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/10/773",
    "status": "Positive",
    "first_published_date": "18/10/2010",
    "last_updated_date": "18/10/2010",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-773"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "nafamostat mesilate",
    "date_of_designation_or_refusal": "20/09/2010",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/10/782",
    "status": "Positive",
    "first_published_date": "18/10/2010",
    "last_updated_date": "18/10/2010",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-782"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-(6-(2-aminophenylamino)-6-oxohexyl)-4-methylbenzamide",
    "date_of_designation_or_refusal": "01/10/2010",
    "intended_use": "Treatment of Friedreich's ataxia",
    "eu_designation_number": "EU/3/10/793",
    "status": "Positive",
    "first_published_date": "14/02/2010",
    "last_updated_date": "14/10/2010",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-793"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pralatrexate",
    "date_of_designation_or_refusal": "01/10/2010",
    "intended_use": "Treatment of Hodgkin's lymphoma",
    "eu_designation_number": "EU/3/10/795",
    "status": "Positive",
    "first_published_date": "14/10/2010",
    "last_updated_date": "14/10/2010",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-795"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(S)-10-[(dimethylamino)methyl]-4-ethyl-9-hydroxy-4-O-[alpha-(2\", 4\", 5\", 7\"-tetranitro-9\"-fluorenylideneaminooxy)propionyl]-1H-pyrano[3', 4', 6', 7']indolizino[1,2-beta]-quinoline-3, 14-(4H, 12H)-dione, hydrochloride",
    "date_of_designation_or_refusal": "01/10/2010",
    "intended_use": "Treatment of hepatocellular carcinoma",
    "eu_designation_number": "EU/3/10/788",
    "status": "Positive",
    "first_published_date": "14/10/2010",
    "last_updated_date": "14/10/2010",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-788"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tacrolimus hydrate",
    "date_of_designation_or_refusal": "14/01/2004",
    "intended_use": "Treatment of vernal keratoconjunctivitis",
    "eu_designation_number": "EU/3/03/185",
    "status": "Withdrawn",
    "first_published_date": "26/04/2004",
    "last_updated_date": "14/10/2010",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-185"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "molgramostim",
    "date_of_designation_or_refusal": "16/07/2010",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "-",
    "status": "Negative",
    "first_published_date": "09/08/2010",
    "last_updated_date": "09/08/2010",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-cystic-fibrosis"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "octenidine dihydrochloride",
    "date_of_designation_or_refusal": "27/07/2010",
    "intended_use": "Prevention of late-onset sepsis in premature infants of ≤ to 32 weeks of gestational age",
    "eu_designation_number": "EU/3/10/755",
    "status": "Positive",
    "first_published_date": "05/08/2010",
    "last_updated_date": "05/08/2010",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-755"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Gastrin 17C diphtheria toxoid conjugate",
    "date_of_designation_or_refusal": "16/07/2010",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "-",
    "status": "Negative",
    "first_published_date": "05/08/2010",
    "last_updated_date": "05/08/2010",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-pancreatic-cancer-0"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "raloxifene hydrochloride",
    "date_of_designation_or_refusal": "10/06/2010",
    "intended_use": "Treatment of hereditary haemorrhagic telangiectasia",
    "eu_designation_number": "EU/3/10/730",
    "status": "Positive",
    "first_published_date": "24/06/2010",
    "last_updated_date": "24/06/2010",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-730"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "cardiotrophin-1",
    "date_of_designation_or_refusal": "28/08/2006",
    "intended_use": "Prevention of the ischemia/reperfusion injury associated with solid organ transplantation",
    "eu_designation_number": "EU/3/06/396",
    "status": "Positive",
    "first_published_date": "24/04/2009",
    "last_updated_date": "23/06/2010",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-396"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "allogeneic human umbilical cord tissue-derived cells",
    "date_of_designation_or_refusal": "01/04/2008",
    "intended_use": "Treatment of retinitis pigmentosa",
    "eu_designation_number": "EU/3/08/534",
    "status": "Withdrawn",
    "first_published_date": "10/07/2008",
    "last_updated_date": "23/06/2010",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-534"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pravastatin;zoledronic acid",
    "date_of_designation_or_refusal": "09/06/2010",
    "intended_use": "Treatment of Hutchinson-Gilford progeria",
    "eu_designation_number": "EU/3/10/748",
    "status": "Positive",
    "first_published_date": "23/06/2010",
    "last_updated_date": "23/06/2010",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-748"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Peptide 144 TGF-beta1-inhibitor (TSLDASIIWAMMQN)",
    "date_of_designation_or_refusal": "28/10/2005",
    "intended_use": "Treatment of localised scleroderma",
    "eu_designation_number": "EU/3/05/329",
    "status": "Positive",
    "first_published_date": "30/05/2007",
    "last_updated_date": "23/06/2010",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-329"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Lumiliximab",
    "date_of_designation_or_refusal": "03/02/2008",
    "intended_use": "Treatment chronic lymphocytic leukaemia",
    "eu_designation_number": "EU/3/08/528",
    "status": "Withdrawn",
    "first_published_date": "10/07/2008",
    "last_updated_date": "23/06/2010",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-528"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "vasoactive Intestinal Peptide",
    "date_of_designation_or_refusal": "22/12/2003",
    "intended_use": "Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension",
    "eu_designation_number": "EU/3/03/173",
    "status": "Positive",
    "first_published_date": "23/09/2009",
    "last_updated_date": "23/06/2010",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-173"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Peptide 144 TGF-beta1-inhibitor (TSLDASIIWAMMQN)",
    "date_of_designation_or_refusal": "28/10/2005",
    "intended_use": "Treatment of systemic sclerosis",
    "eu_designation_number": "EU/3/05/326",
    "status": "Positive",
    "first_published_date": "30/05/2007",
    "last_updated_date": "23/06/2010",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-326"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sinapultide;Dipalmitoylphosphatidylcholine;palmitoyloleoyl phosphatidylglycerol;palmitic acid",
    "date_of_designation_or_refusal": "19/09/2001",
    "intended_use": "Treatment of meconium aspiration syndrome",
    "eu_designation_number": "EU/3/01/054",
    "status": "Withdrawn",
    "first_published_date": "30/05/2007",
    "last_updated_date": "23/06/2010",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-054"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "alpha-1-acid glycoprotein",
    "date_of_designation_or_refusal": "20/03/2003",
    "intended_use": "Treatment of tricyclic anti-depressants poisoning",
    "eu_designation_number": "EU/3/03/138",
    "status": "Withdrawn",
    "first_published_date": "09/04/2003",
    "last_updated_date": "23/06/2010",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-138"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human proinsulin",
    "date_of_designation_or_refusal": "11/02/2009",
    "intended_use": "Treatment of retinitis pigmentosa",
    "eu_designation_number": "EU/3/08/612",
    "status": "Positive",
    "first_published_date": "29/10/2009",
    "last_updated_date": "15/03/2010",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-612"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ciclosporin",
    "date_of_designation_or_refusal": "03/11/2006",
    "intended_use": "Prevention of rejection for corneal transplant",
    "eu_designation_number": "EU/3/06/415",
    "status": "Withdrawn",
    "first_published_date": "02/04/2009",
    "last_updated_date": "15/03/2010",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-415"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "H-Arg-Leu-Phe-Phe-Tyr-Arg-Lys-Ser-Val-OH, acetate salt& H-Tyr-Leu-Phe-Phe-Tyr-Arg-Lys-Ser-Val-OH, acetate salt",
    "date_of_designation_or_refusal": "18/12/2007",
    "intended_use": "Treatment of TERT positive non-small cell lung cancer in HLA-A2 positive patients",
    "eu_designation_number": "EU/3/07/521",
    "status": "Positive",
    "first_published_date": "21/10/2008",
    "last_updated_date": "15/03/2010",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-521"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "arsenic trioxide",
    "date_of_designation_or_refusal": "02/08/2007",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/07/460",
    "status": "Withdrawn",
    "first_published_date": "10/07/2008",
    "last_updated_date": "15/03/2010",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-460"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "arsenic trioxide",
    "date_of_designation_or_refusal": "29/03/2001",
    "intended_use": "Treatment of multiple myeloma",
    "eu_designation_number": "EU/3/01/032",
    "status": "Withdrawn",
    "first_published_date": "04/07/2007",
    "last_updated_date": "15/03/2010",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-032"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "arsenic trioxide",
    "date_of_designation_or_refusal": "29/03/2001",
    "intended_use": "Treatment of myelodysplastic syndromes",
    "eu_designation_number": "EU/3/01/031",
    "status": "Withdrawn",
    "first_published_date": "04/07/2007",
    "last_updated_date": "15/03/2010",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-031"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Givinostat",
    "date_of_designation_or_refusal": "03/02/2010",
    "intended_use": "Treatment of polycythaemia vera",
    "eu_designation_number": "EU/3/09/719",
    "status": "Positive",
    "first_published_date": "04/03/2010",
    "last_updated_date": "04/03/2010",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-719"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Ecopipam",
    "date_of_designation_or_refusal": "03/02/2010",
    "intended_use": "Treatment of Lesch-Nyhan disease",
    "eu_designation_number": "EU/3/09/717",
    "status": "Positive",
    "first_published_date": "04/03/2010",
    "last_updated_date": "04/03/2010",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-717"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Lithium citrate tetrahydrate",
    "date_of_designation_or_refusal": "28/01/2010",
    "intended_use": "Treatment of Huntington’s disease",
    "eu_designation_number": "EU/3/09/706",
    "status": "Positive",
    "first_published_date": "25/02/2010",
    "last_updated_date": "25/02/2010",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-706"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "brivudine",
    "date_of_designation_or_refusal": "28/01/2010",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/09/703",
    "status": "Positive",
    "first_published_date": "25/02/2010",
    "last_updated_date": "25/02/2010",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-703"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "beta-artemether;lumefantrine",
    "date_of_designation_or_refusal": "28/01/2010",
    "intended_use": "Treatment of malaria",
    "eu_designation_number": "EU/3/09/702",
    "status": "Positive",
    "first_published_date": "25/02/2010",
    "last_updated_date": "25/02/2010",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-702"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium oxybate",
    "date_of_designation_or_refusal": "03/02/2003",
    "intended_use": "Treatment of narcolepsy",
    "eu_designation_number": "EU/3/02/131",
    "status": "Withdrawn",
    "first_published_date": "28/02/2007",
    "last_updated_date": "22/02/2010",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-131"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Dexamethasone sodium phosphate encapsulated in human erythrocytes",
    "date_of_designation_or_refusal": "20/10/2004",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/04/230",
    "status": "Positive",
    "first_published_date": "05/11/2009",
    "last_updated_date": "22/02/2010",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-230"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "monoclonal antibody to human interleukin-6",
    "date_of_designation_or_refusal": "18/12/2002",
    "intended_use": "Treatment of post-transplantation lymphoproliferative disorders",
    "eu_designation_number": "EU/3/02/125",
    "status": "Withdrawn",
    "first_published_date": "18/08/2008",
    "last_updated_date": "22/02/2010",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-125"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (Pr1 nanopeptide, sequence 169-177, of proteinase 3)",
    "date_of_designation_or_refusal": "21/12/2004",
    "intended_use": "Treatment of chronic myeloid leukaemia",
    "eu_designation_number": "EU/3/04/252",
    "status": "Withdrawn",
    "first_published_date": "06/01/2006",
    "last_updated_date": "19/11/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-252"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (Pr1 nanopeptide, sequence 169-177, of proteinase 3)",
    "date_of_designation_or_refusal": "21/12/2004",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/04/253",
    "status": "Withdrawn",
    "first_published_date": "06/01/2006",
    "last_updated_date": "19/11/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-253"
  },
  {
    "medicine_name": "Masican; Masiviera",
    "related_ema_product_number": "EMEA/H/C/002670; EMEA/H/C/002659",
    "active_substance": "Masitinib mesilate",
    "date_of_designation_or_refusal": "28/10/2009",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/09/684",
    "status": "Positive",
    "first_published_date": "18/11/2009",
    "last_updated_date": "18/11/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-684"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "NGR-human tumour necrosis factor",
    "date_of_designation_or_refusal": "09/11/2009",
    "intended_use": "Treatment of hepatocellular carcinoma",
    "eu_designation_number": "EU/3/09/686",
    "status": "Positive",
    "first_published_date": "18/11/2009",
    "last_updated_date": "18/11/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-686"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "daunorubicin",
    "date_of_designation_or_refusal": "03/12/2008",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/08/585",
    "status": "Positive",
    "first_published_date": "30/10/2009",
    "last_updated_date": "30/10/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-585"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "4-[[[4-(4-Chlorophenoxy)phenyl]sulfonyl]-methyl]tetrahydro-N-hydroxy-2H-pyran-4-carboxamide",
    "date_of_designation_or_refusal": "10/09/2008",
    "intended_use": "Prevention of graft rejection after liver transplantation",
    "eu_designation_number": "-",
    "status": "Negative",
    "first_published_date": "30/10/2009",
    "last_updated_date": "30/10/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-prevention-graft-rejection-after-liver-transplantation"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Human tumour necrosis factor alpha-derived peptide Cys-Gly-Gln-Arg-Glu-Thr-Pro-Glu-Gly-Ala-Glu-Ala-Lys-Pro-Trp-Tyr-Cys",
    "date_of_designation_or_refusal": "08/10/2009",
    "intended_use": "Treatment of acute lung Injury",
    "eu_designation_number": "EU/3/09/677",
    "status": "Positive",
    "first_published_date": "20/10/2009",
    "last_updated_date": "20/10/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-677"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Doxorubicin carbon;iron magnetically targeted microparticles",
    "date_of_designation_or_refusal": "11/09/2002",
    "intended_use": "Treatment of hepatocellular carcinoma",
    "eu_designation_number": "EU/3/02/112",
    "status": "Withdrawn",
    "first_published_date": "15/10/2009",
    "last_updated_date": "15/10/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-112"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium dichloroacetate",
    "date_of_designation_or_refusal": "02/09/2004",
    "intended_use": "Treatment of systemic monochloroacetate poisoning",
    "eu_designation_number": "EU/3/04/225",
    "status": "Withdrawn",
    "first_published_date": "15/10/2009",
    "last_updated_date": "15/10/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-225"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "thalidomide",
    "date_of_designation_or_refusal": "09/07/2001",
    "intended_use": "Treatment of graft-versus-host disease",
    "eu_designation_number": "EU/3/01/046",
    "status": "Withdrawn",
    "first_published_date": "15/10/2009",
    "last_updated_date": "15/10/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-046"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(Z)-N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (S)-2-hydroxysyccinate",
    "date_of_designation_or_refusal": "10/03/2005",
    "intended_use": "Treatment of malignant gastrointestinal stromal tumours",
    "eu_designation_number": "EU/3/05/267",
    "status": "Withdrawn",
    "first_published_date": "15/10/2009",
    "last_updated_date": "15/10/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-267"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "(Z)-N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (S)-2-hydroxysyccinate",
    "date_of_designation_or_refusal": "10/03/2005",
    "intended_use": "Treatment of renal-cell carcinoma",
    "eu_designation_number": "EU/3/05/268",
    "status": "Withdrawn",
    "first_published_date": "15/10/2009",
    "last_updated_date": "15/10/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-268"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "4,5-Dihydro-2-(2,4-dihydroxyphenyl)-4-methylthiazole-4(S)-carboxylic acid",
    "date_of_designation_or_refusal": "12/12/2003",
    "intended_use": "Treatment of chronic iron overload requiring chelation therapy",
    "eu_designation_number": "EU/3/03/180",
    "status": "Withdrawn",
    "first_published_date": "15/10/2009",
    "last_updated_date": "15/10/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-180"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "thalidomide",
    "date_of_designation_or_refusal": "19/12/2001",
    "intended_use": "Treatment of multiple myeloma",
    "eu_designation_number": "EU/3/01/068",
    "status": "Withdrawn",
    "first_published_date": "15/10/2009",
    "last_updated_date": "15/10/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-068"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2'-O-methyl-phosphorothioate oligonucleotide",
    "date_of_designation_or_refusal": "16/02/2006",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/06/357",
    "status": "Withdrawn",
    "first_published_date": "15/10/2009",
    "last_updated_date": "15/10/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-357"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sabarubicin",
    "date_of_designation_or_refusal": "21/12/2004",
    "intended_use": "Treatment of small cell lung cancer",
    "eu_designation_number": "EU/3/04/255",
    "status": "Withdrawn",
    "first_published_date": "15/10/2009",
    "last_updated_date": "15/10/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-255"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "5,10-Methylene-tetrahydrofolic acid",
    "date_of_designation_or_refusal": "02/09/2004",
    "intended_use": "Treatment of pancreatic cancer in combination with 5-fluorouracil",
    "eu_designation_number": "EU/3/04/221",
    "status": "Withdrawn",
    "first_published_date": "15/10/2009",
    "last_updated_date": "15/10/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-221"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "thalidomide",
    "date_of_designation_or_refusal": "09/07/2001",
    "intended_use": "Treatment of multiple myeloma",
    "eu_designation_number": "EU/3/01/047",
    "status": "Withdrawn",
    "first_published_date": "15/10/2009",
    "last_updated_date": "15/10/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-047"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-acetylsarcosyl-glycyl-L-valyl-D-alloisoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-L-arginyl-L-prolyl-N-ethylamide",
    "date_of_designation_or_refusal": "12/12/2003",
    "intended_use": "Treatment of soft tissue sarcoma",
    "eu_designation_number": "EU/3/03/181",
    "status": "Withdrawn",
    "first_published_date": "15/10/2009",
    "last_updated_date": "15/10/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-181"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tilarginine acetate",
    "date_of_designation_or_refusal": "03/11/2005",
    "intended_use": "Treatment of cardiogenic shock",
    "eu_designation_number": "EU/3/05/330",
    "status": "Withdrawn",
    "first_published_date": "15/10/2009",
    "last_updated_date": "15/10/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-330"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sulfonated monophosphorylated mannose oligosaccharide",
    "date_of_designation_or_refusal": "14/09/2007",
    "intended_use": "Treatment of hepatocellular carcinoma",
    "eu_designation_number": "EU/3/07/482",
    "status": "Withdrawn",
    "first_published_date": "15/10/2009",
    "last_updated_date": "15/10/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-482"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "5-10-Methylene-tetrahydrofolate",
    "date_of_designation_or_refusal": "11/06/2003",
    "intended_use": "Treatment pancreatic cancer in combination with 5-fluorouracil",
    "eu_designation_number": "EU/3/03/143",
    "status": "Withdrawn",
    "first_published_date": "15/10/2009",
    "last_updated_date": "15/10/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-143"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "2-(4-(Diethylamino) phenyl)-6-methyl-2H-benzo[d][1,2,3] triazol-5-amine",
    "date_of_designation_or_refusal": "25/07/2006",
    "intended_use": "Treatment of Duchenne muscular dystrophy",
    "eu_designation_number": "EU/3/06/385",
    "status": "Withdrawn",
    "first_published_date": "15/10/2009",
    "last_updated_date": "15/10/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-385"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "acetylcysteine",
    "date_of_designation_or_refusal": "26/01/2005",
    "intended_use": "Treatment of idiopathic pulmonary fibrosis",
    "eu_designation_number": "EU/3/04/259",
    "status": "Withdrawn",
    "first_published_date": "15/10/2009",
    "last_updated_date": "15/10/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-259"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Lusupultide",
    "date_of_designation_or_refusal": "10/07/2007",
    "intended_use": "Treatment of aspiration pneumonitis requiring intubation and mechanical ventilation",
    "eu_designation_number": "EU/3/07/457",
    "status": "Withdrawn",
    "first_published_date": "15/10/2009",
    "last_updated_date": "15/10/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-457"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Engineered protein inhibitor of human neutrophil elastase",
    "date_of_designation_or_refusal": "09/07/2003",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/03/152",
    "status": "Withdrawn",
    "first_published_date": "15/10/2009",
    "last_updated_date": "15/10/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-152"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "H-Tyrosine-Glycine-Phenylalanine-Glycine-Glycine-OH",
    "date_of_designation_or_refusal": "20/10/2003",
    "intended_use": "Treatment of chronic idiopathic myelofibrosis",
    "eu_designation_number": "EU/3/03/167",
    "status": "Withdrawn",
    "first_published_date": "15/10/2009",
    "last_updated_date": "15/10/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-167"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "myristolated-peptidyl-recombinant SCR1-3 of human complement receptor type I",
    "date_of_designation_or_refusal": "30/07/2002",
    "intended_use": "Prevention of post transplantation graft dysfunction",
    "eu_designation_number": "EU/3/02/108",
    "status": "Withdrawn",
    "first_published_date": "23/09/2009",
    "last_updated_date": "23/09/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-108"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "myristolated-peptidyl-recombinant human CD59",
    "date_of_designation_or_refusal": "11/09/2002",
    "intended_use": "Treatment of paroxysmal nocturnal haemoglobinuria",
    "eu_designation_number": "EU/3/02/114",
    "status": "Withdrawn",
    "first_published_date": "23/09/2009",
    "last_updated_date": "23/09/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-114"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human C1-inhibitor",
    "date_of_designation_or_refusal": "20/02/2007",
    "intended_use": "Prevention of delayed graft function after solid organ transplantation",
    "eu_designation_number": "EU/3/07/435",
    "status": "Positive",
    "first_published_date": "23/09/2009",
    "last_updated_date": "23/09/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-435"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "purified inactivated Japanese encephalitis SA14-4-2 virus vaccine",
    "date_of_designation_or_refusal": "24/01/2006",
    "intended_use": "Prevention of Japanese encephalitis",
    "eu_designation_number": "EU/3/05/348",
    "status": "Withdrawn",
    "first_published_date": "23/09/2009",
    "last_updated_date": "23/09/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-348"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "G17(9) gastrin-Diphtheria Toxoid Conjugate",
    "date_of_designation_or_refusal": "24/01/2003",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/02/129",
    "status": "Positive",
    "first_published_date": "21/09/2009",
    "last_updated_date": "21/09/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-129"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Gimatecan",
    "date_of_designation_or_refusal": "01/12/2003",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/03/174",
    "status": "Positive",
    "first_published_date": "21/09/2009",
    "last_updated_date": "21/09/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-174"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "G17(9) gastrin-Diphtheria Toxoid Conjugate",
    "date_of_designation_or_refusal": "28/01/2003",
    "intended_use": "Treatment of gastric cancer",
    "eu_designation_number": "EU/3/02/130",
    "status": "Positive",
    "first_published_date": "21/09/2009",
    "last_updated_date": "21/09/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-130"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "amiloride hydrochloride dihydrate",
    "date_of_designation_or_refusal": "30/06/2003",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/03/147",
    "status": "Withdrawn",
    "first_published_date": "17/09/2009",
    "last_updated_date": "17/09/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-147"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "alginate oligosaccharide (G-block) fragment",
    "date_of_designation_or_refusal": "14/09/2007",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/07/475",
    "status": "Positive",
    "first_published_date": "17/09/2009",
    "last_updated_date": "17/09/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-475"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ibritumomab tiuxetan",
    "date_of_designation_or_refusal": "01/02/2002",
    "intended_use": "Treatment of B-cell non-Hodgkin`s lymphoma",
    "eu_designation_number": "-",
    "status": "Negative",
    "first_published_date": "17/09/2009",
    "last_updated_date": "17/09/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-b-cell-non-hodgkins-lymphoma"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "17-allylamino-17-demethoxygeldanamycin",
    "date_of_designation_or_refusal": "26/01/2005",
    "intended_use": "Treatment of chronic myeloid leukaemia",
    "eu_designation_number": "EU/3/04/256",
    "status": "Withdrawn",
    "first_published_date": "17/09/2009",
    "last_updated_date": "17/09/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-256"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "17-allylamino-17-demethoxygeldanamycin",
    "date_of_designation_or_refusal": "21/12/2004",
    "intended_use": "Treatment of multiple myeloma",
    "eu_designation_number": "EU/3/04/247",
    "status": "Withdrawn",
    "first_published_date": "17/09/2009",
    "last_updated_date": "17/09/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-247"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ciclosporin",
    "date_of_designation_or_refusal": "24/07/2009",
    "intended_use": "Treatment of atopic keratoconjunctivitis",
    "eu_designation_number": "EU/3/09/651",
    "status": "Positive",
    "first_published_date": "11/09/2009",
    "last_updated_date": "11/09/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-651"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "type I native bovine skin collagen",
    "date_of_designation_or_refusal": "09/02/2009",
    "intended_use": "Treatment of systemic sclerosis",
    "eu_designation_number": "EU/3/08/607",
    "status": "Positive",
    "first_published_date": "29/06/2009",
    "last_updated_date": "29/06/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-607"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "gadodiamide",
    "date_of_designation_or_refusal": "03/12/2008",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/08/583",
    "status": "Positive",
    "first_published_date": "29/06/2009",
    "last_updated_date": "29/06/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-583"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "mifepristone",
    "date_of_designation_or_refusal": "27/02/2009",
    "intended_use": "Treatment of hypercortisolism (Cushing's syndrome) of endogenous origin",
    "eu_designation_number": "EU/3/09/614",
    "status": "Positive",
    "first_published_date": "29/06/2009",
    "last_updated_date": "29/06/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-614"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sapacitabine",
    "date_of_designation_or_refusal": "08/07/2008",
    "intended_use": "Treatment of myelodysplastic syndromes",
    "eu_designation_number": "EU/3/08/557",
    "status": "Positive",
    "first_published_date": "29/06/2009",
    "last_updated_date": "29/06/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-557-0"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human anti-intercellular adhesion molecule-1 monoclonal antibody",
    "date_of_designation_or_refusal": "20/01/2009",
    "intended_use": "Treatment of multiple myeloma",
    "eu_designation_number": "EU/3/08/600",
    "status": "Positive",
    "first_published_date": "15/06/2009",
    "last_updated_date": "15/06/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-600"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "HLA-A2 restricted CD8 T-cell line expressing MART-1 T-cell receptor",
    "date_of_designation_or_refusal": "21/06/2004",
    "intended_use": "Treatment of MART-1 YES malignant melanoma in HLA-A2 YES patients",
    "eu_designation_number": "EU/3/04/202",
    "status": "Positive",
    "first_published_date": "15/06/2009",
    "last_updated_date": "15/06/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-202"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "L-asparaginase encapsulated in erythrocytes",
    "date_of_designation_or_refusal": "15/05/2009",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/09/633",
    "status": "Positive",
    "first_published_date": "09/06/2009",
    "last_updated_date": "09/06/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-633"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "S-[2,3-bispalmitoyloxy-(2R)-propyl]-cysteinyl-GNNDESNISFKEK",
    "date_of_designation_or_refusal": "15/05/2009",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/09/634",
    "status": "Positive",
    "first_published_date": "09/06/2009",
    "last_updated_date": "09/06/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-634"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human cytomegalovirus immunoglobulin",
    "date_of_designation_or_refusal": "31/10/2006",
    "intended_use": "Prevention of congenital cytomegalovirus infection following primary cytomegalovirus infection",
    "eu_designation_number": "EU/3/06/408",
    "status": "Positive",
    "first_published_date": "15/05/2009",
    "last_updated_date": "15/05/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-408"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "phenylephrine hydrochloride",
    "date_of_designation_or_refusal": "20/11/2001",
    "intended_use": "Treatment of ileal pouch anal anastomosis (IPAA) related faecal incontinence",
    "eu_designation_number": "EU/3/01/069",
    "status": "Positive",
    "first_published_date": "15/05/2009",
    "last_updated_date": "15/05/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-069"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "L-Lysine-N-Acetyl-L-Cysteinate",
    "date_of_designation_or_refusal": "14/02/2001",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/01/026",
    "status": "Positive",
    "first_published_date": "15/05/2009",
    "last_updated_date": "15/05/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-026"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Lusupultide",
    "date_of_designation_or_refusal": "17/01/2001",
    "intended_use": "Treatment of acute respiratory distress syndrome (ARDS)",
    "eu_designation_number": "EU/3/00/016",
    "status": "Withdrawn",
    "first_published_date": "15/05/2009",
    "last_updated_date": "15/05/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-00-016"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "thalidomide",
    "date_of_designation_or_refusal": "29/12/2000",
    "intended_use": "Treatment of erythema nodosum leprosum (ENL) or type II lepra reactions",
    "eu_designation_number": "EU/3/00/009",
    "status": "Withdrawn",
    "first_published_date": "15/05/2009",
    "last_updated_date": "15/05/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-00-009"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human alpha-1 antitrypsin",
    "date_of_designation_or_refusal": "30/05/2001",
    "intended_use": "Treatment of emphysema secondary to congenital alpha-1 antitrypsin deficiency",
    "eu_designation_number": "EU/3/01/041",
    "status": "Withdrawn",
    "first_published_date": "15/05/2009",
    "last_updated_date": "15/05/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-041"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "8-cyclopentyl-1, 3-dipropylxanthine",
    "date_of_designation_or_refusal": "29/03/2001",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/01/030",
    "status": "Withdrawn",
    "first_published_date": "15/05/2009",
    "last_updated_date": "15/05/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-030"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Fluorouracil",
    "date_of_designation_or_refusal": "18/10/2000",
    "intended_use": "Treatment of glioblastoma",
    "eu_designation_number": "EU/3/00/004",
    "status": "Withdrawn",
    "first_published_date": "15/05/2009",
    "last_updated_date": "15/05/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-00-004"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sapacitabine",
    "date_of_designation_or_refusal": "10/07/2008",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/08/558",
    "status": "Positive",
    "first_published_date": "15/05/2009",
    "last_updated_date": "15/05/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-558"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "H-Val-Ile-Val-Lys-Leu-Ile-Pro-Ser-Thr-Ser-Ser-Ala-Val-Asp-Thr-Pro-Tyr-Leu-Asp-Ile-Thr-Tyr-His-Phe-Val-Ala-Gln-Arg-Leu-Pro-Leu-OH",
    "date_of_designation_or_refusal": "28/08/2006",
    "intended_use": "Treatment of myasthenia gravis",
    "eu_designation_number": "EU/3/06/398",
    "status": "Withdrawn",
    "first_published_date": "15/05/2009",
    "last_updated_date": "15/05/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-398"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "arsenic trioxide",
    "date_of_designation_or_refusal": "17/01/2001",
    "intended_use": "Treatment of acute promyelocytic leukaemia",
    "eu_designation_number": "EU/3/00/017",
    "status": "Withdrawn",
    "first_published_date": "15/05/2009",
    "last_updated_date": "15/05/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-00-017"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "retroviral gamma c cDNA containing vector",
    "date_of_designation_or_refusal": "30/05/2001",
    "intended_use": "Treatment of severe combined immunodeficiency (SCID)-Xl Disease",
    "eu_designation_number": "EU/3/01/038",
    "status": "Positive",
    "first_published_date": "15/05/2009",
    "last_updated_date": "15/05/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-038"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Octavalent Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate",
    "date_of_designation_or_refusal": "11/12/2001",
    "intended_use": "Prevention of Pseudomonas aeruginosa infections in patients with cystic fibrosis",
    "eu_designation_number": "EU/3/01/076",
    "status": "Withdrawn",
    "first_published_date": "15/05/2009",
    "last_updated_date": "15/05/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-076"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Ibuprofen",
    "date_of_designation_or_refusal": "06/03/2001",
    "intended_use": "Patent ductus arteriosus in premature neonates of less than 34 weeks of gestational age",
    "eu_designation_number": "EU/3/01/027",
    "status": "Withdrawn",
    "first_published_date": "15/05/2009",
    "last_updated_date": "15/05/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-027"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sapacitabine",
    "date_of_designation_or_refusal": "08/07/2008",
    "intended_use": "Treatment of myelodysplastic syndromes",
    "eu_designation_number": "EU/3/08/557",
    "status": "Positive",
    "first_published_date": "15/05/2009",
    "last_updated_date": "15/05/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-557"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Guanabenz",
    "date_of_designation_or_refusal": "29/04/2009",
    "intended_use": "Treatment of traumatic spinal cord injury",
    "eu_designation_number": "EU/3/09/625",
    "status": "Positive",
    "first_published_date": "12/05/2009",
    "last_updated_date": "12/05/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-625"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous Tumor-Derived gp96 Heat Shock Protein-Peptide Complex",
    "date_of_designation_or_refusal": "29/04/2009",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/09/624",
    "status": "Positive",
    "first_published_date": "12/05/2009",
    "last_updated_date": "12/05/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-09-624"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Parathyroid hormone (1-34) transglutaminase fusion protein fibrin matrix complex",
    "date_of_designation_or_refusal": "11/04/2006",
    "intended_use": "Treatment of solitary bone cysts",
    "eu_designation_number": "EU/3/06/367",
    "status": "Positive",
    "first_published_date": "24/04/2009",
    "last_updated_date": "24/04/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-367"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "topotecan hydrochloride",
    "date_of_designation_or_refusal": "05/09/2008",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/08/562",
    "status": "Positive",
    "first_published_date": "24/04/2009",
    "last_updated_date": "24/04/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-562"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Mecasermin rinfabate",
    "date_of_designation_or_refusal": "20/06/2006",
    "intended_use": "Treatment of primary insulin-like growth factor-1 deficiency due to molecular or genetic defects",
    "eu_designation_number": "EU/3/06/378",
    "status": "Withdrawn",
    "first_published_date": "24/04/2009",
    "last_updated_date": "24/04/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-378"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous CD34+ cells transduced with retroviral vector containing the human gp91 (phox) gene",
    "date_of_designation_or_refusal": "13/07/2006",
    "intended_use": "Treatment of chronic granulomatous disease",
    "eu_designation_number": "EU/3/06/393",
    "status": "Withdrawn",
    "first_published_date": "24/04/2009",
    "last_updated_date": "24/04/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-393"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "zosuquidar trihydrochloride",
    "date_of_designation_or_refusal": "17/02/2006",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/06/355",
    "status": "Positive",
    "first_published_date": "24/04/2009",
    "last_updated_date": "24/04/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-355"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "avian polyclonal IgY antibody",
    "date_of_designation_or_refusal": "23/09/2008",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/08/564",
    "status": "Positive",
    "first_published_date": "24/04/2009",
    "last_updated_date": "24/04/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-564"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "opebacan",
    "date_of_designation_or_refusal": "28/08/2006",
    "intended_use": "Treatment of meningococcal disease",
    "eu_designation_number": "EU/3/06/402",
    "status": "Withdrawn",
    "first_published_date": "24/04/2009",
    "last_updated_date": "24/04/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-402"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "genetically modified allogenic (human) tumor cells for the expression of IL-7, GM-CSF, CD80 and CD154, in fixed combination with a DNA-based double stem loop immunomodulator (dSLIM)",
    "date_of_designation_or_refusal": "23/10/2006",
    "intended_use": "Treatment of renal-cell carcinoma",
    "eu_designation_number": "EU/3/06/405",
    "status": "Positive",
    "first_published_date": "24/04/2009",
    "last_updated_date": "24/04/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-405"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "4-[123I] Iodo-L-phenylalanine",
    "date_of_designation_or_refusal": "25/07/2006",
    "intended_use": "Diagnosis of glioma",
    "eu_designation_number": "EU/3/06/386",
    "status": "Positive",
    "first_published_date": "24/04/2009",
    "last_updated_date": "24/04/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-386"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Miltefosine",
    "date_of_designation_or_refusal": "22/09/2008",
    "intended_use": "Treatment of cutaneous T-cell lymphoma",
    "eu_designation_number": "EU/3/08/567",
    "status": "Positive",
    "first_published_date": "24/04/2009",
    "last_updated_date": "24/04/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-567"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "aviptadil",
    "date_of_designation_or_refusal": "28/08/2006",
    "intended_use": "Treatment of acute lung Injury",
    "eu_designation_number": "EU/3/06/395",
    "status": "Positive",
    "first_published_date": "02/04/2009",
    "last_updated_date": "02/04/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-395"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human CXCL8 mutant",
    "date_of_designation_or_refusal": "22/09/2008",
    "intended_use": "Prevention of delayed graft function after solid organ transplantation",
    "eu_designation_number": "EU/3/08/570",
    "status": "Positive",
    "first_published_date": "02/04/2009",
    "last_updated_date": "02/04/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-570"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "doxorubicin hydrochloride",
    "date_of_designation_or_refusal": "27/10/2006",
    "intended_use": "Treatment of soft tissue sarcoma",
    "eu_designation_number": "EU/3/06/410",
    "status": "Positive",
    "first_published_date": "02/04/2009",
    "last_updated_date": "02/04/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-410"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Mecasermin rinfabate",
    "date_of_designation_or_refusal": "20/06/2006",
    "intended_use": "Treatment of growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH",
    "eu_designation_number": "EU/3/06/377",
    "status": "Withdrawn",
    "first_published_date": "02/04/2009",
    "last_updated_date": "02/04/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-377"
  },
  {
    "medicine_name": "Advexin; Advexin",
    "related_ema_product_number": "EMEA/H/C/000919; EMEA/H/C/000919",
    "active_substance": "adenoviral vector containing human p53 gene",
    "date_of_designation_or_refusal": "23/10/2006",
    "intended_use": "Treatment of  Li Fraumeni Syndrome",
    "eu_designation_number": "EU/3/06/404",
    "status": "Positive",
    "first_published_date": "02/04/2009",
    "last_updated_date": "02/04/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-404"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "apomorphine",
    "date_of_designation_or_refusal": "05/12/2001",
    "intended_use": "Treatment of off-periods in Parkinson's disease not responding  to other oral treatment",
    "eu_designation_number": "EU/3/01/072",
    "status": "Withdrawn",
    "first_published_date": "03/03/2009",
    "last_updated_date": "03/03/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-072"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human insulin-like growth factor-I;recombinant human insulin-like growth factor binding protein-3",
    "date_of_designation_or_refusal": "20/10/2004",
    "intended_use": "Treatment of type B extreme insulin resistance syndrome",
    "eu_designation_number": "EU/3/04/235",
    "status": "Withdrawn",
    "first_published_date": "20/02/2009",
    "last_updated_date": "20/02/2009",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-235"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Human Staphylococcus aureus immunoglobulin",
    "date_of_designation_or_refusal": "03/11/2005",
    "intended_use": "Treatment of Staphylococcus aureus bacteraemia",
    "eu_designation_number": "EU/3/05/319",
    "status": "Positive",
    "first_published_date": "18/08/2008",
    "last_updated_date": "18/08/2008",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-319"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant fusion protein of circulary-permuted IL-4 and pseudomonas exotoxin A, [IL-4(38-37)-PE38KDEL]",
    "date_of_designation_or_refusal": "03/06/2008",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/08/553",
    "status": "Positive",
    "first_published_date": "18/08/2008",
    "last_updated_date": "18/08/2008",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-553"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Hepatitis C immunoglobulin",
    "date_of_designation_or_refusal": "08/07/2005",
    "intended_use": "Prevention of recurrent hepatitis C virus induced liver disease in liver transplant recipients",
    "eu_designation_number": "EU/3/05/295",
    "status": "Positive",
    "first_published_date": "18/08/2008",
    "last_updated_date": "18/08/2008",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-295"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant human hepatitis C monoclonal antibody against C4 region of E1",
    "date_of_designation_or_refusal": "06/12/2007",
    "intended_use": "Prevention of recurrent hepatitis C virus induced liver disease in liver transplant recipients",
    "eu_designation_number": "EU/3/07/503",
    "status": "Positive",
    "first_published_date": "18/08/2008",
    "last_updated_date": "18/08/2008",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-503"
  },
  {
    "medicine_name": "Graspa; Graspa",
    "related_ema_product_number": "EMEA/H/C/004736; EMEA/H/C/004055",
    "active_substance": "L-asparaginase encapsulated in erythrocytes",
    "date_of_designation_or_refusal": "27/10/2006",
    "intended_use": "Treatment of acute lymphoblastic leukaemia",
    "eu_designation_number": "EU/3/06/409",
    "status": "Positive",
    "first_published_date": "29/07/2008",
    "last_updated_date": "29/07/2008",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-409"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "alfimeprase",
    "date_of_designation_or_refusal": "28/10/2005",
    "intended_use": "Treatment of acute peripheral arterial occlusion",
    "eu_designation_number": "EU/3/05/322",
    "status": "Withdrawn",
    "first_published_date": "29/07/2008",
    "last_updated_date": "29/07/2008",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-322"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-adamantanyl-N'-Geranyl-ethylenediamine",
    "date_of_designation_or_refusal": "14/09/2007",
    "intended_use": "Treatment of tuberculosis",
    "eu_designation_number": "EU/3/07/479",
    "status": "Positive",
    "first_published_date": "29/07/2008",
    "last_updated_date": "29/07/2008",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-479"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Human Staphylococcus aureus immunoglobulin;human Staphylococcus epidermidis polyclonal immunoglobulin",
    "date_of_designation_or_refusal": "14/12/2005",
    "intended_use": "Late onset sepsis in premature infants of less or equal than 32 weeks of gestational age",
    "eu_designation_number": "EU/3/05/335",
    "status": "Withdrawn",
    "first_published_date": "29/07/2008",
    "last_updated_date": "29/07/2008",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-335"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pyridoxalated hemoglobin polyoxyethylene",
    "date_of_designation_or_refusal": "02/08/2007",
    "intended_use": "Treatment of cardiogenic shock",
    "eu_designation_number": "EU/3/07/463",
    "status": "Positive",
    "first_published_date": "29/07/2008",
    "last_updated_date": "29/07/2008",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-463"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "terguride",
    "date_of_designation_or_refusal": "29/11/2007",
    "intended_use": "Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension",
    "eu_designation_number": "EU/3/07/499",
    "status": "Positive",
    "first_published_date": "29/07/2008",
    "last_updated_date": "29/07/2008",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-499"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "4-Ethoxy-2-(piperazin-1-yl)-7-(pyridin-4-yl)-5H-pyrimido[5,4-b]indol",
    "date_of_designation_or_refusal": "14/11/2007",
    "intended_use": "Treatment of chronic lymphocytic leukaemia",
    "eu_designation_number": "EU/3/07/487",
    "status": "Positive",
    "first_published_date": "29/07/2008",
    "last_updated_date": "29/07/2008",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-487"
  },
  {
    "medicine_name": "Zafiride",
    "related_ema_product_number": "EMEA/H/C/004455",
    "active_substance": "NGR-human tumour necrosis factor",
    "date_of_designation_or_refusal": "03/06/2008",
    "intended_use": "Treatment of malignant mesothelioma",
    "eu_designation_number": "EU/3/08/549",
    "status": "Positive",
    "first_published_date": "29/07/2008",
    "last_updated_date": "29/07/2008",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-549"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human monoclonal antibody against HLA-DR",
    "date_of_designation_or_refusal": "28/02/2006",
    "intended_use": "Treatment of multiple myeloma",
    "eu_designation_number": "EU/3/06/358",
    "status": "Withdrawn",
    "first_published_date": "29/07/2008",
    "last_updated_date": "29/07/2008",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-358"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human monoclonal antibody against HLA-DR",
    "date_of_designation_or_refusal": "16/06/2005",
    "intended_use": "Treatment of Hodgkin's lymphoma",
    "eu_designation_number": "EU/3/05/291",
    "status": "Withdrawn",
    "first_published_date": "29/07/2008",
    "last_updated_date": "29/07/2008",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-291"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "chelidonii radix",
    "date_of_designation_or_refusal": "04/12/2007",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "-",
    "status": "Negative",
    "first_published_date": "29/07/2008",
    "last_updated_date": "29/07/2008",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-pancreatic-cancer"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human monoclonal antibody against HLA-DR",
    "date_of_designation_or_refusal": "24/01/2006",
    "intended_use": "Treatment of chronic lymphocytic leukaemia",
    "eu_designation_number": "EU/3/05/347",
    "status": "Withdrawn",
    "first_published_date": "29/07/2008",
    "last_updated_date": "29/07/2008",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-347"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "troxacitabine",
    "date_of_designation_or_refusal": "26/08/2005",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/05/311",
    "status": "Withdrawn",
    "first_published_date": "29/07/2008",
    "last_updated_date": "29/07/2008",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-311"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "artesunate",
    "date_of_designation_or_refusal": "20/02/2007",
    "intended_use": "Treatment of malaria",
    "eu_designation_number": "EU/3/07/430",
    "status": "Positive",
    "first_published_date": "10/07/2008",
    "last_updated_date": "10/07/2008",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-430"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ammonium tetrathiomolybdate",
    "date_of_designation_or_refusal": "01/04/2008",
    "intended_use": "Treatment of Wilson's disease",
    "eu_designation_number": "EU/3/08/539",
    "status": "Positive",
    "first_published_date": "10/07/2008",
    "last_updated_date": "10/07/2008",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-539"
  },
  {
    "medicine_name": "Akantior",
    "related_ema_product_number": "EMEA/H/C/005858",
    "active_substance": "Polihexanide",
    "date_of_designation_or_refusal": "14/11/2007",
    "intended_use": "Treatment of acanthamoeba keratitis",
    "eu_designation_number": "EU/3/07/498",
    "status": "Positive",
    "first_published_date": "02/07/2008",
    "last_updated_date": "02/07/2008",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-498"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "R-salbutamol sulfate",
    "date_of_designation_or_refusal": "14/09/2007",
    "intended_use": "Treatment of cutaneus forms of lupus erythromatosus",
    "eu_designation_number": "EU/3/07/481",
    "status": "Positive",
    "first_published_date": "02/07/2008",
    "last_updated_date": "02/07/2008",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-481"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "3-methoxy-pregnenolone",
    "date_of_designation_or_refusal": "04/12/2007",
    "intended_use": "Treatment of spinal cord injury",
    "eu_designation_number": "EU/3/07/511",
    "status": "Positive",
    "first_published_date": "01/07/2008",
    "last_updated_date": "01/07/2008",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-511"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "ciclosporin",
    "date_of_designation_or_refusal": "14/04/2004",
    "intended_use": "Treatment of atopic keratoconjunctivitis",
    "eu_designation_number": "EU/3/04/196",
    "status": "Withdrawn",
    "first_published_date": "22/01/2008",
    "last_updated_date": "22/01/2008",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-196"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "4-Amino-1-[5-O-[(2R,4S)-2-oxido-4-(4-pyridinyl)-1,3,2-dioxaphosphorinan-2-yl]-ß-D-arabinofuranosyl]-2(1H)-pyrimidinone",
    "date_of_designation_or_refusal": "14/09/2007",
    "intended_use": "Treatment of hepatocellular carcinoma",
    "eu_designation_number": "EU/3/07/477",
    "status": "Positive",
    "first_published_date": "22/01/2008",
    "last_updated_date": "22/01/2008",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-477"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "aviptadil",
    "date_of_designation_or_refusal": "14/09/2007",
    "intended_use": "Treatment of sarcoidosis",
    "eu_designation_number": "EU/3/07/473",
    "status": "Positive",
    "first_published_date": "22/01/2008",
    "last_updated_date": "22/01/2008",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-473"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Human plasminogen",
    "date_of_designation_or_refusal": "03/08/2007",
    "intended_use": "Treatment of ligneous conjunctivitis",
    "eu_designation_number": "EU/3/07/461",
    "status": "Positive",
    "first_published_date": "17/01/2008",
    "last_updated_date": "17/01/2008",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-461"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "cisplatin",
    "date_of_designation_or_refusal": "08/06/2007",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/07/451",
    "status": "Positive",
    "first_published_date": "04/12/2007",
    "last_updated_date": "04/12/2007",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-451"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "antisense oligonucleotide (TATCCGGAGGGCTCGCCATGCTGCT)",
    "date_of_designation_or_refusal": "17/04/2007",
    "intended_use": "Prevention of corneal graft rejection",
    "eu_designation_number": "EU/3/07/445",
    "status": "Positive",
    "first_published_date": "04/12/2007",
    "last_updated_date": "04/12/2007",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-445"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Human transferrin conjugated to mutant diptheria toxin",
    "date_of_designation_or_refusal": "19/03/2002",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/02/090",
    "status": "Withdrawn",
    "first_published_date": "04/12/2007",
    "last_updated_date": "04/12/2007",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-090"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant modified vaccinia Ankara expressing human 5T4",
    "date_of_designation_or_refusal": "26/01/2007",
    "intended_use": "Treatment of renal-cell carcinoma",
    "eu_designation_number": "EU/3/06/429",
    "status": "Positive",
    "first_published_date": "04/12/2007",
    "last_updated_date": "04/12/2007",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-429"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "capsaicin",
    "date_of_designation_or_refusal": "21/09/2006",
    "intended_use": "Treatment of painful HIV-associated neuropathy",
    "eu_designation_number": "-",
    "status": "Negative",
    "first_published_date": "19/07/2007",
    "last_updated_date": "19/07/2007",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-painful-hiv-associated-neuropathy"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "tramadol hydrochloride",
    "date_of_designation_or_refusal": "21/09/2006",
    "intended_use": "Treatment of painful HIV-associated neuropathy",
    "eu_designation_number": "-",
    "status": "Negative",
    "first_published_date": "19/07/2007",
    "last_updated_date": "19/07/2007",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-painful-hiv-associated-neuropathy-0"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "talactoferrinum alfa",
    "date_of_designation_or_refusal": "05/06/2007",
    "intended_use": "Treatment of renal-cell carcinoma",
    "eu_designation_number": "EU/3/07/448",
    "status": "Positive",
    "first_published_date": "19/07/2007",
    "last_updated_date": "19/07/2007",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-07-448"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Mecasermin",
    "date_of_designation_or_refusal": "26/08/2005",
    "intended_use": "Treatment of primary growth hormone insensitivity syndrome",
    "eu_designation_number": "EU/3/05/307",
    "status": "Positive",
    "first_published_date": "04/07/2007",
    "last_updated_date": "04/07/2007",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-307"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Interferon gamma",
    "date_of_designation_or_refusal": "27/05/2005",
    "intended_use": "Treatment of idiopathic pulmonary fibrosis",
    "eu_designation_number": "EU/3/05/281",
    "status": "Withdrawn",
    "first_published_date": "30/05/2007",
    "last_updated_date": "30/05/2007",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-281"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "oregovomab",
    "date_of_designation_or_refusal": "30/07/2002",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/02/109",
    "status": "Positive",
    "first_published_date": "30/05/2007",
    "last_updated_date": "30/05/2007",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-109"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "decitabine",
    "date_of_designation_or_refusal": "14/02/2003",
    "intended_use": "Treatment of myelodysplastic syndromes",
    "eu_designation_number": "EU/3/03/135",
    "status": "Positive",
    "first_published_date": "30/05/2007",
    "last_updated_date": "30/05/2007",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-135"
  },
  {
    "medicine_name": "Retisert; Retisert",
    "related_ema_product_number": "EMEA/H/C/000787; EMEA/H/C/000787",
    "active_substance": "Fluocinolone acetonide",
    "date_of_designation_or_refusal": "07/03/2005",
    "intended_use": "Treatment of non-infectious uveitis affecting the posterior segment of the eye",
    "eu_designation_number": "EU/3/05/261",
    "status": "Positive",
    "first_published_date": "30/05/2007",
    "last_updated_date": "30/05/2007",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-261"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "5,6,7,8-Tetrahydrobiopterin",
    "date_of_designation_or_refusal": "02/10/2003",
    "intended_use": "Treatment of hyperphenylalaninaemia",
    "eu_designation_number": "EU/3/03/163",
    "status": "Positive",
    "first_published_date": "23/02/2007",
    "last_updated_date": "23/02/2007",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-163"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "nolatrexed",
    "date_of_designation_or_refusal": "02/10/2003",
    "intended_use": "Treatment of hepatocellular carcinoma",
    "eu_designation_number": "EU/3/03/165",
    "status": "Withdrawn",
    "first_published_date": "23/02/2007",
    "last_updated_date": "23/02/2007",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-165"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human engineered monoclonal antibody specific for transforming growth factor ß1",
    "date_of_designation_or_refusal": "04/02/2002",
    "intended_use": "Treatment of systemic sclerosis",
    "eu_designation_number": "EU/3/01/080",
    "status": "Withdrawn",
    "first_published_date": "23/02/2007",
    "last_updated_date": "23/02/2007",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-080"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "bryostatin-1",
    "date_of_designation_or_refusal": "30/04/2002",
    "intended_use": "Treatment of oesophageal cancer",
    "eu_designation_number": "EU/3/02/099",
    "status": "Withdrawn",
    "first_published_date": "23/02/2007",
    "last_updated_date": "23/02/2007",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-099"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-3[[4-(aminoiminomethyl)benzoyl]amino]propyl]-1-[[2,4—dichloro-3-[[2,4-dimethyl-8-quinolinyl)oxy]methyl]phenyl]sulphonyl]-(2S)-2-pyrrolidinecarboxamide, di(methanesulfonate)",
    "date_of_designation_or_refusal": "23/02/2007",
    "intended_use": "Treatment of moderate and severe traumatic brain injury",
    "eu_designation_number": "EU/3/04/188",
    "status": "Positive",
    "first_published_date": "23/02/2007",
    "last_updated_date": "23/02/2007",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-188"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "boswellia serrata",
    "date_of_designation_or_refusal": "21/10/2002",
    "intended_use": "Treatment of peritumoral oedema derived from brain tumours",
    "eu_designation_number": "EU/3/02/117",
    "status": "Withdrawn",
    "first_published_date": "23/02/2007",
    "last_updated_date": "23/02/2007",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-117"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "aldesleukin",
    "date_of_designation_or_refusal": "30/06/2003",
    "intended_use": "Treatment of renal-cell carcinoma",
    "eu_designation_number": "EU/3/03/146",
    "status": "Withdrawn",
    "first_published_date": "23/02/2007",
    "last_updated_date": "23/02/2007",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-146"
  },
  {
    "medicine_name": "Elmisol",
    "related_ema_product_number": "EMEA/H/C/004330",
    "active_substance": "levamisole hydrochloride",
    "date_of_designation_or_refusal": "28/10/2005",
    "intended_use": "Treatment of nephrotic syndrome",
    "eu_designation_number": "EU/3/05/324",
    "status": "Positive",
    "first_published_date": "08/08/2006",
    "last_updated_date": "08/08/2006",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-324"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "vandetanib",
    "date_of_designation_or_refusal": "24/01/2006",
    "intended_use": "Treatment of medullary thyroid carcinoma",
    "eu_designation_number": "EU/3/05/344",
    "status": "Withdrawn",
    "first_published_date": "08/08/2006",
    "last_updated_date": "08/08/2006",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-344"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "E. Coli heat-shock protein 70 with bovine retinal S-antigen",
    "date_of_designation_or_refusal": "24/01/2006",
    "intended_use": "Treatment of autoimmune uveitis",
    "eu_designation_number": "EU/3/05/346",
    "status": "Positive",
    "first_published_date": "08/08/2006",
    "last_updated_date": "08/08/2006",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-346"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "1,2-Bis(methylsulphonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine",
    "date_of_designation_or_refusal": "14/12/2005",
    "intended_use": "Treatment of acute myeloid leukaemia",
    "eu_designation_number": "EU/3/05/332",
    "status": "Positive",
    "first_published_date": "09/02/2006",
    "last_updated_date": "09/02/2006",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-332"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (Pr1 nanopeptide, sequence 169-177, of proteinase 3)",
    "date_of_designation_or_refusal": "21/12/2004",
    "intended_use": "Treatment of myelodysplastic syndromes",
    "eu_designation_number": "EU/3/04/254",
    "status": "Withdrawn",
    "first_published_date": "06/01/2006",
    "last_updated_date": "06/01/2006",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-254"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-(methyl-diazacyclohexyl-methylbenzamide)-azaphenyl-aminothiopyrrole",
    "date_of_designation_or_refusal": "21/12/2004",
    "intended_use": "Treatment of malignant gastrointestinal stromal tumours",
    "eu_designation_number": "EU/3/04/251",
    "status": "Positive",
    "first_published_date": "06/01/2006",
    "last_updated_date": "06/01/2006",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-251"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "oligonucleotide phosphorothioate (TAAACGTTATAACGTTATGACGTCAT), sodium salt",
    "date_of_designation_or_refusal": "28/10/2005",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/05/327",
    "status": "Positive",
    "first_published_date": "04/01/2006",
    "last_updated_date": "04/01/2006",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-327"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "beraprost sodium",
    "date_of_designation_or_refusal": "18/09/2001",
    "intended_use": "Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension",
    "eu_designation_number": "EU/3/01/053",
    "status": "Withdrawn",
    "first_published_date": "04/01/2006",
    "last_updated_date": "04/01/2006",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-053"
  },
  {
    "medicine_name": "Oncophage",
    "related_ema_product_number": "EMEA/H/C/001072",
    "active_substance": "autologous Tumor-Derived gp96 Heat Shock Protein-Peptide Complex",
    "date_of_designation_or_refusal": "11/04/2005",
    "intended_use": "Treatment of renal-cell carcinoma",
    "eu_designation_number": "EU/3/05/270",
    "status": "Positive",
    "first_published_date": "04/01/2006",
    "last_updated_date": "04/01/2006",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-270"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "biotinylated anti-tenascin monoclonal antibody",
    "date_of_designation_or_refusal": "20/10/2004",
    "intended_use": "Treatment of glioma",
    "eu_designation_number": "EU/3/04/232",
    "status": "Positive",
    "first_published_date": "04/01/2006",
    "last_updated_date": "04/01/2006",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-232"
  },
  {
    "medicine_name": "Ethyl Eicosapent soft gelatin capsules; Ethyl Eicosapent soft gelatin capsules",
    "related_ema_product_number": "EMEA/H/C/001148; EMEA/H/C/001148",
    "active_substance": "Ethyl Eicosapentaenoate",
    "date_of_designation_or_refusal": "29/12/2000",
    "intended_use": "Treatment of Huntington’s disease",
    "eu_designation_number": "EU/3/00/013",
    "status": "Positive",
    "first_published_date": "04/01/2006",
    "last_updated_date": "04/01/2006",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-00-013"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Midazolam Hydrochloride",
    "date_of_designation_or_refusal": "01/03/2004",
    "intended_use": "Treatment of status epilepticus",
    "eu_designation_number": "-",
    "status": "Negative",
    "first_published_date": "12/12/2005",
    "last_updated_date": "12/12/2005",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-status-epilepticus"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised antibody fragment (EP-CAM)-truncated Pseudomonas exotoxin A fusion protein",
    "date_of_designation_or_refusal": "20/06/2005",
    "intended_use": "Treatment of  Ep-CAM-YES squamous cell carcinoma of the head and neck",
    "eu_designation_number": "EU/3/05/290",
    "status": "Positive",
    "first_published_date": "12/12/2005",
    "last_updated_date": "12/12/2005",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-290"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "eflornithine hydrochloride",
    "date_of_designation_or_refusal": "19/02/2002",
    "intended_use": "Treatment of familial adenomatous polyposis (FAP)",
    "eu_designation_number": "EU/3/02/087",
    "status": "Withdrawn",
    "first_published_date": "29/11/2005",
    "last_updated_date": "29/11/2005",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-087"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "GM-CSF receptor antagonist",
    "date_of_designation_or_refusal": "18/03/2002",
    "intended_use": "Treatment of juvenile myelomonocytic leukaemia",
    "eu_designation_number": "EU/3/02/089",
    "status": "Withdrawn",
    "first_published_date": "29/11/2005",
    "last_updated_date": "29/11/2005",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-089"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "mitotane",
    "date_of_designation_or_refusal": "11/09/2002",
    "intended_use": "Treatment of adrenal cortical carcinoma",
    "eu_designation_number": "EU/3/02/113",
    "status": "Withdrawn",
    "first_published_date": "29/11/2005",
    "last_updated_date": "29/11/2005",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-113"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "carbamic acid (common)/[[4-[[3-[[4-[1-(4-hydroxyphenyl)-1-methyl-ethyl]phenoxy]methyl]phenyl]methoxy]-phenyl]iminomethyl]-,ethyl ester (amelubant)",
    "date_of_designation_or_refusal": "26/06/2002",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/02/105",
    "status": "Withdrawn",
    "first_published_date": "29/11/2005",
    "last_updated_date": "29/11/2005",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-105"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Deuterium oxide",
    "date_of_designation_or_refusal": "20/10/2004",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/04/239",
    "status": "Withdrawn",
    "first_published_date": "29/11/2005",
    "last_updated_date": "29/11/2005",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-239"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "4-Imino-1, 3-diazobicyclo-[3.1.0]-hexan-2-one",
    "date_of_designation_or_refusal": "27/07/2005",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/05/299",
    "status": "Positive",
    "first_published_date": "29/11/2005",
    "last_updated_date": "29/11/2005",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-299"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "nemorubicin hydrochloride",
    "date_of_designation_or_refusal": "27/07/2005",
    "intended_use": "Treatment of hepatocellular carcinoma",
    "eu_designation_number": "EU/3/05/300",
    "status": "Positive",
    "first_published_date": "27/10/2005",
    "last_updated_date": "27/10/2005",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-300"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sudismase",
    "date_of_designation_or_refusal": "16/06/2005",
    "intended_use": "Treatment of active phase of Peyronie's disease",
    "eu_designation_number": "-",
    "status": "Negative",
    "first_published_date": "27/10/2005",
    "last_updated_date": "27/10/2005",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-active-phase-peyronie039s-disease"
  },
  {
    "medicine_name": "Masipro",
    "related_ema_product_number": "EMEA/H/C/004159",
    "active_substance": "N-(methyl-diazacyclohexyl-methylbenzamide)-azaphenyl-aminothiopyrrole",
    "date_of_designation_or_refusal": "16/11/2004",
    "intended_use": "Treatment of mastocytosis",
    "eu_designation_number": "EU/3/04/242",
    "status": "Positive",
    "first_published_date": "27/10/2005",
    "last_updated_date": "27/10/2005",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-242"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Extract of Sorghum bicolour leaf, Pterocarpus osun stem, Piper guineense seed and Caryophylli flower",
    "date_of_designation_or_refusal": "26/08/2005",
    "intended_use": "Treatment of sickle cell disease",
    "eu_designation_number": "EU/3/05/302",
    "status": "Positive",
    "first_published_date": "27/10/2005",
    "last_updated_date": "27/10/2005",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-302"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "idebenone",
    "date_of_designation_or_refusal": "20/11/2001",
    "intended_use": "Treatment of Friedreich's ataxia",
    "eu_designation_number": "EU/3/01/062",
    "status": "Positive",
    "first_published_date": "11/10/2005",
    "last_updated_date": "",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-062"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Ibuprofen L-Lysinate (salt)",
    "date_of_designation_or_refusal": "24/06/2005",
    "intended_use": "Treatment of patent ductus arteriosus in premature neonates of less than 34 week gestational age",
    "eu_designation_number": "-",
    "status": "Negative",
    "first_published_date": "11/10/2005",
    "last_updated_date": "11/10/2005",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-patent-ductus-arteriosus-premature-neonates-less-34-week-gestational-age"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Ibuprofen L-Lysinate (salt)",
    "date_of_designation_or_refusal": "07/07/2005",
    "intended_use": "Prevention of patent ductus arteriosus in premature neonates of less than 34 week of gestational age",
    "eu_designation_number": "-",
    "status": "Negative",
    "first_published_date": "11/10/2005",
    "last_updated_date": "11/10/2005",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-prevention-patent-ductus-arteriosus-premature-neonates-less-34-week-gestational-age"
  },
  {
    "medicine_name": "Aplidin",
    "related_ema_product_number": "EMEA/H/C/004354",
    "active_substance": "aplidine",
    "date_of_designation_or_refusal": "16/11/2004",
    "intended_use": "Treatment of multiple myeloma",
    "eu_designation_number": "EU/3/04/245",
    "status": "Positive",
    "first_published_date": "11/10/2005",
    "last_updated_date": "11/10/2005",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-245"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "pegylated arginine deiminase",
    "date_of_designation_or_refusal": "20/06/2005",
    "intended_use": "Treatment of hepatocellular carcinoma",
    "eu_designation_number": "EU/3/05/289",
    "status": "Positive",
    "first_published_date": "26/07/2005",
    "last_updated_date": "26/07/2005",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-289"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "N-(methyl-diazacyclohexyl-methylbenzamide)-azaphenyl-aminothiopyrrole",
    "date_of_designation_or_refusal": "20/06/2005",
    "intended_use": "Treatment of multiple myeloma",
    "eu_designation_number": "EU/3/05/286",
    "status": "Positive",
    "first_published_date": "26/07/2005",
    "last_updated_date": "26/07/2005",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-286"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised agonistic anti-CD28 monoclonal antibody",
    "date_of_designation_or_refusal": "11/04/2005",
    "intended_use": "Treatment of B-cell chronic lymphocytic leukaemia",
    "eu_designation_number": "EU/3/05/276",
    "status": "Positive",
    "first_published_date": "01/07/2005",
    "last_updated_date": "01/07/2005",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-276"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "bimosiamose disodium",
    "date_of_designation_or_refusal": "27/05/2005",
    "intended_use": "Treatment of acute lung Injury",
    "eu_designation_number": "EU/3/05/285",
    "status": "Positive",
    "first_published_date": "29/06/2005",
    "last_updated_date": "29/06/2005",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-285"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "sodium butyrate",
    "date_of_designation_or_refusal": "27/05/2005",
    "intended_use": "Prevention of radiation proctitis",
    "eu_designation_number": "EU/3/05/284",
    "status": "Positive",
    "first_published_date": "29/06/2005",
    "last_updated_date": "29/06/2005",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-284"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Porcine lung surfactant",
    "date_of_designation_or_refusal": "19/09/2001",
    "intended_use": "Treatment of acute lung Injury",
    "eu_designation_number": "EU/3/01/057",
    "status": "Withdrawn",
    "first_published_date": "01/06/2005",
    "last_updated_date": "01/06/2005",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-057"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanised anti-HM1.24 monoclonal antibody",
    "date_of_designation_or_refusal": "10/05/2001",
    "intended_use": "Treatment of multiple myeloma",
    "eu_designation_number": "EU/3/01/037",
    "status": "Withdrawn",
    "first_published_date": "28/04/2005",
    "last_updated_date": "28/04/2005",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-037"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "histamine dihydrochloride",
    "date_of_designation_or_refusal": "24/08/2004",
    "intended_use": "Treatment of malignant melanoma",
    "eu_designation_number": "-",
    "status": "Negative",
    "first_published_date": "16/03/2005",
    "last_updated_date": "16/03/2005",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-malignant-melanoma"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "acetylsalicylic acid",
    "date_of_designation_or_refusal": "29/07/2004",
    "intended_use": "Treatment of polycythaemia vera",
    "eu_designation_number": "EU/3/04/208",
    "status": "Positive",
    "first_published_date": "06/12/2004",
    "last_updated_date": "06/12/2004",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-208"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "seocalcitol",
    "date_of_designation_or_refusal": "31/07/2001",
    "intended_use": "Treatment of hepatocellular carcinoma",
    "eu_designation_number": "EU/3/01/052",
    "status": "Withdrawn",
    "first_published_date": "08/11/2004",
    "last_updated_date": "08/11/2004",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-052"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "human Milk Fat Globule 1;yttrium (90Y) human milk fat globule 1 - S p isothiocyanatobenzyl-diethylenetriaminepentaacetic acid",
    "date_of_designation_or_refusal": "30/05/2001",
    "intended_use": "Treatment of ovarian cancer",
    "eu_designation_number": "EU/3/01/043",
    "status": "Withdrawn",
    "first_published_date": "02/06/2004",
    "last_updated_date": "02/06/2004",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-01-043"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "antisense oligonucleotide (TATCCGGAGGGCTCGCCATGCTGCT)",
    "date_of_designation_or_refusal": "02/10/2003",
    "intended_use": "Treatment of retinopathy of prematurity",
    "eu_designation_number": "EU/3/03/160",
    "status": "Positive",
    "first_published_date": "26/04/2004",
    "last_updated_date": "26/04/2004",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-160"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "alpha-1-acid glycoprotein",
    "date_of_designation_or_refusal": "08/10/2009",
    "intended_use": "Treatment of cocaine poisoning",
    "eu_designation_number": "EU/3/03/164",
    "status": "Withdrawn",
    "first_published_date": "26/04/2004",
    "last_updated_date": "26/04/2004",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-164"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "antisense oligonucleotide (TATCCGGAGGGCTCGCCATGCTGCT)",
    "date_of_designation_or_refusal": "02/10/2003",
    "intended_use": "Treatment of neovascular glaucoma",
    "eu_designation_number": "EU/3/03/161",
    "status": "Positive",
    "first_published_date": "26/04/2004",
    "last_updated_date": "26/04/2004",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-161"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "prasterone",
    "date_of_designation_or_refusal": "28/07/2003",
    "intended_use": "Treatment of adrenal insufficiency",
    "eu_designation_number": "EU/3/03/156",
    "status": "Positive",
    "first_published_date": "07/11/2003",
    "last_updated_date": "07/11/2003",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-156"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant dog gastric lipase",
    "date_of_designation_or_refusal": "09/07/2003",
    "intended_use": "Treatment of cystic fibrosis",
    "eu_designation_number": "EU/3/03/157",
    "status": "Positive",
    "first_published_date": "29/10/2003",
    "last_updated_date": "29/10/2003",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-157"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "anti-CD 147 murine monoclonal IgM",
    "date_of_designation_or_refusal": "14/11/2002",
    "intended_use": "Treatment of steroid resistant graft versus host disease (GvHD)",
    "eu_designation_number": "EU/3/02/123",
    "status": "Withdrawn",
    "first_published_date": "07/07/2003",
    "last_updated_date": "07/07/2003",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-123"
  },
  {
    "medicine_name": "Orathecin",
    "related_ema_product_number": "EMEA/H/C/000608",
    "active_substance": "rubitecan",
    "date_of_designation_or_refusal": "10/06/2003",
    "intended_use": "Treatment of pancreatic cancer",
    "eu_designation_number": "EU/3/03/145",
    "status": "Positive",
    "first_published_date": "23/06/2003",
    "last_updated_date": "23/06/2003",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-03-145"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Miltefosine",
    "date_of_designation_or_refusal": "12/06/2002",
    "intended_use": "Treatment of visceral leishmaniasis",
    "eu_designation_number": "EU/3/02/104",
    "status": "Positive",
    "first_published_date": "11/06/2003",
    "last_updated_date": "11/06/2003",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-104"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Humanized anti-KSA monoclonal antibody - human interleukin-2-fusion protein",
    "date_of_designation_or_refusal": "22/03/2002",
    "intended_use": "Treatment of renal-cell carcinoma",
    "eu_designation_number": "EU/3/02/097",
    "status": "Withdrawn",
    "first_published_date": "23/05/2003",
    "last_updated_date": "23/05/2003",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-097"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "Mycobacterial cell wall complex",
    "date_of_designation_or_refusal": "18/12/2002",
    "intended_use": "Treatment of carcinoma in situ of the urinary bladder",
    "eu_designation_number": "-",
    "status": "Negative",
    "first_published_date": "14/01/2003",
    "last_updated_date": "14/01/2003",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-carcinoma-situ-urinary-bladder"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "thymalfasin",
    "date_of_designation_or_refusal": "30/07/2002",
    "intended_use": "Treatment of hepatocellular carcinoma",
    "eu_designation_number": "EU/3/02/110",
    "status": "Positive",
    "first_published_date": "08/01/2003",
    "last_updated_date": "08/01/2003",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-110"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "chlorproguanil hydrochloride;dapsone",
    "date_of_designation_or_refusal": "26/07/2002",
    "intended_use": "Treatment of acute uncomplicated plasmodium falciparum malaria",
    "eu_designation_number": "-",
    "status": "Negative",
    "first_published_date": "08/01/2003",
    "last_updated_date": "08/01/2003",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/refusal-orphan-designation-treatment-acute-uncomplicated-plasmodium-falciparum-malaria"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "autologous Renal Cell Tumour Vaccine",
    "date_of_designation_or_refusal": "21/10/2002",
    "intended_use": "Treatment of renal-cell carcinoma",
    "eu_designation_number": "EU/3/02/116",
    "status": "Positive",
    "first_published_date": "08/01/2003",
    "last_updated_date": "08/01/2003",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-116"
  },
  {
    "medicine_name": "Prohippur",
    "related_ema_product_number": "EMEA/H/C/004150",
    "active_substance": "benzoic acid, sodium salt",
    "date_of_designation_or_refusal": "11/09/2002",
    "intended_use": "Treatment of non-ketotic hyperglycinaemia",
    "eu_designation_number": "EU/3/02/111",
    "status": "Positive",
    "first_published_date": "08/01/2003",
    "last_updated_date": "08/01/2003",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-111"
  },
  {
    "medicine_name": "",
    "related_ema_product_number": "",
    "active_substance": "recombinant glycoprotein gp350 of Epstein-Barr Virus",
    "date_of_designation_or_refusal": "22/10/2002",
    "intended_use": "Prevention of post-transplantation lympho-proliferative disorders",
    "eu_designation_number": "EU/3/02/118",
    "status": "Positive",
    "first_published_date": "17/12/2002",
    "last_updated_date": "17/12/2002",
    "orphan_designation_url": "https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-02-118"
  }
]